FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Sanchez-Reilly, S AF Sanchez-Reilly, Sandra TI The Effects of Cognitive Impairment in Older Cancer Patients SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Editorial Material C1 [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Sanchez-Reilly, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.; Sanchez-Reilly, S (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 BP 295 EP 296 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300023 ER PT J AU Thomas, JD Back, AL Gustin, J Jackson, VA Jacobsen, J Landzaat, LH Levine, SK Neri, V Periyakoil, V Smith, CN AF Thomas, Jane deLima Back, Anthony L. Gustin, Jillian Jackson, Vicki A. Jacobsen, Juliet Landzaat, Lindy H. Levine, Stacie K. Neri, Vanessa Periyakoil, Vyjeyanthi Smith, Christian Nicole TI 2017 AAHPM Fellowship Directors Program: Building a Community of Educators SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Thomas, Jane deLima] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA. [Back, Anthony L.] Univ Washington, Fred Hutchinson Canc Res Ctr, Sch Med, Seattle, WA 98195 USA. [Gustin, Jillian] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA. [Jackson, Vicki A.; Jacobsen, Juliet] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Landzaat, Lindy H.] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA. [Levine, Stacie K.] Univ Chicago, Chicago, IL 60637 USA. [Neri, Vanessa] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Periyakoil, Vyjeyanthi] Stanford Univ, Sch Med, VA Palo Alto Hlth Care Syst, Stanford, CA USA. [Smith, Christian Nicole] Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA P04 BP 305 EP 306 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300035 ER PT J AU Sanders, J Lakin, J Bernacki, R Arnold, C Paladino, J AF Sanders, Justin Lakin, Joshua Bernacki, Rachelle Arnold, Catherine Paladino, Joanna TI Priming the System for Primary Palliative Care: More, Better, and Earlier Conversations with Seriously Ill Patients SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Sanders, Justin; Bernacki, Rachelle] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sanders, Justin; Lakin, Joshua] Harvard Med Sch, Boston, MA USA. [Arnold, Catherine] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Paladino, Joanna] Ariadne Labs, Brookline, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA P10 BP 308 EP 309 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300041 ER PT J AU Hwang, J Battista, V Jacobowski, N Mosher, P Muriel, A Long, C AF Hwang, Jennifer Battista, Vanessa Jacobowski, Natalie Mosher, Pamela Muriel, Anna Long, Carolyn TI "The Doctor Is In: Part 2": Challenging Topics at the Intersection of Pediatric Palliative Care and Psychiatry SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Hwang, Jennifer; Battista, Vanessa; Long, Carolyn] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Jacobowski, Natalie] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mosher, Pamela] Hosp Sick Children, Toronto, ON, Canada. [Muriel, Anna] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA P18 BP 311 EP 312 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300048 ER PT J AU Sudore, R You, J Korfage, I Rietjens, J Le, G Heyland, D AF Sudore, Rebecca You, John Korfage, Ida Rietjens, Judith Le, Gem Heyland, Daren TI Prioritizing Outcomes for Advance Care Planning Research: Consensus from a Multidisciplinary, International Delphi Panel SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA. [Sudore, Rebecca; Le, Gem] Univ Calif San Francisco, San Francisco, CA 94143 USA. [You, John] McMaster Univ, Hamilton, ON, Canada. [Korfage, Ida; Rietjens, Judith] Erasmus Univ, Med Ctr, Rotterdam, Netherlands. [Heyland, Daren] Queens Univ, Kingston, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA TH307A BP 316 EP 317 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300060 ER PT J AU Sudore, R Boscardin, J Barnes, D AF Sudore, Rebecca Boscardin, John Barnes, Deborah TI A Patient-Facing Advance Care Planning (ACP) Website Called PREPARE Increases ACP Documentation and Engagement in a Randomized Trial of Diverse Older Primary Care Patients at a VA Medical Center SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA. [Sudore, Rebecca; Boscardin, John; Barnes, Deborah] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA TH307B BP 317 EP 318 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300061 ER PT J AU Sudore, R Heyland, D Barnes, D Howard, M Fassbender, K Robinson, C Boscardin, J You, J AF Sudore, Rebecca Heyland, Daren Barnes, Deborah Howard, Michelle Fassbender, Konrad Robinson, Carole Boscardin, John You, John TI Measuring Advance Care Planning: Optimizing the Advance Care Planning Engagement Survey SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA. [Sudore, Rebecca; Barnes, Deborah; Boscardin, John] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Heyland, Daren] Queens Univ, Kingston, ON, Canada. [Howard, Michelle; You, John] McMaster Univ, Hamilton, ON, Canada. [Fassbender, Konrad] Covenant Hlth Palliat Inst, Edmonton, AB, Canada. [Robinson, Carole] Univ British Columbia, Kelowna, BC, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA TH307C BP 318 EP 318 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300062 ER PT J AU Zapata, C Wistar, E Horton, C Lum, H Sudore, R AF Zapata, Carly Wistar, Emily Horton, Claire Lum, Hillary Sudore, Rebecca TI Using A Video-Based Advance Care Planning (ACP) Website to Facilitate Group Visits for Diverse Older Adults in Primary Care Is Feasible And Improves ACP Engagement SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Zapata, Carly; Wistar, Emily; Horton, Claire; Sudore, Rebecca] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lum, Hillary] Univ Colorado, Aurora, CO USA. [Lum, Hillary] Eastern Colorado GRECC, Aurora, CO USA. [Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA TH307D BP 318 EP 319 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300063 ER PT J AU Mullin, J Macauley, R AF Mullin, Jonathan Macauley, Robert TI Clinical and Ethical Issues in Terminal Gastrointestinal Dysfunction in Children with Severe Neurological Impairment SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Mullin, Jonathan] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mullin, Jonathan] Boston Childrens Hosp, Boston, MA USA. [Macauley, Robert] Univ Vermont, Burlington, VT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA TH316 BP 322 EP 323 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300071 ER PT J AU Lum, H Garner, K Antoni, C AF Lum, Hillary Garner, Kimberly Antoni, Charlie TI "I Heard Something from Another Veteran'': How to Use Group Visits to Engage Patients in Advance Care Planning SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Lum, Hillary] Univ Colorado, Aurora, CO USA. [Lum, Hillary] VA Eastern Colorado, Aurora, CO USA. [Garner, Kimberly] US Dept Vet Affairs, Little Rock, AR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA TH319 BP 324 EP 324 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300074 ER PT J AU Bekelman, D Allen, L Hattler, B Havranek, E Fairclough, D McBryde, C Meek, P AF Bekelman, David Allen, Larry Hattler, Brack Havranek, Edward Fairclough, Diane McBryde, Connor Meek, Paula TI Primary Results from the Collaborative Care to Alleviate Symptoms and Adjust to Illness in Heart Failure (CASA) Randomized Clinical Trial SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Bekelman, David; McBryde, Connor] Univ Colorado, Denver, CO 80202 USA. [Allen, Larry] Univ Colorado, Sch Med, Aurora, CO USA. [Hattler, Brack] Denver VA Med Ctr, Denver, CO USA. [Havranek, Edward] Denver Hlth Med Ctr, Denver, CO USA. [Fairclough, Diane; Meek, Paula] Univ Colorado, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA TH321D BP 328 EP 329 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300082 ER PT J AU Yeh, IM Shulman, E Hester, J Bernacki, R AF Yeh, Irene M. Shulman, Eliza Hester, Jennifer Bernacki, Rachelle TI After the Conversation: Designing an Electronic Health Record for Dynamic Advance Care Planning SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Yeh, Irene M.; Bernacki, Rachelle] Dana Farber Canc Inst, Boston, MA 02115 USA. [Shulman, Eliza] Atrius Hlth, Needham, MA USA. [Hester, Jennifer] Christ Hosp Hlth Network, Cincinnati, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA TH332 BP 330 EP 330 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300085 ER PT J AU Shaw, H Fronk, J Hui, F Lorenz, K Schroeder, K Kenemuth, R Bober, S AF Shaw, Heather Fronk, Joshua Hui, Felicia Lorenz, Karl Schroeder, Karla Kenemuth, Ruth Bober, Sharon TI The Birds and Bees Do It, So Why Can't We Talk About It? Intimacy and Sexuality in Serious Illness and at the End of Life SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Shaw, Heather] Stanford Univ, Stanford, CA 94305 USA. [Fronk, Joshua] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Hui, Felicia; Lorenz, Karl] Stanford Univ, Palo Alto, CA 94304 USA. [Schroeder, Karla; Kenemuth, Ruth] Stanford Hlth Care, Palo Alto, CA USA. [Bober, Sharon] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA TH366 BP 343 EP 343 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300110 ER PT J AU Decourcey, D Silverman, M Wolfe, J AF Decourcey, Danielle Silverman, Melanie Wolfe, Joanne TI Weighing Distress and Benefit: Understanding the Research Participation Experiences of Bereaved Parents of Children with Medical Complexity SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Decourcey, Danielle; Silverman, Melanie] Boston Childrens Hosp, Boston, MA USA. [Wolfe, Joanne] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA TH370B BP 345 EP 346 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300115 ER PT J AU Straehla, J Barton, K Yi-Frazier, J Baker, S Bona, K Wolfe, J Rosenberg, A AF Straehla, Joelle Barton, Krysta Yi-Frazier, Joyce Baker, Scott Bona, Kira Wolfe, Joanne Rosenberg, Abby TI The Benefits and Burdens of Cancer: A Prospective, Longitudinal Cohort Study of Adolescents and Young Adults SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Straehla, Joelle] Boston Childrens Hosp, Dana Farber Canc Cent, Boston, MA USA. [Barton, Krysta; Yi-Frazier, Joyce] Seattle Childrens Res Inst, Seattle, WA USA. [Baker, Scott] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Bona, Kira; Wolfe, Joanne] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rosenberg, Abby] Seattle Childrens Hosp, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA TH370D BP 346 EP 347 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300117 ER PT J AU Daubman, BR Rosenberg, L Kamdar, M AF Daubman, Bethany Rose Rosenberg, Leah Kamdar, Mihir TI Novel Palliative Care Delivery Mechanisms in an Increasingly Electronic World SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Daubman, Bethany Rose] Massachusetts Gen Hosp, North Billerica, MA USA. [Rosenberg, Leah] Massachusetts Gen Hosp, Cambridge, MA USA. [Kamdar, Mihir] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA FR402 BP 351 EP 351 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300124 ER PT J AU Chen, B Jacobsen, J Jones, J Lewin, W Thomas, JD Tuggey, E AF Chen, Bonnie Jacobsen, Juliet Jones, Joshua Lewin, Warren Thomas, Jane DeLima Tuggey, Erica TI The Professional Working Group-How to Create and Use a Process Group to Build Community, Prevent Burnout, and Make Work-Life Sustainable SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Chen, Bonnie] Kaiser Permanente, Oakland, CA USA. [Jacobsen, Juliet] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Jones, Joshua] Univ Penn Hlth Syst, Philadelphia, PA USA. [Lewin, Warren] Mt Sinai Hosp, New York, NY 10029 USA. [Thomas, Jane DeLima] Dana Farber Canc Inst, Boston, MA 02115 USA. [Tuggey, Erica] Mt Sinai Med Ctr, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA FR417 BP 356 EP 357 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300136 ER PT J AU Balkin, E Wolfe, J Kirkpatrick, J Swetz, K Blume, E Kaufman, B AF Balkin, Emily Wolfe, Joanne Kirkpatrick, James Swetz, Keith Blume, Elizabeth Kaufman, Beth TI Pediatric Cardiologist Attitudes About Palliative Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Balkin, Emily] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Wolfe, Joanne] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kirkpatrick, James] Univ Washington, Seattle, WA 98195 USA. [Swetz, Keith] Univ Alabama Birmingham, Birmingham, AL USA. [Blume, Elizabeth] Boston Childrens Hosp, Boston, MA USA. [Kaufman, Beth] Lucile Packard Childrens Hosp Stanford, Palo Alto, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA FR419C BP 358 EP 359 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300139 ER PT J AU Lakin, J Arnold, C Bernacki, R Cunningham, R Gallagher, J Quigley, M Lamey, J Rangarajan, A AF Lakin, Joshua Arnold, Catherine Bernacki, Rachelle Cunningham, Rebecca Gallagher, Julia Quigley, Martha Lamey, Jan Rangarajan, Arjun TI Three Palliative Care Models in Population Health Management Systems SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Lakin, Joshua] Harvard Med Sch, Boston, MA USA. [Arnold, Catherine; Cunningham, Rebecca] Brigham & Womens Hosp, Boston, MA 02115 USA. [Bernacki, Rachelle] Dana Farber Canc Inst, Boston, MA 02115 USA. [Gallagher, Julia; Quigley, Martha] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lamey, Jan; Rangarajan, Arjun] Brigham & Womens Phys Org, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA FR452 BP 372 EP 373 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300165 ER PT J AU Talebreza, S Lowery, J Bernacki, R AF Talebreza, Shaida Lowery, Jill Bernacki, Rachelle TI Eliciting, Documenting, and Honoring Patient's Goals of Care and Life-Sustaining Treatment Decisions: Building Systems to Ensure Success (FR479) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Talebreza, Shaida] Univ Utah, Salt Lake City, UT USA. [Lowery, Jill] Vet Hlth Adm, Natl Ctr Ethics Hlth Care, Durham, NC USA. [Bernacki, Rachelle] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 BP 384 EP 384 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300187 ER PT J AU Lindvall, C Forsyth, A Barzilay, R Tulsky, J AF Lindvall, Charlotta Forsyth, Alexander Barzilay, Regina Tulsky, James TI Natural Language Processing: An Opportunity to Make Chart Data Come Alive in Palliative Care Research SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Lindvall, Charlotta] Dana Farber Canc Inst Harvard, Boston, MA USA. [Forsyth, Alexander; Barzilay, Regina] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Tulsky, James] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA FR481A BP 385 EP 385 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300189 ER PT J AU Temel, J AF Temel, Jennifer TI Integrating Palliative and Oncology Care: Where Do We Go from Here? SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Temel, Jennifer] Massachusetts Gen Hosp Canc Ctr, Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA SA500 BP 392 EP 392 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300200 ER PT J AU Yeh, I Reville, B AF Yeh, Irene Reville, Barbara TI The Write Stuff: How to Increase Your Writing Productivity SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Yeh, Irene; Reville, Barbara] Dana Farber Canc Inst, Boston, MA 02115 USA. [Reville, Barbara] Brigham & Womens, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA SA504 BP 394 EP 394 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300204 ER PT J AU Franklin, J Painter, J Cooke, K Schluep, J AF Franklin, John Painter, John Cooke, Kelly Schluep, John TI Moral Injury: Invisible Wounds of Combat SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Franklin, John; Painter, John] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Cooke, Kelly] ProHlth Care, Waukesha, WI USA. [Schluep, John] First Congregat Church Tallmadge, Tallmadge, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA SA517 BP 400 EP 401 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300218 ER PT J AU Jacobsen, J Lindenberger, E Smith, C AF Jacobsen, Juliet Lindenberger, Elizabeth Smith, Cardinale TI See One, Do One, Coach One: How Clinical Coaching Can Help Trainees and Colleagues Just When They Need It with Just What They Need SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Jacobsen, Juliet] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lindenberger, Elizabeth; Smith, Cardinale] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA SA516 BP 400 EP 400 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300217 ER PT J AU Williams, B Bailey, FA Goode, P Burgio, K AF Williams, Beverly Bailey, F. Amos Goode, Patricia Burgio, Kathryn TI ''Just Knowing That I Was Going to Be Questioned About His Last Days'': Bereaved Next-Of-Kin's Pre-Interview Cognitive and Affective Work (S703) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Williams, Beverly] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL USA. [Bailey, F. Amos] Univ Colorado, Anschutz Med Campus, Aurora, CO USA. [Goode, Patricia] Univ Alabama Birmingham, Birmingham, AL USA. [Burgio, Kathryn] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 BP 411 EP 411 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300235 ER PT J AU Lee, K Ganta, N Horton, J Chai, E AF Lee, Kathleen Ganta, Niharika Horton, Jay Chai, Emily TI Evidence for Morphine or HydromorphoneInduced Neurotoxicity in Renal Impairment: A Systematic Review (S705) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Lee, Kathleen] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ganta, Niharika] Univ Penn, Aston, PA USA. [Horton, Jay] Icahn Sch Med Mt Sinai, Brooklyn, NY USA. [Chai, Emily] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 BP 412 EP 412 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300237 ER PT J AU Ubhayakar, N Prommer, E Steckart, MJ AF Ubhayakar, Nitin Prommer, Eric Steckart, M. Jillisa TI Palliative Care Consultation from the Emergency Department: Rationale and Patient Characteristics in a Veteran Population SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Ubhayakar, Nitin] Vet Affairs Greater Los Angeles Healthcare, Los Angeles, CA USA. [Prommer, Eric] Greater Los Angeles Healthcare, Los Angeles, CA USA. [Steckart, M. Jillisa] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA S728 BP 424 EP 425 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300260 ER PT J AU Sudore, R Lum, H You, J Hanson, L Meier, D Pantilat, S Matlock, DD Rietjens, J Korfage, IJ Ritchie, C Kutner, JS Teno, JM Thomas, J Heyland, DK AF Sudore, Rebecca Lum, Hillary You, John Hanson, Laura Meier, Diane Pantilat, Steven Matlock, Daniel D. Rietjens, Judith Korfage, Ida J. Ritchie, Christine Kutner, Jean S. Teno, Joan M. Thomas, Judy Heyland, Daren K. TI Proactive Outpatient Palliative Care Consultations for Persons with Advanced Cancer: What's in the "Special Sauce''? SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA. [Sudore, Rebecca; Pantilat, Steven; Ritchie, Christine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lum, Hillary] Univ Colorado, Aurora, CO USA. [Lum, Hillary] Eastern Colorado GRECC, Aurora, CO USA. [You, John] McMaster Univ, Hamilton, ON, Canada. [Hanson, Laura] Univ N Carolina, Chapel Hill, NC USA. [Meier, Diane] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Matlock, Daniel D.; Kutner, Jean S.] Univ Colorado, Sch Med, Aurora, CO USA. [Rietjens, Judith; Korfage, Ida J.] Erasmus Univ, Med Ctr, Rotterdam, Netherlands. [Teno, Joan M.] Univ Washington, Seattle, WA 98195 USA. [Thomas, Judy] Coalit Compassionate Care Calif, Sacramento, CA USA. [Heyland, Daren K.] Queens Univ, Kingston, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA S739 BP 431 EP 432 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300272 ER PT J AU Huang, CHS Kvale, E Bailey, FA Goode, P Burgio, K AF Huang, Chao-Hui Sylvia Kvale, Elizabeth Bailey, F. Amos Goode, Patricia Burgio, Kathryn TI Association Between Mental Health Diagnoses and Process of Care at the End Of Life: Findings from the BEACON Trial SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Huang, Chao-Hui Sylvia; Goode, Patricia] Univ Alabama Birmingham, Birmingham, AL USA. [Kvale, Elizabeth] Univ Alabama Birmingham, Birmingham Ctrat & Support Care, Birmingham, AL USA. [Bailey, F. Amos] Univ Colorado, Anschutz Med Campus, Aurora, CO USA. [Burgio, Kathryn] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA S771 BP 449 EP 449 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300303 ER PT J AU Hansen, L Dieckmann, N Chang, M Naugler, W Kolbeck, K AF Hansen, Lissi Dieckmann, Nathan Chang, Michael Naugler, Willscott Kolbeck, Kenneth TI Symptom Distress in Patients with Advanced Hepatocellular Carcinoma SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Hansen, Lissi; Dieckmann, Nathan; Naugler, Willscott; Kolbeck, Kenneth] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Chang, Michael] Portland VA Med Ctr, Portland, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA S781 BP 455 EP 455 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300313 ER PT J AU Brown, LM Sawey, K Liu, R Baday, YI Lee, S Healy, J Shah, R Sanchez-Reilly, S AF Brown, Lisa -Marie Sawey, Kathryn Liu, Rosemary Baday, Yiressy Izaguirre Lee, Shuko Healy, Jennifer Shah, Ronak Sanchez-Reilly, Sandra TI Do You Really Know What Palliative Care Is? Developing an Electronic Palliative Care Information Card SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Brown, Lisa -Marie; Liu, Rosemary; Healy, Jennifer; Shah, Ronak; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Sawey, Kathryn] Univ Hosp New Braunfels, New Braunfels, TX USA. [Baday, Yiressy Izaguirre] Univ Texas Hlth Sci Ctr San Antonio, Ctr VA Hosp, San Antonio, TX USA. [Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA S784 BP 456 EP 457 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300316 ER PT J AU Khan, H Lee, S Carretero, E San-Chez-Reilly, S AF Khan, Huma Lee, Shuko Carretero, Edgar San-Chez-Reilly, Sandra TI Serving Those Who Served: The Unique Benefit of Inpatient Hospice at the VA SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Khan, Huma; San-Chez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, Shuko; Carretero, Edgar] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA S783 BP 456 EP 456 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300315 ER PT J AU Haverhals, L Manheim, C Levy, C AF Haverhals, Leah Manheim, Chelsea Levy, Cali TI Navigating Multiple Systems to Ensure Delivery of Concurrent Care to US Veterans with Cancer SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 22-25, 2017 CL Phoenix, AZ SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Haverhals, Leah] Denver VA Med Ctr, Denver, CO USA. [Manheim, Chelsea] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Levy, Cali] Univ Colorado, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2017 VL 53 IS 2 MA S806 BP 469 EP 469 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EP1AR UT WOS:000397118300338 ER PT J AU Catalano, OA Masch, WR Catana, C Mahmood, U Sahani, DV Gee, MS Menezes, L Soricelli, A Salvatore, M Gervais, D Rosen, BR AF Catalano, Onofrio Antonio Masch, William Roger Catana, Ciprian Mahmood, Umar Sahani, Dushyant Vasudeo Gee, Michael Stanley Menezes, Leon Soricelli, Andrea Salvatore, Marco Gervais, Debra Rosen, Bruce Robert TI An overview of PET/MR, focused on clinical applications SO ABDOMINAL RADIOLOGY LA English DT Article DE PET/MR; MR/PET; Oncologic imaging; Attenuation correction ID POSITRON-EMISSION-TOMOGRAPHY; CELL LUNG-CANCER; FDG-PET/CT; MULTIPLE-MYELOMA; RECTAL-CANCER; BREAST-CANCER; LYMPH-NODES; ATTENUATION CORRECTION; COMPUTED-TOMOGRAPHY; INITIAL-EXPERIENCE AB Hybrid PET/MR scanners are innovative imaging devices that simultaneously or sequentially acquire and fuse anatomical and functional data from magnetic resonance (MR) with metabolic information from positron emission tomography (PET) (Delso et al. in J Nucl Med 52:1914-1922, 2011; Zaidi et al. in Phys Med Biol 56:3091-3106, 2011). Hybrid PET/MR scanners have the potential to greatly impact not only on medical research but also, and more importantly, on patient management. Although their clinical applications are still under investigation, the increased worldwide availability of PET/MR scanners, and the growing published literature are important determinants in their rising utilization for primarily clinical applications. In this manuscript, we provide a summary of the physical features of PET/MR, including its limitations, which are most relevant to clinical PET/MR implementation and to interpretation. Thereafter, we discuss the most important current and emergent clinical applications of such hybrid technology in the abdomen and pelvis, both in the field of oncologic and non-oncologic imaging, and we provide, when possible, a comparison with clinically consolidated imaging techniques, like for example PET/CT. C1 [Catalano, Onofrio Antonio; Catana, Ciprian; Mahmood, Umar; Rosen, Bruce Robert] Harvard Med Sch, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, 49 13th St, Charlestown, MA 02129 USA. [Catalano, Onofrio Antonio; Sahani, Dushyant Vasudeo; Gee, Michael Stanley; Gervais, Debra] Harvard Med Sch, Massachusetts Gen Hosp, Abdominal Radiol, 55 Fruit St, Boston, MA 02114 USA. [Masch, William Roger] Univ Michigan Hlth Syst, Dept Radiol, Abdominal Imaging, 1550E Med Ctr Dr,SPC5030, Ann Arbor, MI 48109 USA. [Mahmood, Umar] Harvard Med Sch, Massachusetts Gen Hosp, Inst Precis Med, 55 Fruit St, Boston, MA 02114 USA. [Gee, Michael Stanley] Harvard Med Sch, Massachusetts Gen Hosp, Martinos Ctr Pediat Radiol, 55 Fruit St, Boston, MA 02114 USA. [Menezes, Leon] Univ Coll Hosp, Inst Nucl Med, 235 Euston Rd, London NW1 2BU, England. [Soricelli, Andrea] Univ Naples Parthenope, Via Medina 40, I-80133 Naples, Italy. [Salvatore, Marco] Fdn SDN, Med Nucl, Via Gianturco 113, I-80113 Naples, Italy. RP Catalano, OA (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, 49 13th St, Charlestown, MA 02129 USA.; Catalano, OA (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Abdominal Radiol, 55 Fruit St, Boston, MA 02114 USA. EM onofriocata-lano@yahoo.it NR 61 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 2366-004X EI 2366-0058 J9 ABDOM RADIOL JI Abdom. Radiol. PD FEB PY 2017 VL 42 IS 2 BP 631 EP 644 DI 10.1007/s00261-016-0894-5 PG 14 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EM1ND UT WOS:000395083400029 PM 27624499 ER PT J AU Trevathan, JK Yousefi, A Park, HO Bartoletta, JJ Ludwig, KA Lee, KH Lujan, JL AF Trevathan, James K. Yousefi, Ali Park, Hyung Ook Bartoletta, John J. Ludwig, Kip A. Lee, Kendall H. Lujan, J. Luis TI Computational Modeling of Neurotransmitter Release Evoked by Electrical Stimulation: Nonlinear Approaches to Predicting Stimulation-Evoked Dopamine Release SO ACS CHEMICAL NEUROSCIENCE LA English DT Article DE Fast scan cyclic voltammetry; deep brain stimulation; dopamine; artificial neural network; Volterra kernels; machine learning; neurochemical sensing ID SCAN CYCLIC VOLTAMMETRY; CARBON-FIBER MICROELECTRODES; ARTIFICIAL NEURAL-NETWORKS; MEDIAL FOREBRAIN-BUNDLE; RAT DORSAL STRIATUM; SUBTHALAMIC NUCLEUS; EXTRACELLULAR DOPAMINE; RESTRICTED DIFFUSION; KINETIC DIVERSITY; STEREOTAXIC ATLAS AB Neurochemical changes evoked by electrical stimulation of the nervous system have been linked to both therapeutic and undesired effects of neuromodulation therapies used to treat obsessive compulsive disorder, depression, epilepsy, Parkinson's disease, stroke, hypertension, tinnitus, and many other indications. In fact, interest in better understanding the role of neurochemical signaling in neuromodulation therapies has been a focus of recent government-and industry-sponsored programs whose ultimate goal is to usher in an era of personalized medicine by creating neuromodulation therapies that respond to real-time changes in patient status. A key element to achieving these precision therapeutic interventions is the development of mathematical modeling approaches capable of describing the nonlinear transfer function between neuromodulation parameters and evoked neurochemical changes. Here, we propose two computational modeling frameworks, based on artificial neural networks (ANNs) and Volterra kernels, that can characterize the input/output transfer functions of stimulation-evoked neurochemical release. We evaluate the ability of these modeling frameworks to characterize subject-specific neurochemical kinetics by accurately describing stimulation-evoked dopamine release across rodent (R-2 = 0.83 Volterra kernel, R-2 = 0.86 ANN), swine (R-2 = 0.90 Volterra kernel, R-2 = 0.93 ANN), and non-human primate (R-2 = 0.98 Volterra kernel, R-2 = 0.96 ANN) models of brain stimulation. Ultimately, these models will not only improve understanding of neurochemical signaling in healthy and diseased brains but also facilitate the development of neuromodulation strategies capable of controlling neurochemical release via closed-loop strategies. C1 [Trevathan, James K.] Mayo Clin, Mayo Grad Sch, 200 First St SW, Rochester, MN 55905 USA. [Park, Hyung Ook; Bartoletta, John J.; Ludwig, Kip A.; Lee, Kendall H.; Lujan, J. Luis] Mayo Clin, Dept Neurol Surg, 200 First St SW, Rochester, MN 55905 USA. [Lee, Kendall H.; Lujan, J. Luis] Mayo Clin, Dept Physiol & Biomed Engn, 200 First St SW, Rochester, MN 55905 USA. [Lee, Kendall H.] Mayo Clin, Dept Phys Med & Rehabil, 200 First St SW, Rochester, MN 55905 USA. [Yousefi, Ali] Massachusetts Gen Hosp, Dept Neurol Surg, 25 Shattuck St, Boston, MA 02115 USA. [Yousefi, Ali] Harvard Med Sch, 25 Shattuck St, Boston, MA 02115 USA. RP Lujan, JL (reprint author), Mayo Clin, Dept Neurol Surg, 200 First St SW, Rochester, MN 55905 USA. EM lujan.luis@mayo.edu FU National Institutes of Health, NINDS [R01 NS084975, R01 NS75013, R01 NS70872]; Grainger Foundation FX This work was supported by the National Institutes of Health, NINDS (R01 NS084975 award to J.L.L. and R01 NS75013 and R01 NS70872 awards to K.H.L.), and The Grainger Foundation. NR 55 TC 0 Z9 0 U1 3 U2 3 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1948-7193 J9 ACS CHEM NEUROSCI JI ACS Chem. Neurosci. PD FEB PY 2017 VL 8 IS 2 SI SI BP 394 EP 410 DI 10.1021/acschemneuro.6b00319 PG 17 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology GA EL2XH UT WOS:000394483300022 PM 28076681 ER PT J AU Rutrick, D Stein, DJ Subramanian, G Smith, B Fava, M Hasler, G Cha, JH Gasparini, F Donchev, T Ocwieja, M Johns, D Gomez-Mancilla, B AF Rutrick, Daniel Stein, Dan J. Subramanian, Ganesan Smith, Brian Fava, Maurizio Hasler, Gregor Cha, Jang-Ho Gasparini, Fabrizio Donchev, Toni Ocwieja, Magdalena Johns, Donald Gomez-Mancilla, Baltazar TI Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study SO ADVANCES IN THERAPY LA English DT Article DE AFQ056; Glutamate; Mavoglurant; Obsessive-compulsive disorder; Psychiatry; Randomized controlled trial; Selective serotonin reuptake inhibitors ID OBSESSIVE-COMPULSIVE DISORDER; DOUBLE-BLIND; CONTROLLED TRIAL; METAANALYSIS; MANAGEMENT; DIAGNOSIS; MODERATE; DRUG AB To determine if mavoglurant (modified release) as an augmentation therapy to selective serotonin reuptake inhibitors (SSRIs) could have beneficial effects reducing Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score in patients with obsessive-compulsive disorder (OCD) resistant to SSRI treatment. This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 2 study. Patients remained on their SSRI treatment and mavoglurant or placebo was added on. Non-smoking men and women aged 18-65 years primarily diagnosed with OCD according to Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.; DSM-IV-TR) criteria were randomized (1:1) to mavoglurant or placebo groups. After 50 patients were randomized, an interim analysis was conducted to determine whether the study should be continued. The primary outcome measure was absolute change in Y-BOCS from baseline at week 17. Safety was assessed by recording adverse events (AEs) and serious adverse events (SAEs). Interim analysis led to a decision to terminate the study. In total 38 (76.0%) participants completed 17 weeks of treatment and 37 (74.0%) completed the study. There was no significant difference in least squares (LS) mean change from baseline at week 17 in Y-BOCS total score for mavoglurant compared with placebo groups [-6.9 (1.75) vs. -8.0 (1.78), respectively; LS mean difference 1.1; 95% CI -3.9, 6.2; p = 0.671]. The incidence of AEs was higher in the mavoglurant compared with the placebo group (80.8% vs. 70.8%, respectively). This study of mavoglurant in OCD was terminated because of the lack of efficacy at interim analysis. The study did not support the use of an antagonist of mGluR5 receptors for OCD treatment. The study was registered with ClinicalTrials.gov: NCT01813019. This study was sponsored by Novartis Pharma AG, Basel, Switzerland. C1 [Rutrick, Daniel] Adams Clin Trials, Watertown, MA 02472 USA. [Stein, Dan J.] Univ Cape Town, Groote Schuur Hosp, Dept Psychiat, MRC Unit Anxiety & Stress Disorders, ZA-7925 Cape Town, South Africa. [Subramanian, Ganesan] Novartis Healthcare Pvt Ltd, Hyderabad 500081, Andhra Pradesh, India. [Smith, Brian; Cha, Jang-Ho] Novartis Pharmaceut, Cambridge, MA 02139 USA. [Fava, Maurizio] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02115 USA. [Hasler, Gregor] Univ Bern, Psychiat Univ Hosp, Div Mol Psychiat, CH-3000 Bern, Switzerland. [Gasparini, Fabrizio; Ocwieja, Magdalena; Johns, Donald; Gomez-Mancilla, Baltazar] Novartis Pharma AG, Novartis Inst Biomed Res, CH-4056 Basel, Switzerland. [Donchev, Toni] Psychiat Clin, Sofia 1606, Bulgaria. [Johns, Donald] Biogen, 300 Binney St, Cambridge, MA 02142 USA. [Gomez-Mancilla, Baltazar] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada. RP Gomez-Mancilla, B (reprint author), Novartis Pharma AG, Novartis Inst Biomed Res, CH-4056 Basel, Switzerland. EM baltazar.gomezmancilla@novartis.com FU Novartis Pharma AG, Basel, Switzerland; Novartis Pharma AG FX This study was sponsored by Novartis Pharma AG, Basel, Switzerland. The article processing charges for this publication were funded by Novartis Pharma AG. The authors thank Ritu Hans and K Ananda Krishna from Novartis Healthcare Pvt Ltd, Hyderabad, India, for medical writing assistance and incorporating subsequent revisions. All named authors meet the International Committee of Medical Journal Editors (ICJME) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. NR 34 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0741-238X EI 1865-8652 J9 ADV THER JI Adv. Ther. PD FEB PY 2017 VL 34 IS 2 BP 524 EP 541 DI 10.1007/s12325-016-0468-5 PG 18 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA EM6SV UT WOS:000395443300014 PM 28044255 ER PT J AU Yajnik, V Khan, N Dubinsky, M Axler, J James, A Abhyankar, B Lasch, K AF Yajnik, Vijay Khan, Nabeel Dubinsky, Marla Axler, Jeffrey James, Alexandra Abhyankar, Brihad Lasch, Karen TI Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age SO ADVANCES IN THERAPY LA English DT Article DE Crohn's disease; Ulcerative colitis; Vedolizumab ID INFLAMMATORY-BOWEL-DISEASE; ANTI-TNF THERAPY; ADVERSE EVENTS; INCREASED RISK; OLDER AGE; INFECTIONS; THIOPURINES AB The efficacy and safety of vedolizumab, a gut-selective alpha(4)beta(7) integrin antibody, were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18-80 years. We investigated the efficacy and safety of vedolizumab in patients stratified by age from the GEMINI trials. Safety and efficacy, including clinical response, clinical remission, and corticosteroid-free remission, at week 6 and/or 52 were determined post hoc in patients aged < 35, 35 to < 55, and ae55 years. At baseline, 353, 412, and 130 ulcerative colitis (UC) and 582, 443, and 90 Crohn's disease (CD) patients were aged < 35, 35 to < 55, and ae55. Of these patients, 56 were aged ae65 years (UC: 33, CD: 23). Trends favoring vedolizumab over placebo were observed for most efficacy endpoints irrespective of patient age; some variability between subgroups was observed. Safety profiles of vedolizumab and placebo were similar in all age groups. Vedolizumab-treated patients aged ae55 had the lowest incidence of serious infections (0.9 per 100 person-years) and adverse events leading to hospitalization (14.8 per 100 person-years). There were no age-related differences in the incidence of adverse hematological events, malignancy, or death. The safety and efficacy of vedolizumab in patients with UC or CD were similar for all age groups. The number of patients in the oldest age group in these analyses was small; thus further studies of vedolizumab in larger cohorts of elderly patients are warranted. Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International Co.). C1 [Yajnik, Vijay] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Khan, Nabeel] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Dubinsky, Marla] Mt Sinai Hosp, New York, NY 10029 USA. [Axler, Jeffrey] Univ Toronto, Toronto Digest Dis Associates, Toronto, ON, Canada. [James, Alexandra; Abhyankar, Brihad] Takeda Dev Ctr Europe Ltd, London, England. [Lasch, Karen] Takeda Pharmaceut USA Inc, Deerfield, IL USA. RP Yajnik, V (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. EM VYAJNIK@mgh.harvard.edu FU Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International Co.) FX Sponsorship, article processing charges, and the open access charge for this study were funded by Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International Co.). Medical writing assistance was provided by inVentiv Medical Communications and supported by Takeda Pharmaceuticals International Co. Publication management support was provided by Caterina Hatzifoti Ph.D. of Takeda Pharmaceuticals International. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, had full access to all of the data in this study, and take complete responsibility for the integrity of the data and accuracy of the data analysis. NR 31 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0741-238X EI 1865-8652 J9 ADV THER JI Adv. Ther. PD FEB PY 2017 VL 34 IS 2 BP 542 EP 559 DI 10.1007/s12325-016-0467-6 PG 18 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA EM6SV UT WOS:000395443300015 PM 28070861 ER PT J AU Rodriguez, HR Dobalian, A AF Rodriguez, Heather R. Dobalian, Aram TI PROVIDER AND ADMINISTRATOR EXPERIENCES WITH PROVIDING HIV TREATMENT AND PREVENTION SERVICES IN RURAL AREAS SO AIDS EDUCATION AND PREVENTION LA English DT Article ID MENTAL-HEALTH; UNITED-STATES; MEDICAL-CARE; DEEP SOUTH; INFECTED PERSONS; CASE-MANAGEMENT; ADULTS; INTERVENTION; FACILITATORS; PHYSICIANS AB Using Andersen's behavioral model of health services use, this study analyzes data from 62 semistructured interviews of providers and administrators at health clinics and social service agencies in rural Florida. Andersen's model addresses predisposing, enabling, and need factors that influence health services use. ATLASti was used to code all interviews and to extract HIV-related themes. The aim of this study was to: (1) add a new dimension to the literature on HIV care services in rural areas, (2) reveal factors that impact ability to provide care to PLWH in rural areas, and (3) suggest ways in which providers and administrators may address any unmet health care needs of PLWH. Respondents perceived systems factors to be more important determinants of access to care for individuals living with HIV and supported ongoing trainings that would increase staff understanding of the needs of people living with HIV. C1 [Rodriguez, Heather R.] Cent Connecticut State Univ, Dept Sociol, 1615 Stanley St,SSH 317-03, New Britain, CT 06050 USA. [Dobalian, Aram] US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, Washington, DC USA. [Dobalian, Aram] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA. RP Rodriguez, HR (reprint author), Cent Connecticut State Univ, Dept Sociol, 1615 Stanley St,SSH 317-03, New Britain, CT 06050 USA. EM hrodriguez@ccsu.edu FU Agency for Healthcare Research and Quality [U01HS14355]; Department of Veterans Affairs, Veterans Health Administration, Office of Patient Care Services FX This work was supported by grant U01HS14355 from the Agency for Healthcare Research and Quality. Dr Dobalian is supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Patient Care Services. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. government. NR 37 TC 0 Z9 0 U1 0 U2 0 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020 USA SN 0899-9546 EI 1943-2755 J9 AIDS EDUC PREV JI Aids Educ. Prev. PD FEB PY 2017 VL 29 IS 1 BP 77 EP 91 PG 15 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA EM3QP UT WOS:000395230000007 PM 28195782 ER PT J AU Haran, JP Wilsterman, E Zeoli, T Beaudoin, FL Tjia, J Hibberd, PL AF Haran, John P. Wilsterman, Eric Zeoli, Tyler Beaudoin, Francesca L. Tjia, Jennifer Hibberd, Patricia L. TI Elderly patients are at increased risk for treatment failure in outpatient management of purulent skin infections SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID RESISTANT STAPHYLOCOCCUS-AUREUS; COMMUNITY-ACQUIRED PNEUMONIA; SOFT-TISSUE INFECTIONS; ABSCESSES; VALIDATION; GUIDELINES; DIAGNOSIS; SEVERITY; OUTCOMES; PLACEBO AB Objective: Current Infectious Disease Society of America (IDSA) guidelines for the management of purulent skin or soft tissue infections do not account for patient age in treatment recommendations. The study objective was to determine if age was associated with outpatient treatment failure for purulent skin infection after adjusting for IDSA treatment guidelines. Methods: We conducted a multicenter retrospective study of adult patients treated for a purulent skin infection and discharged home from four emergency departments between April and September 2014. Patients were followed for one month to assess for treatment failure (defined as need for a change in antibiotics, surgical intervention, or hospitalization). We used multivariable logistic regression to examine the role of patient age on treatment failure adjusting for demographic variables (gender, race), comorbidities and severity of infection. Results: A total of 467 patients met inclusion criteria (mean age 37.9 years [SD 14.0], 48.2% of whom were women). Overall, 12.4% failed initial therapy. Patients 65 years and older (n = 35) were almost 4 times more likely to fail initial ED therapy in follow-up compared with younger patients (adjusted Odds Ratio (OR) 3.87, 95% Confidence Interval (CI) 1.24-12.10). After adjustment, for every 10 years of advancing age there was a 43% increased odds of failing initial treatment (OR 1.43 95% CI 1.09-1.88). Conclusion: Elderly patients with purulent skin infections, whose providers followed the 2014 IDSA guidelines, were more likely to fail initial treatment than younger patients. This study suggests that there is a need to re-evaluate treatment guidelines in elderly patients. (C) 2016 Elsevier Inc. All rights reserved. C1 [Haran, John P.; Wilsterman, Eric; Zeoli, Tyler] Univ Massachusetts, Sch Med, Dept Emergency Med, Worcester, MA USA. [Beaudoin, Francesca L.] Brown Univ, Alpert Sch Med, Dept Emergency Med, Providence, RI 02912 USA. [Tjia, Jennifer] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA. [Hibberd, Patricia L.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. [Hibberd, Patricia L.] Massachusetts Gen Hosp, Div Global Hlth, Boston, MA 02114 USA. RP Haran, JP (reprint author), 55 Lake Ave North, Worcester, MA 01655 USA. EM john.haran@umassmed.edu FU Department of Emergency Medicine; NIH [5K24AT003683-09] FX This study was designed and carried out at the University of Massachusetts Medical School and was supported by an intradepartmental grant through the Department of Emergency Medicine. PLH is supported by an NIH award 5K24AT003683-09. NR 25 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 EI 1532-8171 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD FEB PY 2017 VL 35 IS 2 BP 249 EP 254 DI 10.1016/j.ajem.2016.10.060 PG 6 WC Emergency Medicine SC Emergency Medicine GA EL9FE UT WOS:000394924600010 PM 27836315 ER PT J AU Pruitt, P Penn, J Peak, D Borczuk, P AF Pruitt, Peter Penn, Joshua Peak, David Borczuk, Pierre TI Identifying patients with mild traumatic intracranial hemorrhage at low risk of decompensation who are safe for ED observation SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article; Proceedings Paper CT National Annual Meeting of the Society-for-Academic-Emergency-Medicine CY MAY 12-15, 2015 CL San Diego, CA SP Soc Acad Emergency Med DE Traumatic intracranial hemorrhage; Subarachnoid hemorrhage; Subdural hematoma; Intraparenchymal hemorrhage; Observation medicine ID DEPARTMENT OBSERVATION UNIT; MINOR HEAD-INJURY; BRAIN-INJURY; SUBARACHNOID HEMORRHAGE; COMPUTED-TOMOGRAPHY; ADULT PATIENTS; MANAGEMENT; ADMISSION; PROTOCOL; CARE AB Background: Patients with traumatic intracranial hemorrhage and mild traumatic brain injury (mTIH) receive broadly variable care which often includes transfer to a trauma center, neurosurgery consultation and ICU admission. However, there may be a low risk cohort of patients who can be managed without utilizing such significant resources. Objective: Describe mTIH patients who are at low risk of clinical or radiographic decompensation and can be safely managed in an ED observation unit (EDOU). Methods: Retrospective evaluation of patients age >= 16, GCS >= 13 with ICH on CT. Primary outcomes included clinical/neurologic deterioration, CT worsening or need for neurosurgery. Results: 1185 consecutive patients were studied. 814 were admitted and 371 observed patients (OP) were monitored in the EDOU or discharged from the ED after a period of observation. None of the OP deteriorated clinically. 299 OP (81%) had a single lesion on CT; 72 had mixed lesions. 120 patients had isolated subarachnoid hemorrhage (iSAH) and they did uniformly well. Of the 119 OP who had subdural hematoma (SDH), 6 had worsening CT scans and 3 underwent burr hole drainage procedures as inpatients due to persistent SDH without new deficit. Of the 39 OP who had cerebral contusions, 3 had worsening CT scans and one required NSG admission. No patient returned to the ED with a complication. Follow-up was obtained on 81% of OP. 2 patients with SDH required burr hole procedure >2 weeks after discharge. Conclusions: Patients with mTIH, particularly those with iSAH, have very low rates of clinical or radiographic deterioration and may be safe for monitoring in an emergency department observation unit. (C) 2016 Elsevier Inc. All rights reserved. C1 [Pruitt, Peter] Northwestern Univ, Feinberg Sch Med, Dept Emergency Med, Chicago, IL USA. [Penn, Joshua] Winchester Hosp, Dept Emergency Med, Winchester, MA USA. [Peak, David; Borczuk, Pierre] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA. [Peak, David; Borczuk, Pierre] Harvard Med Sch, Boston, MA USA. RP Pruitt, P (reprint author), 211 East Ontario St,Suite 200, Chicago, IL 60611 USA. EM peter.pruitt@northwestern.edu FU Agency for Healthcare Research and Quality [(AHRQ)T[HYPHEN]32 HS 000078] FX Dr Pruitt is a National Research Service Award postdoctoral fellow supported by Agency for Healthcare Research and Quality (AHRQ)T[HYPHEN]32 HS 000078 (PI: Jane L. Holl, MD, MPH). AHRQ was not involved in the design or execution of this research. NR 18 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 EI 1532-8171 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD FEB PY 2017 VL 35 IS 2 BP 255 EP 259 DI 10.1016/j.ajem.2016.10.064 PG 5 WC Emergency Medicine SC Emergency Medicine GA EL9FE UT WOS:000394924600011 PM 27838043 ER PT J AU Beri, N Marston, NA Daniels, LB Nowak, RM Schreiber, D Mueller, C Jaffe, A Diercks, DB Wettersten, N DeFilippi, C Peacock, WF Limkakeng, AT Anand, I McCord, J Hollander, JE Wu, AHB Apple, FS Nagurney, JT Berardi, C Cannon, CM Clopton, P Neath, SX Christenson, RH Hogan, C Vilke, G Maisel, A AF Beri, Neil Marston, Nicholas A. Daniels, Lori B. Nowak, Richard M. Schreiber, Donald Mueller, Christian Jaffe, Allan Diercks, Deborah B. Wettersten, Nicholas DeFilippi, Christopher Peacock, W. Frank Limkakeng, Alexander T. Anand, Inder McCord, James Hollander, Judd E. Wu, Alan H. B. Apple, Fred S. Nagurney, John T. Berardi, Cecilia Cannon, Chad M. Clopton, Paul Neath, Sean-Xavier Christenson, Robert H. Hogan, Christopher Vilke, Gary Maisel, Alan TI Necessity of hospitalization and stress testing in low risk chest pain patients SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article DE Myocardial infarction; Hospitalization; Discharge; Stress testing; Copeptin ID ACUTE MYOCARDIAL-INFARCTION; ACUTE CORONARY SYNDROMES; CARDIAC TROPONIN-T; EMERGENCY-DEPARTMENT; RAPID RULE; INCREMENTAL VALUE; COPEPTIN AB Background: Copeptin is a marker of endogenous stress including early myocardial infarction(MI) and has value in early rule out of MI when used with cardiac troponin I(cTnl). Objectives: The goal of this study was to demonstrate that patients with a normal electrocardiogram and cTnl< 0.040 mu g/l and copeptin< 14 pmol/l at presentation and after 2 h may be candidates for early discharge with outpatient follow-up potentially including stress testing. Methods: This study uses data from the CHOPIN trial which enrolled 2071 patients with acute chest pain. Of those, 475 patients with normal electrocardiogram and normal cTnI(<0.040 mu g/l) and copeptin< 14 pmol/l at presentation and after 2 h were considered "low risk" and selected for further analysis. Results: None of the 475 "low risk" patients were diagnosed with MI during the 180 day follow-up period (including presentation). The negative predictive value of this strategy was 100% (95% confidence interval(CI):99.2%-100.0%). Furthermore no one died during follow up. 287 (60.4%) patients in the low risk group were hospitalized. In the "low risk" group, the only difference in outcomes (MI, death, revascularization, cardiac rehospitalization) was those hospitalized underwent revascularization more often (6.3%[95%CI:3.8%-9.7%] versus 0.5%[95%CI:0.0%-2.9%], p = .002). The hospitalized patients were tested significantly more via stress testing or angiogram (68.6%[95%CI:62.9%-74.0%] vs 22.9%[95%Cl:17.1%-29.6%], p < .001). Those tested had less cardiac rehospitalizations during follow-up (1.7% vs 5.1%, p = .040). Conclusions: In conclusion, patients with a normal electrocardiogram, troponin and copeptin at presentation and after 2 h are at low risk for MI and death over 180 days. These low risk patients may be candidates for early outpatient testing and cardiology follow-up thereby reducing hospitalization. (C) 2016 Elsevier Inc. All rights reserved. C1 [Beri, Neil; Marston, Nicholas A.] Univ Calif San Diego, Dept Internal Med, La Jolla, CA USA. [Daniels, Lori B.; Wettersten, Nicholas; Maisel, Alan] Univ Calif San Diego, Dept Internal Med, Div Cardiol, San Diego, CA USA. [Nowak, Richard M.] Henry Ford Hlth Syst, Dept Emergency Med, Detroit, MI USA. [Schreiber, Donald] Stanford Univ, Dept Emergency Med, Palo Alto, CA USA. [Mueller, Christian] Univ Basel Hosp, Dept Internal Med, Div Cardiol, Basel, Switzerland. [Jaffe, Allan] Mayo Clin, Dept Internal Med, Div Cardiol, Rochester, MN USA. [Diercks, Deborah B.] Univ Texas Southwestern, Dept Emergency Med, Dallas, TX USA. [DeFilippi, Christopher] Univ Maryland, Dept Internal Med, Div Cardiol, Baltimore, MD USA. [Peacock, W. Frank] Baylor Coll Med, Dept Emergency Med, Houston, TX USA. [Limkakeng, Alexander T.] Duke Univ, Dept Emergency Med, Durham, NC USA. [Anand, Inder] Vet Affairs Med Ctr, Dept Internal Med, Div Cardiol, Minneapolis, MN USA. [McCord, James] Henry Ford Hlth Syst, Dept Internal Med, Div Cardiol, Detroit, MI USA. [Hollander, Judd E.] Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA USA. [Wu, Alan H. B.] Univ Calif San Francisco, Dept Pathol & Lab Med, San Francisco, CA USA. [Apple, Fred S.] Univ Minnesota, Hennepin Cty Med Ctr, Dept Pathol, Minneapolis, MN USA. [Nagurney, John T.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA. [Berardi, Cecilia] Univ Roma La Sapienza, Sch Med, Rome, Italy. [Cannon, Chad M.] Univ Kansas, Dept Emergency Med, Kansas City, KS USA. [Clopton, Paul] Vet Affairs Med Ctr, Stat, San Diego, CA USA. [Neath, Sean-Xavier; Vilke, Gary] Univ Calif San Diego, Dept Emergency Med, La Jolla, CA USA. [Christenson, Robert H.] Univ Maryland, Dept Pathol, Baltimore, MD USA. [Hogan, Christopher] Virginia Commonwealth Univ, Dept Surg, Richmond, VA USA. RP Beri, N (reprint author), POB 3080, Laguna Hills, CA 92654 USA. EM neil.beri1@gmail.com NR 18 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 EI 1532-8171 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD FEB PY 2017 VL 35 IS 2 BP 274 EP 280 DI 10.1016/j.ajem.2016.10.072 PG 7 WC Emergency Medicine SC Emergency Medicine GA EL9FE UT WOS:000394924600014 PM 27847253 ER PT J AU Wu, CK Shlipak, MG Stawski, RS Peralta, CA Psaty, BM Harris, TB Satterfield, S Shiroma, EJ Newman, AB Odden, MC AF Wu, Chenkai Shlipak, Michael G. Stawski, Robert S. Peralta, Carmen A. Psaty, Bruce M. Harris, Tamara B. Satterfield, Suzanne Shiroma, Eric J. Newman, Anne B. Odden, Michelle C. CA Hlth ABC Study TI Visit-to-Visit Blood Pressure Variability and Mortality and Cardiovascular Outcomes Among Older Adults: The Health, Aging, and Body Composition Study SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE blood pressure; blood pressure variability; hypertension; mortality; stroke; myocardial infarction; aged ID ALL-CAUSE MORTALITY; CORONARY-HEART-DISEASE; LONG-TERM; PROGNOSTIC-SIGNIFICANCE; EPISODIC HYPERTENSION; MYOCARDIAL-INFARCTION; METAANALYSIS; ASSOCIATION; STROKE; RISK AB BACKGROUND Level of blood pressure (BP) is strongly associated with cardiovascular (CV) events and mortality. However, it is questionable whether mean BP can fully capture BP-related vascular risk. Increasing attention has been given to the value of visit-to-visit BP variability. METHODS We examined the association of visit-to-visit BP variability with mortality, incident myocardial infarction (MI), and incident stroke among 1,877 well-functioning elders in the Health, Aging, and Body Composition Study. We defined visit-to-visit diastolic BP (DBP) and systolic BP (SBP) variability as the root-mean-square error of person-specific linear regression of BP as a function of time. Alternatively, we counted the number of considerable BP increases and decreases (separately; 10 mm Hg for DBP and 20 mm Hg for SBP) between consecutive visits for each individual. RESULTS Over an average follow-up of 8.5 years, 623 deaths (207 from CV disease), 153 MIs, and 156 strokes occurred. The median visit-to-visit DBP and SBP variability was 4.96 mmHg and 8.53 mmHg, respectively. After multivariable adjustment, visit-to-visit DBP variability was related to higher all-cause (hazard ratio (HR) = 1.18 per 1 SD, 95% confidence interval (CI) = 1.01-1.37) and CV mortality (HR = 1.35, 95% CI = 1.051.73). Additionally, individuals having more considerable decreases of DBP (>= 10mm Hg between 2 consecutive visits) had higher risk of allcause (HR = 1.13, 95% CI = 0.99-1.28) and CV mortality (HR = 1.30, 95% CI = 1.05-1.61); considerable increases of SBP (>= 20 mm Hg) were associated with higher risk of all-cause (HR = 1.18, 95% CI = 1.03-1.36) and CV mortality (HR = 1.37, 95% CI = 1.08-1.74). CONCLUSIONS Visit-to-visit DBP variability and considerable changes in DBP and SBP were risk factors for mortality in the elderly. C1 [Wu, Chenkai; Odden, Michelle C.] Oregon State Univ, Sch Biol & Populat Hlth Sci, Corvallis, OR 97331 USA. [Shlipak, Michael G.; Peralta, Carmen A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.; Peralta, Carmen A.] San Francisco VA Med Ctr, Kidney Hlth Res Collaborat, Dept Med, San Francisco, CA USA. [Stawski, Robert S.] Oregon State Univ, Sch Social & Human Hlth Sci, Corvallis, OR 97331 USA. [Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA USA. [Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Harris, Tamara B.] NIA, Intramural Res Program, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA. [Satterfield, Suzanne] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA. [Shiroma, Eric J.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA USA. [Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. RP Wu, CK (reprint author), Oregon State Univ, Sch Biol & Populat Hlth Sci, Corvallis, OR 97331 USA. EM wuche@oregonstate.edu FU National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIA [R01-AG028050]; NINR [R01-NR012459]; Intramural Research Program of the NIH, National Institute on Aging; National Institute on Aging [K01AG039387, R01AG46206] FX The Health ABC Study was supported by National Institute on Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grant R01-AG028050, and NINR grant R01-NR012459, and in part by the Intramural Research Program of the NIH, National Institute on Aging. Additional support for this research was provided by National Institute on Aging (K01AG039387, R01AG46206). NR 33 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0895-7061 EI 1941-7225 J9 AM J HYPERTENS JI Am. J. Hypertens. PD FEB PY 2017 VL 30 IS 2 BP 151 EP 158 DI 10.1093/ajh/hpw106 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA EO9QV UT WOS:000397024100010 PM 27600581 ER PT J AU Doshi, JA Lim, R Li, PX Young, PP Lawnicki, VF Troxel, AB Volpp, KG AF Doshi, Jalpa A. Lim, Raymond Li, Pengxiang Young, Peinie P. Lawnicki, Victor F. Troxel, Andrea B. Volpp, Kevin G. TI Synchronized Prescription Refills and Medication Adherence: A Retrospective Claims Analysis SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID ORDER PHARMACY USE; PERSISTENCE; USERS AB OBJECTIVES: Medication adherence is often suboptimal, especially among patients on multiple chronic medications. We examined the association between synchronized medication refill schedules-which typically reduce organizational effort and logistical demands-and adherence. STUDY DESIGN: Retrospective study among patients enrolled in Medicare Advantage prescription drug plans. METHODS: We used 2012 pharmacy, medical, and enrollment data linked with consumer meta-data for Medicare patients filling 2 or more maintenance prescriptions for antihypertensives, lipid-lowering agents, antidiabetic agents, antidepressants, and/or antiosteoporotic agents. Medication adherence for the year was measured using the proportion of days covered (PDC) at the drug class level. Patients were deemed adherent if drug class PDC was = 0.80. Outcomes were compared between 1: 1 propensity score-matched patients on synchronized versus nonsynchronized refill schedules for maintenance medications. RESULTS: The synchronized refill group showed better adherence than the control group, although the magnitude of effects varied by drug class and specific outcome measure. Mean PDC scores ranged from 0.02 higher for antihypertensives to 0.07 higher for antidepressants in the synchronized refill group relative to the control group (P <. 01). Further, compared with the control group, a larger proportion of synchronized refill group members were deemed adherent, ranging from 6 percentage points higher for antihypertensives to 15 percentage points higher for lipid-lowering agents (P <. 01). Differences between the synchronized and control groups were larger among exclusive users of retail versus mail order pharmacies for maintenance medications. CONCLUSIONS: Synchronized medication refill schedules were associated with better medication adherence, particularly for patients filling maintenance medications exclusively at retail pharmacies. C1 [Doshi, Jalpa A.; Lim, Raymond; Li, Pengxiang; Volpp, Kevin G.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Lim, Raymond; Volpp, Kevin G.] Univ Penn, Dept Med Eth, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Doshi, Jalpa A.; Troxel, Andrea B.; Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Young, Peinie P.] Fuse Innovat Lab Cardinal Hlth, Dublin, OH USA. [Lawnicki, Victor F.] Humana Inc, Louisville, KY USA. [Troxel, Andrea B.] NYU, Dept Populat Hlth, New York, NY USA. [Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Doshi, JA (reprint author), Univ Penn, Med, 1223 Blockley Hall, Philadelphia, PA 19104 USA.; Doshi, JA (reprint author), Univ Penn, Ctr Evidence Based Practice, Econ Evaluat Unit, 1223 Blockley Hall, Philadelphia, PA 19104 USA.; Doshi, JA (reprint author), Univ Penn, Ctr Hlth Incent & Behav Econ, Value Based Insurance Design Initiat, 1223 Blockley Hall, Philadelphia, PA 19104 USA. EM jdoshi@mail.med.upenn.edu FU Humana, Inc. FX Humana, Inc. NR 18 TC 0 Z9 0 U1 0 U2 0 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD FEB PY 2017 VL 23 IS 2 BP 98 EP + PG 28 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EO0OJ UT WOS:000396397400008 PM 28245653 ER PT J AU Chen, JJ Wu, PT Middlekauff, HR Nguyen, KL AF Chen, Joseph J. Wu, Pei-Tzu Middlekauff, Holly R. Nguyen, Kim-Lien TI Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Review DE aerobic exercise; anthracyclines; cancer; cardiotoxicity ID SUBCLINICAL CARDIAC DYSFUNCTION; AMERICAN-HEART-ASSOCIATION; CHILDHOOD-CANCER SURVIVORS; DOX-INDUCED CARDIOTOXICITY; BREAST-CANCER; DOXORUBICIN CARDIOTOXICITY; PHYSICAL-ACTIVITY; SPORTS-MEDICINE; CARDIOVASCULAR EVENTS; INDUCED CARDIOMYOCYTE AB Cancer and cardiovascular disease are major causes of morbidity and mortality worldwide. Older cancer patients often wrestle with underlying heart disease during cancer therapy, whereas childhood cancer survivors are living long enough to face long-term unintended cardiac consequences of cancer therapies, including anthracyclines. Although effective and widely used, particularly in the pediatric population, anthracycline-related side effects including dose-dependent association with cardiac dysfunction limit their usage. Currently, there is only one United States Food and Drug Administration-approved drug, dexrazoxane, available for the prevention and mitigation of cardiotoxicity related to anthracycline therapy. While aerobic exercise has been shown to reduce cardiovascular complications in multiple diseases, its role as a therapeutic approach to mitigate cardiovascular consequences of cancer therapy is in its infancy. This systematic review aims to summarize how aerobic exercise can help to alleviate unintended cardiotoxic side effects and identify gaps in need of further research. While published work supports the benefits of aerobic exercise, additional clinical investigations are warranted to determine the effects of different exercise modalities, timing, and duration to identify optimal aerobic training regimens for reducing cardiovascular complications, particularly late cardiac effects, in cancer survivors exposed to anthracyclines. C1 [Chen, Joseph J.; Wu, Pei-Tzu; Middlekauff, Holly R.; Nguyen, Kim-Lien] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90024 USA. [Chen, Joseph J.; Wu, Pei-Tzu; Nguyen, Kim-Lien] Vet Affairs Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA USA. RP Nguyen, KL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,MC 111E, Los Angeles, CA 90024 USA. EM kimliennguyen@mednet.ucla.edu FU Jonsson Comprehensive Cancer Center Foundation; National Center for Advancing Translational Sciences Clinical and Translational Sciences Institute [UL1TR000124] FX This work was supported by a pilot grant from the Jonsson Comprehensive Cancer Center Foundation and National Center for Advancing Translational Sciences Clinical and Translational Sciences Institute grant UL1TR000124. NR 62 TC 0 Z9 0 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 EI 1522-1539 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD FEB PY 2017 VL 312 IS 2 BP H213 EP H222 DI 10.1152/ajpheart.00646.2016 PG 10 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA EN1VF UT WOS:000395797600003 PM 27923793 ER PT J AU Xia, Y Friedmann, P Bello, R Goldstein, D D'Alessandro, D AF Xia, Y. Friedmann, P. Bello, R. Goldstein, D. D'Alessandro, D. TI Does Lung Donation by Heart Donors Have an Impact on Survival in Heart Transplant Recipients? SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article ID FOCUS THEME RETRANSPLANTATION; INTERNATIONAL SOCIETY; MORTALITY PREDICTION; RISK INDEX; REGISTRY; REPORT-2014 AB Lung procurement is increasing during multiorgan recovery and substantially alters the explant process. This study evaluated whether lung donation by a heart donor affects survival in heart transplant recipients. Retrospective analysis of United Network for Organ Sharing (UNOS) adult heart transplantation data from 1998 to 2012 was performed. Lung donors (LDs) were defined as those having at least one lung procured and transplanted. Non-LDs had neither lung transplanted. Heart transplant recipients who had previous transplants, who had heterotopic transplants, who were waitlisted for other organs or who were temporarily delisted were excluded from the analysis. Kaplan-Meier survival analysis and Cox proportional hazards regression were performed. Of 23 590 heart transplant recipients meeting criteria during the study period, 8638 (36.6%) transplants were from LDs. Donors in the LD group had less history of cigarette use (15.5% vs. 29.5%, p < 0.001). On univariate analysis, LDs were associated with improved patient survival (p < 0.001). On multivariate analysis, LDs were not significantly associated with patient survival (adjusted hazard ratio 0.98, 95% confidence interval 0.94-1.03). Analysis of the UNOS registry suggested that donor pulmonary status and lung procurement had no detrimental effect on survival in heart transplant recipients, supporting the present practice of using donor lungs whenever possible. C1 [Xia, Y.; Friedmann, P.; Bello, R.; Goldstein, D.] Montefiore Med Ctr, Dept Cardiovasc & Thorac Surg, 111 E 210th St, Bronx, NY 10467 USA. [D'Alessandro, D.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP D'Alessandro, D (reprint author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. EM dadalessandro@mgh.harvard.edu FU Health Resources and Services Administration [234-2005-370011C] FX We thank the United Network for Organ Sharing for access to donor and recipient data. This work was supported in part by Health Resources and Services Administration contract 234-2005-370011C. NR 13 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD FEB PY 2017 VL 17 IS 2 BP 506 EP 511 DI 10.1111/ajt.13981 PG 6 WC Surgery; Transplantation SC Surgery; Transplantation GA EP5KU UT WOS:000397418300024 PM 27457355 ER PT J AU Wood, GJA Hayden, RP Tanrikut, C AF Wood, G. J. A. Hayden, R. P. Tanrikut, C. TI Successful sperm extraction and live birth after radiation, androgen deprivation and surgical castration for treatment of metastatic prostate cancer SO ANDROLOGIA LA English DT Article DE Fertility preservation; IVF-ICSI; metastatic prostate cancer; radiotherapy; sperm extraction ID FERTILITY PRESERVATION; TESTICULAR HISTOLOGY; SEMEN PARAMETERS; MEN; HORMONE; AGONIST; ISSUES; TESTIS AB Fertility preservation has become an important aspect of cancer treatment given the gonadotoxic effects of oncologic therapies. It is now considered standard of care to offer sperm banking to men undergoing treatment for primaries that affect young individuals. Less is known regarding fertility preservation of patients afflicted with prostate cancer. This cohort has progressively expanded and grown younger in the post-PSA era. Prostatectomy, radiation, chemotherapy and androgen blockade all pose unique challenges to the infertility specialist. Optimum management becomes even more uncertain for those men with metastatic prostate cancer. Most of these individuals will have received multiple forms of therapy, each carrying a distinct insult to the patient's reproductive potential. We describe a case of successful ex vivo sperm extraction and live birth in a patient previously treated with radiation and chronic androgen deprivation for metastatic prostate cancer. The presented case demonstrates that conception after radiation therapy and chronic androgen deprivation is feasible. We propose that fertility counselling and sperm cryopreservation should be considered for all prostate cancer patients. Additionally, for those individuals undergoing external beam radiotherapy, testicular shielding should be routinely offered in the event further family building is desired. C1 [Hayden, R. P.; Tanrikut, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wood, G. J. A.] Univ Sao Paulo, Sch Med, Hosp Clin, Sao Paulo, Brazil. RP Tanrikut, C (reprint author), MGH Fertil Ctr, 55 Fruit St,YAW-10A, Boston, MA 02114 USA. EM ctanrikut@mgh.harvard.edu NR 22 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0303-4569 EI 1439-0272 J9 ANDROLOGIA JI Andrologia PD FEB PY 2017 VL 49 IS 1 AR e12578 DI 10.1111/and.12578 PG 5 WC Andrology SC Endocrinology & Metabolism GA EL3VL UT WOS:000394547300017 ER PT J AU Stone, RM Garcia, J AF Stone, Richard M. Garcia, Jacqueline TI FLT3 Inhibitors in Mutant FLT3 AML SO ANNALS OF HEMATOLOGY LA English DT Meeting Abstract ID ACUTE MYELOID-LEUKEMIA; NORMAL CYTOGENETICS C1 [Stone, Richard M.; Garcia, Jacqueline] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,D2053, Boston, MA 02215 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0939-5555 EI 1432-0584 J9 ANN HEMATOL JI Ann. Hematol. PD FEB PY 2017 VL 96 SU 1 BP S36 EP S37 PG 2 WC Hematology SC Hematology GA EK7KT UT WOS:000394105400030 ER PT J AU Walter, RB Fathi, AT AF Walter, Roland B. Fathi, Amir T. CA SGN33A-001 Study Team TI Vadastuximab Talirine (33a) plus a Hypomethylating Agent (HMA): A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML) SO ANNALS OF HEMATOLOGY LA English DT Meeting Abstract C1 [Walter, Roland B.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Fathi, Amir T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. FU Seattle Genetics Inc. [SGN33A-002] FX Some members of the SGN33A-002 Team are employees of Seattle Genetics Inc., Investigators have received trial funding support. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0939-5555 EI 1432-0584 J9 ANN HEMATOL JI Ann. Hematol. PD FEB PY 2017 VL 96 SU 1 MA 96 BP S85 EP S85 PG 1 WC Hematology SC Hematology GA EK7KT UT WOS:000394105400139 ER PT J AU Pagani-Estevez, GL Swetz, KM McGoon, MD Frantz, RP Tointon, SK Karnyski, AM Durst, LA Watson, JC AF Pagani-Estevez, Gabriel L. Swetz, Keith M. McGoon, Michael D. Frantz, Robert P. Tointon, Susan K. Karnyski, Ann M. Durst, Louise A. Watson, James C. TI Characterization of Prostacyclin-associated Leg Pain in Patients with Pulmonary Arterial Hypertension SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Prostacyclinassociated leg pain is a potentially debilitating adverse effect of prostacyclin therapy for patients with pulmonary arterial hypertension (PAH). However, to our knowledge, this entity has not been systematically studied. Objectives: To characterize the clinical features and metabolic risk factors for prostacyclinassociated leg pain. Methods: At one academic medical center, we assembled and analyzed a case series of patients with PAH and prostacyclin-associated leg pain. Measurements and Main Results: Over a period of 2 years, we identified 11 patients with PAH and prostacyclinassociated leg pain who agreed to participate in this study. Subjects underwent a standardized clinical evaluation, electrodiagnostic assessment, and serologic screen for metabolic causes of peripheral neuropathy. All 11 patients were female; their mean (SD) age was 50 (+/- 9) years; their median (interquartile range) PAH duration was 56 (20-96) months; and their prostacyclin therapy duration was a median (interquartile range) of 20 (14-36) months. All patients reported leg pain beginning soon after prostacyclin initiation and varying with dose. All described a neuropathic pain in a symmetric, distal, stocking distribution. Neurologic examination revealed a sensory, small-fiber, predominantly peripheral neuropathy in seven (78%) patients. Results of autonomic reflex testing and thermoregulatory sweat testing were abnormal in 82% and 90% of patients, respectively, suggesting smallfiber neuropathy. Serologic evaluation identified a new, previously unrecognized contributor to neuropathy in eight (73%) patients, including vitamin B-12 deficiency in six (55%), uncompensated hypothyroidism in three (27%), and diabetes mellitus in one (9%). Conclusions: Chronic prostacyclin-associated leg pain is associated with a small-fiber neuropathy. Treatable metabolic contributors (vitamin B12 deficiency, thyroid dysfunction, or diabetes) appear to be common possible "second hits" that may be underrecognized. We recommend screening for possible metabolic contributors in patients who have otherwise unexplained leg pain in the setting of PAH and current or anticipated prostacyclin therapy. C1 [Pagani-Estevez, Gabriel L.; Watson, James C.] Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA. [McGoon, Michael D.; Frantz, Robert P.; Tointon, Susan K.; Karnyski, Ann M.] Mayo Clin, Dept Med, Cardiovasc Div, Rochester, MN USA. [Watson, James C.] Mayo Clin, Pain Div, Dept Anesthesiol, Rochester, MN USA. [Swetz, Keith M.] Univ Alabama Birmingham, Sch Med, Ctr Palliat & Support Care, Birmingham, AL USA. [Swetz, Keith M.; Durst, Louise A.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Watson, JC (reprint author), Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA. EM watson.james@mayo.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD FEB PY 2017 VL 14 IS 2 BP 206 EP 212 DI 10.1513/AnnalsATS.201609-674OC PG 7 WC Respiratory System SC Respiratory System GA EP5OK UT WOS:000397428000011 PM 27898216 ER PT J AU Parsons, EC Mattox, EA Beste, LA Au, DH Young, BA Chang, MF Palen, BN AF Parsons, Elizabeth C. Mattox, Elizabeth A. Beste, Lauren A. Au, David H. Young, Bessie A. Chang, Michael F. Palen, Brian N. TI Development of a Sleep Telementorship Program for Rural Department of Veterans Affairs Primary Care Providers: Sleep Veterans Affairs Extension for Community Healthcare Outcomes SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Primary care providers (PCPs) frequently encounter sleep complaints, especially in regions with limited specialty care access. Objectives: The U.S. Department of Veterans Affairs Extension for Community Healthcare Outcomes (VA-ECHO) program (based on Project ECHO) has successfully provided rural PCP education in subspecialty areas, including hepatitis C. Wedescribe the feasibility of an ECHO program for sleep medicine. Methods: ECHO creates a virtual learning community through video-teleconferencing, combining didactics with individualized clinical case review. We invited multidisciplinary providers to attend up to 10 stand-alone, 1-hour sessions. Invitees completed a needs assessment, which guided curriculum development. After program completion, we examined participant characteristics and self-reported changes in practice and comfort with managing sleep complaints. We surveyed participation barriers among invitees with low/no attendance. Measurements and Main Results: Of the 39 program participants, 38% worked in rural healthcare. Participants included nurse practitioners (26%), registered nurses (21%), and physicians (15%). Seventeen (44%) completed the summative program evaluation. Respondents anticipated practice change from the program, especially in patient education about sleep disorders (93% of respondents). Respondents reported improved comfort managing sleep complaints, especially sleep-disordered breathing, insomnia, and sleep in post-traumatic stress disorder (80% of respondents each). A follow-up survey of program invitees who attended zero to two sessions reported scheduling conflicts (62%) and lack of protected time (52%) as major participation barriers. Conclusions: Participants in a pilot sleep medicine VA-ECHO program report practice change and increased comfort managing common sleep complaints. Future work is needed to identify objective measures of return on investment and address participation barriers. C1 [Parsons, Elizabeth C.; Mattox, Elizabeth A.; Au, David H.; Palen, Brian N.] Vet Affairs Puget Sound Hlth Care Syst, Pulm & Crit Care Sect, Seattle, WA USA. [Young, Bessie A.] Vet Affairs Puget Sound Hlth Care Syst, Nephrol Sect, Hosp & Specialty Med, Seattle, WA USA. [Beste, Lauren A.] Vet Affairs Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA USA. [Beste, Lauren A.; Au, David H.; Young, Bessie A.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Innovat, Seattle, WA USA. [Parsons, Elizabeth C.; Au, David H.; Palen, Brian N.] Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA. [Beste, Lauren A.] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA. [Young, Bessie A.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Young, Bessie A.] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Chang, Michael F.] Vet Affairs Portland Hlth Care Syst, Gastroenterol & Hepatol Serv, Portland, OR USA. [Chang, Michael F.] Oregon Hlth & Sci Univ, Div Gastroenterol & Hepatol, Portland, OR 97201 USA. RP Parsons, EC (reprint author), 1660 South Columbian Way,S-111 PULM, Seattle, WA 98108 USA. EM elizabeth.parsons@va.gov FU U.S. Department of Veterans Affairs' (VA) Veterans Health Administration Office of Patient Care Services, Specialty Care Services program office; VA Office of Rural Health; VA Northwest Health Network (VISN 20); VA Portland Health Care System (Portland, OR); Boise VA Medical Center (Boise, ID) FX Supported in part through funding by the U.S. Department of Veterans Affairs' (VA) Veterans Health Administration Office of Patient Care Services, Specialty Care Services program office, the VA Office of Rural Health, and the VA Northwest Health Network (VISN 20). This material is the result of work supported with resources and use of the facilities at the VA Puget Sound Health Care System (Seattle, WA), the VA Portland Health Care System (Portland, OR), and Boise VA Medical Center (Boise, ID). NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD FEB PY 2017 VL 14 IS 2 BP 267 EP 274 DI 10.1513/AnnalsATS.201605-361BC PG 8 WC Respiratory System SC Respiratory System GA EP5OK UT WOS:000397428000019 PM 27977293 ER PT J AU Ovsiowitz, RS Pangarkar, S AF Ovsiowitz, Rebecca S. Pangarkar, Sanjog TI Morel-Lavalle lesion SO APPLIED RADIOLOGY LA English DT Editorial Material C1 [Ovsiowitz, Rebecca S.; Pangarkar, Sanjog] Greater Los Angeles VA Med Ctr, Inpatient Pain Serv, Los Angeles, CA 90073 USA. [Ovsiowitz, Rebecca S.; Pangarkar, Sanjog] Univ Calif Los Angeles, David Geffen Sch Med, Med, Los Angeles, CA 90095 USA. RP Ovsiowitz, RS (reprint author), Greater Los Angeles VA Med Ctr, Inpatient Pain Serv, Los Angeles, CA 90073 USA.; Ovsiowitz, RS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Med, Los Angeles, CA 90095 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU ANDERSON PUBLISHING, INC PI SCOTCH PLAINS PA 180 GLENSIDE AVE, SCOTCH PLAINS, NJ 07076 USA SN 0160-9963 EI 1879-2898 J9 APPL RADIOL JI Appl. Radiol. PD FEB PY 2017 VL 46 IS 2 BP 38 EP 39 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EP4HA UT WOS:000397340400006 ER PT J AU Durand, ML Ennis, SC Baker, JN Camuso, JM McEachern, KM Kotton, CN Lewis, GD Garcia, JP MacGillivray, TE AF Durand, Marlene L. Ennis, Stephanie C. Baker, Joshua N. Camuso, Janice M. McEachern, Kathleen M. Kotton, Camille N. Lewis, Gregory D. Garcia, Jose P. MacGillivray, Thomas E. TI Topical Polymyxin-Trimethoprim Prophylaxis May Decrease the Incidence of Driveline Infections in Patients With Continuous-Flow Left Ventricular Assist Devices SO ARTIFICIAL ORGANS LA English DT Article DE Left ventricular assist device; Driveline infection; Chronic antibiotic suppression; Topical antibiotics ID EXIT-SITE INFECTION; BOSTON KERATOPROSTHESIS; DESTINATION THERAPY; CLINICAL-OUTCOMES; PREVENTION; EXPERIENCE; TRANSPLANTATION; ENDOPHTHALMITIS; IMPLANTATION; REGISTRY AB This retrospective cohort study evaluated the effect of topical polymyxin-trimethoprim (poly) prophylaxis on the incidence of driveline infections (DLIs) in patients with continuous-flow left ventricular assist devices. All 84 cases implanted 2005-2014 with device support >= 30 days were reviewed; support ranged 1 m-5.2 yrs. Beginning 2008, poly was applied to the exit site with dressing changes. Sixty-five patients received poly (poly group) for duration of follow-up, 19 did not (no-poly); group baseline characteristics were similar. No patient developed side effects from poly. Nineteen DLIs (10 in no-poly) occurred; not using poly was a risk factor. 89% of poly group DLIs were superficial, 4 were culture-negative. DLI-related bacteremia occurred in 11% of no-poly group and 0% of poly group. Compared with no-poly, poly group demonstrated improved freedom from DLI by Kaplan-Meier analysis (P < 0.0001) and a 75% lower overall and 95% lower deep DLI incidence (P <= 0.001). Deep DLIs occurred in 31.6% of no-poly vs. 1.5% of poly patients (P = 0.0004), although mean support duration (1 yr) and % support >1 yr (38%) were similar. These findings, which should be confirmed with larger comparative studies, suggest that topical polymyxintrimethoprim prophylaxis may be effective in preventing DLIs. C1 [Durand, Marlene L.; Kotton, Camille N.] Massachusetts Gen Hosp, Dept Med, Infect Dis Unit, Boston, MA 02114 USA. [Ennis, Stephanie C.; Camuso, Janice M.; McEachern, Kathleen M.; Garcia, Jose P.; MacGillivray, Thomas E.] Massachusetts Gen Hosp, Dept Cardiac Surg, Boston, MA 02114 USA. [Lewis, Gregory D.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. [Baker, Joshua N.] Missouri Baptist Med Ctr, Dept Cardiothorac Surg, St Louis, MO USA. RP Durand, ML (reprint author), Massachusetts Gen Hosp, Infect Dis Associates, 55 Fruit St, Boston, MA 02114 USA. EM mdurand@partners.org NR 29 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0160-564X EI 1525-1594 J9 ARTIF ORGANS JI Artif. Organs PD FEB PY 2017 VL 41 IS 2 BP 169 EP 175 DI 10.1111/aor.12726 PG 7 WC Engineering, Biomedical; Transplantation SC Engineering; Transplantation GA EL1KA UT WOS:000394378000009 PM 27098102 ER PT J AU Ghilain, CS Parlade, MV McBee, MT Coman, DC Owen, T Gutierrez, A Boyd, B Odom, S Alessandri, M AF Ghilain, Christine S. Parlade, Meaghan V. McBee, Matthew T. Coman, Drew C. Owen, Taylor Gutierrez, Anibal Boyd, Brian Odom, Samuel Alessandri, Michael TI Validation of the Pictorial Infant Communication Scale for preschool-aged children with autism spectrum disorder SO AUTISM LA English DT Article DE autism spectrum disorder; communication; coordinated joint attention; measurement; parent report ID PERVASIVE DEVELOPMENTAL DISORDERS; EARLY LANGUAGE-ACQUISITION; JOINT ATTENTION SKILL; YOUNG-CHILDREN; NONVERBAL-COMMUNICATION; SOCIAL COMMUNICATION; DOWN-SYNDROME; PLAY; DEFICITS; INTERVENTIONS AB Joint attention, or the shared focus of attention between objects or events and a social partner, is a crucial milestone in the development of social communication and a notable area of deficit in children with autism spectrum disorder. While valid parent-report screening measures of social communication are available, the majority of these measures are designed to assess a wide range of behaviors. Targeted assessment of joint attention and related skills is primarily limited to semi-structured, examiner-led interactions, which are time-consuming and laborious to score. The Pictorial Infant Communication Scale is an efficient parent-report measure of joint attention that can be used as a complement to structured assessments in fully characterizing early social communication development. This study examined the psychometric properties of the Pictorial Infant Communication Scale. Results revealed a high degree of internal consistency and strong intercorrelations between subscales. Additionally, confirmatory factor analysis supported a three-factor model of joint attention. Furthermore, significant correlations between the Pictorial Infant Communication Scale and direct clinical measures of child joint attention, language skills, and autism spectrum disorder symptom severity were suggestive of concurrent validity. Findings suggest that the Pictorial Infant Communication Scale is a promising tool for measuring joint attention skills in preschool-aged children with autism spectrum disorder. C1 [Ghilain, Christine S.; Parlade, Meaghan V.; Owen, Taylor; Gutierrez, Anibal; Alessandri, Michael] Univ Miami, Coral Gables, FL 33124 USA. [Ghilain, Christine S.] Emory Univ, Sch Med, 1547 Clifton Rd NE, Atlanta, GA 30322 USA. [McBee, Matthew T.] East Tennessee State Univ, Johnson City, TN USA. [Coman, Drew C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Boyd, Brian; Odom, Samuel] Univ N Carolina, Chapel Hill, NC USA. RP Ghilain, CS (reprint author), Emory Univ, Sch Med, 1547 Clifton Rd NE, Atlanta, GA 30322 USA. EM Christine.ghilain@choa.org FU Institute of Education Sciences, US Department of Education [R324B070219] FX The research reported here was supported by the Institute of Education Sciences, US Department of Education through Grant R324B070219 awarded to UNC-Chapel Hill. NR 73 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1362-3613 EI 1461-7005 J9 AUTISM JI Autism PD FEB PY 2017 VL 21 IS 2 BP 203 EP 216 DI 10.1177/1362361316636757 PG 14 WC Psychology, Developmental SC Psychology GA EL7GX UT WOS:000394790200008 PM 27132009 ER PT J AU Ferguson, BJ Marler, S Altstein, LL Lee, EB Akers, J Sohl, K McLaughlin, A Hartnett, K Kille, B Mazurek, M Macklin, EA McDonnell, E Barstow, M Bauman, ML Margolis, KG Veenstra-VanderWeele, J Beversdorf, DQ AF Ferguson, Bradley J. Marler, Sarah Altstein, Lily L. Lee, Evon Batey Akers, Jill Sohl, Kristin McLaughlin, Aaron Hartnett, Kaitlyn Kille, Briana Mazurek, Micah Macklin, Eric A. McDonnell, Erin Barstow, Mariah Bauman, Margaret L. Margolis, Kara Gross Veenstra-VanderWeele, Jeremy Beversdorf, David Q. TI Psychophysiological Associations with Gastrointestinal Symptomatology in Autism Spectrum Disorder SO AUTISM RESEARCH LA English DT Article DE autism spectrum disorder; gastrointestinal; autonomic nervous system; sympathetic; parasympathetic; anxiety; constipation ID HEART-RATE-VARIABILITY; IRRITABLE-BOWEL-SYNDROME; BRAIN-GUT AXIS; GENERALIZED ANXIETY DISORDER; SENSORY OVER-RESPONSIVITY; CHILDREN; SYMPTOMS; HEALTH; METAANALYSIS; DISEASE AB Autism spectrum disorder (ASD) is often accompanied by gastrointestinal disturbances, which also may impact behavior. Alterations in autonomic nervous system functioning are also frequently observed in ASD. The relationship between these findings in ASD is not known. We examined the relationship between gastrointestinal symptomatology, examining upper and lower gastrointestinal tract symptomatology separately, and autonomic nervous system functioning, as assessed by heart rate variability and skin conductance level, in a sample of 120 individuals with ASD. Relationships with co-occurring medical and psychiatric symptoms were also examined. While the number of participants with significant upper gastrointestinal tract problems was small in this sample, 42.5% of participants met criteria for functional constipation, a disorder of the lower gastrointestinal tract. Heart rate variability, a measure of parasympathetic modulation of cardiac activity, was found to be positively associated with lower gastrointestinal tract symptomatology at baseline. This relationship was particularly strong for participants with co-occurring diagnoses of anxiety disorder and for those with a history of regressive ASD or loss of previously acquired skills. These findings suggest that autonomic function and gastrointestinal problems are intertwined in children with ASD; although it is not possible to assess causality in this data set. Future work should examine the impact of treatment of gastrointestinal problems on autonomic function and anxiety, as well as the impact of anxiety treatment on gastrointestinal problems. Clinicians should be aware that gastrointestinal problems, anxiety, and autonomic dysfunction may cluster in children with ASD and should be addressed in a multidisciplinary treatment plan. Autism Res2017, 10: 276-288. (c) 2016 International Society for Autism Research, Wiley Periodicals, Inc. C1 [Ferguson, Bradley J.; Beversdorf, David Q.] Univ Missouri, Interdisciplinary Neurosci Program, Columbia, MO 65211 USA. [Marler, Sarah] Vanderbilt Univ, Med Ctr, Dept Child & Adolescent Psychiat, Nashville, TN USA. [Altstein, Lily L.; Macklin, Eric A.; McDonnell, Erin; Barstow, Mariah] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA. [Lee, Evon Batey] Vanderbilt Univ, Dept Pediat, Nashville, TN USA. [Lee, Evon Batey] Vanderbilt Univ, Dept Psychiat & Psychol, Nashville, TN USA. [Ferguson, Bradley J.; Akers, Jill; Sohl, Kristin; Mazurek, Micah; Beversdorf, David Q.] Univ Missouri, Thompson Ctr Autism & Neurodev Disorder, Columbia, MO 65211 USA. [Sohl, Kristin] Univ Missouri, Dept Child Hlth, Columbia, MO 65211 USA. [McLaughlin, Aaron] Univ Missouri, Sch Med, Columbia, MO 65211 USA. [Hartnett, Kaitlyn] Univ Missouri, Coll Arts & Sci, Columbia, MO 65211 USA. [Kille, Briana] Univ Missouri, Dept Psychol Sci, Columbia, MO 65211 USA. [Mazurek, Micah] Univ Missouri, Dept Hlth Psychol, Columbia, MO 65211 USA. [Macklin, Eric A.] Harvard Med Sch, Boston, MA USA. [Bauman, Margaret L.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Margolis, Kara Gross] Columbia Univ, Dept Pediat, Div Pediat Gastroenterol Hepatol & Nutr, New York, NY 10027 USA. [Veenstra-VanderWeele, Jeremy] Columbia Univ, Dept Psychiat, New York, NY 10027 USA. [Veenstra-VanderWeele, Jeremy] Columbia Univ, Sackler Inst Dev Psychobiol, New York, NY 10027 USA. [Veenstra-VanderWeele, Jeremy] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Veenstra-VanderWeele, Jeremy] New York Presbyterian Hosp Ctr Autism & Developin, New York, NY 10032 USA. [Beversdorf, David Q.] Univ Missouri, William & Nancy Thompson Chair Radiol, Dept Radiol Neurol & Psychol Sci, Columbia, MO 65211 USA. RP Beversdorf, DQ (reprint author), Univ Missouri, Dept Radiol, DC 069-10,One Hosp Dr, Columbia, MO 65212 USA. EM beversdorfd@health.mssouri.edu FU Health Resources Services Administration (HRSA) [UA3MC11054]; Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) [UA3 MC11054] FX This research was supported by a grant given to the Autism Treatment Network, Autism Intervention Research Network on Physical Health by the Health Resources Services Administration (HRSA Grant# UA3MC11054). We would like to sincerely thank the participants, their families, and all study team members for their time and efforts associated with this study. This project was supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under cooperative agreement UA3 MC11054 - Autism Intervention Research Network on Physical Health. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government. This work was conducted through the Autism Speaks Autism Treatment Network serving as the Autism Intervention Research Network on Physical Health. NR 66 TC 1 Z9 1 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1939-3792 EI 1939-3806 J9 AUTISM RES JI Autism Res. PD FEB PY 2017 VL 10 IS 2 BP 276 EP 288 DI 10.1002/aur.1646 PG 13 WC Behavioral Sciences; Psychology, Developmental SC Behavioral Sciences; Psychology GA EM9QH UT WOS:000395645700008 PM 27321113 ER PT J AU Mattoo, H Stone, JH Pillai, S AF Mattoo, Hamid Stone, John H. Pillai, Shiv TI Clonally expanded cytotoxic CD4(+) T cells and the pathogenesis of IgG4-related disease SO AUTOIMMUNITY LA English DT Review DE IgG4-RD; CD4(+) CTL; fibrosis; lymphoplasmacytic infiltrate ID REGULATORY IMMUNE-REACTIONS; GRASS-POLLEN IMMUNOTHERAPY; B-CELLS; SCLEROSING PANCREATITIS; RHEUMATOID-ARTHRITIS; AUTOIMMUNE-DISEASE; PULMONARY-FIBROSIS; SYSTEMIC-DISEASE; IGG4 PRODUCTION; IFN-GAMMA AB IgG4-related disease (IgG4-RD) is a systemic condition of unknown cause characterized by highly fibrotic lesions, with dense lymphoplasmacytic infiltrates containing a preponderance of IgG4-expressing plasma cells. CD4(+) T cells and B cells constitute the major inflammatory cell populations in IgG4-RD lesions. IgG4-RD patients with active, untreated disease show a marked expansion of plasmablasts in the circulation. Although the therapeutic depletion of B cells suggests a role for these cells in the disease, a direct role for B cells or IgG4 in the pathogenesis of IgG4-RD is yet to be demonstrated. Among the CD4(+) T-cell subsets, Th2 cells were initially thought to contribute to IgG4-RD pathogenesis, but many previous studies were confounded by the concomitant history of allergic diseases in the patients studied and the failure to use multi-color staining to definitively identify T-cell subsets in tissue samples. More recently, using an unbiased approach to characterize CD4(+) T-cell subsets in patients with IgG4-RD - based on their clonal expansion and ability to infiltrate affected tissue sites - CD4(+) CTLs have been identified as the major CD4(+) T-cell subset in disease lesions as well as in the circulation. CD4(+) CTLs in affected tissues secrete pro-fibrotic cytokines including IL-1, TGF-1, and IFN- as well as cytolytic molecules such as perforin and granzymes A and B. In this review, we examine possible mechanisms by which activated B cells and plasmablasts may collaborate with the expanded CD4(+) CTLs in driving the fibrotic pathology of the disease and describe the lacunae in the field and in our understanding of IgG4-RD pathogenesis. C1 [Mattoo, Hamid; Stone, John H.; Pillai, Shiv] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. RP Pillai, S (reprint author), Ragon Inst MGH MIT & Harvard, 400 Tech Sq, Cambridge, MA 02139 USA. EM pillai@helix.mgh.harvard.edu FU Autoimmune Center of Excellence Award from the National Institutes of Health [U19 AI 110495] FX The authors declare that they have no relevant conflicts of interest. This work was supported by an Autoimmune Center of Excellence Award to SP from the National Institutes of Health [U19 AI 110495]. NR 63 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0891-6934 EI 1607-842X J9 AUTOIMMUNITY JI Autoimmunity PD FEB PY 2017 VL 50 IS 1 BP 19 EP 24 DI 10.1080/08916934.2017.1280029 PG 6 WC Immunology SC Immunology GA EM1YB UT WOS:000395112100003 PM 28166682 ER PT J AU Lyttle, DN Gill, JP Shaw, KM Thomas, PJ Chiel, HJ AF Lyttle, David N. Gill, Jeffrey P. Shaw, Kendrick M. Thomas, Peter J. Chiel, Hillel J. TI Robustness, flexibility, and sensitivity in a multifunctional motor control model SO BIOLOGICAL CYBERNETICS LA English DT Article DE Adaptive behavior; Aplysia; Central pattern generator; Sensory feedback; Heteroclinic channel; Limit cycle; Multistability ID CENTRAL PATTERN GENERATOR; APLYSIA-CALIFORNICA; MATHEMATICAL-MODEL; FEEDBACK-CONTROL; WINNERLESS COMPETITION; NEURONAL-ACTIVITY; FEEDING-BEHAVIOR; RETRACTOR MUSCLE; NERVOUS-SYSTEM; BUCCAL MASS AB Motor systems must adapt to perturbations and changing conditions both within and outside the body. We refer to the ability of a system to maintain performance despite perturbations as "robustness," and the ability of a system to deploy alternative strategies that improve fitness as "flexibility." Different classes of pattern-generating circuits yield dynamics with differential sensitivities to perturbations and parameter variation. Depending on the task and the type of perturbation, high sensitivity can either facilitate or hinder robustness and flexibility. Here we explore the role of multiple coexisting oscillatory modes and sensory feedback in allowing multiphasic motor pattern generation to be both robust and flexible. As a concrete example, we focus on a nominal neuromechanical model of triphasic motor patterns in the feeding apparatus of the marine mollusk Aplysia californica. We find that the model can operate within two distinct oscillatory modes and that the system exhibits bistability between the two. In the "heteroclinic mode," higher sensitivity makes the system more robust to changing mechanical loads, but less robust to internal parameter variations. In the "limit cycle mode," lower sensitivity makes the system more robust to changes in internal parameter values, but less robust to changes in mechanical load. Finally, we show that overall performance on a variable feeding task is improved when the system can flexibly transition between oscillatory modes in response to the changing demands of the task. Thus, our results suggest that the interplay of sensory feedback and multiple oscillatory modes can allow motor systems to be both robust and flexible in a variable environment. C1 [Lyttle, David N.] Case Western Reserve Univ, Dept Math & Biol, 10900 Euclid Ave, Cleveland, OH 44106 USA. [Gill, Jeffrey P.] Case Western Reserve Univ, Dept Biol, 10900 Euclid Ave, Cleveland, OH 44106 USA. [Shaw, Kendrick M.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Thomas, Peter J.] Case Western Reserve Univ, Dept Math Appl Math & Stat, 10900 Euclid Ave, Cleveland, OH 44106 USA. [Chiel, Hillel J.] Case Western Reserve Univ, Dept Biol Neurosci & Biomed Engn, 10900 Euclid Ave, Cleveland, OH 44106 USA. RP Lyttle, DN (reprint author), Case Western Reserve Univ, Dept Math & Biol, 10900 Euclid Ave, Cleveland, OH 44106 USA. EM dnlyttle@gmail.com FU Simons Foundation [259837]; Council for the International Exchange of Scholars; NSF [DMS-1413770, DMS-1010434, IIS-1065489]; NSF Postdoctoral Fellowship [1309380] FX This work was partially supported by a Grant from the Simons Foundation (259837 to Peter Thomas), by the Council for the International Exchange of Scholars, and by NSF Grants DMS-1413770, DMS-1010434, and IIS-1065489. David Lyttle was supported by an NSF Postdoctoral Fellowship (Grant 1309380). The authors would like to thank M. Cullins, C. Kehl, E. Lothet, J. McManus, and L. Spardy for stimulating discussions. NR 90 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-1200 EI 1432-0770 J9 BIOL CYBERN JI Biol. Cybern. PD FEB PY 2017 VL 111 IS 1 BP 25 EP 47 DI 10.1007/s00422-016-0704-8 PG 23 WC Computer Science, Cybernetics; Neurosciences SC Computer Science; Neurosciences & Neurology GA EL9RT UT WOS:000394958400002 PM 28004255 ER PT J AU Park, YJ Battistone, MA Kim, B Breton, S AF Park, Yoo-Jin Battistone, Maria Agustina Kim, Bongki Breton, Sylvie TI Relative contribution of clear cells and principal cells to luminal pH in the mouse epididymis SO BIOLOGY OF REPRODUCTION LA English DT Article DE luminal acidification; V-ATPase; NHE3; CFTR ID MALE REPRODUCTIVE-TRACT; NA+/H+ EXCHANGER ISOFORM; RENAL EPITHELIAL-CELLS; KIDNEY COLLECTING DUCT; VACUOLAR H+-ATPASE; V-ATPASE; INTERCALATED CELLS; RAT EPIDIDYMIS; VAS-DEFERENS; APICAL MEMBRANE AB While spermatozoa undergo epididymal maturation, they remain quiescent thanks to the establishment of a low luminal pH. This study is aimed at determining how epithelial cells lining the epididymal lumen work together tomaintain and regulate this acidicmilieu. In particular, we examined the relative contribution of clear cells (CCs) and principal cells (PCs) to this process. Functional analysis in the mouse cauda epididymidis (Cd) perfused in vivo showed that the pH of a control solution remained constant at pH 6.6 after perfusion through the Cd lumen. In contrast, the pH of both an acidic (pH 5.8) and alkaline (pH 7.8) perfusate was progressively restored toward the control acidic pH. Pharmacological studies indicated the contribution of cystic fibrosis transmembrane regulator, previously shown to be present in the apical membrane of PCs, to the recovery from an acidic pH of 5.8. In addition, we found that CCs and PCs equally contribute to the recovery from an alkaline of 7.8, via the H+ pumping vacuolar ATPase (V-ATPase) located in CCs, and the Na+/H+ exchanger type 3 (NHE3) located in PCs. Immunofluorescence labeling showed apical membrane accumulation of the V-ATPase in CCs at pH 7.8, and its internalization at pH 5.8 compared to pH 6.6. Immunofluorescence showed expression of NHE3, but absence of NHE2, in PCs located in the Cd. RT-PCR and western blotting showed expression of NHE3 in all epididymal regions. Luminal 8-(4-chlorophenylthio) adenosine 3,5 -cyclic monophosphate (cpt-cAMP) partially inhibited luminal pH recovery from pH 7.8. However, cpt-cAMP induced an increase in V-ATPase apical membrane accumulation at this pH. Cell fractionation studies showed the apical accumulation of NHE3 from intracellular vesicles at pH 7.8 versus 6.6, and prevention of this effect by cpt-cAMP. These results indicate the participation of both CCs and PCs in the regulation of luminal pH in the epididymis. Our study also shows the dual role of PCs in HCO3(-) and H+ secretion, and that this switch from base to acid secretion depends on the luminal environment. Characterization of the respective roles of CCs and PCs in the regulation of the optimal luminal condition for epididymal sperm maturation should provide new frameworks for the evaluation and treatment of male infertility. Summary Sentence This study shows the equal contribution of clear and principal cells to proton secretion, and the dual role of principal cells in bicarbonate and proton secretion, depending on luminal cues. C1 Massachusetts Gen Hosp, Ctr Syst Biol, Div Nephrol, Program Membrane Biol, Boston, MA USA. [Breton, Sylvie] Harvard Med Sch, Boston, MA USA. RP Breton, S (reprint author), Simches Res Ctr, 185 Cambridge St,Suite 8-204, Boston, MA 02114 USA. EM Breton.sylvie@mgh.harvard.edu FU NIH [HD040793]; Lalor Foundation Fellowships; Boston Area Diabetes and Endocrinology Research Center [DK57521]; Center for the Study of Inflammatory Bowel Disease [DK43351]; NIH Shared Instrumentation Grant [S10 RR031563-01]; Charles and Ann Sanders Research Scholar Award at MGH FX This work was supported by NIH grant HD040793 (to SB) and by Lalor Foundation Fellowships (to YJP and MAB). The Microscopy Core facility of the MGH Program in Membrane Biology receives support from the Boston Area Diabetes and Endocrinology Research Center (DK57521) and the Center for the Study of Inflammatory Bowel Disease (DK43351). The Nikon A1R confocal in the PMB Microscopy Core was purchased using an NIH Shared Instrumentation Grant S10 RR031563-01. SB is a recipient of the Charles and Ann Sanders Research Scholar Award at MGH. NR 66 TC 0 Z9 0 U1 0 U2 0 PU SOC STUDY REPRODUCTION PI MADISON PA 1691 MONROE ST,SUITE # 3, MADISON, WI 53711-2021 USA SN 0006-3363 EI 1529-7268 J9 BIOL REPROD JI Biol. Reprod. PD FEB PY 2017 VL 96 IS 2 BP 366 EP 375 DI 10.1095/biolreprod.116.144857 PG 10 WC Reproductive Biology SC Reproductive Biology GA EP3UW UT WOS:000397308200009 PM 28203710 ER PT J AU Sajjadi, AY Isakoff, SJ Deng, B Singh, B Wanyo, CM Fang, QQ Specht, MC Schapira, L Moy, B Bardia, A Boas, DA Carp, SA AF Sajjadi, Amir Y. Isakoff, Steven J. Deng, Bin Singh, Bhawana Wanyo, Christy M. Fang, Qianqian Specht, Michelle C. Schapira, Lidia Moy, Beverly Bardia, Aditya Boas, David A. Carp, Stefan A. TI Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI) SO BIOMEDICAL OPTICS EXPRESS LA English DT Article ID PATHOLOGICAL COMPLETE RESPONSE; NEAR-INFRARED TOMOGRAPHY; PREOPERATIVE CHEMOTHERAPY; MAMMOGRAPHIC COMPRESSION; CANCER PATIENTS; TUMOR RESPONSE; THERAPY; SPECTROSCOPY; TISSUE; MRI AB We characterize novel breast cancer imaging biomarkers for monitoring neoadjuvant chemotherapy (NACT) and predicting outcome. Specifically, we recruited 30 patients for a pilot study in which NACT patients were imaged using dynamic tomographic optical breast imaging (DTOBI) to quantify the hemodynamic changes due to partial mammographic compression. DTOBI scans were obtained pre-treatment (referred to as day 0), as well as 7 and 30 days into therapy on female patients undergoing NACT. We present data for the 13 patients who participated in both day 0 and 7 measurements and had evaluable data, of which 7 also returned for day 30 measurements. We acquired optical images over 2 minutes following 4-8 lbs (18-36 N) of compression. The timecourses of tissue-volume averaged total hemoglobin (HbT), as well as hemoglobin oxygen saturation (SO2) in the tumor vs. surrounding tissues were compared. Outcome prediction metrics based on the differential behavior in tumor vs. normal areas for responders (>50% reduction in maximum diameter) vs. non-responders were analyzed for statistical significance. At baseline, all patients exhibit an initial decrease followed by delayed recovery in HbT, and SO2 in the tumor area, in contrast to almost immediate recovery in surrounding tissue. At day 7 and 30, this contrast is maintained in non-responders; however, in responders, the contrast in hemodynamic time-courses between tumor and normal tissue starts decreasing at day 7 and substantially disappears at day 30. At day 30 into NACT, responding tumors demonstrate "normalization" of compression induced hemodynamics vs. surrounding normal tissue whereas non-responding tumors did not. This data suggests that DTOBI imaging biomarkers, which are governed by the interplay between tissue biomechanics and oxygen metabolism, may be suitable for guiding NACT by offering early predictions of treatment outcome. (C) 2017 Optical Society of America C1 [Sajjadi, Amir Y.; Deng, Bin; Singh, Bhawana; Wanyo, Christy M.; Boas, David A.; Carp, Stefan A.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Opt Div, Charlestown, MA 02129 USA. [Sajjadi, Amir Y.; Deng, Bin; Singh, Bhawana; Boas, David A.; Carp, Stefan A.] Harvard Med Sch, Dept Radiol, Charlestown, MA 02129 USA. [Isakoff, Steven J.; Specht, Michelle C.; Schapira, Lidia; Moy, Beverly; Bardia, Aditya] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Isakoff, Steven J.; Schapira, Lidia; Moy, Beverly; Bardia, Aditya] Harvard Med Sch, Dept Med, Boston, MA 02114 USA. [Fang, Qianqian] Northeastern Univ, Dept Bioengn, Boston, MA 02115 USA. [Specht, Michelle C.] Harvard Med Sch, Dept Surg, Boston, MA 02114 USA. RP Sajjadi, AY (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Opt Div, Charlestown, MA 02129 USA.; Sajjadi, AY (reprint author), Harvard Med Sch, Dept Radiol, Charlestown, MA 02129 USA. EM asajjadi@nmr.mgh.harvard.edu; sisakoff@mgh.harvard.edu FU NIH [R00EB011889, R01CA142575, R01CA187595]; Cure Foundation [KG200021] FX This work was supported by NIH grants R00EB011889, R01CA142575, R01CA187595 and the Susan G. Komen for the Cure Foundation grant KG200021. The authors would like to thank Ms. Nancy Nagda for coordinating patient scheduling, the staff of the MGH Center for Breast Cancer for their support, and the patients who participated in this project. NR 57 TC 0 Z9 0 U1 0 U2 0 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 2156-7085 J9 BIOMED OPT EXPRESS JI Biomed. Opt. Express PD FEB 1 PY 2017 VL 8 IS 2 BP 555 EP 569 DI 10.1364/BOE.8.000555 PG 15 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA EK8OA UT WOS:000394182100007 PM 28270967 ER PT J AU Tan, L Gurbani, D Weisberg, EL Hunter, JC Li, LB Jones, DS Ficarro, SB Mowafy, S Tam, CP Rao, SM Du, GY Griffin, JD Sorger, PK Marto, JA Westover, KD Gray, NS AF Tan, Li Gurbani, Deepak Weisberg, Ellen L. Hunter, John C. Li, Lianbo Jones, Douglas S. Ficarro, Scott B. Mowafy, Samar Tam, Chun-Pong Rao, Suman Du, Guangyan Griffin, James D. Sorger, Peter K. Marto, Jarrod A. Westover, Kenneth D. Gray, Nathanael S. TI Structure-guided development of covalent TAK1 inhibitors SO BIOORGANIC & MEDICINAL CHEMISTRY LA English DT Article DE Structure-based design; TAK1 kinase inhibitors; Covalent inhibitors; 2,4-Disubstituted pyrimidine; Structure-activity relationship ID KAPPA-B ACTIVATION; RESORCYLIC ACID LACTONE; KINASE TAK1; 5Z-7-OXOZEAENOL; DISCOVERY; MECHANISM; REFMAC5; CANCER; GROWTH; CELLS AB TAK1 (transforming growth factor-beta-activated kinase 1) is an essential intracellular mediator of cytokineand growth factor signaling and a potential therapeutic target for the treatment of immune diseases and cancer. Herein we report development of a series of 2,4-disubstituted pyrimidine covalent TAK1 inhibitors that target Cys 174, a residue immediately adjacent to the 'DFG-motif of the kinase activation loop. Co-crystal structures of TAK1 with candidate compounds enabled iterative rounds of structure-based design and biological testing to arrive at optimized compounds. Lead compounds such as 2 and 10 showed greater than 10-fold biochemical selectivity for TAK1 over the closely related kinases MEK1 and ERK1 which possess an equivalently positioned cysteine residue. These compounds are smaller, more easily synthesized, and exhibit a different spectrum of kinase selectivity relative to previously reported macrocyclic natural product TAK1 inhibitors such as 5Z-7-oxozeanol. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Tan, Li; Ficarro, Scott B.; Mowafy, Samar; Tam, Chun-Pong; Rao, Suman; Du, Guangyan; Marto, Jarrod A.; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Tan, Li; Ficarro, Scott B.; Mowafy, Samar; Tam, Chun-Pong; Rao, Suman; Du, Guangyan; Marto, Jarrod A.; Gray, Nathanael S.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02215 USA. [Gurbani, Deepak; Hunter, John C.; Li, Lianbo; Westover, Kenneth D.] Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. [Gurbani, Deepak; Hunter, John C.; Li, Lianbo; Westover, Kenneth D.] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. [Weisberg, Ellen L.; Griffin, James D.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Weisberg, Ellen L.; Griffin, James D.] Harvard Med Sch, Dept Med, Boston, MA 02215 USA. [Jones, Douglas S.; Rao, Suman; Sorger, Peter K.] Harvard Med Sch, HMS LINCS Ctr, Boston, MA 02215 USA. [Jones, Douglas S.; Rao, Suman; Sorger, Peter K.] Harvard Med Sch, Lab Syst Pharmacol, Boston, MA 02215 USA. [Jones, Douglas S.] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Mowafy, Samar] Misr Int Univ, Km 28 Cairo,Ismailia Rd, Cairo, Egypt. RP Gray, NS (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.; Westover, KD (reprint author), Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM Kenneth.Westover@UTSouthwestem.edu; Nathanael_Gray@dfci.harvard.edu FU LINCS Grant [U54-HL127365]; Welch Research Foundation [1-1829]; CPRIT [R1207, RP140233]; NIH [CA 154303-05]; Pediatric Low Grade Astrocytoma (PLGA) foundation; U.S. Department of Energy, Office of Biological and Environmental Research [DEAC02-06CH11357] FX NSG and PKS were supported by LINCS Grant U54-HL127365. KDW was supported by Welch Research Foundation 1-1829, CPRIT R1207 and CPRIT RP140233. LT and NSG were supported by NIH CA 154303-05 and the Pediatric Low Grade Astrocytoma (PLGA) foundation. Results shown in this article are derived from work performed at Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source. Argonne is operated by U Chicago Argonne, LLC, for the U.S. Department of Energy, Office of Biological and Environmental Research under contract DEAC02-06CH11357. NR 46 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0968-0896 EI 1464-3391 J9 BIOORGAN MED CHEM JI Bioorg. Med. Chem. PD FEB 1 PY 2017 VL 25 IS 3 BP 838 EP 846 DI 10.1016/j.bmc.2016.11.035 PG 9 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry, Organic SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry GA EK8VE UT WOS:000394201900003 PM 28011204 ER PT J AU Gounder, L Moodley, P Drain, PK Hickey, AJ Moosa, MYS AF Gounder, Lilishia Moodley, Pravikrishnen Drain, Paul K. Hickey, Andrew J. Moosa, Mahomed-Yunus S. TI Hepatic tuberculosis in human immunodeficiency virus co-infected adults: a case series of South African adults SO BMC INFECTIOUS DISEASES LA English DT Article DE HIV; TB; Liver; Granuloma; South Africa ID LIVER-DISEASES; BLACK PATIENTS; HIV; COHORT AB Background: Although Mycobacterium tuberculosis (TB) infection may cause extrapulmonary disease in HIV-infected adults, HIV-associated hepatic TB has been poorly characterized. Our objective was to describe hepatic TB in HIV-infected adults. Methods: Retrospective study of patients diagnosed with hepatic TB from 2005-2012 at Infectious Diseases Clinic, King Edward VIII Hospital, Durban, South Africa. Results: Among twenty cases of histology-confirmed HIV-associated hepatic TB, median CD4 count was 47 cells/mu l (inter-quartile range 27-107 cells/mu l) and 75% (15/20) of patients had pre-existing pulmonary TB. The most frequent clinical finding was hepatomegaly (85%). Liver enzyme abnormalities included elevated alkaline phosphatase (median 456 u/L, inter-quartile range 322-1,043 u/L) and gamma-glutamyltransferase (median 422 u/L, inter-quartile range 235-736 u/L). Acid-fast bacilli were cultured from liver tissue in 30% (6/20) of patients; 25% (5/20) identified as TB. With standard anti-TB therapy, liver enzymes improved within six months in 92% (11/12) of patients. One year after diagnosis, twelve patients resolved clinically, two patients developed drug-resistant TB and six patients died. Conclusion: In our case series of HIV-infected patients, hepatic TB occurred in patients with severe immunosuppression, who presented with hepatomegaly and abnormal liver enzymes. More than half of patients had resolution of liver function by six months however the 12-month mortality remained high. C1 [Gounder, Lilishia; Moosa, Mahomed-Yunus S.] Univ KwaZulu Natal, Dept Infect Dis, Nelson R Mandela Sch Med, Durban, South Africa. [Gounder, Lilishia; Moodley, Pravikrishnen] Inkosi Albert Luthuli Cent Hosp, Natl Hlth Lab Serv, Dept Virol, 800 Bellair Rd, ZA-4058 Durban, Mayville, South Africa. [Drain, Paul K.] Univ Washington, Dept Global Hlth Med & Epidemiol, Seattle, WA 98195 USA. [Drain, Paul K.] Harvard Med Sch, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Hickey, Andrew J.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Moosa, Mahomed-Yunus S.] King Edward VIII Hosp, Durban, South Africa. RP Gounder, L (reprint author), Univ KwaZulu Natal, Dept Infect Dis, Nelson R Mandela Sch Med, Durban, South Africa.; Gounder, L (reprint author), Inkosi Albert Luthuli Cent Hosp, Natl Hlth Lab Serv, Dept Virol, 800 Bellair Rd, ZA-4058 Durban, Mayville, South Africa. EM gounder@ukzn.ac.za NR 31 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD FEB 1 PY 2017 VL 17 AR 115 DI 10.1186/s12879-017-2222-2 PG 7 WC Infectious Diseases SC Infectious Diseases GA EP4XD UT WOS:000397382300003 PM 28148232 ER PT J AU DeFilipp, Z Duarte, RF Snowden, JA Majhail, NS Greenfield, DM Miranda, JL Arat, M Baker, KS Burns, LJ Duncan, CN Gilleece, M Hale, GA Hamadani, M Hamilton, BK Hogan, WJ Hsu, JW Inamoto, Y Kamble, RT Lupo-Stanghellini, MT Malone, AK McCarthy, P Mohty, M Norkin, M Paplham, P Ramanathan, M Richart, JM Salooja, N Schouten, HC Schoemans, H Seber, A Steinberg, A Wirk, BM Wood, WA Battiwalla, M Flowers, MED Savani, BN Shaw, BE AF DeFilipp, Z. Duarte, R. F. Snowden, J. A. Majhail, N. S. Greenfield, D. M. Miranda, J. L. Arat, M. Baker, K. S. Burns, L. J. Duncan, C. N. Gilleece, M. Hale, G. A. Hamadani, M. Hamilton, B. K. Hogan, W. J. Hsu, J. W. Inamoto, Y. Kamble, R. T. Lupo-Stanghellini, M. T. Malone, A. K. McCarthy, P. Mohty, M. Norkin, M. Paplham, P. Ramanathan, M. Richart, J. M. Salooja, N. Schouten, H. C. Schoemans, H. Seber, A. Steinberg, A. Wirk, B. M. Wood, W. A. Battiwalla, M. Flowers, M. E. D. Savani, B. N. Shaw, B. E. CA CIBMTR Late Effects Quality Life EBMT Complications Quality Life TI Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT SO BONE MARROW TRANSPLANTATION LA English DT Review ID LONG-TERM SURVIVORS; BONE-MARROW-TRANSPLANTATION; BODY-COMPOSITION ABNORMALITIES; ACUTE LYMPHOBLASTIC-LEUKEMIA; IMPAIRED GLUCOSE-TOLERANCE; RISK-FACTORS; DIABETES-MELLITUS; SCIENTIFIC STATEMENT; GLOBAL BURDEN; HEMATOLOGIC MALIGNANCIES AB Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus and all cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with the estimated prevalence of MetS being 31-49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal of reviewing literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors. C1 [DeFilipp, Z.] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA. [Duarte, R. F.] Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain. [Snowden, J. A.] Univ Sheffield, Sheffield Teaching Hosp NHS Fdn Trust, Dept Haematol, Sheffield, S Yorkshire, England. [Snowden, J. A.] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England. [Majhail, N. S.; Hamilton, B. K.] Cleveland Clin, Dept Hematol & Oncol, Cleveland, OH 44106 USA. [Greenfield, D. M.] Sheffield Teaching Hosp NHS Fdn Trust, Specialized Canc Serv, Shefflied, England. [Miranda, J. L.] Univ Cordoba, Maimonides Inst Biomed Res Cordoba IMIBIC, Reina Sofia Univ Hosp,Dept Med, CIBER Fisiopatol Obesidad Nutr CIBEROB,Inst Salud, Cordoba, Spain. [Arat, M.] Florence Nightingale Sisli Hosp, Hematopoiet Stem Cell Transplantat Unit, Istanbul, Turkey. [Baker, K. S.; Flowers, M. E. D.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA. [Burns, L. J.] Univ Minnesota, Natl Marrow Donor Program, Minneapolis, MN USA. [Duncan, C. N.] Dana Farber Canc Inst, Pediat Stem Cell Transplant, Boston, MA 02115 USA. [Gilleece, M.] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England. [Hale, G. A.] John Hopkins Med, All Childrens Hosp, St Petersburg, FL USA. [Hamadani, M.; Shaw, B. E.] Med Coll Wisconsin, Dept Med, CIBMTR, 9200W Wisconsin Ave, Milwaukee, WI 53226 USA. [Hogan, W. J.] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA. [Hsu, J. W.; Wirk, B. M.] Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL 32610 USA. [Inamoto, Y.] Natl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan. [Kamble, R. T.] Baylor Coll Med, Div Hematol & Oncol, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. [Lupo-Stanghellini, M. T.] Ist Sci San Raffaele, Hematol & Bone Marrow Transplantat Unit, Milan, Italy. [Malone, A. K.; Steinberg, A.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol Oncol, New York, NY 10029 USA. [McCarthy, P.; Paplham, P.] Roswell Pk Canc Inst, BMT Program, Dept Med, Buffalo, NY 14263 USA. [Mohty, M.] Univ Paris 06, Paris, France. [Mohty, M.] Hop St Antoine, AP HP, Paris, France. [Mohty, M.] INSERM, UMRs 938, Paris, France. [Ramanathan, M.] UMass Mem Med Ctr, Dept Hematol Oncol & Bone Marrow Transplant, Worcester, MA USA. [Richart, J. M.] St Louis Univ, Dept Internal Med, Div Hematol & Med Oncol, St Louis, MO 63103 USA. [Salooja, N.] Hammersmith Hosp, London, England. [Schouten, H. C.] Maastricht Univ, Med Ctr, Maastricht, Netherlands. [Schoemans, H.] Univ Hosp Leuven, Dept Hematol, Leuven, Belgium. [Schoemans, H.] Katholieke Univ Leuven, Leuven, Belgium. [Seber, A.] Hosp Samaritano, Sao Paulo, Brazil. [Seber, A.] Assoc Medula Ossea AMEO, Sao Paulo, Brazil. [Wirk, B. M.] SUNY Stony Brook, Med Ctr, Dept Internal Med, Stony Brook, NY 11794 USA. [Wood, W. A.] Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC USA. [Battiwalla, M.] NIH, Hematol Branch, Bldg 10, Bethesda, MD 20892 USA. [Savani, B. N.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. RP Shaw, BE (reprint author), Med Coll Wisconsin, Dept Med, CIBMTR, 9200W Wisconsin Ave, Milwaukee, WI 53226 USA. EM beshaw@mcw.edu FU NCI NIH HHS [U24 CA076518] NR 96 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 EI 1476-5365 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD FEB PY 2017 VL 52 IS 2 BP 173 EP 182 DI 10.1038/bmt.2016.203 PG 10 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA EK7VW UT WOS:000394134300002 PM 27548466 ER PT J AU Whangbo, J Ritz, J Bhatt, A AF Whangbo, J. Ritz, J. Bhatt, A. TI Antibiotic-mediated modification of the intestinal microbiome in allogeneic hematopoietic stem cell transplantation SO BONE MARROW TRANSPLANTATION LA English DT Review ID VERSUS-HOST-DISEASE; REGULATORY T-CELLS; BONE-MARROW-TRANSPLANTATION; MOUSE RADIATION CHIMERAS; GUT MICROBIOTA; PROTECTIVE ENVIRONMENT; INFLAMMATORY DISEASE; SECONDARY DISEASE; BACTERIA; MICE AB Allogeneic hematopoietic stem cell transplantation (HSCT) is curative for many patients with severe benign and malignant hematologic disorders. The success of allogeneic HSCT is limited by the development of transplant-related complications such as acute graft-versus-host disease (GvHD). Early pre-clinical studies suggested that intestinal microflora contribute to the pathogenesis of acute GvHD, and that growth suppression or eradication of intestinal bacteria prevented the development of acute GvHD even in MHC-mismatched transplants. These observations led to the practice of gut decontamination (GD) with oral non-absorbable antibiotics in patients undergoing allogeneic HSCT as a method of acute GvHD prophylaxis. Microbiome studies in the modern sequencing era are beginning to challenge the benefit of this practice. In this review, we provide a historical perspective on the practice of GD and highlight findings from the limited number of clinical trials evaluating the use of GD for acute GvHD prevention in allogeneic HSCT patients. In addition, we examine the role of the gut microbiota in allogeneic HSCT in the context of recent studies linking the microflora to regulation of intestinal immune homeostasis. We discuss the implications of these findings for future strategies to reduce acute GvHD risk by selective manipulation of the microbiota. C1 [Whangbo, J.; Ritz, J.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Whangbo, J.; Ritz, J.] Harvard Med Sch, Boston, MA USA. [Whangbo, J.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. [Bhatt, A.] Stanford Univ, Dept Med, 269 Campus Dr, Stanford, CA 94305 USA. [Bhatt, A.] Stanford Univ, Dept Genet, 269 Campus Dr, Stanford, CA 94305 USA. RP Bhatt, A (reprint author), Stanford Univ, Dept Med, 269 Campus Dr, Stanford, CA 94305 USA.; Bhatt, A (reprint author), Stanford Univ, Dept Genet, 269 Campus Dr, Stanford, CA 94305 USA. EM asbhatt@stanford.edu FU NCI NIH HHS [K08 CA184420] NR 60 TC 0 Z9 0 U1 3 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 EI 1476-5365 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD FEB PY 2017 VL 52 IS 2 BP 183 EP 190 DI 10.1038/bmt.2016.206 PG 8 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA EK7VW UT WOS:000394134300003 PM 27526283 ER PT J AU Maziarz, RT Brazauskas, R Chen, M McLeod, AA Martino, R Wingard, JR Aljurf, M Battiwalla, M Dvorak, CC Geroge, B Guinan, EC Hale, GA Lazarus, HM Lee, JW Liesveld, JL Ramanathan, M Reddy, V Savani, BN Smith, FO Strasfeld, L Taplitz, RA Ustun, C Boeckh, MJ Gea-Banacloche, J Lindemans, CA Auletta, JJ Riches, ML AF Maziarz, R. T. Brazauskas, R. Chen, M. McLeod, A. A. Martino, R. Wingard, J. R. Aljurf, M. Battiwalla, M. Dvorak, C. C. Geroge, B. Guinan, E. C. Hale, G. A. Lazarus, H. M. Lee, J-W Liesveld, J. L. Ramanathan, M. Reddy, V. Savani, B. N. Smith, F. O. Strasfeld, L. Taplitz, R. A. Ustun, C. Boeckh, M. J. Gea-Banacloche, J. Lindemans, C. A. Auletta, J. J. Riches, M. L. TI Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study SO BONE MARROW TRANSPLANTATION LA English DT Article ID HEMATOPOIETIC-CELL TRANSPLANTATION; UNRELATED DONORS; ASPERGILLOSIS; RECIPIENTS; DISEASES; PROPHYLAXIS; FLUCONAZOLE; MORTALITY; VORICONAZOLE; COMBINATION AB Patients with prior invasive fungal infection (IFI) increasingly proceed to allogeneic hematopoietic cell transplantation (HSCT). However, little is known about the impact of prior IFI on survival. Patients with pre-transplant IFI (cases; n = 825) were compared with controls (n = 10247). A subset analysis assessed outcomes in leukemia patients pre-and post 2001. Cases were older with lower performance status (KPS), more advanced disease, higher likelihood of AML and having received cord blood, reduced intensity conditioning, mold-active fungal prophylaxis and more recently transplanted. Aspergillus spp. and Candida spp. were the most commonly identified pathogens. 68% of patients had primarily pulmonary involvement. Univariate and multivariable analysis demonstrated inferior PFS and overall survival (OS) for cases. At 2 years, cases had higher mortality and shorter PFS with significant increases in non-relapse mortality (NRM) but no difference in relapse. One year probability of post-HSCT IFI was 24% (cases) and 17% (control, P < 0.001). The predominant cause of death was underlying malignancy; infectious death was higher in cases (13% vs 9%). In the subset analysis, patients transplanted before 2001 had increased NRM with inferior OS and PFS compared with later cases. Pre-transplant IFI is associated with lower PFS and OS after allogeneic HSCT but significant survivorship was observed. Consequently, pre-transplant IFI should not be a contraindication to allogeneic HSCT in otherwise suitable candidates. Documented pre-transplant IFI is associated with lower PFS and OS after allogeneic HSCT. However, mortality post transplant is more influenced by advanced disease status than previous IFI. Pre-transplant IFI does not appear to be a contraindication to allogeneic HSCT. C1 [Maziarz, R. T.; McLeod, A. A.] Oregon Hlth & Sci Univ, Adult Blood & Marrow Stem Cell Transplant Program, Knight Canc Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. [Brazauskas, R.; Chen, M.] Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. [Brazauskas, R.] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. [Martino, R.] Hosp Santa Creu & Sant Pau, Div Clin Hematol, Barcelona, Spain. [Wingard, J. R.] Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL USA. [Aljurf, M.] King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia. [Battiwalla, M.] NHLBI, Hematol Branch, Bethesda, MD 20892 USA. [Dvorak, C. C.] Univ Calif San Francisco, Dept Pediat, Med Ctr, San Francisco, CA USA. [Geroge, B.] Christian Med Coll & Hosp, Dept Hematol, Vellore, Tamil Nadu, India. [Guinan, E. C.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Hale, G. A.] All Childrens Hosp, Dept Hematol Oncol, St Petersburg, FL USA. [Lazarus, H. M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. [Lee, J-W] Catholic Univ Korea, Seoul St Marys Hosp, BMT Ctr, Seoul, South Korea. [Liesveld, J. L.] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA. [Ramanathan, M.] UMass Mem Med Ctr, Dept Med, Div Hematol & Oncol, Worcester, MA USA. [Reddy, V.] Univ Cent Florida, Coll Med, Dept Internal Med, Orlando, FL 32816 USA. [Savani, B. N.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. [Smith, F. O.] Univ Cincinnati, Inst Canc, Cincinnati, OH USA. [Strasfeld, L.] Oregon Hlth & Sci Univ, Infect Dis Clin, Portland, OR 97201 USA. [Taplitz, R. A.] UC San Diego Hlth, Infect Dis Program, La Jolla, CA USA. [Ustun, C.] Univ Minnesota, Med Ctr, Div Hematol Oncol & Transplantat, Dept Med, Minneapolis, MN 55455 USA. [Boeckh, M. J.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA. [Gea-Banacloche, J.] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA. [Lindemans, C. A.] Univ Med Ctr Utrecht, Pediat Blood & Marrow Transplantat Program, Utrecht, Netherlands. [Auletta, J. J.] Nationwide Childrens Hosp, Div Hematol Oncol, Columbus, OH USA. [Auletta, J. J.] Nationwide Childrens Hosp, Div Bone Marrow Transplantat, Columbus, OH USA. [Auletta, J. J.] Nationwide Childrens Hosp, Div Infect Dis, Columbus, OH USA. [Riches, M. L.] Univ North Carolina Chapel Hill, Div Hematol Oncol, Chapel Hill, NC USA. RP Maziarz, RT (reprint author), Oregon Hlth & Sci Univ, Adult Blood & Marrow Stem Cell Transplant Program, Knight Canc Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM maziarzr@ohsu.edu FU Public Health Service Grant from the National Cancer Institute (NCI) [U24-CA076518]; National Heart, Lung and Blood Institute (NHLBI); National Institute of Allergy and Infectious Diseases (NIAID) Grant from NHLBI [5U10HL069294]; NCI [HHSH250201200016C]; Health Resources and Services Administration (HRSA/DHHS) Grants from the Office of Naval Research [N00014-13-1-0039, N00014-14-1-0028]; Actinium Pharmaceuticals; Allos Therapeutics, Inc.; Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck Co, Inc.; Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; Perkin Elmer, Inc.; Remedy Informatics; Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; TerumoBCT; Teva Neuroscience, Inc.; THERAKOS,Inc.; University of Minnesota; University of Utah; Wellpoint, Inc. FX The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; *Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *TerumoBCT; *Teva Neuroscience, Inc.; *THERAKOS,Inc.; University of Minnesota; University of Utah; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the US Government. *Corporate Members NR 29 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 EI 1476-5365 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD FEB PY 2017 VL 52 IS 2 BP 270 EP 278 DI 10.1038/bmt.2016.259 PG 9 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA EK7VW UT WOS:000394134300017 PM 27991895 ER PT J AU Lee, S Huang, EJ AF Lee, Sebum Huang, Eric J. TI Modeling ALS and FTD with iPSC-derived neurons SO BRAIN RESEARCH LA English DT Review DE Induced pluripotent stem cells (iPSCs); Amyotrophic lateral sclerosis (ALS); Frontotemporal dementia (FM); Frontotemporal lobar degeneration (FTLD) ID AMYOTROPHIC-LATERAL-SCLEROSIS; PLURIPOTENT STEM-CELLS; FRONTOTEMPORAL LOBAR DEGENERATION; HEXANUCLEOTIDE REPEAT EXPANSION; MYOTONIC-DYSTROPHY; MOTOR-NEURONS; NEURODEGENERATIVE DISEASES; BASOPHILIC INCLUSIONS; GENETIC CORRECTION; FUS MUTATIONS AB Recent advances in genetics and neuropathology support the idea that amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTD) are two ends of a disease spectrum. Although several animal models have been developed to investigate the pathogenesis and disease progression in ALS and FTD, there are significant limitations that hamper our ability to connect these models with the neurodegenerative processes in human diseases. With the technical breakthrough in reprogramming biology, it is now possible to generate patient-specific induced pluripotent stem cells (iPSCs) and disease-relevant neuron subtypes. This review provides a comprehensive summary of studies that use iPSC-derived neurons to model ALS and FTD. We discuss the unique capabilities of iPSC-derived neurons that capture some key features of ALS and FTD, and underscore their potential roles in drug discovery. There are, however, several critical caveats that require improvements before iPSC-derived neurons can become highly effective disease models. Published by Elsevier B.V. C1 [Lee, Sebum; Huang, Eric J.] Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave, San Francisco, CA 94143 USA. [Huang, Eric J.] San Francisco VA Med Ctr, Pathol Serv 113B, 505 Parnassus Ave, San Francisco, CA 94143 USA. RP Huang, EJ (reprint author), Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave, San Francisco, CA 94143 USA. EM eric.huang2@ucsf.edu FU National Institute of Health [0D011915]; Veterans Administrations BLR&D Merit Review Award [I01 BX0011-8]; Pilot Award [I21 BX1625]; Muscular Dystrophy Association [217592]; Consortium for Frontotemporal Dementia Research (CFR) FX We thank Dr. Bruce Miller (UCSF Memory & Aging Center), Dr. Fen-Biao Gao (University of Massachusetts) and Dr. Yadong Huang (Gladstone Institute of Neurological Disease & UCSF) for many insightful discussions. Our research on ALS and FTD disease mechanism and pathogenesis has been supported by grants from the National Institute of Health (0D011915), Veterans Administrations BLR&D Merit Review Award (I01 BX0011-8) and Pilot Award (I21 BX1625), Muscular Dystrophy Association (Research Grant #217592), and the Consortium for Frontotemporal Dementia Research (CFR). NR 72 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 EI 1872-6240 J9 BRAIN RES JI Brain Res. PD FEB 1 PY 2017 VL 1656 SI SI BP 88 EP 97 DI 10.1016/j.brainres.2015.10.003 PG 10 WC Neurosciences SC Neurosciences & Neurology GA EK8RE UT WOS:000394190500011 PM 26462653 ER PT J AU Tenforde, AS Nattiv, A Ackerman, K Barrack, MT Fredericson, M AF Tenforde, Adam S. Nattiv, Aurelia Ackerman, Kathryn Barrack, Michelle T. Fredericson, Michael TI Optimising bone health in the young male athlete SO BRITISH JOURNAL OF SPORTS MEDICINE LA English DT Editorial Material ID RISK-FACTORS; CONSENSUS STATEMENT; TRIAD; PARTICIPATION; DENSITY; SPORTS; RETURN; PLAY C1 [Tenforde, Adam S.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Cambridge, MA 02138 USA. [Nattiv, Aurelia] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA USA. [Nattiv, Aurelia] Univ Calif Los Angeles, Dept Orthopaed Surg, Div Sports Med & Nonoperat Orthopaed, Los Angeles, CA USA. [Ackerman, Kathryn] Boston Childrens Hosp, Div Sports Med, Boston, MA USA. [Ackerman, Kathryn] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA. [Ackerman, Kathryn] Harvard Med Sch, Boston, MA USA. [Barrack, Michelle T.] Calif State Univ Long Beach, Dept Family & Consumer Sci, Long Beach, CA 90840 USA. [Fredericson, Michael] Stanford Univ, Sch Med, Div Phys Med & Rehabil, Dept Orthopaed Surg, Palo Alto, CA 94304 USA. RP Tenforde, AS (reprint author), Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Cambridge, MA 02138 USA. EM atenforde@partners.org NR 15 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0306-3674 EI 1473-0480 J9 BRIT J SPORT MED JI Br. J. Sports Med. PD FEB PY 2017 VL 51 IS 3 BP 148 EP 149 DI 10.1136/bjsports-2016-097000 PG 2 WC Sport Sciences SC Sport Sciences GA EL2NF UT WOS:000394455800006 ER PT J AU Baggish, AL Kovacs, RJ AF Baggish, Aaron L. Kovacs, Richard J. TI Preparticipation cardiovascular screening: clinical partnership is the only certainty SO BRITISH JOURNAL OF SPORTS MEDICINE LA English DT Editorial Material ID CARDIOLOGY; RECOMMENDATIONS; DISEASE; SPORTS C1 [Baggish, Aaron L.] Massachusetts Gen Hosp, Cardiovasc Performance Program, Yawkey Suite 5B,55 Fruit St, Boston, MA 02114 USA. [Kovacs, Richard J.] Indiana Univ, Krannert Inst Cardiol, Indianapolis, IN 46204 USA. RP Baggish, AL (reprint author), Massachusetts Gen Hosp, Cardiovasc Performance Program, Yawkey Suite 5B,55 Fruit St, Boston, MA 02114 USA. EM abaggish@partners.org NR 6 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0306-3674 EI 1473-0480 J9 BRIT J SPORT MED JI Br. J. Sports Med. PD FEB PY 2017 VL 51 IS 3 BP 150 EP U90 DI 10.1136/bjsports-2016-096954 PG 2 WC Sport Sciences SC Sport Sciences GA EL2NF UT WOS:000394455800007 ER PT J AU Richards, KA Cesario, S Lim, AH Best, SL Deeren, SM Bushman, W Safdar, N AF Richards, Kyle A. Cesario, Stacy Lim, Amy H. Best, Sara L. Deeren, Susan M. Bushman, Wade Safdar, Nasia TI Utility of routine urinalysis and urine culture testing in an ambulatory urology clinic: a quality improvement initiative in a Veterans healthcare facility SO CANADIAN JOURNAL OF UROLOGY LA English DT Article DE quality control; quality improvement; urine; urine assay; urinary tract infection ID INFECTIOUS-DISEASES-SOCIETY; ASYMPTOMATIC BACTERIURIA; PRACTICE GUIDELINES; TRACT-INFECTION; AMERICA; DIAGNOSIS; ADULTS AB Introduction: Urinalysis (UA) and urine culture (UCx) are commonly performed tests in the urology clinic. Many of these urine studies are performed prior to the patient visit may not always be indicated, thus contributing to unintended consequences such as antibiotic use and costs without enhancing patient care. Our objective was to perform a quality improvement initiative aimed to assess the utility of routine UA/UCx. Materials and methods: The practice pattern at our site's Veteran Affairs (VA) urology clinic prior to 2014 was to obtain routine UA/UCx on most clinic visits prior to patient evaluation. Starting in 2014, we designed an intervention whereby our nurse practitioner triaged all new patient referrals and selectively ordered UA/UCx. We performed multivariable logistic regression to assess for predictors of obtaining UA or UCx. Results: A total of 1308 patients were seen in January March 2013 and 1456 in June-August 2014 and were included in this analysis. Fewer patients in 2014 received UA (59.8% versus 70.0%, p < 0.001) and UCx (49.6% versus 64.2%, p < 0.001). There was a decreased odds of obtaining UA in 2014 (OR 0.52, p < 0.001) as well as a decreased odds of obtaining UCx in 2014 (OR0.38, p < 0.001) on multivariable logistic regression. The results of UA/UCx only rarely resulted in change of management in either cohort (3%). Selective ordering resulted in an estimated cost savings of $4915.08/month in UCx costs alone. Conclusions: Our quality improvement initiatives reduced rates of UA/UCx testing when providers assess patients prior to ordering these tests. The implication of this initiative is significant cost savings for the healthcare system. C1 [Richards, Kyle A.; Cesario, Stacy; Lim, Amy H.; Best, Sara L.; Deeren, Susan M.; Bushman, Wade] William S Middleton Mem Vet Adm Med Ctr, Dept Urol, Madison, WI 53705 USA. [Richards, Kyle A.; Best, Sara L.; Bushman, Wade] Univ Wisconsin Madison, Dept Urol, 1685 Highland Ave, Madison, WI 53705 USA. [Safdar, Nasia] Univ Wisconsin Madison, Dept Med, Madison, WI USA. RP Richards, KA (reprint author), Univ Wisconsin Madison, Dept Urol, 1685 Highland Ave, Madison, WI 53705 USA. FU VA; VAMERIT award FX This material is the result of work supported with resources and the use of facilities at the William S. Memorial Veterans Hospital. Dr. Safdar is supported by a VA funded Patient Safety Center of Inquiry and a VAMERIT award. The contents do not represent the views of the U. S. Department of Veterans Affairs or the United States Government. NR 18 TC 0 Z9 0 U1 0 U2 0 PU CANADIAN J UROLOGY PI ST LAURENT PA 2330 WARD ST, STE 604, ST LAURENT, QUEBEC H4M 2V6, CANADA SN 1195-9479 J9 CAN J UROL JI Can. J. Urol. PD FEB PY 2017 VL 24 IS 1 BP 8627 EP 8633 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA EM5MQ UT WOS:000395356100004 PM 28263127 ER PT J AU Morris, BJ Klausner, JD Krieger, JN Willcox, BJ Crouse, PD Pollock, N AF Morris, Brian J. Klausner, Jeffrey D. Krieger, John N. Willcox, Bradley J. Crouse, Pierre D. Pollock, Neil TI Reply by Authors - Re: Canadian Pediatrics Society position statement on newborn circumcision: a risk-benefit analysis revisited SO CANADIAN JOURNAL OF UROLOGY LA English DT Letter ID HUMAN-PAPILLOMAVIRUS INFECTION; URINARY-TRACT-INFECTIONS; PROSTATE-CANCER; FEMALE PARTNERS; MEN; COLONIZATION; PREVALENCE; PREVENTION; CLEARANCE; SYPHILIS C1 [Morris, Brian J.] Univ Sydney, Sch Med Sci, Bldg F13, Sydney, NSW 2006, Australia. [Morris, Brian J.] Univ Sydney, Bosch Inst, Sydney, NSW, Australia. [Klausner, Jeffrey D.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA. [Klausner, Jeffrey D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA. [Krieger, John N.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Urol Sect, Seattle, WA USA. [Willcox, Bradley J.] Univ Hawaii, Kuakini Med Ctr, Dept Res, Honolulu, HI 96822 USA. [Crouse, Pierre D.] Intramed Med Ctr, Calgary, AB, Canada. [Pollock, Neil] Univ British Columbia, Pollodc Clin, Vancouver, BC V5Z 1M9, Canada. [Pollock, Neil] Univ British Columbia, New Westminster & Fac Med, Vancouver, BC V5Z 1M9, Canada. RP Morris, BJ (reprint author), Univ Sydney, Sch Med Sci, Bldg F13, Sydney, NSW 2006, Australia. NR 38 TC 0 Z9 0 U1 0 U2 0 PU CANADIAN J UROLOGY PI ST LAURENT PA 2330 WARD ST, STE 604, ST LAURENT, QUEBEC H4M 2V6, CANADA SN 1195-9479 J9 CAN J UROL JI Can. J. Urol. PD FEB PY 2017 VL 24 IS 1 BP 8687 EP 8692 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA EM5MQ UT WOS:000395356100017 PM 28263140 ER PT J AU Spring, LM Marshall, MR Warner, ET AF Spring, Laura M. Marshall, Megan R. Warner, Erica T. TI Mammography decision making: Trends and predictors of provider communication in the Health Information National Trends Survey, 2011 to 2014 SO CANCER LA English DT Article DE communication; decision making; mammography; surveys and questionnaires ID BREAST-CANCER STAGE; SCREENING MAMMOGRAPHY; WOMEN; BENEFITS; GUIDELINES; SURVIVAL; HARMS; RECOMMENDATIONS; DIAGNOSIS; ATTITUDES AB BACKGROUNDIn 2009, the US Preventive Services Task Force recommended that the decision to initiate screening mammography before age 50 years should be individualized. Herein, the authors examined whether health care providers are communicating regarding mammography decision making with women and whether communication is associated with screening behavior. METHODSData were drawn from the 2011 to 2014 Health Information National Trends Survey (HINTS). A total of 5915 female respondents aged40 years who responded to the following question were included: Has a doctor or other health professional ever told you that you could choose whether or not to have a mammogram? We used logistic regression to generate odds ratios (ORs) and 95% confidence intervals (95% CIs) for predictors of provider communication and assessed whether provider communication was associated with mammography in the previous 2 years overall and stratified by age. RESULTSFewer than 50% of the women reported provider communication regarding mammogram choice. Women who reported provider communication were not found to be more likely to report no mammogram within the past 2 years (OR, 1.07; 95% CI, 0.87-1.31) compared with those who did not. When stratified by 10-year age group, provider communication was associated with a higher likelihood of no mammogram only among women age 70 years (OR, 1.64; 95% CI, 1.15-2.34), and was associated with a lower likelihood of no mammogram only among women aged 40 to 49 years (OR, 0.63; 95% CI, 0.43-0.92). CONCLUSIONSBetween 2011 and 2014, less than one-half of women received communication regarding mammogram choice despite recommendations from the US Preventive Services Task Force. Provider communication regarding mammogram choice can influence screening behavior, particularly for younger and older women. Cancer 2017;123:401-409. (c) 2016 American Cancer Society. From 2011 to 2014, fewer than one-half of women received provider communication regarding mammogram choice in the study population, despite the recommendations of the US Preventive Services Task Force. Provider communication concerning mammogram choice can influence screening behavior, particularly for women aged 40 to 49 years and those aged 70 years. C1 [Warner, Erica T.] Massachusetts Gen Hosp, Dept Med, Clin Translat Epidemiol Unit, 55 Fruit St,Bartlett 9, Boston, MA 02114 USA. [Spring, Laura M.] Massachusetts Gen Hosp, Breast Med Oncol, Boston, MA 02114 USA. [Marshall, Megan R.] Massachusetts Gen Hosp, Dept Orthoped, Boston, MA 02114 USA. RP Warner, ET (reprint author), Massachusetts Gen Hosp, Dept Med, Clin Translat Epidemiol Unit, 55 Fruit St,Bartlett 9, Boston, MA 02114 USA. EM ewarner@mgh.harvard.edu FU NCI NIH HHS [T32 CA071345, K01 CA188075] NR 32 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD FEB 1 PY 2017 VL 123 IS 3 BP 401 EP 409 DI 10.1002/cncr.30378 PG 9 WC Oncology SC Oncology GA EL6GV UT WOS:000394719300007 PM 27727457 ER PT J AU Kohler, RE Miller, AR Gutnik, L Lee, CN Gopal, S AF Kohler, Racquel E. Miller, Anna R. Gutnik, Lily Lee, Clara N. Gopal, Satish TI Experiences and perceptions regarding clinical breast exam screening by trained laywomen in Malawi SO CANCER CAUSES & CONTROL LA English DT Article DE Breast cancer screening; Lay health worker; Sub-Saharan Africa; Health education; Qualitative interviews ID CANCER; HEALTH; AWARENESS; SERVICES; AFRICA AB Despite the increasing burden, breast cancer control in sub-Saharan Africa is insufficient. Late diagnosis and lack of early detection and screening services contribute to high mortality. Clinical breast exam (CBE) screening can be valuable in low-income countries, including use of community health workers and non-health professionals to conduct exams. We assessed experiences of women who underwent CBE screening by trained laywomen in Lilongwe, Malawi, as part of a pilot program. The pilot study invited women attending urban health clinics to a breast cancer educational talk followed by CBE screening by trained laywomen. We purposively sampled participants from the pilot study and interviewed them about the screening experience and future cancer education programs and services. Overall participants had positive experiences and were willing to undergo CBE screening by trained laywomen. Participants were motivated by the educational talk, shared newly acquired cancer knowledge with their social networks, and encouraged others to seek screening. Screened women suggested strategies for future interventions including combining breast and cervical cancer screening, using female providers, partnering with community leaders to increase uptake, and expanding services into the community. Asymptomatic Malawian women accepted CBE screening by trained laywomen and considered breast cancer an important health issue. Women appreciated combined education and screening services and proposed further linkage of breast and cervical cancer screening. Based on our results, training laywomen to educate the public on breast cancer and conduct CBE is a feasible breast cancer control strategy in sub-Saharan Africa. C1 [Kohler, Racquel E.] Harvard TH Chan Sch Publ Hlth, Dana Farber Canc Inst, Dept Social & Behav Sci, 450 Brookline Ave, Boston, MA 02115 USA. [Miller, Anna R.; Gopal, Satish] Univ North Carolina Chapel Hill, Inst Global Hlth & Infect Dis, 130 Mason Farm Rd, Chapel Hill, NC 27514 USA. [Gutnik, Lily] Univ Utah, Dept Surg, 30 North 1900 East,3B 110 Sch Med, Salt Lake City, UT 84132 USA. [Lee, Clara N.] Univ North Carolina Chapel Hill, Dept Surg, 7041 Burnett Womack, Chapel Hill, NC 27599 USA. [Lee, Clara N.; Gopal, Satish] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. [Gopal, Satish] UNC Project Malawi, Lilongwe, Malawi. RP Kohler, RE (reprint author), Harvard TH Chan Sch Publ Hlth, Dana Farber Canc Inst, Dept Social & Behav Sci, 450 Brookline Ave, Boston, MA 02115 USA. EM racquel_kohler@dfci.harvard.edu FU REK's fellowship; UNC Cancer Care Quality Training Program through the National Cancer Institute [R25 CA116339]; UNC Hopkins Morehouse Tulane Fogarty Global Health Fellows Program through Fogarty International Center [R25 TW009340] FX This study was funded by REK's fellowship with UNC Cancer Care Quality Training Program through the National Cancer Institute (R25 CA116339) and LG's fellowship funded by the UNC Hopkins Morehouse Tulane Fogarty Global Health Fellows Program through Fogarty International Center (R25 TW009340). NR 26 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD FEB PY 2017 VL 28 IS 2 BP 137 EP 143 DI 10.1007/s10552-016-0844-0 PG 7 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA EL2LV UT WOS:000394452100006 PM 28097471 ER PT J AU Campbell, P Rebbeck, TR Nishihara, R Beck, AH Begg, CB Bogdanov, AA Cao, Y Coleman, HG Freeman, GJ Heng, YJJ Huttenhower, C Irizarry, RA Kip, NS Michor, F Nevo, D Peters, U Phipps, AI Poole, EM Qian, ZR Quackenbush, J Robins, H Rogan, PK Slattery, ML Smith-Warner, SA Song, MY VanderWeele, TJ Xia, D Zabor, EC Zhang, XH Wang, ML Ogino, S AF Campbell, Peter T. Rebbeck, Timothy R. Nishihara, Reiko Beck, Andrew H. Begg, Colin B. Bogdanov, Alexei A. Cao, Yin Coleman, Helen G. Freeman, Gordon J. Heng, Yujing J. Huttenhower, Curtis Irizarry, Rafael A. Kip, N. Sertac Michor, Franziska Nevo, Daniel Peters, Ulrike Phipps, Amanda I. Poole, Elizabeth M. Qian, Zhi Rong Quackenbush, John Robins, Harlan Rogan, Peter K. Slattery, Martha L. Smith-Warner, Stephanie A. Song, Mingyang VanderWeele, Tyler J. Xia, Daniel Zabor, Emily C. Zhang, Xuehong Wang, Molin Ogino, Shuji TI Proceedings of the third international molecular pathological epidemiology (MPE) meeting SO CANCER CAUSES & CONTROL LA English DT Review DE Molecular pathological epidemiology; Meeting report; Proceedings ID MICROSATELLITE INSTABILITY STATUS; COLORECTAL-CANCER RISK; LIFE-STYLE FACTORS; BODY-MASS INDEX; BREAST-CANCER; ASPIRIN USE; ETIOLOGIC HETEROGENEITY; CIGARETTE-SMOKING; WIDE ASSOCIATION; PIK3CA MUTATION AB Molecular pathological epidemiology (MPE) is a transdisciplinary and relatively new scientific discipline that integrates theory, methods, and resources from epidemiology, pathology, biostatistics, bioinformatics, and computational biology. The underlying objective of MPE research is to better understand the etiology and progression of complex and heterogeneous human diseases with the goal of informing prevention and treatment efforts in population health and clinical medicine. Although MPE research has been commonly applied to investigating breast, lung, and colorectal cancers, its methodology can be used to study most diseases. Recent successes in MPE studies include: (1) the development of new statistical methods to address etiologic heterogeneity; (2) the enhancement of causal inference; (3) the identification of previously unknown exposure-subtype disease associations; and (4) better understanding of the role of lifestyle/behavioral factors on modifying prognosis according to disease subtype. Central challenges to MPE include the relative lack of transdisciplinary experts, educational programs, and forums to discuss issues related to the advancement of the field. To address these challenges, highlight recent successes in the field, and identify new opportunities, a series of MPE meetings have been held at the Dana-Farber Cancer Institute in Boston, MA. Herein, we share the proceedings of the Third International MPE Meeting, held in May 2016 and attended by 150 scientists from 17 countries. Special topics included integration of MPE with immunology and health disparity research. This meeting series will continue to provide an impetus to foster further transdisciplinary integration of divergent scientific fields. C1 [Campbell, Peter T.] Amer Canc Soc, Epidemiol Res Program, 250 Williams St NW, Atlanta, GA 30303 USA. [Rebbeck, Timothy R.; Nevo, Daniel; Poole, Elizabeth M.; Smith-Warner, Stephanie A.; VanderWeele, Tyler J.; Wang, Molin; Ogino, Shuji] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Rebbeck, Timothy R.; Nishihara, Reiko; Freeman, Gordon J.; Qian, Zhi Rong; Ogino, Shuji] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Nishihara, Reiko; Cao, Yin; Smith-Warner, Stephanie A.; Song, Mingyang] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Beck, Andrew H.; Heng, Yujing J.] Beth Israel Deaconess Canc Ctr, Canc Res Inst, Boston, MA USA. [Beck, Andrew H.; Heng, Yujing J.] Harvard Med Sch, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA USA. [Begg, Colin B.; Zabor, Emily C.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. [Bogdanov, Alexei A.] Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA USA. [Cao, Yin; Song, Mingyang] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA. [Cao, Yin; Poole, Elizabeth M.; Song, Mingyang; Zhang, Xuehong; Ogino, Shuji] Harvard Med Sch, 450 Brookline Ave,Room SM1036, Boston, MA 02215 USA. [Cao, Yin] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Coleman, Helen G.] Queens Univ Belfast, Epidemiol & Hlth Serv Res Grp, Ctr Publ Hlth, Belfast, Antrim, North Ireland. [Huttenhower, Curtis; Irizarry, Rafael A.; Michor, Franziska; Nevo, Daniel; Quackenbush, John] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Huttenhower, Curtis] Broad Inst, Genome Sequencing & Anal Program, Microbial Syst & Communities, Cambridge, MA USA. [Irizarry, Rafael A.; Michor, Franziska; Quackenbush, John] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Kip, N. Sertac] Geisinger Hlth Syst, Lab Med & Pathol, Danville, PA USA. [Peters, Ulrike; Phipps, Amanda I.; Robins, Harlan] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA. [Peters, Ulrike; Phipps, Amanda I.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Poole, Elizabeth M.; Zhang, Xuehong] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Rogan, Peter K.] Univ Western Ontario, Dept Biochem, London, ON, Canada. [Slattery, Martha L.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Xia, Daniel] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. [Ogino, Shuji] Brigham & Womens Hosp, Div MPE Mol Pathol Epidemiol, Dept Pathol, 450 Brookline Ave,Room SM1036, Boston, MA 02215 USA. [Ogino, Shuji] Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02115 USA. RP Campbell, P (reprint author), Amer Canc Soc, Epidemiol Res Program, 250 Williams St NW, Atlanta, GA 30303 USA.; Ogino, S (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.; Ogino, S (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Ogino, S (reprint author), Harvard Med Sch, 450 Brookline Ave,Room SM1036, Boston, MA 02215 USA.; Ogino, S (reprint author), Brigham & Womens Hosp, Div MPE Mol Pathol Epidemiol, Dept Pathol, 450 Brookline Ave,Room SM1036, Boston, MA 02215 USA.; Ogino, S (reprint author), Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02115 USA. EM peter.campbell@cancer.org; Timothy_Rebbeck@dfci.harvard.edu; reiko.nishihara@mail.harvard.edu; abeck2@bidmc.harvard.edu; beggc@mskcc.org; Alexei.Bogdanov@umassmed.edu; yic576@mail.harvard.edu; h.coleman@qub.ac.uk; gordon_freeman@dfci.harvard.edu; yheng@bidmc.harvard.edu; chuttenh@hsph.harvard.edu; rafa@jimmy.harvard.edu; nskip@geisinger.edu; michor@jimmy.harvard.edu; nhdne@channing.harvard.edu; upeters@fredhutch.org; aphipps@fredhutch.org; nhlip@channing.harvard.edu; Zhirong_qian@dfci.harvard.edu; johnq@jimmy.harvard.edu; hrobins@fredhutch.org; progan@uwo.ca; marty.slattery@hsc.utah.edu; swarner@hsph.harvard.edu; msong2@partners.org; tvanderw@hsph.harvard.edu; yxia8@partners.org; zabore@mskcc.org; xuehong.zhang@channing.harvard.edu; stmow@channing.harvard.edu; Shuji_ogino@dfci.harvard.edu OI Rogan, Peter/0000-0003-2070-5254 FU NIH - National Cancer Institute, National Human Genome Research Institute [R13 CA203287]; NIH - National Institute of Environmental Health Sciences; Dana-Farber Harvard Cancer Center Support Grant [R35 CA197735, P30 CA006516]; Dana-Farber Harvard Cancer Center FX Grant support: NIH R13 CA203287 (to S.O.: supported by the National Cancer Institute, National Human Genome Research Institute, and National Institute of Environmental Health Sciences). R35 CA197735 (to S.O.). P30 CA006516 (Dana-Farber Harvard Cancer Center Support Grant; to E.J. Benz;). Nodal Award (to S.P.) from Dana-Farber Harvard Cancer Center. NR 66 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD FEB PY 2017 VL 28 IS 2 BP 167 EP 176 DI 10.1007/s10552-016-0845-z PG 10 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA EL2LV UT WOS:000394452100009 PM 28097472 ER PT J AU Wang, H Hoda, RS Faquin, W Rossi, ED Hotchandani, N Sun, TL Pusztaszeri, M Bizzarro, T Bongiovanni, M Patel, V Jhala, N Fadda, G Gong, Y AF Wang, He Hoda, Raza S. Faquin, William Rossi, Esther Diana Hotchandani, Nihar Sun, Tianlin Pusztaszeri, Marc Bizzarro, Tommaso Bongiovanni, Massimo Patel, Viren Jhala, Nirag Fadda, Guido Gong, Yun TI FNA biopsy of secondary nonlymphomatous malignancies in salivary glands: A multi-institutional study of 184 cases SO CANCER CYTOPATHOLOGY LA English DT Article DE ancillary test; fine-needle aspiration biopsy; metastasis; multi-institutional; salivary gland ID FINE-NEEDLE-ASPIRATION; RENAL-CELL CARCINOMA; OF-THE-LITERATURE; PAROTID-GLAND; CYTOLOGY; TUMORS; NEOPLASMS; LESIONS; MANAGEMENT; DIAGNOSIS AB BACKGROUNDSecondary malignancies of salivary glands (SMSGs) are among the most common malignant neoplasms to involve the salivary glands. Fine-needle aspiration biopsy (FNAB) of SMSG can present diagnostic challenges. The current report presents the largest such FNAB series to date. METHODSA search of the pathology database from 6 academic institutions identified 184 FNAB cases of nonlymphomatous SMSG. RESULTSOf the 184 cases, 171 were of the parotid glands, and 13 were of the submandibular glands; 130 patients were men, and 54 were women, and the mean patient age at diagnosis was 68 years. Metastatic squamous cell carcinoma (SCC) from all sites (n=87) and melanoma (n=67) constituted the majority of SMSGs. Less frequent SMSGs were comprised of metastatic carcinomas from distant organs (n=16), including sites in the breast, lung, kidney, thyroid, pancreatobiliary, prostate, and bladder. Other uncommon SMSGs, including nasopharyngeal carcinoma (n=3), sarcoma (n=4), other metastatic skin-derived carcinomas (n=6), and metastatic chordoma (n=1), also were observed. Ancillary tests were performed on 37 FNAB specimens (20.1%) to aid the evaluation. One hundred forty-seven specimens (79.9%) had a definitive diagnosis with accurate tumor subtyping, 21 (11.4%) had a definitive malignant diagnosis but without specifying subtype, 9 (4.9%) had an indeterminate diagnosis, and 7 (3.8%) had a false-negative diagnosis. CONCLUSIONSSMSGs originate predominately from the head and neck and are more common in older men. Overall, the FNAB diagnosis of SMSG is accurate, but diagnostic challenges can be encountered, especially in SCC types of SMSG. Ancillary studies are needed for the definitive diagnosis of challenging cases. Cancer Cytopathol 2017;125:91-103. (c) 2016 American Cancer Society. The fine-needle aspiration biopsy diagnosis of secondary nonlymphomatous malignancy is accurate overall. However, diagnostic challenges can be encountered, especially in the squamous cell carcinoma type of secondary nonlymphomatous malignancy. C1 [Wang, He; Hotchandani, Nihar; Patel, Viren; Jhala, Nirag] Temple Univ Hosp & Med Sch, Dept Pathol & Lab Med, 3401 North Broad St,350-OPB, Philadelphia, PA 19140 USA. [Hoda, Raza S.; Faquin, William] Harvard Univ, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA. [Rossi, Esther Diana; Bizzarro, Tommaso; Fadda, Guido] Univ Cattolica Sacro Cuore, Dept Anat Pathol & Histol, Rome, Italy. [Sun, Tianlin; Gong, Yun] Univ Texas MD Anderson Canc Ctr, Div Pathol & Lab Med, Dept Pathol, Houston, TX 77030 USA. [Pusztaszeri, Marc] Univ Hosp Geneva, Dept Pathol, Geneva, Switzerland. [Bongiovanni, Massimo] Univ Hosp, Inst Pathol, Lausanne, Switzerland. RP Wang, H (reprint author), Temple Univ Hosp & Med Sch, Dept Pathol & Lab Med, 3401 North Broad St,350-OPB, Philadelphia, PA 19140 USA. EM he.wang@tuhs.temple.edu OI Bongiovanni, Massimo/0000-0001-9846-6682 NR 60 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1934-662X EI 1934-6638 J9 CANCER CYTOPATHOL JI Cancer Cytopathol. PD FEB PY 2017 VL 125 IS 2 BP 91 EP 103 DI 10.1002/cncy.21798 PG 13 WC Oncology; Pathology SC Oncology; Pathology GA EL5DA UT WOS:000394640600004 PM 28001329 ER PT J AU Sawaya, FJ Morice, MC Spaziano, M Mehran, R Didier, R Roy, A Valgimigli, M Kim, HS Park, KW Hong, MK Kim, BK Jang, Y Feres, F Abizaid, A Costa, RA Colombo, A Chieffo, A Giustino, G Stone, GW Bhatt, DL Palmerini, T Gilard, M AF Sawaya, Fadi J. Morice, Marie-Claude Spaziano, Marco Mehran, Roxana Didier, Romain Roy, Andrew Valgimigli, Marco Kim, Hyo-Soo Park, Kyung Woo Hong, Myeong-Ki Kim, Byeong-Keuk Jang, Yangsoo Feres, Fausto Abizaid, Alexandre Costa, Ricardo A. Colombo, Antonio Chieffo, Alaide Giustino, Gennaro Stone, Gregg W. Bhatt, Deepak L. Palmerini, Tullio Gilard, Martine TI Short-Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Women Versus Men: A Sex-Specific Patient-Level Pooled-Analysis of Six Randomized Trials SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE dual antiplatelet therapy duration; major adverse cardiac events; drug-eluting stents; women ID PERCUTANEOUS CORONARY INTERVENTION; COLLABORATIVE METAANALYSIS; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; HEART-ASSOCIATION; CLINICAL-TRIALS; DURATION; EFFICACY; DISEASE; SAFETY AB Background: Whether the efficacy and safety of dual antiplatelet therapy (DAPT) are uniform between sexes is unclear. We sought to compare clinical outcomes between short-(<= 6 months) versus long-term (>= 1 year) DAPT after drug-eluting stent (DES) placement in women and men. Methods and Results: We pooled individual patient data from6 randomized trials of DAPT (EXCELLENT, OPTIMIZE, PRODIGY, RESET, SECURITY, ITALIC PLUS). The primary outcome was 1-year risk of major adverse cardiac events (MACE). The main secondary outcome was 1-year risk of any bleeding. Out of the 11,473 randomized patients included in the pooled dataset, 3,454 (30%) were females. At 1-year follow-up, women had higher risk of MACE (3.6% vs. 2.8%; P=0.01) but similar risk of bleeding (1.9% vs. 1.6%; P=0.16) as compared with men. Compared with long-term DAPT, short-term DAPT was associated with similar rates of MACE in both women (HR 0.88; 95% CI 0.62-1.25) and men (HR 1.25; 95% CI 0.95-1.6; P interaction50.08)]. At 1-year follow-up, short-term DAPTwas associated with lower rates of bleeding as compared with long-term DAPT in both women (HR 0.84; 95% CI 0.51-1.37) and men (HR 0.58; 95% CI 0.40-0.84; P-interaction50.25). The presence of MVD was associated with higher MACE rates in the short-term DAPT group in women (HR: 1.16; CI 0.60-2.23) and men (HR: 2.29; CI 1.22-4.29; P interaction50.25). Conclusions: Short-term DAPT is associated with similar rates of MACE but lower risk of bleeding when as compared with prolonged DAPT. There was no significant difference between sexes in the population studied. (C) 2016 Wiley Periodicals, Inc. C1 [Sawaya, Fadi J.; Morice, Marie-Claude; Spaziano, Marco; Roy, Andrew] Hop Prive Jacques Cartier, Inst Cardiovasc Paris, Dept Cardiol, Gen Sante, Massy, France. [Mehran, Roxana] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Didier, Romain; Gilard, Martine] CHU Cavale Blanche, Dept Cardiol, Brest, France. [Valgimigli, Marco] Erasmus MC, Thoraxctr, Rotterdam, Netherlands. [Kim, Hyo-Soo; Park, Kyung Woo] Seoul Natl Univ, Main Hosp, Dept Cardiol, Seoul, South Korea. [Hong, Myeong-Ki; Kim, Byeong-Keuk; Jang, Yangsoo] Yonsei Univ, Coll Med, Severance Cardiovasc Hosp, Seoul, South Korea. [Feres, Fausto; Abizaid, Alexandre; Costa, Ricardo A.] Ist Dante Pazzanese Cardiol, Sao Paulo, Brazil. [Colombo, Antonio; Chieffo, Alaide; Giustino, Gennaro] Ist Sci San Raffaele, Milan, Italy. [Stone, Gregg W.] Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY USA. [Stone, Gregg W.] Cardiovasc Res Fdn, New York, NY USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, 75 Francis St, Boston, MA 02115 USA. [Bhatt, Deepak L.] Harvard Med Sch, Boston, MA USA. [Palmerini, Tullio] Univ Bologna, Dipartimento Cardiotoracovasc, Bologna, Italy. RP Morice, MC (reprint author), Hop Prive Jacques Cartier, Inst Cardiovasc Paris Sud, Gen Sante, 6 Ave Noyer Lambert, F-91300 Massy, France. EM mc.morice@icps.com.fr FU Abbott Vascular; Eli Lilly; Amarin; AstraZeneca; Bristol-Myers Squibb; Eisai; Ethicon; Forest Laboratories; Ischemix; Medtronic; Pfizer; Roche; Sanofi Aventis; Medicines Company; Lilly; Sanofi; Daiichi Sankyo; Bayer; Boston Scientific; CSL Behring; Covidien; Janssen Pharmaceuticals; Maya Medical; Merck; Osprey Medical Inc.; Regado Biosciences; Watermark Research Partners FX Dr. Palmerini has received a speaker fee from Abbott Vascular; and a research grant from Eli Lilly. Dr. Bhatt discloses the following relationships-Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Vice-Chair), VA CART Research and Publications Committee (Chair); Research Funding: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi Aventis, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical; Trustee: American College of Cardiology; Unfunded Research: FlowCo, PLx Pharma, Takeda. Dr. Mehran has received institutional research grant support from The Medicines Company, AstraZeneca, Bristol-Myers Squibb, Sanofi, Lilly, and Daiichi Sankyo; has received consulting fees from Abbott Vascular, AstraZeneca, Bayer, Boston Scientific, CSL Behring, Covidien, Janssen Pharmaceuticals, Maya Medical, Merck, Osprey Medical Inc., Regado Biosciences, Watermark Research Partners, and Sanofi; and serves on the scientific advisory board of Abbott Laboratories, Boston Scientific Corporation, Covidien, Janssen Pharmaceuticals, The Medicines Company, and Sanofi. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. F.S, M.C.M, M.S contributed equally to the manuscript. NR 43 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD FEB 1 PY 2017 VL 89 IS 2 BP 178 EP 189 DI 10.1002/ccd.26653 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EM9WL UT WOS:000395662000005 PM 27426936 ER PT J AU Klein, LW Harjai, KJ Resnic, F Weintraub, WS Anderson, V Yeh, RW Feldman, DN Gigliotti, OS Rosenfeld, K Duffy, P AF Klein, Lloyd W. Harjai, Kishore J. Resnic, Fred Weintraub, William S. Anderson, Vernon Yeh, Robert W. Feldman, Dmitriy N. Gigliotti, Osvaldo S. Rosenfeld, Kenneth Duffy, Peter TI 2016 Revision of the SCAI Position Statement on Public Reporting SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Editorial Material ID PERCUTANEOUS CORONARY INTERVENTION; CARDIOVASCULAR DATA REGISTRY; ACUTE MYOCARDIAL-INFARCTION; MORTALITY RISK PREDICTION; COLLEGE-OF-CARDIOLOGY; AMERICAN-COLLEGE; NEW-YORK; CARDIOGENIC-SHOCK; CARDIAC-SURGERY; UNITED-STATES C1 [Klein, Lloyd W.] Rush Med Coll, Chicago, IL USA. [Harjai, Kishore J.] Geisinger Med Clin, Wilkes Barre, PA USA. [Resnic, Fred] Lahey Hosp & Med Ctr, Burlington, MA USA. [Resnic, Fred] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Weintraub, William S.] Christiana Care Hlth Syst, Newark, DC USA. [Anderson, Vernon] Univ Texas, McGovern Med Sch, Hlth Sci Ctr Houston, Houston, TX USA. [Yeh, Robert W.] Beth Israel Deaconess Med Ctr, Smith Ctr Outcomes Res Cardiol, Boston, MA USA. [Feldman, Dmitriy N.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA. [Gigliotti, Osvaldo S.] Seton Heart Inst, Austin, TX USA. [Rosenfeld, Kenneth] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. [Duffy, Peter] First Hlth, Pinehurst, NC USA. RP Klein, LW (reprint author), FSCAI, 3000 North Halsted Suite 625, Chicago, IL 60614 USA. EM lloydklein@comcast.net NR 40 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD FEB 1 PY 2017 VL 89 IS 2 BP 269 EP 279 DI 10.1002/ccd.26818 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EM9WL UT WOS:000395662000018 PM 27755653 ER PT J AU Liu, X Lieberman, J AF Liu, Xing Lieberman, Judy TI How ICE lights the pyroptosis fire SO CELL DEATH AND DIFFERENTIATION LA English DT Editorial Material ID HOST-CELL DEATH; NONCANONICAL INFLAMMASOME ACTIVATION; GASDERMIN-D; INTRACELLULAR LPS; CASPASE-11; GSDMD; PORE; SALMONELLA; MECHANISM; FAMILY C1 [Liu, Xing; Lieberman, Judy] Harvard Med Sch, Program Cellular & Mol Med, Childrens Hosp, 200 Longwood Ave,Warren Alpert Bldg 255, Boston, MA 02115 USA. [Liu, Xing; Lieberman, Judy] Harvard Med Sch, Dept Pediat, 200 Longwood Ave,Warren Alpert Bldg 255, Boston, MA 02115 USA. RP Lieberman, J (reprint author), Harvard Med Sch, Program Cellular & Mol Med, Childrens Hosp, 200 Longwood Ave,Warren Alpert Bldg 255, Boston, MA 02115 USA.; Lieberman, J (reprint author), Harvard Med Sch, Dept Pediat, 200 Longwood Ave,Warren Alpert Bldg 255, Boston, MA 02115 USA. EM Judy.Lieberman@childrens.harvard.edu NR 19 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1350-9047 EI 1476-5403 J9 CELL DEATH DIFFER JI Cell Death Differ. PD FEB PY 2017 VL 24 IS 2 BP 197 EP 199 DI 10.1038/cdd.2016.157 PG 3 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA EN1SE UT WOS:000395789500003 PM 28060375 ER PT J AU Norberg, E Lako, A Chen, PH Stanley, IA Zhou, F Ficarro, SB Chapuy, B Chen, LF Rodig, S Shin, D Choi, DW Lee, S Shipp, MA Marto, JA Danial, NN AF Norberg, Erik Lako, Ana Chen, Pei-Hsuan Stanley, Illana A. Zhou, Feng Ficarro, Scott B. Chapuy, Bjoern Chen, Linfeng Rodig, Scott Shin, Donghyuk Choi, Dong Wook Lee, Sangho Shipp, Margaret A. Marto, Jarrod A. Danial, Nika N. TI Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets SO CELL DEATH AND DIFFERENTIATION LA English DT Article ID NON-HODGKIN-LYMPHOMA; OXIDATIVE STRESS; COMPLEX-I; CANCER METABOLISM; MASS-SPECTROMETRY; PROTEIN-SYNTHESIS; FUEL CHOICE; TIGECYCLINE; EXPRESSION; ORGANIZATION AB Diffuse large B-cell lymphomas (DLBCLs) are a highly heterogeneous group of tumors in which subsets share molecular features revealed by gene expression profiles and metabolic fingerprints. While B-cell receptor (BCR)-dependent DLBCLs are glycolytic, OxPhos-DLBCLs rely on mitochondrial energy transduction and nutrient utilization pathways that provide pro-survival benefits independent of BCR signaling. Integral to these metabolic distinctions is elevated mitochondrial electron transport chain (ETC) activity in OxPhos-DLBCLs compared with BCR-DLBCLs, which is linked to greater protein abundance of ETC components. To gain insights into molecular determinants of the selective increase in ETC activity and dependence on mitochondrial energy metabolism in OxPhos-DLBCLs, we examined the mitochondrial translation pathway in charge of the synthesis of mitochondrial DNA encoded ETC subunits. Quantitative mass spectrometry identified increased expression of mitochondrial translation factors in OxPhos-DLBCL as compared with the BCR subtype. Biochemical and functional assays indicate that the mitochondrial translation pathway is required for increased ETC activity and mitochondrial energy reserves in OxPhos-DLBCL. Importantly, molecular depletion of several mitochondrial translation proteins using RNA interference or pharmacological perturbation of the mitochondrial translation pathway with the FDA-approved inhibitor tigecycline (Tigecyl) is selectively toxic to OxPhos-DLBCL cell lines and primary tumors. These findings provide additional molecular insights into the metabolic characteristics of OxPhos-DLBCLs, and mark the mitochondrial translation pathway as a potential therapeutic target in these tumors. C1 [Norberg, Erik; Lako, Ana; Chen, Pei-Hsuan; Stanley, Illana A.; Zhou, Feng; Ficarro, Scott B.; Choi, Dong Wook; Marto, Jarrod A.; Danial, Nika N.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Zhou, Feng; Ficarro, Scott B.; Marto, Jarrod A.] Dana Farber Canc Inst, Blais Prote Ctr, Boston, MA 02115 USA. [Chapuy, Bjoern; Chen, Linfeng; Shipp, Margaret A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Rodig, Scott; Marto, Jarrod A.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Shin, Donghyuk; Lee, Sangho] Sungkyunkwan Univ, Dept Biol Sci, Suwon 16419, South Korea. RP Danial, NN (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave,CLSB 11-143, Boston, MA 02115 USA. EM nika_danial@dfci.harvard.edu FU US National Institutes of Health [R21 CA178860]; V Foundation for Cancer Research [F31 CA171400]; Swedish Society for Medical Research (SSMF); Malin and Lennart Philipson Foundation; Dana-Farber Cancer Institute Strategic Research Initiative; [CA188881] FX We thank Elaura Patton, Meghan Tedoldi, and Heather Sun for technical assistance, Rebecca Acin-Perez and Jose Antonio Enriquez for advice on mitochondrial supercomplexes, and Benjamin Szlyk for graphics. This work was supported by the US National Institutes of Health grants R21 CA178860 (NND and JAM), V Foundation for Cancer Research (NND and MAS), F31 CA171400 (IAS), the Swedish Society for Medical Research (SSMF), and The Malin and Lennart Philipson Foundation (EN). We also acknowledge generous support provided through the Dana-Farber Cancer Institute Strategic Research Initiative and CA188881 (JAM). NR 60 TC 1 Z9 1 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1350-9047 EI 1476-5403 J9 CELL DEATH DIFFER JI Cell Death Differ. PD FEB PY 2017 VL 24 IS 2 BP 251 EP 262 DI 10.1038/cdd.2016.116 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA EN1SE UT WOS:000395789500008 PM 27768122 ER PT J AU Rockette-Wagner, B Storti, KL Edelstein, S Delahanty, LM Galvin, B Jackson, A Kriska, AM AF Rockette-Wagner, Bonny Storti, Kristi L. Edelstein, Sharon Delahanty, Linda M. Galvin, Bryan Jackson, Alexandra Kriska, Andrea M. TI Measuring Physical Activity and Sedentary Behavior in Youth with Type 2 Diabetes SO CHILDHOOD OBESITY LA English DT Article ID ACTIVITY RECALL; COMPUTER-SCIENCE; OLDER-ADULTS; SELF-REPORT; US ADULTS; VALIDITY; CHILDREN; ACCELEROMETER; ADOLESCENTS; HEALTH AB Background: Lifestyle interventions that encourage increasing physical activity (PA) and losing weight are critical for overweight and obese youth with comorbid conditions. Assessing PA within such lifestyle intervention efforts requires measurement tool(s) that are both accurate and appropriate for these youth. This research compares PA levels and sedentary behavior in an ethnically diverse cohort of overweight/obese youth with type 2 diabetes using both accelerometry and a questionnaire previously validated in the general youth population. Methods: Spearman's correlations were used to compare time spent sedentary and in different PA intensities between a questionnaire, the three-day PA recall (3DPAR), and an objective PA measure, the ActiGraph accelerometer, in 236 overweight/obese youth with diabetes. Results: Spearman correlations between 3DPAR and accelerometer results for total PA were small and not significant (rho=0.11, p >0.05 for males and females). Correlations for specific PA intensities (moderate/vigorous and light) were also small and not significant. Sedentary time between instruments was significant, but weakly correlated in females (rho=0.19, p<0.05), but not in males (rho=0.07, p=0.48). Conclusions: Subjective PA measures validated in the general youth population may not be the best method for differentiating levels of movement in overweight/obese youth with type 2 diabetes, who spend most of their time in light-intensity activity and sedentary pursuits with little or no time spent in moderate/vigorous-intensity activities. Objective measures such as accelerometers that can capture the lower end of the movement scale are likely the more appropriate measures under these conditions. C1 [Rockette-Wagner, Bonny; Storti, Kristi L.; Kriska, Andrea M.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Edelstein, Sharon] George Washington Univ, Biostat Ctr, Washington, DC USA. [Delahanty, Linda M.] Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA. [Delahanty, Linda M.] Harvard Med Sch, Boston, MA USA. [Galvin, Bryan] Univ Pittsburgh, Dept Orthoped Surg, Pittsburgh, PA USA. [Jackson, Alexandra] Washington Univ, St Louis, MO USA. RP Rockette-Wagner, B (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, 3512 Fifth Ave,Room 305, Pittsburgh, PA 15261 USA. EM bjr26@pitt.edu FU NIDDK/NIH [U01-DK61212, U01-DK61230, U01-DK61239, U01DK61242, U01-DK61254]; National Center for Research Resources (NCRR) [M01-RR00036, M01-RR00043-45, M01-RR00069, M01-RR00084, M01-RR01066, M01-RR00125, M01-RR14467]; NCRR Clinical and Translational Science Awards [UL1-RR024134, UL1-RR024139, UL1-RR024153, UL1-RR024989, UL1-RR024992, UL1-RR025758, UL1-RR025780] FX The authors would like to acknowledge the youth and their families who participated in this important endeavor and the staff of TODAY for their devotion and hard work. This work was completed with funding from NIDDK/NIH (grant numbers U01-DK61212, U01-DK61230, U01-DK61239, U01DK61242, and U01-DK61254); from the National Center for Research Resources (NCRR) General Clinical Research Centers Program [grant numbers M01-RR00036 (Washington University School of Medicine), M01-RR00043-45 (Children's Hospital Los Angeles), M01-RR00069 (University of Colorado Denver), M01-RR00084 (Children's Hospital of Pittsburgh), M01-RR01066 (Massachusetts General Hospital), M01-RR00125 (Yale University), and M01-RR14467 (University of Oklahoma Health Sciences Center)]; and from the NCRR Clinical and Translational Science Awards [grant numbers UL1-RR024134 (Children's Hospital of Philadelphia), UL1-RR024139 (Yale University), UL1-RR024153 (Children's Hospital of Pittsburgh), UL1-RR024989 (Case Western Reserve University), UL1-RR024992 (Washington University), UL1-RR025758 (Massachusetts General Hospital), and UL1-RR025780 (University of Colorado Denver)]. NR 37 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2153-2168 EI 2153-2176 J9 CHILD OBES JI Child Obes. PD FEB PY 2017 VL 13 IS 1 BP 72 EP 77 DI 10.1089/chi.2015.0151 PG 6 WC Pediatrics SC Pediatrics GA EL3FQ UT WOS:000394505400009 PM 26859798 ER PT J AU Dudzinski, DM Giri, J Rosenfield, K AF Dudzinski, David M. Giri, Jay Rosenfield, Kenneth TI Interventional Treatment of Pulmonary Embolism SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE catheter; percutaneous; pulmonary embolism; team-based care; thrombolysis ID VENA-CAVA FILTERS; DEEP-VEIN THROMBOSIS; PULSELESS ELECTRICAL-ACTIVITY; RIGHT HEART; INTRACRANIAL HEMORRHAGE; RHEOLYTIC THROMBECTOMY; PLASMINOGEN-ACTIVATOR; CARDIOGENIC-SHOCK; EUROPEAN-SOCIETY; TRAUMA PATIENTS AB Pulmonary embolism (PE) is a serious and prevalent cause of vascular disease. Nevertheless, optimal treatment for many phenotypes of PE remains uncertain. Treating PE requires appropriate risk stratification as a first step. For the highest-risk PE, presenting as shock or arrest, emergent systemic thrombolysis or embolectomy is reasonable, while for low-risk PE, anticoagulation alone is often chosen. Normotensive patients with PE but with indicia of right heart dysfunction (by biomarkers or imaging) constitute an intermediate-risk group for whom there is controversy on therapeutic strategy. Some intermediate-risk patients with PE may require urgent stabilization, and approximate to 10% will decompensate hemodynamically and suffer high mortality, though identifying these specific patients remains challenging. Systemic thrombolysis is a consideration, but its risks of major and intracranial hemorrhages rival overall harms from intermediate PE. Multiple hybrid pharmacomechanical approaches have been devised to capture the benefits of thrombolysis while reducing its risks, but there is limited aggregate clinical experience with such novel interventional strategies. One method to counteract uncertainty and generate a consensus multidisciplinary prognostic and therapeutic plan is through a Pulmonary Embolism Response Team, which combines expertise from interventional cardiology, interventional radiology, cardiac surgery, cardiac imaging, and critical care. Such a team can help determine which intervention-catheter-directed fibrinolysis, ultrasound-assisted thrombolysis, percutaneous mechanical thrombus fragmentation, or percutaneous or surgical embolectomy-is best suited to a particular patient. This article reviews these various modalities and the background for each. C1 [Dudzinski, David M.; Rosenfield, Kenneth] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Rosenfield, Kenneth] Massachusetts Gen Hosp, Vasc Med, Boston, MA 02114 USA. [Giri, Jay] Hosp Univ Penn, Div Cardiovasc Med, 3400 Spruce St, Philadelphia, PA 19104 USA. RP Dudzinski, DM (reprint author), Massachusetts Gen Hosp, Yawkey 5B,55 Fruit St, Boston, MA 02115 USA. EM ddudzinski@partners.org FU St Jude Medical; Abbott Vascular; Cardinal Health; Surmodics; Inari Medical; Volcano/Philips; Eximo; Capture Vascular; Silk Road; University of Maryland; VIVA; Atrium/Maquet; Lutonix/Bard; National Institutes of Health FX Dr Giri reports research funding to the institution from St Jude Medical. Dr Rosenfield reports personal fees from Abbott Vascular, Cardinal Health, Surmodics, Inari Medical, Volcano/Philips, Eximo, Capture Vascular, Silk Road, University of Maryland, and VIVA Physicians (a 501c3 educational organization); stock options from Contego, Embolitech, Shockwave, MD Insider, Valcare, Eximo, Micell, Endospan, and Silk Road; equity from MD Insider, Janacare, Primacea, PQ Bypass, Vortex, and Cruzar Systems; and grants from Atrium/Maquet, Lutonix/Bard, National Institutes of Health. Dr Dudzinski reports no conflicts. NR 75 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7640 EI 1941-7632 J9 CIRC-CARDIOVASC INTE JI Circ.-Cardiovasc. Interv. PD FEB PY 2017 VL 10 IS 2 AR e004345 DI 10.1161/CIRCINTERVENTIONS.116.004345 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EL3TN UT WOS:000394542300005 ER PT J AU Sarma, A O'Donoghue, ML AF Sarma, Amy O'Donoghue, Michelle L. TI Conundrums of Platelet Function Testing Does Sex Matter? SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS LA English DT Editorial Material DE Editorials; acute coronary syndrome; platelet aggregation; platelet function tests; sex ID PERCUTANEOUS CORONARY INTERVENTION; CLOPIDOGREL-TREATED PATIENTS; RESPONSE VARIABILITY; ANTIPLATELET THERAPY; REACTIVITY; METAANALYSIS; THROMBOSIS; OUTCOMES; DISEASE; VARIANT C1 [Sarma, Amy] Massachusetts Gen Hosp, Div Cardiovasc, Boston, MA 02114 USA. [O'Donoghue, Michelle L.] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 60 Fenwood Rd,7th Floor, Boston, MA 02115 USA. RP O'Donoghue, ML (reprint author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 60 Fenwood Rd,7th Floor, Boston, MA 02115 USA. EM modonoghue@partners.org NR 20 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7640 EI 1941-7632 J9 CIRC-CARDIOVASC INTE JI Circ.-Cardiovasc. Interv. PD FEB PY 2017 VL 10 IS 2 AR e004872 DI 10.1161/CIRCINTERVENTIONS.117.004872 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EL3TN UT WOS:000394542300014 ER PT J AU Sepucha, KR Wasfy, JH AF Sepucha, Karen R. Wasfy, Jason H. TI Implementing Shared Decision Making in the Rapidly Evolving Field of Valvular Heart Disease SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Editorial Material DE Editorials; anxiety; chest pain; coronary disease; decision making; surgeons ID ASSOCIATION TASK-FORCE; RANDOMIZED-TRIAL; AMERICAN-COLLEGE; GUIDELINE; AID C1 [Sepucha, Karen R.] Harvard Med Sch, Massachusetts Gen Hosp, Div Gen Internal Med, Hlth Decis Sci Ctr, Boston, MA USA. [Wasfy, Jason H.] Harvard Med Sch, Massachusetts Gen Hosp, Div Cardiol, Dept Med, Boston, MA USA. RP Sepucha, KR (reprint author), MGH, Hlth Decis Sci Ctr, 50 Staniford St,Suite 802, Boston, MA 02114 USA. EM ksepucha@mgh.harvard.edu FU Informed Medical Decisions Foundation FX Dr Sepucha receives salary support as a medical editor from the Informed Medical Decisions Foundation, which is now a part of Healthwise, a not-for-profit foundation that develops and distributes patient education and decision support materials. Dr Wasfy reports no conflicts. NR 19 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD FEB PY 2017 VL 10 IS 2 AR UNSP e003549 DI 10.1161/CIRCOUTCOMES.117.003549 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EL4CP UT WOS:000394569400019 ER PT J AU Spahillari, A Talegawkar, S Correa, A Carr, JJ Terry, JG Lima, J Freedman, JE Das, S Kociol, R de Ferranti, S Mohebali, D Mwasongwe, S Tucker, KL Murthy, VL Shah, RV AF Spahillari, Aferdita Talegawkar, Sameera Correa, Adolfo Carr, J. Jeffrey Terry, James G. Lima, Joao Freedman, Jane E. Das, Saumya Kociol, Robb de Ferranti, Sarah Mohebali, Donya Mwasongwe, Stanford Tucker, Katherine L. Murthy, Venkatesh L. Shah, Ravi V. TI Ideal Cardiovascular Health, Cardiovascular Remodeling, and Heart Failure in Blacks The Jackson Heart Study SO CIRCULATION-HEART FAILURE LA English DT Article DE blood pressure; body mass index; heart failure; hypertension; risk factors ID LEFT-VENTRICULAR MASS; ATTRIBUTABLE RISKS; AFRICAN-AMERICANS; ATHEROSCLEROSIS; ASSOCIATION; DISEASE; ALDOSTERONE; PREVALENCE; COHORT; ETHNICITY AB Background-The lifetime risk of heart failure (HF) is higher in the black population than in other racial groups in the United States. Methods and Results-We measured the Life's Simple 7 ideal cardiovascular health metrics in 4195 blacks in the JHS (Jackson Heart Study; 2000-2004). We evaluated the association of Simple 7 metrics with incident HF and left ventricular structure and function by cardiac magnetic resonance (n=1188). Mean age at baseline was 54.4 years (65% women). Relative to 0 to 2 Simple 7 factors, blacks with 3 factors had 47% lower incident HF risk (hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.39-0.73; P<0.0001); and those with >= 4 factors had 61% lower HF risk (HR, 0.39; 95% CI, 0.24-0.64; P=0.0002). Higher blood pressure (HR, 2.32; 95% CI, 1.28-4.20; P=0.005), physical inactivity (HR, 1.65; 95% CI, 1.07-2.55; P=0.02), smoking (HR, 2.04; 95% CI, 1.43-2.91; P<0.0001), and impaired glucose control (HR, 1.76; 95% CI, 1.34-2.29; P<0.0001) were associated with incident HF. The age-/sex-adjusted population attributable risk for these Simple 7 metrics combined was 37.1%. Achievement of ideal blood pressure, ideal body mass index, ideal glucose control, and nonsmoking was associated with less likelihood of adverse cardiac remodeling by cardiac magnetic resonance. Conclusions-Cardiovascular risk factors in midlife (specifically elevated blood pressure, physical inactivity, smoking, and poor glucose control) are associated with incident HF in blacks and represent targets for intensified HF prevention. C1 [Spahillari, Aferdita; Kociol, Robb] Harvard Med Sch, Div Cardiol, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA USA. [Talegawkar, Sameera] George Washington Univ, Milken Inst Sch Publ Hlth, Dept Exercise & Nutr Sci, Washington, DC USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. Vanderbilt Univ, Med Ctr, Dept Radiol, Nashville, TN 37232 USA. [Terry, James G.] Vanderbilt Univ, Dept Radiol, 221 Kirkland Hall, Nashville, TN 37235 USA. [Terry, James G.] Vanderbilt Univ, Vanderbilt Translat & Clin Cardiovasc Res Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA. [Lima, Joao] Johns Hopkins Univ, Dept Cardiol, Baltimore, MD USA. [Freedman, Jane E.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA. [Das, Saumya; Shah, Ravi V.] Harvard Med Sch, Massachusetts Gen Hosp, Div Cardiol, Dept Med, Boston, MA USA. [de Ferranti, Sarah] Childrens Hosp Boston, Dept Pediat, Boston, MA USA. [Mohebali, Donya] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA. [Mwasongwe, Stanford] Jackson State Univ, Jackson Heart Study, Field Ctr, Jackson, MS USA. [Tucker, Katherine L.] Univ Massachusetts Lowell, Dept Biomed & Nutr Sci, Lowell, MA USA. [Murthy, Venkatesh L.] Univ Michigan, Div Cardiovasc Med, Dept Med, Ann Arbor, MI 48109 USA. RP Shah, RV (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.; Murthy, VL (reprint author), Univ Michigan, 1338 Cardiovasc Ctr, Ann Arbor, MI 48109 USA. EM vlmurthy@med.umich.edu; rvshah@partners.org FU National Heart, Lung, and Blood Institute [HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN2682013000 49C, HHSN268201300050C]; National Institute on Minority Health and Health Disparities; National Institutes of Health [K23HL127099]; American Heart Association [16SFRN31740000] FX The JHS is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN2682013000 49C, and HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities. Dr Shah is funded by grants from the National Institutes of Health (K23HL127099) and the American Heart Association (16SFRN31740000). NR 35 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD FEB PY 2017 VL 10 IS 2 DI 10.1161/CIRCHEARTFAILURE.116.003682 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EL3LT UT WOS:000394521300010 ER PT J AU Grauballe, MB Belstrom, D Ostergaard, JA Paster, BJ Schou, S Flyvbjerg, A Holmstrup, P AF Grauballe, M. B. Belstrom, D. Ostergaard, J. A. Paster, B. J. Schou, S. Flyvbjerg, A. Holmstrup, P. TI Ligature-associated bacterial profiles are linked to type 2 diabetes mellitus in a rat model and influenced by antibody treatment against TNF-alpha or RAGE SO CLINICAL AND EXPERIMENTAL DENTAL RESEARCH LA English DT Article DE anti-RAGE; anti-TNF-alpha; diabetes mellitus; diabetes type 2; Periodontal disease; Periodontitis; stages ID CHRONIC PERIODONTITIS; MICROBIAL PROFILES; ORAL MICROBIOME; RODENT MODELS; INFECTIONS; MICROARRAY; DISEASES; GLUCOSE; HEALTH; PLAQUE AB There is a bidirectional relationship between periodontal disease (PD) and type 2 diabetes mellitus (T2D). T2D may lead to ecological perturbations in the oral environment, which may facilitate an altered microbiota. However, previous studies have been inconclusive in determining the effect of T2D on oral bacterial profiles. Therefore, we aimed to evaluate the influence of T2D on the ligature-associated bacterial profile in a diabetic rat model with PD and investigated the impact of blocking inflammatory pathways with antibodies targeting either Tumor Necrosis Factor alpha (TNF-alpha) or the receptor of advanced glycation end-products (RAGE). A total of 62 Zucker obese rats (45 T2D) and 17 lean (non-T2D) were divided into 4 treatment groups; lean with PD, obese with PD, obese with PD and anti-TNF-alpha treatment, and obese with PD with anti-RAGE treatment. Periodontal disease was ligature induced. Ligature-associated bacterial profiles were analyzed using Human Oral Microbe Identification Microarray (HOMIM). Ligature-associated bacterial profiles differed between lean and obese rats. Furthermore, treatment with antibodies against TNF-alpha or RAGE had an impact on subgingival bacterial profiles. T2D phenotypes are associated with different ligature-associated bacterial profiles and influenced by treatment with antibodies against TNF-alpha or RAGE. C1 [Grauballe, M. B.; Holmstrup, P.] Aarhus Univ, Fac Hlth, Sect Periodontol, Dept Dent, Vennelyst Blvd 9, DK-8000 Aarhus C, Denmark. [Belstrom, D.; Holmstrup, P.] Univ Copenhagen, Fac Hlth & Med Sci, Sect Periodontol Microbiol & Community Dent, Dept Odontol, Copenhagen N, Denmark. [Ostergaard, J. A.; Flyvbjerg, A.] Aarhus Univ, Fac Hlth, Dept Clin Med, Med Res Labs, Aarhus C, Denmark. [Ostergaard, J. A.; Flyvbjerg, A.] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Aarhus C, Denmark. [Ostergaard, J. A.; Flyvbjerg, A.] Danish Diabet Acad, Odense, Denmark. [Paster, B. J.] Forsyth Inst, Dept Microbiol, Cambridge, MA USA. [Paster, B. J.] Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA USA. [Schou, S.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Odontol, Sect Oral Surg & Oral Pathol, Copenhagen N, Denmark. [Flyvbjerg, A.] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Aarhus, Denmark. RP Grauballe, MB (reprint author), Aarhus Univ, Fac Hlth, Sect Periodontol, Dept Dent, Vennelyst Blvd 9, DK-8000 Aarhus C, Denmark. EM mcbg@sund.ku.dk FU Danish Medical Research Council; Horslev-Fonden; Simon Spies Foundation; Danish Dental Association; Danish Diabetes Association; Danish Diabetes Academy; Novo Nordisk Foundation FX Danish Medical Research Council; Horslev-Fonden; The Simon Spies Foundation; The Danish Dental Association; The Danish Diabetes Association; Danish Diabetes Academy; Novo Nordisk Foundation NR 36 TC 1 Z9 1 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2057-4347 J9 CLIN EXP DENT RES JI CLIN. EXP. DENT. RES. PD FEB PY 2017 VL 3 IS 1 BP 25 EP 31 DI 10.1002/cre2.54 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA EM0IM UT WOS:000395002000005 PM 28344834 ER PT J AU Kedrin, D Gandhi, SCC Wolf, M Roper, J Yilmaz, O Corey, K Khalili, H Stanford, FC Gala, M AF Kedrin, Dmitriy Gandhi, Shaan-Chirag Chandrahas Wolf, Molly Roper, Jatin Yilmaz, Omer Corey, Kathleen Khalili, Hamed Stanford, Fatima Cody Gala, Manish TI Bariatric Surgery Prior to Index Screening Colonoscopy Is Associated With a Decreased Rate of Colorectal Adenomas in Obese Individuals SO CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY LA English DT Article ID BODY-MASS INDEX; GASTRIC BYPASS-SURGERY; WEIGHT CHANGE; CANCER RISK; METAANALYSIS; MECHANISMS; MORTALITY; ADIPONECTIN; NUTRITION; COHORT AB OBJECTIVES: Obesity is an important risk factor for the development of colorectal cancer (CRC). Although the impact of bariatric surgery on CRC is conflicting, its impact on precursor lesions is unknown. The aim of this study was to determine whether bariatric surgery before index screening colonoscopy is associated with decreased development of colorectal adenomas. METHODS: We performed a retrospective cohort study of bariatric surgery patients who had undergone index, screening colonoscopy at an academic center from 2001 to 2014. Patients who had bariatric surgery at least 1 year before index colonoscopy were compared with those who had surgery after colonoscopy, using multivariable logistic regression to control for presurgical body mass index, sex, gender, race, type of surgery, aspirin use, metformin use, smoking, and age at colonoscopy. RESULTS: One hundred and twenty-five obese individuals who had bariatric surgery before colonoscopy were compared with 223 individuals who had colonoscopy after surgery. Adenomatous polyps were found in 16.8% of individuals who had surgery first vs. 35.5% who had colonoscopy before bariatric surgery (unadjusted odds ratio (OR) 0.37, 95% confidence interval (CI): 0.21-0.64, P=0.0003). After multivariable adjustment, bariatric surgery before index screening colonoscopy was associated with a decreased risk of adenomas at index colonoscopy (adjusted OR 0.37, 95% CI: 0.19-0.69, P=0.002). CONCLUSIONS: Bariatric surgery is associated with a decreased risk of colorectal adenomas in obese individuals without a family history of CRC. C1 [Kedrin, Dmitriy; Gandhi, Shaan-Chirag Chandrahas; Wolf, Molly; Corey, Kathleen; Khalili, Hamed; Gala, Manish] Massachusetts Gen Hosp, Div Gastroenterol, 55 Fruit St,GRJ 825-D, Boston, MA 02114 USA. [Kedrin, Dmitriy; Gandhi, Shaan-Chirag Chandrahas; Wolf, Molly; Corey, Kathleen; Khalili, Hamed; Gala, Manish] Harvard Med Sch, 55 Fruit St,GRJ 825-D, Boston, MA 02114 USA. [Kedrin, Dmitriy; Roper, Jatin; Yilmaz, Omer] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Gandhi, Shaan-Chirag Chandrahas; Wolf, Molly] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA. [Roper, Jatin] Tufts Med Ctr, Div Gastroenterol, Boston, MA USA. [Corey, Kathleen; Stanford, Fatima Cody] Massachusetts Gen Hosp, Massachusetts Gen Weight Ctr, Boston, MA 02114 USA. [Stanford, Fatima Cody] Dept Pediat, Div Endocrinol, Boston, MA USA. RP Gala, M (reprint author), Massachusetts Gen Hosp, Div Gastroenterol, 55 Fruit St,GRJ 825-D, Boston, MA 02114 USA.; Gala, M (reprint author), Harvard Med Sch, 55 Fruit St,GRJ 825-D, Boston, MA 02114 USA. EM mgala@mgh.harvard.edu FU National Institutes of Health [T32 DK007191, R00 AG045144, K23 DK103119]; American College of Gastroenterology FX This study was supported by the National Institutes of Health (T32 DK007191 to D. K.; R00 AG045144 to H. Y; K23 DK103119 to M. G.) and the American College of Gastroenterology (Junior Faculty Development Award to M. G.). Potential competing interests: M. G. has equity interest in New Amsterdam Genomics. NR 31 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2155-384X J9 CLIN TRANSL GASTROEN JI Clin. Transl. Gastroenterol. PD FEB PY 2017 VL 8 AR e73 DI 10.1038/ctg.2017.1 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EP0ZK UT WOS:000397115000001 PM 28181993 ER PT J AU Giugliano, RP Mach, F Zavitz, K Kurtz, C Schneider, J Wang, H Keech, A Pedersen, TR Sabatine, MS Sever, PS Honarpour, N Wasserman, SM Ott, BR AF Giugliano, Robert P. Mach, Francois Zavitz, Kenton Kurtz, Christopher Schneider, Jingjing Wang, Huei Keech, Anthony Pedersen, Terje R. Sabatine, Marc S. Sever, Peter S. Honarpour, Narimon Wasserman, Scott M. Ott, Brian R. CA EBBINGHAUS Investigators TI Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapyA cognitive study of patients enrolled in the FOURIER trial SO CLINICAL CARDIOLOGY LA English DT Article DE Lipid; Clinical trials; Preventive cardiology; Lipidology; Ischemic heart disease ID SERUM-CHOLESTEROL; ALZHEIMERS-DISEASE; REDUCING LIPIDS; METAANALYSIS; ASSOCIATION; PCSK9; RISK; DEMENTIA; PERFORMANCE; EVENTS AB Some observational studies raised concern that statins may cause memory impairment, leading to a US Food and Drug Administration warning. Similar questions were raised regarding proprotein convertase subtilisin/kexin-type 9 inhibitors (PCSK9i) and neurocognitive function. No prospectively designed study has evaluated the relationship between long-term PCSK9i use and cognition changes. Patients with prior cardiovascular disease treated with maximally tolerated statin enrolled in FOURIER (the randomized, double-blind, placebo-controlled cardiovascular outcome study of the PCSK9i evolocumab) could participate in this prospective assessment of cognitive function (EBBINGHAUS). Key additional exclusion criteria for EBBINGHAUS were dementia, cognitive impairment, or other significant mental or neurological disorder. Cognitive testing was performed using the Cambridge Neuropsychological Test Automated Battery, a tablet-based tool assessing executive function, working memory, memory function, and psychomotor speed at baseline, weeks 24 and 48, every 48 weeks thereafter, and study end. The primary endpoint was spatial working memory strategy index of executive function (SWMSI). The primary hypothesis was that evolocumab would be noninferior to placebo in the mean change from baseline over time in SWMSI. Fifteen hundred cognitively normal patients completing the assessments provided approximately 97% power to demonstrate that the upper 95% confidence interval for the treatment difference in mean change from baseline in SWMSI over time is <20% of the SD of the mean change in the placebo group. An exploratory analysis will compare neurocognitive function in patients with post-baseline low-density lipoprotein cholesterol <25 mg/dL. EBBINGHAUS will evaluate whether the addition of evolocumab to statin therapy affects cognitive function over time in patients with stable cardiovascular disease. C1 [Giugliano, Robert P.; Sabatine, Marc S.] Brigham & Womens Hosp, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA. [Mach, Francois] Univ Hosp Geneva, Cantonal Hosp, Div Cardiol, Geneva, Switzerland. [Zavitz, Kenton] Cambridge Cognit, Cambridge, England. [Kurtz, Christopher; Schneider, Jingjing; Wang, Huei; Honarpour, Narimon; Wasserman, Scott M.] Amgen Inc, Thousand Oaks, CA USA. [Keech, Anthony] Univ Sydney, Sydney Med Sch, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia. [Pedersen, Terje R.] Oslo Univ Hosp, Ctr Prevent Med, Ulleval, Norway. [Pedersen, Terje R.] Univ Oslo, Fac Med, N-0316 Oslo, Norway. [Sever, Peter S.] Imperial Coll London, Int Ctr Circulatory Hlth, London, England. [Ott, Brian R.] Brown Univ, Warren Alpert Med Sch, Dept Neurol, Providence, RI 02912 USA. RP Giugliano, RP (reprint author), TIMI Study Grp, 350 Longwood Ave,First Floor Off, Boston, MA 02115 USA. EM rgiugliano@partners.org FU Amgen; Merck FX EBBINGHAUS and FOURIER trials were supported by grants from by Amgen to Dr. Giugliano's institution for the conduct of these studies; Dr. Giugliano's institution also received research-grant support from Merck for his participation in another lipid-lowering trial. NR 46 TC 0 Z9 0 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0160-9289 EI 1932-8737 J9 CLIN CARDIOL JI Clin. Cardiol. PD FEB PY 2017 VL 40 IS 2 BP 59 EP 65 DI 10.1002/clc.22678 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EM0WG UT WOS:000395037800001 PM 28207168 ER PT J AU Ho, SB Monto, A Peyton, A Kaplan, DE Byrne, S Moon, S Copans, A Rossaro, L Roy, A Le, H Dvory-Sobol, H Zhu, YN Brainard, DM Guyer, W Shaikh, O Fuchs, M Morgan, TR AF Ho, Samuel B. Monto, Alexander Peyton, Adam Kaplan, David E. Byrne, Sean Moon, Scott Copans, Amanda Rossaro, Lorenzo Roy, Anupma Le, Hadley Dvory-Sobol, Hadas Zhu, Yanni Brainard, Diana M. Guyer, William Shaikh, Obaid Fuchs, Michael Morgan, Timothy R. CA VALOR Study Team TI Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE VA; DAA; NS5B Inhibitor; Substance Abuse; Clinical Trial ID PSYCHIATRIC-ILLNESS; US VETERANS; VELPATASVIR; PREVALENCE; OUTCOMES; THERAPY; AFFAIRS; ALPHA; CARE AB BACKGROUND & AIMS: We conducted a phase 4, open-label study with limited exclusion criteria to evaluate the safety and efficacy of sofosbuvir and ribavirin in veterans with hepatitis C virus genotype 2 infection, and compensated cirrhosis. This population is often excluded from clinical studies. METHODS: We performed a prospective study of treatment-naive (n = 47) and treatment-experienced (n = 19) patients with chronic hepatitis C virus genotype 2 infection and compensated cirrhosis at 15 Department of Veterans Affairs sites. All subjects were given sofosbuvir (400 mg, once daily) plus ribavirin (1000-1200 mg/day) in divided doses for 12 weeks. Patients with major psychiatric diseases or alcohol or substance use disorders were not excluded. The primary endpoint was sustained virologic response 12 weeks after therapy. RESULTS: Fifty- two patients achieved a sustained virologic response 12 weeks after therapy (79%; 95% confidence interval, 67%-88%); 16 of these patients were treatment experienced (84%; 95% confidence interval, 60%-97%) and 36 were treatment naive (77%; 95% confidence interval, 62%-88%). All patients had at least 1 comorbidity. Thirty-five percent had depression, 24% had posttraumatic stress disorder, and 30% had anxiety disorder. In addition, 29% had current substance use. Of the 7 patients (11%) who discontinued the study treatment prematurely, 3 did so because of adverse events. The most common adverse events were fatigue, anemia, nausea, and headache. Serious adverse events occurred in 8 patients. Only 2 of the serious adverse events (anemia and nausea) were considered to be related to study treatment. CONCLUSIONS: In a phase 4 study, 12 weeks treatment with sofosbuvir and ribavirin led to a sustained virologic response 12 weeks after therapy in almost 80% of veterans with hepatitis C virus genotype 2 infection, compensated cirrhosis, and multiple comorbidities, regardless of their treatment history. ClinicalTrials. gov, Number: NCT02128542 C1 [Ho, Samuel B.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA. [Monto, Alexander] San Francisco Vet Affairs Healthcare Syst, San Francisco, CA USA. [Peyton, Adam] Miami Vet Affairs Healthcare Syst, Miami, FL USA. [Kaplan, David E.] Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia, PA USA. [Byrne, Sean; Moon, Scott; Copans, Amanda; Rossaro, Lorenzo; Roy, Anupma; Le, Hadley; Dvory-Sobol, Hadas; Zhu, Yanni; Brainard, Diana M.; Guyer, William] Gilead Sci, Foster City, CA USA. [Shaikh, Obaid] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Fuchs, Michael] Richmond Vet Affairs Med Ctr, Richmond, VA USA. [Morgan, Timothy R.] Vet Affairs Long Beach Healthcare Syst, Long Beach, CA USA. RP Ho, SB (reprint author), Vet Affairs San Diego Healthcare Syst, San Diego, CA USA. EM samuel.ho2@va.gov FU Gilead Sciences, Inc. FX Funding for this study was provided by Gilead Sciences, Inc. NR 20 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD FEB PY 2017 VL 15 IS 2 BP 282 EP 288 DI 10.1016/j.cgh.2016.05.024 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EP2XH UT WOS:000397246400022 PM 27237429 ER PT J AU Necchi, A Pond, GR Raggi, D Giannatempo, P Vogelzang, NJ Grivas, P Galsky, MD Bellmunt, J Sonpavde, G AF Necchi, Andrea Pond, Gregory R. Raggi, Daniele Giannatempo, Patrizia Vogelzang, Nicholas J. Grivas, Petros Galsky, Matthew D. Bellmunt, Joaquim Sonpavde, Guru TI Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis SO CLINICAL GENITOURINARY CANCER LA English DT Review DE First-line therapy; Meta-analysis; Systemic therapy; Taxanes; Urothelial carcinoma ID TRANSITIONAL-CELL CARCINOMA; CISPLATIN-BASED CHEMOTHERAPY; COOPERATIVE-ONCOLOGY-GROUP; PHASE-II TRIAL; BLADDER-CANCER; ELDERLY-PATIENTS; PACLITAXEL; THERAPY; UNFIT; COMBINATION AB Although gemcitabine plus carboplatin (GCa) is the conventional first-line chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma, its results are suboptimal. A meta-analysis evaluated the results of gemcitabine with either carboplatin or a taxane (GT). Literature was searched for studies including GT (paclitaxel or docetaxel) and GCa. We pooled trial level data including response-rate, progression-free survival, overall survival (OS), and Grade 3 to 4 side effects. Trial characteristics and outcomes were univariably compared between GT and GCa. Those factors, which were recorded in > 12 trials, were analyzed. Multivariable regression models were used adjusting for Eastern Cooperative Oncology Group performance status 2 and the presence of visceral metastases. Each trial was weighted by its sample size. Twenty-seven arms of trials totaling 1032 patients were selected, of which 13 contained GT (n = 484) and 14 GCa (n = 548). The percentage of patients with Eastern Cooperative Oncology Group performance status 2 was statistically significantly different between the 2 groups (median, 8.7% vs. 23.9%; P = .003). No efficacy outcome was statistically significantly different. Median OS was 13.2 months (range, 10-15.8 months) for GT and 10 months (range, 3.3-20 months) for GCa (P = .12). However, statistically significant increases in the frequency of Grade 3 to 4 anemia (P = .010) and thrombocytopenia (P = .010) for GCa, and neuropathy (P = .040) for GT were observed. No difference in OS according to treatment was found multivariably (P = .79). In this analysis, a similar response rate and survival and worse neurotoxicity were observed with GT compared with GCa, for which hematologic toxicity was more frequent. GT is an alternative to GCa for advanced cisplatin-ineligible urothelial cancer. (C) 2016 Elsevier Inc. All rights reserved. C1 [Necchi, Andrea; Raggi, Daniele; Giannatempo, Patrizia] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Via G Venezian 1, I-20133 Milan, Italy. [Pond, Gregory R.] McMaster Univ, Hamilton, ON, Canada. [Vogelzang, Nicholas J.] US Oncol Res, Comprehens Ctr Nevada, Dev Therapeut Comm, Las Vegas, NV USA. [Vogelzang, Nicholas J.] US Oncol Res, Comprehens Ctr Nevada, Co Chair Genitourinary Comm, Las Vegas, NV USA. [Grivas, Petros] Cleveland Clin, Taussig Canc Inst, Hematol & Oncol, Cleveland, OH USA. [Galsky, Matthew D.] Mt Sinai Sch Med, Tisch Canc Inst, Genitourinary Med Oncol, New York, NY USA. [Bellmunt, Joaquim] Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA USA. [Sonpavde, Guru] Harvard Med Sch, Boston, MA USA. [Sonpavde, Guru] UAB Comprehens Canc Ctr, Med Oncol & Hematol, Birmingham, AL USA. RP Necchi, A (reprint author), Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Via G Venezian 1, I-20133 Milan, Italy. EM andrea.necchi@istitutotumori.mi.it NR 46 TC 1 Z9 1 U1 0 U2 0 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 1558-7673 EI 1938-0682 J9 CLIN GENITOURIN CANC JI Clin. Genitourin. Cancer PD FEB PY 2017 VL 15 IS 1 BP 23 EP 30 DI 10.1016/j.clgc.2016.05.003 PG 8 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA EL5AF UT WOS:000394633100003 PM 27324051 ER PT J AU Buisan, O Orsola, A Areal, J Font, A Oliveira, M Martinez, R Ibarz, L AF Buisan, Oscar Orsola, Anna Areal, Joan Font, Albert Oliveira, Mario Martinez, Roberto Ibarz, Luis TI Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer SO CLINICAL GENITOURINARY CANCER LA English DT Article DE MIBC; Neoadjuvant therapy; NLR; RC; Urothelial cancer ID CISPLATIN-BASED CHEMOTHERAPY; UROTHELIAL CELL-CARCINOMA; NEUTROPHIL/LYMPHOCYTE RATIO; CLINICAL-OUTCOMES; GENE-EXPRESSION; PROGNOSIS AB Low pretreatment neutrophil-to-lymphocyte ratio might indicate good outcomes after neoadjuvant chemotherapy in muscle invasive bladder cancer. These findings, combined with established risk factors and novel genetic and molecular predictors, should result in an easily available and inexpensive method to improve risk stratification and decision-making regarding neoadjuvant chemotherapy for muscle invasive bladder cancer. Purpose: The pretreatment neutrophil-to-lymphocyte ratio (NLR) has been associated with cancer prognosis, influencing progression and chemosensitivity. We aimed to define the role of the NLR in predicting the outcomes to neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC). Patients and Methods: The data from patients treated with NAC and radical cystectomy for MIBC from 2007 to 2015 at a tertiary care center were reviewed. The clinicopathologic pretreatment, including the NLR, and post-treatment predictors were documented. The NLR was evaluated as a continuous variable on uni- and multivariate analysis and dichotomized in Kaplan-Meier curves. The relationships with outcomes (progression-free survival [PFS], cancer-specific survival [CSS], and overall survival [OS]) were analyzed using Cox regression analysis and log-rank tests. The pathologic response (PR) included any downstaging from the baseline clinical stage to the final pathologic stage. Results: Of 205 patients with MIBC, 75 underwent NAC (median follow-up, 31 months) with a 5-year PFS, CSS, and OS rate of 56%, 60%, and 52%, respectively, and a PR of 38.6%. On multivariate analysis, the PR, PFS, CSS, and OS were predicted by the NLR (hazard ratio > 0.8, 1.25, 1.27, and 1.12, respectively; P < .05 for all). The NLR with age and clinical stage predicted the PR. A NLR threshold of 2.26 better predicted CSS (P < .05) and OS (P = .055). The limitations included the retrospective design and modest number of cases. Conclusion: We have provided initial evidence that a low NLR helps understand the value of the underlying immune system in predicting a good outcome to NAC. The NLR is a simple and accessible biomarker that is easy to implement in clinical practice. In addition to established prognosticators and newer genomic predictors, the NLR could improve therapeutic algorithms and help in decision-making regarding the need for NAC, which is currently underused, in MIBC patients. C1 [Buisan, Oscar; Areal, Joan; Oliveira, Mario; Martinez, Roberto; Ibarz, Luis] Hosp Badalona Germans Trias & Pujol, Dept Urol, Barcelona, Spain. [Buisan, Oscar; Areal, Joan; Font, Albert; Oliveira, Mario; Martinez, Roberto; Ibarz, Luis] Autonomous Univ Barcelona, Barcelona, Spain. [Orsola, Anna] Dana Farber Canc Inst, Bladder Canc Ctr, 450 Brookline Ave, Boston, MA 02215 USA. [Font, Albert] Hosp Univ GermansTrias & Pujol, Catalan Inst Oncol, Dept Med, Med Oncol Serv, Barcelona, Spain. RP Orsola, A (reprint author), Dana Farber Canc Inst, Bladder Canc Ctr, 450 Brookline Ave, Boston, MA 02215 USA. EM annaorsola@gmail.com NR 32 TC 0 Z9 0 U1 0 U2 0 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 1558-7673 EI 1938-0682 J9 CLIN GENITOURIN CANC JI Clin. Genitourin. Cancer PD FEB PY 2017 VL 15 IS 1 BP 145 EP 151 DI 10.1016/j.clgc.2016.05.004 PG 7 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA EL5AF UT WOS:000394633100019 PM 27364982 ER PT J AU Scott, JL Wirth, JR EuDaly, JG Gilkeson, GS Cunningham, MA AF Scott, Jennifer L. Wirth, Jena R. EuDaly, Jackie G. Gilkeson, Gary S. Cunningham, Melissa A. TI Plasmacytoid dendritic cell distribution and maturation are altered in lupus prone mice prior to the onset of clinical disease SO CLINICAL IMMUNOLOGY LA English DT Article DE Rodent; Dendritic cells; Autoimmunity; Systemic lupus erythematosus ID I INTERFERON; PDC-TREM; SIGLEC-H; RECEPTOR; ERYTHEMATOSUS; ALPHA; AUTOIMMUNITY; EXPRESSION; ANTIGEN-2; IMMUNITY AB Plasmacytoid dendritic cells (pDCs) and their production of type I interferons (IFN) are key pathogenic mediators of systemic lupus erythematosus (SLE). Despite the key role of pDCs in SLE, the mechanism by which pDCs promote disease is not well understood. The first objective for this study was to assess the number and maturation state of pDCs in pre-disease NZM2410 lupus prone mice compared to control mice. Second, we sought to identify mechanisms responsible for the alteration in pDCs in NZM mice prior to onset of clinical disease. We compared the number and percent of pDCs in the spleens and bone marrow (BM) of pre-disease NZM24010 (NZM) mice to C57BL/6 (B6) control mice. In the spleens of pre-disease NZM mice, pDC percent and number were increased. This increase occurs in parallel with a decrease in BM pDC number and percent in the NZM mice. The decrease in BM pDC number suggests the increase in spleen pDCs is a result of altered pDC distribution and not increased production of pDCs in the BM. To determine if pDC developmental potential is altered in lupus prone mice, we cultured BM from NZM and B6 mice in vitro. We found a reduced percentage/number of pDCs developing from the BM of NZM mice compared to B6 mice, which further supports that the increase in pDC number is a result of altered pDC distribution rather than increased pDC production. To better characterize the pDC population, we compared the percentage of mature pDCs in the spleens and BM of NZM mice to controls. In the NZM mice, there is a dramatic reduction in the number of mature pDCs in the BM of NZM mice, suggesting that mature pDCs exit the BM at a higher rate/earlier maturation time compared to healthy mice. We conclude that pDCs contribution to disease pathogenesis in NZM mice may include the alteration of pDC distribution to increase the number of pDCs in the spleen prior to disease onset. (C) 2016 Published by Elsevier Inc. C1 [Scott, Jennifer L.] Med Univ South Carolina, Coll Grad Studies, Dept Microbiol & Immunol, 173 Ashley Ave,BSB 203, Charleston, SC 29425 USA. [Wirth, Jena R.; EuDaly, Jackie G.; Gilkeson, Gary S.; Cunningham, Melissa A.] Med Univ South Carolina, Div Rheumatol & Immunol, Dept Med, 96 Jonathan Lucas St,Suite 816, Charleston, SC 29425 USA. [Gilkeson, Gary S.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, 109 Bee St, Charleston, SC 29401 USA. RP Cunningham, MA (reprint author), Med Univ South Carolina, Dept Med, 96 Jonathan Lucas St,Suite 912, Charleston, SC 29425 USA. EM ScottJL@musc.edu; WirthJ@musc.edu; Eudalyjg@musc.edu; Gilkeson@musc.edu; Cunnima@musc.edu FU VA merit review grant [BX000470]; NIH grant [UT1 TR000062]; American Association of Immunology careers in Immunology Fellowship FX This work was funded by the VA merit review grant BX000470, the NIH grant UT1 TR000062, and American Association of Immunology careers in Immunology Fellowship. NR 24 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 EI 1521-7035 J9 CLIN IMMUNOL JI Clin. Immunol. PD FEB PY 2017 VL 175 BP 109 EP 114 DI 10.1016/j.clim.2016.12.009 PG 6 WC Immunology SC Immunology GA EN4FG UT WOS:000395962800014 PM 28041989 ER PT J AU Mao, Y De Oliveira, IS Hedgire, S Prapruttam, D Harisinghani, M AF Mao, Y. De Oliveira, I. S. Hedgire, S. Prapruttam, D. Harisinghani, M. TI Aetiology, imaging features, and evolution of spontaneous perirenal haemorrhage SO CLINICAL RADIOLOGY LA English DT Article ID RENAL-CELL CARCINOMA; PERINEPHRIC HEMORRHAGE; CT FINDINGS; ABDOMINAL HEMORRHAGE; KIDNEY-DISEASE; MINIMAL FAT; ANGIOMYOLIPOMA; RUPTURE; DIFFERENTIATION; MANAGEMENT AB AIM: To evaluate the aetiology, imaging features, and the evolution of spontaneous perirenal haemorrhage detected by imaging. MATERIALS AND METHODS: In this retrospective study, the hospital database was searched for all cases of spontaneous perinephric haemorrhage detected by imaging between January 2000 and December 2012. Imaging examinations were reviewed and the following parameters were recorded: the location, extension, and total volume of the haematoma, presence of active extravasation, the haematocrit effect, and highest density. The resolution time was calculated using follow-up imaging. The final aetiology for all cases was assessed via clinical, radiological, and histopathological data. Differences in imaging features of haemorrhage according to aetiology group were analysed with independent samples test and Fisher's exact test. RESULTS: Eighty-one haematomas were identified in 78 patients during this 13-year period. Causes of perirenal haemorrhage included coagulation disorders (22/81, 27.1%), ruptured renal cyst (11/81, 13.6%), rupture of abdominal aortic aneurysm (9/81, 11.1%), renal cell carcinoma (9/81, 11.1%), adrenal masses (9/ 81, 11.1%), polycystic kidney disease (7/81, 8.6%), angiomyolipoma (6/81, 7.4%), renal vascular diseases (2/81, 2.4%), and recurrent pyelonephritis (1/81, 1.2%). Haematomas associated with coagulation abnormalities and vascular diseases presented with larger volumes and were more likely to extent to the pararenal space more so than other groups; ruptured renal cyst and renal cell carcinomas tended to be more associated with subcapsular haematomas. The haematocrit effect and haemorrhage involving renal parenchyma were more often observed in the group with coagulation abnormalities. CONCLUSION: Imaging features, such as location and extension, could help radiologists identify possible aetiologies of spontaneous perirenal haemorrhage. (C) 2016 The Royal College of Radiologists. C1 [Mao, Y.] Chongqing Med Univ, Dept Radiol, 1 Youyi Rd, Chongqing 400061, Peoples R China. [De Oliveira, I. S.; Prapruttam, D.; Harisinghani, M.] Harvard Med Sch, Massachusetts Gen Hosp, Div Abdominal Imaging, 55 Fruit St, Boston, MA 02114 USA. [Hedgire, S.] Harvard Med Sch, Massachusetts Gen Hosp, Div Cardiovasc Imaging, 55 Fruit St, Boston, MA 02114 USA. RP Hedgire, S (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Div Cardiovasc Imaging, 55 Fruit St, Boston, MA 02114 USA. EM Hedgire.Sandeep@mgh.harvard.edu NR 27 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0009-9260 EI 1365-229X J9 CLIN RADIOL JI Clin. Radiol. PD FEB PY 2017 VL 72 IS 2 AR 175.e19 DI 10.1016/j.crad.2016.08.010 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EP3FP UT WOS:000397268500015 ER PT J AU Cellamare, M Ventz, S Baudin, E Mitnick, CD Trippa, L AF Cellamare, Matteo Ventz, Steffen Baudin, Elisabeth Mitnick, Carole D. Trippa, Lorenzo TI A Bayesian response-adaptive trial in tuberculosis: The endTB trial SO CLINICAL TRIALS LA English DT Article DE Tuberculosis; clinical trial; Bayesian analysis; adaptive designs; preliminary outcomes ID MULTIDRUG-RESISTANT TUBERCULOSIS; I-SPY 2; CLINICAL-TRIALS; PULMONARY TUBERCULOSIS; TREATMENT OUTCOMES; PHASE-II; DESIGN; BEDAQUILINE; RANDOMIZATION; GLIOBLASTOMA AB Purpose: To evaluate the use of Bayesian adaptive randomization for clinical trials of new treatments for multidrug-resistant tuberculosis. Methods: We built a response-adaptive randomization procedure, adapting on two preliminary outcomes for tuberculosis patients in a trial with five experimental regimens and a control arm. The primary study outcome is treatment success after 73weeks from randomization; preliminary responses are culture conversion at 8weeks and treatment success at 39weeks. We compared the adaptive randomization design with balanced randomization using hypothetical scenarios. Results: When we compare the statistical power under adaptive randomization and non-adaptive designs, under several hypothetical scenarios we observe that adaptive randomization requires fewer patients than non-adaptive designs. Moreover, adaptive randomization consistently allocates more participants to effective arm(s). We also show that these advantages are limited to scenarios consistent with the assumptions used to develop the adaptive randomization algorithm. Conclusion: Given the objective of evaluating several new therapeutic regimens in a timely fashion, Bayesian response-adaptive designs are attractive for tuberculosis trials. This approach tends to increase allocation to the effective regimens. C1 [Cellamare, Matteo; Ventz, Steffen; Trippa, Lorenzo] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. [Cellamare, Matteo; Ventz, Steffen; Trippa, Lorenzo] Harvard TH Chan Sch Publ Hlth, Boston, MA USA. [Cellamare, Matteo] Sapienza Univ Rome, Dept Stat Sci, I-00185 Rome, Italy. [Ventz, Steffen] Univ Rhode Isl, Dept Comp Sci & Stat, Kingston, RI 02881 USA. [Baudin, Elisabeth] Epictr MSF, Dept Clin Res, Paris, France. [Mitnick, Carole D.] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA USA. [Mitnick, Carole D.] Partners Hlth, Boston, MA USA. RP Cellamare, M (reprint author), Sapienza Univ Rome, Dept Stat Sci, I-00185 Rome, Italy. EM matteo.cellamare@uniroma1.it FU Burroughs Wellcome Fund - Regulatory Science and UNITAID; Claudia Adams Barr Award FX This work has been partially funded by Burroughs Wellcome Fund - Regulatory Science and UNITAID and the Claudia Adams Barr Award. NR 51 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1740-7745 EI 1740-7753 J9 CLIN TRIALS JI Clin. Trials PD FEB PY 2017 VL 14 IS 1 BP 17 EP 28 DI 10.1177/1740774516665090 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA EL5HR UT WOS:000394652700002 PM 27559021 ER PT J AU Shaw, PA Yancy, WS Wesby, L Ulrich, V Troxel, AB Huffman, D Foster, GD Volpp, K AF Shaw, Pamela A. Yancy, William S., Jr. Wesby, Lisa Ulrich, Victoria Troxel, Andrea B. Huffman, David Foster, Gary D. Volpp, Kevin TI The design and conduct of Keep It Off: An online randomized trial of financial incentives for weight-loss maintenance SO CLINICAL TRIALS LA English DT Article DE Behavioral economics; financial incentive; obesity; pragmatic trial; randomized trial; weight-loss maintenance ID LOW-CARBOHYDRATE; UNITED-STATES; RISK-FACTORS; OBESITY; OVERWEIGHT; METAANALYSIS; PREVALENCE; PREVENTION; DIETS AB Background Obesity continues to be a serious public health challenge. Rates are increasing worldwide, with nearly 70% of the US adults overweight or obese, leading to increased clinical and economic burden. While successful approaches for achieving weight loss have been identified, techniques for long-term maintenance of initial weight loss have largely been unsuccessful. Financial incentive interventions have been shown in several settings to be successful in motivating participants to adopt healthy behaviors. Purpose Keep It Off is a three-arm randomized controlled trial that compares the efficacy of a lottery-based incentive, traditional direct payment incentive, and control of daily feedback without any incentive for weight-loss maintenance. This design allows comparison of a traditional direct payment incentive with one based on behavioral economic principles that consider the underlying psychology of decision-making. Methods Participants were randomized in a 2:1 ratio for each active arm relative to control, with a targeted 188 participants in total. Eligible participants were those aged 30-80 who lost at least 11lb (5kg) during the first 4months of participation in Weight Watchers, a national weight-loss program, with whom we partnered. The interventions lasted 6months (Phase I); participants were followed for an additional 6months without intervention (Phase II). The primary outcome is weight change from baseline to the end of Phase I, with the change at the end of Phase II a key secondary endpoint. Keep It Off is a pragmatic trial that recruited, consented, enrolled, and followed patients electronically. Participants were provided a wireless weight scale that electronically transmitted daily self-monitored weights. Weights were verified every 3months at a Weight Watchers center local to the participant and electronically transmitted. Results Using the study web-based platform, we integrated recruitment, enrollment, and follow-up procedures into a digital platform that required little staff effort to implement and manage. We randomized 191 participants in less than 1year. We describe the design of Keep It Off and implementation of enrollment. Lessons Learned We demonstrated that our pragmatic design was successful in rapid accrual of participants in a trial of interventions to maintain weight loss. Limitations Despite the nationwide reach of Weight Watchers, the generalizability of study findings may be limited by the characteristics of its members. The interventions under study are appropriate for settings where an entity, such as an employer or health insurance company, could offer them as a benefit. Conclusions Keep It Off was implemented and conducted with minimal staff effort. This study has the potential to identify a practical and effective weight-loss maintenance strategy. C1 [Shaw, Pamela A.; Troxel, Andrea B.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, 606 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Shaw, Pamela A.; Wesby, Lisa; Ulrich, Victoria; Troxel, Andrea B.; Huffman, David; Volpp, Kevin] Univ Penn, Leonard Davis Inst Hlth Econ, Perelman Sch Med, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Shaw, Pamela A.; Wesby, Lisa; Ulrich, Victoria; Troxel, Andrea B.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Yancy, William S., Jr.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Yancy, William S., Jr.] US Dept Vet Affairs, Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Huffman, David] Univ Oxford, Dept Econ, Oxford, England. [Foster, Gary D.] Weight Watchers Int, Dept Sci & Innovat, New York, NY USA. [Foster, Gary D.] Temple Univ, Ctr Obes Res & Educ, Philadelphia, PA USA. [Volpp, Kevin] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Volpp, Kevin] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Volpp, Kevin] Univ Penn, Wharton Sch, Dept Hlth Care Syst, Philadelphia, PA 19104 USA. RP Shaw, PA (reprint author), Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, 606 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM shawp@mail.med.upenn.edu FU National Institute on Aging of the National Institutes of Health [R01-AG045045] FX This study was sponsored by the National Institute on Aging of the National Institutes of Health under award no. R01-AG045045 (Volpp and Yancy, MPIs). NR 34 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1740-7745 EI 1740-7753 J9 CLIN TRIALS JI Clin. Trials PD FEB PY 2017 VL 14 IS 1 BP 29 EP 36 DI 10.1177/1740774516669679 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA EL5HR UT WOS:000394652700003 PM 27646508 ER PT J AU Powe, CE AF Powe, Camille E. TI Early Pregnancy Biochemical Predictors of Gestational Diabetes Mellitus SO CURRENT DIABETES REPORTS LA English DT Review DE Gestational diabetes mellitus; Pregnancy; Biomarkers; Prediction ID HORMONE-BINDING GLOBULIN; C-REACTIVE PROTEIN; PLACENTAL GROWTH-FACTOR; FASTING PLASMA-GLUCOSE; PRO RENIN RECEPTOR; INSULIN SENSITIVITY INDEXES; RANDOMIZED CONTROLLED-TRIAL; POLYCYSTIC-OVARY-SYNDROME; SERUM GLYCATED ALBUMIN; EARLY 2ND TRIMESTER AB Purpose of Review Universal oral glucose tolerance-based screening is employed to identify pregnant women with gestational diabetes mellitus (GDM), as treatment of this condition decreases the risk of associated complications. A simple and accurate blood test which identifies women at low or high risk for GDM in the first trimester would have the potential to decrease costs and improve outcomes through prevention or treatment. This review summarizes published data on early pregnancy biomarkers which have been tested as predictors of GDM. Recent Findings A large number of first-trimester biochemical predictors of GDM have been reported, mostly in small case-control studies. These include glycemic markers (fasting glucose, post-load glucose, hemoglobin A1C), inflammatory markers (C-reactive protein, tumor necrosis factor-alpha), insulin resistance markers (fasting insulin, sex hormone-binding globulin), adipocyte-derived markers (adiponectin, leptin), placenta-derived markers (follistatin-like-3, placental growth factor, placental exosomes), and others (e.g., glycosylated fibronectin, soluble (pro) renin receptor, alanine aminotransferase, ferritin). A few large studies suggest that first-trimester fasting glucose or hemoglobin A1C may be useful for identifying women who would benefit from early GDM treatment. Summary To translate the findings from observational studies of first-trimester biomarkers for GDM to clinical practice, trials or cost-effectiveness analyses of screening and treatment strategies based on these novel biomarkers are needed. C1 [Powe, Camille E.] Massachusetts Gen Hosp, Dept Med, Div Endocrinol, Diabet Unit, 50 Staniford St,Suite 340, Boston, MA 02114 USA. [Powe, Camille E.] Harvard Med Sch, 50 Staniford St,Suite 340, Boston, MA 02114 USA. RP Powe, CE (reprint author), Massachusetts Gen Hosp, Dept Med, Div Endocrinol, Diabet Unit, 50 Staniford St,Suite 340, Boston, MA 02114 USA.; Powe, CE (reprint author), Harvard Med Sch, 50 Staniford St,Suite 340, Boston, MA 02114 USA. EM cpowe@partners.org NR 119 TC 0 Z9 0 U1 0 U2 0 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1534-4827 EI 1539-0829 J9 CURR DIABETES REP JI Curr. Diabetes Rep. PD FEB PY 2017 VL 17 IS 2 AR 12 DI 10.1007/s11892-017-0834-y PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EO7KE UT WOS:000396868800006 PM 28229385 ER PT J AU Martin-Gayo, E Yu, XG AF Martin-Gayo, Enrique Yu, Xu G. TI Dendritic Cell Immune Responses in HIV-1 Controllers SO CURRENT HIV/AIDS REPORTS LA English DT Article DE HIV-1 controllers; Dendritic cells; Dendritic cell immune responses; CD8 Tcells; HIV-1 immune defense ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD4(+) T-CELLS; HIV-1-INFECTED ELITE CONTROLLERS; GMP-AMP SYNTHASE; INTERFERON RESPONSE; TRANS-INFECTION; DC-SIGN; RECEPTORS; PATHWAY; RESTRICTION AB Purpose of Review Robust HIV-1-specific CD8 T cell responses are currently regarded as the main correlate of immune defense in rare individuals who achieve natural, drug-free control of HIV-1; however, the mechanisms that support evolution of such powerful immune responses are not well understood. Dendritic cells (DCs) are specialized innate immune cells critical for immune recognition, immune regulation, and immune induction, but their possible contribution to HIV-1 immune defense in controllers remains ill-defined. Recent Findings Recent studies suggest that myeloid DCs from controllers have improved abilities to recognize HIV-1 through cytoplasmic immune sensors, resulting in more potent, cell-intrinsic type I interferon secretion in response to viral infection. This innate immune response may facilitate DC-mediated induction of highly potent antiviral HIV-1-specific T cells. Moreover, protective HLA class I isotypes restricting HIV-1-specific CD8 T cells may influence DC function through specific interactions with innate myelomonocytic MHC class I receptors from the leukocyte immunoglobulin-like receptor family. Summary Bi-directional interactions between dendritic cells and HIV-1-specific T cells may contribute to natural HIV-1 immune control, highlighting the importance of a fine-tuned interplay between innate and adaptive immune activities for effective antiviral immune defense. C1 [Martin-Gayo, Enrique; Yu, Xu G.] Ragon Inst MGH, Massachusetts Gen Hosp, Harvard, Cambridge, MA 02139 USA. [Martin-Gayo, Enrique; Yu, Xu G.] MIT, Ragon Inst MGH, Cambridge, MA 02139 USA. Massachusetts Gen Hosp, Cambridge, MA 02139 USA. RP Yu, XG (reprint author), MIT, Ragon Inst MGH, 400 Technology Sq, Cambridge, MA 02139 USA. EM EGAYO@mgh.harvard.edu; xyu@mgh.harvard.edu NR 70 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1548-3568 EI 1548-3576 J9 CURR HIV-AIDS REP JI Curr. Hiv/Aids Rep. PD FEB PY 2017 VL 14 IS 1 BP 1 EP 7 DI 10.1007/s11904-017-0345-0 PG 7 WC Infectious Diseases SC Infectious Diseases GA EM2RH UT WOS:000395162800001 PM 28110421 ER PT J AU Reyes, S Varagic, J Ahmad, S VonCannon, J Kon, ND Wang, H Groban, L Cheng, CP Dell'Italia, LJ Ferrario, CM AF Reyes, Santiago Varagic, Jasmina Ahmad, Sarfaraz VonCannon, Jessica Kon, Neal D. Wang, Hao Groban, Leanne Cheng, Che Ping Dell'Italia, Louis J. Ferrario, Carlos M. TI Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/ Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease SO CURRENT HYPERTENSION REPORTS LA English DT Review DE Intracrine; Angiotensin-(1-12); Chymase; Cardiomyocyte; Angiotensin-converting enzyme inhibitor; Angiotensin receptor blockers ID ANGIOTENSIN-CONVERTING-ENZYME; HIGH-RISK PATIENTS; LEFT-VENTRICULAR DYSFUNCTION; RANDOMIZED CONTROLLED-TRIAL; HIGH CARDIOVASCULAR RISK; CORONARY-ARTERY-DISEASE; II-RECEPTOR BLOCKERS; BLOOD-PRESSURE; MYOCARDIAL-INFARCTION; FORMING PATHWAYS AB Purpose of the Review Drugs targeting the renin-angiotensin system (RAS), namely angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers, are the most commonly prescribed drugs for patients with or at risk for cardiovascular events. However, new treatment strategies aimed at mitigating the rise of the heart failure pandemic are warranted because clinical trials show that RAS blockers have limited benefits in halting disease progression. The main goal of this review is to put forward the concept of an intracrine RAS signaling through the novel angiotensin-(1-12)/chymase axis as the main source of deleterious angiotensin II (Ang II) in cardiac maladaptive remodeling leading to heart failure (HF). Recent Findings Expanding traditional knowledge, Ang II can be produced in tissues independently from the circulatory renin-angiotensin system. In the heart, angiotensin-(1-12) [Ang-(1-12)], a recently discovered derivative of angiotensinogen, is a precursor of Ang II, and chymase rather than ACE is the main enzyme contributing to the direct production of Ang II from Ang-(1-12). The Ang-(1-12)/chymase axis is an independent intracrine pathway accounting for the trophic, contractile, and pro-arrhythmic Ang II actions in the human heart. Ang-(1-12) expression and chymase activity have been found elevated in the left atrial appendage of heart disease subjects, suggesting a pivotal role of this axis in the progression of HF. Summary Recent meta-analysis of large clinical trials on the use of ACE inhibitors and angiotensin receptor blockers in cardiovascular disease has demonstrated an imbalance between patients that significantly benefit from these therapeutic agents and those that remain at risk for heart disease progression. Looking to find an explanation, detailed investigation on the RAS has unveiled a previously unrecognized complexity of substrates and enzymes in tissues ultimately associated with the production of Ang II that may explain the shortcomings of ACE inhibition and angiotensin receptor blockade. Discovery of the Ang-(1-12)/chymase axis in human hearts, capable of producing Ang II independently from the circulatory RAS, has led to the notion that a tissue-delimited RAS signaling in an intracrine fashion may account for the deleterious effects of Ang II in the heart, contributing to the transition from maladaptive cardiac remodeling to heart failure. Targeting intracellular RAS signaling may improve current therapies aimed at reducing the burden of heart failure. C1 [Reyes, Santiago; Varagic, Jasmina; Ahmad, Sarfaraz; VonCannon, Jessica; Ferrario, Carlos M.] Wake Forest Univ Hlth Sci, Dept Gen Surg, Med Ctr Blvd, Winston Salem, NC 27157 USA. [Varagic, Jasmina; VonCannon, Jessica; Groban, Leanne] Wake Forest Univ Hlth Sci, Cardiovasc Sci Ctr, Med Ctr Blvd, Winston Salem, NC 27157 USA. [Kon, Neal D.] Wake Forest Univ Hlth Sci, Dept Cardiothorac Surg, Med Ctr Blvd, Winston Salem, NC 27157 USA. [Wang, Hao; Groban, Leanne] Wake Forest Univ Hlth Sci, Dept Anesthesiol, Med Ctr Blvd, Winston Salem, NC 27157 USA. [Wang, Hao] Wake Forest Univ Hlth Sci, Dept Internal Med Mol Med, Med Ctr Blvd, Winston Salem, NC 27157 USA. [Cheng, Che Ping] Wake Forest Univ Hlth Sci, Dept Internal Med Cardiovasc Med, Med Ctr Blvd, Winston Salem, NC 27157 USA. [Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL USA. [Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Microbiol & Physiol, Birmingham, AL USA. [Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL USA. [Dell'Italia, Louis J.] Birmingham Vet Affairs Med Ctr, Dept Vet Affairs, Birmingham, AL USA. [Ferrario, Carlos M.] Wake Forest Univ Hlth Sci, Dept Internal Med, Dept Nephrol, Med Ctr Blvd, Winston Salem, NC 27157 USA. [Ferrario, Carlos M.] Wake Forest Univ Hlth Sci, Dept Physiol Pharmacol, Med Ctr Blvd, Winston Salem, NC 27157 USA. RP Ferrario, CM (reprint author), Wake Forest Univ Hlth Sci, Dept Gen Surg, Med Ctr Blvd, Winston Salem, NC 27157 USA.; Ferrario, CM (reprint author), Wake Forest Univ Hlth Sci, Dept Internal Med, Dept Nephrol, Med Ctr Blvd, Winston Salem, NC 27157 USA.; Ferrario, CM (reprint author), Wake Forest Univ Hlth Sci, Dept Physiol Pharmacol, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM cferrari@wakehealth.edu NR 121 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1522-6417 EI 1534-3111 J9 CURR HYPERTENS REP JI Curr. Hypertens. Rep. PD FEB PY 2017 VL 19 IS 2 AR 16 DI 10.1007/s11906-017-0708-3 PG 11 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA EP3CK UT WOS:000397259900003 PM 28233239 ER PT J AU Brizzi, K AF Brizzi, Kate TI Neurologic Manifestation of Chikungunya Virus SO CURRENT INFECTIOUS DISEASE REPORTS LA English DT Review DE Chikungunya; Neurology; Mosquito-borne viruses; Encephalitis; Guillain-Barre syndrome ID GUILLAIN-BARRE-SYNDROME; REUNION-ISLAND; SOUTH-INDIA; INFECTION; OUTBREAK; EPIDEMIC; FEVER AB Purpose of Review Chikungunya virus (CHIKV) is a RNA arbovirus that typically causes fevers and arthralgias, but reports of neurologic findings have become increasingly common. This article reviews our current understanding of CHIKV-associated neurologic manifestations. Recent Findings In the last 5 years, CHIKV endemicity has spread to the Americas and the number of cases of CHIKVrelated disease has dramatically increased. Evidence suggests increasing neurovirulence of the virus, particularly among the critically ill. The spectrum of neurologic manifestations of the disease includes encephalitis, myelitis, and Guillain-Barre syndrome, but isolated reports of cranial neuropathies and cognitive deficits associated with recent infection also are reported. Summary Though neurologic symptoms associated with CHIKVremain relatively uncommon, their frequency appears to be increasing. Clinicians treating patients with neurologic symptoms from CHIKVendemic areas should be aware of the growing association between CHIKVand neurologic sequelae to help guide diagnostics. Research into the optimal treatment of the disease is needed to inform treatment practices. C1 [Brizzi, Kate] Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA. RP Brizzi, K (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA. EM kbrizzi@partners.org NR 44 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3847 EI 1534-3146 J9 CURR INFECT DIS REP JI Curr. Infect. Dis. Rep. PD FEB PY 2017 VL 19 IS 2 AR 6 DI 10.1007/s11908-017-0561-1 PG 6 WC Infectious Diseases SC Infectious Diseases GA EM0HH UT WOS:000394998900002 PM 28233188 ER PT J AU McFaline-Figueroa, JR Wen, PY AF McFaline-Figueroa, J. Ricardo Wen, Patrick Y. TI The Viral Connection to Glioblastoma SO CURRENT INFECTIOUS DISEASE REPORTS LA English DT Review DE Glioblastoma; Cytomegalovirus; Immunotherapy; Valganciclovir; Herpesvirus ID HUMAN CYTOMEGALOVIRUS; BRAIN-TUMORS; PERIPHERAL-BLOOD; SARCOMA-VIRUS; VALGANCICLOVIR; GLIOMA; HERPESVIRUSES; ASSOCIATION; INFECTION; CELLS AB Purpose of Review The high incidence of and mortality from glioblastoma are matched by a lack of effective therapies. Previous research suggests an association between viral infection and glioma formation. In this manuscript, we review the available evidence for this association and the efficacy of treatment strategies targeted against viral infection. Recent Findings We find that while a wide array of viruses can drive glioma tumor formation in vitro and in xenograft models, the most convincing association is with the human Cytomegalovirus (HCMV). Detection of HCMV in glioblastoma resected from living patients suggests it may either drive gliomagenesis, support tumor growth, or reactivate silently in these tumors. However, there is conflicting evidence on its ubiquity and its role in tumor formation. Valganciclovir may extend survival in glioblastoma patients, though adequate data on its efficacy and mechanism of action are lacking. Immunotherapy provides the opportunity to specifically target the virus and possibly, glioblastoma, though there are no large, randomized trials testing its efficacy to date. Summary Overall, despite mounting evidence for an association between HCMVand glioblastoma, its role as an oncogenic factor and a therapeutic target remains controversial. C1 [McFaline-Figueroa, J. Ricardo] Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA. [McFaline-Figueroa, J. Ricardo] Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA. [Wen, Patrick Y.] Harvard Med Sch, 450 Brookline Ave, Boston, MA 02215 USA. [Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Inst, Ctr Neurooncol, 450 Brookline Ave, Boston, MA 02215 USA. RP McFaline-Figueroa, JR (reprint author), Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.; McFaline-Figueroa, JR (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA. EM jmcfalinefigueroa@partners.org; pwen@partners.org NR 35 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3847 EI 1534-3146 J9 CURR INFECT DIS REP JI Curr. Infect. Dis. Rep. PD FEB PY 2017 VL 19 IS 2 AR 5 DI 10.1007/s11908-017-0563-z PG 5 WC Infectious Diseases SC Infectious Diseases GA EM0HH UT WOS:000394998900001 PM 28233187 ER PT J AU McFarlane, AC Lawrence-Wood, E Van Hooff, M Malhi, GS Yehuda, R AF McFarlane, Alexander Cowell Lawrence-Wood, Eleanor Van Hooff, Miranda Malhi, Gin S. Yehuda, Rachel TI The Need to Take a Staging Approach to the Biological Mechanisms of PTSD and its Treatment SO CURRENT PSYCHIATRY REPORTS LA English DT Review DE PTSD; Staging; Subsyndromal; Neurobiology; Inflammation; Medical comorbidity; Duration of illness; Longitudinal course; Delayed onset; Treatment ID POSTTRAUMATIC-STRESS-DISORDER; PROSPECTIVE COHORT; POLICE OFFICERS; MENTAL-HEALTH; AFGHANISTAN VETERANS; MILITARY DEPLOYMENT; TRAUMATIC STRESSORS; ARMED-FORCES; SYMPTOMS; RISK AB Despite the substantial body of neurobiological research, no specific drug target has been developed to treat PTSD and there are substantial limitations with the available interventions. We propose that advances are likely to depend on the development of better classification of the heterogeneity of PTSD using a staging approach of disease. A primary rationale for staging is to highlight the probability that distinct therapeutic approaches need to be utilised according to the degree of biological progression of the disorder. Prospective studies, particularly of military populations, provide substantial evidence about the emerging biological abnormalities that precede the full-blown disorder. These need to be targeted with tailored interventions to prevent disease progression. Equally, the neurobiology of chronic unremitting PTSD needs to be differentiated from the acute disorder which emerges across a spectrum of severity, and this range of presentations correspondingly needs to be addressed with differing therapeutic strategies. The staging approach also needs to take account of the range of somatic pathological outcomes that are being identified as a consequence of traumatic stress exposure. PTSD should be conceptualised as a systemic disorder underpinned a range of biological dysregulation, including metabolic and altered immune function, reflected in the increased rates of cardiovascular and autoimmune disease. The effectiveness of novel treatments needs to be judged across their effectiveness in addressing the spectrum of trauma-related pathology. C1 [McFarlane, Alexander Cowell; Lawrence-Wood, Eleanor; Van Hooff, Miranda] Univ Adelaide, Ctr Traumat Stress Studies, Level 2,122 Frome St, Adelaide, SA 5000, Australia. [Malhi, Gin S.] Univ Sydney, Sydney Med Sch, Dept Psychiat, Edward Ford Bldg A27,Fisher Rd, Sydney, NSW 2006, Australia. [Yehuda, Rachel] Mt Sinai Sch Med, Traumat Stress Studies Div, James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY USA. RP McFarlane, AC (reprint author), Univ Adelaide, Ctr Traumat Stress Studies, Level 2,122 Frome St, Adelaide, SA 5000, Australia. EM alexander.mcfarlane@adelaide.edu.au FU National Health Medical and Research Council of Australia [568970] FX This research was funded by program grant number 568970 of the National Health Medical and Research Council of Australia. NR 80 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 EI 1535-1645 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD FEB PY 2017 VL 19 IS 2 AR 10 DI 10.1007/s11920-017-0761-2 PG 9 WC Psychiatry SC Psychiatry GA EO7UP UT WOS:000396895900003 PM 28168596 ER PT J AU Speed, JM Trinh, QD Choueiri, TK Sun, M AF Speed, Jacqueline M. Quoc-Dien Trinh Choueiri, Toni K. Sun, Maxine TI Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data SO CURRENT UROLOGY REPORTS LA English DT Article DE Recurrent renal cell carcinoma; Surveillance in renal cell; Biomarkers in renal cell; Risk factors for renal cell recurrence; Localized renal cell carcinoma; Treatment of localized renal cell carcinoma ID NEPHRON-SPARING SURGERY; URINARY COLLECTING SYSTEM; POSTOPERATIVE PROGNOSTIC NOMOGRAM; PARTIAL NEPHRECTOMY; RADICAL NEPHRECTOMY; KIDNEY CANCER; FOLLOW-UP; MOLECULAR SIGNATURES; TUMOR SIZE; EXPRESSION AB Purpose of Review Patients with localized renal cell carcinoma (RCC) are at risk of recurrence. The purpose of this review was to characterize the literature on recurrence rates and risk factors after diagnosis of localized RCC. Recent Findings Our search revealed that existing data examining the prevalence of recurrence rates predominantly originates from cohorts of patients diagnosed and treated in the 1980s to 1990s, and may therefore not be as useful for counseling for current patients today. Many nomograms including the Cindolo Recurrence Risk Formula, the University of California-Los Angeles (UCLA) Integrated Scoring System (UISS), the SSIGN score, the Kattan nomogram, and the Karakiewicz nomogram have shown value in identifying patients at higher risk for recurrence. Biomarkers and gene assays have shown promise in augmenting the predictive accuracy of some of the aforementioned predictive models, especially when multiple gene markers are used in combination. However, more work is needed in not only developing a model but also validating it in other settings prior to clinical use. Adjuvant therapy is a promising new treatment strategy for patients with high-risk disease. Importantly, too many surveillance strategies exist. This may stem from the lack of a consensus in the urological community in how to follow these patients, as well as the variable guideline recommendations. Summary In conclusion, contemporary recurrence rates are needed. Recurrence risk prediction models should be developed based on a series of more contemporary patients, and externally validated prior to routine clinical practice. Surveillance strategies following treatment of localized RCC need to be identified and standardized. Finally, there is a trend toward personalizing surveillance regimens to more appropriately screen patients at higher risk of recurrence. C1 [Speed, Jacqueline M.; Quoc-Dien Trinh; Sun, Maxine] Brigham & Womens Hosp, 45 Francis St,ASB 2-3, Boston, MA 02115 USA. [Choueiri, Toni K.] Dana Farber Canc Inst, Dana 1230,44 Binney St, Boston, MA 02215 USA. RP Sun, M (reprint author), Brigham & Womens Hosp, 45 Francis St,ASB 2-3, Boston, MA 02115 USA. EM jmspeed@partners.org; trinh.qd@gmail.com; Toni_Choueiri@DFCI.HARVARD.EDU; maxinesun@gmail.com NR 92 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1527-2737 J9 CURR UROL REP JI Curr. Urol. Rep. PD FEB PY 2017 VL 18 IS 2 AR 15 DI 10.1007/s11934-017-0661-3 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA EM3AQ UT WOS:000395187300007 PM 28213859 ER PT J AU Shamsi, MM Chekachak, S Soudi, S Quinn, LS Ranjbar, K Chenari, J Yazdi, MH Mandavi, M AF Shamsi, M. Molanouri Chekachak, S. Soudi, S. Quinn, L. S. Ranjbar, K. Chenari, J. Yazdi, M. H. Mandavi, M. TI Combined effect of aerobic interval training and selenium nanoparticles on expression of IL-15 and IL-10/TNF-a ratio in skeletal muscle of 4T1 breast cancer mice with cachexia SO CYTOKINE LA English DT Article DE 4T1 breast cancer; Cachexia; Interleukin-15; Inflammation; Aerobic interval training ID TUMOR-BEARING RATS; RESISTANCE EXERCISE; ANTIOXIDANT SUPPLEMENTATION; MOLECULAR-MECHANISMS; PHYSICAL-ACTIVITY; OXIDATIVE STRESS; ADIPOSE-TISSUE; CELL-GROWTH; TNF-ALPHA; INTERLEUKIN-15 AB Cancer cachexia is characterized by inflammation, loss of skeletal muscle and adipose tissue mass, and functional impairment. Oxidative stress and inflammation are believed to regulate pathways controlling skeletal muscle wasting. The aim of this study was to determine the effects of aerobic interval training and the purported antioxidant treatment, selenium nanoparticle supplementation, on expression of IL-15 and inflammatory cytokines in 4T1 breast cancer-bearing mice with cachexia. Selenium nanopar-ticle supplementation accelerated cachexia symptoms in tumor-bearing mice, while exercise training prevented muscle wasting in tumor-bearing mice. Also, aerobic interval training enhanced the anti-inflammatory indices IL-10/TNF-alpha ratio and IL-15 expression in skeletal muscle in tumor-bearing mice. However, combining exercise training and antioxidant supplementation prevented cachexia and muscle wasting and additionally decreased tumor volume in 4T1 breast cancer mice. These finding suggested that combining exercise training and antioxidant supplementation could be a strategy for managing tumor volume and preventing cachexia in breast cancer. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Shamsi, M. Molanouri; Chekachak, S.; Ranjbar, K.] Tarbiat Modares Univ, Fac Humanities, Phys Educ & Sport Sci Dept, POB 14117-13116, Tehran, Iran. [Soudi, S.] Tarbiat Modares Univ, Fac Med Sci, Dept Immunol, POB 14117-13116, Tehran, Iran. [Quinn, L. S.] Univ Washington, VA Puget Sound Hlth Care Syst, Res Serv, Seattle, WA 98108 USA. [Quinn, L. S.] Univ Washington, Div Gerontol & Geriatr Med, Dept Med, Seattle, WA 98108 USA. [Chenari, J.] Univ Tehran Med Sci, Neurosci Inst, Brain & Spinal Cord Injury Res Ctr, Tehran, Iran. [Yazdi, M. H.] Univ Tehran Med Sci, Sch Pharm, Dept Pharmaceut Biotechnol, Tehran, Iran. [Yazdi, M. H.] Univ Tehran Med Sci, Sch Pharm, Biotechnol Res Ctr, Tehran, Iran. [Mandavi, M.] Pasteur Inst Iran, Dept Immunol, 69 Pasteur Ave, Tehran, Iran. RP Shamsi, MM (reprint author), Tarbiat Modares Univ, Fac Humanities, Phys Educ & Sport Sci Dept, POB 14117-13116, Tehran, Iran.; Soudi, S (reprint author), Tarbiat Modares Univ, Fac Med Sci, Dept Immunol, POB 14117-13116, Tehran, Iran. EM molanouri@modares.ac.ir; soodabeh.chekachak@modares.ac.ir; Soudi@modares.ac.ir; quinnL@uw.edu; kia.ranjbar@modares.ac.ir; chenari.jamal@gmail.com; mohammadhossein61@gmail.com; mandavivac@gmail.com FU Research Center of Tarbiat Modarres University (TMU), Tehran, Iran FX This work was supported by the Research Center of Tarbiat Modarres University (TMU), Tehran, Iran. We wish to thank Professor Yaghob Fathoallahy for his kind help and sincere cooperation. NR 73 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-4666 EI 1096-0023 J9 CYTOKINE JI Cytokine PD FEB PY 2017 VL 90 BP 100 EP 108 DI 10.1016/j.cyto.2016.11.005 PG 9 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA EL1QM UT WOS:000394396100015 ER PT J AU Andrews, JS Trupin, L Hough, CL Daikh, DI Yelin, EH Katz, PP AF Andrews, James S. Trupin, Laura Hough, Catherine L. Daikh, David I. Yelin, Edward H. Katz, Patricia P. TI Serum biomarkers of inflammation and muscle strength among women with systemic lupus erythematosus SO CYTOKINE LA English DT Article DE Systemic lupus erythematosus; Inflammation; Cytokines; Outcomes research ID ACTIVITY QUESTIONNAIRE; PHYSICAL FUNCTION; VALIDITY; DISEASE AB Objectives: Muscle strength is an important determinant of physical function in women with systemic lupus erythematosus (SLE). Serum biomarkers of inflammation, including interleukin-6 (IL-6) and C Reactive Protein (CRP), are associated with differences in muscle strength among individuals without rheumatologic disease. We examined whether serum levels of IL-6 and CRP are associated with upper and lower extremity muscle strength among adult women with SLE. Methods: One hundred thirty-six women with SLE participated in this cross-sectional study. High- sensitivity CRP was analyzed by nephelometry. IL-6 serum levels were analyzed by high sensitivity enzyme-linked immunosorbent assay. Upper and lower extremity muscle strength were assessed by grip strength and peak torque of knee extension and flexion, respectively. Regression analyses modeled asso-ciations of CRP and IL-6 with upper and lower extremity muscle strength controlling for age, SLE dura-tion, physical activity, prednisone use, BMI, plaquenil use, and pain. Results: Higher serum levels of IL-6 and CRP were associated with significantly weaker upper and lower extremity muscle strength even when controlling for covariates. Conclusions: Increased serum IL-6 and CRP are associated with clinically significant differences in upper and lower extremity muscle strength and may be useful in identifying those at risk for weakness and decreased physical function. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Andrews, James S.; Hough, Catherine L.] Univ Washington, Dept Med, Seattle, WA USA. [Trupin, Laura; Daikh, David I.; Yelin, Edward H.; Katz, Patricia P.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Daikh, David I.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Andrews, JS (reprint author), Univ Washington, Div Rheumatol, Box 356420,959 NE Pacific St, Seattle, WA 98195 USA. EM jsa1@uw.edu FU NIH/NIAMS grant [P60 AR053308]; NIH/NCRR UCSF-CTSI Grant [UL1 RR024131]; Rosalind Russell/Ephraim Engleman Rheumatology Research Center for Arthritis FX This research was supported by NIH/NIAMS grant P60 AR053308 and by NIH/NCRR UCSF-CTSI Grant Number UL1 RR024131, and by the Rosalind Russell/Ephraim Engleman Rheumatology Research Center for Arthritis. NR 15 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-4666 EI 1096-0023 J9 CYTOKINE JI Cytokine PD FEB PY 2017 VL 90 BP 109 EP 112 DI 10.1016/j.cyto.2016.11.003 PG 4 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA EL1QM UT WOS:000394396100016 PM 27863333 ER PT J AU Park, IJK Wang, LJ Williams, DR Alegria, M AF Park, Irene J. K. Wang, Lijuan Williams, David R. Alegria, Margarita TI Does Anger Regulation Mediate the Discrimination-Mental Health Link Among Mexican-Origin Adolescents? A Longitudinal Mediation Analysis Using Multilevel Modeling SO DEVELOPMENTAL PSYCHOLOGY LA English DT Article DE anger regulation; anxiety; depression; Mexican-origin adolescents; racial/ethnic discrimination ID PERCEIVED DISCRIMINATION; EMOTION REGULATION; INTERNALIZING SYMPTOMS; AMERICAN ADOLESCENTS; SOCIOECONOMIC-STATUS; FUTURE-DIRECTIONS; BETWEEN-PERSON; WITHIN-PERSON; LATINO YOUTH; RACISM AB Although prior research has consistently documented the association between racial/ethnic discrimination and poor mental health outcomes, the mechanisms that underlie this link are still unclear. The present 3-wave longitudinal study tested the mediating role of anger regulation in the discrimination-mental health link among 269 Mexican-origin adolescents (M-age = 14.1 years, SD = 1.6; 57% girls), 12 to 17 years old. Three competing anger regulation variables were tested as potential mediators: outward anger expression, anger suppression, and anger control. Longitudinal mediation analyses were conducted using multilevel modeling that disaggregated within-person effects from between-person effects. Results indicated that outward anger expression was a significant mediator; anger suppression and anger control were not significant mediators. Within a given individual, greater racial/ethnic discrimination was associated with more frequent outward anger expression. In turn, more frequent outward anger expression was associated with higher levels of anxiety and depression at a given time point. Gender, age, and nativity status were not significant moderators of the hypothesized mediation models. By identifying outward anger expression as an explanatory mechanism in the discrimination-distress link among Latino youths, this study points to a malleable target for prevention and intervention efforts aimed at mitigating the detrimental impact of racism on Latino youths' mental health during the developmentally critical period of adolescence. C1 [Park, Irene J. K.] Indiana Univ Sch Med, Dept Psychiat, South Bend, IN 46617 USA. [Wang, Lijuan] Univ Notre Dame, Dept Psychol, Notre Dame, IN 46556 USA. [Williams, David R.] Harvard Univ, Dept Social & Behav Sci, Harvard TH Chan Sch Publ Hlth, Cambridge, MA 02138 USA. [Williams, David R.] Harvard Univ, Dept African & African Amer Studies, Cambridge, MA 02138 USA. [Alegria, Margarita] Massachusetts Gen Hosp, Dept Med, Dispar Res Unit, Boston, MA 02114 USA. [Alegria, Margarita] Harvard Med Sch, Dept Psychiat, Boston, MA USA. RP Park, IJK (reprint author), Indiana Univ Sch Med, Dept Psychiat, South Bend, IN 46617 USA. EM ijpark@iupui.edu FU National Institute of Mental Health of the National Institutes of Health [R21MH097675] FX This research was supported by the National Institute of Mental Health of the National Institutes of Health under Award R21MH097675 (Irene Park, Principal Investigator). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We thank the participating families, community agencies, and the research staff for their contributions to the larger project: Rosemary Salinas, Misel Ramirez Vasoli, Amarilys Castillo, Jaqueline Martinez, Kristina Martinez, Margaret Schmid, Carlos Uzcategui, and Kimberly Widawski. We are indebted to our community consultant, Gilberto Perez Jr., M. S. W., A. C. S. W., for his liaison work and to Jennifer Burke-Lefever, Ph.D., for her consultation on project implementation. NR 73 TC 1 Z9 1 U1 0 U2 0 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0012-1649 EI 1939-0599 J9 DEV PSYCHOL JI Dev. Psychol. PD FEB PY 2017 VL 53 IS 2 BP 340 EP + DI 10.1037/dev0000235 PG 13 WC Psychology, Developmental SC Psychology GA EN1SB UT WOS:000395789200012 PM 27893238 ER PT J AU Powers, MA Bardsley, J Cypress, M Duker, P Funnell, MM Fischl, AH Maryniuk, MD Siminerio, L Vivian, E AF Powers, Margaret A. Bardsley, Joan Cypress, Marjorie Duker, Paulina Funnell, Martha M. Fischl, Amy Hess Maryniuk, Melinda D. Siminerio, Linda Vivian, Eva TI Diabetes Self-management Education and Support in Type 2 Diabetes A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics SO DIABETES EDUCATOR LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; GLYCEMIC CONTROL; CLINICAL-OUTCOMES; DECISION-MAKING; METAANALYSIS; CARE; ADULTS; PEOPLE; NEEDS AB Diabetes educators are well positioned to help optimize care of the student with diabetes within the school setting. C1 [Powers, Margaret A.] Int Diabet Ctr Pk Nicollet, Minneapolis, MN 55416 USA. [Bardsley, Joan] MedStar Hlth Res Inst, Hyattsville, MD USA. [Bardsley, Joan] MedStar Nursing, Hyattsville, MD USA. [Cypress, Marjorie] ABQ Hlth Partners, Albuquerque, NM USA. [Duker, Paulina] LifeScan, Dubai, U Arab Emirates. [Funnell, Martha M.] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Fischl, Amy Hess] Univ Chicago, Chicago, IL 60637 USA. [Maryniuk, Melinda D.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Siminerio, Linda] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Vivian, Eva] Univ Wisconsin, Madison, WI USA. RP Powers, MA (reprint author), Int Diabet Ctr Pk Nicollet, Minneapolis, MN 55416 USA. EM margaret.powers@parknicollet.com NR 82 TC 0 Z9 0 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0145-7217 EI 1554-6063 J9 DIABETES EDUCATOR JI Diabetes Educ. PD FEB PY 2017 VL 43 IS 1 BP 40 EP 53 DI 10.1177/0145721716689694 PG 14 WC Endocrinology & Metabolism; Public, Environmental & Occupational Health SC Endocrinology & Metabolism; Public, Environmental & Occupational Health GA EL8VB UT WOS:000394897300005 PM 28118121 ER PT J AU Wyte-Lake, T Claver, M Der-Martirosian, C Davis, D Dobalian, A AF Wyte-Lake, Tamar Claver, Maria Der-Martirosian, Claudia Davis, Darlene Dobalian, Aram TI Developing a Home-Based Primary Care Disaster Preparedness Toolkit SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE community health planning; disaster planning; emergency preparedness; home health agencies; standard of care; veterans health ID ADULTS AB Objective: Health agencies working with the homebound play a vital role in bolstering a community's resiliency by improving the preparedness of this vulnerable population. Nevertheless, this role is one for which agencies lack training and resources, which leaves many homebound at heightened risk. This study examined the utility of an evidence-based Disaster Preparedness Toolkit in Veterans Health Administration (VHA) Home-Based Primary Care (HBPC) programs. Methods: We conducted an online survey of all VHA HBPC program managers (N = 77/146; 53% response rate). Results: Respondents with fewer years with the HBPC program rated the toolkit as being more helpful (P<0.05). Of those who implemented their program's disaster protocol most frequently, two-thirds strongly agreed that the toolkit was relevant. Conversely, of those who implemented their disaster protocols very infrequently or never, 23% strongly agreed that the topics covered in the toolkit were relevant to their work (P<0.05). Conclusion: This toolkit helps support programs as they fulfill their preparedness requirements, especially practitioners who are new to their position in HBPC. Programs that implement disaster protocols infrequently may require additional efforts to increase understanding of the toolkit's utility. Engaging all members of the team with their diverse clinical expertise could strengthen a patient's personal preparedness plan. C1 [Wyte-Lake, Tamar; Claver, Maria; Der-Martirosian, Claudia; Dobalian, Aram] Vet Hlth Adm, Vet Emergency Management Evaluat Ctr, 16111 Plummer St,MS 152, Los Angeles, CA 91343 USA. [Davis, Darlene] US Dept Vet Affairs, Natl Off, Home Based Primary Care, Tampa, FL USA. RP Wyte-Lake, T (reprint author), Vet Hlth Adm, Vet Emergency Management Evaluat Ctr, 16111 Plummer St,MS 152, Los Angeles, CA 91343 USA. EM tamar.wyte@va.gov NR 22 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1935-7893 EI 1938-744X J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD FEB PY 2017 VL 11 IS 1 BP 56 EP 63 DI 10.1017/dmp.2016.145 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EM6TB UT WOS:000395444000012 PM 27839522 ER PT J AU Mihos, CG Larrauri-Reyes, M Yucel, E Santana, O AF Mihos, Christos G. Larrauri-Reyes, Maiteder Yucel, Evin Santana, Orlando TI Clinical presentation and echocardiographic characteristics of Uhl's anomaly SO ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES LA English DT Article DE congenital heart disease; echocardiography; heart failure; right ventricle; right ventricular dysfunction; Uhl's anomaly ID SPECTRUM; ADULT AB Uhl's anomaly is a rare cardiac malformation that results in partial or complete absence of the right ventricular myocardium. It most commonly presents in prenatal or newborn infants; however, it may also be found in some adults as advanced right-sided heart failure. Differential diagnoses include arrhythmogenic right ventricular dysplasia and Ebstein's anomaly. Herein, we describe the clinical presentation of Uhl's anomaly in a previously undiagnosed middle-aged adult, and review the echocardiographic criteria used to diagnose and differentiate this rare, albeit important, myocardial disorder. C1 [Mihos, Christos G.; Yucel, Evin] Massachusetts Gen Hosp, Harvard Med Sch, Cardiac Ultrasound Lab, Boston, MA USA. [Larrauri-Reyes, Maiteder; Santana, Orlando] Columbia Univ, Mt Sinai Heart Inst, Div Cardiol, Miami Beach, FL USA. RP Mihos, CG (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Cardiac Ultrasound Lab, Boston, MA USA. EM cmihos@mgh.harvard.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0742-2822 EI 1540-8175 J9 ECHOCARDIOGR-J CARD JI Echocardiography-J. Cardiovasc. Ultrasound Allied Tech. PD FEB PY 2017 VL 34 IS 2 BP 299 EP 302 DI 10.1111/echo.13430 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EP5GT UT WOS:000397407700020 PM 28032368 ER PT J AU Zhang, ZB Liu, YN Huang, H Gao, MH Wu, D Kong, Q Zhang, YL AF Zhang, Zhibin Liu, Yanan Huang, Hao Gao, Minghui Wu, Di Kong, Qing Zhang, Yuelin TI The NLR protein SUMM2 senses the disruption of an immune signaling MAP kinase cascade via CRCK3 SO EMBO REPORTS LA English DT Article DE plant immunity; MAP kinase cascade; MPK4; CRCK3; SUMM2 ID PSEUDOMONAS-SYRINGAE EFFECTOR; RECEPTOR-LIKE KINASE; SYSTEMIC ACQUIRED-RESISTANCE; NADPH OXIDASE RBOHD; INNATE IMMUNITY; III EFFECTOR; DISEASE-RESISTANCE; PLANT IMMUNITY; ARABIDOPSIS-THALIANA; CYTOPLASMIC KINASE AB MAP kinase signaling is an integral part of plant immunity. Disruption of the MEKK1-MKK1/2-MPK4 kinase cascade results in constitutive immune responses mediated by the NLR protein SUMM2, but the molecular mechanism is so far poorly characterized. Here, we report that SUMM2 monitors a substrate protein of MPK4, CALMODULIN-BINDING RECEPTOR-LIKE CYTOPLASMIC KINASE 3 (CRCK3). Similar to SUMM2, CRCK3 was isolated from a suppressor screen of mkk1 mkk2 and is required for the autoimmunity phenotypes in mekk1, mkk1 mkk2, and mpk4 mutants. In wild-type plants, CRCK3 is mostly phosphorylated. MPK4 interacts with CRCK3 and can phosphorylate CRCK3 in vitro. In mpk4 mutant plants, phosphorylation of CRCK3 is substantially reduced, suggesting that MPK4 phosphorylates CRCK3 in vivo. Further, CRCK3 associates with SUMM2 in planta, suggesting SUMM2 senses the disruption of the MEKK1-MKK1/2-MPK4 kinase cascade through CRCK3. Our study suggests that a MAP kinase substrate is used as a guardee or decoy for monitoring the integrity of MAP kinase signaling. C1 [Zhang, Zhibin; Liu, Yanan; Wu, Di; Kong, Qing; Zhang, Yuelin] Univ British Columbia, Dept Bot, Vancouver, BC, Canada. [Huang, Hao; Gao, Minghui] Natl Inst Biol Sci, Beijing, Peoples R China. [Zhang, Zhibin] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA. [Zhang, Zhibin] Harvard Med Sch, Dept Pediat, Boston, MA USA. [Kong, Qing] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Kong, Qing] Harvard Med Sch, Dept Genet, Boston, MA USA. RP Zhang, YL (reprint author), Univ British Columbia, Dept Bot, Vancouver, BC, Canada. EM yuelin.zhang@ubc.ca FU Natural Sciences and Engineering Research Council (NSERC) of Canada [249922] FX We thank Mr. Rowan van Wersch from UBC for careful reading of the manuscript and Dr. Sophien Kamoun from Sainsbury Laboratories for discussion of the manuscript. Natural Sciences and Engineering Research Council (NSERC) of Canada is thanked for their financial support to Y.Z. (Grant #249922). NR 68 TC 1 Z9 1 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-221X EI 1469-3178 J9 EMBO REP JI EMBO Rep. PD FEB PY 2017 VL 18 IS 2 BP 292 EP 302 DI 10.15252/embr.201642704 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA EL5JJ UT WOS:000394657100012 PM 27986791 ER PT J AU Karpahakis, A Dibra, I Pipinikas, C Feber, A Morris, T Francis, J Oukrif, D Mandair, D Pericleous, M Mohmaduvesh, M Serra, S Ogunbiyi, O Novelli, M Luong, T Asa, SL Kulke, M Tourripanakis, C Meyer, T Caplin, M Beck, S Thirlwell, C AF Karpahakis, Anna Dibra, Ilarpreet Pipinikas, Christodoulos Feber, Andrew Morris, Tiffany Francis, Joshua Oukrif, Dahmane Mandair, Dalvinder Pericleous, Marinas Mohmaduvesh, Mullan Serra, Stefano Ogunbiyi, Olagunju Novelli, Marco Luong, TuVinh Asa, Sylvia L. Kulke, Matthew Tourripanakis, Christos Meyer, Tim Caplin, Martyn Beck, Stephan Thirlwell, Christina TI Progressive epigenetic dysregulation in neuroendocrine tumour liver metastases SO ENDOCRINE-RELATED CANCER LA English DT Letter C1 [Karpahakis, Anna; Dibra, Ilarpreet; Pipinikas, Christodoulos; Feber, Andrew; Morris, Tiffany; Oukrif, Dahmane; Mandair, Dalvinder; Novelli, Marco; Meyer, Tim; Beck, Stephan; Thirlwell, Christina] UCL, London, England. [Karpahakis, Anna; Mandair, Dalvinder; Pericleous, Marinas; Mohmaduvesh, Mullan; Ogunbiyi, Olagunju; Luong, TuVinh; Tourripanakis, Christos; Meyer, Tim; Caplin, Martyn; Thirlwell, Christina] Royal Free Hosp, London, England. [Francis, Joshua] Broad Inst, Boston, MA USA. [Serra, Stefano; Asa, Sylvia L.] UHN Princess Margaret Canc Ctr, Toronto, ON, Canada. [Kulke, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Thirlwell, C (reprint author), UCL, London, England.; Thirlwell, C (reprint author), Royal Free Hosp, London, England. EM christina.thirhvell@ucl.ac.uk FU UCL Experimental Cancer Medicine Centre; NIHR UCLH Biomedical Research Centre; Cancer Research UK; Medical Research Council; Wellcome Trust FX This work was supported by the UCL Experimental Cancer Medicine Centre, NIHR UCLH Biomedical Research Centre, Cancer Research UK, Medical Research Council and The Wellcome Trust. NR 10 TC 0 Z9 0 U1 0 U2 0 PU BIOSCIENTIFICA LTD PI BRISTOL PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND SN 1351-0088 EI 1479-6821 J9 ENDOCR-RELAT CANCER JI Endocr.-Relat. Cancer PD FEB PY 2017 VL 24 IS 2 BP L21 EP L25 DI 10.1530/ERC-16-0419 PG 5 WC Oncology; Endocrinology & Metabolism SC Oncology; Endocrinology & Metabolism GA EN3IZ UT WOS:000395903500004 PM 28049633 ER PT J AU Patel, RB Tannenbaum, S Viana-Tejedor, A Guo, J Im, K Morrow, DA Scirica, BM AF Patel, Ravi B. Tannenbaum, Sara Viana-Tejedor, Ana Guo, Jianping Im, KyungAh Morrow, David A. Scirica, Benjamin M. TI Serum potassium levels, cardiac arrhythmias, and mortality following non-ST-elevation myocardial infarction or unstable angina: insights from MERLIN-TIMI 36 SO EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE LA English DT Article DE Arrhythmias; acute coronary syndrome; potassium levels; myocardial infarction; cardiovascular death; ventricular tachycardia ID ACUTE CORONARY SYNDROMES; VENTRICULAR-ARRHYTHMIAS; RISK; HYPERKALEMIA; FIBRILLATION; MAGNITUDE; OUTCOMES AB Background: In acute coronary syndrome (ACS), potassium levels <3.5 mEq/L are associated with ventricular arrhythmias. Current guidelines therefore recommend a potassium target >4.0 mEq/L in ACS. Our study evaluated the association between potassium levels, cardiac arrhythmias, and cardiovascular death in patients with non-ST-segment elevation myocardial infarction or unstable angina. Methods: Potassium levels were measured in 6515 patients prior to randomization to receive either ranolazine or a placebo in the MERLIN-TIMI 36 trial. A seven-day continuous electrocardiographic assessment was obtained to determine the incidence of non-sustained ventricular tachycardia (NSVT) and ventricular pauses. The association between potassium levels and cardiovascular death was evaluated using a Cox proportional hazards regression model with multivariable adjustment. Results: NSVT lasting for at least eight consecutive beats occurred more frequently at potassium levels <3.5 mEq/L than at potassium levels 5 mEq/L (10.1 vs. 4.5%, p=0.03 for trend), whereas the inverse pattern was observed for ventricular pauses >3 s, which occurred more frequently at potassium levels 5 mEq/L than at potassium levels <3.5 mEq/L (5.9 vs. 2.0%, p=0.03 for trend). There was a U-shaped relationship between the potassium level at admission and both early and late risk of cardiovascular death. Compared with patients with potassium levels of 3.5 to <4 mEq/L, a potassium level <3.5 mEq/L was associated with an increased risk of cardiovascular death at day 14 (2.4 vs. 0.8%, HRadj 3.1, p=0.02) and at one year (6.4 vs. 3.0%, HRadj 2.2, p=0.01). The risk of cardiovascular death at one year was also significantly increased at potassium levels 4.5 mEq/L and a similar trend was noted at potassium levels 5 mEq/L. Conclusions: The lowest risk of cardiovascular death was observed in patients with admission potassium levels between 3.5 and 4.5 mEq/L. Both lower and higher levels of potassium were associated with tachyarrhythmias and bradyarrhythmias, suggesting a potential mechanistic explanation for the increased risk of cardiovascular death at the extremes of potassium homeostasis. C1 [Patel, Ravi B.; Tannenbaum, Sara; Guo, Jianping; Im, KyungAh; Morrow, David A.; Scirica, Benjamin M.] Brigham & Womens Hosp, Dept Med, Div Cardiol, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA. [Viana-Tejedor, Ana] Hosp Clin San Carlos, Madrid, Spain. RP Scirica, BM (reprint author), Brigham & Womens Hosp, Cardiovascular Div, TIMI Study Grp, 350 Longwood Ave, Boston, MA 02115 USA. EM bscirica@partners.org FU NHLBI NIH HHS [T32 HL007381] NR 26 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 2048-8726 EI 2048-8734 J9 EUR HEART J-ACUTE CA JI Eur. Heart J.-Acute Cardiovasc. Care PD FEB PY 2017 VL 6 IS 1 BP 18 EP 25 DI 10.1177/2048872615624241 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EL7DD UT WOS:000394780400003 PM 26714972 ER PT J AU Luo, L Guo, KH Fan, WG Lu, YH Chen, LZ Wang, Y Shao, YJ Wu, GX Xu, J Lu, LH AF Luo, Li Guo, Kaihua Fan, Wenguo Lu, Yinghong Chen, Lizhi Wang, Yang Shao, Yijia Wu, Gongxiong Xu, Jie Lu, Lanhai TI Niche astrocytes promote the survival, proliferation and neuronal differentiation of co-transplanted neural stem cells following ischemic stroke in rats SO EXPERIMENTAL AND THERAPEUTIC MEDICINE LA English DT Article; Proceedings Paper CT 2nd Workshop on Paediatric Virology CY OCT 08, 2016 CL Athens, GREECE DE niche astrocyte; neural stem cells; middle cerebral artery occlusion; ischemia; cell transplantation; stem cell therapy ID THERAPY; EXPRESSION; BRAIN; INJURY AB Niche astrocytes have been reported to promote neuronal differentiation through juxtacrine signaling. However, the effects of astrocytes on neuronal differentiation following ischemic stroke are not fully understood. In the present study, transplanted astrocytes and neural stem cells (NSCs) were transplanted into the ischemic striatum of transient middle cerebral artery occlusion (MCAO) model rats 48 h following surgery. It was observed that the co-transplantation of astrocytes and NSCs resulted in a higher ratio of survival and proliferation of the transplanted NSCs, and neuronal differentiation, in MCAO rats compared with NSC transplantation alone. These results demonstrate that the co-administration of astrocytes promotes the survival and neuronal differentiation of NSCs in the ischemic brain. These results suggest that the co-transplantation of astrocytes and NSCs is more effective than NSCs alone in the production of neurons following ischemic stroke in rats. C1 [Luo, Li; Fan, Wenguo; Lu, Lanhai] Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Guanghua Sch Stomatol, 56 LingYuanXi Rd, Guangzhou 510055, Guangdong, Peoples R China. [Luo, Li; Fan, Wenguo; Lu, Lanhai] Sun Yat Sen Univ, Hosp Stomatol, Inst Stomatol Res, 56 LingYuanXi Rd, Guangzhou 510055, Guangdong, Peoples R China. [Luo, Li; Guo, Kaihua; Lu, Yinghong; Chen, Lizhi; Wang, Yang; Shao, Yijia; Xu, Jie] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Anat & Neurobiol, 74 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China. [Luo, Li] Guangdong Pharmaceut Univ, Sch Basic Med, Dept Anat, Guangzhou 510006, Guangdong, Peoples R China. [Wu, Gongxiong] Harvard Med Sch, Div Res, Joslin Diabet Ctr, Boston, MA 02215 USA. RP Lu, LH (reprint author), Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Guanghua Sch Stomatol, 56 LingYuanXi Rd, Guangzhou 510055, Guangdong, Peoples R China.; Lu, LH (reprint author), Sun Yat Sen Univ, Hosp Stomatol, Inst Stomatol Res, 56 LingYuanXi Rd, Guangzhou 510055, Guangdong, Peoples R China.; Xu, J (reprint author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Anat & Neurobiol, 74 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China. EM xujie@mail.sysu.edu.cn; lvlanhai@mail.sysu.edu.cn FU National Natural Science Foundation of China for Youth [81000562]; Fundamental Research Funds for the Central Universities [14ykpy33]; Medical Scientific Research Foundation of Guangdong Province, China [A2015131] FX The present study was supported by The National Natural Science Foundation of China for Youth (grant no. 81000562), the Fundamental Research Funds for the Central Universities (grant no. 14ykpy33) and Medical Scientific Research Foundation of Guangdong Province, China (grant no. A2015131). NR 25 TC 0 Z9 0 U1 0 U2 0 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1792-0981 EI 1792-1015 J9 EXP THER MED JI Exp. Ther. Med. PD FEB PY 2017 VL 13 IS 2 BP 645 EP 650 DI 10.3892/etm.2016.4016 PG 6 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA EL9GH UT WOS:000394927900044 PM 28352345 ER PT J AU Metkar, U Kurra, S Quinzi, D Albanese, S Lavelle, WF AF Metkar, Umesh Kurra, Swamy Quinzi, David Albanese, Stephen Lavelle, William F. TI Magnetically controlled growing rods for scoliosis surgery SO EXPERT REVIEW OF MEDICAL DEVICES LA English DT Review DE Juvenile scoliosis; early onset scoliosis (EOS); growing rods; magnetic growing rods (Magec); magnetically controlled growing rods ID EARLY-ONSET SCOLIOSIS; SPINAL DEFORMITY; YOUNG-CHILDREN; GROWTH RODS; FOLLOW-UP; FUSION; COMPLICATIONS; SINGLE; INSTRUMENTATION; MULTICENTER AB Introduction: Early onset scoliosis can be both a disfiguring as well as a life threatening condition. When more conservative treatments fail, pediatric spinal surgeons are forced to consider operative interventions. Traditionally, these interventions have involved the insertion of a variety of implants into the patient with a limited number of anchor points controlling the spine. In the past, these pediatric patients have had multiple surgeries for elective lengthening of these devices to facilitate their growth while attempting to control the scoliosis. These patients often experience a physical and emotional toll from their multiple repeated surgeries. Growing spine techniques have also had a noted high complication rate due to implant dislodgement and infections. Recently, the development of non-invasively, self-lengthening growing rods has occurred. These devices have the potential to allow for the devices to be lengthened magnetically in a conscious patient in the surgeon's office.Areas covered: This review summarized previously published articles in the English literature using a key word search in PubMed for: magnetically controlled growing rods', Magec rods', magnetic growing rods' and growing rods'.Expert commentary: Magnetically controlled growing rods have an advantage over growing rods in lengthening the growing spine in the absence of repetitive surgeries. C1 [Metkar, Umesh] BIDMC, Spine Ctr, Boston, MA USA. [Kurra, Swamy; Albanese, Stephen; Lavelle, William F.] SUNY Upstate Med Univ, Dept Orthoped Surg, 750 E Adams St, Syracuse, NY 13210 USA. [Quinzi, David] SUNY Upstate Med Univ, 750 E Adams St, Syracuse, NY 13210 USA. RP Lavelle, WF (reprint author), SUNY Upstate Med Univ, Dept Orthoped Surg, 750 E Adams St, Syracuse, NY 13210 USA. EM lavellew@upstate.edu FU IntegraLife; DePuy; Medtronic; Vertebral Technologies, Inc.; Sigmus, Inc.; Spinal Kinetics, Inc.; K2M, Inc; Providence Technolgies; Stryker FX W. Lavelle received grants from IntegraLife, DePuy, Medtronic, Vertebral Technologies, Inc. Sigmus, Inc. Spinal Kinetics, Inc. K2M, Inc, Providence Technolgies, Stryker that are outside of the submitted work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 48 TC 1 Z9 1 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1743-4440 EI 1745-2422 J9 EXPERT REV MED DEVIC JI Expert Rev. Med. Devices PD FEB PY 2017 VL 14 IS 2 BP 117 EP 126 DI 10.1080/17434440.2016.1274230 PG 10 WC Engineering, Biomedical SC Engineering GA EM1TB UT WOS:000395098800004 PM 28044467 ER PT J AU Mahajan, N Wu, HJ Bennett, RL Troche, C Licht, JD Weber, JD Maggi, LB Tomasson, MH AF Mahajan, Nitin Wu, Hua-Jun Bennett, Richard L. Troche, Catalina Licht, Jonathan D. Weber, Jason D. Maggi, Leonard B., Jr. Tomasson, Michael H. TI Sabotaging of the oxidative stress response by an oncogenic noncoding RNA SO FASEB JOURNAL LA English DT Article DE ACA11; multiple myeloma; NRF2; ROS; snoRNA ID SMALL NUCLEOLAR RNAS; MULTIPLE-MYELOMA; GENE-EXPRESSION; CANCER; CELLS; TRANSLOCATION; MMSET; FGFR3 AB Overexpression of the multiple myeloma set domain (MMSET) Wolf-Hirschhorn syndrome candidate 1 gene, which contains an orphan box H/ACA class small nucleolar RNA, ACA11, in an intron, is associated with several cancer types, including multiple myeloma (MM). ACA11 and MMSET are overexpressed cotranscriptionally as a result of the t(4; 14) chromosomal translocation in a subset of patients with MM. RNA sequencing of CD138(+) tumor cells from t(4; 14)-positive and -negativeMMpatient bone marrow samples revealed an enhanced oxidative phosphorylation mRNA signature. Supporting these data, ACA11 overexpression in a t(4; 14)-negative MM cell line, MM1. S, demonstrated enhanced reactive oxygen species (ROS) levels. In addition, an enhancement of cell proliferation, increased soft agar colony size, and elevated ERK1/2 phosphorylation were observed. This ACA11-driven hyperproliferative phenotype depended on increased ROS levels as exogenously added antioxidants attenuate the increased proliferation. A major transcriptional regulator of the cellular antioxidant response, nuclear factor (erythroid-derived 2)-like 2 (NRF2), shuttled to the nucleus, as expected, in response to ACA11-driven increases in ROS; however, transcriptional up-regulation of some of NRF2's antioxidant target genes was abrogated in the presence of ACA11 overexpression. These data show for the first time that ACA11 promotes proliferation through inhibition of NRF2 function resulting in sustained ROS levels driving cancer cell proliferation.-Mahajan, N., Wu, H.-J., Bennett, R. L., Troche, C., Licht, J. D., Weber, J. D., Maggi, L. B., Jr., Tomasson, M. H. Sabotaging of the oxidative stress response by an oncogenic noncoding RNA. C1 [Mahajan, Nitin; Weber, Jason D.; Maggi, Leonard B., Jr.; Tomasson, Michael H.] Washington Univ, Siteman Canc Ctr, Sch Med, Dept Med,Div Oncol, Box 8069,660 South Euclid Ave, St Louis, MO 63110 USA. [Wu, Hua-Jun] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Bennett, Richard L.; Troche, Catalina; Licht, Jonathan D.] Univ Florida, Coll Med, Univ Florida Hlth Canc Ctr, Dept Med,Div Hematol & Oncol, Gainesville, FL USA. RP Maggi, LB; Tomasson, MH (reprint author), Washington Univ, Siteman Canc Ctr, Sch Med, Dept Med,Div Oncol, Box 8069,660 South Euclid Ave, St Louis, MO 63110 USA. EM lmaggi@dom.wustl.edu; tomasson@dom.wustl.edu FU U.S. National Institutes of Health, National Cancer Institute [R01-CA174743, R01-CA-175349] FX This work was supported, in part, by the U.S. National Institutes of Health, National Cancer Institute (Grants R01-CA174743 to M.H.T. and L.B.M., and R01-CA-175349 to M.H.T.). The authors thank M. Bates (University of Iowa, Iowa City, IA, USA) for her critical review. The authors also thank all the members of the M.H.T. laboratory for discussion and suggestions, and the Genome Technology Access Center (Department of Genetics, Washington University School of Medicine) for help with genomic analysis. NR 31 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD FEB PY 2017 VL 31 IS 2 BP 482 EP 490 DI 10.1096/fj.201600654R PG 9 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA EK9HR UT WOS:000394235400005 PM 28148777 ER PT J AU Carnemolla, R Villa, CH Greineder, CF Zaitsev, S Patel, KR Kowalska, MA Atochin, DN Cines, DB Siegel, DL Esmon, CT Muzykantov, VR AF Carnemolla, Ronald Villa, Carlos H. Greineder, Colin F. Zaitsev, Sergei Patel, Kruti R. Kowalska, M. Anna Atochin, Dmitriy N. Cines, Douglas B. Siegel, Don L. Esmon, Charles T. Muzykantov, Vladimir R. TI Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury SO FASEB JOURNAL LA English DT Article DE sepsis; inflammation; coagulation; pharmacokinetics; drug delivery ID ACTIVATED PROTEIN-C; DISSEMINATED INTRAVASCULAR COAGULATION; HUMAN SOLUBLE THROMBOMODULIN; HEMOLYTIC-UREMIC SYNDROME; REDUCES INFARCT VOLUME; LECTIN-LIKE DOMAIN; SEVERE SEPSIS; SEPTIC SHOCK; MEMBRANE RIGIDITY; FUSION PROTEIN AB Endothelial thrombomodulin (TM) regulates coagulation and inflammation via several mechanisms, including production of activated protein C (APC). Recombinant APC and soluble fragments of TM (sTM) have been tested in settings associated with insufficiency of the endogenous TM/APC pathway, such as sepsis. We previously designed a fusion protein of TM [single-chain variable fragment antibody (scFv)/TM] targeted to red blood cells (RBCs) to improve pharmacokinetics and antithrombotic effects without increasing bleeding. Here, scFv/TM was studied in mouse models of systemic inflammation and ischemia-reperfusion injury. Injected concomitantly with or before endotoxin, scFv/TM provided more potent protection against liver injury and release of pathological mediators than sTM, showing similar efficacy at up to 50-fold lower doses. scFv/TM provided protection when injected after endotoxin, whereas sTM did not, and augmented APC production by thrombin similar to 50-fold more than sTM. However, scFv/TM injected after endotoxin did not reduce thrombin/antithrombin complexes; nor did antibodies that block APC anticoagulant activity suppress the prophylactic anti-inflammatory effect of scFv/TM. Therefore, similar to endogenous TM, RBC-anchored scFv/TM activates several protective pathways. Finally, scFv/TM was more effective at reducing cerebral infarct volume and alleviated neurological deficits than sTM after cerebral ischemia/reperfusion injury. These results indicate that RBC-targeted scFv/TM exerts multifaceted cytoprotective effects and may find utility in systemic and focal inflammatory and ischemic disorders. C1 [Carnemolla, Ronald; Villa, Carlos H.; Greineder, Colin F.; Zaitsev, Sergei; Muzykantov, Vladimir R.] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA. [Carnemolla, Ronald; Villa, Carlos H.; Greineder, Colin F.; Zaitsev, Sergei; Esmon, Charles T.; Muzykantov, Vladimir R.] Univ Penn, Ctr Targeted Therapeut & Translat Nanomed, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA. [Villa, Carlos H.; Zaitsev, Sergei; Cines, Douglas B.; Siegel, Don L.] Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA. [Villa, Carlos H.; Zaitsev, Sergei; Cines, Douglas B.; Siegel, Don L.] Univ Penn, Lab Med, Philadelphia, PA 19104 USA. [Patel, Kruti R.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Kowalska, M. Anna] Childrens Hosp Philadelphia, Dept Pediat, Div Hematol, Philadelphia, PA 19104 USA. [Kowalska, M. Anna] Polish Acad Sci, Inst Med Biol, Lodz, Poland. [Atochin, Dmitriy N.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Div Cardiol, Charlestown, MA USA. [Esmon, Charles T.] Oklahoma Med Res Fdn, Dept Pathol, Oklahoma City, OK USA. [Esmon, Charles T.] Oklahoma Med Res Fdn, Dept Biochem & Mol Biol, Coagulat Biol Lab, Oklahoma City, OK USA. RP Muzykantov, VR (reprint author), Univ Penn, Perelman Sch Med, TRC 10-125,3400 Civ Ctr Blvd,Bldg 421, Philadelphia, PA 19104 USA. EM muzykant@mail.med.upenn.edu FU U.S. National Institutes of Health, National Heart, Lung, and Blood Institute [R01 HL121134, R01 HL125462, R01 HL116916-01, R01 HL091950, K08-HL 130430, 7UM1 HL120877-TACTIC] FX The authors thank Dr. Mortimer Poncz, The Children's Hospital of Philadelphia, for his scientific counsel and support of the study. This work was supported by U.S. National Institutes of Health, National Heart, Lung, and Blood Institute Grants R01 HL121134, R01 HL125462, R01 HL116916-01, R01 HL091950, K08-HL 130430, and 7UM1 HL120877-TACTIC. The authors declare no conflicts of interest. NR 68 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD FEB PY 2017 VL 31 IS 2 BP 761 EP 770 DI 10.1096/fj.201600912R PG 10 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA EK9HR UT WOS:000394235400028 PM 27836986 ER PT J AU Isakoff, SJ Puhalla, S Domchek, SM Friedlander, M Kaufman, B Robson, M Telli, ML Dieras, V Han, HS Garber, JE Johnson, EF Maag, D Qin, Q Giranda, VL Shepherd, SP AF Isakoff, Steven J. Puhalla, Shannon Domchek, Susan M. Friedlander, Michael Kaufman, Bella Robson, Mark Telli, Melinda L. Dieras, Veronique Han, Hyo Sook Garber, Judy E. Johnson, Eric F. Maag, David Qin, Qin Giranda, Vincent L. Shepherd, Stacie P. TI A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale SO FUTURE ONCOLOGY LA English DT Article DE BRCA1; BRCA2; breast cancer; DNA damage; PARP; PARP inhibitor; PARP trapping; synthetic lethality; veliparib ID POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; OLAPARIB MAINTENANCE THERAPY; PRIMARY PERITONEAL CANCER; PARP INHIBITORS; EPITHELIAL OVARIAN; CLINICAL-TRIAL; FALLOPIAN-TUBE; DNA-DAMAGE; COMBINATION; ABT-888 AB Veliparib is an orally administered poly(ADP-ribose) polymerase inhibitor that is being studied in Phase I-III clinical trials, including Phase III studies in non-small-cell lung cancer, ovarian cancer and breast cancer. Tumor cells with deleterious BRCA1 or BRCA2 mutations are deficient in homologous recombination DNA repair and are intrinsically sensitive to platinum therapy and poly(ADP-ribose) polymerase inhibitors. We describe herein the design and rationale of a Phase II trial investigating whether the addition of veliparib to temozolomide or carboplatin/paclitaxel provides clinical benefit over carboplatin/paclitaxel with placebo in patients with locally recurrent or metastatic breast cancer harboring a deleterious BRCA1 or BRCA2 germline mutation C1 [Isakoff, Steven J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Puhalla, Shannon] Univ Pittsburgh, Dept Med, Inst Canc, Pittsburgh, PA 15232 USA. [Domchek, Susan M.] Univ Penn, Basser Ctr BRCA, Philadelphia, PA 19104 USA. [Friedlander, Michael] Royal Hosp Women, Gynaecol Canc Ctr, Sydney, NSW 2031, Australia. [Kaufman, Bella] Chaim Sheba Med Ctr, Dept Gen Oncol, IL-52621 Ramat Gan, Israel. [Robson, Mark] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10022 USA. [Telli, Melinda L.] Stanford Univ, Dept Med Oncol, Sch Med, Stanford, CA 94305 USA. [Dieras, Veronique] Inst Curie, Dept Med Oncol, F-75248 Paris, France. [Han, Hyo Sook] H Lee Moffitt Canc Ctr & Res Inst, Ctr Womens Oncol, Tampa, FL 33612 USA. [Garber, Judy E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Johnson, Eric F.; Maag, David; Qin, Qin; Giranda, Vincent L.; Shepherd, Stacie P.] AbbVie Inc, Chicago, IL 60064 USA. RP Isakoff, SJ (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. EM SISAKOFF@mgh.harvard.edu FU Genentech; Pharmamar; AbbVie; Covance-Bayer; Lilly; Incyte; Novartis; Pfizer; AstraZeneca; BioMarin; Puma; Clovis; Medivation; Myriad; Corcept; Karyopharm; Merrimack; Prescient; TapImmune; Myriad Genetics; Ambry Genetics; AbbVie Inc. FX SJ Isakoff: Consultant - AbbVie, Myriad; Research support - Genentech, Pharmamar, AbbVie. S Puhalla: Consultant - AbbVie, Celldex, Pfizer; Research funding to institution, AbbVie, Covance-Bayer, Lilly, Incyte, Novartis, Pfizer, Genentech, AstraZeneca, BioMarin, Puma. S Domchek: Consulting, EMD Serono, AbbVie; Research support (institution) - AbbVie, Clovis, AstraZeneca, Pharmamar. M Friedlander: Advisory boards and honoraria - AstraZeneca, Roche and Pfizer. B Kaufman: Nothing to report. M Robson: Consulting - AstraZeneca; Research support (institution) - AbbVie, BioMarin, Medivation, AstraZeneca, Myriad. M Telli: Research funding (institution) - AbbVie, BioMarin, Medivation, Pharmamar; Consultant - AstraZeneca. V Dieras: Honoraria - AB Roche Genentech, Novartis, Pfizer, AbbVie; Symposia - Roche Genentech, Novartis, Pfizer. HS Han: Research support (institution) - AbbVie, Corcept, Incyte, Karyopharm, Merrimack, Prescient, TapImmune. JE Garber: Consulting or Advisory Role Biogen, GTx Pharmaceuticals (spouse), Helix, Novartis (spouse), Pfizer (spouse), Pfizer, Sequenom, SV Life Sciences (spouse); Research Funding - Myriad Genetics, Novartis (spouse), Pfizer (spouse), Ambry Genetics. E Johnson, D Maag, Q Qin, VL Giranda, SP Shepherd: AbbVie employees and stock owners. AbbVie Inc. provided financial support for this study and participated in the design, study conduct, analysis and interpretation of the data, as well as the writing, review and approval of this manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.; Medical writing support was provided by D Eickermann, PhD, TRM Oncology, Atlanta, GA, funded by AbbVie Inc. NR 60 TC 1 Z9 1 U1 0 U2 0 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1479-6694 EI 1744-8301 J9 FUTURE ONCOL JI Future Oncol. PD FEB PY 2017 VL 13 IS 4 BP 307 EP 320 DI 10.2217/fon-2016-0412 PG 14 WC Oncology SC Oncology GA EL1QI UT WOS:000394394600004 PM 27739325 ER PT J AU Neto, JL Lee, JM Afridi, A Gillis, T Guide, JR Dempsey, S Lager, B Alonso, I Wheeler, VC Pinto, RM AF Luis Neto, Joao Lee, Jong-Min Afridi, Ali Gillis, Tammy Guide, Jolene R. Dempsey, Stephani Lager, Brenda Alonso, Isabel Wheeler, Vanessa C. Pinto, Ricardo Mouro TI Genetic Contributors to Intergenerational CAG Repeat Instability in Huntington's Disease Knock-In Mice SO GENETICS LA English DT Article DE Huntington's disease; intergenerational CAG repeat instability; HD knock-in mouse models; genetic background ID NON-MENDELIAN TRANSMISSION; MYOTONIC-DYSTROPHY LOCUS; MACHADO-JOSEPH-DISEASE; SINGLE SPERM ANALYSIS; AGE-OF-ONSET; (CAG)(N) REPEAT; TRINUCLEOTIDE REPEATS; REDUCED PENETRANCE; HAPLOTYPE ANALYSIS; TRANSGENIC MICE AB Huntington's disease (HD) is a neurodegenerative disorder caused by the expansion of a CAG trinucleotide repeat in exon 1 of the HTT gene. Longer repeat sizes are associated with increased disease penetrance and earlier ages of onset. Intergenerationally unstable transmissions are common in HD families, partly underlying the genetic anticipation seen in this disorder. HD CAG knock-in mouse models also exhibit a propensity for intergenerational repeat size changes. In this work, we examine intergenerational instability of the CAG repeat in over 20,000 transmissions in the largest HD knock-in mouse model breeding datasets reported to date. We confirmed previous observations that parental sex drives the relative ratio of expansions and contractions. The large datasets further allowed us to distinguish effects of paternal CAG repeat length on the magnitude and frequency of expansions and contractions, as well as the identification of large repeat size jumps in the knock-in models. Distinct degrees of intergenerational instability were observed between knock-in mice of six background strains, indicating the occurrence of trans-acting genetic modifiers. We also found that lines harboring a neomycin resistance cassette upstream of Htt showed reduced expansion frequency, indicative of a contributing role for sequences in cis, with the expanded repeat as modifiers of intergenerational instability. These results provide a basis for further understanding of the mechanisms underlying intergenerational repeat instability. C1 [Luis Neto, Joao; Lee, Jong-Min; Afridi, Ali; Gillis, Tammy; Guide, Jolene R.; Wheeler, Vanessa C.; Pinto, Ricardo Mouro] Massachusetts Gen Hosp, Ctr Human Genet Res, 185 Cambridge St, Boston, MA 02114 USA. [Luis Neto, Joao; Alonso, Isabel] UnIGENe, Inst Biol Mol & Celular, P-4200 Oporto, Portugal. [Luis Neto, Joao; Alonso, Isabel] Inst Invest & Inovacao Saude, P-4200 Oporto, Portugal. [Luis Neto, Joao] Univ Porto, Grad Program Areas Basic & Appl Biol, Abel Salazar Biomed Sci Inst, P-4050 Oporto, Portugal. [Alonso, Isabel] Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4050 Oporto, Portugal. [Lee, Jong-Min; Wheeler, Vanessa C.; Pinto, Ricardo Mouro] Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA. [Dempsey, Stephani] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA. [Lager, Brenda] CHDI Fdn, Princeton, NJ 08540 USA. RP Wheeler, VC; Pinto, RM (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, 185 Cambridge St, Boston, MA 02114 USA. EM Wheeler@helix.mgh.harvard.edu; RMouroPinto@mgh.harvard.edu FU Fundacao para a Ciencia e a Tecnologia (FCT) [SFRH/BD/51705/2011]; National Institutes of Health [NS049206] FX J.L.N. is a recipient of a Fundacao para a Ciencia e a Tecnologia (FCT) fellowship (SFRH/BD/51705/2011; www.fct.pt). This work was supported by the National Institutes of Health [NS049206] grant attributed to V.C.W. NR 58 TC 0 Z9 0 U1 0 U2 0 PU GENETICS SOCIETY AMERICA PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 0016-6731 EI 1943-2631 J9 GENETICS JI Genetics PD FEB PY 2017 VL 205 IS 2 BP 503 EP 516 DI 10.1534/genetics.116.195578 PG 14 WC Genetics & Heredity SC Genetics & Heredity GA EK7ZY UT WOS:000394144900004 PM 27913616 ER PT J AU Schnell-Inderst, P Iglesias, CP Arvandi, M Ciani, O Gothe, RM Peters, J Blom, AW Taylor, RS Siebert, U AF Schnell-Inderst, Petra Iglesias, Cynthia P. Arvandi, Marjan Ciani, Oriana Gothe, Raffaella Matteucci Peters, Jaime Blom, Ashley W. Taylor, Rod S. Siebert, Uwe TI A bias-adjusted evidence synthesis of RCT and observational data: the case of total hip replacement SO HEALTH ECONOMICS LA English DT Article DE medical devices; health technology assessment; generalized evidence synthesis; bias adjustment; expert elicitation ID RANDOMIZED CONTROLLED-TRIALS; CEMENTED ALL-POLYETHYLENE; SECONDARY DATA SOURCES; EXTERNAL VALIDITY; MEDICAL DEVICES; ARTHROPLASTY; OUTCOMES; DESIGN; EUROPE; AGE AB Evaluation of clinical effectiveness of medical devices differs in some aspects from the evaluation of pharmaceuticals. One of the main challenges identified is lack of robust evidence and a will to make use of experimental and observational studies (OSs) in quantitative evidence synthesis accounting for internal and external biases. Using a case study of total hip replacement to compare the risk of revision of cemented and uncemented implant fixation modalities, we pooled treatment effect estimates from OS and RCTs, and simplified existing methods for bias-adjusted evidence synthesis to enhance practical application. We performed an elicitation exercise using methodological and clinical experts to determine the strength of beliefs about the magnitude of internal and external bias affecting estimates of treatment effect. We incorporated the bias-adjusted treatment effects into a generalized evidence synthesis, calculating both frequentist and Bayesian statistical models. We estimated relative risks as summary effect estimates with 95% confidence/credibility intervals to capture uncertainty. When we compared alternative approaches to synthesizing evidence, we found that the pooled effect size strongly depended on the inclusion of observational data as well as on the use bias-adjusted estimates. We demonstrated the feasibility of using observational studies in meta-analyses to complement RCTs and incorporate evidence from a wider spectrum of clinically relevant studies and healthcare settings. To ensure internal validity, OS data require sufficient correction for confounding and selection bias, either through study design and primary analysis, or by applying post-hoc bias adjustments to the results. (c) 2017 The Authors. Health Economics published by John Wiley & Sons, Ltd. C1 [Schnell-Inderst, Petra; Arvandi, Marjan; Gothe, Raffaella Matteucci; Siebert, Uwe] UMIT Univ Hlth Sci Med Informat & Technol, Inst Publ Hlth Med Decis Making & Hlth Technol As, Dept Publ Hlth Hlth Serv Res & Hlth Technol Asses, Eduard Wallnoefer Ctr I, A-6060 Hall In Tirol, Austria. [Iglesias, Cynthia P.] Univ York, Dept Hlth Sci, Heslington, England. [Iglesias, Cynthia P.] Univ York, Ctr Hlth Econ, York, N Yorkshire, England. [Iglesias, Cynthia P.] Univ York, Hull & York Med Sch, York, N Yorkshire, England. [Iglesias, Cynthia P.] Luxemboug Inst Hlth, Luxembourg, Luxembourg. [Ciani, Oriana; Peters, Jaime; Taylor, Rod S.] Univ Exeter, Sch Med, Inst Hlth Serv Res, Exeter, Devon, England. [Ciani, Oriana] Bocconi Univ, Ctr Res Hlth & Social Care Management, Milan, Italy. [Blom, Ashley W.] Univ Bristol, Musculoskeletal Res Unit, Bristol, Avon, England. [Siebert, Uwe] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA USA. [Siebert, Uwe] Harvard Med Sch, Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA USA. [Siebert, Uwe] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. RP Schnell-Inderst, P (reprint author), UMIT Univ Hlth Sci Med Informat & Technol, Inst Publ Hlth Med Decis Making & Hlth Technol As, Dept Publ Hlth Hlth Serv Res & Hlth Technol Asses, Eduard Wallnoefer Ctr I, A-6060 Hall In Tirol, Austria. EM petra.schnell-inderst@umit.at FU European Community [HEALTH-F3-2012-305694] FX The research leading to these results has received funding from the European Community's Seventh Framework Programme under grant agreement HEALTH-F3-2012-305694 (Project MedtecHTA 'Methods for Health Technology Assessment of Medical Devices: a European Perspective'). We are extremely grateful to the clinical and methodological experts who took the time from their busy schedules to participate in the study. Without their support, we would have never achieved the results presented in this manuscript. All errors are ours. NR 53 TC 5 Z9 5 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9230 EI 1099-1050 J9 HEALTH ECON JI Health Econ. PD FEB PY 2017 VL 26 SU S1 BP 46 EP 69 DI 10.1002/hec.3474 PG 24 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA EL5FE UT WOS:000394646200005 PM 28139089 ER PT J AU Hung, J Levine, RA AF Hung, Judy Levine, Robert A. TI Pixels or Pixie Dust? Grading of mitral regurgitation using intensity analysis of continuous wave Doppler SO HEART LA English DT Editorial Material ID QUANTIFICATION; FLOW; AREA C1 [Hung, Judy; Levine, Robert A.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. RP Hung, J (reprint author), Massachusetts Gen Hosp, Echocardiog, Blake 256,55 Fruit St, Boston, MA 02114 USA. EM jhung@mgh.harvard.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1355-6037 EI 1468-201X J9 HEART JI Heart PD FEB PY 2017 VL 103 IS 3 BP 177 EP 178 DI 10.1136/heartjnl-2016-310293 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EL3HM UT WOS:000394510200002 PM 27609944 ER PT J AU Kim, JH Ko, YA Hedley, J MacNamara, J Awad, M Taylor, W Healy, S Aida, H Le, NA Wilson, PW White, M Sperling, LS Wilson, JS Baggish, AL AF Kim, Jonathan H. Ko, Yi-An Hedley, Jeff MacNamara, James Awad, Mosaab Taylor, William Healy, Sean Aida, Hiroshi Le, Ngoc-Anh Wilson, Peter W. White, Melissa Sperling, Laurence S. Wilson, Joseph S., Jr. Baggish, Aaron L. TI The impact of moderate distance recreational running and ageing on cardiac physiology SO HEART LA English DT Article ID PROLONGED ENDURANCE EXERCISE; BRAIN NATRIURETIC PEPTIDE; TROPONIN-I; VENTRICULAR DYSFUNCTION; HEART-FAILURE; BIOMARKERS; RECOMMENDATIONS; INCREASES; ASSAY; RUN AB Objective Exercise-induced cardiac dysfunction and corollary biomarker release have been documented following long-distance running events. To what degree these processes occur during shorter distance running events is unknown. Methods 72 healthy recreational runners (54% male/46% female) recruited by age (group 1 (18-20 years old, N=19); group 2 (45-50 years old, N=27); group 3 (70-75 years old, N= 26)) were studied with echocardiography and biochemical profiling during participation in a 10 km running race. Results Despite age-dependent baseline differences in ventricular size and diastolic tissue velocities, there were no significant within group or across group decrements in ventricular systolic or diastolic function following race completion. Postrace increases in cardiac troponin-I (cTnI), B-type natriuretic peptide (BNP) and high-sensitivity C-reactive protein (hs-CRP) were common and demonstrated distinct age dependent profiles. Specifically, BNP increases were most pronounced among older runners (group 3 Delta: 16 +/- 22 pg/mL, p=0.001), hs-CRP increased only among younger runners (group 1 Delta: 1.5 +/- 2.7 mg/L, p=0.03) and cTnI increased in both younger (group 1 Delta: 0.01 +/- 0.02 ng/mL, p=0.028) and older (group 3 Delta: 0.01 +/- 0.01 ng/mL, p=0.007) runners, but not middle aged runners (group 2 Delta: 0.00 +/- 0.00 ng/mL, p=0.57). Conclusions Moderate distance recreational running leads to distinct age-dependent biomarker release but is not associated with cardiac fatigue, a proposed stimulus for pathologic cardiac remodelling that has been observed following longer distance running events. C1 [Kim, Jonathan H.; Hedley, Jeff; MacNamara, James; Awad, Mosaab; Taylor, William; Healy, Sean; Aida, Hiroshi; Wilson, Peter W.; Sperling, Laurence S.] Emory Clin Cardiovasc Res Inst, Div Cardiol, Atlanta, GA USA. [Kim, Jonathan H.; Wilson, Joseph S., Jr.] Atlanta Track Club, Atlanta, GA USA. [Ko, Yi-An] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA USA. [Le, Ngoc-Anh; Wilson, Peter W.] Vet Affairs Med Ctr, Biomarker Core Lab, Atlanta, GA 30033 USA. [White, Melissa] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA. [Baggish, Aaron L.] Massachusetts Gen Hosp, Cardiovasc Performance Program, Boston, MA 02114 USA. RP Kim, JH (reprint author), Emory Univ, Sch Med, Clin Cardiovasc Res Inst, 1462 Clifton Rd,NE,Suite 502, Atlanta, GA 30322 USA. EM jonathan.kim@emory.edu FU National Institutes of Health [K23 HL128795] FX JHK is supported by the National Institutes of Health (K23 HL128795). NR 28 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1355-6037 EI 1468-201X J9 HEART JI Heart PD FEB PY 2017 VL 103 IS 3 BP 219 EP 226 DI 10.1136/heartjnl-2016-310059 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EL3HM UT WOS:000394510200009 PM 27530134 ER PT J AU Young, RH AF Young, Robert H. TI Additional historical comments on pre-invasive testicular germ cell malignancy SO HISTOPATHOLOGY LA English DT Letter C1 [Young, Robert H.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Young, RH (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0309-0167 EI 1365-2559 J9 HISTOPATHOLOGY JI Histopathology PD FEB PY 2017 VL 70 IS 3 BP 499 EP 499 DI 10.1111/his.13061 PG 1 WC Cell Biology; Pathology SC Cell Biology; Pathology GA EM0CG UT WOS:000394985800018 PM 27629103 ER PT J AU Spracklen, CN Smith, CJ Saftlas, AF Triche, EW Bjonnes, A Keating, BJ Saxena, R Breheny, PJ Dewan, AT Robinson, JG Hoh, J Ryckman, KK AF Spracklen, Cassandra N. Smith, Caitlin J. Saftlas, Audrey F. Triche, Elizabeth W. Bjonnes, Andrew Keating, Brendan J. Saxena, Richa Breheny, Patrick J. Dewan, Andrew T. Robinson, Jennifer G. Hoh, Josephine Ryckman, Kelli K. TI Genetic predisposition to elevated levels of C-reactive protein is associated with a decreased risk for preeclampsia SO HYPERTENSION IN PREGNANCY LA English DT Article DE C-reactive protein; genetic epidemiology; genetic risk score; preeclampsia ID HIGH BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; BIRTH-WEIGHT; LATER LIFE; PREGNANCY; VARIANTS; DYSLIPIDEMIA; HYPERTENSION; PATHOGENESIS; METAANALYSIS AB Objective: To examine the association between genetic predisposition to elevated C-reactive protein (CRP)and risk for preeclampsia using validated genetic loci for C-reactive protein. Methods: Preeclampsia cases (n = 177) and normotensive controls (n = 116) were selected from live birth certificates to nulliparous Iowa women during the period August 2002-May 2005. Disease status was verified by the medical chart review. Genetic predisposition to CRP was estimated by a genetic risk score on the basis of established loci for CRP levels. Logistic regression analyses were used to evaluate the relationships between the genotype score and preeclampsia. Replication analyses were performed in an independent, US population of preeclampsia cases (n = 516) and controls (n = 1,097) of European ancestry. Results: The genetic risk score (GRS) related to higher levels of CRP demonstrated a significantly decreased risk of preeclampsia (OR 0.89, 95% CI 0.82-0.96). When the GRS was analyzed by quartile, an inverse linear trend was observed (p = 0.0006). The results were similar after adjustments for the body mass index (BMI), smoking, and leisure-time physical activity. In the independent replication population, the association with the CRP GRS was also marginally significant (OR 0.97, 95% CI 0.92, 1.02). Meta-analysis of the two studies was statistically significant (OR 0.95, 95% CI 0.90, 0.99). Conclusion: Our data suggest an inverse, counterintuitive association between the genetic predisposition to elevated levels of CRP and a decreased risk of preeclampsia. This suggests that the blood CRP level is a marker of preeclampsia, but it does not appear to be a factor on the causal pathway. C1 [Spracklen, Cassandra N.; Smith, Caitlin J.; Saftlas, Audrey F.; Robinson, Jennifer G.; Ryckman, Kelli K.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, 145 Riverside Dr,S471 CPHB, Iowa City, IA 52242 USA. [Triche, Elizabeth W.] Brown Univ, Div Biol & Med, Dept Epidemiol, Providence, RI 02912 USA. [Bjonnes, Andrew; Saxena, Richa] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Bjonnes, Andrew; Saxena, Richa] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Bjonnes, Andrew; Saxena, Richa] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Keating, Brendan J.] Univ Penn, Dept Surg, Penn Transplant Inst, Perelman Sch Med, Philadelphia, PA 19104 USA. [Keating, Brendan J.] Childrens Hosp Philadelphia, Div Genet, Philadelphia, PA 19104 USA. [Breheny, Patrick J.] Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USA. [Dewan, Andrew T.] Yale Sch Publ Hlth, Div Chron Dis Epidemiol, New Haven, CT USA. [Hoh, Josephine] Yale Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT USA. RP Ryckman, KK (reprint author), Univ Iowa, Coll Publ Hlth, Dept Epidemiol, 145 Riverside Dr,S471 CPHB, Iowa City, IA 52242 USA. EM kelli-ryckman@uiowa.edu FU National Institute of Child Health and Human Development; National Institutes of Health [R01 HD32579]; Verto Institute; Society for Obstetric Anesthesia and Perinatology FX The SOPHIA study was supported by the National Institute of Child Health and Human Development, National Institutes of Health R01 HD32579 and the Verto Institute. The replication study was funded in part by a Gertie Marx Grant from the Society for Obstetric Anesthesia and Perinatology. NR 36 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1064-1955 EI 1525-6065 J9 HYPERTENS PREGNANCY JI Hypertens. Pregnancy PD FEB PY 2017 VL 36 IS 1 BP 30 EP 35 DI 10.1080/10641955.2016.1223303 PG 6 WC Obstetrics & Gynecology; Physiology; Peripheral Vascular Disease SC Obstetrics & Gynecology; Physiology; Cardiovascular System & Cardiology GA EM2XJ UT WOS:000395178800005 PM 27657194 ER PT J AU Jian, YQ Ye, J Qi, H Deng, CY Deng, SP Li, FR AF Jian, You-Qiang Ye, Jian Qi, Hui Deng, Chun-Yan Deng, Shao-Ping Li, Fu-Rong TI Anti-CD45RB and donor-specific spleen cells transfusion inhibition allograft skin rejection mediated by memory T cells SO IMMUNOLOGY AND CELL BIOLOGY LA English DT Article AB Donor-reactive memory T (Tm) cells mediate accelerated rejection, which is known as a barrier to the survival of transplanted organs. Selective interference with the anti-CD45RB monoclonal antibody (a-CD45RB) reliably induces donor-specific tolerance. In this study, pre-sensitization to female C57BL/6 mice with the skin of female BLAB/c mice generated a large number of Tm cells and resulted in rapid rejection of the secondly transplanted allografts. alpha-CD45RB did induce the tolerance to skin allograft primarily transplanted but failed to induce tolerance in the pre-sensitized mice. Donor-specific spleen cell transfusion (DST) alone also failed to induce the tolerance in the pre-sensitized recipients. Interestingly, combination of alpha-CD45RB with DST inhibited the rejection induced by memory T cells in the pre-sensitized mice. CD25+ T-cell depletion in alpha-CD45RB combined with DST therapy recipients could prevent skin allograft tolerance from establishing. In addition, adoptive transfer of donorprimed memory T cells into the tolerant recipients markedly broke the established tolerance. Our findings indicate that aCD45RB and DST can synergistically inhibit the accelerated rejection mediated by memory T cells and induce long-term skin allograft acceptance in mice. C1 [Jian, You-Qiang; Ye, Jian; Li, Fu-Rong] Jinan Univ, Clin Med Coll 2, Dept Gen Surg, Shenzhen Peoples Hosp, Shenzhen, Peoples R China. [Jian, You-Qiang; Ye, Jian; Qi, Hui; Deng, Chun-Yan; Deng, Shao-Ping; Li, Fu-Rong] Jinan Univ, Clin Med Coll 2, Key Lab Stem Cell & Cellular Therapy, Shenzhen Peoples Hosp, 1017 Dongmen North Rd, Shenzhen 518020, Peoples R China. [Deng, Shao-Ping] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA. [Li, Fu-Rong] Shenzhen Cell Therapy Publ Serv Platform, Shenzhen, Peoples R China. RP Li, FR (reprint author), Jinan Univ, Clin Med Coll 2, Key Lab Stem Cell & Cellular Therapy, Shenzhen Peoples Hosp, 1017 Dongmen North Rd, Shenzhen 518020, Peoples R China.; Deng, SP (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA. EM sdeng10@yahoo.com; frli62@163.com FU National Natural Science Foundation of China [30772042]; Natural Science Foundation of Guangdong [S2013010014832]; Science and Technology Project of Shenzhen [JCYJ20120618153743791, GJHZ20120618153934353] FX This work was supported by the National Natural Science Foundation of China (No. 30772042), and The Natural Science Foundation of Guangdong (No.S2013010014832) and The Science and Technology Project of Shenzhen (JCYJ20120618153743791, GJHZ20120618153934353). NR 45 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0818-9641 EI 1440-1711 J9 IMMUNOL CELL BIOL JI Immunol. Cell Biol. PD FEB PY 2017 VL 95 IS 2 BP 189 EP 197 DI 10.1038/icb.2016.88 PG 9 WC Cell Biology; Immunology SC Cell Biology; Immunology GA EL1EY UT WOS:000394364500013 PM 27616751 ER PT J AU Truong-Bolduc, QC Khan, NS Vyas, JM Hooper, DC AF Truong-Bolduc, Q. C. Khan, N. S. Vyas, J. M. Hooper, D. C. TI Tet38 Efflux Pump Affects Staphylococcus aureus Internalization by Epithelial Cells through Interaction with CD36 and Contributes to Bacterial Escape from Acidic and Nonacidic Phagolysosomes SO INFECTION AND IMMUNITY LA English DT Article DE CD36; S. aureus; endosomes; internalization; survival ID SMALL-COLONY VARIANTS; ENDOTHELIAL-CELLS; INFECTIONS; RESISTANCE; ADHERENCE; RECEPTOR; PHAGOCYTOSIS; EXPRESSION; APOPTOSIS; IMMUNITY AB We previously reported that the Tet38 efflux pump is involved in internalization of Staphylococcus aureus by A549 lung epithelial cells. A lack of tet38 reduced bacterial uptake by A549 cells to 36% of that of the parental strain RN6390. Using invasion assays coupled with confocal microscopy imaging, we studied the host cell receptor(s) responsible for bacterial uptake via interaction with Tet38. We also assessed the ability of S. aureus to survive following alkalinization of the phagolysosomes by chloroquine. Antibody to the scavenger receptor CD36 reduced the internalization of S. aureus RN6390 by A549 cells, but the dependence on CD36 was reduced in QT7 tet38, suggesting that an interaction between Tet38 and CD36 contributed to S. aureus internalization. Following fusion of the S. aureus-associated endosomes with lysosomes, alkalinization of the acidic environment with chloroquine led to a rapid increase in the number of S. aureus RN6390 bacteria in the cytosol, followed by a decrease shortly thereafter. This effect of chloroquine was not seen in the absence of intact Tet38 in mutant QT7. These data taken together suggest that Tet38 plays a role both in bacterial internalization via interaction with CD36 and in bacterial escape from the phagolysosomes. C1 [Truong-Bolduc, Q. C.; Khan, N. S.; Vyas, J. M.; Hooper, D. C.] Harvard Med Sch, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02115 USA. RP Hooper, DC (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02115 USA. EM dhooper@mgh.harvard.edu FU U.S. Public Health Service from the National Institutes of Health [R37-AI23988, P01-AI083214] FX This work was supported by U.S. Public Health Service grants R37-AI23988 and P01-AI083214 (M. Gilmore, Principal Investigator) from the National Institutes of Health to D.C.H. NR 41 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD FEB PY 2017 VL 85 IS 2 AR e00862-16 DI 10.1128/IAI.00862-16 PG 13 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EL4RZ UT WOS:000394609900019 ER PT J AU Dohlman, TH Ding, J Dana, R Chauhan, SK AF Dohlman, Thomas H. Ding, Julia Dana, Reza Chauhan, Sunil K. TI T Cell-Derived Granulocyte-Macrophage Colony-Stimulating Factor Contributes to Dry Eye Disease Pathogenesis by Promoting CD11b+Myeloid Cell Maturation and Migration SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE cornea; dry eye; Th17 cell; granulocyte-macrophage colony-stimulating factor; monocyte/macrophage ID CYTOKINE GM-CSF; DENDRITIC CELLS; HUMAN-MONOCYTES; OCULAR-SURFACE; TH17 CELLS; AUTOIMMUNITY; INFLAMMATION; EXPRESSION; INDUCTION; BARRIER AB PURPOSE. Growing evidence suggests that granulocyte-macrophage colony-stimulating factor (GM-CSF) contributes to T helper 17 (Th17) cell-associated immunoinflammatory diseases. The purpose of this study was to evaluate the effect of T cell-derived GM-CSF on CD11b+ myeloid cell function in dry eye disease (DED). METHODS. In a murine model of DED, quantitative real-time PCR and ELISA were used to measure GM-CSF expression at the ocular surface, and flow cytometry was used to enumerate GM-CSF producing Th17 cells. A granulocyte-macrophage colony-stimulating factor neutralizing antibody was used topically in vivo and in an in vitro culture system to evaluate the role of GM-CSF in recruiting and maturing CD11b+ cells. Clinical disease severity was evaluated after topical administration of GM-CSF neutralizing antibody. RESULTS. In dry eye disease, GM-CSF is significantly upregulated at the ocular surface and the frequency of GM-CSF producing Th17 cells is significantly increased in the draining lymph nodes. In vitro neutralization of GM-CSF from CD4+ T cells derived from DED mice suppresses major histocompatibility complex II expression by CD11b+ cells and CD11b+ cell migration. Topical neutralization of GM-CSF in a murine model of DED suppresses CD11b+ maturation and migration, as well as Th17 cell induction, yielding a reduction in clinical signs of disease. CONCLUSIONS. T helper 17 cell-derived GM-CSF contributes to DED pathogenesis by promoting CD11b+ cell activation and migration to the ocular surface. C1 [Dohlman, Thomas H.; Ding, Julia; Dana, Reza; Chauhan, Sunil K.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Boston, MA USA. RP Dana, R; Chauhan, SK (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA. EM reza_dana@meei.harvard.edu; sunil_chauhan@meei.harvard.edu FU National Institute of Health [EY024602, EY020889] FX The authors thank Susanne Eiglmeier for her assistance in editing and preparing the manuscript. Supported in part by National Institute of Health Grants EY024602 (SKC) and EY020889 (RD). NR 34 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD FEB PY 2017 VL 58 IS 2 DI 10.1167/iovs.16-20789 PG 7 WC Ophthalmology SC Ophthalmology GA EO8LC UT WOS:000396939600073 ER PT J AU Jakobs, TC AF Jakobs, Tatjana C. TI Ex Vivo Imaging of the Murine Optic Nerve Head SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Editorial Material C1 [Jakobs, Tatjana C.] Harvard Med Sch, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02115 USA. RP Jakobs, TC (reprint author), Harvard Med Sch, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02115 USA. EM Tatjana_Jakobs@meei.harvard.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD FEB PY 2017 VL 58 IS 2 DI 10.1167/iovs.17-21422 PG 1 WC Ophthalmology SC Ophthalmology GA EO8LC UT WOS:000396939600004 PM 28152143 ER PT J AU Kim, EC Toyono, T Berlinicke, CA Zack, DJ Jurkunas, U Usui, T Jun, AS AF Kim, Eun Chul Toyono, Tetsuya Berlinicke, Cynthia A. Zack, Donald J. Jurkunas, Ula Usui, Tomohiko Jun, Albert S. TI Screening and Characterization of Drugs That Protect Corneal Endothelial Cells Against Unfolded Protein Response and Oxidative Stress SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE drug screening; corneal endothelial cells; unfolded protein response; oxidative stress; Fuchs' endothelial corneal dystrophy ID ENDOPLASMIC-RETICULUM STRESS; FUCHS DYSTROPHY; ACTIVATION; APOPTOSIS; DAMAGE; RATS AB PURPOSE. To screen for and characterize compounds that protect corneal endothelial cells against unfolded protein response (UPR) and oxidative stress. METHODS. Bovine corneal endothelial cells (BCECs) were treated for 48 hours with 640 compounds from a Food and Drug Administration (FDA)-approved drug library and then challenged with thapsigargin or H2O2 to induce UPR or oxidative stress, respectively. Cell viability was measured using the CellTiter-Glo survival assay. Selected "hits" were subjected to further dose-response testing, and their ability to modulate expression of UPR and oxidative stress markers was assessed by RT-PCR, Western blot, and measurement of protein carbonyl and 8-hydroxydeoxyguanosine (8-OHdG) adducts in immortalized human corneal endothelial cells (iHCECs). RESULTS. Forty-one drugs at 20 mu M and 55 drugs at 100 mu M increased survival of H2O2-challenged cells, and 8 drugs at 20 mu M and 2 drugs at 100 mu M increased survival of thapsigargin-challenged cells, compared with untreated control cells. Nicergoline, ergothioneine, nimesulide, oxotremorine, and mefenamic acid increased survival of both H2O2- and thapsigargin-challenged cells. Oxotremorine altered DNA damage inducible 3 (CHOP) gene expression, glucose-regulated protein 78 kDa (GRP78) and activating transcription factor 4 (ATF4) protein expression, and protein carbonyl and 8-OHdG levels. Mefenamic acid altered GRP78 protein expression and protein carbonyl and 8-OHdG levels. CONCLUSIONS. Oxotremorine and mefenamic acid are potential survival factors for corneal endothelial cells under UPR and oxidative stress. The described assay can be further expanded to screen additional drugs for potential therapeutic effect in corneal endothelial diseases such as Fuchs' endothelial corneal dystrophy. C1 [Kim, Eun Chul; Toyono, Tetsuya; Berlinicke, Cynthia A.; Zack, Donald J.; Jun, Albert S.] Johns Hopkins Med Inst, Wilmer Eye Inst, 600 N Broadway,Wilmer Woods 376, Baltimore, MD 21287 USA. [Kim, Eun Chul] Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Seoul, South Korea. [Toyono, Tetsuya; Usui, Tomohiko] Univ Tokyo, Dept Ophthalmol, Tokyo, Japan. [Zack, Donald J.] Johns Hopkins Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA. [Zack, Donald J.] Johns Hopkins Med Inst, Inst Med Genet, Baltimore, MD 21205 USA. [Jurkunas, Ula] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Boston, MA USA. RP Jun, AS (reprint author), Johns Hopkins Med Inst, Wilmer Eye Inst, 600 N Broadway,Wilmer Woods 376, Baltimore, MD 21287 USA. EM aljun@jhmi.edu FU J. Willard and Alice S. Marriott Foundation (Bethesda, MD, USA); National Eye Institute (Bethesda, MD, USA) [EY 019874]; Japan Eye Bank Association (Tokyo, Japan); EBAA Richard Lindstrom Research Grant (Washington, DC, USA); Guerrieri Family Foundation (Salisbury, MD, USA) FX Supported by grants from the J. Willard and Alice S. Marriott Foundation (Bethesda, MD, USA), Margaret Andrews, Edward Colburn, Lorraine Collins, Richard Dianich, Mary Finegan, Barbara and Peter Freeman, Stanley Friedler, MD, Ida Jeffries, Herbert Kasoff, Diane Kemker, Jean Mattison, Florenz Ourisman, Lee Silverman, Norman Tunkel, PhD, the National Eye Institute EY 019874 (all to ASJ; Bethesda, MD, USA), Japan Eye Bank Association (Tokyo, Japan) and EBAA Richard Lindstrom Research Grant (TT; Washington, DC, USA), and generous support from the Guerrieri Family Foundation (Salisbury, MD, USA). NR 34 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD FEB PY 2017 VL 58 IS 2 DI 10.1167/iovs.16-20147 PG 9 WC Ophthalmology SC Ophthalmology GA EO8LC UT WOS:000396939600022 PM 28159976 ER PT J AU Wang, R Seifert, P Jakobs, TC AF Wang, Rui Seifert, Philip Jakobs, Tatjana C. TI Astrocytes in the Optic Nerve Head of Glaucomatous Mice Display a Characteristic Reactive Phenotype SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE astrocytes; glial lamina; glaucoma; electron microscopy; confocal microscopy ID ELEVATED INTRAOCULAR-PRESSURE; RETROGRADE AXOPLASMIC-TRANSPORT; INDUCED OCULAR HYPERTENSION; RETINAL GANGLION-CELLS; LAMINA-CRIBROSA; DBA/2J MICE; RAT GLAUCOMA; MOUSE MODEL; INHERITED GLAUCOMA; AXONAL-TRANSPORT AB PURPOSE. Optic nerve head astrocytes, a subtype of white-matter astrocytes, become reactive early in the course of glaucoma. It was shown recently that in the DBA/2J mouse model of inherited glaucoma optic nerve astrocytes extend new longitudinal processes into the axon bundles before ganglion cell loss becomes apparent. The present study aims at testing whether this behavior of astrocytes is typical of early glaucomatous damage. METHODS. Mice expressing green fluorescent protein in individual astrocytes were used to evaluate the early response of astrocytes in the glial lamina of the optic nerve head after increasing the IOP using the microbead occlusion method. Tissue sections from the glial lamina were imaged consecutively by confocal and electron microscopy. RESULTS. Confocal and electron microscope images show that astrocytes close to the myelination transition zone in the hypertensive nerve heads extend new processes that follow the longitudinal axis of the optic nerve and invade axon bundles in the nerve head. Ultrastructurally, the longitudinal processes were largely devoid of subcellular organelles except for degenerating mitochondria. CONCLUSIONS. The longitudinal processes are a common feature of glaucomatous optic nerve astrocytes, whereas they are not observed after traumatic nerve injury. Thus, astrocytes appear to fine-tune their responses to the nature and/or timing of the injury to the neurons that they surround. C1 [Wang, Rui] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China. [Wang, Rui; Seifert, Philip; Jakobs, Tatjana C.] Harvard Med Sch, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA USA. RP Jakobs, TC (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA. EM Tatjana_Jakobs@meei.harvard.edu FU NIH [2R01EY019703, R01EY022092, P30EY003790]; Chinese Scholarship Council; Research to Prevent Blindness FX Supported by NIH Grants 2R01EY019703 and R01EY022092, the NIH Core Grant for vision research P30EY003790, and grants from the Chinese Scholarship Council and Research to Prevent Blindness. NR 69 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD FEB PY 2017 VL 58 IS 2 DI 10.1167/iovs.16-20571 PG 9 WC Ophthalmology SC Ophthalmology GA EO8LC UT WOS:000396939600028 ER PT J AU Williams, M Lewis, W Franco, W AF Williams, Maura Lewis, William Franco, Walfre TI Loss of Tryptophan Fluorescence Correlates With Mechanical Stiffness Following Photo-Crosslinking Treatment of Rabbit Cornea SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE keratoconus; photocrosslinking; fluorescence; spectroscopy ID KERATOCONUS; RIBOFLAVIN; COLLAGEN; MICROSCOPY; LIGHT; IRRADIATION; GENERATION; EYES; TIME AB PURPOSE. A clinical treatment option for keratoconus involves the use of UV-initiated photo-crosslinking with riboflavin to increase corneal stiffness. Our study investigates whether endogenous fluorescence changes following treatment for keratoconus can be correlated to alterations in the stiffness of the cornea, thereby guiding treatment of keratoconus. METHODS. A total of 78 ex vivo rabbit eyes were treated with either riboflavin-dextran solution plus UV light, dextran solution plus UV light, or riboflavin-dextran solution only for half treatment (2.84 J/cm(2)), standard treatment (5.28 J/cm(2)), or prolonged treatment (15.84 J/cm(2)) times. Fluorescent spectroscopy was performed on all samples before and after treatment. The stress-strain relationship was measured for all samples using a uniaxial tensiometer following treatment. RESULTS. We found a dose-dependent decrease in the 290/340 nm excitation/emission fluorescence pair with increase in corneal stiffening following treatment that was significant (P < 0.01) for both standard (5.28 J/cm(2) total fluence) and prolonged treatment (15.84 J/cm(2)) times. We did not observe a significant change in this excitation/emission pair for the dextranplus-UV or riboflavin-only treatment groups. CONCLUSIONS. Loss of fluorescence intensity at the 290/340 nm excitation/emission pair could offer a noninvasive, in situ measurement for guiding the photo-crosslinking treatment of keratoconus. Larger relative decreases in this pair are significantly correlated with longer treatment times and with increases in stiffness and Young's modulus. C1 [Williams, Maura; Lewis, William; Franco, Walfre] Harvard Med Sch, Massachusetts Gen Hosp, Dept Dermatol, Wellman Ctr Photomed, Boston, MA USA. RP Franco, W (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 50 Blossom St, Boston, MA 02114 USA. EM wfranco@mgh.harvard.edu NR 42 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD FEB PY 2017 VL 58 IS 2 DI 10.1167/iovs.16-20750 PG 6 WC Ophthalmology SC Ophthalmology GA EO8LC UT WOS:000396939600048 PM 28196224 ER PT J AU Batson, L Rizzolo, D AF Batson, Lora Rizzolo, Denise TI Otosclerosis: An update on diagnosis and treatment SO JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS LA English DT Article DE otosclerosis; hearing loss; bone remodeling; audiometry; cochlear implant; otic capsule ID FAR-ADVANCED OTOSCLEROSIS; HEARING-LOSS; MEASLES-VIRUS; COCHLEAR IMPLANTATION; STAPEDOTOMY; PREVALENCE AB Otosclerosis is a complex and progressive disease of pathological bone remodeling that affects the otic capsule of the temporal bone, resulting in hearing loss. Although traditional diagnostic methods are still used, improvements in technology and research have paved the way for additional diagnostic techniques and advancements. The traditional treatment of otosclerosis, stapes surgery, is now being augmented or replaced by innovations in hearing aid technology and cochlear implants. Earlier diagnosis of otosclerosis can occur through understanding of the cause, risk factors, and current diagnostic testing. C1 [Batson, Lora] Massachusetts Gen Hosp, Dept Rheumatol, Boston, MA 02114 USA. [Rizzolo, Denise] Kean Univ, PA Program, Union, NJ USA. [Rizzolo, Denise] Pace Complet Program, New York, NY USA. RP Batson, L (reprint author), Massachusetts Gen Hosp, Dept Rheumatol, Boston, MA 02114 USA. NR 35 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1547-1896 EI 0893-7400 J9 JAAPA-J AM ACAD PHYS JI JAAPA-J. Am. Acad. Physician Assist. PD FEB PY 2017 VL 30 IS 2 BP 17 EP 22 DI 10.1097/01.JAA.0000511784.21936.1b PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA EP3KQ UT WOS:000397281600007 PM 28060022 ER PT J AU Phillips, HR Smith, DA AF Phillips, Hayden R., III Smith, David A. TI A patient with a curious case of cyclical vomiting SO JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS LA English DT Article DE cannabis; hyperemesis syndrome; cyclical vomiting; abdominal pain; cannabis adverse reactions; excessive bathing ID CANNABINOID HYPEREMESIS AB Cannabis-related ED visits are on the rise due to wider legalization and availability of marijuana, and habitual daily use is increasingly common. Cannabis abuse has long been associated with various short-term and longterm adverse reactions. One such reaction is cannabinoid hyperemesis syndrome: cyclical vomiting, nausea, and abdominal pain that only resolves with a warm bath or shower. Healthcare providers must understand the signs and symptoms of cannabinoid hyperemesis syndrome so the problem can be recognized early and patients avoid unnecessary testing. C1 [Phillips, Hayden R., III] Sacred Heart Hosp, ED, Allentown, PA 18104 USA. [Smith, David A.] Salus Univ, PA Program, Elkins Pk, PA USA. [Smith, David A.] Philadelphia VA Med Ctr, Surg ICU, Philadelphia, PA USA. [Smith, David A.] Mercy Suburban Hosp East Norriton, ED, Norristown, PA USA. RP Phillips, HR (reprint author), Sacred Heart Hosp, ED, Allentown, PA 18104 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1547-1896 EI 0893-7400 J9 JAAPA-J AM ACAD PHYS JI JAAPA-J. Am. Acad. Physician Assist. PD FEB PY 2017 VL 30 IS 2 DI 10.1097/01.JAA.0000511789.29560.74 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA EP3KQ UT WOS:000397281600003 ER PT J AU Janjua, SA Pursnani, A Mayrhofer, T Puchner, SB Liu, T Lu, MT Maurovich-Horvat, P Woodard, PK Chou, E Fteg, JL Truong, QA Ferencik, M Hoffmann, U AF Janjua, Sumbal A. Pursnani, Amit Mayrhofer, Thomas Puchner, Stefan B. Liu, Ting Lu, Michael T. Maurovich-Horvat, Pal Woodard, Pamela K. Chou, Eric Fteg, Jerome L. Truong, Quynh A. Ferencik, Maros Hoffmann, Udo TI Statin Use Is Associated With Fewer High-Risk Plaques on Coronary CT Angiography SO JACC-CARDIOVASCULAR IMAGING LA English DT Letter ID ACUTE CHEST-PAIN; COMPUTED-TOMOGRAPHY; TRIAL; THERAPY C1 [Janjua, Sumbal A.; Pursnani, Amit; Mayrhofer, Thomas; Puchner, Stefan B.; Liu, Ting; Lu, Michael T.; Maurovich-Horvat, Pal; Woodard, Pamela K.; Chou, Eric; Fteg, Jerome L.; Truong, Quynh A.; Ferencik, Maros; Hoffmann, Udo] Massachusetts Gen Hosp, Div Cardiac MR PET CT, Cardiac MR PET CT Program, 165 Cambridge St,Suite 400, Boston, MA 02114 USA. RP Janjua, SA (reprint author), Massachusetts Gen Hosp, Div Cardiac MR PET CT, Cardiac MR PET CT Program, 165 Cambridge St,Suite 400, Boston, MA 02114 USA. EM sjanjua@partners.org FU National Heart, Lungy and Blood Institute [U01HL092040, U01HL092022]; Bayer; Astellas; National Institutes of Health; National Institutes of Health/National Heart, Lung, and Blood Institute [K23HL098320, L30HL093896]; St. Jude Medical, American College of Radiology Imaging Network; Duke Clinical Research Institute; American Heart Association [13FTF16450001]; National Institutes of Health/National Heart, Lung, and Blood Institute, HeartFlow Inc.; Siemens Healthcare; American College of Radiology Imaging Network; Genentech FX This work was supported by grants from the National Heart, Lungy and Blood Institute (U01HL092040 and U01HL092022). The contents of this letter are solely the responsibility of the authors and do not represent the official views of the National Heart, Lung, and Blood Institute or the U.S. Department of Health and Human Services. Dr. Woodard has received research support from Bayer and Astellas; and funding from the National Institutes of Health. Dr. Truong has received support from the National Institutes of Health/National Heart, Lung, and Blood Institute (K23HL098320 and L30HL093896), St. Jude Medical, American College of Radiology Imaging Network, and Duke Clinical Research Institute. Dr. Ferencik has received grant support from the American Heart Association (13FTF16450001). Dr. Hoffmann has received grant support from National Institutes of Health/National Heart, Lung, and Blood Institute, HeartFlow Inc., Siemens Healthcare, American College of Radiology Imaging Network, and Genentech. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 5 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X EI 1876-7591 J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD FEB PY 2017 VL 10 IS 2 BP 208 EP 210 DI 10.1016/j.jcmg.2016.02.020 PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA EL9FV UT WOS:000394926500015 PM 27085451 ER PT J AU Thobakgale, C Naidoo, K McKinnon, LR Werner, L Samsunder, N Karim, SA Ndung'u, T Altfeld, M Naidoo, K AF Thobakgale, Christina Naidoo, Kewreshini McKinnon, Lyle R. Werner, Lise Samsunder, Natasha Karim, Salim Abdool Ndung'u, Thumbi Altfeld, Marcus Naidoo, Kogieleum TI Interleukin 1-Beta (IL-1 beta) Production by Innate Cells Following TLR Stimulation Correlates With TB Recurrence in ART-Treated HIV-Infected Patients SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE Toll-like receptor; monocytes; myeloid dendritic cells; HIV/TB coinfection; TB recurrence ID MYCOBACTERIUM-TUBERCULOSIS; ANTIRETROVIRAL THERAPY; DENDRITIC CELLS; IN-VITRO; MACROPHAGES; SUSCEPTIBILITY; IMMUNITY; RISK; REINFECTION; EXPRESSION AB Background: Tuberculosis (TB) remains a major cause of global morbidity and mortality, especially in the context of HIV coinfection because immunity is not completely restored following antiretroviral therapy (ART). The identification of immune correlates of risk for TB disease could help in the design of host-directed therapies and clinical management. This study aimed to identify innate immune correlates of TB recurrence in HIV+ ART-treated individuals with a history of previous successful TB treatment. Methods: Twelve participants with a recurrent episode of TB (cases) were matched for age, sex, time on ART, pre-ART CD4 count with 12 participants who did not develop recurrent TB in 60 months of follow-up (controls). Cryopreserved peripheral blood mononuclear cells from time-points before TB recurrence were stimulated with ligands for Toll-like receptors (TLR) including TLR-2, TLR-4, and TLR-7/8. Multicolor flow cytometry and intracellular cytokine staining were used to detect IL-1 beta, TNF-alpha, IL-12, and IP10 responses from monocytes and myeloid dendritic cells (mDCs). Results: Elevated production of IL-1 beta from monocytes following TLR-2, TLR-4, and TLR-7/8 stimulation was associated with reduced odds of TB recurrence. In contrast, production of IL-1 beta from both monocytes and mDCs following Bacillus Calmette-Guerin (BCG) stimulation was associated with increased odds of TB recurrence (risk of recurrence increased by 30% in monocytes and 42% in mDCs, respectively). Conclusion: Production of IL-1 beta by innate immune cells following TLR and BCG stimulations correlated with differential TB recurrence outcomes in ART-treated patients and highlights differences in host response to TB. C1 [Thobakgale, Christina; Naidoo, Kewreshini; Ndung'u, Thumbi] Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, Durban, South Africa. [Thobakgale, Christina; McKinnon, Lyle R.; Werner, Lise; Samsunder, Natasha; Karim, Salim Abdool; Naidoo, Kogieleum] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Ctr AIDS Programme Res South Afr, Durban, South Africa. [Thobakgale, Christina; Ndung'u, Thumbi] MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA USA. [Thobakgale, Christina; Ndung'u, Thumbi] Harvard Univ, Boston, MA 02115 USA. [McKinnon, Lyle R.; Karim, Salim Abdool; Naidoo, Kogieleum] CAPRISA, MRC HIV TB Pathogenesis & Treatment Res Unit, Durban, South Africa. [McKinnon, Lyle R.; Ndung'u, Thumbi] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada. [Ndung'u, Thumbi; Altfeld, Marcus] Univ KwaZulu Natal, Nelson R Mandela Sch Med, KwaZulu Natal Res Inst TB & HIV, Durban, South Africa. [Ndung'u, Thumbi] Max Planck Inst Infect Biol, Berlin, Germany. [Altfeld, Marcus] Leibniz Inst Expt Virol, Heinrich Pette Inst, Hamburg, Germany. RP Thobakgale, C (reprint author), Univ KwaZulu Natal, Nelson R Mandela Sch Med, Duke Med Res Inst, HIV Pathogenesis Programme, Room 114, ZA-4001 Durban, South Africa. EM thobakgalec@ukzn.ac.za FU Doris Duke Charitable Foundation; South African Medical Research Council; Howard Hughes Medical Institute [55007065, 55007427]; Centers for Disease Control and Prevention (CDC) Cooperative Agreement [UY2G/PS001350-02]; US National Institutes for Health's Comprehensive International Program of Research on AIDS grant [AI51794]; Columbia University-South Africa Fogarty AIDS International Training and Research Program (AITRP) [D43 TW000231]; KwaZulu-Natal Department of Health; US President's Emergency Plan for AIDS Relief (PEPFAR); South African Research Chairs Initiative; Victor Daitz Foundation [64809] FX Supported by Doris Duke Charitable Foundation and the South African Medical Research Council. The TRUTH study was supported by the Howard Hughes Medical Institute, Grant # 55007065 and the Centers for Disease Control and Prevention (CDC) Cooperative Agreement Number UY2G/PS001350-02. The research infrastructures to conduct this trial, including the data management, laboratory and pharmacy cores, were established through the US National Institutes for Health's Comprehensive International Program of Research on AIDS grant (CIPRA, Grant # AI51794). Kogieleum Naidoo was supported by the Columbia University-South Africa Fogarty AIDS International Training and Research Program (AITRP, Grant # D43 TW000231). Patient care was supported by the KwaZulu-Natal Department of Health and the US President's Emergency Plan for AIDS Relief (PEPFAR).; T.N. is an International Early Career Scientist of the Howard Hughes Medical Institute (Grant # 55007427) and received additional funding from the South African Research Chairs Initiative and the Victor Daitz Foundation (Grant # 64809). The remaining authors have no conflicts of interest to disclose. NR 39 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD FEB 1 PY 2017 VL 74 IS 2 BP 213 EP 220 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EN4SS UT WOS:000395997800019 PM 27654812 ER PT J AU Zhu, AX Baron, AD Malfertheiner, P Kudo, M Kawazoe, S Pezet, D Weissinger, F Brandi, G Barone, CA Okusaka, T Wada, Y Park, JO Ryoo, BY Cho, JY Chung, HC Li, CP Yen, CJ Lee, KD Chang, SC Yang, L Abada, PB Chau, I AF Zhu, Andrew X. Baron, Ari David Malfertheiner, Peter Kudo, Masatoshi Kawazoe, Seiji Pezet, Denis Weissinger, Florian Brandi, Giovanni Barone, Carlo A. Okusaka, Takuji Wada, Yoshiyuki Park, Joon Oh Ryoo, Baek-Yeol Cho, Jae Yong Chung, Hyun Cheol Li, Chung-Pin Yen, Chia-Jui Lee, Kuan-Der Chang, Shao-Chun Yang, Ling Abada, Paolo B. Chau, Ian TI Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Analysis of REACH Trial Results by Child-Pugh Score SO JAMA ONCOLOGY LA English DT Article ID PHASE-III TRIAL; 1ST-LINE THERAPY; SORAFENIB; EFFICACY; MULTICENTER; BEVACIZUMAB; CIRRHOSIS; SURVIVAL; BRIVANIB; PLACEBO AB IMPORTANCE REACH is the first phase 3 trial to provide information on hepatocellular cancer (HCC) in the second-line (postsorafenib) setting categorized by Child-Pugh score, a scoring system used to measure the severity of chronic liver disease. This exploratory analysis demonstrates the relationship between a potential ramucirumab survival benefit, severity of liver disease, and baseline a-fetoprotein (aFP). OBJECTIVE To assess treatment effects and tolerability of ramucirumab by Child-Pugh score in patients with HCC enrolled in the REACH trial. DESIGN, SETTINGS, AND PARTICIPANTS Randomized, double-blind, phase 3 trial of ramucirumab and best supportive care vs placebo and best supportive care as second-line treatment in patients with HCC enrolled between November 4, 2010 and April 18, 2013, from 154 global sites. Overall, 643 patients were randomized and included in this analysis; 565 patients considered Child-Pugh class A (Child-Pugh scores 5 and 6) and 78 patients considered class B (Child-Pugh scores 7 and 8). INTERVENTIONS Ramucirumab (8mg/kg) or placebo intravenously plus best supportive care every 2 weeks. MAIN OUTCOMES AND MEASURES Overall survival (OS), defined as time from randomization to death from any cause. RESULTS In the randomized population of 643 patients (mean [SD] age, 62.8 [11.1] years) in this analysis, a potential ramucirumab OS benefit was observed for patients with a Child-Pugh score of 5 (hazard ratio [HR], 0.80; 95% CI, 0.63-1.02; P =.06) but no apparent benefit for patients with Child-Pugh scores of 6 or 7 and 8. In patients with baseline aFP levels of 400 ng/mL (to convert ng/mL to mu g/L, multiply by 1.0) or more, a ramucirumab OS benefit was significant for a score of Child-Pugh 5 9HR, 0.61; 95% CI, 0.43-0.87; P =.01) and Child-Pugh 6 (HR, 0.64; 95% CI, 0.42-0.98; P =.04), but was not significant for Child-Pugh 7 and 8. The overall safety profile of ramucirumab, regardless of Child-Pugh score, was considered manageable. Regardless of treatment arm, patients with Child-Pugh scores of 7 and 8 experienced a higher incidence of grade 3 or higher treatment-emergent adverse events, including ascites and asthenia, and special-interest events, including liver injury and/or failure and bleeding, compared with patients with Child-Pugh scores of 5 or 6. CONCLUSIONS AND RELEVANCE In unselected patients, a trend for ramucirumab survival benefit was observed only for patients with a Child-Pugh score of 5. In patients with baseline aFP levels of 400 ng/mL or more, a ramucirumab survival benefit was observed for Child-Pugh scores of 5 and 6. Ramucirumab had a manageable toxic effect profile. These results support the ongoing REACH-2 study of ramucirumab in patients with advanced HCC with underlying Child-Pugh A cirrhosis and baseline aFP levels of 400 ng/mL or more. C1 [Zhu, Andrew X.] Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02115 USA. [Zhu, Andrew X.] Harvard Med Sch, 55 Fruit St, Boston, MA 02115 USA. [Baron, Ari David] Calif Pacific Med Ctr, San Francisco, CA USA. [Malfertheiner, Peter] Otto von Guericke Univ, Magdeburg, Germany. [Kudo, Masatoshi] Kinki Univ, Sch Med, Dept Gastroenterol & Hepatol, Osaka, Japan. [Kawazoe, Seiji] Saga Ken Med Ctr Koseikan, Saga, Japan. [Pezet, Denis] CHU Estaing, Dept Surg, Clermont Ferrand, France. [Weissinger, Florian] Evangel Krankenhaus Bielefeld, Bielefeld, Germany. [Brandi, Giovanni] Policlin St Orsola Malpighi, Bologna, Italy. [Barone, Carlo A.] Univ Cattolica Sacro Cuore, Rome, Italy. [Okusaka, Takuji] Natl Canc Ctr, Div Hepatobiliary & Pancreat Oncol, Tokyo, Japan. [Wada, Yoshiyuki] Natl Hosp Org, Kyushu Med Ctr, Fukuoka, Japan. [Park, Joon Oh] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea. [Ryoo, Baek-Yeol] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea. [Cho, Jae Yong] Gangnam Severance Hosp, Seoul, South Korea. [Chung, Hyun Cheol] Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Yonsei Canc Ctr, Shinchon Dong, South Korea. [Li, Chung-Pin] Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol & Hepatol, Taipei, Taiwan. [Li, Chung-Pin] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan. [Yen, Chia-Jui] Natl Cheng Kung Univ Hosp, Tainan, Taiwan. [Lee, Kuan-Der] Chang Gung Mem Hosp, Chiayi, Taiwan. [Chang, Shao-Chun] Eli Lilly & Co, Bridgewater, NJ USA. [Yang, Ling] AstraZeneca, Wilmington, DE USA. [Abada, Paolo B.] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Chau, Ian] Royal Marsden NHS Fdn Trust, London, England. [Chau, Ian] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England. RP Zhu, AX (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02115 USA.; Zhu, AX (reprint author), Harvard Med Sch, 55 Fruit St, Boston, MA 02115 USA. EM azhu@partners.org FU Eli Lilly and Company FX This research was supported by Eli Lilly and Company. NR 30 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD FEB 1 PY 2017 VL 3 IS 2 BP 235 EP 243 DI 10.1001/jamaoncol.2016.4115 PG 9 WC Oncology SC Oncology GA EM9PU UT WOS:000395644400015 ER PT J AU Scott, AR Alore, EA Naik, AD Berger, DH Suliburk, JW AF Scott, Aaron R. Alore, Elizabeth A. Naik, Aanand D. Berger, David H. Suliburk, James W. TI Mixed-Methods Analysis of Factors Impacting Use of a Postoperative mHealth App SO JMIR MHEALTH AND UHEALTH LA English DT Article DE mHealth; colorectal surgery; smartphone apps ID PROMOTE PHYSICAL-ACTIVITY; COLORECTAL SURGERY; HOSPITAL READMISSION; ENHANCED RECOVERY; MOBILE APPS; PROGRAM; COMPLICATIONS; INTERVENTIONS; QUALITY; PATIENT AB Background: Limited communication and care coordination following discharge from hospitals may contribute to surgical complications. Smartphone apps offer a novel mechanism for communication and care coordination. However, factors which may affect patient app use in a postoperative, at-home setting are poorly understood. Objective: The objectives of this study were to (1) gauge interest in smartphone app use among patients after colorectal surgery and (2) better understand factors affecting patient app use in a postoperative, at-home setting. Methods: A prospective feasibility study was performed at a hospital that principally serves low socioeconomic status patients. After colorectal surgery, patients were enrolled and given a smartphone app, which uses previously validated content to provide symptom-based recommendations. Patients were instructed to use the app daily for 14 days after discharge. Demographics and usability data were collected at enrollment. Usability was measured with the System Usability Scale (SUS). At follow-up, the SUS was repeated and patients underwent a structured interview covering ease of use, willingness to use, and utility of use. Two members of the research team independently reviewed the field notes from follow-up interviews and extracted the most consistent themes. Chart and app log reviews identified clinical endpoints. Results: We screened 115 patients, enrolled 20 patients (17.4%), and completed follow-up interviews with 17 patients (85%). Reasons for nonenrollment included: failure to meet inclusion criteria (47/115, 40.9%), declined to participate (26/115, 22.6%), and other reasons (22/115, 19.1%). There was no difference in patient ratings between usability at first-use and after extended use, with SUS scores greater than the 95th percentile at both time points. Despite high usability ratings, 6/20 (30%) of patients never used the app at home after hospital discharge and 2/20 (10%) only used the app once. Interviews revealed three themes related to app use: (1) patient-related barriers could prevent use even though the app had high usability scores; (2) patients viewed the app as a second opinion, rather than a primary source of information; and (3) many patients viewed the app as an external burden. Conclusions: Use patterns in this study, and response rates after prompts to contact the operative team, suggest that apps need to be highly engaging to be adopted by patients. The growing penetration of smartphones and the proliferation of app-based interventions are unlikely to improve care coordination and communication, unless apps address the barriers and patient perceptions identified in this study. This study shows that high usability alone is not sufficient to motivate patients to use smartphone apps in the postoperative period. C1 [Scott, Aaron R.; Alore, Elizabeth A.; Berger, David H.; Suliburk, James W.] Baylor Coll Med, Michael E DeBakey Dept Surg, One Baylor Plaza,BCM 390, Houston, TX 77030 USA. [Naik, Aanand D.; Berger, David H.] Hlth Serv Res & Dev Ctr Innovat, Michael E DeBakey Vet Affairs Med Ctr, Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA. [Naik, Aanand D.] Baylor Coll Med, Alkek Dept Med, Houston, TX 77030 USA. [Suliburk, James W.] Ben Taub Gen Hosp, Dept Surg, Houston, TX 77030 USA. RP Suliburk, JW (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, One Baylor Plaza,BCM 390, Houston, TX 77030 USA. EM suliburk@bcm.edu FU Cancer Prevention and Research Institute of Texas [RP140102]; Gordon and Betty Moore Foundation Early-Career Investigator [4603]; VA Health Services Research and Development Center of Innovation grant [CIN 13-413]; Seamless Mobile Health, Inc. FX Dr Scott holds a trainee grant from the Cancer Prevention and Research Institute of Texas (RP140102). Dr Suliburk holds a Gordon and Betty Moore Foundation Early-Career Investigator Award (#4603). Dr Naik receives support from a VA Health Services Research and Development Center of Innovation grant (CIN 13-413). This study was sponsored by Seamless Mobile Health, Inc. Sponsorship was limited to access to app, patient compensation, and the cost of a mobile hot-spot used to allow patients to download the app. The authors retained full editorial rights and have no other commercial interest with the sponsor. The Department of Veterans Health was not a performance site for this study and was not involved with any research activities associated with the commercial sponsor. NR 43 TC 0 Z9 0 U1 0 U2 0 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 2291-5222 J9 JMIR MHEALTH UHEALTH JI JMIR mHealth uHealth PD FEB PY 2017 VL 5 IS 2 AR e11 DI 10.2196/mhealth.6728 PG 13 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EN2JY UT WOS:000395837000003 PM 28179215 ER PT J AU Smiley, SL Elmasry, H Hooper, MW Niaura, RS Hamilton, AB Milburn, NG AF Smiley, Sabrina L. Elmasry, Hoda Hooper, Monica Webb Niaura, Raymond S. Hamilton, Alison B. Milburn, Norweeta G. TI Feasibility of Ecological Momentary Assessment of Daily Sexting and Substance Use Among Young Adult African American Gay and Bisexual Men: A Pilot Study SO JMIR RESEARCH PROTOCOLS LA English DT Article DE ecological momentary assessment; mobile phone; text messaging; sexting; marijuana; alcohol; young adult; gay and bisexual; African American ID MARIJUANA USE; SEX; ADOLESCENTS; STUDENTS; BEHAVIOR; RISK AB Background: Recent evidence suggests that sexualized text communication ("sexting") is associated with substance use and sexual risk behaviors among young adults, yet little is known about this relationship among young adult African American gay and bisexual men, a population disproportionately impacted by HIV in the United States. Rapid advances in mobile phone technology indicate a clear need for research using mobile health (mHealth) methods such as ecological momentary assessment (EMA) to serve as a viable counterpart to retrospective evaluation methods by using real-time data collection to assess sexting and substance use among this population. Objective: The objective of this pilot study was to (1) describe the EMA study design and protocol, (2) characterize the study population, and (3) assess the feasibility of a random prompt text message-based thrice-daily EMA over 14 days, as a means of prospectively studying sexting, marijuana, and alcohol use among a sample of young adult African American gay and bisexual men ages 21 to 25. Methods: Participants were recruited through flyers and snowball sampling during spring and summer 2015 at a community-based HIV/AIDS prevention, care, and support organization in Washington, DC. Eligible participants were enrolled in a one-time in-person study visit that consisted of informed written consent to participate in the study, a self-administered survey, a semi-structured interview, and enrollment and training in EMA data collection. Commencing the day after the study visit, a random prompt survey was texted to participants on their personal mobile phones 3 times a day over a 14-day data collection period assessing mood, texts sent, texts received, sexts sent, sexts received, marijuana want, marijuana use, and alcohol use. Results: EMA feasibility was tested with 25 self-identified African American gay (n=16) and bisexual (n=9) men (mean age of 23.48 years, SD 1.5). Each random prompt survey had 8 questions with responses including yes/no and Likert scale options. There were 104 total days of EMA observation, and the retention rate was 72% (18 out of 25 participants). Participants responded to the random prompt surveys with a 57.3% compliance rate providing a total of 544 completed surveys out of 949 surveys. The overall mean response time to complete a survey was 6.1 minutes. There were significant positive associations between EMA texts sent and received questions (rho 0.84, P <.001) as well as sexts sent and received queries (rho 0.72, P <.001). Conclusions: The use of an EMA protocol has the potential to be a very useful research tool for understanding episodic behaviors such as sexting and substance use in this relatively understudied and underserved population, and has implications for practice. Additional research is needed on how to maximize survey compliance. C1 [Smiley, Sabrina L.; Elmasry, Hoda; Niaura, Raymond S.] Truth Initiat, Schroeder Inst Tobacco Res & Policy Studies, 900 G St NW,Fourth Floor, Washington, DC 20001 USA. [Hooper, Monica Webb] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH USA. [Niaura, Raymond S.] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA. [Niaura, Raymond S.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA. [Hamilton, Alison B.; Milburn, Norweeta G.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Hamilton, Alison B.] Vet Adm Greater Los Angeles Healthcare Syst, Vet Adm Ctr Study Healthcare Innovat Implementat, Los Angeles, CA USA. RP Smiley, SL (reprint author), Truth Initiat, Schroeder Inst Tobacco Res & Policy Studies, 900 G St NW,Fourth Floor, Washington, DC 20001 USA. EM ssmiley@truthinitiative.org FU National Institute on Drug Abuse [R25DA035692, 5R25DA035692] FX At the time of the study, Sabrina L Smiley was a Scholar with the HIV/AIDS, Substance Abuse, and Trauma Training Program at the University of California Los Angeles supported through an award from the National Institute on Drug Abuse (R25DA035692). The research reported in this publication was supported by the National Institute on Drug Abuse under grant number 5R25DA035692. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 23 TC 0 Z9 0 U1 0 U2 0 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1929-0748 J9 JMIR RES PROTOC JI JMIR RES. Protoc. PD FEB PY 2017 VL 6 IS 2 AR e9 DI 10.2196/resprot.6520 PG 11 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EN2KH UT WOS:000395837900014 PM 28153816 ER PT J AU Neilan, A Dunville, R Ocfemia, MCB Salomon, J Francke, J Wang, LY Bulteel, A Hsu, K DiNenno, E Parker, R Walensky, R Freedberg, K Ciaranello, A AF Neilan, Anne Dunville, Richard Ocfemia, M. Cheryl Banez Salomon, Joshua Francke, Jordan Wang, Li Yan Bulteel, Alex Hsu, Kathy DiNenno, Elizabeth Parker, Robert Walensky, Rochelle Freedberg, Kenneth Ciaranello, Andrea TI SCREENING ADOLESCENTS AND YOUNG ADULTS FOR HIV IN THE UNITED STATES: A COST-EFFECTIVENESS ANALYSIS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Neilan, Anne; Francke, Jordan; Bulteel, Alex; Parker, Robert; Walensky, Rochelle; Freedberg, Kenneth; Ciaranello, Andrea] Massachusetts Gen Hosp, Boston, MA USA. [Dunville, Richard; Ocfemia, M. Cheryl Banez; Wang, Li Yan; DiNenno, Elizabeth] Ctr Dis Control & Prevent, Atlanta, GA USA. [Salomon, Joshua] Harvard Sch Publ Hlth, Boston, MA USA. [Hsu, Kathy] Boston Med Ctr, Massachusetts Dept Publ Hlth, Boston, MA USA. FU US Centers for Disease Control and Prevention National Center for HIV, Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement [6NU38PS004644]; National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute for Child Health and Human Development [NIAID T32 AI007433, R01 HD079214, R01 AI042006, R01 AI112340] FX This research was funded by US Centers for Disease Control and Prevention National Center for HIV, Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement 6NU38PS004644 as well as the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute for Child Health and Human Development (NIAID T32 AI007433, R01 HD079214, R01 AI042006, R01 AI112340). NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2017 VL 60 IS 2 MA 32 BP S18 EP S18 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA EP3GL UT WOS:000397270700033 ER PT J AU Rimmelin, D Abou-Arraj, NE Kerkar, AP Gupta, J Gupta, N AF Rimmelin, Dodie Abou-Arraj, Nadeem E. Kerkar, Ashwini P. Gupta, Jaya Gupta, Nupur TI USING NEEDLELESS TECHNOLOGY TO EVALUATE THE PREVALENCE OF ANEMIA IN YOUNG ADOLESCENT FEMALES IN RURAL INDIA SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Rimmelin, Dodie] Harvard Med Sch, Boston, MA USA. [Abou-Arraj, Nadeem E.; Kerkar, Ashwini P.] Boston Univ, Sch Med, Boston, MA USA. [Gupta, Jaya] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Gupta, Nupur] Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2017 VL 60 IS 2 MA 52 BP S30 EP S30 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA EP3GL UT WOS:000397270700053 ER PT J AU Rinaudo, PF Hsu, J AF Rinaudo, Paolo F. Hsu, John TI To freeze or not to freeze: heating the debate but cooling the practice? SO JOURNAL OF ASSISTED REPRODUCTION AND GENETICS LA English DT Editorial Material ID ASSISTED-REPRODUCTIVE-TECHNOLOGIES; IMPAIRED ENDOMETRIAL RECEPTIVITY; IN-VITRO FERTILIZATION; THAWED EMBRYO-TRANSFER; TRIAL COMPARING FRESH; OVARIAN STIMULATION; FROZEN; PREGNANCIES; INFERTILITY; RESPONDERS C1 [Rinaudo, Paolo F.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Hsu, John] Massachusetts Gen Hosp, Mongan Inst, Boston, MA 02114 USA. [Hsu, John] Harvard Med Sch, Dept Hlth Care Policy, Cambridge, MA USA. RP Rinaudo, PF (reprint author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. EM rinaudop@obgyn.ucsf.edu NR 17 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1058-0468 EI 1573-7330 J9 J ASSIST REPROD GEN JI J. Assist. Reprod. Genet. PD FEB PY 2017 VL 34 IS 2 BP 187 EP 189 DI 10.1007/s10815-017-0870-1 PG 3 WC Genetics & Heredity; Obstetrics & Gynecology; Reproductive Biology SC Genetics & Heredity; Obstetrics & Gynecology; Reproductive Biology GA EP5IH UT WOS:000397411700005 PM 28091759 ER PT J AU Chen, YH Chauhan, SK Tan, XH Dana, R AF Chen, Yihe Chauhan, Sunil K. Tan, Xuhua Dana, Reza TI Interleukin-7 and-15 maintain pathogenic memory Th17 cells in autoimmunity SO JOURNAL OF AUTOIMMUNITY LA English DT Article DE Memory Th17; Maintenance; IL-7; IL-15 ID CD8 T-CELLS; BASAL HOMEOSTATIC PROLIFERATION; ADVANCED SOLID TUMORS; RHEUMATOID-ARTHRITIS; STAT5 ACTIVATION; CHRONIC COLITIS; DRY EYE; IL-7; INFLAMMATION; GENERATION AB Th17 cells are principal mediators of many autoimmune conditions. Recently, memory Th17 cells have been revealed as crucial in mediating the chronicity of various refractory autoimmune disorders; however, the underlying mechanisms maintaining memory Th17 cells have remained elusive. Here, using a preclinical model of ocular autoimmune disease we show that both IL-7 and IL-15 are critical for maintaining pathogenic memory Th17 cells. Neutralization of these cytokines leads to substantial reduction of memory Th17 cells; both IL-7 and IL-15 provide survival signals via activating STAT5, and IL-15 provides additional proliferation signals via activating both STAT5 and Akt. Topical neutralization of ocular IL-7 or IL-15 effectively reduces memory Th17 cells at the inflammatory site and draining lymphoid tissues, while topical neutralization of IL-17 alone, the major pathogenic cytokine secreted by Th17 cells, does not diminish memory Th17 cells at the draining lymphoid tissues. Our results suggest that the effective removal of pathogenic memory Th17 cells via abolishing environmental IL-7 or IL-15 is likely to be a novel strategy in the treatment of autoimmune diseases. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Chen, Yihe; Chauhan, Sunil K.; Tan, Xuhua; Dana, Reza] Harvard Med Sch, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA. RP Dana, R (reprint author), Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA. EM reza_dana@meei.harvard.edu FU National Institutes of Health [EY20889] FX This work was supported by National Institutes of Health (grant EY20889). NR 46 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0896-8411 EI 1095-9157 J9 J AUTOIMMUN JI J. Autoimmun. PD FEB PY 2017 VL 77 BP 96 EP 103 DI 10.1016/j.jaut.2016.11.003 PG 8 WC Immunology SC Immunology GA EL5AO UT WOS:000394634000009 PM 27899224 ER PT J AU Turcotte, R Wu, JW Lin, CP AF Turcotte, Raphael Wu, Juwell W. Lin, Charles P. TI Intravital multiphoton photoconversion with a cell membrane dye SO JOURNAL OF BIOPHOTONICS LA English DT Article DE Photoconversion; multiphoton; intravital microscopy; cell tracking; bone marrow; two-photon fluorescence microscopy ID FLUORESCENT PROTEIN; IN-VIVO; MICROSCOPY; TRACKING AB Photoconversion, an irreversible shift in a fluorophore emission spectrum after light exposure, is a powerful tool for marking cellular and subcellular compartments and tracking their dynamics in vivo. This paper reports on the photoconversion properties of Di-8-ANEPPS, a commercially available membrane dye. When illuminated with near-infrared femtosecond laser pulses, Di-8-ANEPPS undergoes multiphoton photoconversion as indicated by the supralinear dependence of the conversion rate (pc) on the incident power (pcIexc2.27), and by the ability to photoconvert a thin optical section in a three-dimensional matrix. The characteristic emission spectrum changed from red to blue, and ratiometric analysis on single cells in vitro revealed a 65-fold increase in the blue to red wavelength ratio after photoconversion. The spectral shift is preserved in vivo for hours, making Di-8-ANEPPS a useful dye for intravital cell marking and tracking applications. C1 [Lin, Charles P.] Harvard Med Sch, Massachusetts Gen Hosp, Wellman Ctr Photomed, CPZN 8238,185 Cambridge St, Boston, MA 02114 USA. [Lin, Charles P.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Syst Biol, CPZN 8238,185 Cambridge St, Boston, MA 02114 USA. RP Lin, CP (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Wellman Ctr Photomed, CPZN 8238,185 Cambridge St, Boston, MA 02114 USA. EM lin@helix.mgh.harvard.edu FU NIH [CA086355, HL099997, EB017274, CA194596] FX This work was support by NIH CA086355, HL099997, EB017274, and CA194596. NR 18 TC 0 Z9 0 U1 1 U2 1 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA POSTFACH 101161, 69451 WEINHEIM, GERMANY SN 1864-063X EI 1864-0648 J9 J BIOPHOTONICS JI J. Biophotonics PD FEB PY 2017 VL 10 IS 2 BP 206 EP 210 DI 10.1002/jbio.201600077 PG 5 WC Biochemical Research Methods; Biophysics; Optics SC Biochemistry & Molecular Biology; Biophysics; Optics GA EL8CN UT WOS:000394847900002 PM 27433967 ER PT J AU Chandra, A Lin, T Young, T Tong, W Ma, XY Tseng, WJ Kramer, I Kneissel, M Levine, MA Zhang, YJ Cengel, K Liu, XS Qin, L AF Chandra, Abhishek Lin, Tiao Young, Tiffany Tong, Wei Ma, Xiaoyuan Tseng, Wei-Ju Kramer, Ina Kneissel, Michaela Levine, Michael A. Zhang, Yejia Cengel, Keith Liu, X. Sherry Qin, Ling TI Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE RADIOTHERAPY; SCL-AB; OSTEOBLASTS; MESENCHYMAL PROGENITORS; DNA REPAIR ID MESENCHYMAL STEM-CELLS; TRABECULAR BONE; POSTMENOPAUSAL WOMEN; IRRADIATION ALTERS; MINERAL DENSITY; MURINE MODEL; IN-VIVO; ANTIBODY; MICE; RADIOTHERAPY AB Focal radiotherapy is frequently associated with skeletal damage within the radiation field. Our previous in vitro study showed that activation of Wnt/beta-catenin pathway can overcome radiation-induced DNA damage and apoptosis of osteoblastic cells. Neutralization of circulating sclerostin with a monoclonal antibody (Scl-Ab) is an innovative approach for treating osteoporosis by enhancing Wnt/beta-catenin signaling in bone. Together with the fact that focal radiation increases sclerostin amount in bone, we sought to determine whether weekly treatment with Scl-Ab would prevent focal radiotherapy-induced osteoporosis in mice. MicroCT and histomorphometric analyses demonstrated that Scl-Ab blocked trabecular bone structural deterioration after radiation by partially preserving osteoblast number and activity. Consistently, trabecular bone in sclerostin null mice was resistant to radiation via the same mechanism. Scl-Ab accelerated DNA repair in osteoblasts after radiation by reducing the number of gamma-H2AX foci, a DNA double-strand break marker, and increasing the amount of Ku70, a DNA repair protein, thus protecting osteoblasts from radiation-induced apoptosis. In osteocytes, apart from using similar DNA repair mechanism to rescue osteocyte apoptosis, Scl-Ab restored the osteocyte canaliculi structure that was otherwise damaged by radiation. Using a lineage tracing approach that labels all mesenchymal lineage cells in the endosteal bone marrow, we demonstrated that radiation damage to mesenchymal progenitors mainly involves shifting their fate to adipocytes and arresting their proliferation ability but not inducing apoptosis, which are different mechanisms from radiation damage to mature bone forming cells. Scl-Ab treatment partially blocked the lineage shift but had no effect on the loss of proliferation potential. Taken together, our studies provide proof-of-principle evidence for a novel use of Scl-Ab as a therapeutic treatment for radiation-induced osteoporosis and establish molecular and cellular mechanisms that support such treatment. (C) 2016 American Society for Bone and Mineral Research. C1 [Chandra, Abhishek; Lin, Tiao; Young, Tiffany; Tong, Wei; Ma, Xiaoyuan; Tseng, Wei-Ju; Zhang, Yejia; Liu, X. Sherry; Qin, Ling] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, 424 Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA. [Lin, Tiao] Sun Yat Sen Univ, Musculoskeletal Oncol Ctr, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China. [Tong, Wei] Huazhong Univ Sci & Technol, Dept Orthopaed Surg, Union Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China. [Kramer, Ina; Kneissel, Michaela] Novartis Inst BioMed Res, Musculoskeletal Dis Area, Basel, Switzerland. [Levine, Michael A.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Levine, Michael A.] Childrens Hosp Philadelphia, Div Endocrinol & Diabet, Philadelphia, PA 19104 USA. [Levine, Michael A.] Childrens Hosp Philadelphia, Ctr Bone Hlth, Philadelphia, PA 19104 USA. [Zhang, Yejia] Univ Penn, Philadelphia Vet Affairs Med Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA. [Zhang, Yejia] Univ Penn, Dept Phys Med & Rehabil, Perelman Sch Med, Philadelphia, PA 19104 USA. [Cengel, Keith] Univ Penn, Dept Radiat Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Qin, L (reprint author), Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, 424 Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA. EM qinling@mail.med.upenn.edu FU NIH [NIH/NIAMS R01AR066098, R01DK095803, K01AR066743, P30AR050950]; NICHD [1K08HD049598] FX We thank Dr Henry Kronenberg from Harvard Medical School and Dr Robert Gagel and Dr Huifang Liu from the MD Anderson Cancer Center for their kind suggestions and advice on this project. We thank Dr Eileen Shore for providing qRT-PCR primers for DKK1, PPAR gamma, and aP2 genes. This study was supported by NIH grants NIH/NIAMS R01AR066098, R01DK095803 (to LQ), K01AR066743 (to XSL), P30AR050950 (to Penn Center for Musculoskeletal Disorders), and NICHD 1K08HD049598 (to YZ). The authors gratefully thank Martin Heyworth, MD, for critically editing the manuscript. NR 54 TC 1 Z9 1 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD FEB PY 2017 VL 32 IS 2 BP 360 EP 372 DI 10.1002/jbmr.2996 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EO8JL UT WOS:000396935300018 PM 27635523 ER PT J AU Fulzele, K Lai, F Dedic, C Saini, V Uda, Y Shi, C Tuck, P Aronson, JL Liu, XL Spatz, JM Wein, MN Pajevic, PD AF Fulzele, Keertik Lai, Forest Dedic, Christopher Saini, Vaibhav Uda, Yuhei Shi, Chao Tuck, Padrig Aronson, Jenna L. Liu, Xiaolong Spatz, Jordan M. Wein, Marc N. Pajevic, Paola Divieti TI Osteocyte-Secreted Wnt Signaling Inhibitor Sclerostin Contributes to Beige Adipogenesis in Peripheral Fat Depots SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE SCLEROSTIN; BEIGE ADIPOCYTES; OSTEOCYTES; LEAN PHENOTYPE ID BONE-MINERAL DENSITY; WHITE ADIPOSE-TISSUE; POSTMENOPAUSAL WOMEN; ENERGY-METABOLISM; BODY-COMPOSITION; ADIPOCYTE DIFFERENTIATION; GLUCOSE-HOMEOSTASIS; PARATHYROID-HORMONE; IN-VITRO; RECEPTOR AB Cells of the osteoblast lineage are increasingly identified as participants in whole-body metabolism by primarily targeting pancreatic insulin secretion or consuming energy. Osteocytes, the most abundant bone cells, secrete a Wnt-signaling inhibitor called sclerostin. Here we examined three mouse models expressing high sclerostin levels, achieved through constitutive or inducible loss of the stimulatory subunit of G-proteins (Gs alpha in mature osteoblasts and/or osteocytes). These mice showed progressive loss of white adipose tissue (WAT) with tendency toward increased energy expenditure but no changes in glucose or insulin metabolism. Interestingly beige adipocytes were increased extensively in both gonadal and inguinal WAT and had reduced canonical beta-catenin signaling. To determine if sclerostin directly contributes to the increased beige adipogenesis, we engineered an osteocytic cell line lacking Gsa which has high sclerostin secretion. Conditioned media from these cells significantly increased expression of UCP1 in primary adipocytes, and this effect was partially reduced after depletion of sclerostin from the conditioned media. Similarly, treatment of Gs alpha-deficient animals with sclerostin-neutralizing antibody partially reduced the increased UCP1 expression in WAT. Moreover, direct treatment of sclerostin to wild-type mice significantly increased UCP1 expression in WAT. These results show that osteocytes and/or osteoblasts secrete factors regulating beige adipogenesis, at least in part, through the Wnt-signaling inhibitor sclerostin. Further studies are needed to assess metabolic effects of sclerostin on adipocytes and other metabolic tissues. (C) 2016 American Society for Bone and Mineral Research. C1 [Fulzele, Keertik; Lai, Forest; Dedic, Christopher; Uda, Yuhei; Shi, Chao; Pajevic, Paola Divieti] Boston Univ, Henry M Goldman Sch Dent Med, Mol & Cell Biol, Boston, MA 02215 USA. [Saini, Vaibhav; Tuck, Padrig; Aronson, Jenna L.; Liu, Xiaolong; Spatz, Jordan M.; Wein, Marc N.] Harvard Med Sch, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA USA. RP Fulzele, K; Pajevic, PD (reprint author), 700 Albany St,W201C, Boston, MA 02118 USA. EM kfulzele@bu.edu; pdivieti@bu.edu FU NIH [AR060221, AR059655, DK079161]; GAP award from ASBMR; P&F award from Boston University Clinical and Translational Science Institute (CTSI) [NIH 1UL1TR001430]; P&F award from Center for Skeletal Research (CSR) of Massachusetts General Hospital [NIH NIAMS P30 AR066261]; P&F award from Boston Area Diabetes Endocrinology Research Center (BADERC) FX This work was supported by NIH grants AR060221, AR059655, and DK079161 to PDP. This work was also partially supported by a GAP award from ASBMR to KF, a P&F award from Boston University Clinical and Translational Science Institute (CTSI) (NIH 1UL1TR001430) to KF, a P&F award from Center for Skeletal Research (CSR) of Massachusetts General Hospital (NIH NIAMS P30 AR066261), and a P&F award from Boston Area Diabetes Endocrinology Research Center (BADERC) to PDP. We thank Michaela Kneissel and Novartis for providing the anti-sclerostin antibody. NR 59 TC 2 Z9 2 U1 3 U2 3 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD FEB PY 2017 VL 32 IS 2 BP 373 EP 384 DI 10.1002/jbmr.3001 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EO8JL UT WOS:000396935300019 PM 27653320 ER PT J AU Kittiskulnam, P Carrero, JJ Chertow, GM Kaysen, GA Delgado, C Johansen, KL AF Kittiskulnam, Piyawan Carrero, Juan J. Chertow, Glenn M. Kaysen, George A. Delgado, Cynthia Johansen, Kirsten L. TI Sarcopenia among patients receiving hemodialysis: weighing the evidence SO JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE LA English DT Article DE Low muscle mass; Sarcopenia; Handgrip strength; Gait speed; Hemodialysis ID CLINICALLY RELEVANT WEAKNESS; SKELETAL-MUSCLE MASS; BIOIMPEDANCE SPECTROSCOPY; ALTERNATIVE DEFINITIONS; FUNCTIONAL IMPAIRMENT; PHYSICAL-DISABILITY; OLDER WOMEN; LEAN MASS; PREVALENCE; CUTPOINTS AB BackgroundThere is no consensus on how best to define low muscle mass in patients with end-stage renal disease. Use of muscle mass normalized to height-squared has been suggested by geriatric societies but may underestimate sarcopenia, particularly in the setting of excess adiposity. We compared four definitions of low muscle mass in a prevalent hemodialysis cohort. MethodsACTIVE/ADIPOSE enrolled prevalent patients receiving hemodialysis from the San Francisco and Atlanta areas from June 2009 to August 2011. Whole-body muscle mass was estimated using bioelectrical impedance spectroscopy, performed before a midweek dialysis session (n=645; age 56.714.5years, 41% women). We defined low muscle mass as muscle mass of 2SD or more below sex-specific bioelectrical impedance spectroscopy-derived means for young adults (18-49years) from National Health and Nutrition Examination Survey and indexed to height(2), body weight (percentage), body surface area (BSA) by the DuBois formula, or Quetelet's body mass index (BMI). We compared prevalence of low muscle mass among the four methods and assessed their correlation with strength and physical performance. ResultsThe prevalence of low muscle mass ranged from 8 to 32%. Muscle mass indexed to height(2) classified the smallest percentage of patients as having low muscle mass, particularly among women, whereas indexing by BSA classified the largest percentage. Low muscle mass/height(2) was present almost exclusively among normal or underweight patients, whereas indexing to body weight and BMI classified more overweight and obese patients as having low muscle mass. Handgrip strength was lower among those with low muscle mass by all methods except height(2). Handgrip strength was directly and modestly correlated with muscle mass normalized by percentage of body weight, BSA, and BMI (=0.43, 0.56, and, 0.64, respectively) and less so with muscle/height(2) (=0.31, P<0.001). The difference in grip strength among patients with low vs. normal muscle mass was largest according to muscle/BMI (-6.84kg, 95% CI -8.66 to -5.02, P<0.001). There were significant direct correlations of gait speed with muscle mass indexed to percentage of body weight, BSA, and BMI but not with muscle mass indexed to height(2). ConclusionsSkeletal muscle mass normalized to height(2) may underestimate the prevalence of low muscle mass, particularly among overweight and obese patients on hemodialysis. Valid detection of sarcopenia among obese patients receiving hemodialysis requires adjustment for body size. C1 [Kittiskulnam, Piyawan; Delgado, Cynthia; Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Kittiskulnam, Piyawan; Delgado, Cynthia; Johansen, Kirsten L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Kittiskulnam, Piyawan] Chulalongkorn Univ, Div Nephrol, Dept Med, Bangkok, Thailand. [Kittiskulnam, Piyawan] King Chulalongkorn Mem Hosp, Thai Red Cross Soc, Bangkok, Thailand. [Carrero, Juan J.] Karolinska Inst, Div Renal Med, Ctr Mol Med, Stockholm, Sweden. [Chertow, Glenn M.] Stanford Univ, Dept Med, Div Nephrol, Sch Med, Stanford, CA 94305 USA. [Kaysen, George A.] Univ Calif Davis, Div Nephrol, Sacramento, CA 95616 USA. [Kaysen, George A.] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95616 USA. RP Johansen, KL (reprint author), 111 J San Francisco VA Med Ctr, Nephrol Sect, 4150 Clement St, San Francisco, CA 94121 USA. EM kirsten.johansen@ucsf.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [N01-DK-7-0005, KD-7-5004, K24DK085153]; Department of Veterans Affairs, Clinical Science Research and Development Program [1IK2CX000527-01A2]; International Society of Nephrology; Stockholm County Council; Swedish Research Council FX This work was supported through contracts N01-DK-7-0005 and KD-7-5004 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Dr. Johansen's effort was also supported by K24DK085153 from the NIDDK. Dr. Delgado's work is supported by the Department of Veterans Affairs, Clinical Science Research and Development Program under Career Development Award 1IK2CX000527-01A2. Her contribution is the result of work supported with the resources and the use of facilities at the San Francisco VA Medical Center. This work has been made possible in part by an International Society of Nephrology funded Fellowship to Dr. Kittiskulnam. Dr. Carrero-Roig acknowledges grant support from Stockholm County Council and the Swedish Research Council. NR 39 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2190-5991 EI 2190-6009 J9 J CACHEXIA SARCOPENI JI J. Caxhexia Sarcopenia Muscle PD FEB PY 2017 VL 8 IS 1 BP 57 EP 68 DI 10.1002/jcsm.12130 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA EM0FJ UT WOS:000394993900007 PM 27897415 ER PT J AU McClatchey, PM Wu, F Olfert, IM Ellis, CG Goldman, D Reusch, JEB Frisbee, JC AF McClatchey, P. Mason Wu, Fan Olfert, I. Mark Ellis, Christopher G. Goldman, Daniel Reusch, Jane E. B. Frisbee, Jefferson C. TI Impaired Tissue Oxygenation in Metabolic Syndrome Requires Increased Microvascular Perfusion Heterogeneity SO JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH LA English DT Article DE Microcirculation; Oxygenation; Rodent models of obesity; Blood flow control; Simulation ID OBESE ZUCKER RATS; SKELETAL-MUSCLE; EXERCISE CAPACITY; BLOOD-FLOW; DYSFUNCTION; RESISTANCE; MORTALITY; MODELS; SYSTEM; MEN AB Metabolic syndrome (MS) in obese Zucker rats (OZR) is associated with impaired skeletal muscle performance and blunted hyperemia. Studies suggest that reduced O-2 diffusion capacity is required to explain compromised muscle performance and that heterogeneous microvascular perfusion distribution is critical. We modeled tissue oxygenation during muscle contraction in control and OZR skeletal muscle using physiologically realistic relationships. Using a network model of Krogh cylinders with increasing perfusion asymmetry and increased plasma skimming, we predict increased perfusion heterogeneity and decreased muscle oxygenation in OZR, with partial recovery following therapy. Notably, increasing O-2 delivery had less impact on VO2 than equivalent decreases in O-2 delivery, providing a mechanism for previous empirical work associating perfusion heterogeneity and impaired O-2 extraction. We demonstrate that increased skeletal muscle perfusion asymmetry is a defining characteristic of MS and must be considered to effectively model and understand blood-tissue O-2 exchange in this model of human disease. C1 [McClatchey, P. Mason] Univ Colorado Anschutz Med Campus, Div Endocrinol, Aurora, CO USA. [McClatchey, P. Mason; Reusch, Jane E. B.] Univ Colorado Anschutz Med Campus, Dept Bioengn, Aurora, CO USA. [McClatchey, P. Mason] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA. [Wu, Fan; Reusch, Jane E. B.] Novartis Inst BioMed Res, Drug Metab & Pharmacokinet, E Hanover, NJ USA. [Olfert, I. Mark] West Virginia Univ, Div Exercise Physiol, Hlth Sci Ctr, Morgantown, WV 26506 USA. [Ellis, Christopher G.; Goldman, Daniel; Frisbee, Jefferson C.] Univ Western Ontario, Dept Med Biophys, Schulich Sch Med & Dent, Med Sci Bldg,M407,1151 Richmond St North, London, ON N6A 5C1, Canada. RP Frisbee, JC (reprint author), Univ Western Ontario, Dept Med Biophys, Schulich Sch Med & Dent, Med Sci Bldg,M407,1151 Richmond St North, London, ON N6A 5C1, Canada. EM jfrisbee@uwo.ca FU American Heart Association [IRG 14330015, EIA 0740129N]; National Institutes of Health [RR 2865AR, R01 DK64668]; VA Merit Review [BX002046]; CU SOM Center for Women's Health Research, Bioengineering [5T32HL072738] FX This work was supported by the American Heart Association (IRG 14330015, EIA 0740129N) and the National Institutes of Health (RR 2865AR; R01 DK64668), VA Merit Review BX002046 (JEBR), CU SOM Center for Women's Health Research, Bioengineering T32 (5T32HL072738). NR 34 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1937-5387 EI 1937-5395 J9 J CARDIOVASC TRANSL JI J. Cardiovasc. Transl. Res. PD FEB PY 2017 VL 10 IS 1 BP 69 EP 81 DI 10.1007/s12265-017-9732-6 PG 13 WC Cardiac & Cardiovascular Systems; Medicine, Research & Experimental SC Cardiovascular System & Cardiology; Research & Experimental Medicine GA EM0MP UT WOS:000395012700008 ER PT J AU Wink, LK Pedapati, EV Horn, PS McDougle, CJ Erickson, CA AF Wink, Logan K. Pedapati, Ernest V. Horn, Paul S. McDougle, Christopher J. Erickson, Craig A. TI Multiple Antipsychotic Medication Use in Autism Spectrum Disorder SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY LA English DT Article DE autism; autism spectrum disorder; antipsychotics; physcopharmacology; irritability ID CHILDREN; ADOLESCENTS; POLYPHARMACY; ARIPIPRAZOLE; PROGRAM AB Objective: The purpose of this study was to explore the use of multiple antipsychotic medications in patients with autism spectrum disorder (ASD) by reviewing the longitudinal medication management of 1100 patients consecutively treated for behavioral symptoms associated with ASD at a tertiary care specialty clinic. Methods: We identified all patients with ASD treated with daily doses of two or more antipsychotics for at least two visits at our clinic. For each patient meeting inclusion criteria, diagnostic and demographic data were collected. To evaluate clinical need and effectiveness of antipsychotic medications in this sample, we reviewed symptoms targeted with each antipsychotic medication and concomitant medications prescribed. Clinical Global Impressions-Severity (CGI-S) and Clinical Global Impressions-Improvement (CGI-I) scale ratings had been completed at the time of each visit, and the duration of treatment with antipsychotic medications was determined. To evaluate the safety and tolerability of antipsychotic medication use in ASD, we reviewed reported adverse effects and calculated body mass index (BMI) change with treatment. Results: Seventy patients met the inclusion criteria (6.4% of our sample). The majority of patients were moderately to severely ill Caucasian males, as determined by baseline mean CGI-S of 4.7 (SD=0.8), and were diagnosed with autistic disorder and comorbid intellectual disability. The mean age was 15.1 years (SD=10.9), the primary targeted symptoms were agitation/irritability, physical aggression, and self-injury. The majority of patients remained on two or more antipsychotics for >1 year. In this population, patients demonstrated greater symptomatic improvement and generally tolerated treatment without significant adverse effects. Conclusions: The use of two or more antipsychotic medications may be increasingly common in patients with ASD. This retrospective study demonstrates that this treatment approach may be of some clinical benefit, and is generally well tolerated. Prospective studies focusing on the efficacy and safety of concomitant antipsychotic medication usage in ASD should be considered. C1 [Wink, Logan K.; Pedapati, Ernest V.; Horn, Paul S.; Erickson, Craig A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave MLC 4002, Cincinnati, OH 45229 USA. [McDougle, Christopher J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Lurie Ctr Autism, Boston, MA USA. [McDougle, Christopher J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pediat, Lurie Ctr Autism, Boston, MA USA. [McDougle, Christopher J.] Harvard Med Sch, MassGen Hosp Children, Boston, MA USA. RP Wink, LK (reprint author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave MLC 4002, Cincinnati, OH 45229 USA. EM logan.wink@cchmc.org FU Indiana University School of Medicine Department of Psychiatry; Autism Speaks; John Merck Fund; Riovant Sciences Ltd.; Simons Research Foundation; SynapDx; United Stated Department of Defense FX This work was supported by the Indiana University School of Medicine Department of Psychiatry. Dr. Wink's current research is supported by Autism Speaks, the John Merck Fund, Riovant Sciences Ltd., the Simons Research Foundation, SynapDx, and the United Stated Department of Defense. NR 14 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1044-5463 EI 1557-8992 J9 J CHILD ADOL PSYCHOP JI J. Child Adolesc. Psychopharmacol. PD FEB PY 2017 VL 27 IS 1 BP 91 EP + DI 10.1089/cap.2015.0123 PG 5 WC Pediatrics; Pharmacology & Pharmacy; Psychiatry SC Pediatrics; Pharmacology & Pharmacy; Psychiatry GA EL1JJ UT WOS:000394376300012 PM 26465194 ER PT J AU Nurok, M Cheng, J Romeo, GR Vecino, SM Fields, KG YaDeau, JT AF Nurok, Michael Cheng, Jennifer Romeo, Giulio R. Vecino, Stephanie M. Fields, Kara G. YaDeau, Jacques T. TI Dexamethasone and perioperative blood glucose in patients undergoing total joint arthroplasty: A retrospective study SO JOURNAL OF CLINICAL ANESTHESIA LA English DT Article DE Dexamethasone; Blood glucose; Arthroplasty, replacement, hip; Arthroplasty, replacement, knee; Diabetes mellitus ID RANDOMIZED CONTROLLED-TRIAL; INDUCED HYPERGLYCEMIA; POSTOPERATIVE NAUSEA; LONGITUDINAL-DATA; GLYCEMIC CONTROL; OBESE-PATIENTS; PAIN; SURGERY; RATS AB Study objective: Perioperative dexamethasone is commonly used to prevent nausea. It can also increase blood glucose levels, and recent concern about its blood glucose-elevating effect in humans has been raised. This study aimed to demonstrate relationships between dexamethasone administration and elevated perioperative blood glucose in patients undergoing total joint arthroplasty. Design: Retrospective study. Setting: Academic, orthopedic hospital. Patients: A total of 625 patients (18-99 years) who underwent total hip or total knee arthroplasty with an ASA <= 3 were included in the study. Interventions: Patients who received dexamethasone perioperatively were compared to those who did not receive dexamethasone. Measurements: The primary outcome, which was any postoperative glucose >200 mg/dl, was compared between groups using multiple logistic regression. Demographic information, intraoperative information, incidence of postoperative nausea and vomiting, white blood cell count, medication use, and length of stay were also collected. Main results: Perioperative dexamethasone (median [1st quartile, 3rd quartile] dose = 4 [4, 8] mg) was administered to 76% of patients. Only 5.6% (95% CI: 3.8-7.5) of patients had postoperative glucose levels >200 mg/d1. After covariate adjustment, there was no evidence of a difference in odds of experiencing postoperative glucose levels >200 mg/dl (odds ratio [95% CI]: 0.76 [0.28-2.07]; P = 0594) and maximum glucose levels (P = 0.518) between groups. Dexamethasone-treated patients had greater changes in white blood cell count between baseline and postoperative days 0-1. There was no evidence of a difference in wound healing and length of stay between groups. Conclusions: There was no evidence of an association between perioperative dexamethasone administration and the odds of having postoperative glucose levels >200 mg/dl or higher maximum glucose levels. However, these findings may not be generalizable to patients having different baseline characteristics or procedures. (C) 2016 Elsevier Inc. All rights reserved. C1 [Nurok, Michael; Cheng, Jennifer; YaDeau, Jacques T.] Hosp Special Surg, Dept Anesthesiol, 535 E 70th St, New York, NY 10021 USA. [Romeo, Giulio R.] Joslin Diabet Ctr, Dept Mol & Cellular Pharmacol, Boston, MA 02215 USA. [Vecino, Stephanie M.] Weill Cornell Med Coll, Dept Anesthesiol, New York, NY USA. [Fields, Kara G.] Hosp Special Surg, Healthcare Res Inst, 535 E 70th St, New York, NY 10021 USA. RP Nurok, M (reprint author), Cedars Sinai Heart Inst, 127 San Vicente Blvd,Suite 3100, Los Angeles, CA 90048 USA. EM Michael.Nurok@cshs.org FU Research and Education Fund of the Department of Anesthesiology at the Hospital for Special Surgery; National Center for Advancing Translational Science of the National Institutes of Health [UL1TR000457] FX This work was supported by the Research and Education Fund of the Department of Anesthesiology at the Hospital for Special Surgery and the National Center for Advancing Translational Science of the National Institutes of Health (UL1TR000457). NR 25 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0952-8180 EI 1873-4529 J9 J CLIN ANESTH JI J. Clin. Anesth. PD FEB PY 2017 VL 37 BP 116 EP 122 DI 10.1016/j.jclinane.2016.11.012 PG 7 WC Anesthesiology SC Anesthesiology GA EN4GE UT WOS:000395965200029 PM 28235499 ER PT J AU Goldstein, KM Callegari, LS AF Goldstein, Karen M. Callegari, Lisa S. TI Should a history of assisted reproductive technology be another consideration when assessing cardiovascular risk? SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Editorial Material ID HYPERTENSIVE DISORDERS; PRECONCEPTION CARE; PREGNANCY; RECOMMENDATIONS; MORTALITY; DISEASE; STATE C1 [Goldstein, Karen M.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA. [Goldstein, Karen M.] Duke Univ, Med Ctr, Dept Med, Div Gen Internal Med, Durham, NC 27710 USA. [Callegari, Lisa S.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev, Seattle, WA USA. [Callegari, Lisa S.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Callegari, Lisa S.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Goldstein, KM (reprint author), Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA. EM karen.goldstein@va.gov NR 16 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 EI 1751-7176 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD FEB PY 2017 VL 19 IS 2 BP 170 EP 172 DI 10.1111/jch.12937 PG 3 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA EL3GP UT WOS:000394507900010 PM 28194918 ER PT J AU Perez, CM Munoz, F Andriankaja, OM Ritchie, CS Martinez, S Vergara, J Vivaldi, J Lopez, L Campos, M Joshipura, KJ AF Perez, Cynthia M. Munoz, Francisco Andriankaja, Oelisoa M. Ritchie, Christine S. Martinez, Sasha Vergara, Jose Vivaldi, Jose Lopez, Lydia Campos, Maribel Joshipura, Kaumudi J. TI Cross-sectional associations of impaired glucose metabolism measures with bleeding on probing and periodontitis SO JOURNAL OF CLINICAL PERIODONTOLOGY LA English DT Article DE bleeding on probing; impaired fasting glucose; impaired glucose tolerance; impaired glycated haemoglobin; insulin resistance; periodontitis; pre-diabetes ID NUTRITION EXAMINATION SURVEY; CONTINUOUS NATIONAL-HEALTH; BETA-CELL FUNCTION; INSULIN-RESISTANCE; DIABETES-MELLITUS; FASTING GLUCOSE; ORAL-HEALTH; DISEASE; ADULTS; INFLAMMATION AB Aim: This study assessed the associations of pre-diabetes and insulin resistance with bleeding on probing (BOP) and periodontitis among adults. Materials and methods: We included 1191 Hispanic adults aged 40-65 years, free of diabetes, enrolled in San Juan Overweight Adults Longitudinal Study. Pre-diabetes was defined as impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or impaired glycated haemoglobin. Impaired one-hour plasma glucose (1hPG) was defined as levels >155 mg/dl. Insulin resistance was defined using the study population-specific 75th percentile (HOMA-IR >= 3.13). High BOP was defined as percentage of teeth with bleeding >= 30%. Periodontitis was defined according to the CDC/AAP definition. Results: After multivariable adjustment for age, gender, education, smoking status, alcohol consumption, physical activity, obesity, HDL-C, and plaque index, pre-diabetes with and without 1hPG, IFG, impaired 1hPG, IGT, and HOMA-IR were significantly associated with high BOP; pre-diabetes, IFG, and impaired 1hPG were significantly associated with severe periodontitis. Most of these associations remained significant when the analyses were restricted to non-smokers. Conclusions: This study suggests associations between pre-diabetes and insulin resistance with BOP and periodontitis. Given the high prevalence of impaired glucose metabolism and periodontitis, the assessment of the temporal sequence of these associations is of utmost importance. C1 [Perez, Cynthia M.] Univ Puerto Rico, Dept Biostat & Epidemiol, Grad Sch Publ Hlth, Med Sci Campus,POB 365067, San Juan, PR 00936 USA. [Munoz, Francisco; Andriankaja, Oelisoa M.; Martinez, Sasha; Campos, Maribel; Joshipura, Kaumudi J.] Univ Puerto Rico, Ctr Clin Res & Hlth Promot, Sch Dent Med, Med Sci Campus, San Juan, PR 00936 USA. [Ritchie, Christine S.] San Francisco VA Med Ctr, Ctr Res Aging Jewish Home San Francisco, San Francisco, CA USA. [Vergara, Jose; Vivaldi, Jose] Univ Puerto Rico, Sch Dent Med, Med Sci Campus, San Juan, PR 00936 USA. [Joshipura, Kaumudi J.] Harvard Univ, Dept Epidemiol, Harvard TH Chan Sch Publ Hlth, Cambridge, MA 02138 USA. RP Perez, CM (reprint author), Univ Puerto Rico, Dept Biostat & Epidemiol, Grad Sch Publ Hlth, Med Sci Campus,POB 365067, San Juan, PR 00936 USA. EM cynthia.perez1@upr.edu FU NIDCR NIH HHS [K23 DE025313, R01 DE020111]; NIMHD NIH HHS [U54 MD007587] NR 40 TC 0 Z9 0 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0303-6979 EI 1600-051X J9 J CLIN PERIODONTOL JI J. Clin. Periodontol. PD FEB PY 2017 VL 44 IS 2 BP 142 EP 149 DI 10.1111/jcpe.12662 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA EM8ML UT WOS:000395565400003 PM 27978601 ER PT J AU Comer, JS Furr, JM Kerns, CE Miguel, E Coxe, S Elkins, RM Carpenter, AL Cornacchio, D Cooper-Vince, CE DeSerisy, M Chou, T Sanchez, AL Khanna, M Franklin, ME Garcia, AM Freeman, JB AF Comer, Jonathan S. Furr, Jami M. Kerns, Caroline E. Miguel, Elizabeth Coxe, Stefany Elkins, R. Meredith Carpenter, Aubrey L. Cornacchio, Danielle Cooper-Vince, Christine E. DeSerisy, Mariah Chou, Tommy Sanchez, Amanda L. Khanna, Muniya Franklin, Martin E. Garcia, Abbe M. Freeman, Jennifer B. TI Internet-Delivered, Family-Based Treatment for Early-Onset OCD: A Pilot Randomized Trial SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE behavioral telehealth; videoteleconferencing; OCD; early intervention; early childhood ID OBSESSIVE-COMPULSIVE DISORDER; MENTAL-HEALTH-CARE; COGNITIVE-BEHAVIOR THERAPY; CHILDREN; ADOLESCENTS; TECHNOLOGY; SERIES AB Objective: Despite advances in supported treatments for early onset obsessive-compulsive disorder ( OCD), progress has been constrained by regionally limited expertise in pediatric OCD. Videoteleconferencing ( VTC) methods have proved useful for extending the reach of services for older individuals, but no randomized clinical trials ( RCTs) have evaluated VTC for treating early onset OCD. Method: RCT comparing VTC-delivered family based cognitive-behavioral therapy ( FB-CBT) versus clinic-based FB-CBT in the treatment of children ages 4-8 with OCD ( N = 22). Pretreatment, posttreatment, and 6-month follow-up assessments included mother-/therapist-reports and independent evaluations masked to treatment condition. Primary analyses focused on treatment retention, engagement and satisfaction. Hierarchical linear modeling preliminarily evaluated the effects of time, treatment condition, and their interactions. "Excellent response" was defined as a 1 or 2 on the Clinical Global Impressions-Improvement Scale. Results: Treatment retention, engagement, alliance and satisfaction were high across conditions. Symptom trajectories and family accommodation across both conditions showed outcomes improving from baseline to posttreatment, and continuing through follow-up. At posttreatment, 72.7% of Internet cases and 60% of Clinic cases showed "excellent response," and at follow-up 80% of Internet cases and 66.7% of Clinic cases showed " excellent response." Significant condition differences were not found across outcomes. Conclusions: VTC methods may offer solutions to overcoming traditional barriers to care for early onset OCD by extending the reach of real-time expert services regardless of children's geographic proximity to quality care. C1 [Comer, Jonathan S.; Furr, Jami M.; Miguel, Elizabeth; Coxe, Stefany; Cornacchio, Danielle; Chou, Tommy; Sanchez, Amanda L.] Florida Int Univ, Dept Psychol, Miami, FL 33199 USA. [Kerns, Caroline E.; Elkins, R. Meredith; Carpenter, Aubrey L.] Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA. [Cooper-Vince, Christine E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cooper-Vince, Christine E.] Harvard Univ, Dept Psychiat, Cambridge, MA 02138 USA. [DeSerisy, Mariah] Fordham Univ, Dept Psychol, Bronx, NY 10458 USA. [Khanna, Muniya] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Khanna, Muniya; Franklin, Martin E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Garcia, Abbe M.; Freeman, Jennifer B.] Brown Univ, Dept Psychiat & Human Behav, Providence, RI 02912 USA. RP Comer, JS (reprint author), Florida Int Univ, Dept Psychol, Ctr Children & Families, Mental Hlth Intervent & Technol, 11200 SW 8th St, Miami, FL 33199 USA. EM jocomer@fiu.edu FU International OCD Foundation (IOCDF); NIH [K23 MH090247] FX This work was principally supported by the International OCD Foundation (IOCDF), as well by the NIH (K23 MH090247). Abbe M. Garcia and Jennifer B. Freeman receive book royalties from Oxford University Press. NR 31 TC 0 Z9 0 U1 1 U2 1 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD FEB PY 2017 VL 85 IS 2 BP 178 EP 186 DI 10.1037/ccp0000155 PG 9 WC Psychology, Clinical SC Psychology GA EM0FI UT WOS:000394993800008 PM 27869451 ER PT J AU Schreuder, WH van den Berg, H Westermann, AM Peacock, ZS de Lange, J AF Schreuder, Willem Hans van den Berg, Henk Westermann, Anne Marie Peacock, Zachary Scott de lange, Jan TI Pharmacological and surgical therapy for the central giant cell granuloma: A long-term retrospective cohort study SO JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY LA English DT Article DE Central giant cell granuloma; Interferon; Calcitonin; Maxilla; Mandible; Benign bone lesion ID INTRALESIONAL CORTICOSTEROID INJECTION; CALCITONIN NASAL SPRAY; OF-THE-LITERATURE; ANTIANGIOGENIC THERAPY; INTERFERON-ALPHA; ALTERNATIVE TREATMENT; REPARATIVE GRANULOMA; RADIOLOGIC FEATURES; JAWS; LESIONS AB Purpose: This is a retrospective cohort study of patients with a central giant cell granuloma (CGCG) treated at a single center to assess and compare the different surgical and non-surgical approaches. Material and methods: A cohort with a single histologically proven non-syndrome-related CGCG was selected and reviewed. Patients were allocated to group I (surgery), group II (pharmacotherapy), and group III (pharmacotherapy and surgery). The primary outcome was long-term radiologic response using computed tomography. Secondary outcomes were intermediate radiologic responses and occurrence and severity of side effects. Results: Thirty-three subjects were included in the study. The surgical group (n = 4) included 1 patient with progression during follow-up and a relatively high post-surgical morbidity. Twenty-nine patients started on various pharmacological treatment regimens (groups II and III). Fourteen patients could be managed without addjtional surgery. One of these lesions showed progression during follow-up. The other 15 lesions underwent additional surgery, and none showed progression during follow-up. Interferon treatment was associated with the most side effects. Conclusion: Pharmacological agents have a role in the treatment of aggressive and non-aggressive CGCGs by limiting the renewed progression during long-term follow up and the extent and morbidity of surgical treatment. (C) 2016 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved. C1 [Schreuder, Willem Hans; de lange, Jan] Acad Ctr Dent Amsterdam, Acad Med Ctr, Dept Oral & Maxillofacial Surg, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. [Schreuder, Willem Hans; van den Berg, Henk; Westermann, Anne Marie; de lange, Jan] Univ Amsterdam, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. [van den Berg, Henk] Emma Children Hosp, Acad Med Ctr, Dept Pediat Oncol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. [Westermann, Anne Marie] Acad Med Ctr, Dept Med Oncol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. [Peacock, Zachary Scott] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Fruit St 55, Boston, MA 02114 USA. [Peacock, Zachary Scott] Harvard Sch Dent Med, Fruit St 55, Boston, MA 02114 USA. RP Schreuder, WH (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Oral & Maxillofacial Surg, POB 22660, NL-1100 DD Amsterdam, Netherlands. EM w.h.schreuder@amc.uva.nl; h.vandenberg@amc.uva.nl; a.m.westermann@amc.uva.nl; zpeacock@partners.org; j.delange@amc.uva.nl FU Dutch Government ZonMW Priority Medicines and Rare Disease Program FX This research project was supported by the Dutch Government ZonMW Priority Medicines and Rare Disease Program. NR 82 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1010-5182 EI 1878-4119 J9 J CRANIO MAXILL SURG JI J. Cranio-MaxilloFac. Surg. PD FEB PY 2017 VL 45 IS 2 BP 232 EP 243 DI 10.1016/j.jcms.2016.11.011 PG 12 WC Dentistry, Oral Surgery & Medicine; Surgery SC Dentistry, Oral Surgery & Medicine; Surgery GA EL9DK UT WOS:000394919400011 PM 28087284 ER PT J AU Schonfeld, DJ Shekunov, J Jellinek, M Stein, MT AF Schonfeld, David J. Shekunov, Julia Jellinek, Michael Stein, Martin T. TI A 9-Year-Old Girl Discovers That Her Mother Was Murdered SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS LA English DT Editorial Material DE bereavement; loss of parent; guilt; funeral participation; internal representation ID CHILDHOOD BEREAVEMENT; DEATH AB CASE: Susan was a 9-year-old girl living with her mother; she had never met her father. Her mother returned one evening from her job as a cocktail waitress and Susan met her at the apartment door to let her know they had run out of cat food. Her mother said she would go and buy some the next morning because it was late and she was tired, but Susan insisted she go out that evening because the cat had not eaten all day. Her mother was fatally shot in the parking lot of the convenience store shortly thereafter; since there was no robbery involved, the police suspected it was someone that she knew. Susan's extended family had her move out of the apartment that evening and relocate to live with her aunt and uncle out-of-state. The transition happened quickly. Susan was unable to return to her apartment to pick up any additional belongings and never returned to say goodbye to her friends. The family decided she was too young to attend the funeral. Susan had trouble fitting in with her aunt and uncle's family; they had 2 children who were 8 and 6 years old, and Susan felt she was being treated like a baby. She resented having a bedtime (her mother allowed her to stay up as late as she wished), and she complained that the work at school was boring and her classmates were childish. When the family went to a festival in town, she left abruptly without telling them, which frightened Susan's aunt and uncle. They wanted to be supportive but felt that she needed more structure than her mother had provided her. Susan's aunt and uncle sought bereavement support for Susan from her pediatrician and parenting advice for themselves. C1 [Schonfeld, David J.] Univ Southern Calif, Sch Social Work, Natl Ctr Sch Crisis & Bereavement, Los Angeles, CA 90007 USA. [Schonfeld, David J.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Shekunov, Julia] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Jellinek, Michael] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Stein, Martin T.] Univ Calif San Diego, Rady Childrens Hosp, San Diego, CA 92103 USA. RP Schonfeld, DJ (reprint author), Univ Southern Calif, Sch Social Work, Natl Ctr Sch Crisis & Bereavement, Los Angeles, CA 90007 USA.; Schonfeld, DJ (reprint author), Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0196-206X EI 1536-7312 J9 J DEV BEHAV PEDIATR JI J. Dev. Behav. Pediatr. PD FEB-MAR PY 2017 VL 38 IS 2 SU S BP S76 EP S78 PG 3 WC Behavioral Sciences; Psychology, Developmental; Pediatrics SC Behavioral Sciences; Psychology; Pediatrics GA EL4AW UT WOS:000394563500025 PM 28141729 ER PT J AU LaMotte, AD Taft, CT Weatherill, RP Eckhardt, CI AF LaMotte, Adam D. Taft, Casey T. Weatherill, Robin P. Eckhardt, Christopher I. TI Social Skills Deficits as a Mediator Between PTSD Symptoms and Intimate Partner Aggression in Returning Veterans SO JOURNAL OF FAMILY PSYCHOLOGY LA English DT Article DE posttraumatic stress disorder; social information processing; social skills; violence; aggression ID POSTTRAUMATIC-STRESS-DISORDER; MARITALLY VIOLENT; MILITARY VETERANS; MEN AB This study examined social skills deficits as a mediator of the relationship between posttraumatic stress disorder (PTSD) symptoms and use of intimate partner aggression (IPA) among returning veterans. Prior research with veterans has focused on PTSD-related deficits at the decoding stage of McFall's (1982) social information processing model, and the current study adds to this literature by examining social skills deficits at the decision stage. Participants were 92 male veterans recruited from the greater Boston area. PTSD symptoms were assessed through clinician interview, IPA use was assessed through self-and partner report, and social skills deficits were assessed in a laboratory task in which veterans listened to a series of problematic marital situations and responded with what they would say or do in the situation. Responses were coded for social competency. Bivariate correlations revealed several significant associations among PTSD symptoms, social skills deficits, and use of IPA. When all PTSD symptom clusters were entered into a regression predicting social skills deficits, only emotional numbing emerged as a unique predictor. Finally, social skills deficits significantly mediated the relationship between veterans' PTSD symptoms and use of psychological (but not physical) IPA. Findings extend prior research on McFall's (1982) social information processing model as it relates to veterans' PTSD symptoms and use of IPA. More research is needed to understand the associations between PTSD symptoms and deficits at each individual step of this model. C1 [LaMotte, Adam D.; Taft, Casey T.; Weatherill, Robin P.] VA Boston Healthcare Syst, Natl Ctr PTSD, Behav Sci Div, Boston, MA USA. [Taft, Casey T.; Weatherill, Robin P.] Boston Univ, Dept Psychiat, Sch Med, Boston, MA 02215 USA. [Eckhardt, Christopher I.] Purdue Univ, Dept Psychol Serv, W Lafayette, IN 47907 USA. RP Taft, CT (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, Behav Sci Div, Boston, MA USA.; Taft, CT (reprint author), VA Boston Healthcare Syst 116B 4, 150 South Huntington Ave, Boston, MA 02130 USA. EM casey.taft@va.gov FU Department of Veterans Affairs Merit Review Grant FX This research was supported by a Department of Veterans Affairs Merit Review Grant awarded to Casey T. Taft. The contents of this article do not represent the views of the U.S. Department of Veterans Affairs or the U.S. Government. NR 24 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0893-3200 EI 1939-1293 J9 J FAM PSYCHOL JI J. Fam. Psychol. PD FEB PY 2017 VL 31 IS 1 BP 105 EP 110 DI 10.1037/fam0000215 PG 6 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA EN1QW UT WOS:000395785900013 PM 27148936 ER PT J AU McGinn, MM Hoerster, KD Stryczek, KC Malte, CA Jakupcak, M AF McGinn, Meghan M. Hoerster, Katherine D. Stryczek, Krysttel C. Malte, Carol A. Jakupcak, Matthew TI Relationship Satisfaction, PTSD Symptom Severity, and Mental Healthcare Utilization Among OEF/OIF Veterans SO JOURNAL OF FAMILY PSYCHOLOGY LA English DT Article DE mental health care utilization; PTSD; relationship satisfaction ID AFGHANISTAN VETERANS; COUPLE THERAPY; IRAQ; BARRIERS; SERVICES; STRESS; MODEL AB Despite the availability of evidence-based PTSD treatments at most facilities within the VA Healthcare System, most Iraq and Afghanistan veterans returning from deployments with posttraumatic stress symptoms do not receive an adequate dose of mental health treatment, prompting the need to identify potential barriers to or facilitators of mental health care utilization. Previous research demonstrated self-reported mental health care utilization in the prior year varies as a function of PTSD symptom severity, and the interaction of PTSD symptom severity and romantic relationship satisfaction (Meis et al., 2010). We extended these findings by objectively measuring the degree of utilization over a 1-year period (i. e., number of sessions attended) in a sample of 130 Iraq and Afghanistan veterans who presented to primary care/deployment health and completed an initial mental health evaluation. Results indicated main and interactive effects of PTSD symptom severity and relationship satisfaction, such that greater PTSD symptom severity was associated with greater utilization at average to high relationship satisfaction (p < .05), but not low relationship satisfaction. Implications for future research and couple/family based interventions for veterans with PTSD are discussed. C1 [McGinn, Meghan M.; Hoerster, Katherine D.; Stryczek, Krysttel C.; Malte, Carol A.; Jakupcak, Matthew] VA Puget Sound Healthcare Syst, 1660 South Columbian Way, Seattle, WA 98108 USA. [McGinn, Meghan M.; Hoerster, Katherine D.; Jakupcak, Matthew] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP McGinn, MM (reprint author), VA Puget Sound Healthcare Syst, 1660 South Columbian Way, Seattle, WA 98108 USA. EM meghan.mcginn@va.gov FU Department of Veterans Affairs Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment; VA Puget Sound Healthcare System, Seattle, Washington; University of Washington School of Medicine, Department of Psychiatry & Behavioral Sciences, Seattle, Washington FX This material is the result of work supported by resources from the Department of Veterans Affairs Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, the VA Puget Sound Healthcare System, Seattle, Washington, and the University of Washington School of Medicine, Department of Psychiatry & Behavioral Sciences, Seattle, Washington. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. Some of the ideas and data from an earlier version of this article were presented at the 2013 American Psychological Association's Annual Convention in Honolulu, HI. NR 22 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0893-3200 EI 1939-1293 J9 J FAM PSYCHOL JI J. Fam. Psychol. PD FEB PY 2017 VL 31 IS 1 BP 111 EP 116 DI 10.1037/fam0000224 PG 6 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA EN1QW UT WOS:000395785900014 PM 27668933 ER PT J AU Moradi, A Braun, Y Oflazoglu, K Meijs, T Ring, D Chen, N AF Moradi, A. Braun, Y. Oflazoglu, K. Meijs, T. Ring, D. Chen, N. TI Factors associated with subluxation in mallet fracture SO JOURNAL OF HAND SURGERY-EUROPEAN VOLUME LA English DT Article DE Mallet fracture; subluxation; factor ID DISTAL INTERPHALANGEAL JOINT; FINGER FRACTURES; FIXATION AB Radiographs and medical record of all adult patients with a mallet fracture in three hospitals between 2004 and 2014 were reviewed. International Classification of Diseases, Ninth Revision (ICD-9) codes and text search in radiographic reports were used to identify all acute patients with potential mallet fractures in our institutional database. Manually checking, 392 true mallet fractures were identified among them, 78 had subluxation at the time of diagnosis and 19 had subluxation at a later time point during treatment. Fragment size, fragment displacement, and interval between injury and treatment were associated with initial and late subluxation. Subluxation was not observed when the fracture size was less than 39% of the total articular surface. For each 1% increase in total articular surface involvement in fractures with more than 39% involvement, the risk of subluxation increased by 4% and for each 1% of displacement, the risk of subluxation increased by 4%. Level of Evidence: IV C1 [Moradi, A.; Braun, Y.; Oflazoglu, K.; Meijs, T.; Ring, D.; Chen, N.] Harvard Med Sch, Massachusetts Gen Hosp, Orthoped Hand & Upper Extrem Serv, Boston, MA USA. [Moradi, A.] Mashhad Univ Med Sci, Orthoped Res Ctr, Mashhad, Iran. RP Ring, D (reprint author), Harvard Med Sch, Orthoped Hand & Upper Extrem Serv, Massachusetts Gen Hosp, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org NR 17 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1753-1934 EI 2043-6289 J9 J HAND SURG-EUR VOL JI J. Hand Surg.-Eur. Vol. PD FEB PY 2017 VL 42 IS 2 BP 176 EP 181 DI 10.1177/1753193416669929 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA EL7GR UT WOS:000394789600010 PM 27697897 ER PT J AU Wheldon, CW Kolar, SK Hernandez, ND Daley, EM AF Wheldon, Christopher W. Kolar, Stephanie K. Hernandez, Natalie D. Daley, Ellen M. TI Factorial Invariance and Convergent Validity of the Group-Based Medical Mistrust Scale across Gender and Ethnoracial Identity SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Medical mistrust; psychometrics; minorities; measurement ID HEALTH-CARE; PERCEIVED DISADVANTAGES; AFRICAN-AMERICAN; FIT INDEXES; SATISFACTION; TRUST AB The objective of this study was to assess the factorial invariance and convergent validity of the Group-Based Medical Mistrust Scale (GBMMS) across gender (male and female) and ethnoracial identity (Latino and Black). Minority students (N = 686) attending a southeastern university were surveyed in the fall of 2011. Psychometric analysis of the GBMMS was performed. A three-factor solution fit the data after the omission of two problematic items. This revised version of the GBMMS exhibited sufficient configural, metric, and scalar invariance. Convergence of the GBMMS with conceptually related measures provided further evidence of validity; however, there was variation across ethnoracial identity. The GBMMS has viable psychometric properties across gender and ethnoracial identity in Black and Latino populations. C1 [Wheldon, Christopher W.] NCI, Div Canc Control & Populat Sci, Room 3E-212,9609 Med Ctr Dr, Bethesda, MD 20892 USA. [Kolar, Stephanie K.] US Dept Vet Affairs, Washington, DC USA. [Hernandez, Natalie D.] Univ S Florida, Dept Community Hlth & Prevent Med, Tampa, FL USA. [Daley, Ellen M.] Univ S Florida, Dept Community & Family Hlth, Tampa, FL USA. RP Wheldon, CW (reprint author), NCI, Div Canc Control & Populat Sci, Room 3E-212,9609 Med Ctr Dr, Bethesda, MD 20892 USA. EM christopher.wheldon@nih.gov NR 19 TC 0 Z9 0 U1 0 U2 0 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 EI 1548-6869 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD FEB PY 2017 VL 28 IS 1 BP 88 EP 99 PG 12 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EL6JU UT WOS:000394729200012 PM 28238990 ER PT J AU Makaroun, LK Bowman, C Duan, K Handley, N Wheeler, DJ Pierluissi, E Chen, AH AF Makaroun, Lena K. Bowman, Chelsea Duan, Kevin Handley, Nathan Wheeler, Daniel J. Pierluissi, Edgar Chen, Alice Hm TI Specialty Care Access in the Safety Net-the Role of Public Hospitals and Health Systems SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Specialty care; access to care; safety net; health care reform ID ELECTRONIC REFERRALS; PROVIDERS; GASTROENTEROLOGY; CENTERS AB Access to specialty care in the United States safety net, already strained, is facing increasing pressure with an influx of patients following the passage of the Affordable Care Act (ACA). We surveyed 18 public hospitals and health systems across the country to describe the current state of specialty care delivery in safety-net systems. We elicited information regarding challenges, provider models, metrics of access and productivity, and strategies for improving access. Based on our findings, we propose a framework for assessing and improving specialty care access with a focus on population health planning. C1 [Makaroun, Lena K.] Univ Washington, Dept Med, Div Geriatr, Seattle, WA 98195 USA. [Makaroun, Lena K.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Bowman, Chelsea] Palo Alto Med Fdn, Palo Alto, CA USA. [Duan, Kevin; Pierluissi, Edgar] Univ Calif San Francisco, Dept Med, Div Hosp Med, San Francisco, CA 94143 USA. [Handley, Nathan] Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA. [Wheeler, Daniel J.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Pierluissi, Edgar] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. [Chen, Alice Hm] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA. RP Makaroun, LK (reprint author), Univ Washington, Dept Med, Div Geriatr, VA Puget Sound Healthcare Syst, 1660 South Columbia Way,S-152, Seattle, WA 98108 USA. EM makaroun@uw.edu NR 33 TC 0 Z9 0 U1 0 U2 0 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 EI 1548-6869 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD FEB PY 2017 VL 28 IS 1 BP 566 EP 581 PG 16 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EL6JU UT WOS:000394729200041 PM 28239019 ER PT J AU Lee, MH Appleton, KM El-Shewy, HM Sorci-Thomas, MG Thomas, MJ Lopes-Virella, MF Luttrell, LM Hammad, SM Klein, RL AF Lee, Mi-Hye Appleton, Kathryn M. El-Shewy, Hesham M. Sorci-Thomas, Mary G. Thomas, Michael J. Lopes-Virella, Maria F. Luttrell, Louis M. Hammad, Samar M. Klein, Richard L. TI S1P in HDL promotes interaction between SR-BI and S1PR1 and activates S1PR1-mediated biological functions: calcium flux and S1PR1 internalization SO JOURNAL OF LIPID RESEARCH LA English DT Article DE high density lipoprotein; sphingosine 1-phosphate; protein-fragment complementation assay; scavenger receptor BI; S1P receptors ID HIGH-DENSITY-LIPOPROTEIN; RECEPTOR CLASS-B; APOLIPOPROTEIN-A-I; ENDOTHELIAL-CELL MIGRATION; NITRIC-OXIDE SYNTHASE; SCAVENGER RECEPTOR; SPHINGOSINE 1-PHOSPHATE; PLASMA-MEMBRANE; MASS-SPECTROMETRY; PROTEIN-KINASE AB HDL normally transports about 50-70% of plasma sphingosine 1-phosphate (S1P), and the S1P in HDL reportedly mediates several HDL-associated biological effects and signaling pathways. The HDL receptor, SR-BI, as well as the cell surface receptors for S1P (S1PRs) may be involved partially and/or completely in these HDL-induced processes. Here we investigate the nature of the HDL-stimulated interaction between the HDL receptor, SR-BI, and S1PR1 using a protein-fragment complementation assay and confocal microscopy. In both primary rat aortic vascular smooth muscle cells and HEK293 cells, the S1P content in HDL particles increased intracellular calcium concentration, which was mediated by S1PR1. Mechanistic studies performed in HEK293 cells showed that incubation of cells with HDL led to an increase in the physical interaction between the SR-BI and S1PR1 receptors that mainly occurred on the plasma membrane. Model recombinant HDL (rHDL) particles formed in vitro with S1P incorporated into the particle initiated the internalization of S1PR1, whereas rHDL without supplemented S1P did not, suggesting that S1P transported in HDL can selectively activate S1PR1. In conclusion, these data suggest that S1P in HDL stimulates the transient interaction between SR-BI and S1PRs that can activate S1PRs and induce an elevation in intracellular calcium concentration. C1 [Lee, Mi-Hye; El-Shewy, Hesham M.; Lopes-Virella, Maria F.; Luttrell, Louis M.; Klein, Richard L.] Med Univ South Carolina, Div Endocrinol Metab & Med Genet, Dept Med, Coll Pharm, Charleston, SC 29425 USA. [Appleton, Kathryn M.; Luttrell, Louis M.] Med Univ South Carolina, Dept Pharmaceut & Biomed Sci, Coll Pharm, Charleston, SC USA. [Hammad, Samar M.] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC USA. [Sorci-Thomas, Mary G.] Med Coll Wisconsin, Dept Med, Div Endocrinol Metab & Clin Nutr, Milwaukee, WI 53226 USA. [Thomas, Michael J.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA. [Lopes-Virella, Maria F.; Luttrell, Louis M.; Klein, Richard L.] Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Klein, RL (reprint author), Med Univ South Carolina, Div Endocrinol Metab & Med Genet, Dept Med, Coll Pharm, Charleston, SC 29425 USA.; Klein, RL (reprint author), Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. EM kleinrl@musc.edu FU Department of Veterans Affairs Merit Review Program; National Institutes of Health/National Heart, Lung, and Blood Institute [HL079274, HL127649, HL112276]; National Institutes of Health [RR027777]; National Cancer Institute Center Grant [5P30CA12197] FX This work was supported by the Department of Veterans Affairs Merit Review Program (M.L.V. and R.L.K.) and by National Institutes of Health/National Heart, Lung, and Blood Institute Grants HL079274 (S.M.H.), HL127649, and HL112276 (M.S.T.). The FLIPRTETRA facility was supported by National Institutes of Health Grant RR027777 (L.M.L.). The mass spectroscopy analyses were performed in the Mass Spectrometer Facility of the Comprehensive Cancer Center of Wake Forest School of Medicine supported in part by National Cancer Institute Center Grant 5P30CA12197. The contents of this manuscript do not represent the views of the Department of Veterans Affairs or the United States Government. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 57 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 EI 1539-7262 J9 J LIPID RES JI J. Lipid Res. PD FEB PY 2017 VL 58 IS 2 BP 325 EP 338 DI 10.1194/jlr.M070706 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EM1WW UT WOS:000395108900003 PM 27881715 ER PT J AU Berko, ER Cho, MT Eng, C Shao, YR Sweetser, DA Waxler, J Robin, NH Brewer, F Donkervoort, S Mohassel, P Bonnemann, CG Bialer, M Moore, C Wolfe, LA Tifft, CJ Shen, YF Retterer, K Millan, F Chung, WK AF Berko, Esther R. Cho, Megan T. Eng, Christine Shao, Yunru Sweetser, David A. Waxler, Jessica Robin, Nathaniel H. Brewer, Fallon Donkervoort, Sandra Mohassel, Payam Bonnemann, Carsten G. Bialer, Martin Moore, Christine Wolfe, Lynne A. Tifft, Cynthia J. Shen, Yufeng Retterer, Kyle Millan, Francisca Chung, Wendy K. TI De novo missense variants in HECW2 are associated with neurodevelopmental delay and hypotonia SO JOURNAL OF MEDICAL GENETICS LA English DT Article DE intellectual disability; whole exome sequencing; de novo; HECW2; neurodevelopmental delay ID SEVERE INTELLECTUAL DISABILITY; UBIQUITIN LIGASE; MUTATIONS; P73; MAINTENANCE; DISORDERS; DEFECTS; NEURONS; SERVER; BRAIN AB Background The causes of intellectual disability (ID) are diverse and de novo mutations are increasingly recognised to account for a significant proportion of ID. Methods and results In this study, we performed whole exome sequencing on a large cohort of patients with ID or neurodevelopmental delay and identified four novel de novo predicted deleterious missense variants in HECW2 in six probands with ID/developmental delay and hypotonia. Other common features include seizures, strabismus, nystagmus, cortical visual impairment and dysmorphic facial features. HECW2 is an ubiquitin ligase that stabilises p73, a crucial mediator of neurodevelopment and neurogenesis. Conclusion This study implicates pathogenic genetic variants in HECW2 as potential causes of neurodevelopmental disorders in humans. C1 [Berko, Esther R.; Chung, Wendy K.] Columbia Univ, Med Ctr, Dept Pediat, New York, NY 10032 USA. [Cho, Megan T.; Retterer, Kyle; Millan, Francisca] GeneDx, Gaithersburg, MD USA. [Eng, Christine; Shao, Yunru] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA. [Shao, Yunru] Texas Childrens Hosp, Houston, TX 77030 USA. [Sweetser, David A.; Waxler, Jessica] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Robin, Nathaniel H.; Brewer, Fallon] Univ Alabama Birmingham, Birmingham, AL USA. [Donkervoort, Sandra; Mohassel, Payam; Bonnemann, Carsten G.] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA. [Bialer, Martin; Moore, Christine] Cohen Childrens Med Ctr NY, New Hyde Pk, NY USA. [Wolfe, Lynne A.; Tifft, Cynthia J.] NIH, Off Clin Director, Bldg 10, Bethesda, MD 20892 USA. [Wolfe, Lynne A.; Tifft, Cynthia J.] NIH, Undiagnosed Dis Program, Bldg 10, Bethesda, MD 20892 USA. [Shen, Yufeng] Columbia Univ, Med Ctr, Dept Syst Biol, New York, NY 10032 USA. [Shen, Yufeng] Columbia Univ, Med Ctr, Dept Biomed Informat, New York, NY 10032 USA. [Chung, Wendy K.] Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA. RP Chung, WK (reprint author), Columbia Univ, Med Ctr, New York, NY 10032 USA. EM wkc15@columbia.edu FU Simons Foundation FX This work was supported in part by a grant from the Simons Foundation. NR 35 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-2593 EI 1468-6244 J9 J MED GENET JI J. Med. Genet. PD FEB PY 2017 VL 54 IS 2 BP 93 EP 99 DI 10.1136/jmedgenet-2016-103943 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA EM7WS UT WOS:000395523600002 PM 27389779 ER PT J AU Hou, Y Lee, S Agrawal, V Romano, J Baldini, EH Chen, AB Kozono, DE Killoran, JH Wagar, M Hacker, FL Aerts, HJWL Lewis, JH Mak, RH AF Hou, Ying Lee, Stephanie Agrawal, Vishesh Romano, John Baldini, Elizabeth H. Chen, Aileen B. Kozono, David E. Killoran, Joseph H. Wagar, Matthew Hacker, Fred L. Aerts, Hugo J. W. L. Lewis, John H. Mak, Raymond H. TI Inter-scan and inter-observer tumour volume delineation variability on cone beam computed tomography in patients treated with stereotactic body radiation therapy for early-stage non-small cell lung cancer SO JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY LA English DT Article DE CBCT; inter-observer variability; inter-scan variability; NSCLC; SBRT ID PULMONARY NODULES; RADIOTHERAPY; CT; OUTCOMES AB IntroductionQuantification of volume changes on cone beam computed tomography (CBCT) during lung stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC) may provide a useful radiological marker for radiation response and for adaptive treatment planning. This study quantifies inter-scan and inter-observer variability in tumour volume delineation on CBCT. MethodsThree clinicians independently contoured the primary gross tumour volume (GTV) manually on CBCTs taken immediately before SBRT treatment (pre) and after the same SBRT treatment (post) for 19 NSCLC patients. Relative volume differences (RVD) were calculated between the pre- and post-CBCTs for a given treatment and between any two of three observers for a given CBCT. Coefficient of variation (CV) was used to quantitatively measure and compare the extent of variability. ResultsInter-observer variability had a significantly higher CV of 0.150.13 compared to inter-scan CV of 0.03 +/- 0.04 with P<0.0001. The greatest variability was observed with tumours (<2cm in diameter) versus larger tumours with 95% limit of agreement (LOA) (Mean +/- Standard Deviation) of 1.90%+/- 19.55% vs. -0.97%+/- 12.26% for inter-scan RVD and 29.99%+/- 73.84% vs. 9.37%+/- 29.95% for inter-observer RVD respectively. ConclusionsInter-observer variability was greater than inter-scan variability for tumour volume delineation on CBCT with greatest variability for small tumours (<2cm in diameter). LOA for inter-scan variability (similar to 12%) helps defines a threshold for clinically meaningful tumour volume change during SBRT treatment for tumours with diameter greater than 2cm, with larger thresholds needed for smaller tumours. C1 [Hou, Ying; Lee, Stephanie; Agrawal, Vishesh; Romano, John; Baldini, Elizabeth H.; Chen, Aileen B.; Kozono, David E.; Killoran, Joseph H.; Wagar, Matthew; Hacker, Fred L.; Aerts, Hugo J. W. L.; Lewis, John H.; Mak, Raymond H.] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Baldini, Elizabeth H.; Chen, Aileen B.; Kozono, David E.; Killoran, Joseph H.; Wagar, Matthew; Hacker, Fred L.; Aerts, Hugo J. W. L.; Lewis, John H.; Mak, Raymond H.] Harvard Med Sch, Boston, MA USA. RP Mak, RH (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, 450 Brookline Ave,JF518, Boston, MA 02115 USA. EM rmak@partners.org FU Kaye Award FX This work was funded in part by a Kaye Award. Accepted as a poster at AAPM 2015. NR 17 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1754-9477 EI 1754-9485 J9 J MED IMAG RADIAT ON JI J. Med. Imag. Radiat. Oncol. PD FEB PY 2017 VL 61 IS 1 BP 93 EP 98 DI 10.1111/1754-9485.12537 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EL9SL UT WOS:000394960300013 PM 27709803 ER PT J AU Chen, M Albuquerque, FC Hirsch, J Tarr, RW AF Chen, Michael Albuquerque, Felipe C. Hirsch, Joshua Tarr, Robert W. TI Improving the likelihood of manuscript acceptance; a primer for trainees and young investigators SO JOURNAL OF NEUROINTERVENTIONAL SURGERY LA English DT Editorial Material DE Political ID STROKE C1 [Chen, Michael] Rush Univ, Dept Neurol Sci, Med Ctr, Chicago, IL 60612 USA. [Albuquerque, Felipe C.] Barrow Neurol Inst, Div Neurol Surg, 350 W Thomas Rd, Phoenix, AZ 85013 USA. [Hirsch, Joshua] Massachusetts Gen Hosp, NeuroEndovasc Program, Boston, MA 02114 USA. [Tarr, Robert W.] Univ Hosp Case Med Ctr, Dept Radiol, Wright Patterson AFB, OH USA. RP Chen, M (reprint author), Rush Univ, Med Ctr, Dept Neurol Surg & Neurol Sci, 1725 West Harrison St,Suite 855, Chicago, IL 60612 USA. EM michael_chen@rush.edu NR 8 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1759-8478 EI 1759-8486 J9 J NEUROINTERV SURG JI J. NeuroInterventional Surg. PD FEB PY 2017 VL 9 IS 2 BP 115 EP 116 DI 10.1136/neurintsurg-2015-011670 PG 2 WC Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA EL4TS UT WOS:000394614400007 PM 25665983 ER PT J AU Nogueira, RG Kemmling, A Souza, LM Payabvash, S Hirsch, JA Yoo, AJ Lev, MH AF Nogueira, Raul G. Kemmling, Andre Souza, Leticia M. Payabvash, Seyedmehdi Hirsch, Joshua A. Yoo, Albert J. Lev, Michael H. TI Clinical diffusion mismatch better discriminates infarct growth than mean transit time-diffusion weighted imaging mismatch in patients with middle cerebral artery-M1 occlusion and limited infarct core SO JOURNAL OF NEUROINTERVENTIONAL SURGERY LA English DT Article DE Stroke; CT perfusion; Thrombectomy; MRI; Thrombolysis ID EVALUATION TRIAL EPITHET; ACUTE STROKE; ISCHEMIC-STROKE; COMPUTED-TOMOGRAPHY; MAGNETIC-RESONANCE; POOLED ANALYSIS; DWI MISMATCH; REPERFUSION; SELECTION; THERAPY AB Background and purpose Our purpose was to compare clinical diffusion mismatch (CDM) and mean transit time (MTT)-diffusion mismatch as predictors of infarct growth in patients with proximal middle cerebral artery (MCA) occlusion and small infarct core on presentation. Methods Retrospective analysis of consecutive stroke patients with: (1) MCA-M1 occlusion; (2) MRI performed 10h from symptoms onset; and (3) baseline MRI-diffusion weighted imaging (DWI) volume 25mL. Definitions included: CDM=baseline National Institutes of Health Stroke Scale (NIHSS) score 8 and DWI volume 25mL; MTT-DWI mismatch=visually assessed unthresholded MTT lesion ((MTT-DWI))/DWI) 20% and 10mL larger than the DWI lesion; and significant infarct growth (>20% (5mL) increase in infarct volume on follow-up). Uni-/multivariate analyses were performed to define the predictors of infarct growth. Results 63 stroke patients with MCA-M1 occlusions and MRI within 10h of onset were evaluated. 20 patients were excluded on the basis of DWI volume >25mL leaving 43 patients (mean age 75.8years; median NIHSS=13) in the study cohort. On univariate analysis, larger admission DWI volume (p<0.0001), baseline NIHSS score 8 (p=0.001), lack of IV and/or endovascular treatment (p=0.021), glucose levels >125mg/dL (p=0.024), poor CT angiography collaterals (p=0.046), and lower admission Alberta Stroke Program Early CT score (ASPECTS) (p=0.049) predicted infarct growth. Baseline NIHSS score 8 was the only independent predictor of stroke growth in the multivariate analysis (p=0.001). All patients had MTT-DWI mismatch >20%. There was no significant association between the amount of MTT-DWI mismatch and infarct growth (p=0.33). Conclusions CDM is the most powerful predictor of infarct growth in patients with MCA-M1 occlusion and small infarct core. Most of these patients will have a significant oligemic MTT lesion regardless of admission NIHSS score. C1 [Nogueira, Raul G.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA. [Nogueira, Raul G.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Nogueira, Raul G.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA. [Nogueira, Raul G.] Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA. [Kemmling, Andre; Souza, Leticia M.; Payabvash, Seyedmehdi; Hirsch, Joshua A.; Yoo, Albert J.; Lev, Michael H.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neuroradiol, Boston, MA USA. RP Nogueira, RG (reprint author), Emory Fac Off Bldg,80 Jesse Hill Dr SE,Room 333, Atlanta, GA 30303 USA. EM rnoguei@emory.edu FU Penumbra Inc.; GE Healthcare FX RGN: principal investigator for the TREVO-2 and DAWN trials (Stryker Neurovascular); steering committee member of the SWIFT and SWIFT-Prime Trials, Core Lab of the STAR Trial (Covidien/ev3 Neurovascular), and executive committee member of the 3D Separator Trial (Penumbra). AJY: research grant from Penumbra Inc. MHL: research support from GE Healthcare, and consultant to CoAxia, GE Healthcare, and Millennium Pharmaceuticals. NR 21 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1759-8478 EI 1759-8486 J9 J NEUROINTERV SURG JI J. NeuroInterventional Surg. PD FEB PY 2017 VL 9 IS 2 BP 127 EP 130 DI 10.1136/neurintsurg-2014-011602 PG 4 WC Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA EL4TS UT WOS:000394614400010 PM 26957483 ER PT J AU Deipolyi, A Bailin, A Hirsch, JA Walker, TG Oklu, R AF Deipolyi, Amy Bailin, Alexander Hirsch, Joshua A. Walker, T. Gregory Oklu, Rahmi TI Bilateral inferior petrosal sinus sampling: experience in 327 patients SO JOURNAL OF NEUROINTERVENTIONAL SURGERY LA English DT Article DE Angiography; Catheter; Technique; MRI; Tumor ID DEPENDENT CUSHINGS-SYNDROME; DIFFERENTIAL-DIAGNOSIS; PITUITARY; DISEASE; DESMOPRESSIN; HORMONE AB Objective To describe findings and outcomes of 331 bilateral inferior petrosal sinus sampling (BIPSS) procedures performed in 327 patients evaluated for Cushing disease (CD). Materials and methods The radiology department's electronic database was searched to identify all BIPSS procedures (1990-2013). Electronic medical records were used to identify demographics, laboratory, procedural, surgical and pathologic findings. Results A total of 331 BIPSS procedures were performed in 327 patients (254 F, 73 M), mean age 41 (range 7-81) years. The overall technical success rate was 88% for bilateral cannulation, though nearly two-thirds of the technical failures had unilateral sampling that diagnosed CD. Of the 331 BIPSS procedures, 40 were performed without, and 291 with stimulation by Acthrel or desmopressin. Sensitivity was 89-94% for unstimulated BIPSS, 96% for stimulated BIPSS, and 77% for MRI. BIPSS lateralization was accurate in about half of patients, compared with 75% accuracy for MRI. Mean inferior petrosal sinus (IPS):peripheral adrenocorticotropic hormone ratio was 17.3 (SE 1.8) at baseline, and 99.2 (SE 14.8) at 3min, with decreasing values over time. All patients with follow-up after surgical resection for centralizing BIPSS were reported to be cured, with cortisol levels significantly decreased from 19 to 4g/dL (p<0.0001). Complications from BIPSS were rare, including groin hematoma (2.5%), but no thromboembolic complications were seen. Conclusions BIPSS remains the gold standard' for diagnosing CD. Stimulation with Acthrel or desmopressin is key to increasing specificity. When only one IPS can be successfully cannulated, results may still be diagnostic. BIPSS findings cannot be used to accurately lateralize lesions within the pituitary. C1 [Deipolyi, Amy] NYU, Med Ctr, Dept Radiol, Div Vasc & Intervent Radiol, New York, NY 10016 USA. [Bailin, Alexander; Walker, T. Gregory] Harvard Med Sch, Massachusetts Gen Hosp, Vasc & Intervent Radiol, Boston, MA USA. [Hirsch, Joshua A.] Harvard Med Sch, Massachusetts Gen Hosp, Div Intervent Neuroradiol, Boston, MA USA. [Oklu, Rahmi] Mayo Clin, Vasc & Intervent Radiol, Scottsdale, AZ USA. [Oklu, Rahmi] Harvard Med Sch, Biomaterials Innovat Res Ctr, Brigham & Womens Hosp, Dept Med, Cambridge, MA USA. Mayo Clin, Div Intervent Radiol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA. RP Oklu, R (reprint author), Mayo Clin, Div Intervent Radiol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA. EM oklu.rahmi@mayo.edu OI Deipolyi, Amy/0000-0003-3144-386X NR 17 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1759-8478 EI 1759-8486 J9 J NEUROINTERV SURG JI J. NeuroInterventional Surg. PD FEB PY 2017 VL 9 IS 2 BP 196 EP 199 DI 10.1136/neurintsurg-2015-012164 PG 4 WC Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA EL4TS UT WOS:000394614400024 PM 26880723 ER PT J AU Hirsch, JA Fargen, K Ducruet, AF Tarr, RW AF Hirsch, Joshua A. Fargen, Kyle Ducruet, Andrew F. Tarr, Robert W. TI JNIS podcasts: the early part of our journey SO JOURNAL OF NEUROINTERVENTIONAL SURGERY LA English DT Article DE Technology ID ACUTE ISCHEMIC-STROKE; TRIALS AB Podcasts are an area of innovation in the neurointerventional space that has the potential to convey information in ways that traditional journal articles in peer-reviewed journals do not. BMJ maintains an archive of all of its podcasts on the Journal of NeuroInterventional Surgery (JNIS) website. We sought to analyze this early JNIS podcast experience and assess the impact of content elements and an increased presence in social media. C1 [Hirsch, Joshua A.] Massachusetts Gen Hosp, NeuroEndovasc Program, Boston, MA 02114 USA. [Fargen, Kyle] Med Univ South Carolina, Dept Neurosurg, Charleston, SC USA. [Ducruet, Andrew F.] UPMC, Dept Neurosurg, Pittsburgh, PA USA. [Tarr, Robert W.] Univ Hosp Case Med Ctr, Dept Radiol, Cleveland, OH USA. RP Hirsch, JA (reprint author), Massachusetts Gen Hosp, NeuroEndovasc Program, Boston, MA 02114 USA. EM hirsch@snisonline.org NR 11 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1759-8478 EI 1759-8486 J9 J NEUROINTERV SURG JI J. NeuroInterventional Surg. PD FEB PY 2017 VL 9 IS 2 BP 211 EP 214 DI 10.1136/neurintsurg-2015-012170 PG 4 WC Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA EL4TS UT WOS:000394614400027 PM 26763788 ER PT J AU Fargen, KM Ducruet, AF Hyer, M Hirsch, JA Tarr, RW AF Fargen, Kyle M. Ducruet, Andrew F. Hyer, Madison Hirsch, Joshua A. Tarr, Robert W. TI Expanding the social media presence of the Journal of Neurointerventional Surgery: editor's report SO JOURNAL OF NEUROINTERVENTIONAL SURGERY LA English DT Article DE Economics; Technology ID IMPACT AB The use of social media is pervasive throughout society and serves many purposes. Traditional forms of advertising are being upended as vendors recognize the unique abilities of social media platforms to target their messages to specific customers. Peer reviewed medical and professional journals are beginning to develop their own initiatives using social media to advertize unique content. We present the nascent Journal of NeuroInterventional Surgery experience. C1 [Fargen, Kyle M.; Hyer, Madison] Med Univ South Carolina, Dept Neurosurg, Charleston, SC USA. [Ducruet, Andrew F.] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA. [Hirsch, Joshua A.] Harvard Med Sch, Massachusetts Gen Hosp, Neuroendovasc Serv, Boston, MA USA. [Tarr, Robert W.] Univ Hosp Case Med Ctr, Dept Radiol, Cleveland, OH USA. RP Fargen, KM (reprint author), 96 Jonathan Lucas St,CSB 301, Charleston, SC 29425 USA. EM Fargen@musc.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1759-8478 EI 1759-8486 J9 J NEUROINTERV SURG JI J. NeuroInterventional Surg. PD FEB PY 2017 VL 9 IS 2 BP 215 EP 218 DI 10.1136/neurintsurg-2015-012251 PG 4 WC Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA EL4TS UT WOS:000394614400028 PM 26927814 ER PT J AU Mulvey, TM Peppercorn, J AF Mulvey, Therese Marie Peppercorn, Jeffrey TI Capturing High-Value Cancer Care in the Wild SO JOURNAL OF ONCOLOGY PRACTICE LA English DT Editorial Material ID AMERICAN SOCIETY; FRAMEWORK C1 [Mulvey, Therese Marie; Peppercorn, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Mulvey, TM (reprint author), 102 Endicott St, Danvers, MA 01923 USA. EM tmmulvey@partners.org FU Pfizer FX Pfizer NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 1554-7477 EI 1935-469X J9 J ONCOL PRACT JI J. Oncol. Pract. PD FEB 1 PY 2017 VL 13 IS 2 BP 67 EP + DI 10.1200/JOP.2016.019430 PG 3 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EP3LD UT WOS:000397282900002 ER PT J AU Ferrell, BR Temel, JS Temin, S Smith, TJ AF Ferrell, Betty R. Temel, Jennifer S. Temin, Sarah Smith, Thomas J. TI Integration of Palliative Care Into Standard Oncology Care: ASCO Clinical Practice Guideline Update Summary SO JOURNAL OF ONCOLOGY PRACTICE LA English DT Editorial Material ID CANCER AMERICAN SOCIETY; CELL LUNG-CANCER C1 City Hope Med Ctr, Duarte, CA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ferrell, Betty R.] Amer Soc Clin Oncol, 2318 Mill Rd,Ste 800, Alexandria, VA 22314 USA. Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. RP Ferrell, BR (reprint author), Amer Soc Clin Oncol, 2318 Mill Rd,Ste 800, Alexandria, VA 22314 USA. EM guidelines@asco.org FU Helsinn Therapeutics (Inst); Pfizer (Inst) FX Helsinn Therapeutics (Inst), Pfizer (Inst) NR 9 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 1554-7477 EI 1935-469X J9 J ONCOL PRACT JI J. Oncol. Pract. PD FEB 1 PY 2017 VL 13 IS 2 BP 119 EP + DI 10.1200/JOP.2016.017897 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EP3LD UT WOS:000397282900019 ER PT J AU Neuss, M Rocque, G Zuckerman, D Chiang, A Katta, S Wollins, D Kamin, D Edge, S AF Neuss, Michael Rocque, Gabrielle Zuckerman, Dan Chiang, Anne Katta, Sweatha Wollins, Dana Kamin, Deborah Edge, Stephen TI Establishing a Core Set of Performance Measures to Improve Value in Cancer Care: ASCO Consensus Conference Recommendation Report SO JOURNAL OF ONCOLOGY PRACTICE LA English DT Editorial Material ID UNITED-STATES C1 Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Univ Alabama Birmingham, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. St Lukes Mt States Tumor Inst, Boise, ID USA. Amer Soc Clin Oncol, Alexandria, VA USA. Roswell Pk Canc Inst, Buffalo, NY USA. RP Neuss, M (reprint author), Michael Neuss, 2220 Pierce Ave, Nashville, MD USA.; Rocque, G (reprint author), 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA. EM michael.n.neuss@vanderbilt.edu; cancerpolicy@asco.org FU PackHealth; Medscape; Carevive Systems; Genentech; OncoMed; Millennium; Onyx; Boehringer Ingelheim; Eli Lilly; Bristol Myers Squibb; Medivation FX PackHealth, Medscape, Carevive Systems, Genentech; OncoMed, Millennium, Onyx, Boehringer Ingelheim, Eli Lilly, Bristol Myers Squibb, Medivation NR 7 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 1554-7477 EI 1935-469X J9 J ONCOL PRACT JI J. Oncol. Pract. PD FEB 1 PY 2017 VL 13 IS 2 BP 135 EP + DI 10.1200/JOP.2016.017954 PG 10 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EP3LD UT WOS:000397282900022 ER PT J AU Fell, GL Cho, BS Pan, A Nose, V Anez-Bustillos, L Dao, DT Baker, MA Nandivada, P Gura, KM Puder, M AF Fell, Gillian L. Cho, Bennet S. Pan, Amy Nose, Vania Anez-Bustillos, Lorenzo Dao, Duy T. Baker, Meredith A. Nandivada, Prathima Gura, Kathleen M. Puder, Mark TI A Comparison of Fish Oil Sources for Parenteral Lipid Emulsions in a Murine Model SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article DE parenteral lipid emulsions; fish oil; parenteral nutrition-associated liver disease; intestinal failure; USP 729 ID INJECTABLE EMULSIONS; LIVER AB Background: Fat emulsions are important components of parenteral nutrition (PN). Fish oil (FO) emulsions reverse cholestasis in PN-associated liver disease. There are 2 FO monographs. One is FO; rich in omega-3 fatty acids (NFO). The other, omega-3 acids, (PFO), is enriched in omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The purpose of this study is to compare the effects of 20% NFO and PFO emulsions produced in the laboratory in a murine model. Methods: Emulsions were compounded containing different oils: soybean oil (SO), NFO, and two PFOs differing in percentage of fatty acids as triglycerides (PFO66 and PFO90). Chow-fed mice received saline, one of the above emulsions, or a commercial FO (OM) intravenously (2.4 g/kg/day) for 19 days. On day 19, animals were euthanized. Livers, spleens, and lungs were procured for histologic analysis. Results: OM, SO, NFO, and PFO90 were well-tolerated clinically. PFO66 resulted in tachypnea and lethargy for 1 minute following injections. At euthanasia, PFO66 and PFO90 groups had organomegaly. Histologically, these groups had splenic and hepatic fat-laden macrophages, and lungs had scattered fat deposits. Other groups had normal organs. Conclusions: PFO emulsions present an attractive possibility for improving inflammation in PN-dependent patients by concentrating anti-inflammatory EPA and DHA. However, 20% PFO emulsions were poorly tolerated and precipitated adverse end organ sequelae, suggesting that they may not be safe. Development of novel manufacturing methods may achieve safe 20% PFO parenteral emulsions, but by established formulation methods, these emulsions were clinically suboptimal despite meeting pharmacopeial standards. C1 [Fell, Gillian L.; Cho, Bennet S.; Pan, Amy; Anez-Bustillos, Lorenzo; Dao, Duy T.; Baker, Meredith A.; Puder, Mark] Boston Childrens Hosp, Vasc Biol Program, 300 Longwood Ave,Fegan 3, Boston, MA 02115 USA. [Fell, Gillian L.; Cho, Bennet S.; Pan, Amy; Anez-Bustillos, Lorenzo; Dao, Duy T.; Baker, Meredith A.; Puder, Mark] Boston Childrens Hosp, Dept Surg, 300 Longwood Ave,Fegan 3, Boston, MA 02115 USA. [Nose, Vania] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Nandivada, Prathima] Beth Israel Deaconess Med Ctr, Dept Surg, 330 Brookline Ave, Boston, MA 02215 USA. [Gura, Kathleen M.] Boston Childrens Hosp, Dept Pharm, Boston, MA USA. RP Puder, M (reprint author), Boston Childrens Hosp, Vasc Biol Program, 300 Longwood Ave,Fegan 3, Boston, MA 02115 USA.; Puder, M (reprint author), Boston Childrens Hosp, Dept Surg, 300 Longwood Ave,Fegan 3, Boston, MA 02115 USA. EM mark.puder@childrens.harvard.edu OI Baker, Meredith/0000-0002-9947-9546 FU Boston Children's Hospital Surgical Foundation; National Institutes of Health (NIH) [1F32DK104525-01]; Joshua Ryan Rappaport Fellowship; NIH [5T32HL007734-22, T35HL110843] FX The NFO, PFO66, and PFO90 oils used in this study were generously donated by Pronova Biopharma (all contributors). The Boston Children's Hospital Surgical Foundation provided funding for this study (all contributors). BASF provided funding for this study (all contributors). G.L. Fell received funding through the National Institutes of Health (NIH; grant 1F32DK104525-01). P. Nandivada received funding through the Joshua Ryan Rappaport Fellowship. M.A. Baker received funding through the NIH (grant 5T32HL007734-22). B.S. Cho received funding through the NIH (grant T35HL110843). NR 23 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 EI 1941-2444 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD FEB PY 2017 VL 41 IS 2 BP 181 EP 187 DI 10.1177/0148607116640275 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA EL8UW UT WOS:000394896800006 PM 26993989 ER PT J AU Kudsk, KA Munoz-del-Rio, A Busch, RA Kight, CE Schoeller, DA AF Kudsk, Kenneth A. Munoz-del-Rio, Alejandro Busch, Rebecca A. Kight, Cassandra E. Schoeller, Dale A. TI Stratification of Fat-Free Mass Index Percentiles for Body Composition Based on National Health and Nutrition Examination Survey III Bioelectric Impedance Data SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article DE nutrition assessment; nutrition; outcomes research; quality; nutrition support practice; adult; life cycle ID LENGTH-OF-STAY; HOSPITAL ADMISSION; POSTOPERATIVE COMPLICATIONS; NHANES-III; MALNUTRITION; OUTCOMES; CANCER; RISK; SURGERY; IMPACT AB Background: Loss of protein mass and lower fat-free mass index (FFMI) are associated with longer length of stay, postsurgical complications, and other poor outcomes in hospitalized patients. Normative data for FFMI of U.S. populations do not exist. This work aims to create a stratified FFMI percentile table for the U.S. population using the large bioelectric impedance analysis data obtained from National Health and Nutrition Examination Surveys (NHANES). Methods: Fat-free mass (FFM) was calculated from the NHANES III bioelectric impedance analysis and anthropometric data for males and females ages 12 to >90 years for 3 race/ethnicities (non-Hispanic white, non-Hispanic black, and Mexican American). FFM was normalized by subject height to create an FFMI distribution table for the U.S. population. Selected percentiles were obtained by age, sex, and race/ethnicity. Data were collapsed by race/ethnicity before and after removing obese and underweight participants to create an FFMI decile table for males and females 12 years and older for the healthy-weight U.S. population. Results: FFMI increased during adolescent growth but stabilized in the early 20s. The FFMI deciles were similar by race/ethnicity, with age group remaining relatively stable between ages 25 and 80 years. The FFMI deciles for males and females were significantly different. Conclusions: After eliminating the obese and extremely thin, FFMI percentiles remain stable during adult years allowing creation of age- and race/ethnicity-independent decile tables for males and females. These tables allow stratification of individuals for nutrition intervention trials to depict changing nutrition status during medical, surgical, and nutrition interventions. C1 [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. [Kudsk, Kenneth A.; Munoz-del-Rio, Alejandro; Busch, Rebecca A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. [Munoz-del-Rio, Alejandro] Univ Wisconsin, Dept Radiol, Madison, WI 53706 USA. [Munoz-del-Rio, Alejandro] Univ Wisconsin, Dept Med Phys, 1530 Med Sci Ctr, Madison, WI 53706 USA. [Kight, Cassandra E.] Univ Wisconsin Hosp & Clin, Clin Nutr Serv, Madison, WI 53792 USA. [Schoeller, Dale A.] Univ Wisconsin, Dept Nutr Sci, 1415 Linden Dr, Madison, WI 53706 USA. RP Kudsk, KA (reprint author), William S Middleton Mem Vet Adm Med Ctr, Clin Sci Ctr G5 341, 600 Highland Ave, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU National Institutes of Health Surgical Oncology Research Training Program [T32CA090217] FX The project described was supported in part by the National Institutes of Health Surgical Oncology Research Training Program (grant number T32CA090217; to R.A.B.). This material is the result of work supported with the resources and use of facilities at the William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin. The contents of this article do not represent the views of the Department of Veterans Affairs or the U.S. government. NR 35 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 EI 1941-2444 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD FEB PY 2017 VL 41 IS 2 BP 249 EP 257 DI 10.1177/0148607115592672 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA EL8UW UT WOS:000394896800013 PM 26092851 ER PT J AU Neumeyer, AM Sokoloff, NC McDonnell, E Macklin, EA McDougle, CJ Misra, M AF Neumeyer, Ann M. Sokoloff, Natalia Cano McDonnell, Erin Macklin, Eric A. McDougle, Christopher J. Misra, Madhusmita TI Bone Accrual in Males with Autism Spectrum Disorder SO JOURNAL OF PEDIATRICS LA English DT Article ID MINERAL DENSITY; PHYSICAL-ACTIVITY; MUSCLE STRENGTH; GASTROINTESTINAL SYMPTOMS; SEX STEROIDS; YOUNG-ADULTS; VITAMIN-D; CHILDREN; ADOLESCENTS; CHILDHOOD AB Objective To test the hypothesis that bone accrual over a 4-year period is reduced in boys with autism spectrum disorder (ASD) compared with typically developing controls. Study design Twenty-five boys with ASD and 24 controls were assessed for bone outcomes. Fourteen boys with ASD and 11 controls were assessed both at baseline and after 4 years. The mean subject age was 11.0 +/- 1.6 years at study initiation and 14.9 +/- 1.6 years at follow-up. Bone mineral density (BMD) was measured at the spine, hip, and whole body using dual-energy X-ray absorptiometry and normalized for age, race, and sex (BMD z-scores). Height adjustments were performed as well. We assessed medical history, physical activity using questionnaires, vitamin D and calcium intake using food records, and serum calcium, phosphorus, 25(OH)-vitamin D, and pubertal hormone levels. Results Boys with ASD had lower spine, hip, and whole body BMD z-scores compared with controls. In those subjects assessed both at baseline and after 4 years, bone accrual rates did not differ between the 2 groups; however, spine and hip BMD z-scores remained lower in the boys with ASD than in controls at follow-up. Notably, the ASD group was less physically active at both time points. Conclusion Although pubertal bone accrual was similar to that in controls, BMD in children with ASD remained low over a 4-year follow-up period, suggesting that low BMD is a consequence of prepubertal factors, such as low physical activity. Studies are needed to investigate the causes and consequences of decreased BMD, to assess BMD in females and adults with ASD, and to evaluate therapeutic interventions. C1 [Neumeyer, Ann M.; Sokoloff, Natalia Cano; McDougle, Christopher J.] Massachusetts Gen Hosp, Lurie Ctr Autism, Lexington, MA 02421 USA. [Neumeyer, Ann M.; Macklin, Eric A.; McDougle, Christopher J.] Harvard Med Sch, Boston, MA USA. [McDonnell, Erin; Macklin, Eric A.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [Misra, Madhusmita] Massachusetts Gen Hosp, Pediat Endocrine Unit, Boston, MA 02114 USA. [Misra, Madhusmita] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA. RP Neumeyer, AM (reprint author), MassGeneral Hosp Children, Lurie Ctr, 1 Maguire Rd, Lexington, MA 02421 USA. EM aneumeyer@mgh.harvard.edu FU NCATS NIH HHS [KL2 TR001100]; NCRR NIH HHS [UL1 RR025758]; NICHD NIH HHS [K24 HD071843] NR 39 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD FEB PY 2017 VL 181 BP 195 EP + DI 10.1016/j.jpeds.2016.10.080 PG 13 WC Pediatrics SC Pediatrics GA EN8KL UT WOS:000396249200031 PM 27887681 ER PT J AU Shellhaas, RA Chang, T Wusthoff, CJ Soul, JS Massey, SL Chu, CJ Cilio, MR Bonifacio, SL Abend, NS Tsuchida, TN Glass, HC AF Shellhaas, Renee A. Chang, Taeun Wusthoff, Courtney J. Soul, Janet S. Massey, Shavonne L. Chu, Catherine J. Cilio, M. Roberta Bonifacio, Sonia L. Abend, Nicholas S. Tsuchida, Tammy N. Glass, Hannah C. CA Neonatal Seizure Registry Study Gr TI Treatment Duration After Acute Symptomatic Seizures in Neonates: A Multicenter Cohort Study SO JOURNAL OF PEDIATRICS LA English DT Article ID ARTERIAL ISCHEMIC-STROKE; VARIABILITY; RECURRENCE; OUTCOMES AB We aimed to define determinants of duration of treatment for acute symptomatic neonatal seizures in a contemporary multicenter observational cohort study. After adjustment for potential confounders, only study site and seizure etiology remained significantly associated with the chance of continuing antiseizure medication after discharge to home. C1 [Shellhaas, Renee A.] Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA. [Chang, Taeun; Tsuchida, Tammy N.] George Washington Univ, Sch Med, Dept Neurol, Childrens Natl Hlth Syst, Washington, DC USA. [Wusthoff, Courtney J.; Bonifacio, Sonia L.] Stanford Univ, Dept Neurol, Palo Alto, CA 94304 USA. [Wusthoff, Courtney J.; Bonifacio, Sonia L.] Stanford Univ, Dept Pediat, Palo Alto, CA 94304 USA. [Soul, Janet S.] Boston Childrens Hosp, Dept Neurol, Boston, MA USA. [Massey, Shavonne L.; Abend, Nicholas S.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Massey, Shavonne L.; Abend, Nicholas S.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Chu, Catherine J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Cilio, M. Roberta; Glass, Hannah C.] Univ Calif San Francisco, Dept Neurol, Benioff Childrens Hosp, San Francisco, CA USA. [Cilio, M. Roberta; Glass, Hannah C.] Univ Calif San Francisco, Dept Pediat, Benioff Childrens Hosp, San Francisco, CA USA. [Glass, Hannah C.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Shellhaas, RA (reprint author), CS Mott Childrens Hosp, Pediat Neurol, Room 12-733,1540 E Hosp Dr, Ann Arbor, MI 48109 USA. EM shellhaa@med.umich.edu FU Pediatric Epilepsy Research Foundation; National Institutes of Health (NIH) [R21HD083409]; American Sleep Medicine Foundation; Patient-Centered Outcomes Research Institute [2015C2-1507-31187]; Thrasher Foundation; Cerebral Palsy International Research Foundation; NIH [R01 HD076258, R01 NS066929, K23 NS092923, K23 NS076550, K23 NS66137]; Boston Children's Hospital Intellectual and Developmental Disabilities Research Center; Epilepsy Foundation; Citizens United for Research in Epilepsy; Cerebral Palsy Alliance [PG2314]; Patient-Centered Outcomes Research Institute FX Supported by the Pediatric Epilepsy Research Foundation. R.S. receives support from the National Institutes of Health (NIH; R21HD083409), the American Sleep Medicine Foundation, Patient-Centered Outcomes Research Institute (2015C2-1507-31187), and the Pediatric Epilepsy Research Foundation; serves as a consultant for the Epilepsy Study Consortium; and receives honoraria from UpToDate. T.C. receives support from the Pediatric Epilepsy Research Foundation, the Thrasher Foundation, and the Cerebral Palsy International Research Foundation. J.S. receives support from NIH (R01 HD076258 and R01 NS066929) and Boston Children's Hospital Intellectual and Developmental Disabilities Research Center. C.C. receives research support from NIH (K23 NS092923) and the Pediatric Epilepsy Research Foundation. S.B. receives support from NIH. N.A. receives support from NIH (K23 NS076550) and the Pediatric Epilepsy Research Foundation. T.T. receives support from the Epilepsy Foundation, Citizens United for Research in Epilepsy, and NIH. H.G. receives support from NIH (K23 NS66137), the Cerebral Palsy Alliance (PG2314), Patient-Centered Outcomes Research Institute, and the Pediatric Epilepsy Research Foundation. The authors declare no conflicts of interest. NR 15 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD FEB PY 2017 VL 181 BP 298 EP + DI 10.1016/j.jpeds.2016.10.039 PG 5 WC Pediatrics SC Pediatrics GA EN8KL UT WOS:000396249200048 PM 27829512 ER PT J AU Ellinger, RL Jakien, KM Gallun, FJ AF Ellinger, Rachel L. Jakien, Kasey M. Gallun, Frederick J. TI The role of interaural differences on speech intelligibility in complex multi- talker environments SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article ID MASKING-LEVEL DIFFERENCES; CANCELLATION THEORY; TIME DIFFERENCES; EQUALIZATION; INTENSITY; RELEASE; PHASE AB Interaural differences in time (ITDs) and interaural differences in level (ILDs) contribute to a listener's ability to achieve spatial release from masking (SRM), and help to improve speech intelligibility in noisy environments. In this study, the extent to which ITDs and ILDs contribute to SRM and the relationships with aging and hearing loss were examined. SRM was greatest when stimuli were presented with consistent ITD and ILD, relative to ITD or ILD alone, all of which produced greater SRM than when ITD and ILD cues were in conflict with each other. This pattern was independent of age and hearing loss. C1 [Ellinger, Rachel L.; Jakien, Kasey M.; Gallun, Frederick J.] US Dept Vet Affairs, Natl Ctr Rehabilitat Auditory Res, VA Portland Hlth Care Syst, 3710 Southwest US Vet Hosp Rd,P5 NCRAR, Portland, OR 97239 USA. [Ellinger, Rachel L.] Northwestern Univ, Commun Sci & Disorders Dept, 2240 Campus Dr, Evanston, IL 60208 USA. [Jakien, Kasey M.; Gallun, Frederick J.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. RP Gallun, FJ (reprint author), US Dept Vet Affairs, Natl Ctr Rehabilitat Auditory Res, VA Portland Hlth Care Syst, 3710 Southwest US Vet Hosp Rd,P5 NCRAR, Portland, OR 97239 USA. EM RachelEllinger@gmail.com; Kasey.Jakien@va.gov; Frederick.Gallun@va.gov FU National Institutes of Health/National Institute on Deafness and Other Communication Disorders (NIH/NIDCD) [R01 DC011828]; Department of Veterans Affairs Rehabilitation Research & Development Service; Reed College Department of Psychology FX Thank you to all of the participants who volunteered their time to be involved in this experiment. Thank you to Sean Kampel, Meghan Stansell, and Nirmal Srinivasan for help with data collection, Kathryn Oleson for help with data analysis, and Enriqueta CansecoGonzalez for advisement while working on this experiment and the thesis document. This work was supported by National Institutes of Health/National Institute on Deafness and Other Communication Disorders (NIH/NIDCD; R01 DC011828), Department of Veterans Affairs Rehabilitation Research & Development Service (VA RR&D), and Reed College Department of Psychology. The contents of this article are the private views of the authors and should not be assumed to represent the views of the Department of Veterans Affairs or the United States Government. NR 16 TC 0 Z9 0 U1 0 U2 0 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 EI 1520-8524 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD FEB PY 2017 VL 141 IS 2 BP EL170 EP EL176 DI 10.1121/1.4976113 PG 7 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA EM4VD UT WOS:000395310100015 PM 28253635 ER PT J AU Folmer, RL Vachhani, J McMillan, GP Watson, C Kidd, GR Feeney, MP AF Folmer, Robert L. Vachhani, Jay McMillan, Garnett P. Watson, Charles Kidd, Gary R. Feeney, M. Patrick TI Validation of a Computer-Administered Version of the Digits-in-Noise Test for Hearing Screening in the United States SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Article DE assessment; computer -administered; digits-in-noise; hearing screening; hearing test ID QUALITY-OF-LIFE; OLDER-ADULTS; COGNITIVE DYSFUNCTION; HANDICAP INVENTORY; TELEPHONE; IMPAIRMENT; MILD; INTELLIGIBILITY; DEMENTIA; PEOPLE AB Background: The sooner people receive treatment for hearing loss (HL), the quicker they are able to recognize speech and to master hearing aid technology. Unfortunately, a majority of people with HL wait until their impairments have progressed from moderate to severe levels before seeking auditory rehabilitation. To increase the number of individuals with HL who pursue and receive auditory rehabilitation, it is necessary to improve methods for identifying and informing these people via widely accessible hearing screening procedures. Screening for HL is the first in a chain of events that must take place to increase the number of patients who enter the hearing health-care system. New methods for hearing screening should be readily accessible through a common medium (e.g., telephone or computer) and should be relatively easy and quick for people to self-administer. Purpose: The purpose of this study was to assess a digits-in-noise (DIN) hearing screening test that was delivered via personal computer. Research Design: Participants completed the Hearing Handicap Inventory for Adults (HHIA) questionnaire, audiometric testing in a sound booth, and computerized DIN testing. During the DIN test, sequences of three spoken digits were presented in noise via headphones at varying signal-to-noise ratios (SNRs). Participants entered each three-digit sequence they heard using an on-screen keypad. Study Sample: Forty adults (16 females, 24 males) participated in the study, of whom 20 had normal hearing and 20 had HL (pure-tone average [PTA] thresholds for 0.5, 1, 2, and 4 kHz >25 dB HL). Data Collection and Analysis: DIN SNR and PTA data were analyzed and compared for each ear tested. Receiver operating characteristic curves based on these data were plotted. A measure of overall accuracy of a screening test is the area under the receiver operating characteristic curve (AUC). This measures the average true positive rate across false positives at varying DIN SNR cutoffs. Larger values of the AUC indicate, on average, more accurate screening tests. HHIA responses were analyzed and compared to PTA and DIN SNR results using Pearson correlation statistics. Results: HHIA scores were positively correlated with audiometric PTA and DIN SNR results (p < 0.001 for all correlations). For an HL criterion of one or more frequencies from 0.25 to 8 kHz >25 dB HL, the AUC for the DIN test was 0.95. When a criterion of hearling level was set at one or more frequencies from 0.25 to 8 kHz >20 dB HL, the AUC for the DIN test was 0.96. Conclusions: The computer version of the DIN test demonstrated excellent sensitivity and specificity for our sample of 40 participants. AUC results (>= 0.95) suggest that this DIN test administered via computer should be very useful for adult hearing screening. C1 [Folmer, Robert L.; Vachhani, Jay; McMillan, Garnett P.; Feeney, M. Patrick] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA. [Folmer, Robert L.; Feeney, M. Patrick] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. [McMillan, Garnett P.] Oregon Hlth & Sci Univ, Dept Prevent Med, Portland, OR 97201 USA. [Watson, Charles] Commun Disorders Technol Inc, Bloomington, IN USA. [Kidd, Gary R.] Indiana Univ, Bloomington, IN USA. RP Folmer, RL (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA. EM robert.folmer@va.gov FU NIH/NIDCD [R21 DC011769 01]; VA National Center for Rehabilitative Auditory Research - VA RR&D Center of Excellence at Portland VA Medical Center [C9230C] FX This research was supported by grant R21 DC011769 01 from NIH/NIDCD. Additional support was provided by the VA National Center for Rehabilitative Auditory Research (funded by VA RR&D Center of Excellence grant C9230C) at Portland VA Medical Center. NR 39 TC 0 Z9 0 U1 1 U2 1 PU AMER ACAD AUDIOLOGY PI RESTON PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA SN 1050-0545 EI 2157-3107 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD FEB PY 2017 VL 28 IS 2 BP 161 EP 169 DI 10.3766/jaaa.16038 PG 9 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA EL2VL UT WOS:000394478500007 PM 28240983 ER PT J AU Brink, JA AF Brink, James A. TI Is Achieving "Just Culture" Just Culture, or Something More? SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material C1 [Brink, James A.] Massachusetts Gen Hosp, 55 Fruit St,FND 216, Boston, MA 02114 USA. RP Brink, JA (reprint author), Massachusetts Gen Hosp, 55 Fruit St,FND 216, Boston, MA 02114 USA. EM jabrink@partners.org NR 3 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD FEB PY 2017 VL 14 IS 2 BP 143 EP 144 DI 10.1016/j.jacr.2016.12.018 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EL2VJ UT WOS:000394478300001 PM 28161019 ER PT J AU Rehani, B Brown, I Dandekar, S Sarkodie, B Mwango, G Rehani, MM Lau, L Zhang, YC Dillon, WP AF Rehani, Bhavya Brown, Isaiah Dandekar, Shebani Sarkodie, Benjamin Mwango, Gladys Rehani, Madan M. Lau, Lawrence Zhang, Yi C. Dillon, William P. TI Radiology Education in Africa: Analysis of Results From 13 African Countries SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material C1 [Rehani, Bhavya; Brown, Isaiah; Dandekar, Shebani; Zhang, Yi C.; Dillon, William P.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Sarkodie, Benjamin] Univ Ghana, Sch Med, Accra, Ghana. [Mwango, Gladys] Univ Nairobi, Nairobi, Kenya. [Rehani, Madan M.] Massachusetts Gen Hosp, Dept Radiol, Harvard Med Sch, Boston, MA 02114 USA. RP Rehani, B (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 505 Parnassus Ave, San Francisco, CA 94143 USA. EM bhavya.rehani@ucsf.edu NR 11 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD FEB PY 2017 VL 14 IS 2 BP 247 EP 252 DI 10.1016/j.jacr.2016.08.012 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EL2VJ UT WOS:000394478300022 PM 27818015 ER PT J AU Swan, JS Furtado, VF Keller, LA Lotti, JB Saltalamacchia, CA Lennes, IT Salazar, GM AF Swan, J. Shannon Furtado, Vanessa F. Keller, Lisa A. Lotti, Judith Borsody Saltalamacchia, Catherine A. Lennes, Inga T. Salazar, Gloria M. TI Pilot Study of a Patient-Centered Radiology Process Model SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Patient experience; quality of life; patient-centered care; psychometrics ID TESTING MORBIDITIES INDEX AB Purpose: The Radiology Process Model (RPM) was previously described in terms of its conceptual basis and proposed survey items. The current study describes the first pilot application of the RPM in the field and the results of initial psychometric analysis. Methods: We used an Institutional Review Board approved pilot RPM survey in 100 patients having outpatient interventional radiology procedures. The 24 survey items had 4 or 5 levels of severity. We assessed for missing data, items that patients found confusing, any suggestions by patients for additional items and clarity of items from patient feedback. Factor analysis was performed and internal consistency measured. Construct validity was assessed by correlation of patient responses to the items as a summated scale with a visual analog scale (VAS) they completed indicating their interventional radiology experience. Results: The visual analog scale and the RPM summated scale were strongly correlated (r = 0.7). Factor analysis showed four factors: interactions with facility and doctors/staff; time-sensitive aspects, pain, and anxiety. The items showed high internal consistency (alpha: 0.86) as a group and approximately 0.7 to 0.9 by the factors. Analysis shows that two items could be deleted (cost and communication between radiologist and referrers). Revision of two items and potential addition of others are discussed. Conclusions: The RPM shows initial evidence of psychometric validity and internal consistency reliability. Minor changes are anticipated before wider use. C1 [Swan, J. Shannon] Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA. [Swan, J. Shannon; Lennes, Inga T.; Salazar, Gloria M.] Harbor Med Sch, Boston, MA USA. [Furtado, Vanessa F.; Lotti, Judith Borsody; Saltalamacchia, Catherine A.; Salazar, Gloria M.] MGH Imaging, Boston, MA USA. [Keller, Lisa A.] Univ Massachusetts, Dept Educ Policy Res & Adm, Amherst, MA 01003 USA. [Lennes, Inga T.] MGH Canc Ctr, Boston, MA USA. RP Swan, JS (reprint author), Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA.; Swan, JS (reprint author), Harbor Med Sch, Boston, MA USA. EM jsswan@mgh.harvard.edu NR 13 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD FEB PY 2017 VL 14 IS 2 BP 274 EP 281 DI 10.1016/j.jacr.2016.08.024 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EL2VJ UT WOS:000394478300028 PM 27927589 ER PT J AU Liu, JB Huffman, KM Palis, BE Shulman, LN Winchester, DP Ko, CY Hall, BL AF Liu, Jason B. Huffman, Kristopher M. Palis, Bryan E. Shulman, Lawrence N. Winchester, David P. Ko, Clifford Y. Hall, Bruce L. TI Reliability of the American College of Surgeons Commission on Cancer's Quality of Care Measures for Hospital and Surgeon Profiling SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID LYMPH-NODES; MIX ADJUSTMENT; COLON-CANCER; LUNG-CANCER; DATA-BASE; PATIENT; RETRIEVAL; RESECTION; NUMBER; RISK AB BACKGROUND: Efforts to improve healthcare quality involve profiling hospitals and providers. Whether cancer-specific measures can be used reliably for profiling purposes has not been reported. STUDY DESIGN: Hospitals and surgeons were profiled with 3 measures assessing the adequacy of lymphadenectomy for colon (ie at least 12 regional lymph nodes [12RLN] are removed and pathologically examined for resected colon cancer), gastric (ie at least 15 regional lymph nodes [G15RLN] are removed and pathologically examined for resected gastric cancer), and non-small cell lung (ie at least 10 regional lymph nodes [10RLN] are removed and pathologically examined for American Joint Committee on Cancer stage IA, IB, IIA, and IIB resected non-small cell lung cancer) cancers using hierarchical models. National Cancer Data Base cases spanning 2010 to 2013 were included if they met measure eligibility. Reliability estimates for hospital and surgeon performance across cumulative years of data (2013, 2012 to 2013, 2011 to 2013, and 2010 to 2013) were calculated with and without risk adjustment. Surgeon caseload minimums were projected to achieve reliabilities of 0.40 and 0.70. RESULTS: Reliability estimates tended to increase with longer periods of data collection but at different rates, depending on measure, level of aggregation, and performance outlier status. Profiling hospitals using 12RLN with 2 years of data yielded a median reliability of 0.72 (interquartile range [IQR] 0.55 to 0.83); however, 4 years of data yielded a median reliability of only 0.31 (IQR 0.14 to 0.54) for surgeons. The G15RLN performance was poor overall; 10RLN had high reliability at both hospital (0.74; IQR 0.50 to 0.86) and surgeon (0.61; IQR 0.34 to 0.80) levels using 1 year of data, but the literature questions this measure's validity. Few surgeons could achieve appropriate levels of reliability regardless of increased data collection duration. CONCLUSIONS: Profiling hospitals based on measures such as these can achieve acceptable reliability in reasonable timeframes, but does not always. Either lower levels of reliability should be accepted to profile surgeons with these measures or longer timeframes should be used. (J Am Coll Surg 2017; 224: 180e190. (C) 2016 by the American College of Surgeons. Published by Elsevier Inc. All rights reserved.) C1 [Liu, Jason B.; Huffman, Kristopher M.; Palis, Bryan E.; Winchester, David P.; Ko, Clifford Y.; Hall, Bruce L.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Liu, Jason B.] Univ Chicago Hosp, Dept Surg, Chicago, IL 60637 USA. [Shulman, Lawrence N.] Univ Penn, Dept Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce L.] Washington Univ, Dept Surg, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO USA. [Hall, Bruce L.] St Louis Vet Affairs Med Ctr, St Louis, MO USA. [Hall, Bruce L.] BJC Healthcare, St Louis, MO USA. RP Liu, JB (reprint author), Amer Coll Surg, 633 N St Clair,22nd Floor, Chicago, IL 60611 USA. EM jliu@facs.org FU Department of Surgery, University of Chicago Hospitals; American College of Surgeons Clinical Scholar in Residence Program FX Dr Liu is supported by a research fellowship from the Department of Surgery, University of Chicago Hospitals and the American College of Surgeons Clinical Scholar in Residence Program. NR 44 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD FEB PY 2017 VL 224 IS 2 BP 180 EP 190E8 DI 10.1016/j.jamcollsurg.2016.10.053 PG 19 WC Surgery SC Surgery GA EO9PC UT WOS:000397019600013 PM 27979711 ER PT J AU McGrath, ER Go, AS Chang, YC Borowsky, LH Fang, MC Reynolds, K Singer, DE AF McGrath, Emer R. Go, Alan S. Chang, Yuchiao Borowsky, Leila H. Fang, Margaret C. Reynolds, Kristi Singer, Daniel E. TI Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE ischemic stroke; atrial fibrillation; oral anticoagulants; decision-making ID ANTITHROMBOTIC THERAPY; RANDOMIZED-TRIALS; RISK-FACTORS; WARFARIN USE; PREVENTION; METAANALYSIS; PROPHYLAXIS; POPULATION; PREVALENCE; MORTALITY AB OBJECTIVES: To explore barriers to anticoagulation in older adults with atrial fibrillation (AF) at high risk of stroke and to identify opportunities for interventions that might increase use of oral anticoagulants (OACs). DESIGN: Retrospective cohort study. SETTING: Two large community-based AF cohorts. PARTICIPANTS: Individuals with ischemic stroke surviving hospitalization (N = 1,405, mean age 79). MEASUREMENTS: Using structured chart review, reasons for nonuse of OAC were identified, and 1-year poststroke survival was assessed. Logistic regression was used to identify correlates of OAC nonuse. RESULTS: Median CHA(2)DS(2)-VASc score was 5, yet 44% of participants were not prescribed an OAC at discharge. The most-frequent (nonmutually exclusive) physician reasons for not prescribing OAC included fall risk (26.7%), poor prognosis (19.3%), bleeding history (17.1%), participant or family refusal (14.9%), older age (11.0%), and dementia (9.4%). Older age (odds ratio (OR) = 8.96, 95% confidence interval (CI) = 5.01-16.04 for aged = 85 vs < 65) and disability (OR = 12.58, 95% CI = 5.82-27.21 for severe vs no deficit) were the most-important independent predictors of nonuse of OACs. By 1 year, 42.5% of those not receiving an OAC at discharge had died, versus 19.1% of those receiving an OAC (P <.001), far higher than recurrent stroke rates. CONCLUSION: Despite very high stroke risk, more than 40% of participants were not discharged with an OAC. Dominant reasons included fall risk, poor prognosis, older age, and dementia. These individuals' high 1-year mortality rate confirmed their high level of comorbidity. To improve anticoagulation decisions and outcomes in this population, future research should focus on strategies to mitigate fall risk, improve assessment of risks and benefits of anticoagulation in individuals with AF, and determine whether newer anticoagulants are safer in complex elderly and frail individuals. C1 [McGrath, Emer R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [McGrath, Emer R.] Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA. [McGrath, Emer R.; Chang, Yuchiao; Singer, Daniel E.] Harvard Med Sch, Boston, MA USA. [Go, Alan S.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA. [Go, Alan S.] Univ Calif San Francisco, Dept Med Epidemiol & Biostat, San Francisco, CA 94143 USA. [Go, Alan S.] Stanford Univ, Sch Med, Dept Hlth Res, Stanford, CA 94305 USA. [Go, Alan S.] Stanford Univ, Sch Med, Dept Policy, Stanford, CA 94305 USA. [Chang, Yuchiao; Borowsky, Leila H.; Singer, Daniel E.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA. [Fang, Margaret C.] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA. [Reynolds, Kristi] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA. RP Go, AS (reprint author), Kaiser Permanente, Div Res, 2000 Broadway St, Oakland, CA 94612 USA.; Singer, DE (reprint author), Massachusetts Gen Hosp, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM alan.s.go@kp.org; desinger@mgh.harvard.edu FU National Institute on Aging [R01 AG15478]; National Heart, Lung and Blood Institute [RC2HL101589, U19 HL091179]; Eliot B. and Edith C. Shoolman fund of Massachusetts General Hospital (Boston, MA) FX This study was supported by the National Institute on Aging (R01 AG15478), the National Heart, Lung and Blood Institute (RC2HL101589 and U19 HL091179) and the Eliot B. and Edith C. Shoolman fund of Massachusetts General Hospital (Boston, MA). NR 40 TC 1 Z9 1 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2017 VL 65 IS 2 BP 241 EP 248 DI 10.1111/jgs.14688 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EO9KD UT WOS:000397006700008 PM 28039855 ER PT J AU de Mazieres, CL Morley, JE Levy, C Agenes, F Barbagallo, M Cesari, M Barreto, PD Donini, LM Fitten, J Franco, A Izquierdo, M Kane, RA Martin, FC Onder, G Ouslander, J Pitkala, K Saliba, D Sinclair, A Manas, LR Vellas, B Rolland, Y AF de Mazieres, Clarisse Laffon Morley, John E. Levy, Cari Agenes, Fabien Barbagallo, Mario Cesari, Matteo Barreto, Philipe De Souto Donini, Lorenzo Maria Fitten, Jaime Franco, Alain Izquierdo, Mikel Kane, Rosalie A. Martin, Finbarr C. Onder, Graziano Ouslander, Joseph Pitkala, Kaisu Saliba, Debra Sinclair, Alan Rodriguez Manas, Leocadio Vellas, Bruno Rolland, Yves TI Prevention of Functional Decline by Reframing the Role of Nursing Homes? SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Nursing home; prevention; functional decline; frailty ID EMERGENCY-DEPARTMENT VISITS; RANDOMIZED CONTROLLED-TRIAL; OLDER-ADULTS; HIP FRACTURE; GERIATRIC ASSESSMENT; STIMULATION THERAPY; PHYSICAL RESTRAINTS; ELDERLY-PATIENTS; RESIDENTS; INTERVENTIONS AB Institutionalization is generally a consequence of functional decline driven by physical limitations, cognitive impairments, and/or loss of social supports. At this stage, intervention to reverse functional losses is often too late. To be more effective, geriatric medicine must evolve to intervene at an earlier stage of the disability process. Could nursing homes (NHs) transform from settings in which many residents dwell to settings in which the NH residents and those living in neighboring communities benefit from staff expertise to enhance quality of life and maintain or slow functional decline? A task force of clinical researchers met in Toulouse on December 2, 2015, to address some of these challenges: how to prevent or slow functional decline and disabilities for NH residents and how NHs may promote the prevention of functional decline in community-dwelling frail elderly. The present article reports the main results of the Task Force discussions to generate a new paradigm. (C) 2016 AMDA - The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved. C1 [de Mazieres, Clarisse Laffon; Cesari, Matteo; Barreto, Philipe De Souto; Vellas, Bruno; Rolland, Yves] CHU Toulouse, Toulouse Univ Hosp, Dept Geriatr Med, Gerontopole, Toulouse, France. [de Mazieres, Clarisse Laffon; Cesari, Matteo; Barreto, Philipe De Souto; Vellas, Bruno; Rolland, Yves] INSERM, UMR 1027, Toulouse, France. [Morley, John E.] St Louis Univ, Sch Med, Div Geriatr Med, St Louis, MO 63104 USA. [Morley, John E.] St Louis Univ, Sch Med, Div Endocrinol, St Louis, MO USA. [Levy, Cari] Denver VA Med Ctr, Denver Seattle Ctr Innovat, Denver, CO USA. [Levy, Cari] Univ Colorado, Sch Med, Div Hlth Care Policy & Res, Aurora, CO USA. [Agenes, Fabien] Embassy France US, Off Sci & Technol, French Consulate Los Angeles, Los Angeles, CA USA. [Barbagallo, Mario] Univ Palermo, Geriatr Unit, Palermo, Italy. [Donini, Lorenzo Maria] Sapienza Univ Rome, Rome, Italy. [Fitten, Jaime] Univ Calif Los Angeles, David Geffen Sch Med, Psychiat & Behav Sci, Los Angeles, CA 90095 USA. [Fitten, Jaime] Greater Los Angeles VA, Geriatr Psychiat, Sepulveda Campus, Los Angeles, CA USA. [Martin, Finbarr C.] Univ Nice Sophia Antipolis, Nice, France. [Izquierdo, Mikel] Univ Publ Navarra, Dept Hlth Sci, Pamplona, Spain. [Kane, Rosalie A.] Univ Minnesota, Sch Publ Hlth, Ctr Aging, Div Hlth Policy & Management, Minneapolis, MN USA. [Martin, Finbarr C.] Kings Coll London, London, England. [Onder, Graziano] Univ Cattolica Sacro Cuore, Ctr Med Invecchiamento, Dept Geriatr, Rome, Italy. [Ouslander, Joseph] Florida Atlantic Univ, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA. [Ouslander, Joseph] Florida Atlantic Univ, Christine E Lynn Coll Nursing, Boca Raton, FL 33431 USA. [Pitkala, Kaisu] Univ Helsinki, Helsinki Univ Hosp, Unit Primary Hlth Care, Dept Gen Practice & Primary Hlth Care, Helsinki, Finland. [Saliba, Debra] Univ Calif Los Angeles, UCLA JH Borun Ctr Gerontol Res, Los Angeles, CA USA. [Saliba, Debra] Los Angeles Vet Adm, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Sinclair, Alan] Fdn Diabet Res Older People, Medici Med Practice, Diabet Frail, Luton, Beds, England. [Rodriguez Manas, Leocadio] Univ Europea Madrid, Hosp Univ Getafe, Dept Geriatr, Getafe, Spain. [Rodriguez Manas, Leocadio] Univ Europea Madrid, Sch Hlth Sci, Getafe, Spain. RP de Mazieres, CL (reprint author), Toulouse Univ Hosp, Dept Geriatr Med, Gerontopole, 224 Ave Casselardit,TSA 40031, F-31059 Toulouse 9, France. EM laffondemazieres.c@chu-toulouse.fr FU Office for Science and Technology of the Consulate General of France in Los Angeles, USA FX This work was supported by an educational grant from the Office for Science and Technology of the Consulate General of France in Los Angeles, USA. NR 54 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 EI 1538-9375 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD FEB 1 PY 2017 VL 18 IS 2 BP 105 EP 110 DI 10.1016/j.jamda.2016.11.019 PG 6 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA EP3TB UT WOS:000397303500005 ER PT J AU Biermann, JS Chow, W Reed, DR Lucas, D Adkins, DR Agulnik, M Benjamin, RS Brigman, B Budd, GT Curry, WT Didwania, A Fabbri, N Hornicek, FJ Kuechle, JB Lindskog, D Mayerson, J McGarry, SV Million, L Morris, CD Movva, S O'Donnell, RJ Randall, RL Rose, P Santana, VM Satcher, RL Schwartz, H Siegel, HJ Thornton, K Villalobos, V Bergman, MA Scavone, JL AF Biermann, J. Sybil Chow, Warren Reed, Damon R. Lucas, David Adkins, Douglas R. Agulnik, Mark Benjamin, Robert S. Brigman, Brian Budd, G. Thomas Curry, William T. Didwania, Aarati Fabbri, Nicola Hornicek, Francis J. Kuechle, Joseph B. Lindskog, Dieter Mayerson, Joel McGarry, Sean V. Million, Lynn Morris, Carol D. Movva, Sujana O'Donnell, Richard J. Randall, R. Lor Rose, Peter Santana, Victor M. Satcher, Robert L. Schwartz, Herbert Siegel, Herrick J. Thornton, Katherine Villalobos, Victor Bergman, Mary Anne Scavone, Jillian L. TI NCCN Guidelines (R) Insights Bone Cancer, Version 2.2017 Featured Updates to the NCCN Guidelines SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article ID LOCALIZED EWING-SARCOMA; CHILDRENS-ONCOLOGY-GROUP; SARCOMA/PRIMITIVE NEUROECTODERMAL TUMOR; REFRACTORY SOLID TUMORS; GROUP PHASE-II; PROGNOSTIC-FACTORS; PEDIATRIC-ONCOLOGY; YOUNG-ADULTS; NEOADJUVANT CHEMOTHERAPY; SINGLE-INSTITUTION AB The NCCN Guidelines for Bone Cancer provide interdisciplinary recommendations for treating chordoma, chondrosarcoma, giant cell tumor of bone, Ewing sarcoma, and osteosarcoma. These NCCN Guidelines Insights summarize the NCCN Bone Cancer Panel's guideline recommendations for treating Ewing sarcoma. The data underlying these treatment recommendations are also discussed. C1 [Biermann, J. Sybil; Lucas, David] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Chow, Warren] City Hope Comprehens Canc Ctr, Duarte, CA USA. [Reed, Damon R.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Adkins, Douglas R.] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA. [Adkins, Douglas R.] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Agulnik, Mark; Didwania, Aarati] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. [Benjamin, Robert S.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Brigman, Brian] Duke Canc Inst, Durham, NC USA. [Budd, G. Thomas] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA. [Budd, G. Thomas] Taussig Canc Inst, Cleveland Clin, Cleveland, OH USA. [Curry, William T.; Hornicek, Francis J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Fabbri, Nicola] Mem Sloan Kettering Canc Ctr, New Rochelle, NY USA. [Kuechle, Joseph B.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Lindskog, Dieter] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA. [Mayerson, Joel] Ohio State Univ, James Canc Hosp & Solove Res Inst, Ctr Comprehens Canc, Columbus, OH 43210 USA. [McGarry, Sean V.] Fred Pamela Buffett Canc Ctr, Omaha, NE USA. [Million, Lynn] Stanford Canc Inst, Stanford, CA USA. [Morris, Carol D.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Movva, Sujana] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [O'Donnell, Richard J.] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. [Randall, R. Lor] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. [Rose, Peter] Mayo Clin, Canc Ctr, Rochester, MN USA. [Santana, Victor M.] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA. [Schwartz, Herbert] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Siegel, Herrick J.] Univ Alabama Birmingham, Ctr Comprehens Canc, Tuscaloosa, AL 35487 USA. [Thornton, Katherine] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Villalobos, Victor] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA. [Bergman, Mary Anne; Scavone, Jillian L.] Natl Comprehens Canc Network, Seattle, WA USA. RP Biermann, JS (reprint author), Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. FU Astellas; AstraZeneca; Celldex Therapeutics; Clovis Oncology; Genomic Health, Inc.; Kyowa Hakko Kirin; Jazz Pharmaceuticals; Novartis Pharmaceuticals Corporation; NOVOCURE; Merck Co., Inc FX This activity is supported by educational grants from Astellas, AstraZeneca, Celldex Therapeutics, Clovis Oncology, Genomic Health, Inc., Kyowa Hakko Kirin, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, and NOVOCURE. This activity is supported by an independent educational grant from Merck Co., Inc. NR 75 TC 0 Z9 0 U1 1 U2 1 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD FEB PY 2017 VL 15 IS 2 BP 155 EP 167 PG 13 WC Oncology SC Oncology GA EL9GA UT WOS:000394927100002 PM 28188186 ER PT J AU Kumar, SK Callander, NS Alsina, M Atanackovic, D Biermann, JS Chandler, JC Costello, C Faiman, M Fung, HC Gasparetto, C Godby, K Hofmeister, C Holmberg, L Holstein, S Huff, CA Kassim, A Liedtke, M Martin, T Omel, J Raje, N Reu, FJ Singhal, S Somlo, G Stockerl-Goldstein, K Treon, SP Weber, D Yahalom, J Shead, DA Kumar, R AF Kumar, Shaji K. Callander, Natalie S. Alsina, Melissa Atanackovic, Djordje Biermann, J. Sybil Chandler, Jason C. Costello, Caitlin Faiman, Matthew Fung, Henry C. Gasparetto, Cristina Godby, Kelly Hofmeister, Craig Holmberg, Leona Holstein, Sarah Huff, Carol Ann Kassim, Adetola Liedtke, Michaela Martin, Thomas Omel, James Raje, Noopur Reu, Frederic J. Singhal, Seema Somlo, George Stockerl-Goldstein, Keith Treon, Steven P. Weber, Donna Yahalom, Joachim Shead, Dorothy A. Kumar, Rashmi TI Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Review ID STEM-CELL TRANSPLANTATION; HIGH-DOSE THERAPY; DONOR LYMPHOCYTE INFUSIONS; TERM-FOLLOW-UP; SINGLE-AGENT CARFILZOMIB; NEWLY-DIAGNOSED MYELOMA; FRONT AUTOLOGOUS TRANSPLANTATION; BORTEZOMIB PLUS DEXAMETHASONE; INTERNATIONAL STAGING SYSTEM; BONE-MARROW-TRANSPLANTATION AB Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-related complications include hypercalcemia, renal insufficiency, anemia, and infections. The NCCN Multiple Myeloma Panel members have developed guidelines for the management of patients with various plasma cell dyscrasias, including solitary plasmacytoma, smoldering myeloma, multiple myeloma, systemic light chain amyloidosis, and Waldenstrom's macroglobulinemia. The recommendations specific to the diagnosis and treatment of patients with newly diagnosed MM are discussed in this article. C1 [Kumar, Shaji K.] Mayo Clin, Ctr Canc, Rochester, MN USA. [Callander, Natalie S.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA. [Alsina, Melissa] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Atanackovic, Djordje] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. [Biermann, J. Sybil] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Chandler, Jason C.] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA. [Costello, Caitlin] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA. [Faiman, Matthew] Univ Hosp Seidman, Ctr Canc, Case Comprehens Canc Ctr, Cleveland, OH USA. [Faiman, Matthew] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA. [Fung, Henry C.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Gasparetto, Cristina] Duke Canc Inst, Durham, NC USA. [Godby, Kelly] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA. [Hofmeister, Craig] Ohio State Univ, James Canc Hosp, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Hofmeister, Craig] Solove Res Inst, Columbus, OH USA. [Holmberg, Leona] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98104 USA. [Holstein, Sarah] Fred Pamela Buffett Canc Ctr, Omaha, NE USA. [Huff, Carol Ann] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Kassim, Adetola] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Liedtke, Michaela] Stanford Canc Inst, Stanford, CA USA. [Martin, Thomas] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. [Raje, Noopur] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Reu, Frederic J.] Univ Hosp Seidman, Ctr Canc, Case Comprehens Canc Ctr, Cleveland, OH USA. [Reu, Frederic J.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA. [Singhal, Seema] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. [Somlo, George] City Hope Comprehens Canc Ctr, Duarte, CA USA. [Stockerl-Goldstein, Keith] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA. [Stockerl-Goldstein, Keith] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Treon, Steven P.] Dana Farber Brigham & Womens Canc Ctr, Milford, MA USA. [Weber, Donna] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Yahalom, Joachim] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. RP Kumar, SK (reprint author), Mayo Clin, Ctr Canc, Rochester, MN USA. NR 174 TC 0 Z9 0 U1 1 U2 1 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD FEB PY 2017 VL 15 IS 2 BP 230 EP + PG 26 WC Oncology SC Oncology GA EL9GA UT WOS:000394927100008 PM 28188192 ER PT J AU Angulo, MT Moreno, JA Lippner, G Barabasi, AL Liu, YY AF Angulo, Marco Tulio Moreno, Jaime A. Lippner, Gabor Barabasi, Albert-Laszlo Liu, Yang-Yu TI Fundamental limitations of network reconstruction from temporal data SO JOURNAL OF THE ROYAL SOCIETY INTERFACE LA English DT Article DE network reconstruction; system identification; networked systems ID COMPLEX NETWORKS; BIOLOGICAL NETWORKS; IDENTIFIABILITY; DYNAMICS; SYSTEMS; DISTINGUISHABILITY; INFERENCE; PROFILES; MODELS AB Inferring properties of the interaction matrix that characterizes how nodes in a networked system directly interact with each other is a well-known network reconstruction problem. Despite a decade of extensive studies, network reconstruction remains an outstanding challenge. The fundamental limitations governing which properties of the interaction matrix (e.g. adjacency pattern, sign pattern or degree sequence) can be inferred from given temporal data of individual nodes remain unknown. Here, we rigorously derive the necessary conditions to reconstruct any property of the interaction matrix. Counterintuitively, we find that reconstructing any property of the interaction matrix is generically as difficult as reconstructing the interaction matrix itself, requiring equally informative temporal data. Revealing these fundamental limitations sheds light on the design of better network reconstruction algorithms that offer practical improvements over existing methods. C1 [Angulo, Marco Tulio] Univ Nacl Autonoma Mexico, Inst Math, Juriquilla 76230, Mexico. [Moreno, Jaime A.] Univ Nacl Autonoma Mexico, Inst Engn, Cdmx 04510, Mexico. [Lippner, Gabor] Northeastern Univ, Dept Math, Boston, MA 02115 USA. [Barabasi, Albert-Laszlo] Northeastern Univ, Ctr Complex Networks Res, Boston, MA 02115 USA. [Barabasi, Albert-Laszlo; Liu, Yang-Yu] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA. [Barabasi, Albert-Laszlo] Cent European Univ, Ctr Network Sci, H-1052 Budapest, Hungary. [Liu, Yang-Yu] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA. [Liu, Yang-Yu] Harvard Med Sch, Boston, MA 02115 USA. RP Liu, YY (reprint author), Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA.; Liu, YY (reprint author), Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.; Liu, YY (reprint author), Harvard Med Sch, Boston, MA 02115 USA. EM yyl@channing.harvard.edu FU CONACyT, Mexico [207609]; John Templeton Foundation: Mathematical and Physical Sciences grant [PFI-777]; European Commission (CIMPLEX) [641191] FX This work was supported by CONACyT, Mexico (grant no. 207609), the John Templeton Foundation: Mathematical and Physical Sciences grant PFI-777 and European Commission grant no. 641191 (CIMPLEX) NR 45 TC 0 Z9 0 U1 0 U2 0 PU ROYAL SOC PI LONDON PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND SN 1742-5689 EI 1742-5662 J9 J R SOC INTERFACE JI J. R. Soc. Interface PD FEB 1 PY 2017 VL 14 IS 127 AR 20160966 DI 10.1098/rsif.2016.0966 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN4ZT UT WOS:000396016100023 ER PT J AU Jayakumar, P Teunis, T Gimenez, BB Verstreken, F Di Mascio, L Jupiter, JB AF Jayakumar, Prakash Teunis, Teun Bravo Gimenez, Beatriz Verstreken, Frederik Di Mascio, Livio Jupiter, Jesse B. TI AO Distal Radius Fracture Classification: Global Perspective on Observer Agreement SO JOURNAL OF WRIST SURGERY LA English DT Article DE distal radius fracture; classification; reliability; reproducibility ID INTRAOBSERVER AGREEMENT; INTEROBSERVER; RELIABILITY; REPRODUCIBILITY; SURGEONS; SYSTEMS AB Background The primary objective of this study was to test interobserver reliability when classifying fractures by consensus by AO types and groups among a large international group of surgeons. Secondarily, we assessed the difference in inter- and intraobserver agreement of the AO classification in relation to geographical location, level of training, and subspecialty. Methods A randomized set of radiographic and computed tomographic images from a consecutive series of 96 distal radius fractures (DRFs), treated between October 2010 and April 2013, was classified using an electronic web-based portal by an invited group of participants on two occasions. Results Interobserver reliability was substantial when classifying AO type A fractures but fair and moderate for type B and C fractures, respectively. No difference was observed by location, except for an apparent difference between participants from India and Australia classifying type B fractures. No statistically significant associations were observed comparing interobserver agreement by level of training and no differences were shown comparing subspecialties. Intra-rater reproducibility was substantial for fracture types and fair for fracture groups with no difference accounting for location, training level, or specialty. Conclusion Improved definition of reliability and reproducibility of this classification may be achieved using large international groups of raters, empowering decision making on which system to utilize. Level of Evidence Level III C1 [Jayakumar, Prakash; Teunis, Teun; Jupiter, Jesse B.] OLVG, Dept Gen Surg, Amsterdam, Netherlands. [Bravo Gimenez, Beatriz] Univ Complutense, Hosp Univ Doce Octubre, Orthopaed Upper Extrem Serv, Madrid, Spain. [Verstreken, Frederik] Univ Antwerp Hosp, Monica Hosp, Dept Hand Surg, Edegem, Belgium. [Di Mascio, Livio] Barts & Royal London Hosp, Dept Trauma & Orthopaed Surg, London, England. RP Jupiter, JB (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Orthopaed Hand & Upper Extrem Serv, 55 Fruit St, Boston, MA 02114 USA. EM jjupiter1@partners.org NR 22 TC 0 Z9 0 U1 0 U2 0 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 2163-3916 EI 2163-3924 J9 J WRIST SURG JI J. WRIST SURG. PD FEB PY 2017 VL 6 IS 1 BP 46 EP 53 DI 10.1055/s-0036-1587316 PG 8 WC Orthopedics SC Orthopedics GA EL3HS UT WOS:000394510800007 PM 28119795 ER PT J AU Tavera-Mendoza, LE Brown, M AF Tavera-Mendoza, Luz E. Brown, Myles TI A less invasive method for orthotopic injection of breast cancer cells into the mouse mammary gland SO LABORATORY ANIMALS LA English DT Article DE surgery; tumor model AB Breast cancer is the most common type of cancer diagnosed in women, and the second most common cause of cancer-related deaths in women in North America. The use of laboratory mice in research is an essential tool for the study of breast cancer biology and for pre-clinical therapeutic development. While subcutaneous flank injections of cancer cells are widely used for studying breast cancer biology and for exploring novel therapies, orthotopic xenografting of tumors into the mouse mammary gland allow for the study of breast cancers in a biologically relevant microenvironment. In this study we report a modification of the method of orthotopic injections of cancer cells into the mouse mammary gland which greatly reduces the effects of surgery in mice including decreased wound size, procedure time and anesthesia. It also removes the risk of accidentally puncturing the peritoneal cavity. Consequently post-operative animal handling and stress are significantly reduced. All of these advantages are present without compromising procedure success rate. Therefore, this modification makes orthotopic mammary gland injection a more efficient procedure and greatly improves animal welfare. C1 [Tavera-Mendoza, Luz E.; Brown, Myles] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, Boston, MA USA. [Brown, Myles] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA. RP Brown, M (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM myles_brown@dfci.harvard.edu NR 5 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0023-6772 EI 1758-1117 J9 LAB ANIM-UK JI Lab. Anim. PD FEB PY 2017 VL 51 IS 1 BP 85 EP 88 DI 10.1177/0023677216640706 PG 4 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA EL8UK UT WOS:000394895400008 PM 26994106 ER PT J AU Maxfield, AZ Korkmaz, H Gregorio, LL Busaba, NY Gray, ST Holbrook, EH Guo, R Bleier, BS AF Maxfield, Alice Z. Korkmaz, Hakan Gregorio, Luciano L. Busaba, Nicolas Y. Gray, Stacey T. Holbrook, Eric H. Guo, Rong Bleier, Benjamin S. TI General Antibiotic Exposure Is Associated With Increased Risk of Developing Chronic Rhinosinusitis SO LARYNGOSCOPE LA English DT Article DE Antibiotics; side effects; microbiome; chronic rhinosinusitis; quality of life ID NASAL POLYPS; P-GLYCOPROTEIN; MICROBIOME; RESISTANCE; MANAGEMENT; DIVERSITY; SECRETION; SINUSITIS; CHILDREN; DISEASE AB Objective: Antibiotic use and chronic rhinosinusitis (CRS) have been independently associated with microbiome diversity depletion and opportunistic infections. This study was undertaken to investigate whether antibiotic use may be an unrecognized risk factor for developing CRS. Study Design: Case-control study of 1,162 patients referred to a tertiary sinus center for a range of sinonasal disorders. Methods: Patients diagnosed with CRS according to established consensus criteria (n = 410) were assigned to the case group (273 without nasal polyps [CRSsNP], 137 with nasal polyps [CRSwNP]). Patients with all other diagnoses (n = 752) were assigned to the control group. Chronic rhinosinusitis disease severity was determined using a validated quality of life (QOL) instrument. The class, diagnosis, and timing of previous nonsinusitis-related antibiotic exposures were recorded. Results were validated using a randomized administrative data review of 452 (38.9%) of patient charts. The odds ratio of developing CRS following antibiotic exposure were calculated, as well as the impact of antibiotic use on the subsequent QOL. Results: Antibiotic use significantly increased the odds of developing CRSsNP (odds ratio: 2.21, 95% confidence interval, 1.66-2.93, P < 0.0001) as compared to nonusers. Antibiotic exposure was significantly associated with worse CRS QOL scores (P = 0.0009) over at least the subsequent 2 years. These findings were confirmed by the administrative data review. Conclusion: Use of antibiotics more than doubles the odds of developing CRSsNP and is associated with a worse QOL for at least 2 years following exposure. These findings expose an unrecognized and concerning consequence of general antibiotic use. C1 [Maxfield, Alice Z.; Gregorio, Luciano L.; Busaba, Nicolas Y.; Gray, Stacey T.; Holbrook, Eric H.; Bleier, Benjamin S.] Harvard Med Sch, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, Boston, MA USA. [Korkmaz, Hakan] Ordu Univ, Fac Med, Dept Otorhinolaryngol, Ordu, Turkey. [Guo, Rong] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Stat, Boston, MA USA. RP Bleier, BS (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM benjamin_bleier@meei.harvard.edu NR 41 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD FEB PY 2017 VL 127 IS 2 BP 296 EP 302 DI 10.1002/lary.26232 PG 7 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA EL9TI UT WOS:000394962600011 PM 27549904 ER PT J AU Kohli, P Naik, AN Harruff, EE Nguyen, SA Schlosser, RJ Soler, ZM AF Kohli, Preeti Naik, Akash N. Harruff, E. Emily Nguyen, Shaun A. Schlosser, Rodney J. Soler, Zachary M. TI The Prevalence of Olfactory Dysfunction in Chronic Rhinosinusitis SO LARYNGOSCOPE LA English DT Review DE Olfaction; smell; chronic rhinosinusitis; sinusitis; prevalence ID ENDOSCOPIC SINUS SURGERY; QUALITY-OF-LIFE; COMPUTED-TOMOGRAPHY FINDINGS; CLINICAL-PRACTICE GUIDELINE; SMELL IDENTIFICATION TEST; PLACEBO-CONTROLLED TRIAL; NASAL POLYPOSIS; DOUBLE-BLIND; DISEASE SEVERITY; ALLERGIC RHINITIS AB Objectives: Many studies have reported that olfactory dysfunction frequently occurs in chronic rhinosinusitis (CRS) populations; however, the prevalence and degree of olfactory loss has not been systematically studied. The aims of this study were to use combined data to report the prevalence of olfactory dysfunction and to calculate weighted averages of olfactory test scores in CRS patients. Data Sources: A search was conducted in PubMed and Scopus, following the methods of Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines. Review Methods: Studies reporting the prevalence of olfactory dysfunction using objective measures or olfactory test scores using validated scales were included. Results: A total of 47 articles were included in a systematic review and 35 in the pooled data analysis. The prevalence of olfactory dysfunction in chronic rhinosinusitis was found to be 30.0% using the Brief Smell Identification Test, 67.0% using the 40-item Smell Identification Test, and 78.2% using the total Sniffin' Sticks score. Weighted averages 6 standard deviation of olfactory test scores were 25.96 +/- 7.11 using the 40-item Smell Identification Test, 8.60 +/- 2.81 using the Brief Smell Identification Test, 21.96 +/- 8.88 using total Sniffin' Sticks score, 5.65 +/- 1.51 using Sniffin' Sticks-Threshold, 9.21 +/- 4.63 using Sniffin' Sticks-Discrimination, 9.47 +/- 3.92 using Sniffin' Sticks-Identification, and 8.90 +/- 5.14 using the Questionnaire for Olfactory Disorders-Negative Statements. Conclusions: In CRS populations, a significant percentage of patients experience olfactory dysfunction, and mean olfactory scores are within the dysosmic range. C1 [Kohli, Preeti; Naik, Akash N.; Harruff, E. Emily; Nguyen, Shaun A.; Schlosser, Rodney J.; Soler, Zachary M.] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg, Charleston, SC USA. RP Kohli, P (reprint author), Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM pkohli89@gmail.com FU National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, U.S.A [R03 DC013651-01]; Entellus; Intersect; Optinose; IntersectENT FX This work was supported by grants from the National Institute on Deafness and Other Communication Disorders, one of the National Institutes of Health, Bethesda, Maryland, U.S.A. (R03 DC013651-01; PI: Z.M.S.).; Z.M.S. is supported by grants from Entellus, Intersect, and Optinose, which are not affiliated with this study. Z.M.S. is a consultant for Olympus, which is not affiliated with this study. R.J.S. is supported by grants from OptiNose, Entellus, and IntersectENT, none of which are associated with this study. R.J.S. is a consultant for Olympus and Meda, which are not affiliated with this study. S.A.N. is a consultant for Roche Products Limited (United Kingdom) and CSL Behring, which are not affiliated with this study. NR 74 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD FEB PY 2017 VL 127 IS 2 BP 309 EP 320 DI 10.1002/lary.26316 PG 12 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA EL9TI UT WOS:000394962600013 PM 27873345 ER PT J AU Byne, W AF Byne, William TI Sustaining Progress Toward LGBT Health Equity: A Time for Vigilance, Advocacy, and Scientific Inquiry SO LGBT HEALTH LA English DT Editorial Material DE barriers to care; clinical research; gender identity; health disparities; public policy and advocacy; sexual orientation C1 [Byne, William] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Byne, William] James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY 10468 USA. RP Byne, W (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Byne, W (reprint author), James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY 10468 USA. EM william.byne@mssm.edu NR 18 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2325-8292 EI 2325-8306 J9 LGBT HEALTH JI LGBT Health PD FEB PY 2017 VL 4 IS 1 BP 1 EP 3 DI 10.1089/lgbt.2016.0211 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL3GC UT WOS:000394506600001 PM 28051348 ER PT J AU Awad, MM Chu, QSC Gandhi, L Stephenson, JJ Govindan, R Bradford, DS Bonomi, PD Ellison, DM Eaton, KD Fritsch, H Munzert, G Johnson, BE Socinski, MA AF Awad, Mark M. Chu, Quincy S-C Gandhi, Leena Stephenson, Joe J. Govindan, Ramaswamy Bradford, Daniel S. Bonomi, Philip D. Ellison, David M. Eaton, Keith D. Fritsch, Holger Munzert, Gerd Johnson, Bruce E. Socinski, Mark A. TI An open-label, phase II study of the polo-like kinase-1 (P1k-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC) SO LUNG CANCER LA English DT Article DE Small cell lung cancer; Plk-1 inhibition; Polo-like kinase; BI 2536 ID ADVANCED SOLID TUMORS; TRIAL; PLK1; TOPOTECAN; VOLASERTIB; THERAPY; POLO-LIKE-KINASE-1; CARCINOMA; NETWORK AB Objectives: This phase II, open-label study was designed to evaluate the response rate to the polo-like kinase 1 (Plk-1) inhibitor BI 2536 in patients with sensitive-relapsed small cell lung cancer (SCLC). Secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response, and safety. Materials and methods: Patients were treated with the recommended phase II dose of 200 mg of BI 2536 intravenously every 21 days. This was a two-stage design with an early stopping rule in place if responses were not seen in at least 2 of the first 18 enrolled patients. Results and conclusion: Twenty-three patients were enrolled in the study and 21 patients were evaluable for response. No responses were observed and all 23 patients have progressed. The median PFS was 1.4 months. Treatment was generally well tolerated and the most frequent adverse events were neutropenia, fatigue, nausea, vomiting, and constipation. BI 2536 is not effective in the treatment of sensitive relapsed SCLC. The criteria for expanding the trial to the second stage were not achieved, and the study was terminated for a lack of efficacy. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Awad, Mark M.; Gandhi, Leena; Johnson, Bruce E.] Harvard Med Sch, Lowe Ctr Thorac Oncol, Dana Farber Canc Inst, Boston, MA USA. [Chu, Quincy S-C] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada. [Stephenson, Joe J.] Canc Ctr Carolinas, Greenville, SC USA. [Govindan, Ramaswamy] Washington Univ, Sch Med, St Louis, MO USA. [Bradford, Daniel S.] Highlands Oncol Grp, Fayetteville, AR USA. [Bonomi, Philip D.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Ellison, David M.] Charleston Hematol Oncol Associates, Charleston, SC USA. [Eaton, Keith D.] Seattle Canc Care Alliance, Seattle, WA USA. [Fritsch, Holger; Munzert, Gerd] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany. [Socinski, Mark A.] Univ Pittsburgh, Pittsburgh, PA USA. RP Johnson, BE (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM bruce_johnson@dfci.harvard.edu NR 38 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0169-5002 EI 1872-8332 J9 LUNG CANCER JI Lung Cancer PD FEB PY 2017 VL 104 BP 126 EP 130 DI 10.1016/j.lungcan.2016.12.019 PG 5 WC Oncology; Respiratory System SC Oncology; Respiratory System GA EN2LE UT WOS:000395840900020 PM 28212994 ER PT J AU Vatansever, F Hamblin, MR AF Vatansever, Fatma Hamblin, Michael R. TI Surface-initiated polymerization with poly(n-hexylisocyanate) to covalently functionalize silica nanoparticles SO MACROMOLECULAR RESEARCH LA English DT Article DE polymeric nanocomposites; inorganic-organic interfacing; controlled polymerization; surface initiated polymerization; nanoparticle surface modification; titanium catalyst; n-hexyl isocyanate polymerization ID ISOCYANATE); POLYMERS AB New methods are needed for covalent functionalization of nanoparticles-surface with organic polymer coronas to generate polymeric nanocomposite in a controlled manner. Here we report the use of a surface-initiated polymerization approach, mediated by titanium(IV) catalysis, to grow poly(n-hexylisocyanate) chains from silica surface. Two pathways were used to generate the interfacing in these nano-hybrids. In the first one, the nanoparticles were "seeded" with SiCl4, followed by reaction with 1,6-hexanediol to form hydroxyl groups attached directly to the surface via O-Si-O bonding. In the second pathway, the nanoparticles were initially exposed to a 9:1 mixture of trimethyl silyl chloride and chlorodimethyl octenyl silane which was then followed by hydroboration of the double bonds, to afford hydroxyl groups with a spatially controlled density and surface-attachment via O-Si-C bonding. These functionalized surfaces were then activated with the titanium tetrachloride catalyst. In our approach, surface tethered catalyst provided the sites for n-hexyl isocyanate monomer insertion to "build up" the surface-grown polymer layers from the "bottom-up". A final end-capping, to seal off the chain ends, was done via acetyl chloride. Compounds were characterized by Fourier transform infrared spectroscopy (FTIR), H-1 nuclear magnetic resonance spectroscopy (NMR), gas chromatography-mass spectrometry (GC-MS), gel permeation chromatography (GPC), and thermogravimetric analyses. C1 [Vatansever, Fatma] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Vatansever, Fatma; Hamblin, Michael R.] Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA. [Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Boston, MA 02139 USA. RP Vatansever, F (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.; Vatansever, F; Hamblin, MR (reprint author), Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA.; Hamblin, MR (reprint author), Harvard Mit Div Hlth Sci & Technol, Boston, MA 02139 USA. EM vatansever.fatma@mgh.harvard.edu; hamblin@helix.mgh.harvard.edu FU US NIH [R01AI050875] FX MRH was supported by US NIH grant R01AI050875. NR 38 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1598-5032 EI 2092-7673 J9 MACROMOL RES JI Macromol. Res. PD FEB PY 2017 VL 25 IS 2 BP 97 EP 107 DI 10.1007/s13233-017-5009-9 PG 11 WC Polymer Science SC Polymer Science GA EM1CC UT WOS:000395054600001 ER PT J AU Esmaeili, M Bathen, TF Rosen, BR Andronesi, OC AF Esmaeili, Morteza Bathen, Tone F. Rosen, Bruce R. Andronesi, Ovidiu C. TI Three-dimensional MR spectroscopic imaging using adiabatic spin echo and hypergeometric dual-band suppression for metabolic mapping over the entire brain SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article DE magnetic resonance spectroscopy imaging (MRSI); hypergeometric dual band (HGDB); adiabatic spin echo (ASE); brain; lipid suppression ID OUTER-VOLUME SUPPRESSION; LIPID SUPPRESSION; MAGNETIC-RESONANCE; ANALYTIC SOLUTIONS; WATER-SUPPRESSION; SPECTRAL QUALITY; BLOCH EQUATION; H-1 MRSI; K-SPACE; PULSES AB PurposeLarge lipid and water signals in MR spectroscopic imaging (MRSI) complicate brain metabolite quantification. In this study, we combined adiabatic hypergeometric dual-band (HGDB) lipid and water suppression with gradient offset independent adiabatic (GOIA) spin echo to improve three-dimensional (3D) MRSI of the entire brain. Methods3D MRSI was acquired at 3T with a 32-channel coil. HGDB pulses were used before excitation and during echo time. A brain slab was selected with GOIA-W(16,4) pulses, weighted phase encoded stack of spirals, and real-time motion/shim correction. HGDB alone or in combination with OVS and MEGA (MEscher-GArwood) was compared with OVS only and no suppression. ResultsThe combined HGDB pulses suppressed lipids to 2%-3% of their full unsuppressed signal. The HGDB lipid suppression was on average 5 times better than OVS suppression. HGDB+MEGA provided 30% more suppression compared with a previously described HGDB+OVS scheme. The number of voxels with good metabolic fits was significantly larger in the HGDB data (91%-94%) compared with the OVS data (59%-80%). ConclusionHGDB pulses provided efficient lipid and water suppression for full brain 3D MRSI. The HGDB suppression is superior to traditional OVS, and it can be combined with adiabatic spin echo to provide a sequence that is robust to B-1 inhomogeneity. Magn Reson Med 77:490-497, 2017. (c) 2016 International Society for Magnetic Resonance in Medicine C1 [Esmaeili, Morteza; Rosen, Bruce R.; Andronesi, Ovidiu C.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA USA. [Esmaeili, Morteza; Bathen, Tone F.] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, Olav Kyrres Gate 9, Trondheim, Norway. RP Esmaeili, M (reprint author), Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, Olav Kyrres Gate 9, Trondheim, Norway. EM m.esmaeili@ntnu.no; ovidiu@nmr.mgh.harvard.edu FU National Cancer Institute [1K22CA178269-01]; MGH-MIT Strategic Initiative; Liaison Committee [46056808]; Norwegian University of Science and Technology; National Institutes of Health Shared Instrumentation Grant Program; High-End Instrumentation Grant Program [S10RR021110]; Center for Functional Neuroimaging Technologies [P41EB015896] FX Grant sponsor: National Cancer Institute; Grant number: 1K22CA178269-01 (O.C.A.); Grant sponsor: MGH-MIT Strategic Initiative's Grand Challenge 3 on Neuroscience (O.C.A.); Grant sponsor: Liaison Committee between the Central Norway Regional Health Authority (Grant number: 46056808) and the Norwegian University of Science and Technology (M.E.); Grant sponsor: National Institutes of Health Shared Instrumentation Grant Program and/or High-End Instrumentation Grant Program; Grant number: S10RR021110 B.R.R.); Grant sponsor: MR experiments were performed at the Athinoula A. Martinos Center for Biomedical Imaging; Grant sponsor: Center for Functional Neuroimaging Technologies; Grant number: P41EB015896 [a P41 Regional Resource supported by the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health]) (B.R.R.) NR 40 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0740-3194 EI 1522-2594 J9 MAGN RESON MED JI Magn. Reson. Med. PD FEB PY 2017 VL 77 IS 2 BP 490 EP 497 DI 10.1002/mrm.26115 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EL3UL UT WOS:000394544700005 PM 26840906 ER PT J AU Poulsen, C Wakeman, DG Atefi, SR Luu, P Konyn, A Bonmassar, G AF Poulsen, Catherine Wakeman, Daniel G. Atefi, Seyed Reza Luu, Phan Konyn, Amy Bonmassar, Giorgio TI Polymer thick film technology for improved simultaneous dEEG/MRI recording: Safety and MRI data quality SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article DE fMRI; BOLD; eccentricity maps; anthropomorphic head phantom; ISO10974; temperature measurements; B1 maps ID HIGH-FIELD MRI; EEG CAP; BALLISTOCARDIOGRAM ARTIFACT; FUNCTIONAL MRI; FMRI SIGNAL; BOLD FMRI; 7 TESLA; ELECTRODES; REMOVAL; HEAD AB PurposeTo develop a 256-channel dense-array electroencephalography (dEEG) sensor net (the Ink-Net) using high-resistance polymer thick film (PTF) technology to improve safety and data quality during simultaneous dEEG/MRI. MethodsHeating safety was assessed with temperature measurements in an anthropomorphic head phantom during a 30-min, induced-heating scan at 7T. MRI quality assessment used B1 field mapping and functional MRI (fMRI) retinotopic scans in three humans at 3T. Performance of the 256-channel PTF Ink-Net was compared with a 256-channel MR-conditional copper-wired electroencephalography (EEG) net and to scans with no sensor net. A visual evoked potential paradigm assessed EEG quality within and outside the 3T scanner. ResultsPhantom temperature measurements revealed nonsignificant heating (ISO 10974) in the presence of either EEG net. In human B1 field and fMRI scans, the Ink-Net showed greatly reduced cross-modal artifact and less signal degradation than the copper-wired net, and comparable quality to MRI without sensor net. Cross-modal ballistocardiogram artifact in the EEG was comparable for both nets. ConclusionHigh-resistance PTF technology can be effectively implemented in a 256-channel dEEG sensor net for MR conditional use at 7T and with significantly improved structural and fMRI data quality as assessed at 3T. Magn Reson Med 77:895-903, 2017. (c) 2016 International Society for Magnetic Resonance in Medicine C1 [Poulsen, Catherine; Luu, Phan; Konyn, Amy] Elect Geodes Inc, 500 East 4th Ave,Suite 200, Eugene, OR 97403 USA. [Wakeman, Daniel G.; Atefi, Seyed Reza; Bonmassar, Giorgio] Harvard Med Sch, Massachusetts Gen Hosp, AA Martinos Ctr, Charlestown, MA USA. RP Poulsen, C (reprint author), Elect Geodes Inc, 500 East 4th Ave,Suite 200, Eugene, OR 97403 USA. EM cpoulsen@egi.com FU National Institute of Neurological Disorders and Stroke [R44NS071988, U01 NS075026]; National Institute of Biomedical Imaging and Bioengineering [R21EB016449]; National Institutes of Health Office of the Director [S10OD010759]; National Center for Research Resources [P41RR14075]; MIND Institute FX Grant sponsor: National Institute of Neurological Disorders and Stroke; Grant numbers: R44NS071988, U01 NS075026; Grant sponsor: National Institute of Biomedical Imaging and Bioengineering; Grant number: R21EB016449; Grant sponsor: National Institutes of Health Office of the Director; Grant number: S10OD010759; Grant sponsor: National Center for Research Resources; Grant number: P41RR14075; Grant sponsor: the MIND Institute. NR 55 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0740-3194 EI 1522-2594 J9 MAGN RESON MED JI Magn. Reson. Med. PD FEB PY 2017 VL 77 IS 2 BP 895 EP 903 DI 10.1002/mrm.26116 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EL3UL UT WOS:000394544700048 PM 26876960 ER PT J AU Aires, J Casanova, C Vernal, S Nascimento, M Rodrigues, S Lerner, EA Roselino, AM AF Aires, Juliana Casanova, Claudio Vernal, Sebastian Nascimento, Margarida Rodrigues, Sandra Lerner, Ethan A. Roselino, Ana Maria TI Maxadilan-simile expression in Nyssomyia neivai, a sandfly vector in an endemic region of Brazil, and its immunogenicity in patients with American tegumentary leishmaniasis SO MEMORIAS DO INSTITUTO OSWALDO CRUZ LA English DT Article DE Maxadilan protein; leishmaniasis; Psychodidae ID FLY LUTZOMYIA-LONGIPALPIS; VISCERAL LEISHMANIASIS; CUTANEOUS LEISHMANIASIS; SALIVARY-GLANDS; SOUTHERN BRAZIL; INFECTION; PSYCHODIDAE; PEPTIDE; DIPTERA; PHLEBOTOMINAE AB BACKGROUND Maxadilan (Max) is a salivary component in the sandfly Lutzomyia longipalpis (Lutz & Neiva 1912), a vector of visceral leishmaniasis. Max has a powerful vasodilatory effect and is a candidate vaccine that has been tested in experimental leishmaniasis. Nyssomyia neivai (Pinto 1926) is a vector of the pathogen responsible for American tegumentary leishmaniasis (ATL) in Brazil. OBJECTIVE We searched for Max expression in Ny. neivai and for antibodies against Max in ATL patients. METHODS cDNA and protein were extracted from the cephalic segment, including salivary glands, of Ny. neivai and analysed by polymerase chain reaction, DNA sequencing, and blotting assays. The results were compared with data obtained from Lu. longipalpis samples. We quantified antibodies against Max in serum samples from 41 patients with ATL (31 and 10 with the cutaneous and mucocutaneous forms, respectively) and 63 controls from the endemic northeastern region of Sao Paulo state, using enzyme-linked immunosorbent assay. FINDINGS Recognition of a Max-simile peptide by specific antibodies confirmed expression of a Max sequence in Ny. neivai (GenBank EF601123.1). Compared to controls, patients with ATL presented higher levels of antibodies against Max (p = 0.004); 24.4% of the patients with ATL and 3.2% of the controls presented anti-Max levels above the cutoff index (p = 0.014). The anti-Max levels were not associated with the specific clinical form of ATL, leishmanin skin test response, absence or presence of amastigotes in histopathologic exam, results of indirect immunofluorescence testing for leishmaniasis, or duration of cutaneous form disease. MAIN C CONCLUSION High serum anti-Max levels did not protect patients against ATL, but confirmed previous natural exposure to Ny. neivai bites in this ATL endemic region. C1 [Aires, Juliana; Vernal, Sebastian; Roselino, Ana Maria] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Div Dermatol, Ribeirao Preto, SP, Brazil. [Casanova, Claudio] Secretaria Estado Saude Sao Paulo, Superintendencia Controle Endemias, Mogi Guacu, SP, Brazil. [Nascimento, Margarida] Univ Sao Paulo, Hosp Clin, Fac Med Ribeirao Preto, Lab Sorol, Ribeirao Preto, SP, Brazil. [Rodrigues, Sandra; Roselino, Ana Maria] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Mol Biol Lab, Ribeirao Preto, SP, Brazil. [Lerner, Ethan A.] Massachusetts Gen Hosp, Harvard Med Sch, Cutaneous Biol Res Ctr, Boston, MA 02114 USA. RP Roselino, AM (reprint author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Div Dermatol, Ribeirao Preto, SP, Brazil.; Roselino, AM (reprint author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Mol Biol Lab, Ribeirao Preto, SP, Brazil. EM amfrosel@fmrp.usp.br FU FAEPA; University Hospital; Ribeirao Preto Medical School; University of Sao Paulo, Brazil; CAPES FX FAEPA, University Hospital, Ribeirao Preto Medical School, University of Sao Paulo, Brazil.; SV received a scholarship from CAPES. NR 30 TC 0 Z9 0 U1 1 U2 1 PU FUNDACO OSWALDO CRUZ PI RIO DE JANEIRO, RJ PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL SN 0074-0276 EI 1678-8060 J9 MEM I OSWALDO CRUZ JI Mem. Inst. Oswaldo Cruz PD FEB PY 2017 VL 112 IS 2 BP 116 EP 122 DI 10.1590/0074-02760160351 PG 7 WC Parasitology; Tropical Medicine SC Parasitology; Tropical Medicine GA EK8ED UT WOS:000394155800005 PM 28177045 ER PT J AU Roberts, SE Thibaudeau, S Burrell, JC Zager, EL Cullen, DK Levin, LS AF Roberts, S. E. Thibaudeau, S. Burrell, J. C. Zager, E. L. Cullen, D. K. Levin, L. S. TI To reverse or not to reverse? A systematic review of autograft polarity on functional outcomes following peripheral nerve repair surgery SO MICROSURGERY LA English DT Review ID REGENERATING MOTOR AXONS; REINNERVATION; GUIDANCE; MUSCLES; GRAFTS AB Background: The literature describing the best clinical practice for proximal- distal autograft orientation, otherwise known as nerve graft polarity, is inconsistent. With existing disparities in the peripheral nerve literature, the clinical question remains whether reversing nerve autograft polarity bears an advantage for nerve regeneration. Methods: A comprehensive review of the literature using Embase and PubMed databases (1940June 2015) was performed to retrieve all original articles on the effects of nerve autograft polarity on nerve regeneration and functional recovery following primary repair of peripheral nerve defects. Results: The initial database search yielded 318 titles. Duplicate exclusion, title review and full text review yielded six articles which directly compared nerve autograft polarity. Histological, morphometric, electrophysiological, and behavioral outcomes were reviewed. All retained articles were animal studies, of which none demonstrated significant differences in outcomes between the normal and reversed polarity groups. A reversed graft may ensure that regenerating nerve fibers are not lost at branching points, however this may not translate into improved function. Conclusion: There is insufficient data to suggest that nerve autograft polarity has an impact on nerve regeneration and functional outcomes. C1 [Roberts, S. E.; Burrell, J. C.; Zager, E. L.; Cullen, D. K.] Univ Pennsylvania, Perelman Sch Med, Dept Neurosurgery, Philadelphia, PA USA. [Roberts, S. E.; Burrell, J. C.; Cullen, D. K.] Vet Affairs Med Ctr, Philadelphia, PA USA. [Thibaudeau, S.; Levin, L. S.] Hosp Univ Pennsylvania, Div Plast Surg & Dept Orthoped Surg, Philadelphia, PA USA. RP Thibaudeau, S (reprint author), 3737 Market St Suite 600, Philadelphia, PA 19104 USA. EM sthiba@gmail.com NR 31 TC 0 Z9 0 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0738-1085 EI 1098-2752 J9 MICROSURG JI Microsurgery PD FEB PY 2017 VL 37 IS 2 BP 169 EP 174 DI 10.1002/micr.30133 PG 6 WC Surgery SC Surgery GA EP4ED UT WOS:000397332600013 PM 27935644 ER PT J AU Casassus, F Tearney, GJ Seguy, B Poustis, P Coste, P Gerbaud, E AF Casassus, Frederic Tearney, Guillermo J. Seguy, Benjamin Poustis, Pierre Coste, Pierre Gerbaud, Edouard TI Minimalist immediate mechanical intervention approach in the management of an acute proximal left anterior descending artery occlusion with extensive thrombus burden in the left main coronary artery SO MINERVA CARDIOANGIOLOGICA LA English DT Letter ID ELEVATION MYOCARDIAL-INFARCTION; RANDOMIZED-TRIAL; PRIMARY PCI; ASPIRATION; STEMI; NO C1 [Casassus, Frederic; Seguy, Benjamin; Poustis, Pierre; Coste, Pierre; Gerbaud, Edouard] Hop Haut Leveque, CHU Bordeaux, Soins Intensifs Cardiolog, Plateau Cardiol Interventionnelle, 5 Ave Magellan, F-33604 Pessac, France. [Tearney, Guillermo J.] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA USA. [Tearney, Guillermo J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA USA. Harvard MIT, Div Hlth Sci & Technol, Cambridge, MA USA. [Tearney, Guillermo J.] Harvard Med Sch, Dept Pathol, Wellman Ctr Photomedicine & Massachusetts Gen Hos, Boston, MA USA. RP Gerbaud, E (reprint author), Hop Haut Leveque, CHU Bordeaux, Soins Intensifs Cardiolog, Plateau Cardiol Interventionnelle, 5 Ave Magellan, F-33604 Pessac, France. EM edouard.gerbaud@chu-bordeaux.fr FU Canon, Inc. FX Guillermo J. Tearney receives royalties from Terumo Corporation and MIT. Guillermo J. Tearney's lab receives sponsored research from Canon, Inc. NR 7 TC 0 Z9 0 U1 0 U2 0 PU EDIZIONI MINERVA MEDICA PI TURIN PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY SN 0026-4725 EI 1827-1618 J9 MINERVA CARDIOANGIOL JI Minerva Cardioangiol. PD FEB PY 2017 VL 65 IS 1 BP 102 EP 105 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EP5HE UT WOS:000397408800015 ER PT J AU Oduro, K Masia, R Sillero, MC Ebb, D Mark, E Hedley-Whyte, ET AF Oduro, Kwadwo Masia, Ricard Sillero, Maria Cobos Ebb, David Mark, Eugene Hedley-Whyte, E. Tessa TI Metastatic Atypical Teratoid Rhabdoid Tumor (ATRT) in an Adolescent SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 22 BP 9A EP 9A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300023 ER PT J AU Chebib, I Kurzawa, P Mullen, JT Johnstone, SE Deshpande, V Nielsen, GP AF Chebib, Ivan Kurzawa, Pawel Mullen, John T. Johnstone, Sarah E. Deshpande, Vikram Nielsen, G. Petur TI Prognostic Value of Myogenic Differentiation in Dedifferentiated Liposarcoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Med Sch, Boston, MA USA. Poznan Univ Med Sci, Poznan, Poland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 42 BP 14A EP 14A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300043 ER PT J AU Larque, AB Deshpande, V Nielsen, GP Chebib, I AF Larque, Ana B. Deshpande, Vikram Nielsen, G. Petur Chebib, Ivan TI Prognostic Features in Uniformly Treated Synovial Sarcoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Larque, Ana B.; Deshpande, Vikram; Nielsen, G. Petur; Chebib, Ivan] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 62 BP 18A EP 19A PG 2 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300063 ER PT J AU Biernacka, A Deshpande, Y Brachtel, E AF Biernacka, Anna Deshpande, Yikram Brachtel, Elena TI Loss of XIST - The Potential Breast Cancer X Factor SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 118 BP 32A EP 32A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300119 ER PT J AU Gonzales-Ericcson, P Mayer, IA Jovanovic, B Lehmann, B Estrada, MV Kuba, G Abramson, V Mayer, E Dillon, P Aditya, B Chang, J Forero, A Meszoely, I Grau, A Pietenpol, J Sanders, M AF Gonzales-Ericcson, Paula Mayer, Ingrid A. Jovanovic, Bojana Lehmann, Brian Estrada, Monica V. Kuba, Gabriela Abramson, Vandana Mayer, Erica Dillon, Patrick Aditya, Bardia Chang, Jenny Forero, Andres Meszoely, Ingrid Grau, Ana Pietenpol, Jennifer Sanders, Melinda TI Histopathologic Subgroups of AR plus TNBC Predict Pathologic Complete Response to Neoadjuvant Chemotherapy in Localized Breast Cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA. Dana Farber Canc Ctr, Boston, MA USA. Univ Virginia, Hlth Sci Ctr, Charlottesville, VA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Methodist Hosptal Res Inst, Houston, TX USA. Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 164 BP 43A EP 43A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300164 ER PT J AU Kuba, MG Lester, SC Bowman, T Garber, J Dillon, DA AF Kuba, Maria G. Lester, Susan C. Bowman, Teresa Garber, Judy Dillon, Deborah A. TI Breast Cancer in Li-Fraumeni Syndrome: Morphologic Evaluation of Invasive and In Situ Carcinomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 202 BP 53A EP 53A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300202 ER PT J AU Papadodima, S Masia, R Stone, JR AF Papadodima, Stavroula Masia, Ricard Stone, James R. TI Cardiac Iron Overload Following Liver Transplantation in Patients without Hemochromatosis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Univ Athens, Athens, Greece. Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 320 BP 84A EP 84A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300320 ER PT J AU Darras, N Agarwal, S Faquin, WC Wang, HH Sacks, BA Nishino, M AF Darras, Natasha Agarwal, Shweta Faquin, William C. Wang, Helen H. Sacks, Barry A. Nishino, Michiya TI ThyroSeq Testing for Indeterminate Thyroid Nodules: An Institutional Experience SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 358 BP 92A EP 93A PG 2 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300358 ER PT J AU Eng, G Rao, RA Chebib, I AF Eng, George Rao, Rema A. Chebib, Ivan TI Use of Novel Image Analysis to Characterize and Quantify Nuclear Features of Papillary Thyroid Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. 2New York Presbyterian Hosp, New York, NY USA. Weill Cornell Med Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 364 BP 94A EP 94A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300364 ER PT J AU Hang, JF Charu, V Zhang, MJL Vandenbussche, C AF Hang, Jen-Fan Charu, Vivek Zhang, Mingjuan L. Vandenbussche, Christopher TI Maximum N/C Ratio in the "Atypical Urothelial Cells" Category Correlates with Follow-Up Malignant Results in Liquid-Based Voided Urine Specimens SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 375 BP 97A EP 97A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300375 ER PT J AU Hoda, RS Arpin, R Rosenbaum, MW Pitman, MB AF Hoda, Raza S. Arpin, Ronald Rosenbaum, Matthew W. Pitman, Martha B. TI Risk of Malignancy in Pancreatic Cysts with High-Grade Atypical Cytology SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Hoda, Raza S.; Arpin, Ronald; Rosenbaum, Matthew W.; Pitman, Martha B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 378 BP 98A EP 98A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300378 ER PT J AU Rosenbaum, MW England, JS Hoda, RS Arpin, R Le, L Forcione, DG Iafrate, A Pitman, MB AF Rosenbaum, Matthew W. England, Jonathan S. Hoda, Raza S. Arpin, Ronald Le, Long Forcione, David G. Iafrate, Anthony Pitman, Martha B. TI Next Generation Sequencing Adds Value to Cytology and Fluorescence In Situ Hybridization in the Diagnosis of Bile Duct Brushing Specimens SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Rosenbaum, Matthew W.; England, Jonathan S.; Hoda, Raza S.; Arpin, Ronald; Le, Long; Forcione, David G.; Iafrate, Anthony; Pitman, Martha B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 438 BP 113A EP 114A PG 2 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300438 ER PT J AU Dewar, R Tambouret, RH AF Dewar, Rajan Tambouret, Rosemary H. TI Can Pathology Skills Be Learnt Exclusively Through Online Resources?: MOOC for PAPs - A Massive Open Online Course to Raise Pap Smear Cytoscreener Workforce in Low and Middle Income Countries SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Univ Michigan, Ann Arbor, MI 48109 USA. Udhavum Ullangal NGO, Madras, Tamil Nadu, India. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 549 BP 139A EP 139A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300548 ER PT J AU Farhat, N Xu, B Onernek, AM Tuttle, RM Roman, B Katabi, N Nose, V Sadow, PM Tallini, G Faquin, W Ghossein, R AF Farhat, Nada Xu, Bin Onernek, Ayse Mine Tuttle, R. Michael Roman, Benjamin Katabi, Nora Nose, Vania Sadow, Peter M. Tallini, Giovanni Faquin, William Ghossein, Ronald TI Should Subcentimeter Non-Invasive Encapsulated, Follicular Variant of Papillary Thyroid Carcinoma (NI-EFV PTC) Be Diagnosed as Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP)? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Bologna, Sch Med, Bologna, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 581 BP 147A EP 147A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300580 ER PT J AU Hernandez-Prera, J Machado, R Asa, SL Baloch, Z Faquin, W Ghossein, R LiVolsi, VA Lloyd, RV Mete, O Nikiforov, Y Thompson, LDR Turk, AT Seethala, RR Suster, S Urken, ML Wenig, BM AF Hernandez-Prera, Juan Machado, Rosalie Asa, Sylvia L. Baloch, Zubair Faquin, William Ghossein, Ronald LiVolsi, Virginia A. Lloyd, Ricardo V. Mete, Ozgur Nikiforov, Yuri Thompson, Lester D. R. Turk, Andrew T. Seethala, Raja R. Suster, Saul Urken, Mark L. Wenig, Bruce M. TI Pathologic Reporting of Tall Call Variant of Papillary Thyroid Cancer: Have We Reached Consensus? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Mt Sinai Beth Israel, New York, NY USA. Univ Toronto, Toronto, ON, Canada. Univ Penn, Philadelphia, PA 19104 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. Univ Wisconsin, Madison, WI USA. Univ Pittsburgh, Pittsburgh, PA USA. Southern Calif Permanente Med Grp, Woodland Hills, CA USA. Columbia Univ, New York, NY USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 582 BP 147A EP 148A PG 2 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300581 ER PT J AU Arora, KS Michelakos, T Cai, L Ting, DT Ferrone, C Ferrone, S Deshpande, V AF Arora, Kshitij S. Michelakos, Theodoros Cai, Lei Ting, David T. Ferrone, Cristina Ferrone, Soldano Deshpande, Vikram TI Colonic Carcinomas with Sporadic Loss of Mismatch Repair Proteins Are Associated with Loss of HLA Class I SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Arora, Kshitij S.; Michelakos, Theodoros; Cai, Lei; Ting, David T.; Ferrone, Cristina; Ferrone, Soldano; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 631 BP 159A EP 159A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300630 ER PT J AU Choi, WT Brown, I Ushiku, T Yozu, M Setia, N Srivastava, A Johncilla, M Pai, RK Fukayama, M Misdraji, J Lauwers, GY AF Choi, Won-Tak Brown, Ian Ushiku, Tetsuo Yozu, Masato Setia, Namrata Srivastava, Amitabh Johncilla, Melanie Pai, Rish K. Fukayama, Masashi Misdraji, Joseph Lauwers, Gregory Y. TI Gastric Pyloric Gland Adenoma: A Multicenter Clinicopathologic Study of 65 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 UCSF Med Ctr, San Francisco, CA USA. Envoi Pathol, Kelvin Grove, Qld, Australia. Univ Tokyo, Tokyo, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Chicago, Chicago, IL 60637 USA. Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Mayo Clin, Phoenix, AZ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 662 BP 166A EP 166A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300661 ER PT J AU Horvath, B Brown, I Setia, N Mattia, A Lamps, L Lauwers, GE Misdraji, J AF Horvath, Bela Brown, Ian Setia, Namrata Mattia, Anthony Lamps, Laura Lauwers, Gregory E. Misdraji, Joseph TI A Crohn's-Like Appearance Characterizes Actinomycotic Appendicitis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Envoi Specialist Pathologists, Kelvin Grove, Qld, Australia. Univ Chicago, Chicago, IL 60637 USA. Univ Arkansas Med Sci, Little Rock, AR 72205 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 698 BP 175A EP 175A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300697 ER PT J AU Jayakumar, R Qin, J Siddiqi, MA Gupta, R AF Jayakumar, Rajeswari Qin, Jia Siddiqi, M. A. Gupta, Raavi TI EZH2 as a Useful Diagnostic Tool for Grading Gastrointestinal (GI) Neuroendocrine Tumors SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 707 BP 177A EP 178A PG 2 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300706 ER PT J AU Jeck, WR Arora, KS Brachtel, E Deshpande, V AF Jeck, William Richard Arora, Kshitij S. Brachtel, Elena Deshpande, Vikram TI Harnessing TCGA RNAseq Data as a Springboard to Novel Tumor Markers SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Jeck, William Richard; Arora, Kshitij S.; Brachtel, Elena; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 708 BP 178A EP 178A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467300707 ER PT J AU Oduro, K Arora, KS Deshpande, V AF Oduro, Kwadwo Arora, Kshitij S. Deshpande, Vikram TI Chromogenic In Situ Hybridization (CISH) Based Tracking of Donor Derived Lymphocytes Augments the Histologic Evaluation of Human Acute Graft versus Host Disease (GVHD) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Oduro, Kwadwo; Arora, Kshitij S.; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 765 BP 191A EP 191A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301038 ER PT J AU Rosenbaum, MW Bledsoe, JR Kem, M Huynh, T Mino-Kenudson, M AF Rosenbaum, Matthew W. Bledsoe, Jacob R. Kem, Marina Huynh, Tiffany Mino-Kenudson, Mari TI Immune Checkpoint Expression and the Tumor Immune Environment in Colorectal Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Massachusetts, Sch Med, Worcester, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 789 BP 197A EP 197A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301062 ER PT J AU Calagua, C Shaw, K Russo, J Schaefer, R Lis, R Zhang, ZW Loda, M Taplin, ME Balk, SP Sun, Y Ye, HH AF Calagua, Carla Shaw, Kristin Russo, Joshua Schaefer, Rachel Lis, Rosina Zhang, Zhenwei Loda, Massimo Taplin, Mary-Ellen Balk, Steven P. Sun, Yue Ye, Huihui TI Effect of Neoadjuvant Intense Androgen Deprivation Therapy in PD-L1 Expression in Prostate Cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 873 BP 217A EP 217A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301146 ER PT J AU Elfandy, H Pederzoli, F Pullman, E Tyekucheva, S Schultz, N Loda, M AF Elfandy, Habiba Pederzoli, Filippo Pullman, Eli Tyekucheva, Svitlana Schultz, Nicholas Loda, Massimo TI Molecular Characterization of Prostatic Adenocarcinoma Gleason 4, Cribriform Pattern SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA. Cairo Univ, Natl Canc Inst, Cairo, Egypt. Univ Vita Salute San Raffaele, Milan, Italy. George Washington Univ, Washington, DC USA. Harvard Sch Publ Hlth, Boston, MA USA. Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. Harvard Med Sch, BWH, Boston, MA USA. DFCI, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 897 BP 222A EP 223A PG 2 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301171 ER PT J AU Kandukuri, S Choueiri, TK Hirsch, MS AF Kandukuri, Shivani Choueiri, Toni K. Hirsch, Michelle S. TI PD-L1 Expression in High Grade Locally-Advanced Renal Cell Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 949 BP 234A EP 234A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301223 ER PT J AU Montaser, L Calagua, C Schaefer, R Lis, R Zhang, ZW Loda, M Taplin, ME Balk, SP Ye, HH AF Montaser, Laleh Calagua, Carla Schaefer, Rachel Lis, Rosina Zhang, Zhenwei Loda, Massimo Taplin, Mary-Ellen Balk, Steven P. Ye, Huihui TI Effect of Neoadjuvant Intense Androgen Deprivation Therapy in Neuroendocrine Differentiation of Prostate Cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 East Tennessee State Univ, Johnson City, TN USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 987 BP 244A EP 244A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301261 ER PT J AU Obeng, RC Lorentz, A Alqassab, U Laganosky, D Keith, C Lian, F Ogan, K Master, VA Pattaras, JG Rossi, M Arnold, R Goecks, J Petros, JA Osunkoya, AO AF Obeng, Rebecca C. Lorentz, Adam Alqassab, Usama Laganosky, Dean Keith, Christopher Lian, Fei Ogan, Kenneth Master, Viraj A. Pattaras, John G. Rossi, Michael Arnold, Rebecca Goecks, Jeremy Petros, John A. Osunkoya, Adeboye O. TI Genomic Mapping of Primary Unifocal and Multifocal Renal Cell Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Emory Univ, Atlanta, GA 30322 USA. Beth Isreal Deaconess Med Ctr, Boston, MA USA. George Washington Univ, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 995 BP 246A EP 246A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301269 ER PT J AU Bennett, J Nardi, V Rouzbahman, M Morales-Oyarvide, V Kim, KR Nielsen, GP Oliva, E AF Bennett, Jennifer Nardi, Valentina Rouzbahman, Marjan Morales-Oyarvide, Vicente Kim, Kyu-Rae Nielsen, G. P. Oliva, Esther TI Inflammatory Myofibroblastic Tumor of the Uterus: A Clinicopathological, Immunohistochemical, and Molecular Analysis of 13 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Lahey Hosp, Burlington, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Toronto Gen Hosp, Toronto, ON, Canada. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Ulsan, Seoul, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1109 BP 275A EP 276A PG 2 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301385 ER PT J AU Bennett, J Pesci, A Badrinarain, J Da Silva, A Oliva, E AF Bennett, Jennifer Pesci, Anna Badrinarain, Jason Da Silva, Annacarolina Oliva, Esther TI Mismatch Repair Protein Expression in Endometrioid Carcinoma of the Ovary: Incidence and Clinicopathologic Associations in 77 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Lahey Hosp, Burlington, MA USA. Osped Sacro Cuore Don Calabria, Verona, Italy. Dana Farber Canc Inst, Boston, MA 02115 USA. [Bennett, Jennifer; Pesci, Anna; Badrinarain, Jason; Da Silva, Annacarolina; Oliva, Esther] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1110 BP 276A EP 276A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301386 ER PT J AU Bosse, T Nout, RA McAlpine, JN McConechy, M Britton, H Ganesan, R Steele, JC Harrison, BT Oliva, E Matias-Guiu, X Gilks, B Soslow, R AF Bosse, Tjalling Nout, Remi A. McAlpine, Jessica N. McConechy, Melissa Britton, Heidi Ganesan, Raji Steele, Jane C. Harrison, Beth T. Oliva, Esther Matias-Guiu, Xavier Gilks, Blake Soslow, Robert TI Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Leiden Univ, Med Ctr, Leiden, Netherlands. Univ British Columbia, Vancouver, BC, Canada. BC Canc Agcy, Vancouver, BC, Canada. Birmingham Womens HS Fdn Trust, Birmingham, W Midlands, England. Massachussets Gen Hosp, Boston, MA USA. Hosp Arnau Vilanova, Lleida, Spain. Hosp Univ Bellvitge, Lleida, Spain. Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. McGill Univ, Montreal, PQ, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1113 BP 277A EP 277A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301389 ER PT J AU Chiang, S Hensley, M Antonescu, CR Oliva, E Soslow, R AF Chiang, Sarah Hensley, Martee Antonescu, Cristina R. Oliva, Esther Soslow, Robert TI BCOR Is a Robust Diagnostic Immunohistochemical Marker of YWHAE-Rearranged High-Grade Endometrial Stromal Sarcoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1125 BP 280A EP 280A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301401 ER PT J AU Howitt, BE Garcia, E Shall, LM Lindeman, NI MacConaill, LE Dong, F Hirsch, MS Nucci, MR Crum, CP McCluggage, WG Mirkovic, J AF Howitt, Brooke E. Garcia, Elizabeth Shall, Lynette M. Lindeman, Neal I. MacConaill, Laura E. Dong, Fei Hirsch, Michelle S. Nucci, Marisa R. Crum, Christopher P. McCluggage, W. Glenn Mirkovic, Jelena TI Targeted Genomic Profiling of Female Adnexal Tumors of Probable Wolffian Origin SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1162 BP 289A EP 289A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301438 ER PT J AU Kiystel-Whittemore, M Oliva, E AF Kiystel-Whittemore, Melissa Oliva, Esther TI Patterns of Recurrences in Grade 1 Endometrioid Endometrial Adenocarcinoma (EEC) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Kiystel-Whittemore, Melissa; Oliva, Esther] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1186 BP 294A EP 295A PG 2 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301462 ER PT J AU Stolnicu, S Barsan, I Hoang, L Terinte, C Pesci, A Aviel-Ronen, S Kiyokawa, T Alvarado-Cabrero, I Park, K Oliva, E Soslow, R AF Stolnicu, Simon Barsan, Iulia Hoang, Lien Terinte, Cristina Pesci, Anna Aviel-Ronen, Sarit Kiyokawa, Takako Alvarado-Cabrero, Isabel Park, Kay Oliva, Esther Soslow, Robert TI International Endocervical Criteria and Classification: Mucinous Endocervical Adenocarcinomas (MEA) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Univ Med & Pharm, Targu Mures, Romania. Vancouver Gen Hosp, Vancouver, BC, Canada. Inst Oncol, Iasi, Romania. Osped Sacro Coure Don Calabria, Negrar, Italy. Sheba Med Ctr, Tel Hashomer, Israel. Jikei Univ, Sch Med, Tokyo, Japan. Hosp Oncol, Mexico City, DF, Mexico. MSKCC, New York, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1245 BP 310A EP 310A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301521 ER PT J AU Stolnicu, S Barsan, I Hoang, L Terinte, C Pesci, A Aviel-Ronen, S Kiyokawa, T Alvarado-Cabrero, I Park, K Oliva, E Soslow, R AF Stolnicu, Simona Barsan, Iulia Hoang, Lien Terinte, Cristina Pesci, Anna Aviel-Ronen, Sarit Kiyokawa, Takako Alvarado-Cabrero, Isabel Park, Kay Oliva, Esther Soslow, Robert TI International Endocervical Adenocarcinoma Criteria and Classification (IECC) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Univ Med & Pharm, Targu Mures, Mures, Romania. Vancouver Gen Hosp, Vancouver, BC, Canada. Inst Oncol, Iasi, Romania. Osped Sacro Coure Don Calabria, Negrar, Italy. Sheba Med Ctr, Tel Hashomer, Israel. Jikei Univ, Sch Med, Tokyo, Japan. Hosp Oncol, Mexico City, DF, Mexico. MSKCC, New York, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1244 BP 310A EP 310A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301520 ER PT J AU Wong, A Borger, D Oliva, E AF Wong, Adele Borger, Darrell Oliva, Esther TI Clinicopathological Features of Uterine Neuroendocrine Tumors (NET)s SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. KK Womens & Childrens Hosp, Singapore, Singapore. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1265 BP 315A EP 315A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301541 ER PT J AU Wong, A Arora, KS Ordulu, Z Deshpande, V Oliva, E AF Wong, Adele Arora, Kshitij S. Ordulu, Zehra Deshpande, Vikram Oliva, Esther TI TERRA Amplified (+) Primary Leiomyosarcomas (LMS) of the Gynecologic (GYN)-Tract SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. KK Womens & Childrens Hosp, Singapore, Singapore. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1266 BP 315A EP 315A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301542 ER PT J AU Bundele, MM Weinreb, I Xu, B Chiosea, S Faquin, W Dias-Santagata, D Seethala, RR AF Bundele, Manish M. Weinreb, Ilan Xu, Bin Chiosea, Simon Faquin, William Dias-Santagata, Dora Seethala, Raja R. TI Mucoacinar Carcinoma: A Rare Intercalated Duct/Acinar Variant of Mucoepidermoid Carcinoma, Hybrid Tumor, or Distinct Entity? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Tan Tock Seng Hosp, SG, Singapore, Singapore. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Hlth Network, Toronto, ON, Canada. Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1294 BP 322A EP 322A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301570 ER PT J AU Jo, VY Chau, NG Hornick, JL Krane, JF Sholl, LM AF Jo, Vickie Y. Chau, Nicole G. Hornick, Jason L. Krane, Jeffrey F. Sholl, Lynette M. TI Recurrent IDH2 R172X Mutations Define Sinonasal Undifferentiated Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1310 BP 326A EP 326A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301586 ER PT J AU Boiocchi, L Ferry, JA Deshpande, V AF Boiocchi, Leonardo Ferry, Judith A. Deshpande, Vikram TI Lymph Node Fibrosis in IgG4-Related Disease SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Boiocchi, Leonardo; Ferry, Judith A.; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1362 BP 339A EP 339A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301638 ER PT J AU Boyer, D McKelvie, P de Leval, L Edlefsen, KL Ko, YH Aberman, Z Kovach, A Masih, A Nishino, H Weiss, L Meeker, A Nardi, V Palisoc, M Shao, LN Pittaluga, S Ferry, JA Harris, N Sohani, A AF Boyer, Daniel McKelvie, Penelope de Leval, Laurence Edlefsen, Kerstin L. Ko, Young-Hyeh Aberman, Zachary Kovach, Alexandra Masih, Aneal Nishino, Ha Weiss, Lawrence Meeker, Alan Nardi, Valentina Palisoc, Maryknoll Shao, Lina Pittaluga, Stefania Ferry, Judith A. Harris, Nancy Sohani, Aliyah TI Fibrin-Associated EBV plus Large B-Cell Lymphoma: An Indolent Neoplasm Distinct from DLBCL-CI SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Univ Michigan, Ann Arbor, MI 48109 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. St Vincents Hosp, Melbourne, Vic, Australia. CHU Vaudois, Lausanne, Switzerland. Univ Washington, Seattle, WA 98195 USA. Sungkyunkwan Univ, Seoul, South Korea. Florida Int Univ, Miami, FL 33199 USA. Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA. Holmes Reg Med Ctr, Melbourne, FL USA. North Shore Med Ctr, Salem, MA USA. NeoGen Labs, Aliso Viejo, CA USA. Johns Hopkins Univ, Baltimore, MD USA. NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1363 BP 339A EP 340A PG 2 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301639 ER PT J AU Crotty, R Pozdnyakova, O Chen, YB Ballen, K Hasserjian, RP AF Crotty, Rory Pozdnyakova, Olga Chen, Yi-Bin Ballen, Karen Hasserjian, Robert P. TI Lymphoid Proliferations Following Umbilical Cord Stem Cell Transplant SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1381 BP 344A EP 344A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467301657 ER PT J AU Margolskee, E Mikita, G Oak, J Allen, MB Zuo, Z Wang, S Arber, DA George, T Hasserjian, RP Orazi, A AF Margolskee, Elizabeth Mikita, Geoffrey Oak, Jean Allen, M. B. Zuo, Zhuang Wang, Sa Arber, Daniel A. George, Tracy Hasserjian, Robert P. Orazi, Attilio TI Acute Myeloid Leukemia with Erythroid Predominance: Are All Cases MDS-Related? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA. Stanford Univ, Stanford, CA 94305 USA. Univ New Mexico, Albuquerque, NM 87131 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1452 BP 362A EP 362A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302031 ER PT J AU Maryamchik, E Van Cott, EM AF Maryamchik, Elena Van Cott, Elizabeth M. TI The Effects of Rivaroxaban on Activated Protein C Resistance and Protein S Testing SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Maryamchik, Elena; Van Cott, Elizabeth M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1454 BP 363A EP 363A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302033 ER PT J AU Shih, A Bledsoe, JR McKelvie, P Harris, N Zukerberg, L AF Shih, Angela Bledsoe, Jacob R. McKelvie, Penny Harris, Nancy Zukerberg, Lawrence TI CD5-Negative Mantle Cell Lymphoma Shows a More Indolent Outcome and Variable SOX11 Staining SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Shih, Angela; Bledsoe, Jacob R.; McKelvie, Penny; Harris, Nancy; Zukerberg, Lawrence] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1513 BP 378A EP 378A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302092 ER PT J AU Tashakori, M Sanchez, J Michalowski, SM Louissaint, A Inamdar, KV Gomez-Gelvez, J Carey, JL Menon, MP AF Tashakori, Mehrnoosh Sanchez, Jessica Michalowski, Susan M. Louissaint, Abner Inamdar, Kedar V. Gomez-Gelvez, Juan Carey, John L. Menon, Madhu P. TI Follicular Lymphoma Transforming to Double and Triple Hit Lymphoma; a Clinicopathologic, Morphologic and Cytogenetic Analysis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Henry Ford Hlth Syst, Detroit, MI USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1525 BP 380A EP 381A PG 2 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302104 ER PT J AU Weinberg, OK Gibson, CJ Pozdnyakova, O Kuo, FC Ebert, B Hasserjian, RP AF Weinberg, Olga K. Gibson, Christopher J. Pozdnyakova, Olga Kuo, Frank C. Ebert, Benjamin Hasserjian, Robert P. TI Specific Dysplastic Findings Correlate with Gene Mutations in De Novo AML SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Boston Childrens Hosp, Boston, MA USA. Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1542 BP 385A EP 385A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302121 ER PT J AU Wertheim, G Pillai, V Sargent, R Paessler, M Lewen, M Li, J Master, S Carroll, M Luskin, M AF Wertheim, Gerald Pillai, Vinodh Sargent, Rachel Paessler, Michele Lewen, Margaret Li, Jie Master, Stephen Carroll, Martin Luskin, Marlise TI EVI1 Immunohistochemistry Identifies AML Subtypes with Distinct Genetics and Prognosis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Childrens Hosp Phila, Philadelphia, PA USA. Hosp Univ Penn, Philadelphia, PA USA. Weill Cornell Med Coll, New York, NY USA. Boston Childrens Hosp, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1544 BP 385A EP 386A PG 2 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302122 ER PT J AU Wong, WJ Baltay, MT Kuo, FC Fuhrman, K Hasserjian, RP Pozdnyakova, O AF Wong, Waihay J. Baltay, Michele T. Kuo, Frank C. Fuhrman, Kit Hasserjian, Robert P. Pozdnyakova, Olga TI Integrated Molecular and Histologic Analysis Identifies Distinctive Gene Expression Patterns in Primary Myelofibrosis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Nanostring Technol Inc, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1546 BP 386A EP 386A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302124 ER PT J AU Xia, D Sayed, S Moloo, Z Gakinya, S Mutuiri, A Courville, EL Hasseijian, RP Sohani, A AF Xia, Daniel Sayed, Shahin Moloo, Zahir Gakinya, Samuel Mutuiri, Anderson Courville, Elizabeth L. Hasseijian, Robert P. Sohani, Aliyah TI Clinicopathologic Characterization of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Kenya SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Aga Khan Univ Hosp, Nairobi, Kenya. Univ Minnesota, Minneapolils, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1547 BP 386A EP 386A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302125 ER PT J AU Fu, XJ Bautista, P Lennerz, JK Onozato, M Iafrate, A Yagi, Y AF Fu, Xiujun Bautista, Pinky Lennerz, Jochen K. Onozato, Maristela Iafrate, Anthony Yagi, Yukako TI Apply a Confocal WSI Scanner for FISH Slides Imaging, 3D Reconstruction, and Semi-Automated Diagnosis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1585 BP 396A EP 396A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302163 ER PT J AU Faulkner-Jones, BE Law, C Rosen, M Rosen, D Luffman, CI Rosen, S AF Faulkner-Jones, Beverly E. Law, Charles Rosen, Milan Rosen, Devin Luffman, Christina I. Rosen, Seymour TI Renal Biopsy Data Analysis from Whole Slide Imaging: A Novel "Holistic" Approach SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 BIDMC, Boston, MA USA. Kitware Inc, Clifton Pk, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1624 BP 406A EP 406A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302201 ER PT J AU Lee, M de Gonzalez, AK Remotti, HE Gandhi, M Levinson, S Deshpande, V Lagana, SM AF Lee, Michael de Gonzalez, Anne Koehne Remotti, Helen E. Gandhi, Manoj Levinson, Shauna Deshpande, Vikram Lagana, Stephen M. TI In-Situ Hybridization for Glypican-3 RNA Is More Sensitive Than Immunohistochemistry in Hepatocellular Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Columbia Univ, New York, NY USA. Affymetrix, Santa Clara, CA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1679 BP 419A EP 419A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302252 ER PT J AU Solomon, D Goode, B Hyun, MD Joseph, NM Van Ziffle, J Butowski, N Brat, DJ Kleinschmidt-DeMasters, B Rodriguez, F Louis, DN Yong, W Lopes, B Rosenblum, M Tihan, T Bollen, A Perry, A AF Solomon, David Goode, Benjamin Hyun, Michael D. Joseph, Nancy M. Van Ziffle, Jessica Butowski, Nicholas Brat, Daniel J. Kleinschmidt-DeMasters, Bette Rodriguez, Fausto Louis, David N. Yong, William Lopes, Beatriz Rosenblum, Marc Tihan, Tank Bollen, Andrew Perry, Arie TI A Recurrent Kinase Domain Mutation p.D463H in PRKCA Defines Chordoid Glioma of the Third Ventricle SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Emory Univ, Atlanta, GA 30322 USA. Univ Colorado, Denver, CO 80202 USA. Johns Hopkins Univ, Baltimore, MD USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Calif Los Angeles, Los Angeles, CA USA. Univ Virginia, Charlottesville, VA USA. Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1753 BP 437A EP 437A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302327 ER PT J AU Williams, E Kim, J Muzikansky, A Shaw, M Iafrate, J Plotkin, S Suva, M Stemmer-Rachamimov, A AF Williams, Erik Kim, James Muzikansky, Alona Shaw, McKenzie Iafrate, John Plotkin, Scott Suva, Mario Stemmer-Rachamimov, Anat TI Molecular and Histologic Features of a Series of Sporadic and Familial Schwannomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Broad Inst MIT & Harvard, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1763 BP 439A EP 439A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302337 ER PT J AU Nowak, JA Wu, YR Qian, ZR Rubinson, DA Morales-Oyarvide, V Dunne, RF Findeis-Hosey, JJ Hornick, JL Brais, L Da Silva, A Welch, M Yuan, C Kozak, M Ducar, M Thorner, A Wollison, B Fuchs, C Ogino, S Hezel, A Koong, A Wolpin, B AF Nowak, Jonathan A. Wu, Yiru Qian, Zhirong Rubinson, Douglas A. Morales-Oyarvide, Vicente Dunne, Richard F. Findeis-Hosey, Jennifer J. Hornick, Jason L. Brais, Lauren Da Silva, Annacarolina Welch, Marisa Yuan, Chen Kozak, Margaret Ducar, Matthew Thorner, Aaron Wollison, Bruce Fuchs, Charles Ogino, Shuji Hezel, Aram Koong, Albert Wolpin, Brian TI Molecular Correlates of Major Morphologic Subtypes of Pancreatic Ductal Adenocarcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Rochester, Rochester, NY USA. Stanford Univ, Stanford, CA 94305 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1803 BP 449A EP 449A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302377 ER PT J AU Marino-Enriquez, A Kuo, FC Baltay, M Demetri, G Lindeman, NI Fletcher, J Sholl, LM AF Marino-Enriquez, Adrian Kuo, Frank C. Baltay, Michele Demetri, George Lindeman, Neal I. Fletcher, Jonathan Sholl, Lynette M. TI Identification of Sarcoma Fusion Genes by Multiplex Detection of Aberrant 3 ' to 5 ' Expression Ratios SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1847 BP 459A EP 460A PG 2 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302420 ER PT J AU Glass, CH Redig, AJ Hung, YP French, C Sholl, LM AF Glass, Carolyn H. Redig, Amanda J. Hung, Yin P. French, Christopher Sholl, Lynette M. TI SMARCA4 Loss in Lung Cancer Is Associated with Distinct Clinicopathologic Features SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1926 BP 479A EP 479A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302498 ER PT J AU Hung, YR Dong, F Nardi, V Watkins, JC Godleski, J Dal Cin, P Crum, CP Chirieac, LR AF Hung, Yin (Rex) Dong, Fei Nardi, Valentina Watkins, Jaclyn C. Godleski, John Dal Cin, Paola Crum, Christopher P. Chirieac, Lucian R. TI A Subset of Diffuse Malignant Peritoneal Mesothelioma Have Novel ALK Rearrangements and Distinct Clinicopathologic Features SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1931 BP 480A EP 480A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302503 ER PT J AU Hwang, DH Mentzer, SJ Johnson, BE Sholl, LM AF Hwang, David H. Mentzer, Steven J. Johnson, Bruce E. Sholl, Lynette M. TI Next Generation Sequencing Frequently Contradicts Surgical Pathology Impression of Relatedness of Multiple Tumors in the Lung SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1932 BP 480A EP 480A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302504 ER PT J AU Jin, Y Matsubara, O Yamanaka, K Mark, E AF Jin, Yasuto Matsubara, Osamu Yamanaka, Kazuki Mark, Eugene TI Intratumoral Programmed Cell Death-Ligand 1 (PD-L1) and Intratumoral CD8(+) T Cell Expression in Lung Cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Kyosai Hosp, Hiratsuka, Kanagawa, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1935 BP 481A EP 481A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302507 ER PT J AU Ordulu, Z Kem, M Huynh, T Dias-Santagata, D Iafrate, J Mino-Kenudson, M AF Ordulu, Zebra Kem, Marina Huynh, Tiffany Dias-Santagata, Dora Iafrate, John Mino-Kenudson, Mari TI PDL-1 Expression in Synchronous Lung Nodules: Association with Driver Mutations and CD8+Cytotoxic T Lymphocytes SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Ordulu, Zebra; Kem, Marina; Huynh, Tiffany; Dias-Santagata, Dora; Iafrate, John; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1963 BP 487A EP 487A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302534 ER PT J AU Ritterhouse, L Vivero, M Mino-Kenudson, M Sholl, LM Iafrate, J Nardi, V Dong, F AF Ritterhouse, Lauren Vivero, Marina Mino-Kenudson, Mari Sholl, Lynette M. Iafrate, John Nardi, Valentina Dong, Fei TI GNAS Mutations in Mucinous and Non-Mucinous Lung Carcinomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1977 BP 491A EP 491A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302548 ER PT J AU Rosen, LE Ananthanarayanan, V Gallan, A Tjota, MY Attanoos, R Alchami, FS Brcic, L Butnor, K Hiroshima, K Klampatsa, A Litzky, L Marchevsky, AM Medeiros, F Montero-Fernandez, MA Moore, DA Nabeshima, K Pavlisko, EN Sharma, A Sheaff, M Walts, AE Galateau, F Le Stang, N Krausz, T Husain, AN AF Rosen, Lauren E. Ananthanarayanan, Vijayalakshmi Gallan, Alexander Tjota, Melissa Yuwono Attanoos, Richard Alchami, Fouad S. Brcic, Luka Butnor, Kelly Hiroshima, Kenzo Klampatsa, Astero Litzky, Leslie Marchevsky, Alberto M. Medeiros, Filomena Montero-Fernandez, M. Angeles Moore, David A. Nabeshima, Kazuki Pavlisko, Elizabeth N. Sharma, Anupama Sheaff, Michael Walts, Ann E. Galateau, Francoise Le Stang, Nolwenn Krausz, Thomas Husain, Aliya N. TI Nuclear Grade, Necrosis and Solid Growth Pattern Predict Survival in Epithelioid Malignant Mesothelioma: An International, Multi Institutional Study SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Univ Chicago, Chicago, IL 60637 USA. Loyola, Maywood, IL USA. Univ Wales Coll Cardiff, Cardiff, S Glam, Wales. Med Univ Graz, Graz, Austria. Univ Vermont, Burlington, VT USA. Tokyo Womens Med Ctr, Kawadacho, Japan. Univ Penn, Philadelphia, PA 19104 USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. Basildon & Thurrock Univ Hosp, Basildon, England. Royal Brompton & Harefield Hosp, London, England. Univ Leicester, Leicester, Leics, England. Fukuoka Univ, Fukuoka, Japan. Duke Univ, Durham, NH USA. Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Barts Hlth NHS Trust, London, England. Ctr Leon Berard, Lyon, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1980 BP 492A EP 492A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302551 ER PT J AU Shih, A Fu, XJ Hariri, L Huynh, T Mark, E Yagi, Y Mino-Kenudson, M AF Shih, Angela Fu, Xiujun Hariri, Lida Huynh, Tiffany Mark, Eugene Yagi, Yukako Mino-Kenudson, Mari TI Alveolar Framework Alterations in Fibrosing Interstitial Lung Disease: A Three-Dimensional Reconstruction Study SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Shih, Angela; Fu, Xiujun; Hariri, Lida; Huynh, Tiffany; Mark, Eugene; Yagi, Yukako; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1992 BP 495A EP 495A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302563 ER PT J AU Shih, A Uruga, H Muzikansky, A Bozkurtlar, E Chung, JH Hariri, L Minami, Y Moreira, AL Wang, H Yoshizawa, A Mino-Kenudson, M AF Shih, Angela Uruga, Hironori Muzikansky, Alona Bozkurtlar, Emine Chung, Jin-Haeng Hariri, Lida Minami, Yuko Moreira, Andre L. Wang, He Yoshizawa, Akihiko Mino-Kenudson, Mari TI Reproducibility in Classification of Small Lung Adenocarcinomas: An International Interobserver Study SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Marmara Univ, Istanbul, Turkey. Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea. Ibarakihigashi Natl Hosp, Natl Hosp Org, Naka, Ibaraki, Japan. NYU, Langone Med Ctr, New York, NY USA. Temple Univ, Sch Med, Philadelphia, PA 19122 USA. Kyoto Univ Hosp, Kyoto, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 1993 BP 495A EP 495A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302564 ER PT J AU Zhang, MJL Kem, M Campo, MJ Huynh, T Gainor, JF Mino-Kenudson, M AF Zhang, Mingjuan L. Kem, Marina Campo, Meghan J. Huynh, Tiffany Gainor, Justin F. Mino-Kenudson, Mari TI Differential Expression of Immune Inhibitory Markers in Association with the Immune Microenvironment in Resected Lung Adenocarcinomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Zhang, Mingjuan L.; Kem, Marina; Campo, Meghan J.; Huynh, Tiffany; Gainor, Justin F.; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 2012 BP 500A EP 500A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302583 ER PT J AU Crotty, R Prasad, S Brachtel, E Deshpande, V AF Crotty, Rosy Prasad, Shilpa Brachtel, Elena Deshpande, Vikram TI XIST as a Tool for Resolving Specimen Contamination Events SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Boston Univ, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 2028 BP 504A EP 504A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302599 ER PT J AU Maglantay, RJ Cunningham, VL Goodwin, MT Feeney, M Keefe, J Sohani, A Tambouret, RH AF Maglantay, Remegio J. Cunningham, Vickie L. Goodwin, Michele T. Feeney, Margaret Keefe, Joan Sohani, Aliyah Tambouret, Rosemary H. TI Evaluation of Body Fluids: Detection of Malignancy in Specimens Submitted for Cell Count and Differential in the Hematology Laboratory SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Maglantay, Remegio J.; Cunningham, Vickie L.; Goodwin, Michele T.; Feeney, Margaret; Keefe, Joan; Sohani, Aliyah; Tambouret, Rosemary H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 2059 BP 511A EP 511A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302630 ER PT J AU Maglantay, RJ Wang, JL Pozdnyakova, O Ly, A AF Maglantay, Remegio J. Wang, Jessica L. Pozdnyakova, Olga Ly, Amy TI Comparison of Two Methods for Cytologic Evaluation of Cerebrospinal Fluids SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Atrius Hlth, Needham, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 2060 BP 512A EP 512A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302631 ER PT J AU Qin, J Tambouret, RH AF Qin, Jia Tambouret, Rosemary H. TI Rapid FNA Diagnosis of Lymphadenopathy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Qin, Jia; Tambouret, Rosemary H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 2078 BP 516A EP 516A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302649 ER PT J AU Wong, A Bhan, A Lennerz, JK Brachtel, E AF Wong, Adele Bhan, Atul Lennerz, Jochen K. Brachtel, Elena TI HER2/ERBB2 Testing in Breast Carcinoma by Next Generation Sequencing SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 2101 BP 522A EP 522A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302672 ER PT J AU Bedoya, F Frigault, MJ Maus, MV AF Bedoya, Felipe Frigault, Matthew J. Maus, Marcela V. TI The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy SO MOLECULAR THERAPY LA English DT Review ID CHIMERIC ANTIGEN RECEPTORS; CYTOKINE RELEASE SYNDROME; ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; VERSUS-HOST-DISEASE; GENE-TRANSFER; MANAGEMENT; BLINATUMOMAB; REMISSIONS; REGRESSION AB Autologous T cells modified to recognize novel antigen targets are a novel form of therapy for cancer. We review the various potential forms of observed and hypothetical toxicities associated with genetically modified T cells. Despite the focus on toxicities in this review, re-directed T cells represent a powerful and highly effective form of anti-cancer therapy; we remain optimistic that the common toxicities will become routinely manageable and that some theoretical toxicity will be exceedingly rare, if ever observed. C1 [Bedoya, Felipe; Frigault, Matthew J.; Maus, Marcela V.] Massachusetts Gen Hosp, Ctr Canc, Cellular Immunotherapy Program, Boston, MA 02114 USA. [Bedoya, Felipe; Frigault, Matthew J.; Maus, Marcela V.] Harvard Med Sch, Boston, MA 02115 USA. RP Maus, MV (reprint author), 149 13th St,Room 7-219, Charlestown, MA 02129 USA. EM mvmaus@mgh.harvard.edu FU NIH [K08CA166039]; Gabrielle's Angel Foundation; V Foundation FX M. V. M. was supported by NIH K08CA166039, Gabrielle's Angel Foundation, and the V Foundation. NR 57 TC 0 Z9 0 U1 1 U2 1 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1525-0016 EI 1525-0024 J9 MOL THER JI Mol. Ther. PD FEB 1 PY 2017 VL 25 IS 2 BP 314 EP 320 DI 10.1016/j.ymthe.2016.11.011 PG 7 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA EP3UT UT WOS:000397307900005 PM 28153085 ER PT J AU Gyorgy, B Sage, C Indzhykulian, AA Scheffer, DI Brisson, AR Tan, S Wu, XD Volak, A Mu, DK Tamvakologos, PI Li, YQ Fitzpatrick, Z Ericsson, M Breakefield, XO Corey, DP Maguire, CA AF Gyorgy, Bence Sage, Cyrille Indzhykulian, Artur A. Scheffer, Deborah I. Brisson, Alain R. Tan, Sisareuth Wu, Xudong Volak, Adrienn Mu, Dakai Tamvakologos, Panos I. Li, Yaqiao Fitzpatrick, Zachary Ericsson, Maria Breakefield, Xandra O. Corey, David P. Maguire, Casey A. TI Rescue of Hearing by Gene Delivery to Inner-Ear Hair Cells Using Exosome-Associated AAV SO MOLECULAR THERAPY LA English DT Article ID ADENOASSOCIATED VIRUS VECTORS; EFFICIENT TRANSDUCTION; EXTRACELLULAR VESICLES; IN-VIVO; THERAPY; DEAFNESS; ROBUST; MICE; TMHS AB Adeno-associated virus (AAV) is a safe and effective vector for gene therapy for retinal disorders. Gene therapy for hearing disorders is not as advanced, in part because gene delivery to sensory hair cells of the inner ear is inefficient. Although AAV transduces the inner hair cells of the mouse cochlea, outer hair cells remain refractory to transduction. Here, we demonstrate that a vector, exosome-associated AAV (exo-AAV), is a potent carrier of transgenes to all inner ear hair cells. ExoAAV1-GFP is more efficient than conventional AAV1-GFP, both in mouse cochlear explants in vitro and with direct cochlear injection in vivo. Exo-AAV shows no toxicity in vivo, as assayed by tests of auditory and vestibular function. Finally, exo-AAV1 gene therapy partially rescues hearing in a mouse model of hereditary deafness (lipoma HMGIC fusion partner-like 5/ tetraspan membrane protein of hair cell stereocilia [Lhfpl5/ Tmh(-/-)]). Exo-AAV is a powerful gene delivery system for hair cell research and may be useful for gene therapy for deafness. C1 [Gyorgy, Bence; Sage, Cyrille; Indzhykulian, Artur A.; Scheffer, Deborah I.; Wu, Xudong; Tamvakologos, Panos I.; Li, Yaqiao; Corey, David P.] Harvard Med Sch, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA. [Gyorgy, Bence; Sage, Cyrille; Indzhykulian, Artur A.; Scheffer, Deborah I.; Wu, Xudong; Tamvakologos, Panos I.; Li, Yaqiao; Corey, David P.] Harvard Med Sch, Howard Hughes Med Inst, 220 Longwood Ave, Boston, MA 02115 USA. [Gyorgy, Bence; Volak, Adrienn; Mu, Dakai; Fitzpatrick, Zachary; Breakefield, Xandra O.; Maguire, Casey A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Bldg 149, Charlestown, MA 02129 USA. [Gyorgy, Bence; Volak, Adrienn; Mu, Dakai; Fitzpatrick, Zachary; Breakefield, Xandra O.; Maguire, Casey A.] Harvard Med Sch, NeuroDiscovery Ctr, Bldg 149, Charlestown, MA 02129 USA. [Brisson, Alain R.; Tan, Sisareuth] Univ Bordeaux, IPB, CNRS, Mol Imaging & NanoBioTechnol,UMR 5248,CBMN, Allee Geoffroy St Hilaire, F-33600 Pessac, France. [Ericsson, Maria] Harvard Med Sch, Dept Cell Biol, 220 Longwood Ave, Boston, MA 02115 USA. [Breakefield, Xandra O.] Harvard Med Sch, Program Neurosci, Bldg 149, Charlestown, MA 02129 USA. RP Corey, DP (reprint author), Harvard Med Sch, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.; Corey, DP (reprint author), Harvard Med Sch, Howard Hughes Med Inst, 220 Longwood Ave, Boston, MA 02115 USA.; Maguire, CA (reprint author), Massachusetts Gen Hosp, Dept Neurol, Bldg 149, Charlestown, MA 02129 USA. EM dcorey@hms.harvard.edu; cmaguire@mgh.harvard.edu FU NIH/NINDS [R21 NS081374-01]; NIH/NIDCD [R01 DC002281]; American Brain Tumor Association Discovery grant; Cure Alzheimer's Fund FX This work was supported by NIH/NINDS grant R21 NS081374-01 (C.A.M.), NIH/NIDCD grant R01 DC002281 (D.P.C.), an American Brain Tumor Association Discovery grant (C.A.M.), and a Cure Alzheimer's Fund (C.A.M.). We acknowledge the Nucleic Acid Quantitation Core at MGH Neuroscience Center for quantitative PCR analysis. B.G. is an Associate and D.P.C. is an Investigator of the Howard Hughes Medical Institute. We thank Hunter Elliott (Harvard, Image and Data Analysis Core) for assistance with image analysis. We also thank Nick Andrews and Trishala Chari (Boston Children's Hospital, Neurodevelopmental Behavioral Core) for helping with behavioral analysis. NR 28 TC 1 Z9 1 U1 3 U2 3 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1525-0016 EI 1525-0024 J9 MOL THER JI Mol. Ther. PD FEB 1 PY 2017 VL 25 IS 2 BP 379 EP 391 DI 10.1016/j.ymthe.2016.12.010 PG 13 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA EP3UT UT WOS:000397307900011 PM 28082074 ER PT J AU Raskind, WH Friedman, JR Roze, E Meneret, A Chen, DH Bird, TD AF Raskind, Wendy H. Friedman, Jennifer R. Roze, Emmanuel Meneret, Aurelie Chen, Dong-Hui Bird, Thomas D. TI ADCY5-related dyskinesia: Comments on characteristic manifestations and variant-associated severity SO MOVEMENT DISORDERS LA English DT Letter ID FAMILIAL DYSKINESIA; FACIAL MYOKYMIA C1 [Raskind, Wendy H.] Univ Washington, Dept Med Med Genet, Seattle, WA 98195 USA. [Raskind, Wendy H.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Raskind, Wendy H.; Bird, Thomas D.] US Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, Seattle, WA 98174 USA. [Friedman, Jennifer R.] Univ Calif San Diego, Dept Neurosci & Pediat, San Diego, CA 92103 USA. [Friedman, Jennifer R.] Rady Childrens Hosp, San Diego, CA USA. [Roze, Emmanuel; Meneret, Aurelie] UPMC Univ Paris 06, Sorbonne Univ, Inst Cerveau & Moelle Epiniere, Inserm,CNRS,UMR 7225,UMR S 1127,U1127, Paris, France. [Roze, Emmanuel; Meneret, Aurelie] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Paris, France. [Chen, Dong-Hui; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. RP Raskind, WH (reprint author), Univ Washington, Dept Med Med Genet, Seattle, WA 98195 USA.; Raskind, WH (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.; Raskind, WH (reprint author), US Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, Seattle, WA 98174 USA. EM wendyrun@uw.edu FU National Institute of Neurological Diseases and Stroke [R01 NS069719]; Department of Veterans Affairs; Athena Diagnostics; CNRS; INSERM (COSSEC),; AP-HP (DRC-PHRC); MerzPharma; Orkyn; Aguettant; IP sante; Ultragenix; UCB pharma; Teva; Sanofi-Genzyme; Dystonia Coalition; Dystonia Medical Research Foundation; Movement Disorders Society; JNLF (Journees de Neurologie en Langue Francaise) FX Dr. Raskind is funded by the National Institute of Neurological Diseases and Stroke (R01 NS069719) and the Department of Veterans Affairs. She receives licensing fees from Athena Diagnostics for Patent 7655401 "Mutations in PKCc are the cause for spinocerebellar ataxia." Dr. Friedman reports family financial interest in biotechnology. Dr. Roze received research support from CNRS, INSERM (COSSEC), AP-HP (DRC-PHRC), MerzPharma, Orkyn, Aguettant, IP sante, Ultragenix, UCB pharma; served on scientific advisory boards for Orkyn, Ultragenix, and Merz-Pharma; received speech honoraria from Orkyn, Aguettant, Merz-Pharma, and Ultragenix; and received travel funding from Teva, Sanofi-Genzyme, the Dystonia Coalition, the Dystonia Medical Research Foundation, and the Movement Disorders Society. Dr. Meneret received a grant from JNLF (Journees de Neurologie en Langue Francaise). Dr. Chen receives licensing fees from Athena Diagnostics for Patent 7655401 "Mutations in PKCc are the cause for spinocerebellar ataxia." Dr. Bird receives licensing fees from Athena Diagnostics for Patent 7655401 "Mutations in PKCc are the cause for spinocerebellar ataxia." He is funded by the Department of Veterans Affairs. NR 5 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB PY 2017 VL 32 IS 2 BP 305 EP 306 DI 10.1002/mds.26888 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA EM9QJ UT WOS:000395645900026 PM 27933653 ER PT J AU Wang, CN AF Wang, Changning TI A Novel PET Imaging Probe Targeting Monoacylglycerol Lipase In The Brain SO MULTIPLE SCLEROSIS JOURNAL LA English DT Meeting Abstract CT Forum of the Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) CY FEB 23-25, 2017 CL Orlando, FL SP Americas Comm Treatment & Res Multiple Sclerosis C1 [Wang, Changning] Harvard Med Sch, Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 EI 1477-0970 J9 MULT SCLER J JI Mult. Scler. J. PD FEB PY 2017 VL 23 IS 1 SU 1 MA P124 BP 64 EP 64 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EM5YB UT WOS:000395388800147 ER PT J AU Gong, YX Schumacher, SE Wu, WH Tang, FY Beroukhim, R Chan, TA AF Gong, Yongxing Schumacher, Steven E. Wu, Wei H. Tang, Fanying Beroukhim, Rameen Chan, Timothy A. TI Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis SO NEOPLASIA LA English DT Article ID MYC-DRIVEN LYMPHOMAGENESIS; COPY-NUMBER ALTERATION; CELL-DEATH; LUNG-CANCER; MITOCHONDRIAL DEPOLARIZATION; PROTEIN FAMILY; GENE; LIGASE; MICE; ASSOCIATION AB Mutation of the PARK2 gene can promote both Parkinson's Disease and cancer, yet the underlying mechanisms of how PARK2 controls cellular physiology is incompletely understood. Here, we show that the PARK2 tumor suppressor controls the apoptotic regulator BCL-XL and modulates programmed cell death. Analysis of approximately 10,000 tumor genomes uncovers a striking pattern of mutual exclusivity between PARK2 genetic loss and amplification of BCL2L1, implicating these genes in a common pathway. PARK2 directly binds to and ubiquitinates BCL-XL. Inactivation of PARK2 leads to aberrant accumulation of BCL-XL both in vitro and in vivo, and cancer-specific mutations in PARK2 abrogate the ability of the ubiquitin E3 ligase to target BCL-XL for degradation. Furthermore, PARK2 modulates mitochondrial depolarization and apoptosis in a BCL-XL-dependent manner. Thus, like genes at the nodal points of growth arrest pathways such as p53, the PARK2 tumor suppressor is able to exert its antiproliferative effects by regulating both cell cycle progression and programmed cell death. C1 [Gong, Yongxing; Wu, Wei H.; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY USA. [Schumacher, Steven E.] Broad Inst Harvard, Cambridge, MA USA. [Schumacher, Steven E.] MIT, Cambridge, MA USA. [Schumacher, Steven E.; Beroukhim, Rameen; Chan, Timothy A.] Dana Farber Canc Inst, Dept Canc Biol, Cambridge, MA USA. [Schumacher, Steven E.; Beroukhim, Rameen; Chan, Timothy A.] Weill Cornell Coll Med, New York, NY USA. [Tang, Fanying; Chan, Timothy A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [Beroukhim, Rameen] Dana Farber Canc Inst, Ctr Canc Genome Characterizat, Boston, MA USA. [Beroukhim, Rameen; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY USA. [Beroukhim, Rameen; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Immunogen & Precis Oncol Platform, New York, NY USA. RP Chan, TA (reprint author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 10065, New York, NY USA. EM chant@mskcc.org FU National Institutes of Health [RO1 NS086875-01, R01 CA188228]; MSKCC Brain Tumor Center; Sontag Foundation; Pediatric Low-Grade Astrocytoma Foundation; Frederick Adler Fund; Paine Webber Chair FX This work was supported by the National Institutes of Health (RO1 NS086875-01 and R01 CA188228) (T.A.C. and R.B.), the MSKCC Brain Tumor Center (T.A.C.), the Sontag Foundation (T.A.C. and R.B.), the Pediatric Low-Grade Astrocytoma Foundation (R.B.), the Frederick Adler Fund (T.A.C.), and the Paine Webber Chair (T.A.C.). NR 46 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1476-5586 J9 NEOPLASIA JI Neoplasia PD FEB PY 2017 VL 19 IS 2 BP 75 EP 83 DI 10.1016/j.neo.2016.12.006 PG 9 WC Oncology SC Oncology GA EO9JO UT WOS:000397005200003 PM 28038320 ER PT J AU Jones, C Karajannis, MA Jones, DTW Kieran, MW Monje, M Baker, SJ Becher, OJ Cho, YJ Gupta, N Hawkins, C Hargrave, D Haas-Kogan, DA Jabado, N Li, XN Mueller, S Nicolaides, T Packer, RJ Persson, AI Phillips, JJ Simonds, EF Stafford, JM Tang, YJ Pfister, SM Weiss, WA AF Jones, Chris Karajannis, Matthias A. Jones, David T. W. Kieran, Mark W. Monje, Michelle Baker, Suzanne J. Becher, Oren J. Cho, Yoon-Jae Gupta, Nalin Hawkins, Cynthia Hargrave, Darren Haas-Kogan, Daphne A. Jabado, Nada Li, Xiao-Nan Mueller, Sabine Nicolaides, Theo Packer, Roger J. Persson, Anders I. Phillips, Joanna J. Simonds, Erin F. Stafford, James M. Tang, Yujie Pfister, Stefan M. Weiss, William A. TI Pediatric high-grade glioma: biologically and clinically in need of new thinking SO NEURO-ONCOLOGY LA English DT Article DE clinical trials; DIPG; genomics; glioma; pediatric ID INTRINSIC PONTINE GLIOMA; CHILDRENS ONCOLOGY GROUP; BRAIN-STEM GLIOMA; CANCER-STUDY-GROUP; PHASE-III TRIAL; MALIGNANT GLIOMAS; HYPERFRACTIONATED RADIOTHERAPY; PILOCYTIC ASTROCYTOMAS; THERAPEUTIC TARGETS; GENOMIC LANDSCAPE AB High-grade gliomas in children are different from those that arise in adults. Recent collaborative molecular analyses of these rare cancers have revealed previously unappreciated connections among chromatin regulation, developmental signaling, and tumorigenesis. As we begin to unravel the unique developmental origins and distinct biological drivers of this heterogeneous group of tumors, clinical trials need to keep pace. It is important to avoid therapeutic strategies developed purely using data obtained from studies on adult glioblastoma. This approach has resulted in repetitive trials and ineffective treatments being applied to these children, with limited improvement in clinical outcome. The authors of this perspective, comprising biology and clinical expertise in the disease, recently convened to discuss the most effective ways to translate the emerging molecular insights into patient benefit. This article reviews our current understanding of pediatric high-grade glioma and suggests approaches for innovative clinical management. C1 [Jones, Chris] Inst Canc Res, Div Mol Pathol, London, England. [Jones, Chris] Inst Canc Res, Div Canc Therapeut, London, England. [Karajannis, Matthias A.] NYU, Langone Med Ctr, Div Pediat Hematol Oncol, New York, NY USA. [Jones, David T. W.; Pfister, Stefan M.] German Canc Res Ctr, Div Pediat Neurooncol, Heidelberg, Germany. [Pfister, Stefan M.] Univ Heidelberg Hosp, Dept Pediat Hematol & Oncol, Heidelberg, Germany. [Kieran, Mark W.] Dana Farber Canc Inst, Pediat Med Neurooncol, Boston, MA 02115 USA. [Monje, Michelle; Cho, Yoon-Jae] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA USA. [Baker, Suzanne J.] St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA. [Becher, Oren J.] Duke Univ, Med Ctr, Dept Pediat, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA. [Becher, Oren J.] Duke Univ, Med Ctr, Dept Pathol, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA. [Gupta, Nalin; Mueller, Sabine; Nicolaides, Theo; Persson, Anders I.; Phillips, Joanna J.; Simonds, Erin F.; Weiss, William A.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. [Gupta, Nalin; Mueller, Sabine; Nicolaides, Theo; Persson, Anders I.; Phillips, Joanna J.; Simonds, Erin F.; Weiss, William A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Gupta, Nalin; Mueller, Sabine; Nicolaides, Theo; Persson, Anders I.; Phillips, Joanna J.; Simonds, Erin F.; Weiss, William A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA. [Hawkins, Cynthia] Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON, Canada. [Hargrave, Darren] Great Ormond St Hosp Sick Children, Neurooncol & Expt Therapeut, London, England. [Haas-Kogan, Daphne A.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Jabado, Nada] McGill Univ, Dept Pediat, Montreal, PQ, Canada. [Li, Xiao-Nan] Baylor Coll Med, Dept Pediat, Texas Childrens Canc Ctr, Brain Tumor Program, Houston, TX 77030 USA. [Packer, Roger J.] Childrens Natl Hlth Syst, Ctr Neurosci & Behav Med, Washington, DC USA. [Stafford, James M.] NYU, Dept Biochem, Langone Med Ctr, New York, NY 10016 USA. [Tang, Yujie] Shanghai Jiao Tong Univ, Sch Med, Key Lab Cell Differentiat & Apoptosis, Natl Minist Educ,Dept Pathophysiol, Shanghai, Peoples R China. RP Jones, C (reprint author), Inst Canc Res, Div Mol Pathol, 15 Cotswold Rd, Sutton, Surrey, England.; Jones, C (reprint author), Inst Canc Res, Div Canc Therapeut, 15 Cotswold Rd, Sutton, Surrey, England. EM chris.jones@icr.ac.uk NR 90 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD FEB PY 2017 VL 19 IS 2 BP 153 EP 161 DI 10.1093/neuonc/now101 PG 9 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA EP3KF UT WOS:000397280500003 ER PT J AU Rosenberg, S Verreault, M Schmitt, C Guegan, J Guehennec, J Levasseur, C Marie, Y Bielle, F Mokhtari, K Hoang-Xuan, K Ligon, K Sanson, M Delattre, JY Idbaih, A AF Rosenberg, Shai Verreault, Maite Schmitt, Charlotte Guegan, Justine Guehennec, Jeremy Levasseur, Camille Marie, Yannick Bielle, Franck Mokhtari, Karima Hoang-Xuan, Khe Ligon, Keith Sanson, Marc Delattre, Jean-Yves Idbaih, Ahmed TI Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors SO NEURO-ONCOLOGY LA English DT Article DE cancer; cell lines; genome; glioblastoma ID LUNG-CANCER; HETEROGENEITY; CHALLENGES; SIGNATURES; MUTATIONS; LANDSCAPE; PROFILES; SUBTYPES; SAMPLES; MODELS AB Background. Glioblastoma (GBM) is the deadliest primary brain cancer in adults. Emerging innovative therapies hold promise for personalized cancer treatment. Improving therapeutic options depends on research relying on relevant preclinical models. In this line we have established in the setting of the GlioTex project (GBM and Experimental Therapeutics) a GBM patient-derived cell line (GBM-PDCL) library. A multi-omic approach was used to determine the molecular landscape of PDCL and the extent to which they represent GBM tumors. Methods. Single nucleotide polymorphism array, expression arrays, exome sequencing, and RNA sequencing were used to measure and compare the molecular landscapes of 20 samples representing 10 human GBM tumors and paired GBM-PDCLs. Results. Copy number variations were similar for a median of 85% of the genome and for 59% of the major focal events. Somatic point mutations were similar in a median of 41%. Mutations in GBM driver and " druggable" genes were maintained in 67% of events. Mutations that were not conserved in the PDCL were mainly low allelic fraction and/ or non-driver mutations. Based on RNA expression profiling, PDCLs cluster closely to their parental tumor with overexpression of pathways associated with cancer progression in PDCL. Conclusions. Overall, PDCLs recapitulate pivotal molecular alterations of paired-parental tumors supporting their use as a preclinical model of GBM. However, some driver aberrations are lost or gained in the passage from tumor to PDCL. Our results support using PDCL as a relevant preclinical model of GBM. Further investigations of changes between PDCLs and their parental tumor may provide insights into GBM biology. C1 [Rosenberg, Shai; Verreault, Maite; Schmitt, Charlotte; Guegan, Justine; Levasseur, Camille; Bielle, Franck; Mokhtari, Karima; Hoang-Xuan, Khe; Sanson, Marc; Delattre, Jean-Yves; Idbaih, Ahmed] UPMC Univ Paris 06, Sorbonne Univ, INSERM,U1127,CNRS,UMR 7225, UMR S 1127,Inst Cerveau & Moelle Epiniere,ICM, F-75013 Paris, France. [Guegan, Justine] ICM, IHU A ICM, Bioinformat Biostat Core Facil, Inst Cerveau & Moelle Epiniere, F-75013 Paris, France. [Marie, Yannick] Inst Cerveau & Moelle Epiniere ICM, Plateforme Gonotypage Sequencage, F-75013 Paris, France. [Bielle, Franck; Mokhtari, Karima] Hop Univ La Pitie Salpetriere Charles Foix, AP HP, Serv Neuropathol Escourolle, F-75013 Paris, France. [Hoang-Xuan, Khe; Sanson, Marc; Delattre, Jean-Yves; Idbaih, Ahmed] Hop Univ La Pitie Salpetriere Charles Foix, AP HP, Serv Neurol Mazarin 2, 47-83 Blvd Hop, F-75013 Paris, France. [Rosenberg, Shai] Hadassah Hebrew Univ, Med Ctr, Jerusalem, Israel. [Ligon, Keith] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Idbaih, A (reprint author), Hop Univ La Pitie Salpetriere Charles Foix, AP HP, Serv Neurol Mazarin 2, 47-83 Blvd Hop, F-75013 Paris, France. EM ahmed.idbaih@aphp.fr FU Foundation ARC pour la Recherche sur le Cancer; Institut Universitaire de Cancerologie (IUC); OncoNeuroTheque; Hadassah France FX This work is part of the GlioTex (Glioblastoma and Experimental Therapeutics) project funded by the Foundation ARC pour la Recherche sur le Cancer; The Institut Universitaire de Cancerologie (IUC); OncoNeuroTheque; Hadassah France. NR 28 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD FEB PY 2017 VL 19 IS 2 BP 219 EP 228 DI 10.1093/neuonc/now160 PG 10 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA EP3KF UT WOS:000397280500009 ER PT J AU Wahl, M Phillips, JJ Molinaro, AM Lin, Y Perry, A Haas-Kogan, DA Costello, JF Dayal, M Butowski, N Clarke, JL Prados, M Nelson, S Berger, MS Chang, SM AF Wahl, Michael Phillips, Joanna J. Molinaro, Annette M. Lin, Yi Perry, Arie Haas-Kogan, Daphne A. Costello, Joseph F. Dayal, Manisha Butowski, Nicholas Clarke, Jennifer L. Prados, Michael Nelson, Sarah Berger, Mitchel S. Chang, Susan M. TI Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide SO NEURO-ONCOLOGY LA English DT Article DE clinical trials; low-grade glioma; molecular markers ID RADIATION-THERAPY; HEMISPHERIC GLIOMAS; RESPONSE ASSESSMENT; PLUS PROCARBAZINE; RANDOMIZED-TRIAL; TERM; OLIGODENDROGLIOMA; RADIOTHERAPY; RESECTION; EXTENT AB Background. Optimal adjuvant management of adult low-grade gliomas is controversial. Recently described tumor classification based on molecular subtype has the potential to individualize adjuvant therapy but has not yet been evaluated as part of a prospective trial. Methods. Patients aged 18 or older with newly diagnosed World Health Organization grade II low-grade gliomas and gross residual disease after surgical resection were enrolled in the study. Patients received monthly cycles of temozolomide for up to 1 year or until disease progression. For patients with available tissue, molecular subtype was assessed based upon 1p/19q codeletion and isocitrate dehydrogenase-1 R132H mutation status. The primary outcome was radiographic response rate; secondary outcomes included progression-free survival (PFS) and overall survival (OS). Results. One hundred twenty patients were enrolled with median follow-up of 7.5 years. Overall response rate was 6%, with median PFS and OS of 4.2 and 9.7 years, respectively. Molecular subtype was associated with rate of disease progression during treatment (P<. 001), PFS (P=. 007), and OS (P<. 001). Patients with 1p/19q codeletion demonstrated a 0% risk of progression during treatment. In an exploratory analysis, pretreatment lesion volume was associated with both PFS (P<. 001) and OS (P<. 001). Conclusions. While our study failed to meet the primary endpoint for objective radiographic response, patients with high-risk low-grade glioma receiving adjuvant temozolomide demonstrated a high rate of radiographic stability and favorable survival outcomes while meaningfully delaying radiotherapy. Patients with 1p/19q codeletion are potential candidates for omission of adjuvant radiotherapy, but further work is needed to directly compare chemotherapy with combined modality therapy. C1 [Wahl, Michael] Univ Calif San Francisco, Dept Radiat Oncol, 1600 Div St,Suite H1031, San Francisco, CA 94143 USA. [Phillips, Joanna J.; Perry, Arie] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA. [Phillips, Joanna J.; Molinaro, Annette M.; Lin, Yi; Perry, Arie; Costello, Joseph F.; Butowski, Nicholas; Clarke, Jennifer L.; Prados, Michael; Berger, Mitchel S.; Chang, Susan M.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA. [Molinaro, Annette M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA. [Lin, Yi] China Med Univ, Affiliated Hosp 1, Dept Neurosurg, Taichung, Taiwan. [Haas-Kogan, Daphne A.] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA. [Dayal, Manisha; Nelson, Sarah] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA USA. [Clarke, Jennifer L.; Nelson, Sarah] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Clarke, Jennifer L.; Nelson, Sarah] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA USA. RP Wahl, M (reprint author), Univ Calif San Francisco, Dept Radiat Oncol, 1600 Div St,Suite H1031, San Francisco, CA 94143 USA. EM Michael.Wahl@ucsf.edu FU Roche; Dabierre family FX This study was funded by Roche, with support from the Dabierre family. NR 41 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD FEB PY 2017 VL 19 IS 2 BP 242 EP 251 DI 10.1093/neuonc/now176 PG 10 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA EP3KF UT WOS:000397280500011 ER PT J AU Coutinho, AM Coutu, JP Lindemer, ER Rosas, HD Rosen, BR Salat, DH AF Coutinho, Artur Martins Coutu, Jean-Philippe Lindemer, Emily Rose Rosas, H. Diana Rosen, Bruce R. Salat, David H. TI Differential associations between systemic markers of disease and cortical thickness in healthy middle-aged and older adults SO NEUROIMAGE LA English DT Article DE Magnetic resonance imaging; Gray matter; Aging; Insulin; Kidney; Cholesterol ID HUMAN CEREBRAL-CORTEX; MAGNETIC-RESONANCE IMAGES; MILD COGNITIVE IMPAIRMENT; SURFACE-BASED ANALYSIS; TEMPORAL-LOBE ATROPHY; WHITE-MATTER LESIONS; ALZHEIMERS-DISEASE; DIABETES-MELLITUS; BLOOD-PRESSURE; BRAIN VOLUME AB Aside from cortical damage associated with age, cerebrovascular and neurodegenerative diseases, it's an outstanding question if factors of global health, including normal variation in blood markers of metabolic and systemic function, may also be associated with individual variation in brain structure. This cross-sectional study included 138 individuals between 40 to 86 years old who were physically healthy and cognitively intact. Eleven markers (total cholesterol, HDL, LDL, triglycerides, insulin, fasting glucose, glycated hemoglobin, creatinine, blood urea nitrogen, albumin, total protein) and five derived indicators (estimated glomerular filtration rate, creatinine clearance rate, insulin-resistance, average glucose, and cholesterol/HDL ratio) were obtained from blood sampling of all participants. Ti-weighted 3T MRI scans were used to evaluate gray matter cortical thickness. The markers were clustered into five factors, and factor scores were related to cortical thickness by general linear model. Two factors, one linked to insulin/metabolic health and the other to kidney function (KFF) showed regionally selective associations with cortical thickness including lateral and medial temporal, temporoparietal, and superior parietal regions for both factors and frontoparietal regions for KFF. An association between the increasing cholesterol and greater thickness in frontoparietal and occipital areas was also noted. Associations persisted independently of age, presence of cardiovascular risk factors and ApoE gene status. These findings may provide information on distinct mechanisms of inter-individual cortical variation as well as factors contributing to trajectories of cortical thinning with advancing age. C1 [Coutinho, Artur Martins; Coutu, Jean-Philippe; Lindemer, Emily Rose; Rosas, H. Diana; Rosen, Bruce R.; Salat, David H.] Harvard Med Sch, Massachusetts Gen Hosp, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA USA. [Coutinho, Artur Martins] Univ Sao Paulo, Dept Radiol, Sch Med, Ctr Med Nucl LIM 43, Sao Paulo, Brazil. [Coutinho, Artur Martins] Hosp Sirio Libanes, Nucl Med & PET CT Serv, Sao Paulo, Brazil. [Coutu, Jean-Philippe] Biospective Inc, Montreal, PQ, Canada. [Lindemer, Emily Rose] MIT, Harvard Massachusetts Inst Technol Div Hlth Sci &, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Rosas, H. Diana] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA. [Rosen, Bruce R.; Salat, David H.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. [Salat, David H.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, Boston, MA USA. RP Coutinho, AM (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Room 2301,149 13th St, Charlestown, MA 02129 USA. EM artur.coutinho@hc.fm.usp.br FU National Institutes of Health NIH [R01NR010827, NS042861, NS058793]; Center for Functional Neuroimaging Technologies [P41RR14075]; Biomedical Technology Program of the National Center for Research Resources (NCRR); NCRR Shared Instrumentation Grant Program; High-End Instrumentation Grant Program [S1ORR021110, S10RR019307, S10RR019254, S10RR023043] FX This work was supported by the National Institutes of Health NIH (grant number R01NR010827, using resources provided by NIH grants NS042861, NS058793); by the Center for Functional Neuroimaging Technologies (P41RR14075), a P41 Regional Resource supported by the Biomedical Technology Program of the National Center for Research Resources (NCRR), NIH; and by the NCRR Shared Instrumentation Grant Program and/or High-End Instrumentation Grant Program (grant numbers S1ORR021110, , S10RR019307, S10RR019254 and S10RR023043). NR 57 TC 0 Z9 0 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD FEB 1 PY 2017 VL 146 BP 19 EP 27 DI 10.1016/j.neuroimage.2016.11.021 PG 9 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA EL3ZX UT WOS:000394560700002 PM 27847345 ER PT J AU Piantoni, G Halgren, E Cash, SS AF Piantoni, Giovanni Halgren, Eric Cash, Sydney S. TI Spatiotemporal characteristics of sleep spindles depend on cortical location SO NEUROIMAGE LA English DT Article DE Sleep; Spindles; Local; Co-occurrence; Propagation ID SURFACE-BASED ANALYSIS; EYE-MOVEMENT SLEEP; HUMAN K-COMPLEX; SLOW OSCILLATION; INDIVIDUAL-DIFFERENCES; EPILEPTIC ACTIVITY; INTRACRANIAL EEG; CEREBRAL-CORTEX; HUMANS; BRAIN AB Since their discovery almost one century ago, sleep spindles, 0.5-2 s long bursts of oscillatory activity at 9-16 Hz during NREM sleep, have been thought to be global and relatively uniform throughout the cortex. Recent work, however, has brought this concept into question but it remains unclear to what degree spindles are global or local and if their properties are uniform or location-dependent. We addressed this question by recording sleep in eight patients undergoing evaluation for epilepsy with intracranial electrocorticography, which combines high spatial resolution with extensive cortical coverage. We find that spindle characteristics are not uniform but are strongly influenced by the underlying cortical regions, particularly for spindle density and fundamental frequency. We observe both highly isolated and spatially distributed spindles, but in highly skewed proportions: while most spindles are restricted to one or very few recording channels at any given time, there are spindles that occur over widespread areas, often involving lateral prefrontal cortices and superior temporal gyri. Their co-occurrence is affected by a subtle but significant propagation of spindles from the superior prefrontal regions and the temporal cortices towards the orbitofrontal cortex. This work provides a brain-wide characterization of sleep spindles as mostly local graphoelements with heterogeneous characteristics that depend on the underlying cortical area. We propose that the combination of local characteristics and global organization reflects the dual properties of the thalamo-cortical generators and provides a flexible framework to support the many functions ascribed to sleep in general and spindles specifically. C1 [Piantoni, Giovanni; Cash, Sydney S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Piantoni, Giovanni; Cash, Sydney S.] Harvard Med Sch, Boston, MA USA. [Halgren, Eric] Univ Calif San Diego, La Jolla, CA 92093 USA. RP Piantoni, G (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA. EM gio@gpiantoni.com FU BIAL Foundation [220/12]; Office of Naval Research [N00014-13-1-0672]; National Institute of Health [R01 EB009282, MH099645] FX This work was supported by BIAL Foundation (220/12) to GP; Office of Naval Research (N00014-13-1-0672); and National Institute of Health (R01 EB009282 and MH099645). We thank Jason Naftulin and Mia Borzello for their support and assistance in gathering data; Jean-Baptiste Eichenlaub, Alice Lam, and Sujith Vijayan for helpful comments on the manuscript; the staff of the Epilepsy Monitoring Unit at MGH for technical assistance; and the patients for their participation. NR 74 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD FEB 1 PY 2017 VL 146 BP 236 EP 245 DI 10.1016/j.neuroimage.2016.11.010 PG 10 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA EL3ZX UT WOS:000394560700021 PM 27840241 ER PT J AU Williams, VJ Hayes, JP Forman, DE Salat, DH Sperling, RA Verfaellie, M Hayes, SM AF Williams, Victoria J. Hayes, Jasmeet P. Forman, Daniel E. Salat, David H. Sperling, Reisa A. Verfaellie, Mieke Hayes, Scott M. TI Cardiorespiratory fitness is differentially associated with cortical thickness in young and older adults SO NEUROIMAGE LA English DT Article DE Aerobic fitness; Physical activity; Lifespan; Aging; Brain maintenance; MRI ID WHITE-MATTER INTEGRITY; VOXEL-BASED MORPHOMETRY; SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; AGE-RELATED-CHANGES; PHYSICAL-ACTIVITY; AEROBIC FITNESS; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; COORDINATE SYSTEM AB Aging is associated with reductions in gray matter volume and cortical thickness. One factor that may play a role in mitigating age-associated brain decline is cardiorespiratory fitness (CRF). Although previous work has identified a positive association between CRF and gray matter volume, the relationship between CRF and cortical thickness, which serves as a more sensitive indicator of gray matter integrity, has yet to be assessed in healthy young and older adults. To address this gap in the literature, 32 young and 29 older adults completed treadmill-based progressive maximal exercise testing to assess CRF (peak VO2), and structural magnetic resonance imaging (MRI) to determine vertex-wise surface-based cortical thickness metrics. Results indicated a significant CRF by age group interaction such that Peak VO2 was associated with thicker cortex in older adults but with thinner cortex in young adults. Notably, the majority of regions demonstrating a positive association between peak VO2 and cortical thickness in older adults overlapped with brain regions showing significant age related cortical thinning. Further, when older adults were categorized as high or low fit based on normative data, we observed a stepwise pattern whereby cortex was thickest in young adults, intermediate in high fit older adults and thinnest in low fit older adults. Overall, these results support the notion that CRF-related neuroplasticity may reduce although not eliminate age-related cortical atrophy. C1 [Williams, Victoria J.; Verfaellie, Mieke; Hayes, Scott M.] VA Boston Healthcare Syst, Memory Disorders Res Ctr, 151A,150 South Huntington Ave, Boston, MA 02130 USA. [Williams, Victoria J.; Verfaellie, Mieke; Hayes, Scott M.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Williams, Victoria J.; Hayes, Jasmeet P.; Salat, David H.; Verfaellie, Mieke; Hayes, Scott M.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, Boston, MA USA. [Hayes, Jasmeet P.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA. [Hayes, Jasmeet P.; Verfaellie, Mieke; Hayes, Scott M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Geriatr Cardiol Sect, Pittsburgh, PA USA. [Salat, David H.] MGH Radiol, Athinoula A Martins Ctr Biomed Imaging, Charlestown, MA USA. [Sperling, Reisa A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA. [Sperling, Reisa A.] Brigham & Womens Hosp, Dept Neurol, Ctr Alzheimers Res & Treatment, 75 Francis St, Boston, MA 02115 USA. RP Williams, VJ (reprint author), VA Boston Healthcare Syst, Memory Disorders Res Ctr, 151A,150 South Huntington Ave, Boston, MA 02130 USA. EM tori85@gmail.com FU Department of Veterans Affairs, Rehabilitation, Research & Development Service [e7822w]; Department of Veterans Affairs, Clinical Science Research & Development Services; National Institute of Aging [K24AG035007] FX This work was supported by the Department of Veterans Affairs, Rehabilitation, Research & Development Service (Career Development Award e7822w awarded to S.M.H.), the Department of Veterans Affairs, Clinical Science Research & Development Services (M.V.), and the National Institute of Aging (K24AG035007 awarded to R.A.S.). Assistance with participant recruitment was provided by the Massachusetts Alzheimer's Disease Research Center (P50-AG005134), and the Boston University Alzheimer's Disease Center (P30-AG13846). This work was further supported with resources and use of facilities at the Neuroimaging Research for Veterans Center, VA Boston Healthcare System. The authors thank Kelly Allsup, M.A., Pantel Vokonas, M.D., Huiting Liu, M.A., Margaret Cadden, and Rebecca Lysiak for assistance with data collection. The contents of this article do not represent the views of the U.S. Department of Veterans Affairs, the National Institutes of Health, or the United States Government. The authors have no conflicts of interest to report. NR 62 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD FEB 1 PY 2017 VL 146 BP 1084 EP 1092 DI 10.1016/j.neuroimage.2016.10.033 PG 9 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA EL3ZX UT WOS:000394560700094 PM 27989841 ER PT J AU Armstrong, RA Mckee, AC Stein, TD Alvarez, VE Cairns, NJ AF Armstrong, R. A. Mckee, A. C. Stein, T. D. Alvarez, V. E. Cairns, N. J. TI A quantitative study of tau pathology in 11 cases of chronic traumatic encephalopathy SO NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY LA English DT Article DE astrocytic tangles; chronic traumatic encephalopathy; neurofibrillary tangles; principal components analysis; tau ID ARGYROPHILIC GRAIN DISEASE; FRONTOTEMPORAL LOBAR DEGENERATION; ALZHEIMERS-DISEASE; DEMENTIA-PUGILISTICA; DIAGNOSTIC-CRITERIA; FRONTAL-CORTEX; PICKS-DISEASE; BRAIN-INJURY; HEAD-INJURY; NEUROPATHOLOGY AB Aims: To quantify tau pathology of chronic traumatic encephalopathy (CTE) and investigate influence of dot-like lesions (DL), brain region, comorbidity and sporting career length. Methods: Densities of neurofibrillary tangles (NFT), astrocytic tangles (AT), DL, oligodendroglial inclusions (GI), neuropil threads (NT), vacuoles, neurons and enlarged neurons (EN) were measured in tau-immunoreactive sections of upper cortical laminae of frontal and temporal lobes, hippocampus (HC), amygdala and substantia nigra (SN) in 11 cases of CTE. Results: DL were a consistent finding in CTE. Densities of NFT, NT and DL were greatest in sectors CA1 and CA2 of the HC. Densities of AT were lower than NFT, small numbers of GI were recorded in temporal lobe and low densities of vacuoles and EN were consistently present. beta-Amyloid-containing neuritic plaques (NP) also occurred at low density. Densities of NFT, NT, DL and AT were greater in sulci than gyri, while vacuole density was greater in gyri. Principal components analysis (PCA) suggested that sporting career length and densities of NFT in entorhinal cortex, NT in CA2 and SN and vacuolation in the DG were significant sources of variation among cases. Conclusion: DL are frequent in CTE suggesting affinity with argyrophilic grain disease (AGD) and Parkinson's disease dementia (PD-Dem). Densities of AT in all regions and NT/DL in sectors CA2/4 were consistent features of CTE. The 11 cases are neuropathologically heterogeneous which may result from genetic diversity, and variation in anatomical pathways subjected to trauma. C1 [Armstrong, R. A.] Aston Univ, Vis Sci, Birmingham B4 7ET, W Midlands, England. [Mckee, A. C.] VA Boston HealthCare Syst, Boston, MA USA. [Mckee, A. C.; Alvarez, V. E.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Mckee, A. C.; Stein, T. D.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA. [Stein, T. D.; Alvarez, V. E.] Dept Vet Affairs Med Ctr, Bedford, MA USA. [Cairns, N. J.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA. [Cairns, N. J.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA. RP Armstrong, RA (reprint author), Aston Univ, Vis Sci, Birmingham B4 7ET, W Midlands, England. EM R.A.Armstrong@aston.ac.uk FU National Institute of Neurological Disorders and Stroke [1UO1NS086659- 01]; Department of Veterans Affairs, the Veterans Affairs Biorepository [CSP 501]; Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS); Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; National Institute of Aging Boston University Alzheimer's Disease Center [P30AG13846, 0572063345-5]; Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA from the National Institute on Aging [P50 AG05681, P01 AG03991] FX The authors gratefully acknowledge the use of the resources and facilities at the Edith Nourse Rogers Memorial Veterans Hospital (Bedford, MA, USA). We also gratefully acknowledge the help of all members of the Chronic Traumatic Encephalopathy Program at Boston University School of Medicine, VA Boston and the Bedford VA, as well as the individuals and families whose participation and contributions made this work possible. This work was supported by the National Institute of Neurological Disorders and Stroke (1UO1NS086659- 01); Department of Veterans Affairs, the Veterans Affairs Biorepository (CSP 501); the Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS); the Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B6796-C); and the National Institute of Aging Boston University Alzheimer's Disease Center (P30AG13846; supplement 0572063345-5). This work was supported by the Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA (P50 AG05681 and P01 AG03991) from the National Institute on Aging. NR 42 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0305-1846 EI 1365-2990 J9 NEUROPATH APPL NEURO JI Neuropathol. Appl. Neurobiol. PD FEB PY 2017 VL 43 IS 2 BP 154 EP 166 DI 10.1111/nan.12323 PG 13 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA EO8JB UT WOS:000396934200005 PM 26998921 ER PT J AU Waring, JD Dimsdale-Zucker, HR Flannery, S Budson, AE Kensinger, EA AF Waring, J. D. Dimsdale-Zucker, H. R. Flannery, S. Budson, A. E. Kensinger, E. A. TI Effects of mild cognitive impairment on emotional scene memory SO NEUROPSYCHOLOGIA LA English DT Article DE Aging; Mild cognitive impairment; Selective memory; Emotion; Divided attention ID ALZHEIMERS ASSOCIATION WORKGROUPS; OLDER-ADULTS; RECOGNITION MEMORY; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; DIVIDED ATTENTION; FALSE RECOGNITION; SELECTIVE MEMORY; NEURAL PROCESSES; WORKING-MEMORY AB Young and older adults experience benefits in attention and memory for emotional compared to neutral information, but this memory benefit is greatly diminished in Alzheimer's disease (AD). Little is known about whether this impairment arises early or late in the time course between healthy aging and AD. This study compared memory for positive, negative, and neutral items with neutral backgrounds between patients with mild cognitive impairment (MCI) and healthy older adults. We also used a divided attention condition in older adults as a possible model for the deficits observed in MCI patients. Results showed a similar pattern of selective memory for emotional items while forgetting their backgrounds in older adults and MCI patients, but MCI patients had poorer memory overall. Dividing attention during encoding disproportionately reduced memory for backgrounds (versus items) relative to a full attention condition. Participants performing in the lower half on the divided attention task qualitatively and quantitatively mirrored the results in MCI patients. Exploratory analyses comparing lower- and higher-performing MCI patients showed that only higher-performing MCI patients had the characteristic scene memory pattern observed in healthy older adults. Together, these results suggest that the effects of emotion on memory are relatively well preserved for patients with MCI, although emotional memory patterns may start to be altered once memory deficits become more pronounced. C1 [Waring, J. D.] St Louis Univ, Dept Psychol, Morrissey Hall,3700 Lindell Blvd, St Louis, MO 63103 USA. [Waring, J. D.; Dimsdale-Zucker, H. R.; Kensinger, E. A.] Boston Coll, Dept Psychol, Chestnut Hill, MA 02167 USA. [Dimsdale-Zucker, H. R.] Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA. [Flannery, S.; Budson, A. E.] VA Boston Healthcare Syst, Ctr Translat Cognit Neurosci, Boston, MA USA. [Flannery, S.; Budson, A. E.] Boston Univ, Alzheimers Dis Ctr, Sch Med, Dept Neurol, Boston, MA USA. RP Waring, JD (reprint author), St Louis Univ, Dept Psychol, Morrissey Hall,3700 Lindell Blvd, St Louis, MO 63103 USA. EM waringjd@slu.edu FU National Institutes of Health [MH080833, P30 AG13846]; Boston University Alzheimer's Disease Center; American Psychological Association FX Support for this research was provided by National Institutes of Health grants MH080833 (EAK) and P30 AG13846 (AEB), the Boston University Alzheimer's Disease Center, and the American Psychological Association (JDW). NR 72 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 EI 1873-3514 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD FEB PY 2017 VL 96 BP 240 EP 248 DI 10.1016/j.neuropsychologia.2017.01.011 PG 9 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA EM3LQ UT WOS:000395216900024 PM 28089697 ER PT J AU Gallinat, C Keuthen, NJ Stefini, A Backenstrass, M AF Gallinat, Christina Keuthen, Nancy J. Stefini, Annette Backenstrass, Matthias TI The assessment of skin picking in adolescence: psychometric properties of the Skin Picking Scale-Revised (German version) SO NORDIC JOURNAL OF PSYCHIATRY LA English DT Article DE Excoriation; adolescence; skin picking scale; reliability; validity ID EXPLORATORY FACTOR-ANALYSIS; SELF-REPORT INSTRUMENT; PSYCHOLOGICAL-RESEARCH; BODY DISSATISFACTION; GENDER-DIFFERENCES; QUALITY-ASSURANCE; PREVALENCE; STUDENTS; DERMATILLOMANIA; COMORBIDITY AB Background: Skin picking disorder has received growing attention since the release of DSM-5, yet there are no evidence-based assessment instruments for adolescent samples.Aim: The present study examines the psychometric properties of the Skin Picking Scale-Revised (SPS-R, German version) in adolescents.Methods: A total of 76 adolescents (96% female) completed the SPS-R, the Clinical Psychological Diagnostic System (KPD-38), and a questionnaire assessing demographics and clinical characteristics online.Results: The SPS-R had high internal consistency (=0.89) and significant small-to-medium correlations with reduced competence skills, psychological impairment, general life satisfaction, social support, and social problems on the KPD-38. Similar to prior findings for adults, an exploratory factor analysis suggested a two-factor model for the SPS-R in adolescents. Group comparisons failed to show significant differences on SPS-R scores between participants with and without dermatological conditions.Conclusions: The current results suggest that the SPS-R can be useful in adolescent samples as a reliable and valid instrument for the assessment of skin picking severity. Future research investigating scale validity and factor structure in a clinical sample of adolescent skin pickers is warranted. C1 [Gallinat, Christina] Univ Heidelberg Hosp, Ctr Psychotherapy Res, Bergheimer Str 54, D-69115 Heidelberg, Germany. [Keuthen, Nancy J.] Harvard Med Sch, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA USA. [Stefini, Annette] Univ Heidelberg Hosp, Gen Psychiat, Heidelberg, Germany. [Backenstrass, Matthias] Hosp Stuttgart, Inst Clin Psychol, Stuttgart, Germany. [Backenstrass, Matthias] Heidelberg Univ, Inst Psychol, Dept Clin Psychol & Psychotherapy, Heidelberg, Germany. RP Gallinat, C (reprint author), Univ Heidelberg Hosp, Ctr Psychotherapy Res, Bergheimer Str 54, D-69115 Heidelberg, Germany. EM christina.gallinat@med.uni-heidelberg.de NR 29 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0803-9488 EI 1502-4725 J9 NORD J PSYCHIAT JI Nord. J. Psychiatr. PD FEB PY 2017 VL 71 IS 2 BP 145 EP 150 DI 10.1080/08039488.2016.1259427 PG 6 WC Psychiatry SC Psychiatry GA EL2IE UT WOS:000394442500010 PM 27885889 ER PT J AU Cummings, DE Schauer, PR AF Cummings, David E. Schauer, Philip R. TI Endoscopic Gastric Plication for Obesity: Where Might It Fit in the Scheme of Things? SO OBESITY LA English DT Editorial Material ID SURGERY; WEIGHT C1 [Cummings, David E.] Univ Washington, Seattle, WA 98195 USA. [Cummings, David E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Schauer, Philip R.] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA. RP Cummings, DE (reprint author), Univ Washington, Seattle, WA 98195 USA.; Cummings, DE (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA. EM davidec@u.washington.edu FU Johnson Johnson; Ethicon; Medtronic; The Medicines Company; Pacira Pharmaceuticals FX Dr. Cummings reports research funding from Johnson & Johnson, and he is on the Scientific Advisory Board of Metavention. Dr. Schauer reports grants and consulting fees from Ethicon, grants from Medtronic, consulting fees from The Medicines Company, and grants from Pacira Pharmaceuticals, as well as stock in SE Healthcare Quality Consulting and SurgiQuest. NR 7 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD FEB PY 2017 VL 25 IS 2 BP 284 EP 285 DI 10.1002/oby.21766 PG 2 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA EL9WF UT WOS:000394970100006 PM 28124503 ER PT J AU Pearl, RL Wadden, TA Hopkins, CM Shaw, JA Hayes, MR Bakizada, ZM Alfaris, N Chao, AM Pinkasavage, E Berkowitz, RI Alamuddin, N AF Pearl, Rebecca L. Wadden, Thomas A. Hopkins, Christina M. Shaw, Jena A. Hayes, Matthew R. Bakizada, Zayna M. Alfaris, Nasreen Chao, Ariana M. Pinkasavage, Emilie Berkowitz, Robert I. Alamuddin, Naji TI Association Between Weight Bias Internalization and Metabolic Syndrome Among Treatment-Seeking Individuals with Obesity SO OBESITY LA English DT Article ID STIGMA; DISCRIMINATION; OVERWEIGHT; HEALTH; ADULTS; DEPRESSION; IMPACT; METAANALYSIS; ATTITUDES; RACISM AB Objective: Weight stigma is a chronic stressor that may increase cardiometabolic risk. Some individuals with obesity self-stigmatize ( i. e., weight bias internalization, WBI). No study to date has examined whether WBI is associated with metabolic syndrome. Methods: Blood pressure, waist circumference, and fasting glucose, triglycerides, and high-density lipoprotein cholesterol were measured at baseline in 178 adults with obesity enrolled in a weight-loss trial. Medication use for hypertension, dyslipidemia, and prediabetes was included in criteria for metabolic syndrome. One hundred fifty-nine participants ( 88.1% female, 67.3% black, mean BMI541.1 kg/m(2)) completed the Weight Bias Internalization Scale and Patient Health Questionnaire ( PHQ-9, to assess depressive symptoms). Odds ratios and partial correlations were calculated adjusting for demographics, BMI, and PHQ-9 scores. Results: Fifty-one participants ( 32.1%) met criteria for metabolic syndrome. Odds of meeting criteria for metabolic syndrome were greater among participants with higher WBI, but not when controlling for all covariates ( OR=1.46, 95% CI=1.00-2.13, P=0.052). Higher WBI predicted greater odds of having high triglycerides ( OR=1.88, 95% CI=1.14-3.09, P=0.043). Analyzed categorically, high ( vs. low) WBI predicted greater odds of metabolic syndrome and high triglycerides ( Ps<0.05). Conclusions: Individuals with obesity who self-stigmatize may have heightened cardiometabolic risk. Biological and behavioral pathways linking WBI and metabolic syndrome require further exploration. C1 [Pearl, Rebecca L.; Wadden, Thomas A.; Hopkins, Christina M.; Shaw, Jena A.; Hayes, Matthew R.; Bakizada, Zayna M.; Chao, Ariana M.; Pinkasavage, Emilie; Berkowitz, Robert I.; Alamuddin, Naji] Univ Penn, Dept Psychiat, Ctr Weight & Eating Disorders, Perelman Sch Med, Philadelphia, PA 19104 USA. [Hopkins, Christina M.] Duke Univ, Dept Psychol, Durham, NC 27706 USA. [Hayes, Matthew R.] Univ Penn, Sch Nursing, Dept Biobehav Hlth Sci, Philadelphia, PA 19104 USA. [Alfaris, Nasreen] Massachusetts Gen Hosp, Dept Med, Gastrointestinal Unit, Weight Ctr, Boston, MA 02114 USA. [Chao, Ariana M.] Univ Penn, Sch Nursing, Dept Family & Community Hlth, Philadelphia, PA 19104 USA. [Berkowitz, Robert I.] Childrens Hosp Philadelphia, Dept Psychiat & Behav Sci, Philadelphia, PA 19104 USA. [Alamuddin, Naji] Univ Penn, Dept Med, Inst Diabet Obes & Metab, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Pearl, RL (reprint author), Univ Penn, Dept Psychiat, Ctr Weight & Eating Disorders, Perelman Sch Med, Philadelphia, PA 19104 USA. EM rpearl@mail.med.upenn.edu FU Eisai Pharmaceutical Co.; NRSA postdoctoral fellowship from the NINR/NIH [T32NR007100] FX This study was supported by an investigator-initiated grant from Eisai Pharmaceutical Co. (TAW). AMC was supported by an NRSA postdoctoral fellowship from the NINR/NIH #T32NR007100. NR 42 TC 1 Z9 1 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD FEB PY 2017 VL 25 IS 2 BP 317 EP 322 DI 10.1002/oby.21716 PG 6 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA EL9WF UT WOS:000394970100012 PM 28124502 ER PT J AU Thomas, GA Cartmel, B Harrigan, M Fiellin, M Capozza, S Zhou, Y Ercolano, E Gross, CP Hershman, D Ligibel, J Schmitz, K Li, FY Sanft, T Irwin, ML AF Thomas, Gwendolyn A. Cartmel, Brenda Harrigan, Maura Fiellin, Martha Capozza, Scott Zhou, Yang Ercolano, Elizabeth Gross, Cary P. Hershman, Dawn Ligibel, Jennifer Schmitz, Kathryn Li, Fang-Yong Sanft, Tara Irwin, Melinda L. TI The Effect of Exercise on Body Composition and Bone Mineral Density in Breast Cancer Survivors Taking Aromatase Inhibitors SO OBESITY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; ADJUVANT HORMONAL-THERAPY; POSTMENOPAUSAL WOMEN; PHYSICAL-ACTIVITY; WEIGHT-LOSS; MASS INDEX; FOLLOW-UP; RISK; PREVENTION; TAMOXIFEN AB Objective: This study examined the effect of 12 months of aerobic and resistance exercise versus usual care on changes in body composition in postmenopausal breast cancer survivors taking aromatase inhibitors ( AIs). Methods: The Hormones and Physical Exercise study enrolled 121 breast cancer survivors and randomized them to either supervised twice-weekly resistance exercise training and 150 min/wk of aerobic exercise ( N=61) or a usual care ( N=60) group. Dual-energy X-ray absorptiometry scans were conducted at baseline, 6 months, and 12 months to assess changes in body mass index, percent body fat, lean body mass, and bone mineral density. Results: At 12 months, the exercise group relative to the usual care group had a significant increase in lean body mass ( 0.32 vs. -0.88 kg, P=0.03), a decrease in percent body fat ( -1.4% vs. 0.48%, P = 0.03), and a decrease in body mass index ( 0.73 vs. 0.17 kg/m(2), P=0.03). Change in bone mineral density was not significantly different between groups at 12 months ( 0.001 vs. -0.006 g/cm(2), P=0.37). Conclusions: A combined resistance and aerobic exercise intervention improved body composition in breast cancer survivors taking AIs. Exercise interventions may help to mitigate the negative side effects of AIs and improve health outcomes in breast cancer survivors. C1 [Thomas, Gwendolyn A.] Syracuse Univ, Dept Exercise Sci, Syracuse, NY 13210 USA. [Cartmel, Brenda; Harrigan, Maura; Fiellin, Martha; Capozza, Scott; Zhou, Yang; Ercolano, Elizabeth; Gross, Cary P.; Li, Fang-Yong; Sanft, Tara; Irwin, Melinda L.] Yale Univ, Yale Canc Ctr, New Haven, CT USA. [Hershman, Dawn] Columbia Univ, New York, NY USA. [Ligibel, Jennifer] Dana Farber Canc Inst, Boston, MA 02115 USA. [Schmitz, Kathryn] Penn State Univ, Hershey, PA USA. RP Thomas, GA (reprint author), Syracuse Univ, Dept Exercise Sci, Syracuse, NY 13210 USA. EM gwthomas@syr.edu OI Irwin, Michael/0000-0001-5801-274X FU National Cancer Institute [R01 CA132931]; Breast Cancer Research Foundation; Yale Cancer Center Support Grant [P30 CA016359]; Clinical and Translational Science Award from the National Center for Advancing Translational Science, a component of the National Institutes of Health [UL1 TR000142] FX This research was supported by National Cancer Institute Grant No. R01 CA132931 and in part by a grant from the Breast Cancer Research Foundation (to MLI), Yale Cancer Center Support Grant No. P30 CA016359, and Clinical and Translational Science Award Grant No. UL1 TR000142 from the National Center for Advancing Translational Science, a component of the National Institutes of Health. Certain data used in this study were obtained from the Connecticut Tumor Registry, located in the Connecticut Department of Public Health. NR 37 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD FEB PY 2017 VL 25 IS 2 BP 346 EP 351 DI 10.1002/oby.21729 PG 6 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA EL9WF UT WOS:000394970100016 PM 28026901 ER PT J AU Xiao, L Lv, N Rosas, LG Au, D Ma, J AF Xiao, Lan Lv, Nan Rosas, Lisa G. Au, David Ma, Jun TI Validation of Clinic Weights from Electronic Health Records Against Standardized Weight Measurements in Weight Loss Trials SO OBESITY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE; LIFE-STYLE; UNITED-STATES; OBESITY; INTERVENTION; VALIDITY; ADULTS AB Objective: To validate clinic weights in electronic health records against researcher-measured weights for outcome assessment in weight loss trials. Methods: Clinic and researcher-measured weights from a published trial ( BE WELL) were compared using Lin's concordance correlation coefficient, Bland and Altman's limits of agreement, and polynomial regression model. Changes in clinic and researcher-measured weights in BE WELL and another trial, ELITE, were analyzed using growth curve modeling. Results: Among BE WELL ( n = 330) and E-LITE ( n = 241) participants, 96% and 90% had clinic weights ( mean [ SD] of 5.8 [ 6.1] and 3.7 [ 3.9] records) over 12 and 15 months of follow-up, respectively. The concordance correlation coefficient was 0.99, and limits of agreement plots showed no pattern between or within treatment groups, suggesting overall good agreement between researcher-measured and nearest-in-time clinic weights up to 3 months. The 95% confidence intervals for predicted percent differences fell within 63% for clinic weights within 3 months of the researcher-measured weights. Furthermore, the growth curve slopes for clinic and researcher-measured weights by treatment group did not differ significantly, suggesting similar inferences about treatment effects over time, in both trials. Conclusions: Compared with researcher-measured weights, close-in-time clinic weights showed high agreement and inference validity. Clinic weights could be a valid pragmatic outcome measure in weight loss studies. C1 [Xiao, Lan; Lv, Nan; Rosas, Lisa G.; Ma, Jun] Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA. [Rosas, Lisa G.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA. [Au, David] Univ Washington, Div Pulm & Crit Care Med, VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA 98195 USA. [Ma, Jun] Univ Illinois, Dept Hlth Policy & Adm, Sch Publ Hlth, Chicago, IL 60607 USA. [Ma, Jun] Univ Illinois, Div Acad Internal Med & Geriatr, Dept Med, Coll Med, Chicago, IL 60607 USA. RP Ma, J (reprint author), Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA.; Ma, J (reprint author), Univ Illinois, Dept Hlth Policy & Adm, Sch Publ Hlth, Chicago, IL 60607 USA.; Ma, J (reprint author), Univ Illinois, Div Acad Internal Med & Geriatr, Dept Med, Coll Med, Chicago, IL 60607 USA. EM maj2015@uic.edu FU National Institute of Diabetes and Digestive and Kidney Diseases; American Heart Association [0830362N]; National Heart, Lung, and Blood Institute [R01HL094466]; Palo Alto Medical Foundation Research Institute FX The E-LITE study was supported by grant R34DK080878 from the National Institute of Diabetes and Digestive and Kidney Diseases and a Scientist Development Grant award (0830362N) from the American Heart Association, and the BE WELL study was supported by grant R01HL094466 from the National Heart, Lung, and Blood Institute. This study was also supported by internal funding from the Palo Alto Medical Foundation Research Institute. NR 21 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD FEB PY 2017 VL 25 IS 2 BP 363 EP 369 DI 10.1002/oby.21737 PG 7 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA EL9WF UT WOS:000394970100019 PM 28059466 ER PT J AU Wilson, ER Kyle, TK Nadglowski, JF Stanford, FC AF Wilson, Elizabeth Ruth Kyle, Theodore K. Nadglowski, Joseph F., Jr. Stanford, Fatima Cody TI Obesity Coverage Gap: Consumers Perceive Low Coverage for Obesity Treatments Even When Workplace Wellness Programs Target BMI SO OBESITY LA English DT Article ID WEIGHT-LOSS; COST-EFFECTIVENESS; CLINICAL EFFECTIVENESS; FINANCIAL INCENTIVES; OVERWEIGHT; SURGERY; EMPLOYEES; SAVINGS; ADULTS; STATES AB Objective: Evidence-based obesity treatments, such as bariatric surgery, are not considered essential health benefits under the Affordable Care Act. Employer-sponsored wellness programs with incentives based on biometric outcomes are allowed and often used despite mixed evidence regarding their effectiveness. This study examines consumers' perceptions of their coverage for obesity treatments and exposure to workplace wellness programs. Methods: A total of 7,378 participants completed an online survey during 2015-2016. Respondents answered questions regarding their health coverage for seven medical services and exposure to employer wellness programs that target weight or body mass index ( BMI). Using chi(2) tests, associations between perceptions of exposure to employer wellness programs and coverage for medical services were examined. Differences between survey years were also assessed. Results: Most respondents reported they did not have health coverage for obesity treatments, but more of the respondents with employer wellness programs reported having coverage. Neither the perception of coverage for obesity treatments nor exposure to wellness programs increased between 2015 and 2016. Conclusions: Even when consumers have exposure to employer wellness programs that target BMI, their health insurance often excludes obesity treatments. Given the clinical and cost-effectiveness of such treatments, reducing that coverage gap may mitigate obesity's individual-and population-level effects. C1 [Wilson, Elizabeth Ruth] Harvard Kennedy Sch, Cambridge, MA USA. [Kyle, Theodore K.] ConscienHealth, Pittsburgh, PA USA. [Kyle, Theodore K.; Nadglowski, Joseph F., Jr.] Obes Act Coalit, Tampa, FL USA. [Stanford, Fatima Cody] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med Gastroenterol, Weight Ctr, Boston, MA 02115 USA. [Stanford, Fatima Cody] Harvard Med Sch, Dept Pediat Endocrinol, Weight Ctr, MGH, Boston, MA 02115 USA. RP Stanford, FC (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Med Gastroenterol, Weight Ctr, Boston, MA 02115 USA.; Stanford, FC (reprint author), Harvard Med Sch, Dept Pediat Endocrinol, Weight Ctr, MGH, Boston, MA 02115 USA. EM fstanford@mgh.harvard.edu FU Obesity Action Coalition FX This work was funded by the Obesity Action Coalition. NR 33 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD FEB PY 2017 VL 25 IS 2 BP 370 EP 377 DI 10.1002/oby.21746 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA EL9WF UT WOS:000394970100020 PM 28063213 ER PT J AU Quinot, C Dumas, O Henneberger, PK Varraso, R Wiley, AS Speizer, FE Goldberg, M Zock, JP Camargo, CA Le Moual, N AF Quinot, C. Dumas, O. Henneberger, P. K. Varraso, R. Wiley, A. S. Speizer, F. E. Goldberg, M. Zock, J. P. Camargo, C. A., Jr. Le Moual, N. TI Development of a job-task-exposure matrix to assess occupational exposure to disinfectants among US nurses SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID HEALTH-CARE PROFESSIONALS; OBSTRUCTIVE PULMONARY-DISEASE; IN-HOSPITAL WORKERS; NEW-ONSET ASTHMA; RISK-FACTORS; CLEANING PRODUCTS; WORKPLACE; QUESTIONNAIRE; PERFORMANCE; PREVENTION AB Objectives Occupational exposure to disinfectants is associated with work-related asthma, especially in healthcare workers. However, little is known about the specific products involved. To evaluate disinfectant exposures, we designed job-exposure (JEM) and job-task-exposure (JTEM) matrices, which are thought to be less prone to differential misclassification bias than self-reported exposure. We then compared the three assessment methods: self-reported exposure, JEM and JTEM. Methods Disinfectant use was assessed by an occupational questionnaire in 9073 US female registered nurses without asthma, aged 49-68 years, drawn from the Nurses' Health Study II. A JEM was created based on self-reported frequency of use (1-3, 4-7 days/week) of 7 disinfectants and sprays in 8 nursing jobs. We then created a JTEM combining jobs and disinfection tasks to further reduce misclassification. Exposure was evaluated in 3 classes (low, medium, high) using product-specific cut-offs (eg, <30%, 30-49.9%, >= 50%, respectively, for alcohol); the cut-offs were defined from the distribution of self-reported exposure per job/task. Results The most frequently reported disinfectants were alcohol (weekly use: 39%), bleach (22%) and sprays (20%). More nurses were classified as highly exposed by JTEM (alcohol 41%, sprays 41%, bleach 34%) than by JEM (21%, 30%, 26%, respectively). Agreement between JEM and JTEM was fair-to-moderate (kappa 0.3-0.5) for most disinfectants. JEM and JTEM exposure estimates were heterogeneous in most nursing jobs, except in emergency room and education/administration. Conclusions The JTEM may provide more accurate estimates than the JEM, especially for nursing jobs with heterogeneous tasks. Use of the JTEM is likely to reduce exposure misclassification. C1 [Quinot, C.; Dumas, O.; Varraso, R.; Goldberg, M.; Le Moual, N.] INSERM, U1168, VIMA Aging & Chron Dis, Epidemiol & Publ Hlth Approaches, F-94807 Villejuif, France. [Quinot, C.; Dumas, O.; Varraso, R.; Goldberg, M.; Le Moual, N.] Univ Versailles St Quentin En Yvelines, UMR S 1168, F-78180 Montigny Le Bretonneux, France. [Dumas, O.; Wiley, A. S.; Speizer, F. E.; Camargo, C. A., Jr.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Dumas, O.; Wiley, A. S.; Speizer, F. E.; Camargo, C. A., Jr.] Harvard Med Sch, Boston, MA USA. [Dumas, O.; Camargo, C. A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Henneberger, P. K.] NIOSH, Div Resp Dis Studies, Morgantown, WV 26505 USA. [Goldberg, M.] INSERM, UVSQ, UMS 011, Villejuif, France. [Zock, J. P.] Netherlands Inst Hlth Serv Res NIVEL, Utrecht, Netherlands. [Zock, J. P.] Ctr Res Environm Epidemiol CREAL, ISGlobal, Barcelona, Spain. [Zock, J. P.] UPF, Barcelona, Spain. [Zock, J. P.] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain. RP Quinot, C (reprint author), INSERM, UMRS 1168, VIMA Aging & Chron Dis, Epidemiol & Publ Hlth Approaches, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France. EM catherine.quinot@inserm.fr RI LeMoual, Nicole/R-8976-2016 OI LeMoual, Nicole/0000-0002-2723-5569 FU Centers for Disease Control and Prevention [R01 OH-10359]; National Institutes of Health [UM1 CA176726]; Hubert Curien Partnerships for French-Dutch cooperation; French Ministry of Higher Education and Research; OCW Dutch Ministry (Ministerie van Onderwijs, Cultuur en Wetenschap) [PHC Van Gogh 33653RF]; University of Versailles Saint-Quentin-en-Yvelines EDSP doctoral grant FX Centers for Disease Control and Prevention R01 OH-10359; National Institutes of Health UM1 CA176726; Hubert Curien Partnerships for French-Dutch cooperation, French Ministry of Higher Education and Research and OCW Dutch Ministry (Ministerie van Onderwijs, Cultuur en Wetenschap) PHC Van Gogh 33653RF; University of Versailles Saint-Quentin-en-Yvelines EDSP doctoral grant. NR 40 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 EI 1470-7926 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD FEB PY 2017 VL 74 IS 2 BP 130 EP 137 DI 10.1136/oemed-2016-103606 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL3KB UT WOS:000394516900008 PM 27566782 ER PT J AU Rathi, VK Wang, B Ross, JS Downing, NS Kesselheim, AS Gray, ST AF Rathi, Vinay K. Wang, Bo Ross, Joseph S. Downing, Nicholas S. Kesselheim, Aaron S. Gray, Stacey T. TI Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014 SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE otolaryngology; medical device; FDA; premarket approval ID MEDICAL DEVICES; FDA APPROVAL; THERAPY; TRIALS AB The US Food and Drug Administration (FDA) approves high-risk medical devices based on premarket pivotal clinical studies demonstrating reasonable assurance of safety and effectiveness and may require postapproval studies (PAS) to further inform benefit-risk assessment. We conducted a cross-sectional analysis using publicly available FDA documents to characterize industry-sponsored pivotal studies and PAS of high-risk devices used in the treatment of otolaryngologic diseases. Between 2000 and 2014, the FDA approved 23 high-risk otolaryngologic devices based on 28 pivotal studies. Median enrollment was 118 patients (interquartile range, 67-181), and median duration of longest primary effectiveness end point follow-up was 26 weeks (interquartile range, 16-96). Fewer than half were randomized (n = 13, 46%), blinded (n = 12, 43%), or controlled (n = 10, 36%). The FDA required 23 PASs for 16 devices (70%): almost two-thirds (n = 15, 65%) monitored long-term performance, and roughly one-third (n = 8, 35%) focused on subgroups. Otolaryngologists should be aware of limitations in the strength of premarket evidence when considering the use of newly approved devices. C1 [Rathi, Vinay K.; Wang, Bo; Ross, Joseph S.; Downing, Nicholas S.; Kesselheim, Aaron S.; Gray, Stacey T.] Massachusetts Eye & Ear Infirm, Dept Otolaryngology Head & Neck Surg, 243 Charles St, Boston, MA 02114 USA. RP Gray, ST (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngology Head & Neck Surg, 243 Charles St, Boston, MA 02114 USA. EM stacey_gray@meei.harvard.edu NR 26 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2017 VL 156 IS 2 BP 285 EP 288 DI 10.1177/0194599816684094 PG 4 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA EL8WP UT WOS:000394901400010 PM 28093943 ER PT J AU Nipp, RD Zanconato, A Zheng, H Ferrone, CR Lillemoe, KD Wo, JY Hong, TS Clark, JW Ryan, DP Fernandez-del Castillo, C AF Nipp, Ryan D. Zanconato, Andrea Zheng, Hui Ferrone, Cristina R. Lillemoe, Keith D. Wo, Jennifer Y. Hong, Theodore S. Clark, Jeffrey W. Ryan, David P. Fernandez-del Castillo, Carlos TI Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment SO PANCREAS LA English DT Article DE pancreatic neoplasms; neoadjuvant therapy; combined modality therapy; comorbidity; aged ID AGE COMORBIDITY INDEX; CONSECUTIVE PANCREATICODUODENECTOMIES; DUCTAL ADENOCARCINOMA; GERIATRIC ASSESSMENT; PROGNOSTIC-FACTORS; CANCER STATISTICS; TUMOR GRADE; SURVIVAL; FOLFIRINOX; OUTCOMES AB Objectives: Neoadjuvant treatments are increasingly used for patients with pancreatic ductal adenocarcinoma (PDAC), yet some experience early mortality after resection. We sought to identify predictors of early mortality after PDAC resection and determine their interaction with neo-adjuvant therapy. Methods: We performed a retrospective study of patients with PDAC resection from March 2011 to March 2014. We compared those who died within one year after surgery to those living beyond 1 year, and those who received neoadjuvant therapy to those taken directly to surgery. We used logistic regression to identify predictors of early mortality and determine their interaction with neoadjuvant therapy. Results: Of 191 patients who underwent resection, 59 (30.9%) died within 1 year and 79 (41.4%) received neoadjuvant therapy. Early mortality patients were older, with higher comorbidity, and more likely to have lymph node positivity. Patients receiving neoadjuvant therapy were younger, with lower comorbidity, and more likely to have upfront unresectable disease. Predictors of early mortality included: higher comorbidity, poorly differentiated tumor grade, and lymph node positivity. We found that neoadjuvant therapy moderated the effects of comorbidity and lymph node positivity on early mortality risk. Conclusions: We identified predictors of early mortality after PDAC resection and determined their interaction with neoadjuvant therapy. C1 [Nipp, Ryan D.; Clark, Jeffrey W.; Ryan, David P.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA USA. [Zanconato, Andrea; Ferrone, Cristina R.; Lillemoe, Keith D.; Fernandez-del Castillo, Carlos] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA USA. [Zheng, Hui] Harvard Med Sch, Massachusetts Gen Hosp, Biostat Ctr, Boston, MA USA. [Wo, Jennifer Y.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. RP Nipp, RD (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA. EM RNipp@MGH.Harvard.edu NR 50 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD FEB PY 2017 VL 46 IS 2 BP 183 EP 189 DI 10.1097/MPA.0000000000000731 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EL2JS UT WOS:000394446500007 PM 27846142 ER PT J AU Hagmann, SHF LaRocque, RC Ryan, ET AF Hagmann, Stefan H. F. LaRocque, Regina C. Ryan, Edward T. TI Preparing Pediatric International Travelers for Travelers' Diarrhea Insights From the Global TravEpiNet SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Letter ID CHILDREN C1 [Hagmann, Stefan H. F.] Steven & Alexandra Cohen Childrens Med Ctr New Yo, Div Pediat Infect Dis, New Hyde Pk, NY 11040 USA. [Hagmann, Stefan H. F.] Hofstra Northwell Sch Med, Hempstead, NY 11549 USA. [LaRocque, Regina C.; Ryan, Edward T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [LaRocque, Regina C.; Ryan, Edward T.] Harvard Univ, Dept Med, Boston, MA 02115 USA. RP Hagmann, SHF (reprint author), Steven & Alexandra Cohen Childrens Med Ctr New Yo, Div Pediat Infect Dis, New Hyde Pk, NY 11040 USA.; Hagmann, SHF (reprint author), Hofstra Northwell Sch Med, Hempstead, NY 11549 USA. EM shagmann@northwell.edu FU NCEZID CDC HHS [U01 CK000175, U01 CK000490] NR 4 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD FEB PY 2017 VL 36 IS 2 BP 242 EP 243 DI 10.1097/INF.0000000000001402 PG 3 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA EL1AI UT WOS:000394352500030 PM 28079839 ER PT J AU Marathe, CS Rayner, CK Lange, K Bound, M Wishart, J Jones, KL Kahn, SE Horowitz, M AF Marathe, Chinmay S. Rayner, Christopher K. Lange, Kylie Bound, Michelle Wishart, Judith Jones, Karen L. Kahn, Steven E. Horowitz, Michael TI Relationships of the early insulin secretory response and oral disposition index with gastric emptying in subjects with normal glucose tolerance SO PHYSIOLOGICAL REPORTS LA English DT Article DE Gastric emptying; insulin secretory response; oral disposition index; oral glucose tolerance test ID DEPENDENT DIABETES-MELLITUS; GLUCAGON-LIKE PEPTIDE-1; INHIBITORY POLYPEPTIDE; POSTPRANDIAL GLYCEMIA; INCRETIN RESPONSES; CARBOHYDRATE MEAL; DUODENAL GLUCOSE; HEALTHY-SUBJECTS; HORMONES; EXTRACTION AB The oral disposition index, the product of the early insulin secretory response during an oral glucose tolerance test and insulin sensitivity, is used widely for both the prediction of, and evaluation of the response to interventions, in type 2 diabetes. Gastric emptying, which determines small intestinal exposure of nutrients, modulates postprandial glycemia. The aim of this study was to determine whether the insulin secretory response and the disposition index (DI) related to gastric emptying in subjects with normal glucose tolerance. Thirty-nine subjects consumed a 350 mL drink containing 75 g glucose labeled with Tc-99m-sulfur colloid. Gastric emptying (by scintigraphy), blood glucose (G) and plasma insulin (I) were measured between t = 0-120 min. The rate of gastric emptying was derived from the time taken for 50% emptying (T-50) and expressed as kcal/min. The early insulin secretory response was estimated by the ratio of the change in insulin (Delta I0-30) to that of glucose at 30 min (Delta G(0-30)) represented as Delta I0-30/Delta G(0-30). Insulin sensitivity was estimated as 1/fasting insulin and the DI was then calculated as Delta I0-30/Delta G(0-30) x 1/fasting insulin. There was a direct relationship between Delta G(0-30) and gastric emptying (r = 0.47, P = 0.003). While there was no association of either Delta I0-30 (r = -0.16, P = 0.34) or fasting insulin (r = 0.21, P = 0.20), there were inverse relationships between the early insulin secretory response (r = -0.45, P = 0.004) and the DI (r = -0.33, P = 0.041), with gastric emptying. We conclude that gastric emptying is associated with both insulin secretion and the disposition index in subjects with normal glucose tolerance, such that when gastric emptying is relatively more rapid, both the early insulin secretory response and the disposition index are less. These findings should be interpreted as "hypothesis generating" and provide the rationale for longitudinal studies to examine the impact of baseline rate of gastric emptying on the prospective risk of type 2 diabetes. C1 [Marathe, Chinmay S.; Rayner, Christopher K.; Lange, Kylie; Bound, Michelle; Wishart, Judith; Jones, Karen L.; Horowitz, Michael] Univ Adelaide, Royal Adelaide Hosp, Discipline Med, Adelaide, SA, Australia. [Marathe, Chinmay S.; Rayner, Christopher K.; Lange, Kylie; Bound, Michelle; Wishart, Judith; Jones, Karen L.; Horowitz, Michael] Univ Adelaide, Ctr Res Excellence Translating Nutr Sci Good Hlth, Adelaide, SA, Australia. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. RP Marathe, CS (reprint author), Univ Adelaide, Royal Adelaide Hosp, Ctr Res Excellence CRE Translating Nutr Sci Good, Adelaide, SA 5005, Australia. EM chinmaymarathe@gmail.com FU National Health and Medical Research Council, Australia FX This study was funded by a grant from the National Health and Medical Research Council, Australia. NR 29 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2051-817X J9 PHYSIOL REP JI PHYSIOL. REP. PD FEB PY 2017 VL 5 IS 4 AR e13122 DI 10.14814/phy2.13122 PG 6 WC Physiology SC Physiology GA EP5PN UT WOS:000397431000013 ER PT J AU Tritos, NA Biller, BMK AF Tritos, Nicholas A. Biller, Beverly M. K. TI Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly SO PITUITARY LA English DT Article DE Acromegaly; Growth hormone; Growth hormone receptor (antagonist); Pegvisomant; Pituitary adenoma ID LONG-TERM TREATMENT; FACTOR-I; SOMATOSTATIN ANALOGS; CLINICAL-PRACTICE; NUDE-MICE; EXPERIENCE; RESISTANT; THERAPY; SAFETY; RADIOTHERAPY AB To review published data on pegvisomant and its therapeutic role in acromegaly. Electronic searches of the published literature were conducted using the keywords: acromegaly, growth hormone (GH) receptor (antagonist), pegvisomant, therapy. Relevant articles (n = 141) were retrieved and considered for inclusion in this manuscript. Pegvisomant is a genetically engineered, recombinant growth hormone receptor antagonist, which is effective in normalizing serum insulin-like growth factor 1 (IGF-1) levels in the majority of patients with acromegaly and ameliorating symptoms and signs associated with GH excess. Pegvisomant does not have direct antiproliferative effects on the underlying somatotroph pituitary adenoma, which is the etiology of GH excess in the vast majority of patients with acromegaly. Therefore, patients receiving pegvisomant monotherapy require regular pituitary imaging in order to monitor for possible increase in tumor size. Adverse events in patients on pegvisomant therapy include skin rashes, lipohypertrophy at injection sites, and idiosyncratic liver toxicity (generally asymptomatic transaminitis that is reversible upon drug discontinuation), thus necessitating regular patient monitoring. Pegvisomant is an effective therapeutic agent in patients with acromegaly who are not in remission after undergoing pituitary surgery. It mitigates excess GH action, as demonstrated by IGF-1 normalization, but has no direct effects on pituitary tumors causing acromegaly. Regular surveillance for possible tumor growth and adverse effects (hepatotoxicity, skin manifestations) is warranted. C1 [Tritos, Nicholas A.; Biller, Beverly M. K.] Massachusetts Gen Hosp, Neuroendocrine Unit, Zero Emerson Pl 112, Boston, MA 02114 USA. [Tritos, Nicholas A.; Biller, Beverly M. K.] Harvard Med Sch, Boston, MA 02115 USA. RP Tritos, NA (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, Zero Emerson Pl 112, Boston, MA 02114 USA.; Tritos, NA (reprint author), Harvard Med Sch, Boston, MA 02115 USA. EM ntritos@partners.org FU Ipsen; Novartis; Novo Nordisk; Pfizer FX NAT has received institution-directed research support from Ipsen, Novartis, Novo Nordisk and Pfizer and has consulted for Ipsen. BMKB has received institution-directed research support from Novartis and has consulted for Novartis, Ipsen and Pfizer. NR 57 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1386-341X EI 1573-7403 J9 PITUITARY JI Pituitary PD FEB PY 2017 VL 20 IS 1 BP 129 EP 135 DI 10.1007/s11102-016-0753-y PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EN5QO UT WOS:000396060800017 PM 27631335 ER PT J AU Maiti, A Terracina, KA Das, A Chatterjee, S AF Maiti, Abhishek Terracina, Katherine A. Das, Avash Chatterjee, Saurav TI A tale of two hearts SO POSTGRADUATE MEDICAL JOURNAL LA English DT Editorial Material ID TRANSPLANTATION C1 [Maiti, Abhishek; Terracina, Katherine A.] Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, Houston, TX 77030 USA. [Das, Avash] Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02114 USA. [Chatterjee, Saurav] St Lukes Roosevelt Hosp Mt Sinai Hlth Syst, Div Cardiol, New York, NY USA. RP Maiti, A (reprint author), 6431 Fannin,MSB 1-134, Houston, TX 77030 USA. EM abhishek.maiti87@gmail.com NR 4 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0032-5473 EI 1469-0756 J9 POSTGRAD MED J JI Postgrad. Med. J. PD FEB PY 2017 VL 93 IS 1096 BP 107 EP 107 DI 10.1136/postgradmedj-2016-134309 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA EL5MI UT WOS:000394664800012 PM 27466412 ER PT J AU Der-Martirosian, C Radcliff, TA Gable, AR Riopelle, D Hagigi, FA Brewster, P Dobalian, A AF Der-Martirosian, Claudia Radcliff, Tiffany A. Gable, Alicia R. Riopelle, Deborah Hagigi, Farhad A. Brewster, Pete Dobalian, Aram TI Assessing Hospital Disaster Readiness Over Time at the US Department of Veterans Affairs SO PREHOSPITAL AND DISASTER MEDICINE LA English DT Article DE assessment; capabilities; disaster readiness; emergency management; hospital preparedness ID EMERGENCY MANAGEMENT; SURGE CAPACITY; PREPAREDNESS AB Introduction: There have been numerous initiatives by government and private organizations to help hospitals become better prepared for major disasters and public health emergencies. This study reports on efforts by the US Department of Veterans Affairs (VA), Veterans Health Administration, Office of Emergency Management's (OEM) Comprehensive Emergency Management Program (CEMP) to assess the readiness of VA Medical Centers (VAMCs) across the nation. Hypothesis/Problem: This study conducts descriptive analyses of preparedness assessments of VAMCs and examines change in hospital readiness over time. Methods: To assess change, quantitative analyses of data from two phases of preparedness assessments (Phase I: 2008-2010; Phase II: 2011-2013) at 137 VAMCs were conducted using 61 unique capabilities assessed during the two phases. The initial five-point Likert-like scale used to rate each capability was collapsed into a dichotomous variable: "not-developed = 0" versus "developed = 1." To describe changes in preparedness over time, four new categories were created from the Phase I and Phase II dichotomous variables: (1) rated developed in both phases; (2) rated not-developed in Phase I but rated developed in Phase II; (3) rated not-developed in both phases; and (4) rated developed in Phase I but rated not-developed in Phase II. Results: From a total of 61 unique emergency preparedness capabilities, 33 items achieved the desired outcome - they were rated either "developed in both phases" or "became developed" in Phase II for at least 80% of VAMCs. For 14 items, 70%-80% of VAMCs achieved the desired outcome. The remaining 14 items were identified as "low-performing" capabilities, defined as less than 70% of VAMCs achieved the desired outcome. Conclusion: Measuring emergency management capabilities is a necessary first step to improving those capabilities. Furthermore, assessing hospital readiness over time and creating robust hospital readiness assessment tools can help hospitals make informed decisions regarding allocation of resources to ensure patient safety, provide timely access to high-quality patient care, and identify best practices in emergency management during and after disasters. Moreover, with some minor modifications, this comprehensive, all-hazardsbased, hospital preparedness assessment tool could be adapted for use beyond the VA. C1 [Der-Martirosian, Claudia] 16111 Plummer St MS 152, North Hills, CA 91343 USA. [Der-Martirosian, Claudia; Radcliff, Tiffany A.; Gable, Alicia R.; Hagigi, Farhad A.; Dobalian, Aram] US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, North Hills, CA USA. [Radcliff, Tiffany A.] Texas A&M Univ, Sch Publ Hlth, Dept Hlth Policy Management, College Stn, TX USA. [Riopelle, Deborah] VA Greater Angeles Healthcare Syst, VA Hlth Serv Res & Dev Ctr Study Healthcare Innov, North Hills, CA USA. [Hagigi, Farhad A.] Univ Calif Angeles, Sch Med, Dept Family Med, Los Angeles, CA USA. [Hagigi, Farhad A.] Univ Calif Angeles, Anderson Sch Management, Los Angeles, CA USA. [Brewster, Pete] Dept Vet Affairs, Vet Hlth Adm, Off Emergency Management, Martinsburg, WV USA. [Dobalian, Aram] Univ Calif Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Dobalian, Aram] Univ Calif Angeles, Sch Nursing, Los Angeles, CA USA. RP Der-Martirosian, C (reprint author), 16111 Plummer St MS 152, North Hills, CA 91343 USA. EM Claudia.Der-Martirosian@va.gov FU Department of Veterans Affairs (VA), Veterans Health Administration, Office of Patient Care Services (PCS; Washington DC, USA) FX This material is based upon work supported by the Department of Veterans Affairs (VA), Veterans Health Administration, Office of Patient Care Services (PCS; Washington DC, USA). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the VA or the US government. NR 32 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1049-023X EI 1945-1938 J9 PREHOSPITAL DISASTER JI Prehospital Disaster Med. PD FEB PY 2017 VL 32 IS 1 BP 46 EP 57 DI 10.1017/S1049023X16001266 PG 12 WC Emergency Medicine SC Emergency Medicine GA EL5LY UT WOS:000394663800007 PM 27964767 ER PT J AU Teran, VG Fuentes, MA Atallah, DG Yang, Y AF Teran, Vincenzo G. Fuentes, Milton A. Atallah, Devin G. Yang, Yi TI Risk and Protective Factors Impacting Burnout in Bilingual, Latina/o Clinicians: An Exploratory Study SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article DE job burnout; Latina/os; training; bilingualism; psychotherapy ID MENTAL-HEALTH-SERVICES; RESIDENTS; AMERICANS; SPANISH; ACCESS; STAFF; CARE AB While there is a paucity of information in the research examining the training and professional experience of bilingual, Latina/o clinicians who provide mental health services in Spanish, a growing body of research has highlighted a series of challenges unique to this group of providers, including their concerns about burnout due to such challenges. This exploratory study is the first (to the best of our knowledge) to measure the levels of burnout among these clinicians and to examine the interrelationship between burnout and sociodemographic and individual characteristics. The extent to which these clinicians experience the challenges identified in previous studies was also investigated. Participants included 66 bilingual, English-Spanish, Latina/o clinicians. The results suggest that bilingual, Latina/o clinicians endorse lower degrees of burnout relative to their monolingual, English counterparts and that specific sociodemographic and individual characteristics influence burnout. Furthermore, the results support previous research findings highlighting the unique set of challenges encountered by these clinicians. Understanding the characteristics and dynamics that contribute to and protect against burnout has major implications for the training, support, and retention of bilingual, English-Spanish, Latina/o psychologists. C1 [Teran, Vincenzo G.] Cambridge Hlth Alliance, Harvard Med Sch, 163 Gore St, Cambridge, MA 02141 USA. [Fuentes, Milton A.] Montclair State Univ, Montclair, NJ USA. [Atallah, Devin G.] Pontif Cathol Univ, Santiago, Chile. [Yang, Yi] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA USA. RP Teran, VG (reprint author), Cambridge Hlth Alliance, Harvard Med Sch, 163 Gore St, Cambridge, MA 02141 USA. EM vteran@cha.harvard.edu NR 32 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 EI 1939-1323 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD FEB PY 2017 VL 48 IS 1 BP 22 EP 29 DI 10.1037/pro0000126 PG 8 WC Psychology, Multidisciplinary SC Psychology GA EM6JY UT WOS:000395419900003 ER PT J AU Edmunds, JM Brodman, DM Ringle, VA Read, KL Kendall, PC Beidas, RS AF Edmunds, Julie M. Brodman, Douglas M. Ringle, Vanesa A. Read, Kendra L. Kendall, Philip C. Beidas, Rinad S. TI Examining Adherence to Components of Cognitive-Behavioral Therapy for Youth Anxiety After Training and Consultation SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article DE evidence-based practice; cognitive-behavioral therapy; training; fidelity; adherence ID MENTAL-HEALTH SYSTEM; AFFORDABLE CARE ACT; TREATMENT INTEGRITY; DISSEMINATION TRIAL; PATIENT PROTECTION; TREATMENT FIDELITY; EXPOSURE THERAPY; IMPLEMENTATION; STRATEGIES; DISORDERS AB The present study examined 115 service providers' adherence to components of cognitive-behavioral therapy (CBT) for youth anxiety before training, postworkshop training, and after 3 months of weekly consultation. Adherence was measured using a role play with a trained actor. We examined differences in individual adherence to CBT components across time and the relationship between number of consultation sessions attended and adherence ratings after consultation. Findings indicated that somatic arousal identification and relaxation were the most used treatment components before training. Adherence to all components of CBT increased after workshop training, except the usage of problem-solving. Adherence to problem-solving, positive reinforcement, the identification of anxious self-talk, and the creation of coping thoughts increased after consultation but usage of problem-solving remained low compared with other treatment components. Overall adherence remained less than optimal at the final measurement point. The number of consultation sessions attended predicted postconsultation adherence to identification of somatic arousal, identification of anxious self-talk, and positive reinforcement. Implications include tailoring future training based on baseline levels of adherence and spending more time during training and consultation on underutilized CBT components, such as problem-solving. Limitations of the present study, including how adherence was measured, are discussed. This study adds to the implementation science literature by providing more nuanced information on changes in adherence over the course of training and consultation of service providers. C1 [Edmunds, Julie M.] Massachusetts Gen Hosp, Boston, MA USA. [Edmunds, Julie M.] Harvard Med Sch, Dept Psychiat, Boston, MA USA. [Brodman, Douglas M.] New York Univ Langone Med Ctr, New York, NY USA. [Brodman, Douglas M.; Read, Kendra L.; Beidas, Rinad S.] Temple Univ, Clin Psychol, Philadelphia, PA 19122 USA. [Ringle, Vanesa A.] Univ Miami, Coral Gables, FL 33124 USA. [Read, Kendra L.] Seattle Childrens Hosp, Seattle, WA USA. [Read, Kendra L.] Univ Washington Sch Med, Dept Psychiat & Behav Sci, Seattle, WA USA. [Kendall, Philip C.] Temple Univ, Philadelphia, PA 19122 USA. [Kendall, Philip C.] Virginia Commonwealth Univ, Psychiat Clin, Richmond, VA 23284 USA. [Beidas, Rinad S.] Univ Penn, Philadelphia, PA 19104 USA. [Beidas, Rinad S.] Univ Penn Perelman Sch Med, Dept Psychiat, Philadelphia, PA USA. RP Edmunds, JM (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Dept Psychiat, 151 Merrimac St,3rd Floor, Boston, MA 02114 USA. EM jedmunds@mgh.harvard.edu FU National Institute of Mental Health [MH083333, MH099179, MH086438, R25 MH080916]; Implementation Research Institute (IRI) at the George Warren Brown School of Social Work, Washington University in St. Louis; Quality Enhancement Research Initiative (QUERI); Department of Veterans Affairs Contract, Veterans Health Administration, Office of Research and Development; Health Services Research and Development Service FX FUNDING FOR this research project was supported by the following grants from the National Institute of Mental Health: MH083333 and MH099179 (Rinad S. Beidas) and MH086438 (Philip C. Kendall). In addition, the preparation of this article was supported in part by the Implementation Research Institute (IRI) at the George Warren Brown School of Social Work, Washington University in St. Louis, through an award from the National Institute of Mental Health (R25 MH080916) and the Quality Enhancement Research Initiative (QUERI), Department of Veterans Affairs Contract, Veterans Health Administration, Office of Research and Development, and Health Services Research and Development Service. Rinad S. Beidas was an IRI fellow from 2012 to 2014. NR 44 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 EI 1939-1323 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD FEB PY 2017 VL 48 IS 1 BP 54 EP 61 DI 10.1037/pro0000100 PG 8 WC Psychology, Multidisciplinary SC Psychology GA EM6JY UT WOS:000395419900007 ER PT J AU Zhang, X AF Zhang, Xi TI Detergents: Friends not foes for high-performance membrane proteomics toward precision medicine SO PROTEOMICS LA English DT Review DE Detergents; Membrane protein; Posttranslational modification; Precision medicine; Structural proteomics; Target engagement; Technology ID CYTOCHROME-C-OXIDASE; PROTEIN-COUPLED RECEPTOR; TANDEM MASS-SPECTROMETRY; PHOTOSYNTHETIC REACTION CENTER; SIZE-EXCLUSION CHROMATOGRAPHY; ALKYL GLYCOSIDE DETERGENTS; HUMAN GAMMA-SECRETASE; BLUE-NATIVE/SDS-PAGE; AGE-RELATED-CHANGES; GATED ION-CHANNEL AB Precision medicine, particularly therapeutics, emphasizes the atomic-precise, dynamic, and systems visualization of human membrane proteins and their endogenous modifiers. For years, bottom-up proteomics has grappled with removing and avoiding detergents, yet faltered at the therapeutic-pivotal membrane proteins, which have been tackled by classical approaches and are known for decades refractory to single-phase aqueous or organic denaturants. Hydrophobicity and aggregation commonly challenge tissue and cell lysates, biofluids, and enriched samples. Frequently, expected membrane proteins and peptides are not identified by shotgun bottom-up proteomics, let alone robust quantitation. This review argues the cause of this proteomic crisis is not detergents per se, but the choice of detergents. Recently, inclusion of compatible detergents for membrane protein extraction and digestion has revealed stark improvements in both quantitative and structural proteomics. This review analyzes detergent properties behind recent proteomic advances, and proposes that rational use of detergents may reconcile outstanding membrane proteomics dilemmas, enabling ultradeep coverage and minimal artifacts for robust protein and endogenous PTM measurements. The simplicity of detergent tools confers bottom-up membrane proteomics the sophistication toward precision medicine. C1 [Zhang, Xi] Massachusetts Gen Hosp, Dept Anesthesia, Crit Care & Pain Med, 32 Fruit St, Boston, MA 02114 USA. [Zhang, Xi] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA USA. RP Zhang, X (reprint author), Massachusetts Gen Hosp, Dept Anesthesia, Crit Care & Pain Med, 32 Fruit St, Boston, MA 02114 USA. EM xi.zhang.edu@gmail.com FU National Institute of General Medical Sciences [GM058448]; Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital FX The author thanks Dr. Shelagh M. Ferguson-Miller for discussions of detergents and membrane proteins. The author also thanks Dr. Royd Carlson for helping with editing the manuscript. Early stage of this work was supported in part by the National Institute of General Medical Sciences (GM058448, to Dr. Keith W. Miller) and the Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital. NR 177 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1615-9853 EI 1615-9861 J9 PROTEOMICS JI Proteomics PD FEB PY 2017 VL 17 IS 3-4 SI SI AR UNSP 1600209 DI 10.1002/pmic.201600209 PG 18 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EO9MM UT WOS:000397012800002 ER PT J AU Irwin, K AF Irwin, Kelly TI Tobacco treatment for patients with severe mental illness and cancer SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Irwin, Kelly] Massachusetts Gen Hosp, Boston, MA 02114 USA. FU National Cancer Institute [5 R01 CA166147-05]; Program in Cancer Outcomes Research Training Fellowship [R25CA092203] FX National Cancer Institute (5 R01 CA166147-05) and Program in Cancer Outcomes Research Training Fellowship, (R25CA092203) NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA 15.1 BP 25 EP 25 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700050 ER PT J AU Park, E AF Park, Elyse TI Tobacco assistance for recently diagnosed cancer patients: Who does not receive assistance? SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Park, Elyse] Massachusetts Gen Hosp, Boston, MA 02114 USA. FU National Cancer Institute [5 R01 CA166147-05] FX National Cancer Institute (5 R01 CA166147-05) NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA 15.3 BP 25 EP 26 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700052 ER PT J AU Perez, G AF Perez, Giselle TI Smoking cessation program needs among Black and Hispanic cancer patients SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Perez, Giselle] Massachusetts Gen Hosp, Boston, MA 02114 USA. FU National Cancer Institute [3R01CA166147 - 02S1] FX National Cancer Institute (3R01CA166147 - 02S1). NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA 15.2 BP 25 EP 25 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700051 ER PT J AU Cooley, M AF Cooley, Mary TI Decision support for symptom self-management during cancer treatment SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Cooley, Mary] Dana Farber Canc Inst, Boston, MA 02115 USA. FU Patient Centered Outcomes Research Institute [PI-12-001] FX This work was supported by The Patient Centered Outcomes Research Institute grant PI-12-001. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA 17.1 BP 27 EP 27 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700056 ER PT J AU Corveleyn, A AF Corveleyn, Amy TI Proactive psychiatry consultation and case management for patients with cancer and serious mental illness and their caregivers: A pilot study SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Corveleyn, Amy] Massachusetts Gen Hosp, Boston, MA 02114 USA. FU American Cancer Society FX American Cancer Society NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA 17.4 BP 28 EP 29 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700059 ER PT J AU Jacobs, J AF Jacobs, Jamie TI Patient, family, and stakeholder engagement in a PCORI-funded study SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Jacobs, Jamie] Massachusetts Gen Hosp, Boston, MA 02114 USA. FU Patient-Centered Outcomes Research Institute Award [IHS-1306-03616] FX Research reported in this publication was funded through a Patient-Centered Outcomes Research Institute Award (IHS-1306-03616). The statements presented in this work are solely the responsibility of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its board of governors, or methodology committee. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA 17.3 BP 28 EP 28 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700058 ER PT J AU Braun, I AF Braun, Ilana TI Key informants' perspectives on medical marijuana use in oncology SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Braun, Ilana] Dana Farber Canc Inst, Boston, MA USA. FU Hans and Mavis Lopater Foundation FX The Hans and Mavis Lopater Foundation. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA 24.4 BP 39 EP 39 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700085 ER PT J AU Muriel, A Brand, S Renzi, D Loucas, C AF Muriel, Anna Brand, Sarah Renzi, Danielle Loucas, Caitlyn TI Psychosocial risk and predictors of mood in parents of children with cancer SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Muriel, Anna; Brand, Sarah; Renzi, Danielle] Dana Farber Canc Inst, Boston, MA USA. [Loucas, Caitlyn] Amer Univ, Washington, DC 20016 USA. FU Harvard University Milton Fund FX Harvard University Milton Fund NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA 26.1 BP 41 EP 41 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700090 ER PT J AU Irwin, K Fields, L Corveleyn, A Park, ER Greer, J Jacobs, J Ryan, D Pirl, W AF Irwin, Kelly Fields, Lauren Corveleyn, Amy Park, Elyse R. Greer, Joseph Jacobs, Jamie Ryan, David Pirl, William TI Proactive psychiatry consultation for patients with severe mental illness and cancer: A pilot study SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Irwin, Kelly; Fields, Lauren; Corveleyn, Amy; Park, Elyse R.; Jacobs, Jamie; Ryan, David] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Greer, Joseph] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Pirl, William] Sylvester Canc Ctr, Miami, FL USA. FU National Institutes of Health/National Cancer Institute Program in Cancer Outcomes Research Training; American Cancer Society; Massachusetts General Hospital Cancer Center; Department of Psychiatry FX National Institutes of Health/National Cancer Institute Program in Cancer Outcomes Research Training, American Cancer Society Institutional Review Grant, Massachusetts General Hospital Cancer Center and Department of Psychiatry NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA 28.2 BP 45 EP 45 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700099 ER PT J AU Reese, J Beach, MC Smith, KC Bantug, ET Casale, KE Porter, LS Bober, SL Tulsky, JA Daly, MB Lepore, SJ AF Reese, Jennifer Beach, Mary Catherine Smith, Katherine Clegg Bantug, Elissa T. Casale, Kristen E. Porter, Laura S. Bober, Sharon L. Tulsky, James A. Daly, Mary B. Lepore, Stephen J. TI Effective patient-provider communication about sexual concerns in breast cancer: A qualitative study of patients and providers SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Reese, Jennifer; Casale, Kristen E.; Daly, Mary B.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Beach, Mary Catherine; Smith, Katherine Clegg] Johns Hopkins Sch Med, Baltimore, MD USA. [Bantug, Elissa T.] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Porter, Laura S.] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Bober, Sharon L.; Tulsky, James A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lepore, Stephen J.] Temple Univ, Philadelphia, PA 19122 USA. FU American Cancer Society [MRSG-14-031-CPPB]; National Cancer Institute [R21CA191354, P30CA006927] FX This study was supported by MRSG-14-031-CPPB from the American Cancer Society and R21CA191354 and P30CA006927 from the National Cancer Institute. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA T12 BP 51 EP 52 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700113 ER PT J AU Fields, L Corveleyn, A Pirl, W Park, E Greer, J Kotagiri, N Hagan, T Irwin, K AF Fields, Lauren Corveleyn, Amy Pirl, William Park, Elyse Greer, Joseph Kotagiri, Nayanika Hagan, Teresa Irwin, Kelly TI Tailoring research design for patients with severe mental illness and cancer SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Fields, Lauren; Corveleyn, Amy; Park, Elyse; Greer, Joseph; Hagan, Teresa; Irwin, Kelly] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Pirl, William] Sylvester Canc Ctr, Miami, FL USA. [Kotagiri, Nayanika] Tufts Univ, Medford, MA 02155 USA. FU National Institutes of Health/National Cancer Institute Program in Cancer Outcomes Research Training; American Cancer Society; Massachusetts General Hospital Cancer Center; Department of Psychiatry FX National Institutes of Health/National Cancer Institute Program in Cancer Outcomes Research Training, American Cancer Society Institutional Review Grant, Massachusetts General Hospital Cancer Center, and Department of Psychiatry NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA T24 BP 56 EP 57 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700125 ER PT J AU Friedman, E Park, E Traeger, L AF Friedman, Emily Park, Elyse Traeger, Lara TI Depression and psychosocial support service utilization among lung cancer patients SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Friedman, Emily; Park, Elyse; Traeger, Lara] Massachusetts Gen Hosp, Boston, MA 02114 USA. FU National Institutes of Health/National Cancer Institute [U54-CA156732] FX This study was funded by grant U54-CA156732 to Drs Park and Cannon from the National Institutes of Health/National Cancer Institute. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA T64 BP 73 EP 74 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700165 ER PT J AU Rabin, J Perez, GK Hall, DL Hagan, T Quain, K Jimenez, R Park, ER Peppercorn, J AF Rabin, Julia Perez, Giselle K. Hall, Daniel L. Hagan, Teresa Quain, Katharine Jimenez, Rachel Park, Elyse R. Peppercorn, Jeffrey TI Prevalence and predictors of fear of recurrence among adult patients with cancer SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Rabin, Julia; Perez, Giselle K.; Hall, Daniel L.; Hagan, Teresa; Quain, Katharine; Jimenez, Rachel; Park, Elyse R.; Peppercorn, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA. FU MGH Cancer Center FX This study was funded by the MGH Cancer Center. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA T67 BP 75 EP 75 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700168 ER PT J AU Geller, J Ranby, K Maikovich-Fong, A Simoneau, T Kilbourn, K Avram, D AF Geller, Jessica Ranby, Krista Maikovich-Fong, Andrea Simoneau, Teri Kilbourn, Kristin Avram, David TI Perceived social support effectiveness: A dyadic predictor of psychosocial distress in patients undergoing autologous hematopoietic stem cell transplant (HSCT) SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Geller, Jessica; Simoneau, Teri] Denver Vet Affairs Med Ctr, Denver, CO USA. [Ranby, Krista; Kilbourn, Kristin; Avram, David] Univ Colorado, Denver, CO 80202 USA. [Maikovich-Fong, Andrea] Colorado Blood Canc Inst Presbyterian, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA F2 BP 78 EP 79 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700177 ER PT J AU Park, E Stephenson, E Moore, C Levy, D Muriel, A AF Park, Eliza Stephenson, Elise Moore, Cynthia Levy, David Muriel, Anna TI How does cancer stage influence parenting concerns? Parenting concerns questionnaire scores in adults with metastatic and nonmetastatic cancer SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Park, Eliza; Stephenson, Elise; Levy, David] Univ N Carolina, Chapel Hill, NC USA. [Moore, Cynthia] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Muriel, Anna] Dana Farber Canc Inst, Boston, MA 02115 USA. FU University Cancer Research Fund of North Carolina; National Center for Advancing Translational Sciences (NCATS), National Institutes of Health [1UL1TR001111, 1KL2TR001109, R03 CA126394-01] FX The study was supported by the University Cancer Research Fund of North Carolina and the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through grant awards 1UL1TR001111 and 1KL2TR001109 (Dr. Park) and R03 CA126394-01 (Dr Muriel). NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA F6 BP 80 EP 80 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700181 ER PT J AU Strauss, N Rabin, J Temel, B Philpotts, L Ostroff, J Park, ER Perez, GK AF Strauss, Nicole Rabin, Julia Temel, Brandon Philpotts, Lisa Ostroff, Jamie Park, Elyse R. Perez, Giselle K. TI Smoking cessation interventions for Black and Hispanic cancer patients: A systematic review of tobacco trials SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Strauss, Nicole; Rabin, Julia; Temel, Brandon; Philpotts, Lisa; Park, Elyse R.; Perez, Giselle K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ostroff, Jamie] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. FU National Cancer Institute [3R01CA166147 - 02S1] FX This study was funded by the National Cancer Institute (3R01CA166147 - 02S1). NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA F22 BP 87 EP 87 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700196 ER PT J AU Schmidt, EM Krahn, DD McGuire, MH Tavakoli, S Wright, DM Solares, HE Lemke, S Trafton, J AF Schmidt, Eric M. Krahn, Dean D. McGuire, Marsden H. Tavakoli, Sara Wright, David M. Solares, Hugo E. Lemke, Sonne Trafton, Jodie TI Using Organizational and Clinical Performance Data to Increase the Value of Mental Health Care SO PSYCHOLOGICAL SERVICES LA English DT Article DE mental health services; veterans; quality improvement; quality indicators; program evaluation; organization and administration ID QUALITY-OF-CARE; INFORMATION-TECHNOLOGY; ACCOUNTABLE CARE; SERVICES; IMPLEMENTATION; IMPROVEMENT; CONTINUITY; INSURANCE; SCIENCE; SYSTEM AB U.S. health systems, policy makers, and patients increasingly demand high-value care that improves health outcomes at lower cost. This study describes the initial design and analysis of the Mental Health Management System (MHMS), a performance data and quality improvement tool used by the Veterans Health Administration (VHA) to increase the value of its mental health care. The MHMS evaluates access to and quality of mental health care, organizational structure and efficiency, implementation of innovative treatment options, and, in collaboration with management, resource needs for delivering care. Performance on 31 measures was calculated for all U.S. VHA facilities (N = 139). Pearson correlations revealed that better access to care was significantly associated with fewer mental health provider staffing vacancies (r = -.24) and higher staff-topatient ratios for psychiatrists (r =.19) and other outpatient mental health providers (r =.27). Higher staff-to-patient ratios were significantly associated with higher performance on a number of patient and provider satisfaction measures (range of r =.18-.51) and continuity of care measures (range of r =.26-.43). Relationships observed between organizational and clinical performance measures suggest that the MHMS is a robust informatics and quality improvement tool that can serve as a model for health systems planning to adopt a value perspective. Future research should expand the MHMS framework to measure patient and health systems costs and psychosocial outcomes, as well as evaluate whether quality improvement solutions implemented as a result of using organizational information leads to higher-value mental health care. C1 [Schmidt, Eric M.; Tavakoli, Sara; Wright, David M.; Solares, Hugo E.; Lemke, Sonne; Trafton, Jodie] Vet Affairs Palo Alto Hlth Care Syst, Menlo Pk, CA USA. [Krahn, Dean D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [McGuire, Marsden H.] Vet Affairs Cent Off, Washington, DC USA. [McGuire, Marsden H.] Johns Hopkins Univ, Baltimore, MD USA. [Schmidt, Eric M.; Trafton, Jodie] Stanford Univ, Stanford, CA USA. [McGuire, Marsden H.] Univ Maryland, College Pk, MD USA. [Tavakoli, Sara; Wright, David M.; Solares, Hugo E.; Lemke, Sonne; Trafton, Jodie] VA Off Mental Hlth Operat, Washington, DC USA. RP Trafton, J (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Menlo Pk, CA USA. EM jodie.trafton@va.gov FU Department of Veterans Affairs (VA) Office of Academic Affiliations Advanced Fellowship in Health Services Research and Development (HSRD); VA HSRD Service FX Dr. Eric M. Schmidt was supported by the Department of Veterans Affairs (VA) Office of Academic Affiliations Advanced Fellowship in Health Services Research and Development (HSR&D) and the VA HSR&D Service. NR 43 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2017 VL 14 IS 1 BP 13 EP 22 DI 10.1037/ser0000098 PG 10 WC Psychology, Clinical SC Psychology GA EM0QJ UT WOS:000395022500002 PM 28134553 ER PT J AU Dopp, AR Hanson, RF Saunders, BE Dismuke, CE Moreland, AD AF Dopp, Alex R. Hanson, Rochelle F. Saunders, Benjamin E. Dismuke, Clara E. Moreland, Angela D. TI Community-Based Implementation of Trauma-Focused Interventions for Youth: Economic Impact of the Learning Collaborative Model SO PSYCHOLOGICAL SERVICES LA English DT Article DE cost-effectiveness; implementation; trauma-focused cognitive-behavioral therapy; training; community services ID COST-EFFECTIVENESS; CHILD MALTREATMENT; ADOLESCENTS; DISORDERS; DISSEMINATION; CLINICIAN AB This study investigated the economics of the learning collaborative (LC) model in the implementation of Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT), an evidence-based intervention for traumatic stress in youth. We evaluated the cost-effectiveness of the LC model based on data from 13 LCs completed in the southeastern United States. Specifically, we calculated cost-effectiveness ratios (CERs) for 2 key service outcomes: (a) clinician TF-CBT competence, based on pre-and post-LC self-ratings (n = 574); and (b) trauma-related mental health symptoms (i.e.,traumatic stress and depression), selfand caregiver-reported, for youth who received TF-CBT (n = 1,410). CERs represented the cost of achieving 1 standard unit of change on a measure (i.e., d = 1.0). The results indicated that (a) costs of $18,679 per clinician were associated with each unit increase in TF-CBT competency and (b) costs from $5,318 to $6,548 per youth were associated with each unit decrease in mental health symptoms. Thus, although the impact of LC participation on clinician competence did not produce a favorable CER, subsequent reductions in youth psychopathology demonstrated high cost-effectiveness. Clinicians and administrators in community provider agencies should consider these findings in their decisions about implementation of evidence-based interventions for youth with traumatic stress disorders. C1 [Dopp, Alex R.; Hanson, Rochelle F.; Saunders, Benjamin E.; Moreland, Angela D.] Med Univ South Carolina, Columbia, SC USA. [Dismuke, Clara E.] Med Univ South Carolina, Charleston, SC 29425 USA. [Dismuke, Clara E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Dopp, AR (reprint author), Univ Arkansas, Dept Psychol Sci, 216 Mem Hall, Fayetteville, AR 72701 USA. EM dopp@uark.edu FU National Institute of Mental Health [5 R34 MH104470]; Substance Abuse and Mental Health Services Administration [5 U79 SM061269]; Duke Endowment [1582-SP] FX This research was supported by grants from the National Institute of Mental Health (5 R34 MH104470), Substance Abuse and Mental Health Services Administration (5 U79 SM061269), and the Duke Endowment (1582-SP). We sincerely thank the many families who participated in this project as well as the therapists and other community professionals, too numerous to mention individually, who participated in the learning collaboratives. Finally, we extend special thanks to Faraday Davies, Sara delMas, and Emily Fanguy for their assistance with data collection and management. NR 41 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2017 VL 14 IS 1 BP 57 EP 65 DI 10.1037/ser0000131 PG 9 WC Psychology, Clinical SC Psychology GA EM0QJ UT WOS:000395022500006 PM 28134556 ER PT J AU Moore, JT AF Moore, Jon T. TI Multicultural and Idiosyncratic Considerations for Measuring the Relationship Between Religious and Secular Forms of Spirituality With Positive Global Mental Health SO PSYCHOLOGY OF RELIGION AND SPIRITUALITY LA English DT Article DE secular; multicultural; spiritual values; belief in God; mental health ID WELL-BEING QUESTIONNAIRE; VALIDATION; PSYCHOLOGY; SCALE; LIFE; INVOLVEMENT; FITNESS AB The current study espouses an alternative methodology using an ideologically diverse sample of 4,667 respondents who reported their spirituality levels (i.e., the extent one lives in accordance with one's self-defined spiritual values) and their mental health levels. The sample predominately included agnostic, atheist, Buddhist, Christian, Jewish, and spiritual nonreligious participants. Multigroup analyses within structural equation models revealed that spirituality held a large relationship strength with mental health for both religious and secular forms of spirituality, even with multiple configurations determining the constituents of the secular group. An exploratory analysis demonstrated that when spirituality, demographic factors, social support, and spiritual coping usage were all examined as predictors of mental health, religious and secular forms of spirituality were the only variables that maintained a large predictive strength. The results indicated that living in accordance with one's spiritual values, even when defined in a variety of ways, is characteristic of greater mental health. C1 [Moore, Jon T.] Vet Affairs Puget Sound Hlth Care Syst, Amer Lake Div, 9600 Vet Dr A-116, Tacoma, WA 98493 USA. [Moore, Jon T.] Univ Oregon, Dept Psychol, Eugene, OR 97403 USA. RP Moore, JT (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Amer Lake Div, 9600 Vet Dr A-116, Tacoma, WA 98493 USA. EM jonmoorephd@gmail.com NR 72 TC 0 Z9 0 U1 0 U2 0 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1941-1022 EI 1943-1562 J9 PSYCHOL RELIG SPIRIT JI Psychol. Relig. Spiritual. PD FEB PY 2017 VL 9 IS 1 BP 21 EP 33 DI 10.1037/rel0000083 PG 13 WC Psychology, Multidisciplinary; Religion SC Psychology; Religion GA EM8JJ UT WOS:000395557100003 ER PT J AU McCaffery, JM Jablonski, KA Franks, PW Delahanty, LM Aroda, V Marrero, D Hamman, RF Horton, ES Dagogo-Jack, S Wylie-Rosett, J Barrett-Connor, E Kitabchi, A Knowler, WC Wing, RR Florez, JC AF McCaffery, Jeanne M. Jablonski, Kathleen A. Franks, Paul W. Delahanty, Linda M. Aroda, Vanita Marrero, David Hamman, Richard F. Horton, Edward S. Dagogo-Jack, Samuel Wylie-Rosett, Judith Barrett-Connor, Elizabeth Kitabchi, Abbas Knowler, William C. Wing, Rena R. Florez, Jose C. CA Diabet Prevention Program Res Grp TI Replication of the Association of BDNF and MC4R Variants With Dietary Intake in the Diabetes Prevention Program SO PSYCHOSOMATIC MEDICINE LA English DT Article DE obesity; diet; total caloric intake; BDNF; MC4R; FTO ID NEUROTROPHIC FACTOR BDNF; GENOME-WIDE ASSOCIATION; EXCESSIVE WEIGHT-GAIN; BODY-MASS INDEX; ENERGY-INTAKE; LIFE-STYLE; FOOD-FREQUENCY; MELANOCORTIN-4 RECEPTOR; MACRONUTRIENT INTAKE; OBESITY AB Objective: Genomewide association studies (GWAS) have identified consistent associations with obesity, with a number of studies implicating eating behavior as a primary mechanism. Few studies have replicated genetic associations with dietary intake. This study evaluates the association between obesity susceptibility loci and dietary intake. Methods: Data were obtained as part of the Diabetes Prevention Program (DPP), a clinical trial of diabetes prevention in persons at high risk of diabetes. The association of 31 genomewide association studies identified obesity risk alleles with dietary intake, measured through a food frequency questionnaire, was investigated in 3,180 participants from DPP at baseline. Results: The minor allele at BDNF, identified as protective against obesity, was associated with lower total caloric intake (beta = -106.06, SE = 33.13; p = .0014) at experimentwide statistical significance (p = .0016), whereas association of MC4R rs571312 with higher caloric intake reached nominal significance (beta = 61.32, SE = 26.24; p = .0194). Among non-Hispanic white participants, the association of BDNF rs2030323 with total caloric intake was stronger (beta = -151.99, SE = 30.09; p < .0001), and association of FTO rs1421085 with higher caloric intake (beta = 56.72, SE = 20.69; p = .0061) and percentage fat intake (beta = 0.37, SE = 0.08; p =. 0418) was also observed. Conclusions: These results demonstrate with the strength of independent replication that BDNF rs2030323 is associated with 100 to 150 greater total caloric intake per allele, with additional contributions of MC4R and, in non-Hispanic white individuals, FTO. As it has been argued that an additional 100 kcal/d could account for the trends in weight gain, prevention focusing on genetic profiles with high dietary intake may help to quell adverse obesity trends. C1 [McCaffery, Jeanne M.; Wing, Rena R.] Miriam Hosp, Weight Control & Diabet Res Ctr, Providence, RI 02906 USA. [McCaffery, Jeanne M.; Wing, Rena R.] Brown Univ, Warren Alpert Sch, Providence, RI 02912 USA. [Jablonski, Kathleen A.] George Washington Univ, Biostat Ctr, Rockville, MD USA. [Franks, Paul W.] Lund Univ, Dept Clin Sci, Genet & Mol Epidemiol Unit, Malmo, Sweden. Umea Univ, Dept Med, Umea, Sweden. Harvard Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Delahanty, Linda M.] Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA. Harvard Med Sch, Dept Med, Boston, MA USA. [Aroda, Vanita] Medstar Hlth Res Inst, Hyattsville, MD USA. [Marrero, David] Indiana Univ, Indianapolis, IN 46204 USA. [Hamman, Richard F.] Univ Colorado Denver, Dept Epidemiol, Colorado Sch Publ Hlth, Aurora, CO USA. [Horton, Edward S.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Dagogo-Jack, Samuel] Univ Tennessee, Memphis, TN USA. [Wylie-Rosett, Judith] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [Barrett-Connor, Elizabeth] Univ Calif San Diego, La Jolla, CA 92093 USA. [Kitabchi, Abbas] Univ Pittsburgh, Pittsburgh, PA USA. [Knowler, William C.] Natl Inst Diabet & Digest & Kidney Dis, Diabet Epidemiol & Clin Res Sect, Phoenix, AZ USA. [Florez, Jose C.] Massachusetts Gen Hosp, Diabet Unit, Diabet Res Ctr, Boston, MA 02114 USA. [Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. Harvard Med Sch, Dept Med, Boston, MA USA. Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. RP McCaffery, JM (reprint author), Miriam Hosp, Weight Control & Diabet Res Ctr, Providence, RI 02906 USA.; McCaffery, JM (reprint author), Brown Univ, Warren Alpert Sch, Providence, RI 02912 USA.; McCaffery, JM (reprint author), George Washington Univ, Ctr Biostat, Diabet Prevent Program Coordinating Ctr, 6110 Execut Blvd,Suite 750, Rockville, MD 20852 USA. EM dppmail@bsc.gwu.edu FU NIDDK of the National Institutes of Health; NIDDK; Indian Health Service; General Clinical Research Center Program, National Center for Research Resources; Office of Research on Minority Health; National Institute of Child Health and Human Development; National Institute on Aging; Centers for Disease Control and Prevention, Office of Research on Women's Health; Department of Veterans Affairs; American Diabetes Association FX Diabetes Prevention Program: The NIDDK of the National Institutes of Health provided funding to the clinical centers and the Coordinating Center for the design and conduct of the study; and collection, management, analysis, and interpretation of the data. The Southwestern American Indian Centers were supported directly by the NIDDK and the Indian Health Service. The General Clinical Research Center Program, National Center for Research Resources supported data collection at many of the clinical centers. Funding for data collection and participant support was also provided by the Office of Research on Minority Health, the National Institute of Child Health and Human Development, the National Institute on Aging, the Centers for Disease Control and Prevention, Office of Research on Women's Health, the Department of Veterans Affairs, and the American Diabetes Association. Bristol-Myers Squibb and Parke-Davis provided medication. This research was also supported, in part, by the intramural research program of the NIDDK. LifeScan Inc, Health O Meter, Hoechst Marion Roussel, Inc, Merck-Medco Managed Care, Inc, Merck and Co, Nike Sports Marketing, Slim Fast Foods Co, and Quaker Oats Co donated materials, equipment, or medicines for concomitant conditions. McKesson BioServices Corp, Matthews Media Group, Inc, and the Henry M. Jackson Foundation provided support services under subcontract with the Coordinating Center. The opinions expressed are those of the investigators and do not necessarily reflect the views of the Indian Health Service or other funding agencies. A complete list of centers, investigators, and staff can be found in the online Appendix, Supplemental Digital Content 2, http://links.lww.com/PSYMED/A316. NR 55 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0033-3174 EI 1534-7796 J9 PSYCHOSOM MED JI Psychosom. Med. PD FEB-MAR PY 2017 VL 79 IS 2 BP 224 EP 233 DI 10.1097/PSY.0000000000000380 PG 10 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA EL2IH UT WOS:000394442800012 PM 27551991 ER PT J AU van Loon, J Even, AJG Aerts, HJWL Ollers, M Hoebers, F van Elmpt, W Dubois, L Dingemans, AMC Lalisang, RI Kempers, P Brans, B Winnepenninckx, V Speel, EJ Thunnissen, E Smits, KM Boellaard, R Vugts, DJ De Ruysscher, D Lambin, P AF van Loon, Judith Even, Aniek J. G. Aerts, Hugo J. W. L. Ollers, Michel Hoebers, Frank van Elmpt, Wouter Dubois, Ludwig Dingemans, Anne-Marie C. Lalisang, Roy I. Kempers, Pascal Brans, Boudewijn Winnepenninckx, Veronique Speel, Ernst-Jan Thunnissen, Eric Smits, Kim M. Boellaard, Ronald Vugts, Danielle J. De Ruysscher, Dirk Lambin, Philippe TI PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer SO RADIOTHERAPY AND ONCOLOGY LA English DT Article DE Zr-89-cetuximab; EGFR; Immuno-PET; Phase I trial ID GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; PLUS CETUXIMAB; 1ST-LINE CHEMOTHERAPY; EGFR-INHIBITION; IMMUNO-PET; EXPRESSION; RADIOTHERAPY; CARCINOMA; SURVIVAL AB Background and purpose: PET imaging of cetuximab uptake may help selecting cancer patients with the highest chance of benefit. The aim of this phase I trial was to determine the safety of the tracer (89)zr-cetuximab and to assess tumour uptake. Methods: Two dose schedules were used; two consecutive doses of 60 MBq Zr-89-cetuximab or a single dose of 120 MBq, both preceded by 400 mg/m(2) of unlabelled cetuximab. Toxicity (CTCAE 3.0) was scored twice weekly. PET-CT scans were acquired on days 4, 5 and 6 (step 1) or 5, 6, 7 (step 2). Because tumour uptake could not be assessed satisfactorily, a third step was added including EGFR overexpressing tumours. Results: Nine patients were included (6 NSCLC; 3 HNC). No additional toxicity was associated with administration of 89Zr-cetuximab compared to standard cetuximab. A tumour to blood ratio (TBR) > 1 was observed in all but one patient, with a maximum of 4.56. TBR was not different between dose schedules. There was a trend for higher TBR at intervals > 5 days after injection. Conclusions: Both presented 89Zr-cetuximab administration schedules are safe. The recommended dose for future trials is 60 MBq, with a minimum time interval for scanning of 6 days. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [van Loon, Judith; Even, Aniek J. G.; Aerts, Hugo J. W. L.; Ollers, Michel; Hoebers, Frank; van Elmpt, Wouter; Dubois, Ludwig; Smits, Kim M.; De Ruysscher, Dirk; Lambin, Philippe] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Radiat Oncol MAASTRO, Maastricht, Netherlands. [Aerts, Hugo J. W. L.] Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA USA. [Aerts, Hugo J. W. L.] Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, Dept Radiol, Boston, MA USA. [Dingemans, Anne-Marie C.] Maastricht Univ, Med Ctr, Dept Pulmonol, Maastricht, Netherlands. [Lalisang, Roy I.] Maastricht Univ, Med Ctr, Dept Med Oncol, Maastricht, Netherlands. [Kempers, Pascal; Brans, Boudewijn] Maastricht Univ, Med Ctr, Dept Nucl Med, Maastricht, Netherlands. [Winnepenninckx, Veronique; Speel, Ernst-Jan] Maastricht Univ, Med Ctr, Dept Pathol, Maastricht, Netherlands. [Thunnissen, Eric] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands. [Boellaard, Ronald; Vugts, Danielle J.] Vrije Univ Amsterdam, Med Ctr, Dept Radiol & Nucl Med, Amsterdam, Netherlands. [De Ruysscher, Dirk] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Radiat Oncol, Leuven, Belgium. RP van Loon, J (reprint author), MAASTRO Clin, Dr Tanslaan 12, NL-6229 ET Maastricht, Netherlands. EM Judith.vanloon@maastro.nl FU CTMM framework (AIRFORCE); EU 6th and 7th framework program (Euroxy, Metoxia and ARTFORCE); Kankeronderzoekfonds Limburg (Health Foundation Limburg); National Institute of Health [NIH-USA U01 CA 143062-01]; Dutch Cancer Society [KWF UM 2008-4210, 2009-4454, 2011-5020, KWF MAC 2013-6425] FX We acknowledge financial support from the CTMM framework (AIRFORCE), EU 6th and 7th framework program (Euroxy, Metoxia and ARTFORCE), Interreg (www.eurocat.info), Kankeronderzoekfonds Limburg (Health Foundation Limburg), the National Institute of Health (NIH-USA U01 CA 143062-01) and the Dutch Cancer Society (KWF UM 2008-4210, 2009-4454, 2011-5020 and KWF MAC 2013-6425). NR 33 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-8140 J9 RADIOTHER ONCOL JI Radiother. Oncol. PD FEB PY 2017 VL 122 IS 2 BP 267 EP 273 DI 10.1016/jsadonc.2016.11.020 PG 7 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EM9BZ UT WOS:000395607300016 PM 28012793 ER PT J AU Melzer, AC Ghassemieh, BJ Gillespie, SE Lindenauer, PK McBurnie, MA Mularski, RA Naureckas, ET Vollmer, WM Au, DH AF Melzer, Anne C. Ghassemieh, Bijan J. Gillespie, Suzanne E. Lindenauer, Peter K. McBurnie, Mary Ann Mularski, Richard A. Naureckas, Edward T. Vollmer, William M. Au, David H. TI Patient characteristics associated with poor inhaler technique among a cohort of patients with COPD SO RESPIRATORY MEDICINE LA English DT Article DE Chronic obstructive pulmonary disease (COPD); Inhaled therapy; Technique; Adherence ID OBSTRUCTIVE PULMONARY-DISEASE; METERED-DOSE INHALER; INCORRECT INHALATION TECHNIQUE; HEALTH LITERACY; ASTHMA; MANAGEMENT; ADHERENCE; EDUCATION AB Background: Inhaled therapies are the cornerstone of pharmacologic management for COPD. Each device requires a unique series of steps to be most effective, making appropriate instruction in inhaler technique a key part of the management of COPD. Objectives: Examine characteristics of patients and devices associated with poor technique among patients with COPD. Methods: Cross-sectional study of subjects with COPD using at least one of: metered dose inhaler, Advair Diskus, Spiriva Handihaler, identified from the COPD Outcomes-based Network for Clinical Effectiveness and Research Translation (CONCERT) registry. Technique was assessed face-to-face using manufacturer provided dummy inhalers, with standardized checklists for each device. We used logistic regression to model associations with poor inhaler technique, defined as an error in >= 20% of the steps, as a function of patient characteristics, with educational attainment the primary predictor. Results: 688 individuals meet eligibility criteria, 65.5% had poor technique for at least one device. In adjusted analyses, Black race was associated with poor technique (OR 3.25, 95%CI 1.86-5.67) while greater than high school education was associated with decreased odds of poor technique (OR 0.35, 95% CI 0.17-0.70 for trade school/some college, OR 0.25, 95%Cl 0.11-0.61 for college or more, p <= 0.001 for test of linear trend). The percentage of errors varied between devices, with subjects making proportionally the most errors for MDIs. Conclusions: Poor inhaler technique is common among individuals with COPD, varies between devices, and is associated with race and educational attainment. Tailored educational interventions to teach inhaler technique should be part of the process of initiating and monitoring inhaled therapies. Published by Elsevier Ltd. C1 [Melzer, Anne C.; Ghassemieh, Bijan J.; Au, David H.] Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA. [Melzer, Anne C.; Au, David H.] VA Puget Sound, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA. [Gillespie, Suzanne E.; McBurnie, Mary Ann; Mularski, Richard A.; Vollmer, William M.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Lindenauer, Peter K.] Baystate Med Ctr, Dept Med, Springfield, MA 01199 USA. [Naureckas, Edward T.] Univ Chicago, Dept Med, Chicago, IL 60637 USA. [Melzer, Anne C.] VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,Mailstop S-152, Seattle, WA 98108 USA. RP Melzer, AC (reprint author), Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA.; Melzer, AC (reprint author), VA Puget Sound, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA.; Melzer, AC (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,Mailstop S-152, Seattle, WA 98108 USA.; Melzer, AC (reprint author), 1 Vet Dr, Minneapolis, MN 55417 USA. EM acmelzer@uw.edu FU National Heart, Lung, and Blood Institute [HL101618] FX This material is based upon work supported by the Department of Veterans Affairs, Health Services Research and Development (HSR&D), who provided access to data, office space, and programming and data management. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. We would like to acknowledge the other member sites of the CONCERT Consortium, without whom this project could not have been completed. Dr. Au has personally reviewed the data, understands the statistical methods employed for efficacy analysis, and confirms an understanding of this analysis, that the methods are clearly described and that they are a fair way to report the results. Dr. Melzer was supported by an institutional F-32 (HL007287) through the University of Washington Department of Pulmonary and Critical Care. Additional support was received through the VA Health Services Research and Development (HSR&D). Support for this project was also provided by the National Heart, Lung, and Blood Institute (HL101618) for the CONCERT group. The views presented are that of the researchers and do not necessary reflect those of the Department of Veterans Affairs. NR 39 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 EI 1532-3064 J9 RESP MED JI Respir. Med. PD FEB PY 2017 VL 123 BP 124 EP 130 DI 10.1016/j.rmed.2016.12.011 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA EL1QY UT WOS:000394397300018 PM 28137488 ER PT J AU Madden, EB Robinson, RM Kendall, DL AF Madden, Elizabeth Brookshire Robinson, Reva M. Kendall, Diane L. TI Phonological Treatment Approaches for Spoken Word Production in Aphasia SO SEMINARS IN SPEECH AND LANGUAGE LA English DT Review DE Aphasia; anomia; phonology; treatment; phonomotor ID PHONOMOTOR TREATMENT; COMPONENTS-ANALYSIS; NAMING IMPAIRMENTS; LEXICAL ACCESS; THERAPY; RETRIEVAL; ANOMIA; ALEXIA; REHABILITATION; PROGRAM AB This article provides an overview of phonological treatment approaches for anomia in individuals with aphasia. The role of phonology in language processing, as well as the impact of phonological impairment on communication is initially discussed. Then, traditional phonologically based treatment approaches, including phonological, orthographic, indirect, guided, and mixed cueing methods, are described. Collectively, these cueing treatment approaches aim to facilitate word retrieval by stimulating residual phonological abilities. An alternative treatment approach, phonomotor treatment, is also examined. Phonomotor treatment aims to rebuild sublexical, phonological sequence knowledge and phonological awareness as a means to strengthen lexical processing and whole-word naming. This treatment is supported by a parallel-distributed processing model of phonology and therefore promotes multimodal training of individual phonemes and phoneme sequences in an effort to enhance the neural connectivity supporting underlying phonological processing mechanisms. The article concludes with suggestions for clinical application and implementation. C1 [Madden, Elizabeth Brookshire] Florida State Univ, Sch Commun Sci & Disorders, Tallahassee, FL 32306 USA. [Robinson, Reva M.] Univ Washington, Dept Speech & Hearing Sci, Seattle, WA 98195 USA. [Kendall, Diane L.] Univ Washington, Dept Speech & Hearing Sci, VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA. [Kendall, Diane L.] Univ Pretoria, Dept Speech Language Pathol & Audiol, Pretoria, South Africa. RP Madden, EB (reprint author), 201 West Bloxham St, Tallahassee, FL 32306 USA. EM ebmadden@fsu.edu FU United States Department of Veterans Affairs [RRD3-15-12W, 1I01RX001145-01A1] FX The authors would like to acknowledge the United States Department of Veterans Affairs for providing tremendous funding for aphasia research, especially for the two grants (#RRD3-15-12W and #1I01RX001145-01A1) that supported this work. NR 46 TC 0 Z9 0 U1 0 U2 0 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0734-0478 EI 1098-9056 J9 SEMIN SPEECH LANG JI Semin. Speech Lang. PD FEB PY 2017 VL 38 IS 1 BP 62 EP 74 DI 10.1055/s-0036-1597258 PG 13 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA EM6CC UT WOS:000395399400008 PM 28201838 ER PT J AU Pfeiffer, PN Valenstein, M Ganoczy, D Henry, J Dobscha, SK Piette, JD AF Pfeiffer, Paul N. Valenstein, Marcia Ganoczy, Dara Henry, Jennifer Dobscha, Steven K. Piette, John D. TI Pilot study of enhanced social support with automated telephone monitoring after psychiatric hospitalization for depression SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY LA English DT Article DE Depression; Discharge; Inpatient; Peer support; Family; Mobile; Monitoring ID PEER SUPPORT; PSYCHOMETRIC PROPERTIES; RANDOMIZED-TRIAL; CARE; SUICIDE; SCALE; INTERVENTION; PREFERENCES; PATIENT; CRISIS AB Following discharge, patients hospitalized for depression are at high risk for poor retention in outpatient care and adverse outcomes. Pilot tests a post-hospital monitoring and enhanced support program for depression. 48 patients at a Veterans Affairs Medical Center discharged following a depression-related inpatient stay received weekly visits or phone calls for 6 months from their choice of either a family member/friend (n = 19) or a certified peer support specialist (n = 29). Participants also completed weekly automated telephone monitoring calls assessing depressive symptoms and antidepressant medication adherence. Over 90% of participants were more satisfied with their care due to the service. The mean change from baseline to 6 months in depression symptoms was -7.9 (p < 0.05) according to the Patient Health Questionnaire and -11.2 (p < 0.05) according to the Beck Depression Inventory-II for those supported by a family member/friend, whereas those supported by a peer specialist had mean changes of -3.5 (p < 0.05) and -1.7 (p > 0.10), respectively. Increased contact with a chosen support person coupled with automated telephone monitoring after psychiatric hospitalization is an acceptable service for patients with depression. Those who received the service, and particularly those supported by a family member/friend, experienced reductions in symptoms of depression. C1 [Pfeiffer, Paul N.; Valenstein, Marcia; Piette, John D.] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA. [Pfeiffer, Paul N.; Valenstein, Marcia; Ganoczy, Dara; Henry, Jennifer; Piette, John D.] VA Ann Arbor Healthcare Syst, VA Ctr Clin Management Res, Ann Arbor, MI 48105 USA. [Dobscha, Steven K.] Portland VA Med Ctr, VA Ctr Vet Involvement Care, Portland, MI USA. [Dobscha, Steven K.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Piette, John D.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. RP Pfeiffer, PN (reprint author), Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA.; Pfeiffer, PN (reprint author), VA Ann Arbor Healthcare Syst, VA Ctr Clin Management Res, Ann Arbor, MI 48105 USA. EM ppfeiffe@umich.edu NR 30 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0933-7954 EI 1433-9285 J9 SOC PSYCH PSYCH EPID JI Soc. Psychiatry Psychiatr. Epidemiol. PD FEB PY 2017 VL 52 IS 2 BP 183 EP 191 DI 10.1007/s00127-016-1288-2 PG 9 WC Psychiatry SC Psychiatry GA EM3EL UT WOS:000395197200010 PM 27783130 ER PT J AU Ramanadhan, S Nagler, RH McCloud, R Kohler, R Viswanath, K AF Ramanadhan, Shoba Nagler, Rebekah H. McCloud, Rachel Kohler, Racquel Viswanath, Kasisomayajula TI Graphic health warnings as activators of social networks: A field experiment among individuals of low socioeconomic position SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE Social networks; Low socioeconomic position; Tobacco; Egocentric; Graphic health warnings ID CIGARETTE PACK WARNINGS; INTERPERSONAL-COMMUNICATION; SMOKING-CESSATION; MEDIA CAMPAIGN; SMOKERS; CONSEQUENCES; MESSAGES; TALKING; LABELS; INTERVENTIONS AB Rationale: Graphic health warnings (GHWs) on cigarette packages present an important tobacco control opportunity, particularly for vulnerable populations suffering a disproportionate tobacco burden. One mechanism by which GHWs may influence smoking outcomes is by prompting interpersonal discussions within health discussion networks (the set of personal contacts with whom an individual discusses health issues). Objective: The study examined the association between GHW-prompted conversations within health discussion networks and key tobacco-related outcomes, with attention to valence and content of the discussions. Method: Between August 2013 and April 2014, we recruited 1200 individuals from three communities in Massachusetts, emphasizing recruitment of individuals of low socioeconomic position (SEP) and members of other selected vulnerable groups. Respondents were exposed to the nine GHWs proposed by the FDA in 2011, asked a series of questions, and assessed at follow-up a few weeks later. Results: A total of 806 individuals were included in this analysis. About 51% of respondents reported having a health discussion network, with significantly lower reports among African-Americans and Hispanics compared to Whites. Around 70% of respondents (smokers and nonsmokers) with health discussion networks reported having one or more conversations about the GHWs with network members, the bulk of which were negative and focused on warning others about smoking. For smokers, we found a small but positive association between the percentage of network conversations that were negative and reports of quit attempts. Conclusion: The results point to a potential mechanism by which GHWs may impact tobacco-related outcomes, prompting further inquiry into the role of health discussion networks (and discussion networks, more broadly) in tobacco control among low SEP individuals. (C) 2017 Elsevier Ltd. All rights reserved. C1 [Ramanadhan, Shoba; McCloud, Rachel; Kohler, Racquel; Viswanath, Kasisomayajula] Dana Farber Canc Inst, Ctr Community Based Res, 450 Brookline Ave,LW601, Boston, MA 02215 USA. [Ramanadhan, Shoba; Kohler, Racquel; Viswanath, Kasisomayajula] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington Ave, Boston, MA 02115 USA. [Nagler, Rebekah H.] Univ Minnesota, Sch Journalism & Mass Commun, 206 Church St SE, Minneapolis, MN 55455 USA. RP Ramanadhan, S (reprint author), 450 Brookline Ave,LW 601, Boston, MA 02215 USA. EM shoba_ramanadhan@dfci.harvard.edu; nagle026@umn.edu; rachel_faulkenberry@dfci.harvard.edu; racquel_kohler@dfci.harvard.edu; vish_viswanath@dfci.harvard.edu FU National Cancer Institute [3P50CA148596-03S1] FX The authors thank our community partners in Boston, Lawrence, and Worcester, MA for their assistance and support in recruiting and retaining study participants. The study was funded by the National Cancer Institute (3P50CA148596-03S1, Viswanath Study PI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors also thank three anonymous reviewers for their insightful comments and critiques. NR 66 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD FEB PY 2017 VL 175 BP 219 EP 227 DI 10.1016/j.socscimed.2016.12.044 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA EM5OG UT WOS:000395360500026 PM 28108053 ER PT J AU El Husseini, N Fonarow, GC Smith, EE Ju, C Schwamm, LH Hernandez, AF Schulte, PJ Xian, Y Goldstein, LB AF El Husseini, Nada Fonarow, Gregg C. Smith, Eric E. Ju, Christine Schwamm, Lee H. Hernandez, Adrian F. Schulte, Phillip J. Xian, Ying Goldstein, Larry B. TI Renal Dysfunction Is Associated With Poststroke Discharge Disposition and In-Hospital Mortality: Findings From Get With The Guidelines-Stroke SO STROKE LA English DT Article DE acute kidney injury; glomerular filtration rate; kidney disease; Medicare; outcomes; stroke ID CHRONIC KIDNEY-DISEASE; ISCHEMIC-STROKE; OUTCOMES; POPULATION; REGISTRY; FAILURE; CODES; RISK AB Background and Purpose Kidney disease is a frequent comorbidity in patients presenting with acute ischemic stroke. We evaluated whether the estimated glomerular filtration rate (eGFR) on admission is associated with poststroke in-hospital mortality or discharge disposition. Methods In this cohort study, data from ischemic stroke patients in Get With The Guidelines-Stroke linked to fee-for-service Medicare data were analyzed. The Modification of Diet in Renal Disease study equation was used to calculate the eGFR (mL/min/1.73 m(2)). Dialysis was identified by International Classification of Diseases, Ninth Revision codes. Adjusted multivariable Cox proportional hazards models were used to determine the independent associations of eGFR with discharge disposition and in-hospital mortality. Adjusted individual models also examined whether the association of clinical and demographic factors with outcomes varied by eGFR level. Results Of 232236 patients, 47.3% had an eGFR 60, 26.6% an eGFR 45 to 59, 16.8% an eGFR 30 to 44, 5.6% an eGFR 15 to 29, 0.7% an eGFR<15 without dialysis, and 2.8% were receiving dialysis. Of the total cohort, 11.8% died during the hospitalization or were discharged to hospice, and 38.6% were discharged home. After adjusting for other relevant variables, renal dysfunction was independently associated with an increased risk of in-hospital mortality that was highest among those with eGFR <15 without dialysis (odds ratio, 2.52; 95% confidence interval, 2.07-3.07). An eGFR 15 to 29 (odds ratio, 0.82; 95% confidence interval, 0.78-0.87), eGFR <15 (odds ratio, 0.72; 95% confidence interval, 0.61-0.86), and dialysis (odds ratio, 0.86; 95% confidence interval, 0.79-0.94) remained associated with lower odds of being discharged home. In addition, the associations of several clinical and demographic factors with outcomes varied by eGFR level. Conclusions eGFR on admission is an important predictor of poststroke short-term outcomes. C1 [El Husseini, Nada] Wake Forest Baptist Univ Hlth Sci, Dept Neurol, Winston Salem, NC USA. [Ju, Christine; Hernandez, Adrian F.; Schulte, Phillip J.; Xian, Ying] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [El Husseini, Nada; Xian, Ying] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA. [Fonarow, Gregg C.] Ronald Reagan UCLA, Med Ctr, UCLA Div Cardiol, Los Angeles, CA USA. [Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB T2N 1N4, Canada. [Schwamm, Lee H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Goldstein, Larry B.] Univ Kentucky, Dept Neurol, Lexington, KY 40506 USA. RP El Husseini, N (reprint author), Wake Forest Baptist Med Ctr, Dept Neurol, Div Vasc Neurol, 6th Floor Janeway Tower,Med Ctr Blvd, Winston Salem, NC 27157 USA. EM nelhusse@wakehealth.edu FU Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership; American Heart Association Pharmaceutical Roundtable; Boehringer-Ingelheim; Merck; National Institute of Diabetes and Digestive and Kidney Diseases [P30DK096493] FX The Get With The Guidelines (GWTG)-Stroke program is supported in part by a charitable contribution from Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership and the American Heart Association Pharmaceutical Roundtable. GWTG-Stroke has been funded in the past through support from Boehringer-Ingelheim and Merck. This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (P30DK096493). NR 17 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD FEB PY 2017 VL 48 IS 2 BP 327 EP 334 DI 10.1161/STROKEAHA.116.014601 PG 8 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA EL3HN UT WOS:000394510300026 PM 28034963 ER PT J AU Man, SM Cox, M Patel, P Smith, EE Reeves, MJ Saver, JL Bhatt, DL Xian, Y Schwamm, LH Fonarow, GC AF Man, Shumei Cox, Margueritte Patel, Puja Smith, Eric E. Reeves, Mathew J. Saver, Jeffrey L. Bhatt, Deepak L. Xian, Ying Schwamm, Lee H. Fonarow, Gregg C. TI Differences in Acute Ischemic Stroke Quality of Care and Outcomes by Primary Stroke Center Certification Organization SO STROKE LA English DT Article DE certification; ischemic stroke; outcome; primary stroke center; quality of care ID GUIDELINES-STROKE; PERFORMANCE-MEASURES; HOSPITALIZATION; THROMBOLYSIS; ASSOCIATION; MORTALITY; ATTACK AB Background and Purpose Primary stroke center (PSC) certification was established to identify hospitals providing evidence-based care for stroke patients. The numbers of PSCs certified by Joint Commission (JC), Healthcare Facilities Accreditation Program, Det Norske Veritas, and State-based agencies have significantly increased in the past decade. This study aimed to evaluate whether PSCs certified by different organizations have similar quality of care and in-hospital outcomes. Methods The study population consisted of acute ischemic stroke patients who were admitted to PSCs participating in Get With The Guidelines-Stroke between January 1, 2010, and December 31, 2012. Measures of care quality and outcomes were compared among the 4 different PSC certifications. Results A total of 477297 acute ischemic stroke admissions were identified from 977 certified PSCs (73.8% JC, 3.7% Det Norske Veritas, 1.2% Healthcare Facilities Accreditation Program, and 21.3% State-based). Composite care quality was generally similar among the 4 groups of hospitals, although State-based PSCs underperformed JC PSCs in a few key measures, including intravenous tissue-type plasminogen activator use. The rates of tissue-type plasminogen activator use were higher in JC and Det Norske Veritas (9.0% and 9.8%) and lower in State and Healthcare Facilities Accreditation Program certified hospitals (7.1% and 5.9%) (P<0.0001). Door-to-needle times were significantly longer in Healthcare Facilities Accreditation Program hospitals. State PSCs had higher in-hospital risk-adjusted mortality (odds ratio 1.23, 95% confidence intervals 1.07-1.41) compared with JC PSCs. Conclusions Among Get With The Guidelines-Stroke hospitals with PSC certification, acute ischemic stroke quality of care and outcomes may differ according to which organization provided certification. These findings may have important implications for further improving systems of care. C1 [Man, Shumei] Wright State Univ, Dept Neurol, Miami Valley Hosp, Boonshoft Sch Med, Dayton, OH 45435 USA. [Cox, Margueritte; Xian, Ying] Duke Clin Res Ctr, Durham, NC USA. [Patel, Puja] Amer Heart Assoc, Dept Advocacy & Qual, Dallas, TX USA. [Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Hotchkiss Brain Inst, Calgary, AB T2N 1N4, Canada. [Reeves, Mathew J.] Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA. [Saver, Jeffrey L.] Univ Calif Los Angeles, Div Neurol, Los Angeles, CA USA. [Bhatt, Deepak L.] Harvard Univ, Brigham & Womens Hosp, Heart & Vasc Ctr, Harvard Med Sch, Boston, MA 02115 USA. [Xian, Ying] Duke Univ, Dept Neurol, Med Ctr, Durham, NC USA. [Schwamm, Lee H.] Massachusetts Gen Hosp, Div Neurol, Boston, MA 02114 USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA. RP Fonarow, GC (reprint author), UCLA Med Ctr, Ahmanson UCLA Cardiomyopathy Ctr, 10833 LeConte Ave,Room 47-123 CHS, Los Angeles, CA 90095 USA. EM gfonarow@mednet.ucla.edu FU American Heart Association; Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership; American Heart Association Pharmaceutical Roundtable; Boehringer-Ingelheim; Merck FX The American Heart Association receives a portion of the fees paid by hospitals to the Joint Commission for Primary Stroke Certification. The GWTG-Stroke program is currently supported in part by a charitable contribution from Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership and the American Heart Association Pharmaceutical Roundtable. GWTG-Stroke has been funded in the past through support from Boehringer-Ingelheim and Merck. These funding agencies did not participate in design or analysis, manuscript preparation, or approval of this study. NR 15 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD FEB PY 2017 VL 48 IS 2 BP 412 EP 419 DI 10.1161/STROKEAHA.116.014426 PG 8 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA EL3HN UT WOS:000394510300039 PM 28008094 ER PT J AU Liu, Y Zheng, Y Karatas, H Wang, XY Foerch, C Lo, EH van Leyen, K AF Liu, Yu Zheng, Yi Karatas, Hulya Wang, Xiaoying Foerch, Christian Lo, Eng H. van Leyen, Klaus TI 12/15-Lipoxygenase Inhibition or Knockout Reduces Warfarin-Associated Hemorrhagic Transformation After Experimental Stroke SO STROKE LA English DT Article DE atrial fibrillation; brain; hemorrhage; stroke; warfarin ID ACUTE ISCHEMIC-STROKE; ATRIAL-FIBRILLATION; INTRACEREBRAL HEMORRHAGE; INTRACRANIAL HEMORRHAGE; CEREBRAL-ISCHEMIA; ANTICOAGULATION; THERAPY; BRAIN; LIPOXYGENASE; MORTALITY AB Background and Purpose For stroke prevention, patients with atrial fibrillation typically receive oral anticoagulation. The commonly used anticoagulant warfarin increases the risk of hemorrhagic transformation (HT) when a stroke occurs; tissue-type plasminogen activator treatment is therefore restricted in these patients. This study was designed to test the hypothesis that 12/15-lipoxygenase (12/15-LOX) inhibition would reduce HT in warfarin-treated mice subjected to experimental stroke. Methods Warfarin was dosed orally in drinking water, and international normalized ratio values were determined using a Coaguchek device. C57BL6J mice or 12/15-LOX knockout mice were subjected to transient middle cerebral artery occlusion with 3 hours severe ischemia (model A) or 2 hours ischemia and tissue-type plasminogen activator infusion (model B), with or without the 12/15-LOX inhibitor ML351. Hemoglobin was determined in brain homogenates, and hemorrhage areas on the brain surface and in brain sections were measured. 12/15-LOX expression was detected by immunohistochemistry. Results Warfarin treatment resulted in reproducible increased international normalized ratio values and significant HT in both models. 12/15-LOX knockout mice suffered less HT after severe ischemia, and ML351 reduced HT in wild-type mice. When normalized to infarct size, ML351 still independently reduced hemorrhage. HT after tissue-type plasminogen activator was similarly reduced by ML351. Conclusions In addition to its benefits in infarct size reduction, 12/15-LOX inhibition also may independently reduce HT in warfarin-treated mice. ML351 should be further evaluated as stroke treatment in anticoagulated patients suffering a stroke, either alone or in conjunction with tissue-type plasminogen activator. C1 [Liu, Yu; Zheng, Yi; Karatas, Hulya; Wang, Xiaoying; Lo, Eng H.; van Leyen, Klaus] Harvard Med Sch, Massachusetts Gen Hosp, Neuroprotect Res Lab, Charlestown, MA USA. [Liu, Yu] Harbin Med Univ, Affiliated Hosp 2, Dept Neurol, Harbin, Peoples R China. [Foerch, Christian] Goethe Univ, Dept Neurol, Frankfurt, Germany. [Karatas, Hulya] Hacettepe Univ, Inst Neurol Sci & Psychiat, Ankara, Turkey. RP van Leyen, K (reprint author), Massachusetts Gen Hosp, Neuroprotect Res Labs, 149 13th St,R 2401, Charlestown, MA 02129 USA. EM klaus_vanleyen@hms.harvard.edu FU National Institutes of Health [R01 NS069939, R01 NS049430] FX Support from the National Institutes of Health (grants R01 NS069939 and R01 NS049430 to Dr van Leyen) is gratefully acknowledged. NR 35 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD FEB PY 2017 VL 48 IS 2 BP 445 EP 451 DI 10.1161/STROKEAHA.116.014790 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA EL3HN UT WOS:000394510300043 PM 28057806 ER PT J AU Lubitz, SA Yin, XY McManus, DD Weng, LC Aparicio, HJ Walkey, AJ Romero, JR Kase, CS Ellinor, PT Wolf, PA Seshadri, S Benjamin, EJ AF Lubitz, Steven A. Yin, Xiaoyan McManus, David D. Weng, Lu-Chen Aparicio, Hugo J. Walkey, Allan J. Romero, Jose Rafael Kase, Carlos S. Ellinor, Patrick T. Wolf, Philip A. Seshadri, Sudha Benjamin, Emelia J. TI Stroke as the Initial Manifestation of Atrial Fibrillation: The Framingham Heart Study SO STROKE LA English DT Article DE atrial fibrillation; atrial flutter; incidence; mass screening; stroke ID COST-EFFECTIVENESS; COHORT; ECG AB Background and Purpose-To prevent strokes that may occur as the first manifestation of atrial fibrillation (AF), screening programs have been proposed to identify patients with undiagnosed AF who may be eligible for treatment with anticoagulation. However, the frequency with which patients with AF present with stroke as the initial manifestation of the arrhythmia is unknown. Methods-We estimated the frequency with which AF may present as a stroke in 1809 community-based Framingham Heart Study participants with first-detected AF and without previous strokes, by tabulating the frequencies of strokes occurring on the same day, within 30 days before, 90 days before, and 365 days before first-detected AF. Using previously reported AF incidence rates, we estimated the incidence of strokes that may represent the initial manifestation of AF. Results-We observed 87 strokes that occurred 1 year before AF detection, corresponding to 1.7% on the same day, 3.4% within 30 days before, 3.7% within 90 days before, and 4.8% 1 year before AF detection. We estimated that strokes may present as the initial manifestation of AF at a rate of 2 to 5 per 10000 person-years, in both men and women. Conclusions-We observed that stroke is an uncommon but measureable presenting feature of AF. Our data imply that emphasizing cost-effectiveness of population-wide AF-screening efforts will be important given the relative infrequency with which stroke represents the initial manifestation of AF. C1 [Lubitz, Steven A.; Weng, Lu-Chen; Ellinor, Patrick T.] Boston Univ, Cardiovasc Res Ctr, Massachusetts Gen Hosp, Boston, MA 02215 USA. [Lubitz, Steven A.; Ellinor, Patrick T.] Boston Univ, Cardiac Arrhythmia Serv, Massachusetts Gen Hosp, Boston, MA 02215 USA. [Yin, Xiaoyan; Romero, Jose Rafael; Wolf, Philip A.; Seshadri, Sudha; Benjamin, Emelia J.] Natl Heart Lung & Blood Inst Framingham Heart Stu, Framingham, MA USA. [McManus, David D.] Univ Massachusetts, Div Cardiol, Dept Med, Sch Med, Worcester, MA USA. [Aparicio, Hugo J.; Romero, Jose Rafael; Wolf, Philip A.; Seshadri, Sudha; Benjamin, Emelia J.] Boston Univ, Sch Med, Boston, MA USA. [Aparicio, Hugo J.; Romero, Jose Rafael; Kase, Carlos S.; Seshadri, Sudha] Boston Med Ctr, Dept Neurol, Boston, MA USA. [Walkey, Allan J.] Boston Univ, Sch Med, Ctr Pulm, Boston, MA USA. [Walkey, Allan J.] Boston Univ, Sch Med, Sect Pulm & Crit Care Med, Boston, MA USA. [Walkey, Allan J.] Boston Univ, Sch Med, Dept Med, Boston, MA USA. [Benjamin, Emelia J.] Boston Univ, Sch Med, Prevent Med Sect, Dept Med, Boston, MA USA. RP Lubitz, SA (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv & Cardiovascular Res Ctr, 55 Fruit St,GRB 109, Boston, MA 02114 USA. EM slubitz@mgh.harvard.edu FU National Institutes of Health grants [K23HL114724, 2R01HL092577, 1R01HL128914, 1R01HL102214, R01HL104156, K24HL105780, R01NS017950, 1U01HL105268-01, R01 HL126911, KL2TR000160, HHSN268201500001I, N01-HC-25195]; Doris Duke Charitable Foundation Clinical Scientist Development Award [2014105]; American Heart Association Established Investigator Award [13EIA14220013] FX This study was supported by National Institutes of Health grants K23HL114724 (Dr Lubitz), 2R01HL092577, 1R01HL128914 (Drs Ellinor and Benjamin), 1R01HL102214 (Dr Benjamin), R01HL104156, K24HL105780 (Dr Ellinor), R01NS017950 (Dr Seshadri), 1U01HL105268-01, R01 HL126911 and KL2TR000160 (Dr McManus), HHSN268201500001I, and N01-HC-25195 (Framingham Heart Study); Doris Duke Charitable Foundation Clinical Scientist Development Award 2014105 (Dr Lubitz); and American Heart Association Established Investigator Award 13EIA14220013 (Dr Ellinor). NR 15 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD FEB PY 2017 VL 48 IS 2 BP 490 EP 492 DI 10.1161/STROKEAHA.116.015071 PG 3 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA EL3HN UT WOS:000394510300051 PM 28082669 ER PT J AU Barnes, SM Bahraini, NH Forster, JE Stearns-Yoder, KA Hostetter, TA Smith, G Nagamoto, HT Nock, MK AF Barnes, Sean M. Bahraini, Nazanin H. Forster, Jeri E. Stearns-Yoder, Kelly A. Hostetter, Trisha A. Smith, Geoffrey Nagamoto, Herbert T. Nock, Matthew K. TI Moving Beyond Self-Report: Implicit Associations about Death/Life Prospectively Predict Suicidal Behavior among Veterans SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID RISK-ASSESSMENT; INJURIOUS THOUGHTS; IDEATION; ADOLESCENTS; DEPRESSION; COGNITION; MIND AB Reliance on self-report limits clinicians' ability to accurately predict suicidal behavior. In this study the predictive validity of an objective measure, the death/suicide Implicit Association Test (d/sIAT), was tested among psychiatrically hospitalized veterans. Following acute stabilization, 176 participants completed the d/sIAT and traditional suicide risk assessments. Participants had similar d/sIAT scores regardless of whether they had recently attempted suicide. However, d/sIAT scores significantly predicted suicide attempts during the 6-month follow-up above and beyond other known risk factors for suicidal behavior (OR=1.89; 95% CI: 1.15-3.12; based on 1SD increase). The d/sIAT may augment the accuracy of suicide risk assessment. C1 [Barnes, Sean M.; Bahraini, Nazanin H.; Forster, Jeri E.; Stearns-Yoder, Kelly A.; Hostetter, Trisha A.; Smith, Geoffrey; Nagamoto, Herbert T.] Rocky Mt Mental Illness Res Educ & Clin Ctr, Denver, CO USA. [Barnes, Sean M.; Bahraini, Nazanin H.; Nagamoto, Herbert T.] Univ Colorado, Sch Med, Dept Psychiat, Anschutz Med Campus, Aurora, CO USA. [Bahraini, Nazanin H.; Forster, Jeri E.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Anschutz Med Campus, Aurora, CO USA. [Forster, Jeri E.] Univ Colorado, Sch Med, Dept Biostat & Informat, Anschutz Med Campus, Aurora, CO USA. [Nock, Matthew K.] Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA. RP Barnes, SM (reprint author), Denver VA Med Ctr, Rocky Mt MIRECC, 1055 Clermont St, Denver, CO 80220 USA. EM Sean.Barnes2@va.gov FU Military Suicide Research Consortium, through the Office of the Assistant Secretary of Defense for Health Affairs; Rocky Mountain Mental Illness, Research, Education, and Clinical Center; U.S. Government. Denver VA Medical Center [W81XWH-10-2-0178] FX This research was funded by the Military Suicide Research Consortium, through the Office of the Assistant Secretary of Defense for Health Affairs, and by the Rocky Mountain Mental Illness, Research, Education, and Clinical Center. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Military Suicide Research Consortium, Department of Defense, Department of Veterans Affairs, or the U.S. Government. Denver VA Medical Center Grant Number: W81XWH-10-2-0178. NR 23 TC 0 Z9 0 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD FEB PY 2017 VL 47 IS 1 BP 67 EP 77 DI 10.1111/sltb.12265 PG 11 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA EL9QI UT WOS:000394954700007 PM 27387836 ER PT J AU Bonatti, H Sifri, CD Larcher, C Schneeberger, S Kotton, C Geltner, C AF Bonatti, Hugo Sifri, Costi D. Larcher, Clara Schneeberger, Stefan Kotton, Camille Geltner, Christian TI Use of Cidofovir for Cytomegalovirus Disease Refractory to Ganciclovir in Solid Organ Recipients SO SURGICAL INFECTIONS LA English DT Article DE Cytomegalovirus; cidofovir; immunosuppression; solid organ transplantation ID HEART-TRANSPLANT RECIPIENT; SINGLE-CENTER EXPERIENCE; RESISTANT CYTOMEGALOVIRUS; ORAL GANCICLOVIR; CMV DISEASE; VALGANCICLOVIR PROPHYLAXIS; IMMUNOCOMPROMISED PATIENTS; CELL TRANSPLANTATION; PREEMPTIVE THERAPY; VIRAL-INFECTIONS AB Background: Solid organ transplantation (SOT) frequently is complicated by cytomegalovirus (CMV) infections. Cidofovir (CDV) is active against CMV, including many ganciclovir (GCV)-resistant mutants, but often is considered to be too nephrotoxic for use after organ transplantation. Patients and Methods: Seven males and two females (median age 50.1 years), including two kidney/pancreas, four lung, one small bowel, and two hand recipients, received CDV for refractory CMV disease. Results: Three recipients were CMV seronegative, but all nine received grafts from CMV-seropositive donors. Five patients were given antithymocyte globulin, four received daclizumab induction, seven experienced rejection (five with multiple episodes), and one suffered from common variable immunodeficiency. Six presented with other infections (five invasive fungal and four bacterial). Eight patients had received prophylactic GCV, and eight had been treated for CMV infection/disease (GCV eight; CMV immunoglobulin three; foscarnet three). The indications for CDV were UL97 CMV mutation (n = 2), GCV-induced neutropenia with continued CMV disease (n = 4), and clinical resistance to GCV (n = 3). Seven patients cleared CMV, and two had a partial response. Four experienced CMV relapse requiring GCV (n = 2), repeat CDV (n = 1), or CMV immunoglobulin (n = 1). Four patients had mild nephrotoxicity, and three developed renal failure, all in association with additional factors. No patient died directly from CMV disease alone. Two patients died of uncontrolled infections and concurrent CMV disease, one with invasive aspergillosis and another with nocardiosis. Conclusions: Cidofovir was useful for the treatment of GCV-refractory CMV disease after SOT. Although nephrotoxicity was a common complication of CDV, several patients completed a course of therapy successfully and demonstrated effective treatment of CMV disease. C1 [Bonatti, Hugo] Univ Maryland, Dept Surg, Shore Hlth Syst, 503 Dutchmans Lane, Easton, MD 21601 USA. [Larcher, Clara] MB LAB Mikrobiol Labor, Innsbruck, Austria. [Bonatti, Hugo; Schneeberger, Stefan] Med Univ Innsbruck, Dept Visceral Transplant & Thorac Surg, Innsbruck, Austria. [Sifri, Costi D.] Univ Virginia Hlth Syst, Div Infect Dis & Int Hlth, Dept Med, Charlottesville, VA USA. [Kotton, Camille] Harvard Med Sch, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA USA. [Geltner, Christian] Klinikum Klagenfurt, Dept Pulmonol, Klagenfurt, Austria. RP Bonatti, H (reprint author), Univ Maryland, Dept Surg, Shore Hlth Syst, 503 Dutchmans Lane, Easton, MD 21601 USA. EM hugo.bonatti@dr.com NR 80 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-2964 EI 1557-8674 J9 SURG INFECT JI Surg. Infect. PD FEB-MAR PY 2017 VL 18 IS 2 BP 128 EP 136 DI 10.1089/sur.2015.266 PG 9 WC Infectious Diseases; Surgery SC Infectious Diseases; Surgery GA EL3DU UT WOS:000394500600008 PM 27849440 ER PT J AU Ashong, CN Raheem, SA Hunter, AS Mindru, C Barshes, NR AF Ashong, Chester N. Raheem, Shazia A. Hunter, Andrew S. Mindru, Cezarina Barshes, Neal R. TI Methicillin-Resistant Staphylococcus aureus in Foot Osteomyelitis SO SURGICAL INFECTIONS LA English DT Article DE diabetes; MRSA; MSSA; osteomyelitis; staphylococcal infections ID INFECTIONS; DIAGNOSIS; PATHOGENS; BONE AB Background: Conflicting studies exist regarding the impact of methicillin-resistant Staphylococcus aureus (MRSA) on increased time to wound healing, future need for surgical procedures, and likelihood of treatment failure in patients with diabetic foot osteomyelitis. The purpose of this study is to determine the overall significance of MRSA in predicting treatment failure in bone infections of the foot and to determine an appropriate pre-operative and empiric post-operative antibiotic regimen. Patients and Methods: Patients presenting with an initial episode of "probable" or "definite" foot osteomyelitis were included for review and analysis if the following criteria were met: (1) Osteomyelitis occurred in the foot (i.e., distal to the malleoli of the ankle); episodes occurring above the ankle were excluded. (2) Patients received either no antibiotics or only oral antibiotics for long-term treatment; episodes managed with long-term parenteral antibiotics were excluded. (3) The infection was managed initially with medical therapy or conservative surgical therapy; episodes managed with major (above-ankle) amputation as the initial treatment were excluded. The primary objective of this study was to assess whether episodes of foot osteomyelitis associated with MRSA resulted in treatment failure more frequently than not. Results: Of 178 episodes included in the study, 50 (28.1%) episodes had treatment failure. Median time-to-treatment failure was 60 days (range 7-598 days). In 28.1% (9/32 episodes) in which treatment failure occurred and 39.0% (41/105) episodes in which no treatment failure occurred, MRSA was present. The presence of MRSA was not significantly associated with treatment failure (p = 0.99). Conclusions: The presence of MRSA in bone culture and whether antibiotic use had anti-MRSA activity was not associated with increased treatment failure of diabetic foot osteomyelitis in our institution. Empiric antibiotic coverage of MRSA may not be necessary for many patients presenting with foot osteomyelitis. C1 [Ashong, Chester N.; Raheem, Shazia A.; Hunter, Andrew S.] Michael E DeBakey VA Med Ctr, Dept Pharm, Houston, TX USA. [Mindru, Cezarina] Michael E DeBakey VA Med Ctr, Dept Infect Dis, Houston, TX USA. [Barshes, Neal R.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Div Vasc & Endovasc Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. RP Barshes, NR (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Div Vasc & Endovasc Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM nbarshes@bcm.tmc.edu FU Michael E. DeBakey Veterans Affairs Medical Center FX We would like to acknowledge research support from the Michael E. DeBakey Veterans Affairs Medical Center. Dr. Barshes has received $25,000 from the Michael E. DeBakey Veterans Affairs Medical Center, a federal institution, for the study of foot osteomyelitis. NR 18 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-2964 EI 1557-8674 J9 SURG INFECT JI Surg. Infect. PD FEB-MAR PY 2017 VL 18 IS 2 BP 143 EP 148 DI 10.1089/sur.2016.165 PG 6 WC Infectious Diseases; Surgery SC Infectious Diseases; Surgery GA EL3DU UT WOS:000394500600010 PM 27898266 ER PT J AU O'Donnell, EK Raje, NS AF O'Donnell, Elizabeth K. Raje, Noopur S. TI New monoclonal antibodies on the horizon in multiple myeloma SO THERAPEUTIC ADVANCES IN HEMATOLOGY LA English DT Review DE monoclonal antibodies; multiple myeloma; novel therapies ID CELL MATURATION ANTIGEN; LOW-DOSE DEXAMETHASONE; BONE-MARROW; PLASMA-CELLS; OPEN-LABEL; DARATUMUMAB MONOTHERAPY; ACTIVATING FACTOR; PHASE-2 TRIAL; CANCER CELLS; SINGLE-ARM AB Across all cancers, monoclonal antibodies have emerged as a potential strategy for cancer therapy. Monoclonal antibodies target antigens expressed on the surface of cancer cells and accessory cells. This targeted approach uses the host's immune system to promote the killing of cancer cells. Multiple myeloma (MM) is the second most common hematologic malignancy that remains incurable in the majority of patients. The treatment of MM has evolved dramatically over the past decade and continues to evolve with the approval of four new drugs in 2015. Most recently the United States Food and Drug Administration (US FDA) approved two monoclonal antibodies for the treatment of this disease. Monoclonal antibodies are generally well-tolerated and offer a novel method of action for treated relapsed and refractory disease and are now being studied in the upfront setting. In this article, we review the evidence for the existing approved monoclonal antibodies and discuss promising targeted therapies and innovative strategies for the treatment of MM. C1 [O'Donnell, Elizabeth K.; Raje, Noopur S.] Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. RP O'Donnell, EK (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM ekodonnell@mgh.harvard.edu NR 72 TC 0 Z9 0 U1 2 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 2040-6207 EI 2040-6215 J9 THER ADV HEMATOL JI Ther. Adv. Hematol. PD FEB PY 2017 VL 8 IS 2 BP 41 EP 53 DI 10.1177/2040620716682490 PG 13 WC Hematology SC Hematology GA EL5NT UT WOS:000394668500001 PM 28203341 ER PT J AU Shen, Q Yu, WR Fang, Y Yao, M Yang, PG AF Shen, Qiong Yu, Weirong Fang, Yong Yao, Min Yang, Penggao TI Beta-catenin can induce hair follicle stem cell differentiation into transit-amplifying cells through c-myc activation SO TISSUE & CELL LA English DT Article DE Hair follicle stem cell; Transit-amplifying cell; beta-Catenin; c-myc ID KERATINOCYTE DIFFERENTIATION; WNT/BETA-CATENIN; DERMAL PAPILLA; NICHE; SKIN; EXPRESSION; WNT; REGENERATION; EPIDERMIS; GROWTH AB Hair follicle stem cells play important roles in maintaining homeostasis and skin tissue self-renewal. Transit-amplifying cells represent the transition of cells from hair follicle stem cells into differentiated epidermal cells. Thus far, the signaling pathway and the molecular biological mechanism that regulate the proliferation and differentiation of hair follicle stem cells remain unclear. In this paper, we studied the relationship between beta-catenin and c-myc during the process of the differentiation of hair follicle stem cells into transit-amplifying cells. Based on our results, the expression of beta-catenin can activate the nuclear gene c-myc and regulate the expression of transit-amplifying cell markers K15, K19, a6-integrin and beta 1-integrin, indicating that beta-catenin is involved in the transformation process from hair follicle stem cells to transit-amplifying cells and suggesting that beta-catenin plays an important biological role in the induction of this differentiation process. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Shen, Qiong] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Ultrasound Diag, Sch Med, Shanghai 201999, Peoples R China. [Yu, Weirong; Fang, Yong; Yao, Min; Yang, Penggao] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Burns & Plast Surg, Sch Med, Floor 15,Surg Bldg,280 Mohe Rd, Shanghai 201999, Peoples R China. [Fang, Yong; Yao, Min] Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, Shanghai 201999, Peoples R China. [Yao, Min] Harvard Med Sch, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Yang, PG (reprint author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Burns & Plast Surg, Sch Med, Floor 15,Surg Bldg,280 Mohe Rd, Shanghai 201999, Peoples R China. EM ypg_999@163.com FU Nature Science Foundation of Shanghai Ninth People's Hospital; Shanghai JiaoTong University School of Medicine [644] FX Nature Science Foundation of Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine; grant number: 644. NR 43 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0040-8166 J9 TISSUE CELL JI Tissue Cell PD FEB PY 2017 VL 49 IS 1 BP 28 EP 34 DI 10.1016/j.tice.2016.12.005 PG 7 WC Anatomy & Morphology; Cell Biology SC Anatomy & Morphology; Cell Biology GA EM7RB UT WOS:000395508900005 PM 28049551 ER PT J AU Barroso-Sousa, R Tolaney, SM AF Barroso-Sousa, Romualdo Tolaney, Sara M. TI CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer SO TRANSLATIONAL CANCER RESEARCH LA English DT Article DE Breast cancer (BC); cyclin-dependent kinase inhibitors; palbociclib; abemaciclib; ribociclib ID ENDOCRINE THERAPY; PALBOCICLIB; COMBINATION; ABEMACICLIB; RIBOCICLIB; MUTATIONS; LETROZOLE; CDK6 AB Approximately 70% of breast cancers (BC) are classified as hormone receptor-positive (HRpositive), comprising those expressing estrogen receptors and/or progesterone receptors. BC deaths are ultimately caused by metastatic disease. In this setting, although estrogen pathway blockade is an initially highly effective therapy, virtually all patients will develop resistance to endocrine therapy (de novo or acquired). Further understanding of the underlying mechanisms related to endocrine therapy resistance is vital and can ultimately lead to new therapies for this population. Recently, cyclin-dependent kinase (CDK) 4/6 inhibitors have emerged as one of the most important groups of drugs that synergize with endocrine therapy. In this perspective article we will discuss the recent data from the phase III MONALEESA-2 trial, which evaluated the addition of ribociclib with letrozole in the first line of treatment for patients with advanced HR-positive BC, and we will put the results in context with clinical data of other CDK 4/6 inhibitors. In addition, we will discuss future directions in the field. C1 [Barroso-Sousa, Romualdo; Tolaney, Sara M.] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Yawkey 1257, Boston, MA 02215 USA. RP Tolaney, SM (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Yawkey 1257, Boston, MA 02215 USA. EM Sara_Tolaney@dfci.harvard.edu FU Pfizer; Lilly; Novartis; Merck; Genentech; AstraZeneca; Exelixis FX SM Tolaney has research funding from Pfizer, Lilly, Novartis, Merck, Genentech, AstraZeneca, and Exelixis. NR 25 TC 0 Z9 0 U1 0 U2 0 PU AME PUBL CO PI SHEUNG WAN PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG 00000, PEOPLES R CHINA SN 2218-676X EI 2219-6803 J9 TRANSL CANCER RES JI Transl. Cancer Res. PD FEB PY 2017 VL 6 SU 1 BP S205 EP S209 DI 10.21037/tcr.2017.02.16 PG 5 WC Oncology SC Oncology GA EP3UB UT WOS:000397306100055 ER PT J AU ten Hacken, E Gruber, M AF ten Hacken, Elisa Gruber, Michaela TI CRISPR made easy in human and murine hematopoietic precursors SO TRANSLATIONAL CANCER RESEARCH LA English DT Editorial Material ID EFFICIENCY; REPAIR; CELLS C1 [ten Hacken, Elisa; Gruber, Michaela] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Gruber, Michaela] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Med 1, Vienna, Austria. RP ten Hacken, E (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. EM Elisa_TenHacken@dfci.harvard.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU AME PUBL CO PI SHEUNG WAN PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG 00000, PEOPLES R CHINA SN 2218-676X EI 2219-6803 J9 TRANSL CANCER RES JI Transl. Cancer Res. PD FEB PY 2017 VL 6 SU 1 BP S44 EP S46 DI 10.21037/tcr.2017.02.21 PG 3 WC Oncology SC Oncology GA EP3UB UT WOS:000397306100016 ER PT J AU Mehta, SR Logan, C Kotton, CN Kumar, D Aslam, S AF Mehta, Sanjay R. Logan, Cathy Kotton, Camille N. Kumar, Deepali Aslam, Saima TI Use of organs from donors with bloodstream infection, pneumonia, and influenza: Results of a survey of infectious diseases practitioners SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE organ donor infection; solid organ transplant; survey ID KIDNEY-TRANSPLANTATION; LIVER-TRANSPLANTATION; PRESERVATION FLUID; RECIPIENTS; OUTCOMES; RISK; COMPLICATIONS; TRANSMISSION; COMPETITION; ARTERITIS AB BackgroundPotential organ donors may be admitted with an infection to an intensive care unit, or contract a nosocomial infection during their stay, increasing the risk of potential transmission to the recipient. Because of a lack of practice guidelines and large-scale data on this topic, we undertook a survey to assess the willingness of transplant infectious diseases (ID) physicians to accept such organs. MethodsWe performed a 10-question survey of ID providers from the American Society of Transplantation Infectious Disease Community of Practice to determine the scope of practice regarding acceptance of organs from donors with bloodstream infection, pneumonia, and influenza prior to organ procurement, as well as management of such infections following transplantation. ResultsAmong 60 respondents to our survey, a majority indicated that organs would be accepted from donors bacteremic with streptococci (76%) or Enterobacteriaceae (73%) without evidence of drug resistance. Acceptance rates varied based on infecting organism, type of organ, and center size. Ten percent of respondents would accept an organ from a donor bacteremic with a carbapenem-resistant organism. Over 90% of respondents would accept an organ other than a lung from a donor with influenza on treatment, compared with 52% that would accept a lung in the same setting. ConclusionsThis study is the first to our knowledge to survey transplant ID providers regarding acceptance of organs based on specific infections in the donor. These decisions are often based on limited published data and experience. Better characterization of the outcomes from donors with specific types of infection could lead to liberalization of organ acceptance practices across centers. C1 [Mehta, Sanjay R.; Logan, Cathy; Aslam, Saima] Univ Calif San Diego, Div Infect Dis, La Jolla, CA 92093 USA. [Mehta, Sanjay R.] San Diego Vet Affairs Med Ctr, Div Infect Dis, San Diego, CA USA. [Kotton, Camille N.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Kumar, Deepali] Univ Toronto, Div Infect Dis, Toronto, ON, Canada. RP Mehta, SR (reprint author), Univ Calif San Diego, Div Infect Dis, La Jolla, CA 92093 USA. EM srmehta@ucsd.edu FU NIH [K23 AI093163] FX This work was supported by NIH grants: K23 AI093163 (S.R.M.). NR 23 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-2273 EI 1399-3062 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD FEB PY 2017 VL 19 IS 1 DI 10.1111/tid.12645 PG 8 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA EL4HQ UT WOS:000394582700022 ER PT J AU Farahmand, S Safavi, S Shahriarian, S Arbab, M Basirghafoori, H Bagheri-Hariri, S AF Farahmand, Shervin Safavi, Somayeh Shahriarian, Shahriar Arbab, Mona Basirghafoori, Hamed Bagheri-Hariri, Shahram TI Preferred view and transducer in lumbar ultrasound in overweight and obese patients SO ULTRASOUND LA English DT Article DE Ultrasound; lumbar puncture ID PUNCTURE; LANDMARKS AB Background: Ultrasound can be used to facilitate lumbar puncture, especially in obese patients. Methods: In this study, midline and paramedian approaches with curved and linear transducers were compared in patients with Body Mass Index (BMI) above 25 kg/m(2) for the identification of spinal landmarks. In each view, six major landmarks, including spinous process, ligamentum flavum, laminae, epidural space, subarachnoid space and posterior longitudinal ligament, were detected by emergency medicine residents and were then reviewed by radiologists. Results: Sixty patients with a mean BMI of 29.18 enrolled in the study. This study showed that a curved transducer detected major landmarks more accurately compared to a linear transducer. There was also a poor kappa correlation between these transducers in the midline and paramedian approaches. Conclusion: This study showed that ultrasound can detect lumbar landmarks in overweight and obese patients, with the paramedian approach and a curved transducer being superior to the midline approach and a linear transducer in detecting these landmarks. C1 [Farahmand, Shervin; Safavi, Somayeh; Bagheri-Hariri, Shahram] Univ Tehran Med Sci, Dept Emergency Med, Tehran, Iran. [Shahriarian, Shahriar] Univ Tehran Med Sci, Dept Radiol, Tehran, Iran. [Arbab, Mona] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Basirghafoori, Hamed] Iran Univ Med Sci, Emergency Dept, Tehran, Iran. RP Bagheri-Hariri, S (reprint author), Imam Khomeini Complex Hosp, Emergency Dept, Keshavarz Blvd, Tehran 1419733141, Iran. EM hariri.shahram@gmail.com NR 9 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1742-271X EI 1743-1344 J9 ULTRASOUND JI Ultrasound PD FEB PY 2017 VL 25 IS 1 BP 45 EP 52 DI 10.1177/1742271X16689590 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EL5DM UT WOS:000394641800006 PM 28228824 ER PT J AU Zhou, J Chong, SY Lim, A Singh, BK Sinha, RA Salmon, AB Yen, PM AF Zhou, Jin Chong, Shu Yun Lim, Andrea Singh, Brijesh K. Sinha, Rohit A. Salmon, Adam B. Yen, Paul M. TI Changes in macroautophagy, chaperone-mediated autophagy, and mitochondrial metabolism in murine skeletal and cardiac muscle during aging SO AGING-US LA English DT Article DE aging; muscle; heart; autophagy; chaperone-mediated autophagy (CMA); fatty acid oxidation; ceramide ID INSULIN-RESISTANCE; DISEASE; HUMANS; DYSFUNCTION; STRESS; OBESE; STIMULATION; INHIBITION; LIPIDATION; SIGNATURE AB Aging causes a general decline in cellular metabolic activity, and function in different tissues and whole body homeostasis. However, the understanding about the metabolomic and autophagy changes in skeletal muscle and heart during aging is still limited. We thus examined markers for macroautophagy, chaperone-mediated autophagy (CMA), mitochondrial quality control, as well as cellular metabolites in skeletal and cardiac muscle from young (5 months old) and aged (27 months old) mice. We found decreased autophagic degradation of p62 and increased ubiquitinated proteins in both tissues from aged mice, suggesting a decline in macroautophagy during aging. In skeletal muscle from aged mice, there also was a decline in LC3B-I conjugation to phosphatidylethanolamine (PE) possibly due to decreased protein levels of ATG3 and ATG12-ATG5. The CMA markers, LAMP-2A and Hsc70, and mitochondrial turnover markers, Drp1, PINK1 and PGC1 alpha also were decreased. Metabolomics analysis showed impaired a-oxidation in heart of aged mice, whereas increased branched-chain amino acids (BCAAs) and ceramide levels were found in skeletal muscle of aged mice that in turn, may contribute to insulin resistance in muscle. Taken together, our studies showed similar declines in macroautophagy but distinct effects on CMA, mitochondrial turnover, and metabolic dysfunction in muscle vs. heart during aging. C1 [Zhou, Jin; Lim, Andrea; Singh, Brijesh K.; Sinha, Rohit A.; Yen, Paul M.] Duke NUS Med Sch Singapore, Program Cardiovas & Metab Disorders, Singapore 169857, Singapore. [Chong, Shu Yun] Nanyang Technol Univ, Dept Biomed Sci, Singapore 637551, Singapore. [Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Dept Mol Med, San Antonio, TX 78245 USA. [Salmon, Adam B.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Yen, Paul M.] Duke Univ, Med Ctr, Duke Mol Physiol Inst, Dept Med & Pharmacol, Durham, NC 27710 USA. [Yen, Paul M.] Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA. RP Yen, PM (reprint author), Duke NUS Med Sch Singapore, Program Cardiovas & Metab Disorders, Singapore 169857, Singapore.; Yen, PM (reprint author), Duke Univ, Med Ctr, Duke Mol Physiol Inst, Dept Med & Pharmacol, Durham, NC 27710 USA.; Yen, PM (reprint author), Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA. EM paul.yen@duke-nus.edu.sg FU Duke-NUS Medical School Faculty Funds; Singapore National Medical Research Council grant [NMRC/CSA/0054/2013, NMRC/CIRG/1340/2012]; National Institute of Health [R01 AG050797]; American Heart Association [15BGIA23220016]; Geriatric Research, Education and Clinical Center of the South Texas Veterans Health Care System FX This work was supported by Duke-NUS Medical School Faculty Funds (to PMY), Singapore National Medical Research Council grant NMRC/CSA/0054/2013 (to PMY), NMRC/CIRG/1340/2012 (to PMY), National Institute of Health R01 AG050797 (to ABS), the American Heart Association 15BGIA23220016 (to ABS) and the Geriatric Research, Education and Clinical Center of the South Texas Veterans Health Care System (to ABS). NR 45 TC 0 Z9 0 U1 0 U2 0 PU IMPACT JOURNALS LLC PI ORCHARD PARK PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA SN 1945-4589 J9 AGING-US JI Aging-US PD FEB PY 2017 VL 9 IS 2 BP 583 EP 599 DI 10.18632/aging.101181 PG 17 WC Cell Biology SC Cell Biology GA EO7TH UT WOS:000396892500022 PM 28238968 ER PT J AU Khoury, CC Chan, KE AF Khoury, Charbel C. Chan, Kevin E. TI More monitoring: Non-vitamin K-dependent oral anticoagulant agent use in chronic kidney disease patients SO AMERICAN HEART JOURNAL LA English DT Editorial Material ID ATRIAL-FIBRILLATION; RISK; PROGRESSION; INJURY AB Non-vitamin K-dependent oral anticoagulant agents (NOACs) are increasingly becoming the drug of choice for preventing atrial fibrillation (AF) related strokes in the general population, given that these drugs have less drug interaction, require no INR monitoring, and have been shown to be equal if not superior to warfarin in pivotal phase 3 randomized trials. (1) However, the prescription of NOACs in AF patients with chronic kidney disease (CKD) requires special consideration and presents clinicians with specific challenges. All NOACs are dependent on the kidney for clearance and studies have shown that CKD is a progressive disease in that the creatinine clearance (CrCl) is expected to decline over time. Additionally, such patients are more prone to acute kidney injury (AKI), which associates with sudden decreases in renal drug clearance. (2) As such, the major challenge of NOAC use in CKD is adjusting the dose of the medication in line with the changes in renal clearance, in order to maintain NOAC drug levels within a therapeutic window. If NOAC dosing is not reduced when the creatinine clearance falls, drug levels can bioaccumalate and precipitate unintended major or fatal bleeding. When the creatinine clearance (CrCl) falls below 30 mL/min, NOAC use may become dangerous. The 2014 AHA/ACC/HRS guideline recommends warfarin as the anticoagulant of choice because these patients were excluded from phase 3 randomized NOAC trials and there is no data to support their efficacy and safety in patients with advanced CKD. (3) C1 [Khoury, Charbel C.; Chan, Kevin E.] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA. RP Chan, KE (reprint author), Massachusetts Gen Hosp, Renal Associates, Suite 302,165 Cambridge St, Boston, MA 02114 USA. EM KECHAN@mgh.harvard.edu NR 12 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD FEB PY 2017 VL 184 DI 10.1016/j.ahj.2016.10.023 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EO0LJ UT WOS:000396389000020 PM 28224929 ER PT J AU Shah, R Yow, E Jones, W Kohl, LP Kosinski, AS Hoffmann, U Lee, KL Fordyce, CB Mark, DB Lowe, A Douglas, PS Patel, MR AF Shah, Rohan Yow, Eric Jones, WilliamSchuyler Kohl, Louis P., III Kosinski, Andrzej S. Hoffmann, Udo Lee, Kerry L. Fordyce, Christopher B. Mark, Daniel B. Lowe, Alicia Douglas, Pamela S. Patel, Manesh R. TI Comparison of visual assessment of coronary stenosis with independent quantitative coronary angiography: Findings from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial SO AMERICAN HEART JOURNAL LA English DT Article ID INTEROBSERVER VARIABILITY; LESION SEVERITY; INTRAOBSERVER; ARTERIOGRAPHY; ANGIOPLASTY; DISEASE AB Background The outcomes in patients by visual assessment and quantitative coronary angiography (QCA) for obstructive coronary artery disease (CAD) are not known. Our objectives were to compare visual and QCA estimates of obstructive CAD and to assess their relationship to outcomes in stable patients with symptoms of CAD. Methods The PROMISE trial randomized 10,003 patients with CAD symptoms to anatomical or functional testing. Site reports of invasive angiography detailing visual stenosis and independent, blinded QCA were performed for obstructive CAD (>= 50% stenosis). Disagreement between methods was determined and compared with outcomes (death, myocardial infarction, unstable angina hospitalization, or major procedural complications). Results Of 929 patients (9.3% of PROMISE cohort) with angiograms assessed by sites and QCA, 593 (64%) had obstructive CAD per site reports, whereas 428 (46%) had stenosis >= 50% per QCA. Results differed in 177 patients (disagreement rate 19.1%, k = 0.63), of whom 171 had CAD per sites but not per QCA. One-year unadjusted Kaplan-Meier event rates were highest (5.1%) when QCA and visual assessment agreed for CAD, lowest (0.9%) when the 2 agreed for no obstructive CAD, and intermediate (3.1%) for patients who had CAD per visual assessment but not per QCA. Conclusions Visual estimation of angiograms results in more frequent diagnosis of obstructive CAD as compared with QCA. Concordance of results for presence or absence of obstructive CAD was associated with high and low event rates, respectively. Disagreement was associated with intermediate event rates, suggesting that cardiologists integrated clinical information into routine visual assessment of angiograms. C1 [Shah, Rohan; Yow, Eric; Jones, WilliamSchuyler; Kosinski, Andrzej S.; Lee, Kerry L.; Fordyce, Christopher B.; Mark, Daniel B.; Lowe, Alicia; Douglas, Pamela S.; Patel, Manesh R.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC 27715 USA. [Jones, WilliamSchuyler; Mark, Daniel B.; Douglas, Pamela S.; Patel, Manesh R.] Duke Univ, Sch Med, Dept Med, Div Cardiol, Durham, NC 27715 USA. [Kohl, Louis P., III] Hennepin Cty Med Ctr, Minneapolis, MN USA. [Hoffmann, Udo] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hoffmann, Udo] Harvard Med Sch, Boston, MA USA. RP Patel, MR (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, POB 17969,2400 Pratt St, Durham, NC 27715 USA. EM manesh.patel@duke.edu NR 17 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD FEB PY 2017 VL 184 DI 10.1016/j.ahj.2016.10.014 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EO0LJ UT WOS:000396389000003 ER PT J AU Voora, D Coles, A Lee, KL Hoffmann, U Wingrove, JA Rhees, B Huang, L Daniels, SE Monane, M Rosenberg, S Shah, SH Kraus, WE Ginsburg, GS Douglas, PS AF Voora, Deepak Coles, Adrian Lee, Kerry L. Hoffmann, Udo Wingrove, James A. Rhees, Brian Huang, Lin Daniels, Susan E. Monane, Mark Rosenberg, Steven Shah, Svati H. Kraus, William E. Ginsburg, Geoffrey S. Douglas, Pamela S. TI An age- and sex-specific gene expression score is associated with revascularization and coronary artery disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial SO AMERICAN HEART JOURNAL LA English DT Article ID NONDIABETIC PATIENTS; HEART-ASSOCIATION; ANGIOGRAPHY; BIOMARKERS; STENOSIS; OUTCOMES; COMPASS; EXTENT; RISK AB Background Identifying predictors of coronary artery disease (CAD)-related procedures and events remains a priority. Methods We measured an age-and sex-specific gene expression score (ASGES) previously validated to detect obstructive CAD (oCAD) in symptomatic nondiabetic patients in the PROMISE trial. The outcomes were oCAD (>= 70% stenosis in >= 1 vessel or >= 50% left main stenosis on CT angiography [CTA]) and a composite endpoint of death, myocardial infarction, revascularization, or unstable angina. Results The ASGES was determined in 2370 nondiabetic participants (47.5% male, median age 59.5 years, median follow-up 25 months), including 1137 with CTA data. An ASGES > 15 was associated with oCAD (odds ratio 2.5 [95% CI 1.6-3.8], P < .001) and the composite endpoint (hazard ratio [HR] 2.6 [95% CI 1.8-3.9], P < .001) in unadjusted analyses. After adjustment for Framingham risk, an ASGES > 15 remained associated with the composite endpoint (P = .02); the only component that was associated was revascularization (adjusted HR 2.69 [95% CI 1.52-4.79], P < .001). Compared to noninvasive testing, the ASGES improved prediction for the composite (increase in c-statistic = 0.036; continuous net reclassification index = 43.2%). Patients with an ASGES = 15 had a composite endpoint rate no different from those with negative noninvasive test results (3.2% vs. 2.6%, P = .29). Conclusions A blood-based genomic test for detecting oCAD significantly predicts near-term revascularization procedures, but not non-revascularization events. Larger studies will be needed to clarify the risk with non-revascularization events. C1 [Voora, Deepak; Ginsburg, Geoffrey S.] Duke Univ, Sch Med, Duke Ctr Appl Genom & Precis Med, 101 Sci Dr,DUMC 3382, Durham, NC 27710 USA. [Voora, Deepak; Shah, Svati H.; Kraus, William E.; Ginsburg, Geoffrey S.; Douglas, Pamela S.] Duke Univ, Sch Med, Dept Med, Durham, NC 27710 USA. [Coles, Adrian; Lee, Kerry L.; Shah, Svati H.; Douglas, Pamela S.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC 27710 USA. [Hoffmann, Udo] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Wingrove, James A.; Rhees, Brian; Huang, Lin; Daniels, Susan E.; Monane, Mark; Rosenberg, Steven] CardioDx Inc, Redwood City, CA USA. RP Voora, D (reprint author), Duke Univ, Sch Med, Duke Ctr Appl Genom & Precis Med, 101 Sci Dr,DUMC 3382, Durham, NC 27710 USA. EM Deepak.voora@duke.edu OI Voora, Deepak/0000-0003-0015-5179 FU National Heart, Lung, and Blood Institute (NHLBI) [R01 HL098237, R01 HL098236, R01 HL098305, R01 HL098235] FX This PROMISE substudy was supported in part by CardioDx, Inc., which performed all RNA sample processing, and generation of generated ASGES in a blinded fashion, and shared in the interpretation of the data, and preparation, review, and approval of the manuscript. An Executive Committee of Duke/DCRI co-authors oversaw substudy design and study conduct, final data review, and presentation and publication of results, independently making the decision to publish. All analyses including the definition of the composite and secondary endpoints were pre- specified as part of a statistical analysis plan that was finalized before analyses were performed. No authors from CardioDx had access to the clinical data or were able to perform statistical analyses using the data. Only two co-authors, both of whom are academic (AC and KLL), had full access to the data and neither receives any financial support from CardioDx. Duke/DCRI investigators independently drafted the manuscript and take full responsibility for the accuracy and completeness of data analyses.; The PROMISE trial was funded by National Heart, Lung, and Blood Institute (NHLBI) grants R01 HL098237, R01 HL098236, R01 HL098305, and R01 HL098235. The NHLBI had no role in the design and conduct of this substudy; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The views expressed in this article do not necessarily represent the official views of the NHLBI. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper, and its final contents. NR 24 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD FEB PY 2017 VL 184 DI 10.1016/j.ahj.2016.11.004 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EO0LJ UT WOS:000396389000018 PM 28224927 ER PT J AU de Jong, D Roemer, MGM Chan, JKC Goodlad, J Gratzinger, D Chadburn, A Jaffe, ES Said, J Natkunam, Y AF de Jong, Daphne Roemer, Margaretha G. M. Chan, John K. C. Goodlad, John Gratzinger, Dita Chadburn, Amy Jaffe, Elaine S. Said, Jonathan Natkunam, Yasodha TI B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency 2015 SH/EAHP Workshop Report-Part 2 SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Article DE PD-L1; 9p24; Iatrogenic immunodeficiency; Posttransplant lymphoproliferative disorder; Autoimmunity; Primary immunodeficiency; Large B-cell lymphoma; Classical Hodgkin lymphoma; T-cell/histiocyte-rich B-cell lymphoma; Marginal zone lymphoma ID POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS; SOLID-ORGAN TRANSPLANTATION; HEALTH-ORGANIZATION CLASSIFICATION; MARGINAL ZONE LYMPHOMA; FRENCH REGISTRY; EXPRESSION; THERAPY; DISEASE; RISK; MANAGEMENT AB Objectives: The 2015 Workshop of the Society for Hematopathology/European Association for Haematopathology submitted small and large B-cell lymphomas (BCLs), including classical Hodgkin lymphoma (CHL), in the context of immunodeficiency. Methods: Clinicopathologic and molecular features were studied to explore unifying concepts in malignant B-cell proliferations across immunodeficiency settings. Results: Cases submitted to the workshop spanned small BCLs presenting as nodal or extranodal marginal zone lymphoma and lymphoplasmacytic lymphoma, Epstein-Barr virus (EBV) positive in 75% of cases. Submitted large BCLs formed a spectrum from diffuse large B-cell lymphoma (DLBCL) to CHL across immunodeficiency settings. Additional studies demonstrated overexpression of PD-L1 and molecular 9p24 alterations in the large BCL spectrum and across different immunodeficiency settings. Conclusions: Small BCLs occur in all immunodeficiency settings, and EBV positivity is essential for their recognition as immunodeficiency related. Large BCLs include a spectrum from DLBCL to CHL across all immunodeficiency settings; immunohistochemical and molecular features are suggestive of shared pathogenetic mechanisms involving PD-L1 immune checkpoints. C1 [de Jong, Daphne; Roemer, Margaretha G. M.] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands. [Roemer, Margaretha G. M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chan, John K. C.] Queen Elizabeth Hosp, Kowloon, Hong Kong, Peoples R China. [Goodlad, John] St James Univ Hosp, HMDS, Leeds, W Yorkshire, England. [Gratzinger, Dita; Natkunam, Yasodha] Stanford Univ, Sch Med, L235,300 Pasteur Dr, Stanford, CA 94305 USA. [Chadburn, Amy] Cornell Univ, Weill Med Coll, New York, NY 10021 USA. [Jaffe, Elaine S.] NIH, Bldg 10, Bethesda, MD 20892 USA. [Said, Jonathan] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. RP Natkunam, Y (reprint author), Stanford Univ, Sch Med, L235,300 Pasteur Dr, Stanford, CA 94305 USA. EM yaso@stanford.edu NR 63 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9173 EI 1943-7722 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD FEB PY 2017 VL 147 IS 2 BP 153 EP 170 DI 10.1093/ajcp/aqw216 PG 18 WC Pathology SC Pathology GA EP2QS UT WOS:000397228900002 ER PT J AU Yarns, BC Glass, OM AF Yarns, Brandon C. Glass, Oliver M. TI Why Trainees Should Consider a Career in Geriatric Psychiatry: Reflections From Two AAGP Trainee Board Members SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Editorial Material C1 [Yarns, Brandon C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med, 10940 Wilshire Blvd,Suite 710, Los Angeles, CA 90024 USA. [Yarns, Brandon C.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Glass, Oliver M.] East Carolina Univ, Dept Psychiat & Behav Med, Greenville, NC USA. RP Yarns, BC (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med, 10940 Wilshire Blvd,Suite 710, Los Angeles, CA 90024 USA. EM byarns@mednet.ucla.edu FU VA Office of Academic Affiliations through the VA National Clinician Scholars Program [TPH 65-005] FX Dr. Yarns was supported by the VA Office of Academic Affiliations through the VA National Clinician Scholars Program, funding ID #TPH 65-005. NR 7 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD FEB PY 2017 VL 25 IS 2 BP 204 EP 206 DI 10.1016/j.jagp.2016.11.016 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA EP1FF UT WOS:000397130100014 PM 28040428 ER PT J AU Farvid, MS Malekshah, AF Pourshams, A Poustchi, H Sepanlou, SG Sharafkhah, M Khoshnia, M Farvid, M Abnet, CC Kamangar, F Dawsey, SM Brennan, P Pharoah, PD Boffetta, P Willett, WC Malekzadeh, R AF Farvid, Maryam S. Malekshah, Akbar F. Pourshams, Akram Poustchi, Hossein Sepanlou, Sadaf G. Sharafkhah, Maryam Khoshnia, Masoud Farvid, Mojtaba Abnet, Christian C. Kamangar, Farin Dawsey, Sanford M. Brennan, Paul Pharoah, Paul D. Boffetta, Paolo Willett, Walter C. Malekzadeh, Reza TI Dietary Protein Sources and All-Cause and Cause-Specific Mortality: The Golestan Cohort Study in Iran SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID PROCESSED MEAT CONSUMPTION; CANCER-RISK; ESOPHAGEAL CANCER; FISH CONSUMPTION; ZEAXANTHIN CONCENTRATIONS; CARDIOVASCULAR-DISEASE; PHASEOLUS-VULGARIS; COLORECTAL-CANCER; EGG CONSUMPTION; GASTRIC-CANCER AB Introduction: Dietary protein comes from foods with greatly different compositions that may not relate equally with mortality risk. Few cohort studies from non-Western countries have examined the association between various dietary protein sources and cause-specific mortality. Therefore, the associations between dietary protein sources and all-cause, cardiovascular disease, and cancer mortality were evaluated in the Golestan Cohort Study in Iran. Methods: Among 42,403 men and women who completed a dietary questionnaire at baseline, 3,291 deaths were documented during 11 years of follow up (2004-2015). Cox proportional hazards models estimated age-adjusted and multivariate-adjusted hazard ratios (HRs) and 95% CIs for all cause and disease-specific mortality in relation to dietary protein sources. Data were analyzed from 2015 to 2016. Results: Comparing the highest versus the lowest quartile, egg consumption was associated with lower all-cause mortality risk (HR=0.88, 95% CI=0.79, 0.97, ptrend=0.03). In multivariate analysis, the highest versus the lowest quartile of fish consumption was associated with reduced risk of total cancer (HR=0.79, 95% CI=0.64, 0.98, ptrend=0.03) and gastrointestinal cancer (HR=0.75, 95% CI=0.56, 1.00, ptrend=0.02) mortality. The highest versus the lowest quintile of legume consumption was associated with reduced total cancer (HR=0.72, 95% CI=0.58, 0.89, ptrend=0.004), gastrointestinal cancer (HR=0.76, 95% CI=0.58, 1.01, ptrend=0.05), and other cancer (HR=0.66, 95% CI=0.47, 0.93, ptrend=0.04) mortality. Significant associations between total red meat and poultry intake and allcause, cardiovascular disease, or cancer mortality rate were not observed among all participants. Conclusions: These findings support an association of higher fish and legume consumption with lower cancer mortality, and higher egg consumption with lower all-cause mortality. (C) 2016 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved. C1 [Farvid, Maryam S.; Willett, Walter C.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Farvid, Maryam S.; Malekshah, Akbar F.; Pourshams, Akram; Sepanlou, Sadaf G.; Sharafkhah, Maryam; Malekzadeh, Reza] Univ Tehran Med Sci, Res Inst, Digest Dis Res Ctr, Digest Dis, Tehran, Iran. [Farvid, Maryam S.] Massachusetts Gen Hosp, Harvard MGH Ctr Genom Vulnerable Populat & Hlth D, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Malekshah, Akbar F.; Poustchi, Hossein; Sepanlou, Sadaf G.] Univ Tehran Med Sci, Res Inst, Digest Oncol Res Ctr, Digest Dis, Tehran, Iran. [Pourshams, Akram; Poustchi, Hossein; Sharafkhah, Maryam; Malekzadeh, Reza] Univ Tehran Med Sci, Digest Dis Res Inst, Shariati Hosp, Liver & Pancreatobiliary Dis Res Ctr, Tehran, Iran. [Sharafkhah, Maryam] Univ Tehran Med Sci, Dept Epidemiol & Biostat, Tehran, Iran. [Khoshnia, Masoud] Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, Iran. [Farvid, Mojtaba] Linnaeus Univ, Vaxjo, Sweden. [Abnet, Christian C.; Dawsey, Sanford M.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Kamangar, Farin] Morgan State Univ, Dept Publ Hlth Anal, Sch Community Hlth & Policy, Baltimore, MD 21239 USA. [Brennan, Paul] Int Agcy Res Canc, Genet Epidemiol Grp, Lyon, France. [Pharoah, Paul D.] Univ Cambridge, Dept Oncol, Cambridge, England. [Pharoah, Paul D.] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England. [Boffetta, Paolo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA. [Boffetta, Paolo] Icahn Sch Med Mt Sinai, Inst Translat Epidemiol, New York, NY 10029 USA. [Willett, Walter C.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Willett, Walter C.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Willett, Walter C.] Harvard Med Sch, Boston, MA USA. RP Farvid, MS (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.; Malekzadeh, R (reprint author), Shariati Hosp, Digest Dis Res Inst, Dis Res Ctr, N Kargar St, Tehran, Iran. EM mfarvid@hsph.harvard.edu; malek@tums.ac.ir FU Tehran University of Medical Sciences [82-603]; Cancer Research United Kingdom [C20/A5860]; Intramural Research Program of the U.S. National Cancer Institute at NIH National Institutes of Health [Z01 CP000185-03]; Social Security Organization of Iran, Golestan Branch; Takemi Fellowship Program FX This work was supported by Tehran University of Medical Sciences (Grant No. 82-603), Cancer Research United Kingdom (grant No: C20/A5860), the Intramural Research Program of the U.S. National Cancer Institute at NIH National Institutes of Health (Z01 CP000185-03), and various collaborative research agreements with the International Agency for Research on Cancer. Many individuals have contributed to this study. We wish to thank the study participants for their cooperation over many years and the Behvarz' working in the study areas for their help. We thank the directors of the public health districts of Gonbad and Kalaleh for their collaboration. We express our special thanks to general physicians, nurses, and nutritionists in the enrollment teams for their collaboration and assistance. We received special support from the Social Security Organization of Iran, Golestan Branch. We have enjoyed the close collaboration of the Golestan health deputies and the Chief of the Gonbad health district. Dr. Maryam Farvid would like to express appreciation to the Japan Pharmaceutical Manufacturers Association for their financial support of the Takemi Fellowship Program. NR 46 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2017 VL 52 IS 2 BP 237 EP 248 DI 10.1016/j.amepre.2016.10.041 PG 12 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EO9DP UT WOS:000396989700016 PM 28109460 ER PT J AU Baker, K Haydar, B Mankad, S AF Baker, Keith Haydar, Bishr Mankad, Shawn TI A Feedback and Evaluation System That Provokes Minimal Retaliation by Trainees SO ANESTHESIOLOGY LA English DT Article ID GRADE INFLATION; NATIONAL-SURVEY; T-TEST; PERFORMANCE; CLERKSHIP; NORMALITY; DIRECTORS; CHOICE; SCALE; POWER AB Background: Grade inflation is pervasive in educational settings in the United States. One driver of grade inflation may be faculty concern that assigning lower clinical performance scores to trainees will cause them to retaliate and assign lower teaching scores to the faculty member. The finding of near-zero retaliation would be important to faculty members who evaluate trainees. Methods: The authors used a bidirectional confidential evaluation and feedback system to test the hypothesis that faculty members who assign lower clinical performance scores to residents subsequently receive lower clinical teaching scores. From September 1, 2008, to February 15, 2013, 177 faculty members evaluated 188 anesthesia residents (n = 27,561 evaluations), and 188 anesthesia residents evaluated 204 faculty members (n = 25,058 evaluations). The authors analyzed the relationship between clinical performance scores assigned by faculty members and the clinical teaching scores received using linear regression. The authors used complete dyads between faculty members and resident pairs to conduct a mixed effects model analysis. All analyses were repeated for three different epochs, each with different administrative attributes that might influence retaliation. Results: There was no relationship between mean clinical performance scores assigned by faculty members and mean clinical teaching scores received in any epoch (P >= 0.45). Using only complete dyads, the authors' mixed effects model analysis demonstrated a very small retaliation effect in each epoch (effect sizes of 0.10, 0.06, and 0.12; P <= 0.01). Conclusions: These results imply that faculty members can provide confidential evaluations and written feedback to trainees with near-zero impact on their mean teaching scores. C1 [Baker, Keith] Harvard Med Sch, Boston, MA USA. [Baker, Keith] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA. [Haydar, Bishr] Univ Michigan, Dept Anesthesiol, Div Pediat Anesthesia, Ann Arbor, MI 48109 USA. [Mankad, Shawn] Cornell Univ, Samuel Curtis Johnson Grad Sch Management, Ithaca, NY USA. RP Baker, K (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA. EM khbaker@partners.org NR 42 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD FEB PY 2017 VL 126 IS 2 BP 327 EP 337 PG 11 WC Anesthesiology SC Anesthesiology GA EO8CO UT WOS:000396916700017 PM 27977462 ER PT J AU Raines, DE AF Raines, Douglas E. TI Flumazenil Modulation of the gamma-Aminobutyric Acid Type A Receptor: Competitive versus Noncompetitive Antagonism at the Agonist-binding Site SO ANESTHESIOLOGY LA English DT Letter ID GABA(A) RECEPTORS C1 [Raines, Douglas E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Raines, DE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM draines@partners.org NR 6 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD FEB PY 2017 VL 126 IS 2 BP 350 EP 351 PG 3 WC Anesthesiology SC Anesthesiology GA EO8CO UT WOS:000396916700023 PM 28098614 ER PT J AU Cardoso, F Harbeck, N Barrios, CH Bergh, J Cortes, J El Saghir, N Francis, PA Hudis, CA Ohno, S Partridge, AH Sledge, GW Smith, IE Gelmon, KA AF Cardoso, F. Harbeck, N. Barrios, C. H. Bergh, J. Cortes, J. El Saghir, N. Francis, P. A. Hudis, C. A. Ohno, S. Partridge, A. H. Sledge, G. W. Smith, I. E. Gelmon, K. A. TI Research needs in breast cancer SO ANNALS OF ONCOLOGY LA English DT Article DE breast cancer; clinical research; medical needs ID RANDOMIZED CONTROLLED-TRIAL; INTERNATIONAL CONSENSUS GUIDELINES; CLINICAL-PRACTICE GUIDELINE; ADJUVANT ENDOCRINE THERAPY; PRIMARY TUMOR; YOUNG-WOMEN; AMERICAN SOCIETY; INTRATUMOR HETEROGENEITY; EUROPEAN-ORGANIZATION; TARGETED THERAPIES AB New research questions emerge as medical needs continue to evolve and as we improve our understanding of cancer biology and treatment of malignancies. Although significant advances have been made in some areas of breast cancer research resulting in improvements in therapies and outcomes over the last few decades, other areas have not benefited to the same degree and we continue to have many gaps in our knowledge. This article summarizes the 12 short and medium-term clinical research needs in breast cancer deemed as priorities in 2016 by a panel of experts, in an attempt to focus and accelerate future research in the most needed areas: (i) de-escalate breast cancer therapies in early breast cancer without sacrificing outcomes; (ii) explore optimal adjuvant treatment durations; (iii) develop better tools and strategies to identify patients with genetic predisposition; (iv) improve care in young patients with breast cancer; (v) develop tools to speed up drug development in biomarker-defined populations; (vi) identify and validate targets that mediate resistance to chemotherapy, endocrine therapy and anti-HER2 therapies; (vii) evaluate the efficacy of local-regional treatments for metastatic disease; (viii) better define the optimal sequence of treatments in the metastatic setting; (ix) evaluate the clinical impact of intra-patient heterogeneity (intratumor, inter-tumor and inter-lesion heterogeneity); (x) better understand the biology and identify new targets in triplenegative breast cancer; (xi) better understand immune surveillance in breast cancer and further develop immunotherapies; and (xii) increase survivorship research efforts including supportive care and quality of life. C1 [Cardoso, F.] Champalimaud Clin Ctr, Breast Unit, Ave Brasilia S-N, P-1400038 Lisbon, Portugal. [Harbeck, N.] Univ Munich LMU, Dept Obstet & Gynaecol, Breast Ctr, Munich, Germany. [Barrios, C. H.] Pontificia Univ Catolica Rio Grande do Sul, Sch Med, Porto Alegre, RS, Brazil. [Bergh, J.] Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden. [Bergh, J.] Univ Hosp, Stockholm, Sweden. [Cortes, J.] Hosp Ramon & Cajal, Breast Canc Unit, Madrid, Spain. [Cortes, J.] VHIO, Dept Med Oncol, Barcelona, Spain. [El Saghir, N.] Amer Univ Beirut, Med Ctr, NK Basile Canc Inst, Dept Internal Med, Beirut, Lebanon. [Francis, P. A.] Univ Melbourne, St Vincents Hosp, Peter MacCallum Canc Ctr, Div Canc Med, Melbourne, Vic, Australia. [Hudis, C. A.] Amer Soc Clin Oncol, Alexandria, VA USA. [Ohno, S.] Canc Inst Hosp, Ctr Breast Oncol, Koto Ku, Tokyo, Japan. [Partridge, A. H.] Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02115 USA. [Sledge, G. W.] Stanford Univ, Dept Med, Stanford, CA 94305 USA. [Smith, I. E.] Royal Marsden Hosp, Breast Unit, London, England. [Gelmon, K. A.] BC Canc Agcy, Dept Med Oncol, Vancouver, BC, Canada. RP Cardoso, F (reprint author), Champalimaud Clin Ctr, Breast Unit, Ave Brasilia S-N, P-1400038 Lisbon, Portugal. EM fatimacardoso@fundacaochampalimaud.pt NR 95 TC 1 Z9 1 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2017 VL 28 IS 2 BP 208 EP 217 DI 10.1093/annonc/mdw571 PG 10 WC Oncology SC Oncology GA EP3JJ UT WOS:000397278300007 ER PT J AU Musto, P Anderson, KC Attal, M Richardson, PG Badros, A Hou, J Comenzo, R Du, J Durie, BGM San Miguel, J Einsele, H Chen, WM Garderet, L Pietrantuono, G Hillengass, J Kyle, RA Moreau, P Lahuerta, JJ Landgren, O Ludwig, H Larocca, A Mahindra, A Cavo, M Mazumder, A McCarthy, PL Nouel, A Rajkumar, SV Reiman, A Serra, ER Sezer, O Terpos, E Turesson, I Usmani, S Weiss, BM Palumbo, A AF Musto, P. Anderson, K. C. Attal, M. Richardson, P. G. Badros, A. Hou, J. Comenzo, R. Du, J. Durie, B. G. M. San Miguel, J. Einsele, H. Chen, W. M. Garderet, L. Pietrantuono, G. Hillengass, J. Kyle, R. A. Moreau, P. Lahuerta, J. J. Landgren, O. Ludwig, H. Larocca, A. Mahindra, A. Cavo, M. Mazumder, A. McCarthy, P. L. Nouel, A. Rajkumar, S. V. Reiman, A. Serra, E. R. Sezer, O. Terpos, E. Turesson, I. Usmani, S. Weiss, B. M. Palumbo, A. CA Int Myeloma Working Grp TI Second primary malignancies in multiple myeloma: an overview and IMWG consensus SO ANNALS OF ONCOLOGY LA English DT Review DE multiple myeloma; second primary malignancy; SPM; risk factors; lenalidomide; International Myeloma Working Group ID STEM-CELL TRANSPLANTATION; LOW-DOSE DEXAMETHASONE; BORTEZOMIB-MELPHALAN-PREDNISONE; SECONDARY PRIMARY MALIGNANCIES; MYELODYSPLASTIC SYNDROME; AUTOLOGOUS TRANSPLANTATION; LENALIDOMIDE MAINTENANCE; DARATUMUMAB MONOTHERAPY; MYELOMONOCYTIC LEUKEMIA; INELIGIBLE PATIENTS AB Background: Therapeutic advancements following the introduction of autologous stem cell transplantation and ` novel' agents have significantly improved clinical outcomes for patients with multiple myeloma (MM). Increased life expectancy, however, has led to renewed concerns about the long-term risk of second primary malignancies (SPMs). This review outlines the most up-to-date knowledge of possible host-, disease-, and treatment-related risk factors for the development of SPMs in patients with MM, and provides practical recommendations to assist physicians. Design: A Panel of International Myeloma Working Group members reviewed the most relevant data published in the literature as full papers, or presented at meetings of the American Society of Clinical Oncology, American Society of Hematology, European Hematology Association, or International Myeloma Workshops, up to June 2016. Here, we present the recommendations of the Panel, based on this literature review. Results: Overall, the risk of SPMs in MM is low, multifactorial, and partially related to the length of patients' survival and MM intrinsic susceptibility. Studies suggest a significantly increased incidence of SPMs when lenalidomide is administered either following, or concurrently with, oral melphalan. Increased SPM incidence has also been reported with lenalidomide maintenance following high-dose melphalan, albeit to a lesser degree. In both cases, the risk of death from MM was significantly higher than the risk of death from SPMs, with lenalidomide possibly providing a survival benefit. No increase in SPM incidence was reported with lenalidomide plus dexamethasone (without melphalan), or with bortezomib plus oral melphalan, dexamethasone, or thalidomide. Conclusion: In general, the risk of SPMs should not alter the current therapeutic decision- making process in MM. However, regimens such as lenalidomide plus dexamethasone should be preferred to prolonged exposure to lenalidomide plus oral melphalan. SPM risk should be carefully discussed with the patient in the context of benefits and risks of different treatment options. C1 [Musto, P.] IRCCS CROB, Referral Canc Ctr Basilicata, Sci Direct, Via Padre Pio 1, I-85028 Rionero In Vulture, Pz, Italy. [Anderson, K. C.; Richardson, P. G.] Dana Farber Canc Inst, Hematol Oncol, Boston, MA 02115 USA. [Attal, M.] Inst Univ Canc Toulouse Oncopole, Hematol, Toulouse, France. [Badros, A.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Hou, J.] Second Mil Med Univ, Changzheng Hosp, Myeloma & Lymphoma Ctr, Dept Hematol, Shanghai, Peoples R China. [Comenzo, R.] Tufts Med Ctr, Hematol Oncol, Boston, MA USA. [Durie, B. G. M.] Cedars Sinai Med Ctr, Samuel Oschin Canc Ctr, Los Angeles, CA 90048 USA. [San Miguel, J.] Univ Navarra Clin, CIMA, Pamplona, Spain. [Einsele, H.] Univ Hosp Wuerzburg, Internal Med 2, Wurzburg, Germany. [Chen, W. M.] Capital Med Univ, Beijing Chaoyang Hosp, Beijing, Peoples R China. [Garderet, L.] Hop St Antoine, Hematol Clin, Paris, France. [Pietrantuono, G.] Referral Canc Ctr Basilicata, IRCCS CROB, Unit Hematol & Stem Cell Transplantat, Rionero In Vulture, Italy. [Hillengass, J.] Heidelberg Univ, Dept Hematol & Oncol, Heidelberg, Germany. [Hillengass, J.] German Canc Res Ctr, Heidelberg, Germany. [Kyle, R. A.; Rajkumar, S. V.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA. [Moreau, P.] Univ Hosp, Hematol, Nantes, France. [Lahuerta, J. J.] Hosp Univ 12 Octubre, Spanish Myeloma Grp, Madrid, Spain. [Landgren, O.] Mem Sloan Kettering Canc Ctr, Hematol Oncol, 1275 York Ave, New York, NY 10021 USA. [Ludwig, H.] Wilhelminenspital Stat Wien, Med Dept & Oncol 1, Vienna, Austria. [Larocca, A.; Palumbo, A.] Univ Torino, Div Hematol, Azienda Osped Univ Citta Salute & Sci Torino, Turin, Italy. [Mahindra, A.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Cavo, M.] Univ Bolgona, Dept Specialized Expt & Diagnost Med, Bologna, Italy. [Mazumder, A.] NYU Comprehens Canc Ctr, Med Oncol, New York, NY USA. [McCarthy, P. L.] Roswell Pk Canc Ctr, Dept Med, Buffalo, NY USA. [Nouel, A.] Hosp Univ Rutz & Paez, Dept Hematol, Bolivar, Venezuela. [Reiman, A.] St Johns Hosp, Dept Oncol, St John, NB, Canada. [Serra, E. R.] Hosp Clin Montevideo, Dept Hematol, Montevideo, Uruguay. [Sezer, O.] Mem Hosp, Dept Hematol, Istanbul, Turkey. [Terpos, E.] Univ Athens, Sch Med, Athens, Greece. [Turesson, I.] Skane Univ Hosp, Dept Hematol & Coagulat Disorders, Malmo, Sweden. [Usmani, S.] Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA. [Weiss, B. M.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. RP Musto, P (reprint author), IRCCS CROB, Referral Canc Ctr Basilicata, Sci Direct, Via Padre Pio 1, I-85028 Rionero In Vulture, Pz, Italy. EM p.musto@crob.it FU Italian Ministry of Health Current Research [RRC 2015-2360451, RRC 2016-2361120]; Celgene Corporation FX This paper was supported by two Italian Ministry of Health Current Research grants to IRCCS-CROB (Grant numbers RRC 2015-2360451 and RRC 2016-2361120). Medical writing support was provided by Baxter Jeffs and Sandralee Lewis of the Investigator Initiated Research Writing Group (an initiative from Ashfield Healthcare Communications, part of UDG Healthcare plc), and was funded by Celgene Corporation. NR 101 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2017 VL 28 IS 2 BP 228 EP 245 DI 10.1093/annonc/mdw606 PG 18 WC Oncology SC Oncology GA EP3JJ UT WOS:000397278300009 ER PT J AU Yu, HA Sima, C Feldman, D Liu, LL Vaitheesvaran, B Cross, J Rudin, CM Kris, MG Pao, W Michor, F Riely, GJ AF Yu, H. A. Sima, C. Feldman, D. Liu, L. L. Vaitheesvaran, B. Cross, J. Rudin, C. M. Kris, M. G. Pao, W. Michor, F. Riely, G. J. TI Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers SO ANNALS OF ONCOLOGY LA English DT Article DE EGFR-mutant lung cancer; acquired resistance; evolutionary modeling; EGFR T790M; pulse dose erlotinib ID TYROSINE KINASE INHIBITORS; NERVOUS-SYSTEM METASTASES; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; DOSING SCHEDULES; OPEN-LABEL; GEFITINIB; MUTATION; CHEMOTHERAPY; I/II AB Background: Patients with EGFR-mutant lung cancers treated with EGFR tyrosine kinase inhibitors (TKIs) develop clinical resistance, most commonly with acquisition of EGFR T790M. Evolutionary modeling suggests that a schedule of twice weekly pulse and daily low-dose erlotinib may delay emergence of EGFR T790M. Pulse dose erlotinib has superior central nervous system (CNS) penetration and may result in superior CNS disease control. Methods: We evaluated toxicity, pharmacokinetics, and efficacy of twice weekly pulse and daily low-dose erlotinib. We assessed six escalating pulse doses of erlotinib. Results: We enrolled 34 patients; 11 patients (32%) had brain metastases at study entry. We observed 3 dose-limiting toxicities in dose escalation: transaminitis, mucositis, and rash. The MTD was erlotinib 1200mg days 1-2 and 50mg days 3-7 weekly. The most frequent toxicities (any grade) were rash, diarrhea, nausea, fatigue, and mucositis. 1 complete and 24 partial responses were observed (74%, 95% CI 60-84%). Median progression-free survival was 9.9 months (95% CI 5.8-15.4 months). No patient had progression of an untreated CNS metastasis or developed a new CNS lesion while on study (0%, 95% CI 0-13%). Of the 18 patients with biopsies at progression, EGFR T790M was identified in 78% (95% CI 54-91%). Conclusion: This is the first clinical implementation of an anti-cancer TKI regimen combining pulse and daily low-dose administration. This evolutionary modeling-based dosing schedule was well-tolerated but did not improve progression-free survival or prevent emergence of EGFR T790M, likely due to insufficient peak serum concentrations of erlotinib. This dosing schedule prevented progression of untreated or any new central nervous system metastases in all patients. C1 [Yu, H. A.; Feldman, D.; Rudin, C. M.; Kris, M. G.; Riely, G. J.] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, Div Solid Tumor Oncol, 1275 York Ave, New York, NY 10021 USA. [Yu, H. A.; Rudin, C. M.; Kris, M. G.; Riely, G. J.] Weill Cornell Med Coll, New York, NY USA. [Yu, H. A.; Rudin, C. M.; Kris, M. G.; Riely, G. J.] Weill Cornell Med Coll, New York, NY USA. [Sima, C.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA. [Liu, L. L.; Michor, F.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Liu, L. L.; Michor, F.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Pao, W.] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Catherine C Marron Canc Metab Ctr Vanderbilt Ingr, Dept Med, New York, NY USA. RP Yu, HA (reprint author), Mem Sloan Kettering Canc Ctr, Dept Med, 300 East 66th St, New York, NY 10065 USA. EM yuh@mskcc.org FU Astellas Pharmaceutical Global Development, Inc; National Institutes of Health [U54 CA193461, P01 CA129243, P30 CA008748]; Dallepezze Foundation; Free to Breathe FX This work was supported, in part, by Astellas Pharmaceutical Global Development, Inc, the National Institutes of Health [U54 CA193461 to F.M.,P01 CA129243 to M.K., P30 CA008748 to MSKCC], the Dallepezze Foundation and a Young Investigator grant from Free to Breathe. NR 39 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2017 VL 28 IS 2 BP 278 EP 284 DI 10.1093/annonc/mdw556 PG 7 WC Oncology SC Oncology GA EP3JJ UT WOS:000397278300013 ER PT J AU Liao, Z Rodrigues, MC Poynter, JN Amatruda, JF Rodriguez-Galindo, C Frazier, AL AF Liao, Z. Rodrigues, M. C. Poynter, J. N. Amatruda, J. F. Rodriguez-Galindo, C. Frazier, A. L. TI Risk of second malignant neoplasms in women and girls with germ cell tumors SO ANNALS OF ONCOLOGY LA English DT Article DE germ cell tumors; SEER; second cancers; ovarian cancers ID LONG-TERM SURVIVORS; TESTICULAR-CANCER; UNITED-STATES; TRENDS; CHEMOTHERAPY AB Background: While an elevated risk of second malignant neoplasms (SMNs) has been observed in men treated for germ cell tumors (GCTs), risk of SMNs have not been quantified in adult women or in girls treated for GCTs. Patients and methods: One-year survivors of primary GCTs diagnosed between January 1980 and December 2012 were identified from Surveillance, Epidemiology, and End Results (SEER 9) registries. Risk of SMNs was calculated using SEER* Stat. Results: Among 1507 patients, a total of 47 SMNs were identified. The overall risk of SMNs was not elevated in females overall or in females treated for GCT during adulthood although SMN sites (pancreas, soft tissue, bladder, kidney, and thyroid) and trends were comparable with those inmen. There were too few childhood GCT cases with SMNs for further analysis. Conclusions: Unlike men, women treated for GCTs did not have a statistically significant elevated risk of SMNs [ standardized incidence ratio = 1.11; 95% confidence interval (CI) = 0.81-1.47]. The fact that SMNs in women occur in sites similar to those observed in men indicate that long-term follow-up of a larger cohort of females treated for GCT is warranted. C1 [Liao, Z.; Frazier, A. L.] Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA. [Liao, Z.] Wellesley Coll, Interdept Program Biochem, Wellesley, MA 02181 USA. [Rodrigues, M. C.] Fac Ciencias Med Santa Casa Sao Paulo, Med Sci, Sao Paulo, Brazil. [Poynter, J. N.] Univ Minnesota, Dept Pediat, Div Epidemiol & Clin Res, Minneapolis, MN 55455 USA. [Poynter, J. N.] Univ Minnesota, Dept Pediat, Mason Canc Ctr, Minneapolis, MN 55455 USA. [Amatruda, J. F.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA. [Amatruda, J. F.] Univ Texas Southwestern Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA. [Amatruda, J. F.] Childrens Med Ctr, Ctr Canc & Blood Disorders, Dallas, TX 75235 USA. [Rodriguez-Galindo, C.] St Jude Childrens Res Hosp, Dept Global Pediat Med, 332 N Lauderdale St, Memphis, TN 38105 USA. RP Frazier, AL (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,D-3127, Boston, MA 02216 USA.; Frazier, AL (reprint author), Boston Childrens Hosp, 450 Brookline Ave,D-3127, Boston, MA 02216 USA. EM lindsay_frazier@dfci.harvard.edu FU Global Engagement Internship; Department of Biological Sciences at Wellesley College FX Global Engagement Internship and Department of Biological Sciences at Wellesley College. No grant number is applicable. NR 10 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2017 VL 28 IS 2 BP 329 EP 332 DI 10.1093/annonc/mdw609 PG 4 WC Oncology SC Oncology GA EP3JJ UT WOS:000397278300020 ER PT J AU Menzies, AM Johnson, DB Ramanujam, S Atkinson, VG Wong, ANM Park, JJ McQuade, JL Shoushtari, AN Tsai, KK Eroglu, Z Klein, O Hassel, JC Sosman, JA Guminski, A Sullivan, RJ Ribas, A Carlino, MS Davies, MA Sandhu, SK Long, GV AF Menzies, A. M. Johnson, D. B. Ramanujam, S. Atkinson, V. G. Wong, A. N. M. Park, J. J. McQuade, J. L. Shoushtari, A. N. Tsai, K. K. Eroglu, Z. Klein, O. Hassel, J. C. Sosman, J. A. Guminski, A. Sullivan, R. J. Ribas, A. Carlino, M. S. Davies, M. A. Sandhu, S. K. Long, G. V. TI Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab SO ANNALS OF ONCOLOGY LA English DT Article DE PD-1; immunotherapy; autoimmunity; autoimmune disorder; cancer; melanoma ID CELL LUNG-CANCER; UNTREATED MELANOMA; NIVOLUMAB; PEMBROLIZUMAB; CHEMOTHERAPY; DOCETAXEL; SAFETY; TRIAL AB Background: Anti-PD-1 antibodies (anti-PD-1) have clinical activity in a number of malignancies. All clinical trials have excluded patients with significant preexisting autoimmune disorders (ADs) and only one has included patients with immunerelated adverse events (irAEs) with ipilimumab. We sought to explore the safety and efficacy of anti-PD-1 in such patients. Patients and methods: Patients with advanced melanoma and preexisting ADs and/or major immune-related adverse events (irAEs) with ipilimumab (requiring systemic immunosuppression) that were treated with anti-PD-1 between 1 July 2012 and 30 September 2015 were retrospectively identified. Results: One hundred and nineteen patients from 13 academic tertiary referral centers were treated with anti-PD-1. In patients with preexisting AD (N = 52), the response rate was 33%. 20 (38%) patients had a flare of AD requiring immunosuppression, including 7/13 with rheumatoid arthritis, 3/3 with polymyalgia rheumatica, 2/2 with Sjogren's syndrome, 2/2 with immune thrombocytopaenic purpura and 3/8 with psoriasis. No patients with gastrointestinal (N = 6) or neurological disorders (N = 5) flared. Only 2 (4%) patients discontinued treatment due to flare, but 15 (29%) developed other irAEs and 4 (8%) discontinued treatment. In patients with prior ipilimumab irAEs requiring immunosuppression (N = 67) the response rate was 40%. Two (3%) patients had a recurrence of the same ipilimumab irAEs, but 23 (34%) developed new irAEs (14, 21% grade 3-4) and 8 (12%) discontinued treatment. There were no treatment-related deaths. Conclusions: In melanoma patients with preexisting ADs or major irAEs with ipilimumab, anti-PD-1 induced relatively frequent immune toxicities, but these were often mild, easily managed and did not necessitate discontinuation of therapy, and a significant proportion of patients achieved clinical responses. The results support that anti-PD-1 can be administered safely and can achieve clinical benefit in patients with preexisting ADs or prior major irAEs with ipilimumab. C1 [Menzies, A. M.; Ramanujam, S.; Guminski, A.; Carlino, M. S.; Long, G. V.] Melanoma Inst Australia, Sydney, NSW, Australia. [Menzies, A. M.; Ramanujam, S.; Guminski, A.; Carlino, M. S.; Long, G. V.] Univ Sydney, Sydney, NSW, Australia. [Menzies, A. M.; Guminski, A.; Long, G. V.] Royal North Shore & Mater Hosp, Sydney, NSW, Australia. [Johnson, D. B.; Sosman, J. A.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Atkinson, V. G.] Princess Alexandra Hosp, Brisbane, Qld, Australia. [Atkinson, V. G.] Univ Queensland, Brisbane, Qld, Australia. [Wong, A. N. M.; Sandhu, S. K.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. [Park, J. J.; Carlino, M. S.] Crown Princess Mary Canc Ctr Westmead, Sydney, NSW, Australia. [McQuade, J. L.; Davies, M. A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Shoushtari, A. N.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Tsai, K. K.] Univ Calif San Francisco, Dept Med Oncol, San Francisco, CA 94143 USA. [Eroglu, Z.] H Lee Moffitt Canc Ctr & Res Inst, Dept Med Oncol, Tampa, FL USA. [Klein, O.] Austin Hlth, Olivia Newton John Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia. [Klein, O.] Austin Hlth, Canc Res Inst, Melbourne, Vic, Australia. [Hassel, J. C.] Heidelberg Univ, Dept Dermatol, Heidelberg, Germany. [Sullivan, R. J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Ribas, A.] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA USA. RP Menzies, AM (reprint author), Melanoma Inst Australia, 40 Rocklands Rd, Sydney, NSW 2060, Australia. EM alexander.menzies@sydney.edu.au FU Cancer Institute NSW fellowship FX AMM had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The authors wish to acknowledge the assistance of Anna Hoadley RN, Georgia Cairns RN, Elizabeth Liniker MD and Maria Czupryn RN. AMM is supported by a Cancer Institute NSW fellowship. NR 22 TC 2 Z9 2 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2017 VL 28 IS 2 BP 368 EP 376 DI 10.1093/annonc/mdw443 PG 9 WC Oncology SC Oncology GA EP3JJ UT WOS:000397278300026 ER PT J AU Jacobs, JP Lahey, SJ Nichols, FC Levett, JM Johnston, GG Freeman, RK Louis, JDS Painter, J Yohe, C Wright, CD Kanter, KR Mayer, JE Naunheim, KS Rich, JB Bavaria, JE AF Jacobs, Jeffrey P. Lahey, Stephen J. Nichols, Francis C. Levett, James M. Johnston, George Gilbert Freeman, Richard K. Louis, James D. St. Painter, Julie Yohe, Courtney Wright, Cameron D. Kanter, Kirk R. Mayer, John E., Jr. Naunheim, Keith S. Rich, Jeffrey B. Bavaria, Joseph E. CA Soc Thoracic Surg Workforce Coding TI How Is Physician Work Valued? SO ANNALS OF THORACIC SURGERY LA English DT Article ID RELATIVE VALUE SCALE; VALUATION AB Strategies to value physician work continue to evolve. The Society of Thoracic Surgeons and The Society of Thoracic Surgeons National Database have an increasingly important role in this evolution. An understanding of the Current Procedural Terminology (CPT) system (American Medical Association [AMA], Chicago, IL) and the Relative Value Scale Update Committee (RUC) is necessary to comprehend how physician work is valued. In 1965, with the dawn of increasingly complex medical care, immense innovation, and the rollout of Medicare, the need for a common language describing medical services and procedures was recognized as being of critical importance. In 1966, the AMA, in cooperation with multiple major medical specialty societies, developed the CPT system, which is a coding system for the description of medical procedures and medical services. The RUC was created by the AMA in response to the passage of the Omnibus Budget Reconciliation Act of 1989, legislation of the United States of America Federal government that mandated that the Centers for Medicare & Medicaid Services adopt a relative value methodology for Medicare physician payment. The role of the RUC is to develop relative value recommendations for the Centers for Medicare & Medicaid Services. These recommendations include relative value recommendations for new procedures or services and also updates to relative value recommendations for previously valued procedures or services. These recommendations pertain to all physician work delivered to Medicare beneficiaries and propose relative values for all physician services, including updates to those based on the original resource-based relative value scale developed by Hsaio and colleagues. In so doing, widely differing work and services provided can be reviewed and comparisons of their relative value (to each other) can be established. The resource-based relative value scale assigns value to physician services using relative value units (RVUs), which consist of three components: work RVU, practice expense RVU, and malpractice RVU, also known as professional liability insurance RVU. The Centers for Medicare & Medicaid Services retains the final decision-making authority on the RVUs associated with each procedure or service. The purpose of this article is to discuss the role that the CPT codes and the RUC play in the valuation of physician work and to provide an example of how the methodology for valuation of physician work continues to evolve. (C) 2017 by The Society of Thoracic Surgeons C1 [Jacobs, Jeffrey P.] Johns Hopkins Univ Sch Med, Dept Surg, Div Cardiac Surg, Baltimore, MD USA. [Jacobs, Jeffrey P.] Johns Hopkins All Childrens Hosp, Johns Hopkins All Childrens Heart Inst, Dept Surg, Div Cardiovasc Surg, St Petersburg, FL USA. [Jacobs, Jeffrey P.] Johns Hopkins All Childrens Hosp, Johns Hopkins All Childrens Heart Inst, Dept Surg, Div Cardiovasc Surg, Orlando, FL USA. [Jacobs, Jeffrey P.] Florida Hosp Children, St Petersburg, FL USA. [Jacobs, Jeffrey P.] Florida Hosp Children, Orlando, FL USA. [Lahey, Stephen J.] Univ Connecticut Sch Med, Dept Surg, Div Cardiothorac Surg, Farmington, CT USA. [Nichols, Francis C.] Mayo Clin, Div Gen Thorac Surg, Rochester, MN USA. [Levett, James M.] Cedar Rapids, Clin Iowa, Iowa City, IA USA. [Johnston, George Gilbert] US Dept State Off Med Serv, Washington, DC USA. [Freeman, Richard K.] St Vincents Hlth & Hosp Syst, Indianapolis, IN USA. [Louis, James D. St.] Univ Missouri, Kansas City Sch Med, Kansas City, MO 65211 USA. [Painter, Julie] Med Reimbursement Anal & Solut, Thornton, CO USA. [Yohe, Courtney] Govt Relat, Soc Thorac Surgeons, Washington, DC USA. [Wright, Cameron D.] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA USA. [Kanter, Kirk R.] Emory Univ, Atlanta, GA 30322 USA. [Mayer, John E., Jr.] Harvard Med Sch, Boston Childrens Hosp, Dept Cardiac Surg, Boston, MA USA. [Naunheim, Keith S.] St Louis Univ Sch Med, St Louis, MO USA. [Rich, Jeffrey B.] Vue Based HealthCare Solut, Virginia Beach, VA USA. [Bavaria, Joseph E.] Univ Penn, Philadelphia, PA 19104 USA. [Soc Thoracic Surg Workforce Coding] Soc Thorac Surgeons, Chicago, IL USA. RP Jacobs, JP (reprint author), Johns Hopkins All Childrens Hosp, Johns Hopkins All Childrens Heart Inst, 601 Fifth St S,Ste 607, St Petersburg, FL 33701 USA.; Jacobs, JP (reprint author), Florida Hosp Children, St Petersburg, FL 33701 USA. EM jeffjacobs@jhmi.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD FEB PY 2017 VL 103 IS 2 BP 373 EP 380 DI 10.1016/j.athoracsur.2016.11.059 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EP1SU UT WOS:000397165400035 PM 28109347 ER PT J AU Badhwar, V Rankin, JS He, M Jacobs, JP Furnary, AP Fazzalari, FL O'Brien, S Gammie, JS Shahian, DM AF Badhwar, Vinay Rankin, J. Scott He, Max Jacobs, Jeffrey P. Furnary, Anthony P. Fazzalari, Frank L. O'Brien, Sean Gammie, James S. Shahian, David M. TI Performing Concomitant Tricuspid Valve Repair at the Time of Mitral Valve Operations Is Not Associated With Increased Operative Mortality SO ANNALS OF THORACIC SURGERY LA English DT Article ID RING ANNULOPLASTY; NORTH-AMERICA; REGURGITATION; SURGERY; REPLACEMENT; MANAGEMENT; DISEASE; DILATATION; GUIDELINES; OUTCOMES AB Background. The performance of concomitant tricuspid valve repair (TVr) at the time of mitral valve repair or replacement (MVRR) has previously been associated with elevated short-term risk. Outcomes were assessed at incremental grades of tricuspid regurgitation (TR) to quantify the contemporary risk of concomitant TVr. Methods. Between July 2011 and June 2014, 88,473 patients undergoing MVRR were examined using The Society of Thoracic Surgeons database. Outcomes with or without TVr, after isolated MVRR (n = 62,118) and MVRR with coronary artery bypass graft surgery (CABG [n = 26,355]), were independently analyzed at three levels of TR: none-mild, moderate, and severe. Risk-adjusted morbidity and mortality associated with the performance of concomitant TVr were evaluated using multivariable logistic regression. Results. The TR was graded as none-mild in 74.3% of patients (65,769 of 88,473), moderate in 17.2% (15,222 of 88,473), and severe in 8.5% (7,482 of 88,473). The rate of TVr by TR grade was 3.5% (2,308 of 65,769) for none-mild, 30.6% (4,661 of 15,222) for moderate, and 75.6% (5,654 of 7,482) for severe. Overall risk-adjusted occurrence of any morbidity associated with performance of TVr was increased in both groups (MVRR odds ratio [OR] 1.36, 95% confidence interval [CI]: 1.24 to 1.48; and MVRR plus CABG OR 1.33, 95% CI: 1.19 to 1.49). However, at all grades of TR, TVr was not associated with increased risk-adjusted mortality (MVRR OR 0.99, 95% CI: 0.84 to 1.17; and MVRR plus CABG OR 1.04, 95% CI: 0.85 to 1.27). Conclusions. In contemporary patients, concomitant TVr is not associated with a risk-adjusted increase in mortality, regardless of TR severity. A more liberal approach to TVr at the time of MVRR may be justified when long-term benefits are thought to outweigh incremental short-term morbidity risk. Further investigation of longitudinal TVr outcomes is warranted. (C) 2017 by The Society of Thoracic Surgeons C1 [Badhwar, Vinay] West Virginia Univ, Div Cardiothorac Surg, 1 Med Ctr Dr, Morgantown, WV 26506 USA. Duke Clin Res Inst, Durham, NC USA. Johns Hopkins Univ, Childrens Hosp, Childrens Heart Inst, Sch Med, St Petersburg, FL USA. Johns Hopkins Univ, Childrens Hosp, Childrens Heart Inst, Sch Med, Baltimore, MD USA. Starr Wood Cardiac Grp, Portland, OR USA. Univ Michigan, Dept Cardiac Surg, Ann Arbor, MI USA. Univ Maryland, Div Cardiac Surg, Baltimore, MD USA. Massachusetts Gen Hosp, Dept Surg, Boston, MA USA. Massachusetts Gen Hosp, Ctr Qual & Safety, Boston, MA USA. RP Badhwar, V (reprint author), West Virginia Univ, Div Cardiothorac Surg, 1 Med Ctr Dr, Morgantown, WV 26506 USA. EM vinay.badhwar@wvumedicine.org FU Edwards Lifesciences FX Dr Gammie discloses a financial relationship with Edwards Lifesciences. NR 31 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD FEB PY 2017 VL 103 IS 2 BP 587 EP 594 DI 10.1016/j.athoracsur.2016.06.004 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EP1SU UT WOS:000397165400064 PM 27570159 ER PT J AU Mihos, CG Santana, O AF Mihos, Christos G. Santana, Orlando TI Pay Attention to Mitral Valve Repair With Autologous Pericardial Leaflet Augmentation Reply SO ANNALS OF THORACIC SURGERY LA English DT Letter C1 [Mihos, Christos G.] Massachusetts Gen Hosp, Harvard Med Sch, Cardiac Ultrasound Lab, Boston, MA 02114 USA. [Santana, Orlando] Columbia Univ, Mt Sinai Heart Inst, Miami Beach, FL USA. RP Mihos, CG (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Cardiac Ultrasound Lab, Boston, MA 02114 USA. EM cmihos@mgh.harvard.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD FEB PY 2017 VL 103 IS 2 BP 689 EP 690 PG 2 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EP1SU UT WOS:000397165400083 PM 28109360 ER PT J AU Osho, AA Azzoli, CJ Pai, S Mino-Kenudson, M Faquin, WC Huynh, TG Lanuti, M Mathisen, DJ Muniappan, A AF Osho, Asishana A. Azzoli, Christopher J. Pai, Sara Mino-Kenudson, Mari Faquin, William C. Huynh, Tiffany G. Lanuti, Michael Mathisen, Douglas J. Muniappan, Ashok TI Successful Treatment of an Aggressive Tracheal Malignancy With Immunotherapy SO ANNALS OF THORACIC SURGERY LA English DT Editorial Material ID CELL LUNG-CANCER; DOCETAXEL; NIVOLUMAB AB Immune checkpoint inhibitors are emerging as therapeutic options for oncology patients in whom conventional treatment regimens have failed. These immunotherapies counteract tumor-induced tolerance and have been shown to be effective in thoracic malignancies, including non-small cell lung cancer (NSCLC). This report highlights the successful use of nivolumab-an immunotherapeutic agent that binds to proteins involved in T-cell proliferation-for the management of recurrent tracheal squamous cell cancer after exhaustion of conventional surgical, chemotherapeutic, and radiation therapy options. Observations provide a strong indication of the potential value of checkpoint inhibitors for managing a wide array of thoracic malignancies. (C) 2017 by The Society of Thoracic Surgeons C1 Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Thorac Surg, Boston, MA 02114 USA. RP Muniappan, A (reprint author), Massachusetts Gen Hosp, Div Thorac Surg, 55 Fruit St,GRB 425, Boston, MA 02114 USA. EM amuniappan@mgh.harvard.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD FEB PY 2017 VL 103 IS 2 BP E123 EP E125 DI 10.1016/j.athoracsur.2016.08.021 PG 3 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EP1SU UT WOS:000397165400004 PM 28109369 ER PT J AU Gonzalez, DA Soble, JR Marceaux, JC McCoy, KJM AF Gonzalez, David Andres Soble, Jason R. Marceaux, Janice C. McCoy, Karin J. M. TI An Evaluation of the Texas Functional Living Scale's Latent Structure and Subscales SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Everyday functioning; Test construction; Assessment AB Objective: Performance-based functional assessment is a critical component of neuropsychological practice. The Texas Functional Living Scale (TFLS) has promise given its brevity, nationally representative norms, and co-norming with Wechsler scales. However, its subscale structure has not been evaluated. The purpose of this study was to evaluate the TFLS in a mixed clinical sample (n = 197). Method: Reliability and convergent and discriminant validity coefficients were calculated with neurocognitive testing and collateral reports and factor analysis was performed. Results: The Money and Calculation subscale had the best psychometric properties of the subscales. The evidence did not support solitary interpretation of the Time subscale. A three-factor latent structure emerged representing memory and semantic retrieval, performance and visual scanning, and financial calculation. Conclusions: This study added psychometric support for interpretation of the TFLS total score and some of its subscales. Study limitations included sample characteristics (e.g., gender ratio) and low power for collateral report analyses. C1 [Gonzalez, David Andres; Soble, Jason R.; Marceaux, Janice C.; McCoy, Karin J. M.] South Texas Vet Hlth Care Syst, Psychol Serv 116B, San Antonio, TX USA. [Gonzalez, David Andres] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, 8300 Floyd Curl Dr MC 7883, San Antonio, TX 78229 USA. RP Gonzalez, DA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, 8300 Floyd Curl Dr MC 7883, San Antonio, TX 78229 USA. EM gonzalezD15@uthscsa.edu NR 21 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD FEB PY 2017 VL 32 IS 1 BP 104 EP 109 DI 10.1093/arclin/acw082 PG 6 WC Psychology, Clinical; Psychology SC Psychology GA EO9KJ UT WOS:000397007300013 PM 28122769 ER PT J AU Renfroe, JB Turner, TH Hinson, VK AF Renfroe, Jenna B. Turner, Travis H. Hinson, Vanessa K. TI Assessing Visuospatial Skills in Parkinson's: Comparison of Neuropsychological Assessment Battery Visual Discrimination to the Judgment of Line Orientation SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Parkinson's disease; Assessment ID MILD COGNITIVE IMPAIRMENT; SOCIETY TASK-FORCE; ALZHEIMERS-DISEASE; BENTON JUDGMENT; LEWY BODIES; SHORT FORMS; DEMENTIA; CRITERIA AB Objective: Judgment of Line Orientation (JOLO) test is widely used in assessing visuospatial deficits in Parkinson's disease (PD). The neuropsychological assessment battery (NAB) offers the Visual Discrimination test, with age and education correction, parallel forms, and co-normed standardization sample for comparisons within and between domains. However, NAB Visual Discrimination has not been validated in PD, and may not measure the same construct as JOLO. Method: A heterogeneous sample of 47 PD patients completed the JOLO and NAB Visual Discrimination within a broader neuropsychological evaluation. Pearson correlations assessed relationships between JOLO and NAB Visual Discrimination performances. Results: Raw and demographically corrected scores from JOLO and Visual Discrimination were only weakly correlated. NAB Visual Discrimination subtest was moderately correlated with overall cognitive functioning, whereas the JOLO was not. Conclusions: Despite apparent virtues, results do not support NAB Visual Discrimination as an alternative to JOLO in assessing visuospatial functioning in PD. C1 [Renfroe, Jenna B.; Turner, Travis H.; Hinson, Vanessa K.] Med Univ South Carolina, Dept Neurol, 208 B Rutledge Ave,MSC 108, Charleston, SC 29425 USA. [Hinson, Vanessa K.] Ralph H Johnson VAMC, Neurol Serv, Charleston, SC USA. RP Renfroe, JB (reprint author), Med Univ South Carolina, Dept Neurol, 208 B Rutledge Ave,MSC 108, Charleston, SC 29425 USA. EM jennarenfroephd@gmail.com FU Michael J. Fox Foundation FX This work was supported by the Michael J. Fox Foundation. NR 21 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD FEB PY 2017 VL 32 IS 1 BP 123 EP 127 DI 10.1093/arclin/acw102 PG 5 WC Psychology, Clinical; Psychology SC Psychology GA EO9KJ UT WOS:000397007300016 PM 28122771 ER PT J AU Provencher, MT Sanchez, G Schantz, K Ferrari, M Sanchez, A Frangiamore, S Mannava, S AF Provencher, Matthew T. Sanchez, George Schantz, Katrina Ferrari, Marcio Sanchez, Anthony Frangiamore, Salvatore Mannava, Sandeep TI Anatomic Humeral Head Reconstruction With Fresh Osteochondral Talus Allograft for Recurrent Glenohumeral Instability With Reverse Hill-Sachs Lesion SO ARTHROSCOPY TECHNIQUES LA English DT Article ID ANTERIOR SHOULDER INSTABILITY; BONE DEFECTS; FOLLOW-UP; MANAGEMENT; REMPLISSAGE; DISLOCATION; DIAGNOSIS; LATARJET; CONTACT; REPAIRS AB The treatment of recurrent glenohumeral instability, especially with a concomitant bony lesion, remains challenging. This is especially true in the case of posterior instability given its less common incidence. Moreover, the presence of an engaging reverse Hill-Sachs lesion in combination with posterior instability will result in the need for a more aggressive treatment option. In comparison with a Hill-Sachs lesion, a reverse Hill-Sachs lesion features greater chondral deficiency that must be addressed during treatment. We propose the talus allograft as a potential allograft for treatment of an engaging reverse Hill-Sachs lesion. The superior articular surface of the talus may be used to reconstruct the articular surface of the humeral head. In this technical note, we describe our preferred primary technique for treatment of an engaging reverse Hill-Sachs lesion with recurrent glenohumeral instability through use of a fresh osteochondral talus allograft, as well as discuss the advantages and disadvantages of this allograft option. C1 [Provencher, Matthew T.; Sanchez, George; Ferrari, Marcio] Steadman Philippon Res Inst, Vail, CO USA. [Provencher, Matthew T.; Frangiamore, Salvatore; Mannava, Sandeep] Steadman Clin, 181 W Meadow Dr,Ste 4000, Vail, CO 81657 USA. [Schantz, Katrina] Massachusetts Gen Hosp, Sports Med Serv, Boston, MA 02114 USA. [Sanchez, Anthony] Jackson Mem Hosp, Miami, FL 33136 USA. RP Provencher, MT (reprint author), Steadman Clin, 181 W Meadow Dr,Ste 4000, Vail, CO 81657 USA. EM mprovencher@thesteadmanclinic.com FU Arthrex; JRF Ortho FX M.T.P. receives support from Arthrex, JRF Ortho. Consultant. Patent numbers (issued) 9226743, 20150164498, 20150150594, 20110040339. Arthrex, SLACK. Publishing royalties. NR 26 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2212-6287 J9 ARTHROSC TEC JI Arthrosc. Tec. PD FEB PY 2017 VL 6 IS 1 BP E255 EP E261 DI 10.1016/j.eats.2016.10.017 PG 7 WC Orthopedics SC Orthopedics GA EP4ZT UT WOS:000397389300040 ER PT J AU Cao, HT Gibson, TE Bashan, A Liu, YY AF Cao, Hong-Tai Gibson, Travis E. Bashan, Amir Liu, Yang-Yu TI Inferring human microbial dynamics from temporal metagenomics data: Pitfalls and lessons SO BIOESSAYS LA English DT Article DE dynamics inference; ecological modeling; human microbiome; temporal metagenomics ID LOTKA-VOLTERRA EQUATION; REPLICATOR DYNAMICS; VARIABLE SELECTION; GUT MICROBIOTA; REGULARIZATION; CLASSIFICATION; REGRESSION; MODELS; MATLAB; LASSO AB The human gut microbiota is a very complex and dynamic ecosystem that plays a crucial role in health and well-being. Inferring microbial community structure and dynamics directly from time-resolved metagenomics data is key to understanding the community ecology and predicting its temporal behavior. Many methods have been proposed to perform the inference. Yet, as we point out in this review, there are several pitfalls along the way. Indeed, the uninformative temporal measurements and the compositional nature of the relative abundance data raise serious challenges in inference. Moreover, the inference results can be largely distorted when only focusing on highly abundant species by ignoring or grouping low-abundance species. Finally, the implicit assumptions in various regularization methods may not reflect reality. Those issues have to be seriously considered in ecological modeling of human gut microbiota. C1 [Cao, Hong-Tai; Gibson, Travis E.; Bashan, Amir; Liu, Yang-Yu] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA. [Cao, Hong-Tai] Univ Southern Calif, Dept Elect Engn, Los Angeles, CA 90089 USA. [Cao, Hong-Tai] Zhejiang Univ, Chu Kochen Honors Coll, Coll Elect Engn, Hangzhou, Zhejiang, Peoples R China. [Bashan, Amir] Bar Ilan Univ, Dept Phys, Ramat Gan, Israel. [Liu, Yang-Yu] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA. RP Liu, YY (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.; Liu, YY (reprint author), Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA. EM yyl@channing.harvard.edu FU John Templeton Foundation [51977] FX This work was partially supported by the John Templeton Foundation (award number 51977). NR 43 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0265-9247 EI 1521-1878 J9 BIOESSAYS JI Bioessays PD FEB PY 2017 VL 39 IS 2 AR UNSP 1600188 DI 10.1002/bies.201600188 PG 12 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA EP2IK UT WOS:000397206400008 ER PT J AU Montillo, M O'Brien, S Tedeschi, A Byrd, JC Dearden, C Gill, D Brown, JR Barrientos, JC Mulligan, SP Furman, RR Cymbalista, F Plascencia, C Chang, S Hsu, E James, DF Hillmen, P AF Montillo, M. O'Brien, S. Tedeschi, A. Byrd, J. C. Dearden, C. Gill, D. Brown, J. R. Barrientos, J. C. Mulligan, S. P. Furman, R. R. Cymbalista, F. Plascencia, C. Chang, S. Hsu, E. James, D. F. Hillmen, P. TI Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study SO BLOOD CANCER JOURNAL LA English DT Letter ID INHIBITION; DIAGNOSIS; ARTHRITIS; CELL C1 [Montillo, M.; Tedeschi, A.] Niguarda Canc Ctr, Milan, Italy. [O'Brien, S.] MD Anderson Canc Ctr, Houston, TX USA. [Byrd, J. C.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Dearden, C.] Royal Marsden Hosp, London, England. [Gill, D.] Princess Alexandra Hosp, Brisbane, Qld, Australia. [Brown, J. R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Barrientos, J. C.] Hofstra Northwell Sch Med, Hempstead, NY USA. [Mulligan, S. P.] Royal North Shore Hosp, Sydney, NSW, Australia. [Furman, R. R.] New York Presbyterian Hosp, Weill Cornell Med College, York, NY USA. [Cymbalista, F.] Hop Avicenne, Paris, France. [Plascencia, C.; Chang, S.; Hsu, E.; James, D. F.] Pharmacyclics LLC, Sunnyvale, CA USA. [Plascencia, C.; Chang, S.; Hsu, E.; James, D. F.] AbbVie Co, Sunnyvale, CA USA. [Hillmen, P.] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England. RP Montillo, M (reprint author), Niguarda Canc Ctr, Milan, Italy. EM marco.montillo@ospedaleniguarda.it FU Pharmacyclics LLC, an AbbVie Company FX This study was supported by research funding from Pharmacyclics LLC, an AbbVie Company. Ingrid Koo, PhD, a medical writer supported by funding from Pharmacyclics LLC, an AbbVie Company, provided drafts and editorial assistance to the authors during preparation of this manuscript. NR 15 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2044-5385 J9 BLOOD CANCER J JI Blood Cancer J. PD FEB PY 2017 VL 7 AR e524 DI 10.1038/bcj.2017.5 PG 4 WC Oncology SC Oncology GA EO8BD UT WOS:000396912900005 PM 28157216 ER PT J AU Swords, RT Watts, J Erba, HP Altman, JK Maris, M Anwer, F Hua, Z Stein, H Faessel, H Sedarati, F Dezube, BJ Giles, FJ Medeiros, BC DeAngelo, DJ AF Swords, R. T. Watts, J. Erba, H. P. Altman, J. K. Maris, M. Anwer, F. Hua, Z. Stein, H. Faessel, H. Sedarati, F. Dezube, B. J. Giles, F. J. Medeiros, B. C. DeAngelo, D. J. TI Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes SO BLOOD CANCER JOURNAL LA English DT Letter ID MLN4924; CANCER; CELLS C1 [Swords, R. T.; Watts, J.] Sylvester Comprehens Canc Ctr, Leukemia Program, Miami, FL 33136 USA. [Erba, H. P.] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI 48109 USA. [Altman, J. K.; Giles, F. J.] Northwestern Univ, Northwestern Med Dev Therapeut Inst, Chicago, IL 60611 USA. [Maris, M.] Colorado Blood Canc Inst, Denver, CO USA. [Anwer, F.] Univ Arizona, Ctr Canc, Tucson, AZ USA. [Hua, Z.; Stein, H.; Faessel, H.; Sedarati, F.; Dezube, B. J.] T Takeda Pharmaceut Int Co, Cambridge, MA USA. [Medeiros, B. C.] Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA. [DeAngelo, D. J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Swords, RT (reprint author), Sylvester Comprehens Canc Ctr, Leukemia Program, Miami, FL 33136 USA. EM rswords@med.miami.edu FU Takeda Pharmaceuticals, Inc.; NIH [1KL2TR000461] FX This research was supported by Takeda Pharmaceuticals, Inc. This study is registered with ClinicalTrials.gov, number NCT00677170. RTS received support from grant NIH 1KL2TR000461. NR 15 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2044-5385 J9 BLOOD CANCER J JI Blood Cancer J. PD FEB PY 2017 VL 7 AR e520 DI 10.1038/bcj.2017.1 PG 4 WC Oncology SC Oncology GA EO8BD UT WOS:000396912900001 PM 28157218 ER PT J AU Sinha, N Dauwels, J Kaiser, M Cash, SS Westover, MB Wang, YJ Taylor, PN AF Sinha, Nishant Dauwels, Justin Kaiser, Marcus Cash, Sydney S. Westover, M. Brandon Wang, Yujiang Taylor, Peter N. TI Predicting neurosurgical outcomes in focal epilepsy patients using computational modelling SO BRAIN LA English DT Article DE epilepsy; focal seizures; computational models; intracranial EEG; surgical outcome prediction ID TEMPORAL-LOBE EPILEPSY; STRUCTURAL CONNECTIVITY; FUNCTIONAL CONNECTIVITY; PRESURGICAL EVALUATION; SEIZURE DYNAMICS; SURGERY; NETWORK; EEG; ABNORMALITIES; OSCILLATIONS AB Surgery can be a last resort for patients with intractable, medically refractory epilepsy. For many of these patients, however, there is substantial risk that the surgery will be ineffective. The prediction of who is likely to benefit from a surgical approach is crucial for being able to inform patients better, conduct principled prospective clinical trials, and ultimately tailor therapeutic approaches to these patients more effectively. Dynamical computational models, informed with patient data, can be used to make predictions and give mechanistic insight. In this study, we develop patient-specific dynamical network models of epileptogenic cortex. We infer the network connectivity matrix from non-seizure electrographic recordings of patients and use these connectivity matrices as the network structure in our model. The model simulates the dynamics of a bi-stable switch at every node in this network, meaning that every node starts in a background state, but has the ability to transit to a co-existing seizure state. Whether a transition happens in a node is partly determined by the stochastic nature of the input to the node, but also by the input the node receives from other connected nodes in the network. By conducting simulations with such a model, we can detect the average transition time for nodes in a given network, and therefore define nodes with a short transition time as highly epileptogenic. In a retrospective study, we found that in some patients the regions with high epileptogenicity in the model overlap with those identified clinically as the seizure onset zone. Moreover, it was found that the resection of these regions in the model reduces the overall likelihood of a seizure. Following removal of these regions in the model, we predicted surgical outcomes and compared these to actual patient outcomes. Our predictions were found to be 81.3% accurate on a dataset of 16 patients with intractable epilepsy. Intriguingly, in patients with unsuccessful outcomes, the proposed computational approach is able to suggest alternative resection sites. The model presented here gives mechanistic insight as to why surgery may be unsuccessful in some patients. This may aid clinicians in presurgical evaluation by providing a tool to explore various surgical options, offering complementary information to existing clinical techniques. C1 [Sinha, Nishant; Dauwels, Justin] Nanyang Technol Univ, Sch Elect & Elect Engn, Singapore, Singapore. [Kaiser, Marcus; Wang, Yujiang; Taylor, Peter N.] Newcastle Univ, Fac Med Sci, Interdisciplinary Comp & Complex BioSyst ICOS, Newcastle Upon Tyne, Tyne & Wear, England. [Kaiser, Marcus; Taylor, Peter N.] Newcastle Univ, Fac Med Sci, Inst Neurosci, Newcastle Upon Tyne, Tyne & Wear, England. [Cash, Sydney S.; Westover, M. Brandon] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cash, Sydney S.; Westover, M. Brandon] Harvard Med Sch, Boston, MA USA. [Taylor, Peter N.] UCL, Inst Neurol, London, England. RP Sinha, N (reprint author), Nanyang Technol Univ, Sch Elect & Elect Engn, Singapore, Singapore.; Taylor, PN (reprint author), Newcastle Univ, Fac Med Sci, Inst Neurosci, Newcastle Upon Tyne, Tyne & Wear, England. EM nishant002@e.ntu.edu.sg; peter.taylor@newcastle.ac.uk FU Ministry of Education (MOE) as a part of Complexity Institute, Nanyang Technological University, Singapore [M4011102 RGC3/13]; Engineering and Physical Sciences Research Council of the United Kingdom [EP/K026992/1]; Wellcome Trust [105617/Z/14/Z]; NIH-NINDS [R01 NS062092, K24 NS088568]; U.S. National Institute of Neurological Disorders and Stroke [U24NS06930]; [EP/N031962/1] FX N.S. and J.D. were supported by the Ministry of Education (MOE) Tier 1 Grant M4011102 RGC3/13 as a part of Complexity Institute, Nanyang Technological University, Singapore. P.T. and M.K. were supported by the Engineering and Physical Sciences Research Council of the United Kingdom (EP/K026992/1) as part of the Human Green Brain Project. P.T. was supported by Wellcome Trust (105617/Z/14/Z). M.K. was supported by grant EP/N031962/1. SSC was supported by NIH-NINDS R01 NS062092 and K24 NS088568 grant. Access to the image(s) and/or data was supported by Award number U24NS06930 from the U.S. National Institute of Neurological Disorders and Stroke. The content of this publication/presentation is solely the responsibility of the authors, and does not necessarily represent the official views of the U.S. National Institute for Neurological Disorders and Stroke or the U.S. National Institutes of Health. NR 75 TC 1 Z9 1 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 EI 1460-2156 J9 BRAIN JI Brain PD FEB PY 2017 VL 140 BP 319 EP 332 DI 10.1093/aww332 PN 2 PG 14 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EP3XV UT WOS:000397315900017 PM 28011454 ER PT J AU Collins, JA Montal, V Hochberg, D Quimby, M Mandelli, ML Makris, N Seeley, WW Gorno-Tempini, ML Dickerson, BC AF Collins, Jessica A. Montal, Victor Hochberg, Daisy Quimby, Megan Mandelli, Maria Luisa Makris, Nikos Seeley, William W. Gorno-Tempini, Maria Luisa Dickerson, Bradford C. TI Focal temporal pole atrophy and network degeneration in semantic variant primary progressive aphasia SO BRAIN LA English DT Article DE atrophy; resting state connectivity; primary progressive aphasia; semantic dementia; temporal lobe ID FRONTOTEMPORAL LOBAR DEGENERATION; MIDDLE LONGITUDINAL FASCICLE; INTRINSIC FUNCTIONAL CONNECTIVITY; SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; ALZHEIMERS-DISEASE; WHITE-MATTER; HUMAN BRAIN; STRUCTURAL CONNECTIVITY; RESTING-STATE AB A wealth of neuroimaging research has associated semantic variant primary progressive aphasia with distributed cortical atrophy that is most prominent in the left anterior temporal cortex; however, there is little consensus regarding which region within the anterior temporal cortex is most prominently damaged, which may indicate the putative origin of neurodegeneration. In this study, we localized the most prominent and consistent region of atrophy in semantic variant primary progressive aphasia using cortical thickness analysis in two independent patient samples (n = 16 and 28, respectively) relative to age-matched controls (n = 30). Across both samples the point of maximal atrophy was located in the same region of the left temporal pole. This same region was the point of maximal atrophy in 100% of individual patients in both semantic variant primary progressive aphasia samples. Using resting state functional connectivity in healthy young adults (n = 89), we showed that the seed region derived from the semantic variant primary progressive aphasia analysis was strongly connected with a large-scale network that closely resembled the distributed atrophy pattern in semantic variant primary progressive aphasia. In both patient samples, the magnitude of atrophy within a brain region was predicted by that region's strength of functional connectivity to the temporopolar seed region in healthy adults. These findings suggest that cortical atrophy in semantic variant primary progressive aphasia may follow connectional pathways within a large-scale network that converges on the temporal pole. C1 [Collins, Jessica A.; Hochberg, Daisy; Quimby, Megan; Dickerson, Bradford C.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA. [Montal, Victor] Univ Autonoma Barcelona, Inst Invest Biomed St Pau, Dept Neurol, Hosp St Pau, Barcelona, Spain. [Mandelli, Maria Luisa; Seeley, William W.; Gorno-Tempini, Maria Luisa] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Makris, Nikos] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. [Seeley, William W.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA. RP Collins, JA (reprint author), MGH Frontotemporal Disorders Unit, 149 13th St, Charlestown, MA 02129 USA. EM jcollins21@mgh.harvard.edu FU National Institutes of Health [R21 NS077059, R01 NS050915, P01 AG005134]; National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health; NIH; [S10RR023401]; [S10RR023043]; [S10RR021110] FX This work was supported by the following National Institutes of Health Grants: R21 NS077059, R01 NS050915, P01 AG005134. This research was carried out in whole or in part at the Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital, using resources provided by the Center for Functional Neuroimaging Technologies, P41EB015896, a P41 Biotechnology Resource Grant supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health. This work also involved the use of instrumentation supported by the NIH Shared Instrumentation Grant Program and/ or High-End Instrumentation Grant Program; specifically, grant number(s) S10RR023401, S10RR023043, S10RR021110. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health. NR 109 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 EI 1460-2156 J9 BRAIN JI Brain PD FEB PY 2017 VL 140 BP 457 EP 471 DI 10.1093/brain/aww313 PN 2 PG 15 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EP3XV UT WOS:000397315900027 PM 28040670 ER PT J AU Darby, RR Laganiere, S Pascual-Leone, A Prasad, S Fox, MD AF Darby, R. Ryan Laganiere, Simon Pascual-Leone, Alvaro Prasad, Sashank Fox, Michael D. TI Finding the imposter: brain connectivity of lesions causing delusional misidentifications SO BRAIN LA English DT Article DE Capgras; fregoli; delusions; delusional misidentifications; connectivity ID CAPGRAS DELUSION; PREDICTION ERROR; NETWORKS; RECOGNITION; ATTENTION; RESPONSES; BELIEF; CORTEX; MEMORY; DAMAGE AB Focal brain injury can sometimes lead to bizarre symptoms, such as the delusion that a family member has been replaced by an imposter (Capgras syndrome). How a single brain lesion could cause such a complex disorder is unclear, leading many to speculate that concurrent delirium, psychiatric disease, dementia, or a second lesion is required. Here we instead propose that Capgras and other delusional misidentification syndromes arise from single lesions at unique locations within the human brain connectome. This hypothesis is motivated by evidence that symptoms emerge from sites functionally connected to a lesion location, not just the lesion location itself. First, 17 cases of lesion-induced delusional misidentifications were identified and lesion locations were mapped to a common brain atlas. Second, lesion network mapping was used to identify brain regions functionally connected to the lesion locations. Third, regions involved in familiarity perception and belief evaluation, two processes thought to be abnormal in delusional misidentifications, were identified using meta-analyses of previous functional magnetic resonance imaging studies. We found that all 17 lesion locations were functionally connected to the left retrosplenial cortex, the region most activated in functional magnetic resonance imaging studies of familiarity. Similarly, 16 of 17 lesion locations were functionally connected to the right frontal cortex, the region most activated in functional magnetic resonance imaging studies of expectation violation, a component of belief evaluation. This connectivity pattern was highly specific for delusional misidentifications compared to four other lesion-induced neurological syndromes (P < 0.0001). Finally, 15 lesions causing other types of delusions were connected to expectation violation (P < 0.0001) but not familiarity regions, demonstrating specificity for delusion content. Our results provide potential neuroanatomical correlates for impaired familiarity perception and belief evaluation in patients with delusional misidentifications. More generally, we demonstrate a mechanism by which a single lesion can cause a complex neuropsychiatric syndrome based on that lesion's unique pattern of functional connectivity, without the need for pre-existing or hidden pathology. C1 [Darby, R. Ryan; Laganiere, Simon; Pascual-Leone, Alvaro; Fox, Michael D.] Harvard Med Sch, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA USA. [Darby, R. Ryan; Laganiere, Simon; Pascual-Leone, Alvaro; Fox, Michael D.] Harvard Med Sch, Div Cognit Neurol, Dept Neurol, Beth Israel Deaconess Med Ctr, Boston, MA USA. [Darby, R. Ryan; Fox, Michael D.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA. [Darby, R. Ryan] Harvard Med Sch, McLean Psychiat Hosp, Dept Neurol, Belmont, MA USA. [Prasad, Sashank] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurol, Boston, MA USA. [Fox, Michael D.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. RP Darby, RR (reprint author), Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, 330 Brookline Ave,Kirstein Bldg KS 158, Boston, MA 02215 USA. EM rdarby@bidmc.harvard.edu FU Sidney R. Baer, Jr. Foundation; NIH [R01HD069776, R01NS073601, R21 NS082870, R21 MH099196, R21 NS085491, R21 HD07616, R25NS065743, K23NS083741]; Football Players Health Study at Harvard University; Harvard Catalyst | The Harvard Clinical and Translational Science Center (NCRR and the NCATS NIH) [UL1 RR025758]; American Brain Foundation FX This work was supported by funding from the Sidney R. Baer, Jr. Foundation (R.D., S.L., M.F., A.P.L.), the NIH (R01HD069776, R01NS073601, R21 NS082870, R21 MH099196, R21 NS085491, R21 HD07616 to A.P.L.; R25NS065743, K23NS083741 to M.F.), the Football Players Health Study at Harvard University (A.P.L.), and Harvard Catalyst | The Harvard Clinical and Translational Science Center (NCRR and the NCATS NIH, UL1 RR025758 to A.P.L.), and the American Brain Foundation (M.F.). NR 45 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 EI 1460-2156 J9 BRAIN JI Brain PD FEB PY 2017 VL 140 BP 497 EP 507 DI 10.1093/brain/aww288 PN 2 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EP3XV UT WOS:000397315900030 PM 28082298 ER PT J AU Osborn, HA Glicksman, JT Brandt, MG Doyle, PC Fung, K AF Osborn, Heather Ann Glicksman, Jordan T. Brandt, Michael G. Doyle, Philip C. Fung, Kevin TI Primary care specialty career choice among Canadian medical students Understanding the factors that influence their decisions SO CANADIAN FAMILY PHYSICIAN LA English DT Article ID FAMILY PHYSICIANS AB Objective To identify which factors influence medical students' decision to choose a career in family medicine and pediatrics, and which factors influence their decision to choose careers in non-front-line specialties. Design Survey that was created based on a comprehensive literature review to determine which factors are considered important when choosing practice specialty. Setting Ontario medical school. Participants An open cohort of medical students in the graduating classes of 2008 to 2011 (inclusive). Main outcome measures The main factors that influenced participants' decision to choose a career in primary care or pediatrics, and the main factors that influenced participants' decision to choose a career in a non-frontline specialty. Results A total of 323 participants were included in this study. Factors that significantly influenced participants' career choice in family medicine or pediatrics involved work-life balance (acceptable hours of practice [P =.005], acceptable on-call demands [P =.012], and lifestyle flexibility [P =.006]); a robust physician-patient relationship (ability to promote individual health promotion [P =.014] and the opportunity to form longterm relationships [P <.001], provide comprehensive care [P =.001], and treat patients and their families [P =.006]); and duration of residency program (P =.001). The career-related factors that significantly influenced participants' decision to choose a non-front-line specialty were as follows: becoming an expert (P <.001), maintaining a focused scope of practice (P <.001), having a procedure-focused practice (P =.001), seeing immediate results from one's actions (P <.001), potentially earning a high income (P <.001), and having a perceived status among colleagues (P <.001). Conclusion In this study, 8 factors were found to positively influence medical students' career choice in family medicine and pediatrics, and 6 factors influenced the decision to choose a career in a non-front-line specialty. Medical students can be encouraged to explore a career in family medicine or pediatrics by addressing misinformation, by encouraging realistic expectations of career outcomes in the various specialties, and by demonstrating the capacity of primary care fields to incorporate specific motivating factors. C1 [Osborn, Heather Ann] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Boston, MA USA. [Glicksman, Jordan T.] Univ Penn, Philadelphia, PA USA. [Brandt, Michael G.] Univ Toronto, Dept Otolaryngol Head & Neck Surg, Toronto, ON, Canada. [Doyle, Philip C.] Univ Western Ontario, Sch Commun Sci & Disorders, Dept Otolaryngol Head & Neck Surg, London, ON, Canada. [Fung, Kevin] Univ Western Ontario, Dept Otolaryngol Head & Neck Surg, Dept Oncol, London, ON, Canada. RP Osborn, HA (reprint author), Harvard Med Sch, Massachusetts Eye & Ear Infirm, Boston, MA USA. EM heather_osborn@meei.harvard.edu NR 20 TC 0 Z9 0 U1 0 U2 0 PU COLL FAMILY PHYSICIANS CANADA PI MISSISSAUGA PA 2630 SKYMARK AVE, MISSISSAUGA, ONTARIO L4W 5A4, CANADA SN 0008-350X EI 1715-5258 J9 CAN FAM PHYSICIAN JI Can. Fam. Phys. PD FEB PY 2017 VL 63 IS 2 BP E107 EP E113 PG 7 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA EP1KA UT WOS:000397142600004 PM 28209702 ER PT J AU Doughty, CT Yawetz, S Lyons, J AF Doughty, Christopher T. Yawetz, Sigal Lyons, Jennifer TI Emerging Causes of Arbovirus Encephalitis in North America: Powassan, Chikungunya, and Zika Viruses SO CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS LA English DT Review DE Arboviruses; Encephalitis; Zika virus; Chikungunya virus; Powassan virus ID DEER TICK VIRUS; MALE SEXUAL TRANSMISSION; NEW-ENGLAND DEER; NEW-YORK; REUNION ISLAND; UNITED-STATES; CASE SERIES; LA-REUNION; BORNE FLAVIVIRUSES; AEDES-ALBOPICTUS AB Arboviruses are arthropod-borne viruses transmitted by the bite of mosquitoes, ticks, or other arthropods. Arboviruses are a common and an increasing cause of human illness in North America. Powassan virus, Chikungunya virus, and Zika virus are arboviruses that have all recently emerged as increasing causes of neurologic illness. Powassan virus almost exclusively causes encephalitis, but cases are rare, sporadic, and restricted to portions of North America and Russia. Chikungunya virus has spread widely across the world, causing millions of infections. Encephalitis is a rare manifestation of illness but is more common and severe in neonates and older adults. Zika virus has recently spread through much of the Americas and has been associated mostly with microcephaly and other congenital neurologic complications. Encephalitis occurring in infected adults has also been recently reported. This review will discuss the neuropathogenesis of these viruses, their transmission and geographic distribution, the spectrum of their neurologic manifestations, and the appropriate method of diagnosis. C1 [Doughty, Christopher T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Doughty, Christopher T.; Lyons, Jennifer] Brigham & Womens Hosp, Dept Neurol, Div Neurol Infect & Inflammatory Dis, 45 Francis St, Boston, MA 02115 USA. [Doughty, Christopher T.; Yawetz, Sigal; Lyons, Jennifer] Harvard Med Sch, Boston, MA USA. [Yawetz, Sigal] Brigham & Womens Hosp, Dept Internal Med, Div Infect Dis, Boston, MA 02115 USA. RP Lyons, J (reprint author), Brigham & Womens Hosp, Dept Neurol, Div Neurol Infect & Inflammatory Dis, 45 Francis St, Boston, MA 02115 USA.; Lyons, J (reprint author), Harvard Med Sch, Boston, MA USA. EM jlyons5@partners.org NR 120 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1528-4042 EI 1534-6293 J9 CURR NEUROL NEUROSCI JI Curr. Neurol. Neurosci. Rep. PD FEB PY 2017 VL 17 IS 2 AR 12 DI 10.1007/s11910-017-0724-3 PG 16 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EO9TS UT WOS:000397031600008 PM 28229397 ER PT J AU Hassan, RI Gaffo, AL AF Hassan, Romina I. Gaffo, Angelo L. TI Rituximab in ANCA-Associated Vasculitis SO CURRENT RHEUMATOLOGY REPORTS LA English DT Article DE Rituximab. Vasculitis; ANCA; Granulomatosis with polyangiitis (GPA); Microscopic polyangiitis (MPA); Eosinophilicgranulomatosiswith polyangiitis (EGPA) ID ANTIBODY-ASSOCIATED VASCULITIS; WEGENERS-GRANULOMATOSIS; RANDOMIZED-TRIAL; RENAL VASCULITIS; PLASMA-EXCHANGE; CYCLOPHOSPHAMIDE; INDUCTION; REMISSION; THERAPY; MAINTENANCE AB Purpose of Review The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and maintenance therapy in ANCA-associated vasculitis (AAV). Recent Findings A PubMed search was carried out to track down articles published between February 2006 and February 2016. Randomized controlled trials (RCTs) that encompassed patients with AAV were included. The American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) 2014-2015 online abstracts were also reviewed whether they were RTCs or not. Ten PubMed RCTs were analyzed along with eight ACR and four EULAR abstracts. RTX was not inferior to cyclophosphamide (CYC) for remission induction in AAV; it was superior to CYC in patients with relapsing disease and superior for remission maintenance in comparison with azathioprine (AZA). Summary Rituximab is a therapeutic option to induce and maintain remission in patients with AAV. C1 [Hassan, Romina I.] JM Ramos Mejia Hosp, Div Rheumatol, 609 Gen Urquiza St, RA-1221 Buenos Aires, DF, Argentina. [Gaffo, Angelo L.] Birmingham VA Med Ctr, 700 19th St S, Birmingham, AL 35233 USA. [Gaffo, Angelo L.] Univ Alabama Birmingham, Div Rheumatol & Clin Immunol, 1825 Univ Blvd,SHEL 306, Birmingham, AL 35294 USA. RP Hassan, RI (reprint author), JM Ramos Mejia Hosp, Div Rheumatol, 609 Gen Urquiza St, RA-1221 Buenos Aires, DF, Argentina. EM rominahassan@gmail.com NR 35 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3774 EI 1534-6307 J9 CURR RHEUMATOL REP JI Curr. Rheumatol. Rep. PD FEB PY 2017 VL 19 IS 2 AR 6 DI 10.1007/s11926-017-0632-1 PG 8 WC Rheumatology SC Rheumatology GA EP0XM UT WOS:000397110000004 PM 28155022 ER PT J AU O'Malley, BW Crowley, WF AF O'Malley, Bert W. Crowley, William F. TI In Memoriam, P. Michael Conn, PhD (1949-2016) SO ENDOCRINOLOGY LA English DT Biographical-Item C1 [O'Malley, Bert W.] Baylor Coll Med, Mol & Cellular Biol, Houston, TX 77030 USA. [Crowley, William F.] Harvard Med Sch, Massachusetts Gen Hosp, Reprod Endocrine Unit, Harvard Reprod Endocrine Sci Ctr,Dept Med, Boston, MA 02114 USA. RP O'Malley, BW (reprint author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA. EM berto@bcm.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD FEB PY 2017 VL 158 IS 2 BP 197 EP 198 DI 10.1210/en.2016-1906 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EP0UH UT WOS:000397101700001 ER PT J AU Hogan, MF Liu, AW Peters, MJ Willard, JR Rabbani, Z Bartholomew, EC Ottley, A Hull, RL AF Hogan, Meghan F. Liu, Amy W. Peters, Michael J. Willard, Joshua R. Rabbani, Zaheen Bartholomew, Erik C. Ottley, Adam Hull, Rebecca L. TI Markers of Islet Endothelial Dysfunction Occur in Male B6.BKS(D)- Lepr(db)/J Mice and May Contribute to Reduced Insulin Release SO ENDOCRINOLOGY LA English DT Article ID GLYCATION END-PRODUCTS; PANCREATIC BETA-CELL; DIABETES-MELLITUS; OXIDATIVE STRESS; BLOOD-VESSELS; DB/DB MICE; IN-VITRO; EXPRESSION; MOUSE; RATS AB Islet endothelial cells produce paracrine factors that support beta-cell function and growth. Endothelial dysfunction underlies diabetic microvascular complications; thus, we hypothesized that in diabetes, islet endothelial cells become dysfunctional, which may contribute to beta-cell secretory dysfunction. Islets/islet endothelial cells were isolated from diabetic B6.BKS(D)-Lepr(db)/J male (db/db) mice, treated with or without the glucose-lowering agent phlorizin, or from C57BL/6J mice fed a high-fat diet for 18 weeks and appropriate controls. Messenger RNA(mRNA) and/or the protein levels of the cell adhesion molecule E-selectin (Sele), proinflammatory cytokine interleukin-6 (II6), vasoconstrictor endothelin-1 (Edn1), and endothelial nitric oxide synthase (Nos3; Nos3) were evaluated, alongwith advanced glycation end product immunoreactivity. Furthermore, an islet endothelial cell line(MS-1) was exposed to diabetic factors (glucose, palmitate, insulin, and tumor necrosis factor-a) for six days. Conditioned media were collected from these cells, incubated with isolated islets, and glucose-stimulated insulin secretion and insulin content were assessed. Islet endothelial cells from db/db mice exhibited increased Sele, II6, and Edn1 mRNA levels, decreased Nos3 protein, and accumulation of advanced glycation end products. Phlorizin treatment significantly increased Nos3 protein levels but did not alter expression of the other markers. High-fat feeding in C57BL/6J mice resulted in increased islet Sele, II6, andEdn1 but no change in Nos3. Exposure of islets to conditionedmedia from MS-1 cells cultured in diabetic conditions resulted in a 50% decrease in glucose-stimulated insulin secretion and 30% decrease in insulin content. These findings demonstrate that, in diabetes, islet endothelial cells show evidence of a dysfunctional phenotype, which may contribute to loss of beta-cell function. C1 [Hogan, Meghan F.; Liu, Amy W.; Peters, Michael J.; Willard, Joshua R.; Rabbani, Zaheen; Hull, Rebecca L.] Vet Affairs Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Hogan, Meghan F.; Liu, Amy W.; Rabbani, Zaheen; Bartholomew, Erik C.; Ottley, Adam; Hull, Rebecca L.] Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Hull, RL (reprint author), Vet Affairs Puget Sound Hlth Care Syst 151, 1660 South Columbian Way, Seattle, WA 98108 USA. EM rhull@uw.edu FU Department of Veterans Affairs, Veterans Affairs Puget Sound Health Care System; National Institutes of Health (University of Washington Diabetes Research Center) [R01DK088082, P30DK017047]; University of Washington Royalty Research; HHMI Medical Research Fellows Program; National Institute of Diabetes and Digestive Kidney Diseases Medical Research Program in Diabetes [T32 DK007247]; University of Washington Medical Student Research Training Program; [T32HL007028]; [F32DK109584] FX This work was supported by the Department of Veterans Affairs, Veterans Affairs Puget Sound Health Care System (Seattle, WA), National Institutes of Health grants R01DK088082 (R.L.H.) and P30 DK017047 (University of Washington Diabetes Research Center), and a University of Washington Royalty Research Fund Award. A.W.L. was supported by the HHMI Medical Research Fellows Program and the National Institute of Diabetes and Digestive and Kidney Diseases Medical Research Program in Diabetes through grant T32 DK007247. M.F.H. was supported by grants T32 HL007028 and F32 DK109584. Z.R., A.O., and E.C.B. were supported by the University of Washington Medical Student Research Training Program and the National Institute of Diabetes and Digestive and Kidney Diseases Medical Research Program in Diabetes through T32 DK007247. NR 41 TC 1 Z9 1 U1 0 U2 0 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD FEB PY 2017 VL 158 IS 2 BP 293 EP 303 DI 10.1210/en.2016-1393 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EP0UH UT WOS:000397101700012 PM 27870582 ER PT J AU Kessler, RC van Loo, HM Wardenaar, KJ Bossarte, RM Brenner, LA Ebert, DD de Jonge, P Nierenberg, AA Rosellini, AJ Sampson, NA Schoevers, RA Wilcox, MA Zaslavsky, AM AF Kessler, R. C. van Loo, H. M. Wardenaar, K. J. Bossarte, R. M. Brenner, L. A. Ebert, D. D. de Jonge, P. Nierenberg, A. A. Rosellini, A. J. Sampson, N. A. Schoevers, R. A. Wilcox, M. A. Zaslavsky, A. M. TI Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder SO EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES LA English DT Article DE Depression; epidemiology; evidence-based psychiatry; research design and methods; treatment allocation ID RANDOMIZED CONTROLLED-TRIAL; COLLABORATIVE RESEARCH-PROGRAM; SEROTONIN REUPTAKE INHIBITORS; COGNITIVE-BEHAVIORAL THERAPY; LATE-LIFE DEPRESSION; LONG-TERM COURSE; PSYCHOTHERAPY-PHARMACOTHERAPY COMBINATIONS; RECURSIVE PARTITIONING ANALYSIS; NATIONAL-COMORBIDITY-SURVEY; INTERPERSONAL PSYCHOTHERAPY AB Backgrounds. Clinicians need guidance to address the heterogeneity of treatment responses of patients with major depressive disorder (MDD). While prediction schemes based on symptom clustering and biomarkers have so far not yielded results of sufficient strength to inform clinical decision-making, prediction schemes based on big data predictive analytic models might be more practically useful. Method. We review evidence suggesting that prediction equations based on symptoms and other easily- assessed clinical features found in previous research to predict MDD treatment outcomes might provide a foundation for developing predictive analytic clinical decision support models that could help clinicians select optimal (personalised) MDD treatments. These methods could also be useful in targeting patient subsamples for more expensive biomarker assessments. Results. Approximately two dozen baseline variables obtained from medical records or patient reports have been found repeatedly in MDD treatment trials to predict overall treatment outcomes (i. e., intervention nu. control) or differential treatment outcomes (i. e., intervention A v. intervention B). Similar evidence has been found in observational studies of MDD persistence-severity. However, no treatment studies have yet attempted to develop treatment outcome equations using the full set of these predictors. Promising preliminary empirical results coupled with recent developments in statistical methodology suggest that models could be developed to provide useful clinical decision support in personalised treatment selection. These tools could also provide a strong foundation to increase statistical power in focused studies of biomarkers and MDD heterogeneity of treatment response in subsequent controlled trials. Conclusions. Coordinated efforts are needed to develop a protocol for systematically collecting information about established predictors of heterogeneity of MDD treatment response in large observational treatment studies, applying and refining these models in subsequent pragmatic trials, carrying out pooled secondary analyses to extract the maximum amount of information from these coordinated studies, and using this information to focus future discovery efforts in the segment of the patient population in which continued uncertainty about treatment response exists. C1 [Kessler, R. C.; Ebert, D. D.; Rosellini, A. J.; Sampson, N. A.; Zaslavsky, A. M.] Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA. [van Loo, H. M.; Wardenaar, K. J.; de Jonge, P.; Schoevers, R. A.] Univ Groningen, Univ Med Ctr Groningen, Interdisciplinary Ctr Psychopathol & Emot Regulat, Groningen, Netherlands. [Bossarte, R. M.] Off Publ Hlth, Dept Vet Affairs, Washington, DC USA. [Brenner, L. A.] Univ Colorado, VISN Mental Illness Res Educ & Clin Ctr 19, Anschutz Med Campus, Anschulz, CO USA. [Ebert, D. D.] Friedrich Alexander Univ Nuremberg Erlangen, Dept Psychol Clin Psychol & Psychotherapy, Erlangen, Germany. [Nierenberg, A. A.] Harvard Med Sch, Dept Psychiat, Boston, MA USA. [Nierenberg, A. A.] Harvard Med Sch, Depress Clin & Res Program, Boston, MA USA. [Nierenberg, A. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wilcox, M. A.] Janssen Res & Dev, Dept Epidemiol, Titusville, NJ USA. RP Kessler, RC (reprint author), Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA. EM Kessler@hcp.med.harvard.edu FU National Institute of Mental Health(NIMH) [R01MH46376, R01MH070884]; National Institute on Drug Abuse(NIDA) [R01DA012058]; Netherlands organisation for Scientific research (NWO-ZonMW) [91812607]; John D. and Catherine T. MacArthur Foundation; US Public Health Service [R13MH066849, R01MH069864, R01DA016558]; Pfizer Foundation; Fogarty International Center (FIRCA) [R03TW006481]; Pan American Health Organization; Eli Lilly and Company; Ortho-McNeil Pharmaceutical, Inc.; GlaxoSmithKline; Bristol-Myers Squibb; Janssen Pharmaceuticals FX The NCS data collection was supported by the National Institute of Mental Health (NIMH; R01MH46376). The NCS-2 data collection was supported by the National Institute on Drug Abuse (NIDA; R01DA012058). Dr de Jonge was supported by a VICI grant (no. 91812607) from the Netherlands organisation for Scientific research (NWO-ZonMW). The NCS surveys were carried out in conjunction with the World Health Organization World Mental Health (WMH) Survey Initiative, which was supported by the National Institute of Mental Health (R01MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the US Public Health Service (R13MH066849, R01MH069864 and R01DA016558), the Fogarty International Center (FIRCA R03TW006481), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical, Inc., GlaxoSmithKline, and Bristol-Myers Squibb. Dr de Jonge was supported by a VICI grant (no. 91812607) from the Netherlands organization for Scientific research (NWO-ZonMW). Preparation of this report was supported by Janssen Pharmaceuticals. NR 136 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 2045-7960 EI 2045-7979 J9 EPIDEMIOL PSYCH SCI JI Epidemiol. Psychiatr. Sci. PD FEB PY 2017 VL 26 IS 1 BP 22 EP 36 DI 10.1017/S2045796016000020 PG 15 WC Psychiatry SC Psychiatry GA EP0OJ UT WOS:000397086300006 PM 26810628 ER PT J AU Kopans, DB AF Kopans, Daniel B. TI More misinformation on breast cancer screening SO GLAND SURGERY LA English DT Article DE Mammography; breast; breast cancer; screening ID CARCINOMA MORTALITY; TUMOR SIZE; MAMMOGRAPHY; WOMEN; REDUCTION; UPDATE; TRENDS; IMPACT; RISK; US AB Unfortunately, a great deal of misinformation has accumulated in the breast cancer screening literature that is based on flawed analyses in an effort to reduce access to screening. Quite remarkably, much of this has come from publications in previously highly respected medical journals. In several papers the intervention (mammography screening) is faulted yet the analyses provided no data on who participated in mammography screening, and which cancers were detected by mammography screening. It is remarkable that a highly respected journal can fault an intervention with no data on the intervention. Claims of massive over diagnosis of invasive breast cancer due to breast cancer screening have been made using "guesses" that have no scientific basis. No one has ever seen a mammographically detected, invasive breast cancer, disappear on its own, yet analysts have claimed that this occurs thousands of times each year. In fact, the" miraculous" resolution, without intervention, of a handful of breast cancers have all been palpable cancers, yet there is no suggestion to stop treating palpable cancers. A review of several publications in the New England Journal of Medicine shows some of the flaws in these analyses. There is clearly a problem with peer review that is allowing scientifically unsupportable material, which is misleading women and their physicians, to be published in prestigious journals. C1 [Kopans, Daniel B.] Harvard Med Sch Boston, Boston, MA USA. RP Kopans, DB (reprint author), Harvard Med Sch, Radiol, 20 Manitoba Rd, Waban, MA 02468 USA.; Kopans, DB (reprint author), Massachusetts Gen Hosp, Breast Imaging Div, 20 Manitoba Rd, Waban, MA 02468 USA. EM dkopans@partners.org NR 33 TC 0 Z9 0 U1 0 U2 0 PU AME PUBL CO PI SHEUNG WAN PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG 00000, PEOPLES R CHINA SN 2227-684X EI 2227-8575 J9 GLAND SURG JI Gland Surg. PD FEB PY 2017 VL 6 IS 1 BP 125 EP 129 DI 10.21037/gs.2016.12.15 PG 5 WC Surgery SC Surgery GA EP2YB UT WOS:000397248400019 PM 28210564 ER PT J AU Khodyakov, D Stockdale, SE Smith, N Booth, M Altman, L Rubenstein, LV AF Khodyakov, Dmitry Stockdale, Susan E. Smith, Nina Booth, Marika Altman, Lisa Rubenstein, Lisa V. TI Patient engagement in the process of planning and designing outpatient care improvements at the Veterans Administration Health-care System: findings from an online expert panel SO HEALTH EXPECTATIONS LA English DT Article DE ExpertLens; modified Delphi; online expert panel; patient engagement; quality improvement; VA ID QUALITY-IMPROVEMENT; PUBLIC INVOLVEMENT; DECISION-MAKING; SERVICES; PARTICIPATION; STRATEGIES; FRAMEWORK; CANCER AB Context There is a strong interest in the Veterans Administration (VA) Health-care System in promoting patient engagement to improve patient care. Methods We solicited expert opinion using an online expert panel system with a modified Delphi structure called ExpertLens (TM). Experts reviewed, rated and discussed eight scenarios, representing four patient engagement roles in designing and improving VA outpatient care (consultant, implementation advisor, equal stakeholder and lead stakeholder) and two VA levels (local and regional). Rating criteria included desirability, feasibility, patient ability, physician/ staff acceptance and impact on patient-centredness and care quality. Data were analysed using the RAND/UCLA Appropriateness Method for determining consensus. Findings Experts rated consulting with patients at the local level as the most desirable and feasible patient engagement approach. Engagement at the local level was considered more desirable than engagement at the regional level. Being an equal stakeholder at the local level received the highest ratings on the patient-centredness and health-care quality criteria. Conclusions Our findings illustrate expert opinion about different approaches to patient engagement and highlight the benefits and challenges posed by each. Although experts rated local consultations with patients on an as-needed basis as most desirable and feasible, they rated being an equal stakeholder at the local level as having the highest potential impact on patient-centredness and care quality. C1 [Khodyakov, Dmitry; Booth, Marika; Rubenstein, Lisa V.] RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA. [Stockdale, Susan E.; Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst 152, Ctr Study Healthcare Innovat Implementat & Policy, Med & Publ Hlth, VISN Vet Assessment & Improvement PACT Demonstrat, Los Angeles, CA USA. [Smith, Nina] VA Greater Los Angeles Healthcare Syst 152, Ctr Implementat Practice & Res Support CIPRS, Los Angeles, CA USA. [Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst 152, Ctr Implementat Practice & Res Support CIPRS, Med & Publ Hlth, Los Angeles, CA USA. [Altman, Lisa] VA Greater Los Angeles Healthcare Syst GLA, Off Healthcare Transformat & Innovat, Healthcare Transformat, Los Angeles, CA USA. [Stockdale, Susan E.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Altman, Lisa] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Khodyakov, D (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA. EM Dmitry_Khodyakov@rand.org FU VA Office of Patient-Centered Care and Cultural Transformation; VA Quality Enhancement and Research Initiative's (QUERI's) Center for Implementation Practice and Research Support (CIPRS) [TRA 08-379] FX This study is co-funded by the VA Office of Patient-Centered Care and Cultural Transformation and the VA Quality Enhancement and Research Initiative's (QUERI's) Center for Implementation Practice and Research Support (CIPRS) grant number TRA 08-379. NR 48 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1369-6513 EI 1369-7625 J9 HEALTH EXPECT JI Health Expect. PD FEB PY 2017 VL 20 IS 1 BP 130 EP 145 DI 10.1111/hex.12444 PG 16 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EP0PK UT WOS:000397089000013 PM 26914249 ER PT J AU Rozen, G Ptaszek, L Zilberman, I Cordaro, K Heist, EK Beeckler, C Altmann, A Ying, Z Liu, ZJ Ruskin, JN Govari, A Mansour, M AF Rozen, Guy Ptaszek, Leon Zilberman, Israel Cordaro, Kevin Heist, E. Kevin Beeckler, Christopher Altmann, Andres Ying, Zhang Liu, Zhenjiang Ruskin, Jeremy N. Govari, Assaf Mansour, Moussa TI Prediction of radiofrequency ablation lesion formation using a novel temperature sensing technology incorporated in a force sensing catheter SO HEART RHYTHM LA English DT Article DE Radiofrequency; Catheter ablation; Lesion assessment; Contact force sensing; Catheter orientation; Thermocouple ID PULMONARY VEIN ISOLATION; TIME CONTACT FORCE; ATRIAL-FIBRILLATION; TISSUE TEMPERATURE; IMPEDANCE DECREASE; TIP ABLATION; ELECTRODE; FEASIBILITY; ARRHYTHMIAS; INSIGHTS AB BACKGROUND Real-time radiofrequency (RF) ablation lesion assessment is a major unmet need in cardiac electrophysiology. OBJECTIVE The purpose of this study was to assess whether improved temperature measurement using a novel thermocoupling (TC) technology combined with information derived from impedance change, contact force (CF) sensing, and catheter orientation allows accurate real-time prediction of ablation lesion formation. METHODS RF ablation lesions were delivered in the ventricles of 15 swine using a novel externally irrigated-tip catheter containing 6 miniature TC sensors in addition to force sensing technology. Ablation duration, power, irrigation rate, impedance drop, CF, and temperature from each sensor were recorded. The catheter "orientation factor" was calculated using measurements from the different TC sensors. Information derived from all the sources was included in a mathematical model developed to predict lesion depth and validated against histologic measurements. RESULTS A total of 143 ablation lesions were delivered to the left ventricle (n = 74) and right ventricle (n = 69). Mean CF applied during the ablations was 14.34 +/- 3.55g, and mean impedance drop achieved during the ablations was 17.5 +/- 6.41 ohm. Mean difference between predicted and measured ablation lesion depth was 0.72 +/- 0.56 mm. In the majority of lesions (91.6%), the difference between estimated and measured depth was <= 1.5 mm. CONCLUSION Accurate real-time prediction of RF lesion depth is feasible using a novel ablation catheter-based system in conjunction with a mathematical prediction model, combining elaborate temperature measurements with information derived from catheter orientation, CF sensing, impedance change, and additional ablation parameters. C1 [Rozen, Guy; Ptaszek, Leon; Cordaro, Kevin; Heist, E. Kevin; Ying, Zhang; Liu, Zhenjiang; Ruskin, Jeremy N.; Mansour, Moussa] Massachusetts Gen Hosp, Ctr Heart, Boston, MA 02114 USA. [Zilberman, Israel; Beeckler, Christopher; Altmann, Andres; Govari, Assaf] Biosense Webster Inc, Diamond Bar, CA USA. RP Mansour, M (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, GRB 109,55 Fruit St, Boston, MA 02114 USA. EM mmansour@mgh.harvard.edu FU Biosense Webster; Deane Institute for Integrative Research in Atrial Fibrillation; Stroke at the Massachusetts General Hospital FX The study was funded by a research grant from Biosense Webster and Deane Institute for Integrative Research in Atrial Fibrillation and Stroke at the Massachusetts General Hospital. Dr. Zilberman, Christopher Beeckler, Andres Altmann, and Dr. Govari are employees of Biosense Webster. Dr. Ruskin received consulting fees/honoraria from- Cardioinsight, Medtronic Inc. Dr. Mansour received consulting fees/honoraria - Biosense Webster, Inc., St. Jude Medical, Sentreheart. Research grants: Biosense Webster, Inc., St. Jude Medical, Boston Scientific Corp. Drs. Rozen and Ptaszek contributed equally to this study and manuscript preparation. Address reprint requests and correspondence: Dr. Moussa Mansour, Cardiac Arrhythmia Service, Massachusetts General Hospital, GRB 109, 55 Fruit St, Boston, MA02114. NR 32 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1547-5271 EI 1556-3871 J9 HEART RHYTHM JI Heart Rhythm PD FEB PY 2017 VL 14 IS 2 BP 248 EP 254 DI 10.1016/j.hrthm.2016.11.013 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EP2WD UT WOS:000397243400018 PM 28104089 ER PT J AU Tucker, NR Mahida, S Ye, JC Abraham, EJ Mina, JA Parsons, VA McLellan, MA Shea, MA Hanley, A Benjamin, EJ Milan, DJ Lin, HH Ellinor, PT AF Tucker, Nathan R. Mahida, Saagar Ye, Jiangchuan Abraham, Elizabeth J. Mina, Julie A. Parsons, Victoria A. McLellan, Michael A. Shea, Marisa A. Hanley, Alan Benjamin, Emelia J. Milan, David J. Lin, Honghuang Ellinor, Patrick T. TI Gain-of-function mutations in GATA6 lead to atrial fibrillation SO HEART RHYTHM LA English DT Article DE Atrial fibrillation; Mutation; Transcription factor; Genetics ID TRANSCRIPTION FACTORS; FAMILIAL AGGREGATION; GENETIC-VARIATION; HEART; EXPRESSION; VARIANTS; ENHANCER; DEFECTS AB BACKGROUND The genetic basis of atrial fibrillation (AF) and congenital heart disease remains incompletely understood. OBJECTIVE We sought to determine the causative mutation in a family with AF, atrial septal defects, and ventricular septal defects. METHODS We evaluated a pedigree with 16 family members, 1 with an atrial septal defect, 1 with a ventricular septal defect, and 3 with AF; we performed whole exome sequencing in 3 affected family members. Given that early-onset AF was prominent in the family, we then screened individuals with early-onset AF, defined as an age of onset <66 years, for mutations in GATA6. Variants were functionally characterized using reporter assays in a mammalian cell line. RESULTS Exome sequencing in 3 affected individuals identified a conserved mutation, R585L, in the transcription factor gene GATA6. In the Massachusetts General Hospital Atrial Fibrillation (MGH AF) Study, the mean age of AF onset was 47.1 +/- 10.9 years; 79% of the participants were men; and there was no evidence of structural heart disease. We identified 3 GATA6 variants (P91S, A177T, and A543G). Using wild-type and mutant GATA6 constructs driving atrial natriuretic peptide promoter reporter, we found that 3 of the 4 variants had a marked upregulation of luciferase activity (R585L: 4.1-fold, P<.0001; P91S: 2.5-fold, P=.0002; A177T; 1.7-fold, P=.03). In addition, when co-overexpressed with GATA4 and MEF2C, GATA6 variants exhibited upregulation of the alpha myosin heavy chain and atrial natriuretic peptide reporter activity. CONCLUSION Overall, we found gain-of-function mutations in GATA6 in both a family with early-onset AF and atrioventricular septal defects as well as in a family with sporadic, early-onset AF. C1 [Shea, Marisa A.; Milan, David J.; Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Benjamin, Emelia J.] NHLBI, Framingham, MA USA. [Benjamin, Emelia J.] Boston Univ, Framingham Heart Study, Framingham, MA USA. [Benjamin, Emelia J.] Boston Univ, Sch Med, Dept Med, Prevent Med & Cardiovasc Med Sect, Boston, MA 02215 USA. [Lin, Honghuang] Boston Univ, Sch Med, Dept Med, Computat Biomed Sect, Boston, MA 02215 USA. RP Ellinor, PT (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, 55 Fruit St,Gray109, Boston, MA 02114 USA. EM ellinor@mgh.harvard.edu FU Bayer Healthcare FX The first 2 authors contributed equally to this work. Dr Ellinor is a principal investigator of a grant from Bayer Healthcare to the Broad Institute. NR 30 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1547-5271 EI 1556-3871 J9 HEART RHYTHM JI Heart Rhythm PD FEB PY 2017 VL 14 IS 2 BP 284 EP 291 DI 10.1016/j.hrthm.2016.10.014 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EP2WD UT WOS:000397243400024 PM 27756709 ER PT J AU Su, F Green, PK Berry, K Ioannou, GN AF Su, Feng Green, Pamela K. Berry, Kristin Ioannou, George N. TI The Association Between Race/Ethnicity and the Effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection SO HEPATOLOGY LA English DT Article ID GENOTYPE 1 INFECTION; SUSTAINED VIROLOGICAL RESPONSE; SIMEPREVIR PLUS SOFOSBUVIR; HEPATOCELLULAR-CARCINOMA; CHRONIC HCV; PEGINTERFERON ALPHA-2A; TREATMENT-NAIVE; BLACK PATIENTS; LIVER-DISEASE; US VETERANS AB Black race and Hispanic ethnicity were associated with lower rates of sustained virologic response (SVR) to interferonbased treatments for chronic hepatitis C virus infection, whereas Asian race was associated with higher SVR rates compared to white patients. We aimed to describe the association between race/ ethnicity and effectiveness of new direct-acting antiviral regimens in the Veterans Affairs health care system nationally. We identified 21,095 hepatitis C virus-infected patients (11,029 [52%] white, 6,171 [29%] black, 1,187 [6%] Hispanic, 348 [2%] Asian/ Pacific Islander/ American Indian/ Alaska Native, and 2,360 [11%] declined/ missing race or ethnicity) who initiated antiviral treatment with regimens containing sofosbuvir, simeprevir + sofosbuvir, ledipasvir/ sofosbuvir, or paritaprevir/ ombitasvir/ ritonavir/ dasabuvir during the 18-month period from January 1, 2014, to June 30, 2015. Overall SVR rates were 89.8% (95% confidence interval [CI] 89.2-90.4) in white, 89.8% (95% CI 89.0-90.6) in black, 86.0% (95% CI 83.7-88.0) in Hispanic, and 90.7% (95% CI 87.0-93.5) in Asian/ Pacific Islander/ American Indian/ Alaska Native patients. However, after adjustment for baseline characteristics, black (adjusted odds ratio 5 0.77, P < 0.001) and Hispanic (adjusted odds ratio = 0.76, P = 0.007) patients were less likely to achieve SVR than white patients, a difference that was not explained by early treatment discontinuations. Among genotype 1-infected patients treated with ledipasvir/ sofosbuvir monotherapy, black patients had significantly lower SVR than white patients when treated for 8 weeks but not when treated for 12 weeks. Conclusion: Direct-acting antivirals produce high SVR rates in white, black, Hispanic, and Asian/ Pacific Islander/ American Indian/ Alaska Native patients; but after adjusting for baseline characteristics, black race and Hispanic ethnicity remain independent predictors of treatment failure. Short 8-week ledipasvir/ sofosbuvir monotherapy regimens should perhaps be avoided in black patients with genotype 1 hepatitis C virus. C1 [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, S-111Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, S-111Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU Clinical Science Research and Development, Office of Research and Development, US Department of Veterans Affairs [I01CX000320, I01CX001156] FX Supported by Clinical Science Research and Development, Office of Research and Development, US Department of Veterans Affairs (Merit Review grants I01CX000320 and I01CX001156, to G. N. I.). NR 48 TC 1 Z9 1 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD FEB PY 2017 VL 65 IS 2 BP 426 EP 438 DI 10.1002/hep.28901 PG 13 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EP3RZ UT WOS:000397300700007 PM 27775854 ER PT J AU Jarraya, M Diaz, LE Arndt, WF Roemer, FW Guermazi, A AF Jarraya, Mohamed Diaz, Luis E. Arndt, William F. Roemer, Frank W. Guermazi, Ali TI Imaging of patellar fractures SO INSIGHTS INTO IMAGING LA English DT Review DE Patella; Fracture; Extensor mechanism rupture; Conventional radiograph; MRI ID DORSAL DEFECT; KNEE; BIPARTITE AB Patellar fractures account for approximately 1% of all skeletal fractures and may result from direct, indirect, or combined trauma. Because of the importance of patellar integrity for knee extension and the risk of associated injury to the extensor mechanism, accurate reporting and description of fracture type is paramount for appropriate management. This pictorial essay aims to review the normal anatomy of the patella, the mechanisms of injury and different types of patellar fractures, with a brief introduction to therapeutic management. Teaching Points Patellar fractures are classified according to their morphology and degree of displacement. Direct trauma results in stellate fractures. Indirect trauma results in transverse fractures. Displacement should raise suspicion for retinacular injury. C1 [Jarraya, Mohamed] Mercy Catholic Med Ctr, Dept Radiol, 1500 Lansdowne Ave, Darby, PA 19023 USA. [Jarraya, Mohamed; Guermazi, Ali] Boston Univ, Sch Med, Dept Radiol, Boston, MA 02118 USA. [Diaz, Luis E.; Arndt, William F.] VA Boston Healthcare Syst, Dept Radiol, Boston, MA USA. [Roemer, Frank W.] Univ Erlangen Nurnberg, Dept Radiol, Erlangen, Germany. RP Jarraya, M (reprint author), Mercy Catholic Med Ctr, Dept Radiol, 1500 Lansdowne Ave, Darby, PA 19023 USA.; Jarraya, M (reprint author), Boston Univ, Sch Med, Dept Radiol, Boston, MA 02118 USA. EM mohamedjarraya@gmail.com NR 22 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1869-4101 J9 INSIGHTS IMAGING JI Insights Imaging PD FEB PY 2017 VL 8 IS 1 BP 49 EP 57 DI 10.1007/s13244-016-0535-0 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EP2WV UT WOS:000397245200005 PM 27905071 ER PT J AU Karamouzian, M Madani, N Doroudi, F Haghdoost, AA AF Karamouzian, Mohammad Madani, Navid Doroudi, Fardad Haghdoost, Ali Akbar TI Improving the Quality and Quantity of HIV Data in the Middle East and North Africa: Key Challenges and Ways Forward SO INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT LA English DT Editorial Material DE Data; Middle East and North Africa (MENA) ID HIV/AIDS; IRAN; SURVEILLANCE; PREVALENCE; REGION AB Although the HIV pandemic is witnessing a decline in the number of new infections in most regions of the world, the Middle East and North Africa (MENA) has a rapidly growing HIV problem. While generating HIV data has been consistently increasing since 2005, MENA's contribution to the global HIV literature is just over 1% and the existing evidence often falls behind the academic standards. Several factors could be at play that contribute to the limited quantity and quality of HIV data in MENA. This editorial tries to explore and explain the barriers to collecting high-quality HIV data and generating precise estimates in MENA. These barriers include a number of logistic and socio-political challenges faced by researchers, public health officials, and policy-makers. Looking at successful regional HIV programs, we explore examples were policies have shifted and lessons could be learned in developing appropriate responses to HIV across the region. C1 [Karamouzian, Mohammad; Haghdoost, Ali Akbar] Kerman Univ Med Sci, HIV STI Surveillance Res Ctr, Kerman, Iran. [Karamouzian, Mohammad; Haghdoost, Ali Akbar] Kerman Univ Med Sci, WHO Collaborating Ctr HIV Surveillance, Inst Futures Studies Hlth, Kerman, Iran. [Karamouzian, Mohammad] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada. [Madani, Navid] Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Immunol & Virol, Dept Global Hlth & Social Med, Boston, MA USA. [Doroudi, Fardad] UNAIDS, Tehran, Iran. RP Haghdoost, AA (reprint author), Kerman Univ Med Sci, HIV STI Surveillance Res Ctr, Kerman, Iran.; Haghdoost, AA (reprint author), Kerman Univ Med Sci, WHO Collaborating Ctr HIV Surveillance, Inst Futures Studies Hlth, Kerman, Iran. EM ahaghdoost@kmu.ac.ir NR 32 TC 0 Z9 0 U1 0 U2 0 PU KERMAN UNIV MEDICAL SCIENCES PI KERMAN PA JAHAD BLVD, KERMAN, 7619813159, IRAN SN 2322-5939 J9 INT J HEALTH POLICY JI Int. J. Health Policy Manag. PD FEB PY 2017 VL 6 IS 2 BP 65 EP 69 DI 10.15171/ijhpm.2016.112 PG 5 WC Health Policy & Services SC Health Care Sciences & Services GA EO9WX UT WOS:000397039900001 ER PT J AU Economopoulos, KP Mylonas, KS Stamou, AA Theocharidis, V Sergentanis, TN Psaltopoulou, T Richards, ML AF Economopoulos, Konstantinos P. Mylonas, Konstantinos S. Stamou, Aliki A. Theocharidis, Vasileios Sergentanis, Theodoros N. Psaltopoulou, Theodora Richards, Melanie L. TI Laparoscopic versus robotic adrenalectomy: A comprehensive meta-analysis SO INTERNATIONAL JOURNAL OF SURGERY LA English DT Review DE Laparoscopic adrenalectomy; Robot-assisted adrenalectomy; Robotic adrenalectomy; Meta-analysis ID POSTERIOR RETROPERITONEOSCOPIC ADRENALECTOMY; LUIS FELIPE BRANDAO; EUR UROL 2014; TRANSPERITONEAL ADRENALECTOMY; RICCARDO AUTORINO; CUSHINGS-SYNDROME; HUMBERTO LAYDNER; EXPERIENCE; PHEOCHROMOCYTOMA; OUTCOMES AB Background: The benefit of robotic adrenalectomy (RA) compared to laparoscopic adrenalectomy (LA) is still debatable. The purpose of this paper was to systematically review and synthesize all available evidence comparing RA to LA so as to evaluate which procedure provides superior clinical outcomes. Methods: A systematic literature search of PubMed and Scopus databases was performed with respect to the PRISMA statement (end-of-search date: January 31, 2016). Data on perioperative variables were extracted by three independent reviewers. Data were pooled using a random-effects model. Results: Twenty-seven studies were included in this review (13 comparative and 14 non-comparative). Overall, 1162 patients underwent adrenalectomy (747 treated with RA and 415 with LA). There was no significant difference between the robotic and the laparoscopic groups for intraoperative complications (OR: 1.20; 95% CI, 0.33-4.38), postoperative complications (OR: 0.69; 95% CI, 0.36-1.31), mortality (OR: 0.42; 95% CI, 0.07-2.72), conversion to laparotomy (OR: 0.51; 95% CI, 0.21-1.23), conversion to laparotomy or laparoscopy (OR: 0.73; 95% CI, 0.32-1.69) and blood loss (WMD: -9.78; 95%, -22.10 to 2.53). For patients treated with RA, there was a significantly shorter hospital stay (WMD: -0.40; 95% CI, -0.64 to -0.17) and a significantly longer operating time (WMD: 15.60; 95% CI, 2.12 to 29.08). Conclusions: Robotic adrenalectomy is a safe and feasible procedure with similar clinical outcomes as the laparoscopic approach in selected patient populations. High quality RCTs as well as uniform and detailed reporting of outcomes are needed to determine the role and cost-effectiveness of robotic adrenal surgery in the years to come. (C) 2016 IJS Publishing Group Ltd. C1 [Economopoulos, Konstantinos P.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA USA. [Economopoulos, Konstantinos P.; Mylonas, Konstantinos S.; Stamou, Aliki A.; Theocharidis, Vasileios; Sergentanis, Theodoros N.] Soc Jr Doctors, Athens, Greece. [Mylonas, Konstantinos S.] Aristotle Univ Thessaloniki, Sch Med, Thessaloniki, Greece. [Stamou, Aliki A.; Theocharidis, Vasileios] Univ Athens, Sch Med, Athens, Greece. [Sergentanis, Theodoros N.; Psaltopoulou, Theodora] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens, Greece. [Richards, Melanie L.] Mayo Clin, Dept Surg, Rochester, MN USA. RP Economopoulos, KP (reprint author), Harvard Med Sch, Simches Res Ctr, Massachusetts Gen Hosp, Dept Surg, 4th Floor,185 Cambridge Str, Boston, MA 02114 USA. EM economopoulos@sni.gr OI Mylonas, Konstantinos/0000-0002-2356-6694 NR 50 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1743-9191 EI 1743-9159 J9 INT J SURG JI Int. J. Surg. PD FEB PY 2017 VL 38 BP 95 EP 104 DI 10.1016/j.ijsu.2016.12.118 PG 10 WC Surgery SC Surgery GA EO9TK UT WOS:000397030800025 PM 28043926 ER PT J AU Weng, QY Raff, AB Cohen, JM Gunasekera, N Okhovat, JP Vedak, P Joyce, C Kroshinsky, D Mostaghimi, A AF Weng, Qing Yu Raff, Adam B. Cohen, Jeffrey M. Gunasekera, Nicole Okhovat, Jean-Phillip Vedak, Priyanka Joyce, Cara Kroshinsky, Daniela Mostaghimi, Arash TI Costs and Consequences Associated With Misdiagnosed Lower Extremity Cellulitis SO JAMA DERMATOLOGY LA English DT Article ID SOFT-TISSUE INFECTIONS; RISK-FACTORS; DERMATOLOGY CONSULTATION; HOSPITALIZED-PATIENTS; LOWER-LIMB; SKIN; ERYSIPELAS; ANTIBIOTICS; MANAGEMENT; DIARRHEA AB IMPORTANCE Inflammatory dermatoses of the lower extremity are often misdiagnosed as cellulitis (aka "pseudocellulitis") and treated with antibiotics and/or hospitalization. There is limited data on the cost and complications from misdiagnosed cellulitis. OBJECTIVE To characterize the national health care burden of misdiagnosed cellulitis in patients admitted for treatment of lower extremity cellulitis. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study using patients admitted from the emergency department (ED) of a large urban hospital with a diagnosis of lower extremity cellulitis between June 2010 and December 2012. Patients who were discharged with a diagnosis of cellulitis were categorized as having cellulitis, while those who were given an alternative diagnosis during the hospital course, on discharge, or within 30 days of discharge were considered to have pseudocellulitis. A literature review was conducted for calculation of large-scale costs and complication rates. We obtained national cost figures from the Medical Expenditure Panel Survey (MEPS), provided by the Agency for Healthcare Research and Quality (AHRQ) for 2010 to calculate the hospitalization costs per year attributed to misdiagnosed lower extremity pseudocellulitis. EXPOSURES The exposed group was composed of patients who presented to and were admitted from the ED with a diagnosis of lower extremity cellulitis. MAIN OUTCOMES AND MEASURES Patient characteristics, hospital course, and complications during and after hospitalization were reviewed for each patient, and estimates of annual costs of misdiagnosed cellulitis in the United States. RESULTS Of 259 patients, 79 (30.5%) were misdiagnosed with cellulitis, and 52 of these misdiagnosed patients were admitted primarily for the treatment of cellulitis. Forty-four of the 52 (84.6%) did not require hospitalization based on ultimate diagnosis, and 48 (92.3%) received unnecessary antibiotics. We estimate cellulitis misdiagnosis leads to 50 000 to 130 000 unnecessary hospitalizations and $195 million to $515 million in avoidable health care spending. Unnecessary antibiotics and hospitalization for misdiagnosed cellulitis are projected to cause more than 9000 nosocomial infections, 1000 to 5000 Clostridium difficile infections, and 2 to 6 cases of anaphylaxis annually. CONCLUSIONS AND RELEVANCE Misdiagnosis of lower extremity cellulitis is common and may lead to unnecessary patient morbidity and considerable health care spending. C1 [Weng, Qing Yu; Raff, Adam B.; Vedak, Priyanka; Kroshinsky, Daniela] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. [Cohen, Jeffrey M.; Gunasekera, Nicole; Okhovat, Jean-Phillip; Mostaghimi, Arash] Brigham & Womens Hosp, Dept Dermatol, 75 Francis St, Boston, MA 02115 USA. [Joyce, Cara] Tulane Sch Publ Hlth & Trop Med, Dept Biostat & Bioinformat, New Orleans, LA USA. RP Mostaghimi, A (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Dept Dermatol, 15 Francis St,PBB-B 421, Boston, MA 02115 USA. EM amostaghimi@bwh.harvard.edu NR 33 TC 3 Z9 3 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD FEB 1 PY 2017 VL 153 IS 2 BP 141 EP 146 DI 10.1001/jamadermatol.2016.3816 PG 6 WC Dermatology SC Dermatology GA EM9ZT UT WOS:000395670800007 ER PT J AU Liu, KX Raff, AB Lee, MS AF Liu, Kevin X. Raff, Adam B. Lee, Margaret S. TI Painful Ulcerative Lesions on Bilateral Lower Extremities SO JAMA DERMATOLOGY LA English DT Editorial Material ID ANTINEUTROPHIL CYTOPLASMIC ANTIBODY; LUPUS-LIKE SYNDROME; VASCULITIS; METHIMAZOLE C1 [Liu, Kevin X.] Harvard Med Sch, Boston, MA USA. [Raff, Adam B.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Dermatol, Boston, MA USA. [Lee, Margaret S.] Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA. RP Lee, MS (reprint author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA. EM margaret.lee@bmc.org NR 10 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD FEB 1 PY 2017 VL 153 IS 2 BP 223 EP 224 DI 10.1001/jamadermatol.2016.3401 PG 2 WC Dermatology SC Dermatology GA EM9ZT UT WOS:000395670800023 ER PT J AU Stelmack, JA Tang, XC Wei, Y Wilcox, DT Morand, T Brahm, K Sayers, S Massof, RW AF Stelmack, Joan A. Tang, X. Charlene Wei, Yongliang Wilcox, Denise Thomas Morand, Timothy Brahm, Karen Sayers, Scott Massof, Robert W. CA LOVIT II Study Grp TI Outcomes of the Veterans Affairs Low Vision Intervention Trial II (LOVIT II) SO JAMA OPHTHALMOLOGY LA English DT Article ID VISUAL FUNCTIONING QUESTIONNAIRE; OF-THE-LITERATURE; MACULAR DEGENERATION; IMPAIRED VISION; REHABILITATION; HEALTH; DEPRESSION; PEOPLE; PARTICIPATION; IMPAIRMENTS C1 [Stelmack, Joan A.; Sayers, Scott] Edward Hines Jr Vet Affairs Hosp, Blind Rehabil Ctr, Mail Stop 124,5000 S Fifth Ave, Hines, IL 60141 USA. [Stelmack, Joan A.; Sayers, Scott] Univ Illinois, Sch Med, Dept Ophthalmol & Visual Sci, Chicago, IL USA. [Stelmack, Joan A.] Illinois Coll Optometry, Chicago, IL USA. [Tang, X. Charlene; Wei, Yongliang] Edward Hines Jr Vet Affairs Hosp, Vet Affairs Cooperat Studies Program, Coordinating Ctr, Hines, IL USA. [Wilcox, Denise Thomas] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA. [Morand, Timothy] Dayton Vet Affairs Med Ctr, Rehabil Med Serv, Dayton, OH USA. [Brahm, Karen] William S Middleton Mem Vet Adm Med Ctr, Surg Serv, Madison, WI USA. [Massof, Robert W.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA. RP Stelmack, JA (reprint author), Edward Hines Jr Vet Affairs Hosp, Blind Rehabil Ctr, Mail Stop 124,5000 S Fifth Ave, Hines, IL 60141 USA. EM joan.stelmack@va.gov FU Department of Veterans Affairs (VA) Rehabilitation Research and Development [C6958R]; Department of Veterans Affairs Prosthetics Service FX Funding for this research was provided by Department of Veterans Affairs (VA) Rehabilitation Research and Development grant C6958R. Funding for the low-vision devices prescribed and dispensed to veteran participants was provided by the Department of Veterans Affairs Prosthetics Service. NR 47 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6165 EI 2168-6173 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD FEB 1 PY 2017 VL 135 IS 2 BP 96 EP 104 DI 10.1001/jamaophthalmol.2016.4742 PG 9 WC Ophthalmology SC Ophthalmology GA EM9PE UT WOS:000395642800009 ER PT J AU Grotting, LA Davoudi, S Palenzuela, D Papaliodis, GN Sobrin, L AF Grotting, Lindsay A. Davoudi, Samaneh Palenzuela, Deanna Papaliodis, George N. Sobrin, Lucia TI Association of Low Vitamin D Levels With Noninfectious Anterior Uveitis SO JAMA OPHTHALMOLOGY LA English DT Article ID BEHCETS-DISEASE; 1,25-DIHYDROXYVITAMIN-D3; EXPRESSION; TH17 AB IMPORTANCE Vitamin D plays an important role in both the innate and adaptive immune systems. It has been shown to contribute to the etiology of T-cell-mediated autoimmune diseases through the upregulation of type 2 anti-inflammatory T helper cells and the suppression of type 1 T helper cells. Noninfectious uveitis is postulated to be caused by immune dysfunction. OBJECTIVE To determine whether there is an association between vitamin D levels and noninfectious anterior uveitis. DESIGN, SETTING, AND PARTICIPANTS This was a case-control study. We identified patients with and without noninfectious uveitis using the Massachusetts Eye and Ear Infirmary Ocular Inflammation Database and electronic medical records from March 1, 2008, to December 12, 2015, at the Massachusetts Eye and Ear Infirmary Uveitis and Comprehensive Ophthalmology Clinics. One hundred patients with noninfectious anterior uveitis and 100 patients without uveitis were recruited. Patients with noninfectious uveitis were diagnosed by fellowship-trained uveitis specialists after exclusion of infectious causes and neoplastic masquerades of uveitis. All patients included had a total 25-hydroxyvitamin D level recorded. Multivariate regression models were constructed to determine the association between vitamin D levels and the presence of uveitis. MAIN OUTCOME AND MEASURE Presence of noninfectious anterior uveitis. RESULTS We identified 100 patients (64 white, 8 African American, 25 Asian, and 3 Hispanic) with a mean (SD) age of 51.8 (15.9) years (26 men) and 100 control individuals (58 white, 23 African American, 8 Asian, and 11 Hispanic) with a mean (SD) age of 53.6 (16.2) years (27 men). Hypovitaminosis D was associated with noninfectious uveitis in the univariate analysis (odds ratio, 2.53; 95% CI, 1.42-4.51; P = .002). The association in multivariate regression after adjusting for age, sex, and race/ethnicity was 2.96 (95% CI, 1.60-5.50; P = .001). The odds of developing uveitis were 4% lower for every 1-ng/mL increase in vitamin D level (odds ratio, 0.96; 95% CI, 0.93-0.99; P = .01) in the main multivariate analysis. CONCLUSIONS AND RELEVANCE In this retrospective study, lower vitamin D levels were associated with an increased risk of noninfectious anterior uveitis. However, this does not confirm a causal effect. C1 [Grotting, Lindsay A.; Davoudi, Samaneh; Papaliodis, George N.; Sobrin, Lucia] Massachusetts Eye & Ear, Harvard Dept Ophthalmol, Boston, MA USA. [Palenzuela, Deanna] Harvard Med Sch, Boston, MA USA. RP Sobrin, L (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM lucia_sobrin@meei.harvard.edu NR 11 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6165 EI 2168-6173 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD FEB 1 PY 2017 VL 135 IS 2 BP 150 EP 153 DI 10.1001/jamaophthalmol.2016.4888 PG 4 WC Ophthalmology SC Ophthalmology GA EM9PE UT WOS:000395642800018 ER PT J AU Osazuwa-Peters, N Boakye, EA Chen, BY Clancy, J Vallot, PL Su, JL Beck, GE Varvares, MA AF Osazuwa-Peters, Nosayaba Boakye, Eric Adjei Chen, Betty Y. Clancy, Jennifer Vallot, Patrice L. Su, Jonathan L. Beck, Geoffrey E. Varvares, Mark A. TI Sociodemographic Factors Associated With Knowledge and Risk Perception of Human Papillomavirus and Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma Among a Predominantly Black Population SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID ORAL-CANCER KNOWLEDGE; UNITED-STATES; NECK-CANCER; PUBLIC AWARENESS; HPV KNOWLEDGE; HEAD; VACCINATION; PREDICTORS; INFECTION; BEHAVIOR AB IMPORTANCE The incidence of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing in the United States and may be underestimated among black individuals. Characterizing the current knowledge level among black individuals is critical to developing interventions to increase awareness. OBJECTIVE To describe the sociodemographic correlates of knowledge and risk perception of HPV and HPV-associated OPSCC among a predominantly black population. DESIGN, SETTING, AND PARTICIPANTS A cross-sectional surveywas conducted at a drag racing event on September 12 and 13, 2015, in Madison, Illinois. The setting was a community-based oral head and neck cancer screening and education initiative. Participants were 301 drag race attendees 18 years or older who were conveniently sampled from attendees at an annual drag racing event predominantly patronized by black individuals. MAIN OUTCOMES AND MEASURES The primary outcomewas knowledge and risk perception of HPV and HPV-associated OPSCC. An electronic-based questionnaire elicited sociodemographic information and contained oral cancer knowledge and risk perception items, which were combined to form knowledge and risk perception scores. Multivariable linear regression analysis assessed estimates of knowledge and risk perception of HPV and HPV-associated OPSCC. RESULTS Of the 301 participants (111 female and 190 male) completing the questionnaire, 194 (64.5%) were black. Overall, respondents ranged in age from 18 to 78 years, with a mean (SD) age of 48.0 (13.0) years. The mean (SD) knowledge score was 5.7 (4.6) of 15, and the mean (SD) risk perception score was 2.2 (1.4) of 6. Using multivariable linear regression, we found that, for every 1-year increase in age, knowledge of HPV-associated OPSCC decreased by 5.0% and was worse in men (beta = -1.26; 95% CI, -2.33 to -0.18), black vs white individuals (beta = -1.29; 95% CI, -2.35 to -0.23), and those with a high school diploma or less vs college graduates (beta = -3.23; 95% CI, -4.67 to -1.80). Black individuals also had lower perceived risk of developing HPV-associated OPSCC (beta = -0.36; 95% CI, -0.69 to -0.02) compared with white individuals, and participants with a high school diploma or less had lower perceived risk of developing HPV-associated OPSCC compared with those with a college degree or higher (beta = -0.59; 95% CI, -1.04 to -0.14). CONCLUSIONS AND RELEVANCE Age and sex were independent correlates of knowledge of HPV-associated OPSCC, while race and education level were correlates of both knowledge and risk perception of HPV-associated OPSCC. These findings should inform future interventions targeted at increasing knowledge of HPV-associated OPSCC in black communities. C1 [Osazuwa-Peters, Nosayaba] St Louis Univ, Dept Otolaryngol Head & Neck Surg, Sch Med, 3635 Vista Ave,Sixth Floor,Desloge Towers, St Louis, MO 63110 USA. [Osazuwa-Peters, Nosayaba] St Louis Univ, Ctr Canc, St Louis, MO 63103 USA. [Osazuwa-Peters, Nosayaba] St Louis Univ, Dept Epidemiol, Coll Publ Hlth & Social Justice, St Louis, MO 63103 USA. [Boakye, Eric Adjei] St Louis Univ, Ctr Outcomes Res SLUCOR, St Louis, MO 63103 USA. [Chen, Betty Y.; Clancy, Jennifer; Vallot, Patrice L.; Su, Jonathan L.; Beck, Geoffrey E.] St Louis Univ, Sch Med, St Louis, MO USA. [Varvares, Mark A.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA USA. RP Osazuwa-Peters, N (reprint author), St Louis Univ, Dept Otolaryngol Head & Neck Surg, Sch Med, 3635 Vista Ave,Sixth Floor,Desloge Towers, St Louis, MO 63110 USA. EM nosazuwa@slu.edu FU United Black Drag Racers Association FX This study was supported by the United Black Drag Racers Association St Louis members and executives; Scott Fosko, MD, Dell Yates, MA, and Michell Nickerson, all from St Louis University Cancer Center; Rebecca L. Rohde, BS, St Louis University School of Medicine; Tami Hanks, BS, REDCap Product Manager, Ronald J. Walker, MD, Jastin Antisdel, MD, Josh Hentzelman, MD, Sean T. Massa, MD, Lauren Cass, MD, MPH, Matt Gropler, MD, Matt Leach, MD, and Zach Bear, MD, all from St Louis University; and medical student volunteers. None received any compensation. NR 37 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD FEB PY 2017 VL 143 IS 2 BP 117 EP 124 DI 10.1001/jamaoto.2016.2784 PG 8 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA EN0KM UT WOS:000395698800004 PM 27711922 ER PT J AU Laury, AM Bowe, SN Lospinoso, J AF Laury, Adrienne M. Bowe, Sarah N. Lospinoso, Joshua TI Integrating Morbidity and Mortality Core Competencies and Quality Improvement in Otolaryngology SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID SURGICAL MORBIDITY; UTILITY AB IMPORTANCE To date, an otolaryngology-specific morbidity and mortality (M&M) conference has never been reported or evaluated. OBJECTIVE To propose a novel otolaryngology-specific M&M format and to assess its success using a validated assessment tool. DESIGN, SETTING, AND PARTICIPANTS Preintervention and postintervention cohort study spanning 14 months (September 2014 to November 2015), with 32 faculty, residents, and medical students attending the department of otolaryngology M& M conference, conducted at the the San Antonio Uniformed Services Health Education Consortium. INTERVENTIONS A novel quality assurance conference was implemented in the department of otolaryngology at the San Antonio Uniformed Services Health Education Consortium. This conference incorporates patient safety reports, otolaryngology-specific qualitymetrics, and individual case presentations. The revised format integrates the Accreditation Council for Graduate Medical Education (ACGME) core competencies and Quality Improvement and Patient Safety (QI/PS) system. This format was evaluated by faculty, residents, and medical students every other month for 14 months to assess changes in attitudes regarding the M&M conference as well as changes in presentation quality. RESULTS Overall, 13 faculty, 12 residents, and 7 medical students completed 232 evaluations. Summary statistics of both resident and faculty attitudes about the success of the M&M format seem to improve over the 14 months between the prequestionnaires and postquestionnaires. General attitudes for both residents and faculty significantly improved from the pretest to posttest (odds ratio, 0.32 per month; 95% CI, 0.29-0.35). In the pretest period, "established presentation format" was considered the most necessary improvement, whereas in the posttest period this changed to "incorporate more QI." For resident presentations evaluated using the situation, background, assessment, and review/recommendations (SBAR) tool, all evaluations, from all participants, improved over time. CONCLUSIONS AND RELEVANCE The M&M conference is an essential component of all otolaryngology residency programs and provides a unique opportunity to successfully incorporate the ACGME core competencies and regularly implement QI/PS. C1 [Laury, Adrienne M.] San Antonio Uniformed Serv Hlth Educ Consortium, Dept Otolaryngol Head & Neck Surg, Ft Sam Houston, TX USA. [Bowe, Sarah N.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. [Lospinoso, Joshua] Detachment Texas, Mil Intelligence Battal 782, Ft Sam Houston, TX USA. RP Laury, AM (reprint author), San Antonio Uniformed Serv Hlth Educ Consortium, Dept Otolaryngol Head & Neck Surg, ATTN MCHE SDT Otolaryngol, JBSA, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA. EM Adrienne.laury@gmail.com NR 17 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD FEB PY 2017 VL 143 IS 2 BP 135 EP 140 DI 10.1001/jamaoto.2016.2910 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA EN0KM UT WOS:000395698800007 PM 27768160 ER PT J AU Lin, BM Hu, FB Curhan, GC AF Lin, Brian M. Hu, Frank B. Curhan, Gary C. TI Association Between Benzodiazepine Receptor Agonists and Snoring Among Women in the Nurses' Health Study SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID OBSTRUCTIVE SLEEP-APNEA; EXCESSIVE DAYTIME SLEEPINESS; RISK-FACTORS; CARDIOVASCULAR-DISEASE; GENERAL-POPULATION; HYPERTENSION; SNORERS; MORTALITY; HYPOPNEA; DURATION AB IMPORTANCE Snoring is highly prevalent among adults. The use of benzodiazepine receptor agonists is also common, with higher prevalence of use with more advanced age. Benzodiazepine receptor agonists cause muscle relaxation, which may affect muscle tone and airway dynamics and thereby increase snoring. Previous studies examining the association between use of benzodiazepine receptor agonists and snoring were underpowered to detect clinically meaningful differences or did not report the magnitude of association. OBJECTIVE To investigate the association between use of benzodiazepine receptor agonists and snoring in women. DESIGN, SETTING, AND PARTICIPANTS Women aged 62 to 86 years provided information on snoring and covariates of interest in the 2008 survey of the Nurses' Health Study, a cross-sectional cohort study of female registered nurses in the United States. Potential effect modification of the association between use of benzodiazepine receptor agonists and snoring by age, body mass index, waist circumference, smoking, alcohol consumption, and physical activity was explored. Logistic regression was used to adjust for potential confounders. Data analysis was conducted from November 2015 to March 2016. MAIN OUTCOMES AND MEASURES Self-reported habitual snoring, defined as a few nights a week or more. RESULTS Of 52 504 participants (mean [SD] age, 72.4 [6.7] years), 14 831 (28.2%) reported habitual snoring. There was a slightly higher prevalence of benzodiazepine receptor agonist use among habitual snorers (11.4%) compared with nonhabitual snorers (10.6%) (absolute difference, 0.8%; 95% CI, 0.2%-1.4%). After multivariable adjustment, use of benzodiazepine receptor agonists was not associated with snoring (odds ratio, 1.01; 95% CI, 0.95-1.07) compared with women who did not use benzodiazepine receptor agonists. Although there was no significant interaction with smoking, there were higher odds of snoring with use of benzodiazepine receptor agonists among current smokers (odds ratio, 1.34; 95% CI, 1.04-1.73). CONCLUSIONS AND RELEVANCE Use of benzodiazepine receptor agonists is not associated with odds of snoring in middle-aged and elderly women. C1 [Lin, Brian M.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. [Lin, Brian M.; Hu, Frank B.; Curhan, Gary C.] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Lin, Brian M.; Hu, Frank B.; Curhan, Gary C.] Harvard Med Sch, Boston, MA USA. [Lin, Brian M.; Hu, Frank B.; Curhan, Gary C.] Harvard Med Sch, Boston, MA USA. [Hu, Frank B.; Curhan, Gary C.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Curhan, Gary C.] Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA. RP Lin, BM (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM brian_lin@meei.harvard.edu FU National Institutes of Health [UM1CA186107, DK91417] FX This work was supported by grants UM1CA186107 and DK91417 from the National Institutes of Health. NR 28 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD FEB PY 2017 VL 143 IS 2 BP 162 EP 167 DI 10.1001/jamaoto.2016.3174 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA EN0KM UT WOS:000395698800012 PM 27893000 ER PT J AU Dawes, AJ Dawes, DM Maggard-Gibbons, M AF Dawes, Aaron J. Dawes, Danielle M. Maggard-Gibbons, Melinda TI Corrected vs Uncorrected Obesity in Childbearing Women-What Really Drives Fetal Risks SO JAMA SURGERY LA English DT Editorial Material C1 [Dawes, Aaron J.; Maggard-Gibbons, Melinda] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 757 Westwood Plaza,Room B711, Los Angeles, CA 90095 USA. [Dawes, Danielle M.] Magella Med Grp Inc, Maternal Fetal Med Practice, Long Beach, CA USA. [Maggard-Gibbons, Melinda] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Dawes, AJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 757 Westwood Plaza,Room B711, Los Angeles, CA 90095 USA. EM adawes@mednet.ucla.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD FEB PY 2017 VL 152 IS 2 BP 135 EP 135 DI 10.1001/jamasurg.2016.3597 PG 1 WC Surgery SC Surgery GA EM9HZ UT WOS:000395623800007 PM 27760247 ER PT J AU Klebanoff, MJ Chhatwal, J Nudel, JD Corey, KE Kaplan, LM Hur, C AF Klebanoff, Matthew J. Chhatwal, Jagpreet Nudel, Jacob D. Corey, Kathleen E. Kaplan, Lee M. Hur, Chin TI Cost-effectiveness of Bariatric Surgery in Adolescents With Obesity SO JAMA SURGERY LA English DT Article ID LAPAROSCOPIC SLEEVE GASTRECTOMY; MORBID-OBESITY; UNITED-STATES; WEIGHT-LOSS; IMPACT; BYPASS; TRIAL; METAANALYSIS; CHILDHOOD; CHILDREN AB IMPORTANCE Severe obesity affects 4% to 6% of US youth and is increasing in prevalence. Bariatric surgery for the treatment of adolescents with severe obesity is becoming more common, but data on cost-effectiveness are limited. OBJECTIVE To assess the cost-effectiveness of bariatric surgery for adolescents with obesity using recently published results from the Teen-Longitudinal Assessment of Bariatric Surgery study. DESIGN, SETTING, AND PATIENTS A state-transition model was constructed to compare 2 strategies: no surgery and bariatric surgery. In the no surgery strategy, patients remained at their initial body mass index (calculated as weight in kilograms divided by height in meters squared) over time. In the bariatric surgery strategy, patients were subjected to risks of perioperative mortality and complications as well as initial morbidity but also experienced longer-term quality-of-life improvements associated with weight loss. Cohort demographic information-of the 228 patients included, the mean (SD) age was 17 (1.6) years, the mean (range) body mass index was 53 (34-88), and 171 (75.0%) were female-surgery-related outcomes, and base case time horizon (3 years) were based on data from the Teen-Longitudinal Assessment of Bariatric Surgery study. One-way and probabilistic sensitivity analyses were performed. MAIN OUTCOMES AND MEASURES Quality-adjusted life-years (QALYs), total costs (in US dollars adjusted to 2015-year values using the Consumer Price Index), and incremental cost-effectiveness ratios (ICERs). A willingness-to-pay threshold of $100 000 per QALY was used to assess cost-effectiveness. RESULTS After 3 years, surgery led to a gain of 0.199 QALYs compared with no surgery at an incremental cost of $ 30 747, yielding an unfavorable ICER of $ 154 684 per QALY. When the clinical study results were extrapolated to 4 years, the ICER decreased to $ 114 078 per QALY and became cost-effective by 5 years with an ICER of $ 91 032 per QALY. Outcomes were robust in most 1-way and probabilistic sensitivity analyses. CONCLUSIONS AND RELEVANCE Bariatric surgery incurs substantial initial cost and morbidity. We found that surgery could be a cost-effective treatment for adolescents with severe obesity if assessed over a time horizon of 5 years. Our study underscores the need for long-term clinical trials in adolescents with at least 5 years of follow-up data that capture financial and quality-of-life end points. C1 [Klebanoff, Matthew J.; Chhatwal, Jagpreet; Hur, Chin] Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA. [Klebanoff, Matthew J.; Chhatwal, Jagpreet; Corey, Kathleen E.; Kaplan, Lee M.; Hur, Chin] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Klebanoff, Matthew J.] Yale Sch Med, New Haven, CT USA. [Chhatwal, Jagpreet; Nudel, Jacob D.; Corey, Kathleen E.; Kaplan, Lee M.; Hur, Chin] Harvard Med Sch, Boston, MA USA. [Nudel, Jacob D.] Boston Univ, Dept Surg, Boston, MA 02215 USA. RP Hur, C (reprint author), Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA. EM chur@mgh.harvard.edu NR 38 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD FEB PY 2017 VL 152 IS 2 BP 136 EP 141 DI 10.1001/jamasurg.2016.3640 PG 6 WC Surgery SC Surgery GA EM9HZ UT WOS:000395623800008 PM 27784062 ER PT J AU Fernandez-Bustamante, A Frendl, G Sprung, J Kor, DJ Subramaniam, B Ruiz, RM Lee, JW Henderson, WG Moss, A Mehdiratta, N Colwell, MM Bartels, K Kolodzie, K Giquel, J Melo, MFV AF Fernandez-Bustamante, Ana Frendl, Gyorgy Sprung, Juraj Kor, Daryl J. Subramaniam, Bala Ruiz, Ricardo Martinez Lee, Jae-Woo Henderson, William G. Moss, Angela Mehdiratta, Nitin Colwell, Megan M. Bartels, Karsten Kolodzie, Kerstin Giquel, Jadelis Melo, Marcos Francisco Vidal TI Postoperative Pulmonary Complications, Early Mortality, and Hospital Stay Following Noncardiothoracic Surgery A Multicenter Study by the Perioperative Research Network Investigators SO JAMA SURGERY LA English DT Article ID RESPIRATORY-DISTRESS-SYNDROME; RANDOMIZED CONTROLLED-TRIAL; TIDAL-VOLUME VENTILATION; OPEN ABDOMINAL-SURGERY; NONCARDIAC SURGERY; PRACTICE PATTERNS; PATIENT-CARE; LUNG INJURY; RISK; PREDICTORS AB IMPORTANCE Postoperative pulmonary complications (PPCs), a leading cause of poor surgical outcomes, are heterogeneous in their pathophysiology, severity, and reporting accuracy. OBJECTIVE To prospectively study clinical and radiological PPCs and respiratory insufficiency therapies in a high-risk surgical population. DESIGN, SETTING, AND PARTICIPANTS We performed a multicenter prospective observational study in 7 US academic institutions. American Society of Anesthesiologists physical status 3 patients who presented for noncardiothoracic surgery requiring 2 hours or more of general anesthesia with mechanical ventilation from May to November 2014 were included in the study. We hypothesized that PPCs, even mild, would be associated with early postoperative mortality and use of hospital resources. We analyzed their association with modifiable perioperative variables. EXPOSURE Noncardiothoracic surgery. MAIN OUTCOMES AND MEASURES Predefined PPCs occurring within the first 7 postoperative days were prospectively identified. We used bivariable and logistic regression analyses to study the association of PPCs with ventilatory and other perioperative variables. RESULTS This study included 1202 patients who underwent predominantly abdominal, orthopedic, and neurological procedures. The mean (SD) age of patients was 62.1 (13.8) years, and 636 (52.9%) were men. At least 1 PPC occurred in 401 patients (33.4%), mainly the need for prolonged oxygen therapy by nasal cannula (n = 235; 19.6%) and atelectasis (n = 206; 17.1%). Patients with 1 or more PPCs, even mild, had significantly increased early postoperative mortality, intensive care unit (ICU) admission, and ICU/hospital length of stay. Significant PPC risk factors included nonmodifiable (emergency [yes vs no]: odds ratio [OR], 4.47, 95% CI, 1.59-12.56; surgical site [abdominal/pelvic vs nonabdominal/pelvic]: OR, 2.54, 95% CI, 1.67-3.89; and age [in years]: OR, 1.03, 95% CI, 1.02-1.05) and potentially modifiable (colloid administration [yes vs no]: OR, 1.75, 95% CI, 1.03-2.97; preoperative oxygenation: OR, 0.86, 95% CI, 0.80-0.93; blood loss [in milliliters]: OR, 1.17, 95% CI, 1.05-1.30; anesthesia duration [in minutes]: OR, 1.14, 95% CI, 1.05-1.24; and tidal volume [in milliliters per kilogram of predicted body weight]: OR, 1.12, 95% CI, 1.01-1.24) factors. CONCLUSIONS AND RELEVANCE Postoperative pulmonary complications are common in patients with American Society of Anesthesiologists physical status 3, despite current protective ventilation practices. Even mild PPCs are associated with increased early postoperative mortality, ICU admission, and length of stay (ICU and hospital). Mild frequent PPCs (eg, atelectasis and prolonged oxygen therapy need) deserve increased attention and intervention for improving perioperative outcomes. C1 [Fernandez-Bustamante, Ana; Bartels, Karsten] Univ Colorado, Sch Med, Aurora, CO USA. [Frendl, Gyorgy; Mehdiratta, Nitin] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Sprung, Juraj; Kor, Daryl J.] Mayo Clin, Coll Med, Rochester, MN USA. [Subramaniam, Bala] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Ruiz, Ricardo Martinez; Giquel, Jadelis] Univ Miami, Palmetto Bay, FL USA. [Lee, Jae-Woo; Kolodzie, Kerstin] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Henderson, William G.; Moss, Angela] Univ Colorado, Sch Med, Adult & Children Outcomes Res & Delivery Syst, Aurora, CO USA. [Colwell, Megan M.; Melo, Marcos Francisco Vidal] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Fernandez-Bustamante, A (reprint author), Univ Colorado, Sch Med, Dept Anesthesiol, 12631 E 17th Ave,AO-1 Bldg,R2012,MS 8202, Aurora, CO 80045 USA. EM ana.fernandez-bustamante@ucdenver.edu FU National Institutes of Health [R34HL123438, K23HL112855]; Foundation for Anesthesia Education and Research Mentored Research Training Grant-Clinical/Translational FX This work was partially supported by grants R34HL123438 (Drs Vidal Melo, Fernandez-Bustamante, and Sprung) and K23HL112855 (Dr Kor) from the National Institutes of Health, and by the 2012 Foundation for Anesthesia Education and Research Mentored Research Training Grant-Clinical/Translational (Dr Fernandez-Bustamante). NR 32 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD FEB PY 2017 VL 152 IS 2 BP 157 EP 166 DI 10.1001/jamasurg.2016.4065 PG 10 WC Surgery SC Surgery GA EM9HZ UT WOS:000395623800014 PM 27829093 ER PT J AU Hall, DE Arya, S Schmid, KK Blaser, C Carlson, MA Bailey, TL Purviance, G Bockman, T Lynch, TG Johanning, J AF Hall, Daniel E. Arya, Shipra Schmid, Kendra K. Blaser, Casey Carlson, Mark A. Bailey, Travis L. Purviance, Georgia Bockman, Tammy Lynch, Thomas G. Johanning, Jason TI Development and Initial Validation of the Risk Analysis Index for Measuring Frailty in Surgical Populations SO JAMA SURGERY LA English DT Article ID MORTALITY; MORBIDITY; SURGERY; SPECIALTIES; DISABILITY; PREDICTOR; OUTCOMES; HEALTH; CARE AB IMPORTANCE Growing consensus suggests that frailty-associated risks should inform shared surgical decision making. However, it is not clear how best to screen for frailty in preoperative surgical populations. OBJECTIVE To develop and validate the Risk Analysis Index (RAI), a 14-item instrument used to measure surgical frailty. It can be calculated prospectively (RAI-C), using a clinical questionnaire, or retrospectively (RAI-A), using variables from the surgical quality improvement databases (Veterans Affairs or American College of Surgeons National Surgical Quality Improvement Projects). DESIGN, SETTING, AND PARTICIPANTS Single-site, prospective cohort from July 2011 to September 2015 at the Veterans Affairs Nebraska-Western Iowa Heath Care System, a Level 1b Veterans Affairs Medical Center. The study included all patients presenting to the medical center for elective surgery. EXPOSURES We assessed the RAI-C for all patients scheduled for surgery, linking these scores to administrative and quality improvement data to calculate the RAI-A and the modified Frailty Index. MAIN OUTCOMES AND MEASURES Receiver operator characteristics and C statistics for each measure predicting postoperative mortality and morbidity. RESULTS Of the participants, the mean (SD) age was 60.7 (13.9) years and 249 participants (3.6%) were women. We assessed the RAI-C 10 698 times, from which we linked 6856 unique patients to mortality data. The C statistic predicting 180-day mortality for the RAI-C was 0.772. Of these 6856 unique patients, we linked 2785 to local Veterans Affairs Surgeons National Surgical Quality Improvement Projects data and calculated the C statistic for both the RAI-A (0.823) and RAI-C (0.824), along with the correlation between the 2 scores (r = 0.478; P < .001). Of these 2785 patients, there were sufficient data to calculate the modified Frailty Index for 1021, in which the C statistics were 0.865 (RAI-A), 0.797 (RAI-C), and 0.811 (modified Frailty Index). The correlation between the RAI-A and RAI-C was 0.547, and the correlations of the modified Frailty Index to the RAI-A and RAI-C were 0.301 and 0.269, respectively (all P < .001). A cutoff of RAI-C of at least 21 classified 18.3% patients as "frail" with a sensitivity of 0.50 and specificity of 0.82, whereas the RAI-A was less sensitive (0.25) and more specific (0.97), classifying only 3.7% as "frail." CONCLUSIONS AND RELEVANCE The RAI-C and RAI-A represent effective tools for measuring frailty in surgical populations with predictive ability on par with other frailty tools. Moderate correlation between the measures suggests convergent validity. The RAI-C offers the advantage of prospective, preoperative assessment that is proved feasible for large-scale screening in clinical practice. However, further efforts should be directed at determining the optimal components of preoperative frailty assessment. C1 [Hall, Daniel E.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Hall, Daniel E.] Univ Pittsburgh, Pittsburgh, PA USA. [Arya, Shipra] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Arya, Shipra] Emory Univ, Atlanta, GA 30322 USA. [Schmid, Kendra K.; Blaser, Casey; Carlson, Mark A.; Johanning, Jason] Univ Nebraska Med Ctr, Omaha, NE USA. [Carlson, Mark A.; Bailey, Travis L.; Purviance, Georgia; Bockman, Tammy; Johanning, Jason] Vet Affairs Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA. [Bailey, Travis L.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Lynch, Thomas G.] Vet Affairs Cent Off, Washington, DC USA. RP Hall, DE (reprint author), UPMC Presbyterian, 200 Lothrop St,Ste 1264, Pittsburgh, PA 15213 USA. EM hallde@upmc.edu FU US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development [CDA 08-281] FX This research was supported by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (CDA 08-281; Dr Hall). NR 24 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD FEB PY 2017 VL 152 IS 2 BP 175 EP 182 DI 10.1001/jamasurg.2016.4202 PG 8 WC Surgery SC Surgery GA EM9HZ UT WOS:000395623800017 PM 27893030 ER PT J AU Biederman, J Fried, R Tarko, L Surman, C Spencer, T Pope, A Grossman, R McDermott, K Woodworth, KY Faraone, SV AF Biederman, Joseph Fried, Ronna Tarko, Laura Surman, Craig Spencer, Thomas Pope, Amanda Grossman, Rebecca McDermott, Katie Woodworth, K. Yvonne Faraone, Stephen V. TI Memantine in the Treatment of Executive Function Deficits in Adults With ADHD: A Pilot-Randomized Double-Blind Controlled Clinical Trial SO JOURNAL OF ATTENTION DISORDERS LA English DT Article DE ADHD; adult; adult ADHD treatment; executive function deficits; memantine ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; HYPERACTIVITY DISORDER; SUBTHRESHOLD DIAGNOSES; STIMULANT MEDICATION; FUNCTION PERFORMANCE; WORKING-MEMORY; LATE-ONSET; CHILDREN; METHYLPHENIDATE; GLUTAMATE AB Objective: To evaluate the efficacy and safety of memantine hydrochloride as an adjunct to stimulant pharmacotherapy for treating executive function deficits (EFDs) in adults with ADHD. Method: This was a 12-week, double-blind, placebo-controlled, randomized clinical trial of memantine added to open-label treatment with stimulant medication. Because of the small sample size, we considered a standardized mean difference (equivalent to effect size) of 0.5 and odds ratios 2 as indicators of trend improvements. Results: Twelve participants received memantine and 14 received a placebo. Trend improvements favoring memantine were observed on Behavior Rating Inventory of Executive Functions-Adult Inhibition and Self-Monitor subscales when compared with Placebo. No significant changes were noted on the Cambridge Neuropsychological Test Automated Battery. Conclusion: Among adults with ADHD and EFDs, adjunct treatment with memantine to osmotic release oral system-methylphenidate (OROS-MPH) was associated with improvements in selective areas of executive functioning, supporting the need for further research. C1 [Biederman, Joseph; Tarko, Laura; Surman, Craig; Spencer, Thomas; Pope, Amanda; Grossman, Rebecca; McDermott, Katie; Woodworth, K. Yvonne] Massachusetts Gen Hosp, Pediat Psychopharmacol & Adult ADHD Program, Boston, MA 02114 USA. [Fried, Ronna] Massachusetts Gen Hosp, Pediat Psychopharmacol & Adult ADHD Program, Neuropsychol, Boston, MA 02114 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Med Genet Res Ctr, Syracuse, NY 13210 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Psychiat & Neurosci & Physiol, Syracuse, NY 13210 USA. RP Biederman, J (reprint author), Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, 55 Fruit St,Warren 705, Boston, MA 02114 USA.; Biederman, J (reprint author), Massachusetts Gen Hosp, Clin & Res Program Adult ADHD, 55 Fruit St,Warren 705, Boston, MA 02114 USA. EM jbiederman@partners.org FU Pond Family Foundation/APSARD ADHD Research Fund FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by a grant to Dr. Biederman from the Pond Family Foundation/APSARD ADHD Research Fund. NR 51 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1087-0547 EI 1557-1246 J9 J ATTEN DISORD JI J. Atten. Disord. PD FEB PY 2017 VL 21 IS 4 BP 343 EP 352 DI 10.1177/1087054714538656 PG 10 WC Psychology, Developmental; Psychiatry SC Psychology; Psychiatry GA EO8KV UT WOS:000396938900008 PM 24970718 ER PT J AU Bianchi, MT Phillips, AJK Wang, W Klerman, EB AF Bianchi, Matt T. Phillips, Andrew J. K. Wang, Wei Klerman, Elizabeth B. TI Statistics for Sleep and Biological Rhythms Research: From Distributions and Displays to Correlation and Causation SO JOURNAL OF BIOLOGICAL RHYTHMS LA English DT Article DE statistics; correlations; biological rhythms; mathematical analyses; circadian; rhythms AB The Journal of Biological Rhythms will be publishing articles exploring analysis and statistical topics relevant to researchers in biological rhythms and sleep research. The goal is to provide an overview of the most common issues that arise in the analysis and interpretation of data in these fields. By using case examples and highlighting the pearls and pitfalls of statistical inference, the authors will identify and explain ways in which experimental scientists can avoid common analytical and statistical mistakes and use appropriate analytical and statistical methods in their research. In this first article, we address the first steps in analysis of data: understanding the underlying statistical distribution of the data and establishing associative versus causal relationships. These ideas are then applied to sample size, power calculations, correlation testing, differences between description and prediction, and the narrative fallacy. C1 [Bianchi, Matt T.] Massachusetts Gen Hosp, Dept Neurol, Wang 7 Neurology,55 Fruit St, Boston, MA 02114 USA. [Bianchi, Matt T.; Phillips, Andrew J. K.; Wang, Wei; Klerman, Elizabeth B.] Harvard Med Sch, Div Sleep Med, Boston, MA USA. [Phillips, Andrew J. K.; Wang, Wei; Klerman, Elizabeth B.] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, Boston, MA 02115 USA. RP Bianchi, MT (reprint author), Massachusetts Gen Hosp, Dept Neurol, Wang 7 Neurology,55 Fruit St, Boston, MA 02114 USA. EM mtbianchi@partners.org FU NIH [K99 / R00 HL119618, K24-HL105664, R01-HL-114088, R01-GM-105018, P01-AG009975]; NSBRI [HFP02802]; MGH Neurology Department (MTB) FX The authors thank Ellen Frank, Karen Gamble, William J. Schwartz, and Katie Sharkey for helpful discussions. This work was supported by NIH K99 / R00 HL119618 (AJKP); NIH K24-HL105664 (EBK), R01-HL-114088, R01-GM-105018 and P01-AG009975, and NSBRI HFP02802; MGH Neurology Department (MTB). NR 12 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0748-7304 EI 1552-4531 J9 J BIOL RHYTHM JI J. Biol. Rhythms PD FEB PY 2017 VL 32 IS 1 BP 7 EP 17 DI 10.1177/0748730416670050 PG 11 WC Biology; Physiology SC Life Sciences & Biomedicine - Other Topics; Physiology GA EP2WI UT WOS:000397243900002 PM 27836938 ER PT J AU Klerman, EB Wang, W Phillips, AJK Bianchi, MT AF Klerman, Elizabeth B. Wang, Wei Phillips, Andrew J. K. Bianchi, Matt T. TI Statistics for Sleep and Biological Rhythms Research: Longitudinal Analysis of Biological Rhythms Data SO JOURNAL OF BIOLOGICAL RHYTHMS LA English DT Article DE statistics; longitudinal analyses; circadian rhythms; biological rhythms; periodicity ID CIRCADIAN PHASE; MATHEMATICAL-MODEL; MELATONIN AB This article is part of a Journal of Biological Rhythms series exploring analysis and statistical topics relevant to researchers in biological rhythms and sleep research. The goal is to provide an overview of the most common issues that arise in the analysis and interpretation of data in these fields. In this article, we address issues related to the collection of multiple data points from the same organism or system at different times, since such longitudinal data collection is fundamental to the assessment of biological rhythms. Rhythmic longitudinal data require additional specific statistical considerations, ranging from curve fitting to threshold definitions to accounting for correlation structure. We discuss statistical analyses of longitudinal data including issues of correlational structure and stationarity, markers of biological rhythms, demasking of biological rhythms, and determining phase, waveform, and amplitude of biological rhythms. C1 [Bianchi, Matt T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Klerman, Elizabeth B.; Wang, Wei; Phillips, Andrew J. K.; Bianchi, Matt T.] Harvard Med Sch, Div Sleep Med, Boston, MA USA. [Klerman, Elizabeth B.; Wang, Wei; Phillips, Andrew J. K.] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, Boston, MA 02115 USA. RP Klerman, EB (reprint author), BWH, Div Sleep & Circadian Disorders, 221 Longwood Ave, Boston, MA 02115 USA. EM ebklerman@hms.harvard.edu FU NIH [K99/R00 HL119618, K24-HL105664, R01-HL-114088, R01-GM-105018, P01-AG009975]; NSBRI [HFP02802]; MGH Neurology Department (MTB) FX The authors thank Ellen Frank, Karen Gamble, William J. Schwartz, and Katie Sharkey for helpful discussions. This work was supported by NIH K99/R00 HL119618 (AJKP); NIH K24-HL105664 (EBK), R01-HL-114088, R01-GM-105018 and P01-AG009975, and NSBRI HFP02802; MGH Neurology Department (MTB). NR 6 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0748-7304 EI 1552-4531 J9 J BIOL RHYTHM JI J. Biol. Rhythms PD FEB PY 2017 VL 32 IS 1 BP 18 EP 25 DI 10.1177/0748730416670051 PG 8 WC Biology; Physiology SC Life Sciences & Biomedicine - Other Topics; Physiology GA EP2WI UT WOS:000397243900003 PM 27836939 ER PT J AU Cain, SW Chang, AM Vlasac, I Tare, A Anderson, C Czeisler, CA Saxena, R AF Cain, Sean W. Chang, Anne-Marie Vlasac, Irma Tare, Archana Anderson, Clare Czeisler, Charles A. Saxena, Richa TI Circadian Rhythms in Plasma Brain-derived Neurotrophic Factor Differ in Men and Women SO JOURNAL OF BIOLOGICAL RHYTHMS LA English DT Article DE brain derived neurotrophic factor; circadian; Val66Met; constant routine; sex differences ID RAT SUPRACHIASMATIC NUCLEUS; BDNF MESSENGER-RNA; SYNAPTIC PLASTICITY; SEX-DIFFERENCES; PHASE; TRKB; METAANALYSIS; HIPPOCAMPUS; EXPRESSION; PACEMAKER AB The measurement of circulating levels of brain-derived neurotrophic factor (BDNF) has been proposed to be a marker of disease and an indicator of recovery. Thus, knowing the temporal pattern and influence of potential circadian rhythms is important. Although several studies have measured BDNF at different times of day, no studies have done so while controlling for potential masking influences such as sleep and activity. Further, no previous study has examined circadian rhythms within individuals. We examined circadian rhythms in plasma BDNF while minimizing masking from behavioral and environmental factors using a 30-h constant routine (CR) protocol. In a sample of 39 healthy adults, we found significant circadian rhythms in 75% of women and 52% of men. The timing of the acrophase of the BDNF rhythm, however, was unrelated to clock time in women, while it was related to clock time in men. These results indicate that the use of single-sample measures of plasma BDNF as a marker of disease will be unreliable, especially in women. Repeated plasma BDNF samples over a 24-h period within individuals would be needed to reveal abnormalities related to disease states. C1 [Cain, Sean W.; Chang, Anne-Marie; Anderson, Clare; Czeisler, Charles A.; Saxena, Richa] Brigham & Womens Hosp, Dept Med, Div Sleep & Circadian Disorders, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. [Cain, Sean W.; Chang, Anne-Marie; Anderson, Clare; Czeisler, Charles A.] Harvard Med Sch, Div Sleep & Circadian Disorders, Boston, MA USA. [Cain, Sean W.; Anderson, Clare] Monash Univ, Sch Psychol Sci, 18 Innovation Walk,Clayton Campus, Clayton, Vic 3800, Australia. Monash Univ, Monash Inst Cognit & Clin Neurosci, Clayton, Vic 3800, Australia. [Chang, Anne-Marie] Penn State Univ, Dept Biobehav Hlth, University Pk, PA USA. [Vlasac, Irma; Tare, Archana; Saxena, Richa] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Anesthesia, Crit Care & Pain Med, Boston, MA 02114 USA. [Saxena, Richa] Broad Inst Harvard, Med & Populat Genet, Cambridge, MA USA. MIT, Cambridge, MA 02139 USA. RP Cain, SW (reprint author), Monash Univ, Sch Psychol Sci, 18 Innovation Walk,Clayton Campus, Clayton, Vic 3800, Australia. EM Sean.cain@monash.edu FU National Space Biomedical Research Institute (NSBRI) [HFP01601]; National Center for Research Resources (NCRR) of the National Institutes of Health (NIH) [UL1 RR025758] FX We thank the study participants as well as the staff of the Harvard Clinical and Translational Science Center (CTSC) and the Chronobiology Core of the Division of Sleep Medicine of Brigham and Women's Hospital (BWH) for their contributions. The work presented in this manuscript was performed at the Division of Sleep and Circadian Disorders, Department of Medicine and Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts; the Division of Sleep Medicine, Harvard Medical School, Boston, Massachusetts; and the Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts. This study was supported by the National Space Biomedical Research Institute (NSBRI) grant HFP01601. Inpatient studies were conducted in the CTSC and supported in part by UL1 RR025758 from the National Center for Research Resources (NCRR) of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NSBRI, NCRR, NIH or BWH. NR 45 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0748-7304 EI 1552-4531 J9 J BIOL RHYTHM JI J. Biol. Rhythms PD FEB PY 2017 VL 32 IS 1 BP 75 EP 82 DI 10.1177/0748730417693124 PG 8 WC Biology; Physiology SC Life Sciences & Biomedicine - Other Topics; Physiology GA EP2WI UT WOS:000397243900008 PM 28326910 ER PT J AU McMillan, S Rader, C Jorfi, M Pickrell, G Foster, EJ AF McMillan, Sean Rader, Chris Jorfi, Mehdi Pickrell, Gary Foster, E. Johan TI Mechanically switchable polymer fibers for sensing in biological conditions SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE biomedical optics; polymers; materials; fiber optic sensors; fiber optic applications ID OPTICAL-FIBER; PH; SENSOR; FABRICATION; FLUORESCEIN; ABSORPTION; EXPOSURE; PROBE AB The area of in vivo sensing using optical fibers commonly uses materials such as silica and polymethyl methacrylate, both of which possess much higher modulus than human tissue. The mechanical mismatch between materials and living tissue has been seen to cause higher levels of glial encapsulation, scarring, and inflammation, leading to failure of the implanted medical device. We present the use of a fiber made from polyvinyl alcohol (PVA) for use as an implantable sensor as it is an easy to work with functionalized polymer that undergoes a transition from rigid to soft when introduced to water. This ability to switch from stiff to soft reduces the severity of the immune response. The fabricated PVA fibers labeled with fluorescein for sensing applications showed excellent response to various stimuli while exhibiting mechanical switchability. For the dry fibers, a tensile storage modulus of 4700 MPa was measured, which fell sharply to 145 MPa upon wetting. The fibers showed excellent response to changing pH levels, producing values that were detectable in a range consistent with those seen in the literature and in proposed applications. The results show that these mechanically switchable fibers are a viable option for future sensing applications. (c) 2017 Society of Photo-Optical Instrumentation Engineers (SPIE) C1 [McMillan, Sean; Rader, Chris; Pickrell, Gary; Foster, E. Johan] Virginia Tech, Dept Mat Sci & Engn, Blacksburg, VA 24061 USA. [Jorfi, Mehdi] MIT, Dept Chem Engn, Cambridge, MA 02139 USA. [Jorfi, Mehdi] Massachusetts Gen Hosp, Harvard Med Sch, Ctr Engn Med, Boston, MA 02114 USA. RP Foster, EJ (reprint author), Virginia Tech, Dept Mat Sci & Engn, Blacksburg, VA 24061 USA. EM johanf@vt.edu FU Virginia Tech Materials Science and Engineering Department; Digges Faculty Fellowship FX This work was financially supported by the Virginia Tech Materials Science and Engineering Department and the Digges Faculty Fellowship. NR 30 TC 0 Z9 0 U1 0 U2 0 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 EI 1560-2281 J9 J BIOMED OPT JI J. Biomed. Opt. PD FEB PY 2017 VL 22 IS 2 AR 027001 DI 10.1117/1.JBO.22.2.027001 PG 7 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA EP3FJ UT WOS:000397267900018 ER PT J AU Sakadzic, S Boas, DA Carp, S AF Sakadzic, Sava Boas, David A. Carp, Stefan TI Theoretical model of blood flow measurement by diffuse correlation spectroscopy SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE diffuse correlation spectroscopy; diffusing-wave spectroscopy; scattering; random media; autocorrelation function; blood flow; correlation transfer equation; correlation diffusion equation ID DEEP TISSUE; SCATTERING; VALIDATION; MOTION; WAVE; MRI AB Diffuse correlation spectroscopy (DCS) is a noninvasive method to quantify tissue perfusion from measurements of the intensity temporal autocorrelation function of diffusely scattered light. However, DCS auto-correlation function measurements in tissue better match theoretical predictions based on the diffusive motion of the scatterers than those based on a model where the advective nature of blood flow dominates the stochastic properties of the scattered light. We have recently shown using Monte Carlo (MC) simulations and assuming a simplistic vascular geometry and laminar flow profile that the diffusive nature of the DCS autocorrelation function decay is likely a result of the shear-induced diffusion of the red blood cells. Here, we provide theoretical derivations supporting and generalizing the previous MC results. Based on the theory of diffusing-wave spectroscopy, we derive an expression for the autocorrelation function along the photon path through a vessel that takes into account both diffusive and advective scatterer motion, and we provide the solution for the DCS autocorrelation function in a semi-infinite geometry. We also derive the correlation diffusion and correlation transfer equation, which can be applied for an arbitrary sample geometry. Further, we propose a method to take into account realistic vascular morphology and flow profile. (C) 2017 Society of Photo-Optical Instrumentation Engineers (SPIE) C1 [Sakadzic, Sava] Massachusetts Gen Hosp, Charlestown, MA USA. Athinoula Martinos Ctr Biomed Imaging, Harvard Med Sch, Dept Radiol, Charlestown, MA USA. RP Sakadzic, S (reprint author), Massachusetts Gen Hosp, Charlestown, MA USA. EM sava.sakadzic@mgh.harvard.edu FU National Institutes of Health [NS091230, EB015896, CA187595] FX We would like to express our gratitude for support from the National Institutes of Health under Grants Nos. NS091230, EB015896, and CA187595. NR 24 TC 0 Z9 0 U1 0 U2 0 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 EI 1560-2281 J9 J BIOMED OPT JI J. Biomed. Opt. PD FEB PY 2017 VL 22 IS 2 AR 027006 DI 10.1117/1.JBO.22.2.027006 PG 7 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA EP3FJ UT WOS:000397267900023 PM 28241276 ER PT J AU O'Malley, BW Crowley, WF AF O'Malley, Bert W. Crowley, William F. TI In Memoriam, P. Michael Conn, PhD (1949-2016) IN MEMORIAM SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Biographical-Item C1 [O'Malley, Bert W.] Baylor Coll Med, Mol & Cellular Biol, Houston, TX 77030 USA. [Crowley, William F.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Harvard Reprod Endocrine Sci Ctr,Reprod Endocrine, Boston, MA 02114 USA. RP O'Malley, BW (reprint author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA. EM berto@bcm.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD FEB 1 PY 2017 VL 102 IS 2 BP 337 EP 338 DI 10.1210/jc.2016-3896 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EP2VE UT WOS:000397240900001 ER PT J AU Ordonez-Mena, JM Maalmi, H Schottker, B Saum, KU Holleczek, B Wang, TJ Burwinkel, B Brenner, H AF Ordonez-Mena, Jose Manuel Maalmi, Haifa Schoettker, Ben Saum, Kai-Uwe Holleczek, Bernd Wang, Thomas J. Burwinkel, Barbara Brenner, Hermann TI Genetic Variants in the Vitamin D Pathway, 25( OH) D Levels, and Mortality in a Large Population-Based Cohort Study SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID 25-HYDROXYVITAMIN D CONCENTRATIONS; GENOME-WIDE ASSOCIATION; MENDELIAN RANDOMIZATION; PARATHYROID-HORMONE; ALL-CAUSE; HEALTH; METAANALYSIS; DISEASE; OUTCOMES; GERMANY AB Context: Low 25-hydroxyvitamin D[25(OH) D] concentrations have been consistently associated with excess mortality in epidemiological studies, but this association could be due to confounding by health impairments associated with low 25(OH) D levels. An association of vitamin D-related genetic variants with all-cause mortality could strengthen the claims of causality, because this association is assumed to be unaffected by confounding. Objective: To assess the associations of low 25(OH) D with mortality in the presence or absence of genetic variants in the vitamin D pathway. Design, Setting, and Participants: The study consisted of a population-based cohort of 8417 German older adults in whom genetic variants were genotyped. Main Outcome Measures: The primary outcome measure was all-cause mortality. Results: Two single nucleotide polymorphisms (SNPs), rs3755967 (GC) and rs11603330 (DHCR7), were associated with higher risk of low vitamin D status [odds ratio (95% confidence interval) per minor allele, 1.27 (1.18 to 1.36) and 1.16 (1.08 to 1.25), respectively]. Low 25(OH) D (less than the seasonspecific 33rd percentile) was associated with increased mortality. However, none of the SNPs was associated with increased mortality. Furthermore, the increase in mortality for those with low 25(OH) D was generally smaller in the presence of the risk alleles for low 25(OH) D ["genetically low 25(OH) D"] than in the absence of those risk alleles ["otherwise low 25(OH) D"]. Conclusions: Although we may have been limited by a low statistical power to detect small associations, our study showed that the strong relationship between low 25(OH) D and increased mortality may be at least partly due to other factors related to low 25(OH) D levels. C1 [Ordonez-Mena, Jose Manuel; Maalmi, Haifa; Schoettker, Ben; Saum, Kai-Uwe; Brenner, Hermann] Div Clin Epidemiol & Aging Res, Heidelberg, Germany. [Burwinkel, Barbara] German Canc Res Ctr, Mol Epidemiol, D-69120 Heidelberg, Germany. [Ordonez-Mena, Jose Manuel; Maalmi, Haifa; Schoettker, Ben; Brenner, Hermann] Heidelberg Univ, Network Aging Res, D-69115 Heidelberg, Germany. [Ordonez-Mena, Jose Manuel] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6GG, England. [Holleczek, Bernd] Saarland Canc Registry, Saarbrucken 66119, Germany. [Wang, Thomas J.] Harvard Med Sch, Massachusetts Gen Hosp, Cardiovascular Res Ctr, Boston, MA 02114 USA. [Burwinkel, Barbara] Heidelberg Univ, Dept Gynecol & Obstet, Mol Biol Breast Canc, D-69120 Heidelberg, Germany. RP Brenner, H (reprint author), Div Clin Epidemiol & Aging Res, Heidelberg, Germany.; Brenner, H (reprint author), Heidelberg Univ, Network Aging Res, D-69115 Heidelberg, Germany. EM h.brenner@dkfz.de FU Baden-Wurttemberg state Ministry of Science, Research and Arts (Stuttgart, Germany); Federal Ministry of Education and Research (Berlin, Germany); Federal Ministry of Family Affairs, Senior Citizens, Women and Youth (Berlin, Germany); German Cancer Aid [108250, 108426] FX The ESTHER study was funded by the Baden-Wurttemberg state Ministry of Science, Research and Arts (Stuttgart, Germany), the Federal Ministry of Education and Research (Berlin, Germany), and the Federal Ministry of Family Affairs, Senior Citizens, Women and Youth (Berlin, Germany). Measurements of 25(OH)D in men were conducted in the context of the German Cancer Aid projects no. 108250 and 108426. NR 32 TC 0 Z9 0 U1 0 U2 0 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD FEB 1 PY 2017 VL 102 IS 2 BP 470 EP 477 DI 10.1210/jc.2016-2468 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EP2VE UT WOS:000397240900019 PM 27732326 ER PT J AU Anderson, JG Hundt, E Dean, M Keim-Malpass, J Lopez, RP AF Anderson, Joel G. Hundt, Elizabeth Dean, Morgan Keim-Malpass, Jessica Lopez, Ruth Palan TI "The Church of Online Support": Examining the Use of Blogs Among Family Caregivers of Persons With Dementia SO JOURNAL OF FAMILY NURSING LA English DT Article DE family caregivers; dementia; blog; social media ID DISEASE CLINICAL-TRIAL; ILLNESS BLOGS; SOCIAL MEDIA; HEALTH INFORMATION; INTERNET USE; COMMUNICATION; CANCER; COMMUNITIES; NARRATIVES; CARE AB Many individuals, including dementia caregivers, use blogs to share their experiences. These blogs contain rich narratives representing an untapped resource for understanding the psychosocial impact of caring for a person with dementia at the family level. The present study used blogs written by caregivers of persons with dementia to explore how these individuals leveraged this medium as part of the caregiving experience. Blogs written by self-identified informal caregivers of persons with dementia were identified using a systematic search method, and data were analyzed using a qualitative thematic analysis. Four themes emerged from the narratives: social support through communication and engagement, information gathering and seeking, reminiscing and legacy building, and altruism. By understanding the ways in which individuals providing care for persons with dementia use social media as part of the caregiving experience, family nurses can develop interventions and services aimed at improving caregiver burden and quality of life. C1 [Anderson, Joel G.] Univ Tennessee, Coll Nursing, 1200 Volunteer Blvd,Room 153, Knoxville, TN 37996 USA. [Hundt, Elizabeth; Dean, Morgan; Keim-Malpass, Jessica] Univ Virginia, Sch Nursing, Charlottesville, VA 22903 USA. [Lopez, Ruth Palan] Massachusetts Gen Hosp, Inst Hlth Profess, Charlestown, MA USA. RP Anderson, JG (reprint author), Univ Tennessee, Coll Nursing, 1200 Volunteer Blvd,Room 153, Knoxville, TN 37996 USA. EM jande147@utk.edu NR 67 TC 2 Z9 2 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1074-8407 EI 1552-549X J9 J FAM NURS JI J. Fam. Nurs. PD FEB PY 2017 VL 23 IS 1 BP 34 EP 54 DI 10.1177/1074840716681289 PG 21 WC Family Studies; Nursing SC Family Studies; Nursing GA EP2KG UT WOS:000397211300003 ER PT J AU McFarland, EJ Powell, TM Onyango-Makumbi, C Zhang, WM Melander, K Naluyima, P Okurut, S Eller, MA Fowler, MG Janoff, EN AF McFarland, Elizabeth J. Powell, Tina M. Onyango-Makumbi, Carolyne Zhang, Weiming Melander, Kelsey Naluyima, Prossy Okurut, Samuel Eller, Michael A. Fowler, Mary Glenn Janoff, Edward N. TI Ontogeny of CD4(+) T Lymphocytes With Phenotypic Susceptibility to HIV-1 During Exclusive and Nonexclusive Breastfeeding in HIV-1-Exposed Ugandan Infants SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE HIV-1; breastfeeding; postnatal transmission; CD4+T lymphocytes; lymphocyte activation; T cell homing; CCR5; alpha 4 beta 7. ID ACUTE CYTOMEGALOVIRUS-INFECTION; UNINFECTED CHILDREN BORN; INTEGRIN ALPHA(4)BETA(7); IMMUNODEFICIENCY-VIRUS; TRANSMISSION; CELLS; MOTHER; EXPRESSION; MUCOSAL; GUT AB Background. Among infants exposed to human immunodeficiency virus (HIV) type 1, mixed breastfeeding is associated with higher postnatal HIV-1 transmission than exclusive breastfeeding, but the mechanisms of this differential risk are uncertain. Methods. HIV-1-exposed Ugandan infants were prospectively assessed during the first year of life for feeding practices and T-cell maturation, intestinal homing (beta 7(hi)), activation, and HIV-1 coreceptor (CCR5) expression in peripheral blood. Infants receiving only breast milk and those with introduction of other foods before 6 months were categorized as exclusive and nonexclusive, respectively. Results. Among CD4(+) and CD8(+) T cells, the expression of memory, activation, and CCR5 markers increased rapidly from birth to week 2, peaking at week 6, whereas cells expressing the intestinal homing marker increased steadily in the central memory ( CM) and effector memory T cells over 48 weeks. At 24 weeks, when feeding practices had diverged, nonexclusively breastfed infants showed increased frequencies and absolute counts of beta 7(hi) CM CD4+ and CD8+ T cells, including the HIV-1-targeted cells with CD4(+)beta 7(hi)/CCR5(+) coexpression, as well as increased activation. Conclusions. The T-cell phenotype associated with susceptibility to HIV-1 infection (CCR5(+), gut-homing, CM CD4+ T cells) was preferentially expressed in nonexclusively breastfed infants, a group of infants at increased risk for HIV-1 acquisition. C1 [McFarland, Elizabeth J.; Powell, Tina M.] Univ Colorado Anschutz Med Campus, Colorado Sch Publ Hlth, Dept Pediat, Aurora, CO USA. [Melander, Kelsey; Janoff, Edward N.] Univ Colorado Anschutz Med Campus, Colorado Sch Publ Hlth, Dept Med, Aurora, CO USA. [Zhang, Weiming] Univ Colorado Anschutz Med Campus, Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. [McFarland, Elizabeth J.; Janoff, Edward N.] Univ Colorado Anschutz Med Campus, Mucosal & Vaccine Res Program Colorado Infect Dis, Aurora, CO USA. [Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Eller, Michael A.] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD USA. [Eller, Michael A.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA. [Fowler, Mary Glenn] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Onyango-Makumbi, Carolyne; Fowler, Mary Glenn] Makerere Univ, Johns Hopkins Univ Res Collaborat, Kampala, Uganda. [Naluyima, Prossy; Okurut, Samuel] Makerere Univ Walter Reed Project, Kampala, Uganda. RP McFarland, EJ (reprint author), Univ Colorado, Childrens Hosp Colorado, Div Pediat Infect Dis, Anschutz Med Campus,13123 E 16th Ave, Aurora, CO 80045 USA. EM betsy.mcfarland@ucdenver.edu NR 49 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 1 PY 2017 VL 215 IS 3 BP 368 EP 377 DI 10.1093/infdis/jiw553 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP2HT UT WOS:000397204700006 PM 27932619 ER PT J AU Neelamegam, R Yokell, DL Rice, PA Furumoto, S Kudo, Y Okamura, N El Fakhri, G AF Neelamegam, Ramesh Yokell, Daniel L. Rice, Peter A. Furumoto, Shozo Kudo, Yukitsuka Okamura, Nobuyuki El Fakhri, Georges TI A report of the automated radiosynthesis of the tau positron emission tomography radiopharmaceutical, [(18F)]-THK-5351 SO JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS LA English DT Article DE fluorine-18; PET; Tau; THK-5351 ID ALZHEIMERS-DISEASE; NEUROFIBRILLARY PATHOLOGY; IMAGING TRACERS; PET TRACER; DERIVATIVES; LANSOPRAZOLE; RADIOLIGAND; ASTEMIZOLE; TANGLES; T807 AB The radiotracer, [F-18]-THK-5351, is a highly selective and high-binding affinity PET imaging agent for aggregates of hyper-phosphorylated tau protein. Our report is a simplified 1-pot, 2-step radiosynthesis of [F-18]-THK-5351. This report is broadly applicable for routine clinical production and multi-center trials on account of favorable half-life of flourine-18 and the use of a commercially available radiosynthesis module, the GE TRACERlab T FXFN. First, the O-THP protected tosyl precursor underwent nucleophilic fluorinating reaction with potassium cryptand fluoride ([F-18] fluoride (K[F-18]/K222)) in Dimethyl sulfoxide at 110 degrees C for 10 minutes followed by O-THP removal by using diluted hydrochloric acid (HCl) at same temperature. [F-18]-THK-5351 was purified via semi-preparative high-performance liquid chromatography and formulated by using 10% EtOH, United States Pharmacopeia (USP) in 0.9% sodium chloride for injection, USP and an uncorrected radiochemical yield of 21 +/- 3.5%, with a specific activity of 153.11 +/- 25.9 GBq/mu mol (4138 +/- 700 mCi/mu mol) at the end of synthesis (63 minutes; n = 3). C1 [Neelamegam, Ramesh; Yokell, Daniel L.; Rice, Peter A.; El Fakhri, Georges] Massachusetts Gen Hosp, Dept Radiol, Gordon Ctr Med Imaging, Boston, MA USA. [Neelamegam, Ramesh; Yokell, Daniel L.; El Fakhri, Georges] Harvard Med Sch, Dept Radiol, Boston, MA USA. [Furumoto, Shozo] Tohoku Univ, Div Radiopharmaceut Chem, Ctr Cyclotron & Radioisotope, Sendai, Miyagi, Japan. [Kudo, Yukitsuka] Tohoku Univ, Div Neuroimaging, Inst Dev Aging & Canc, Sendai, Miyagi, Japan. [Okamura, Nobuyuki] Tohoku Med & Pharmaceut Univ, Div Pharmacol, Fac Med, Sendai, Miyagi, Japan. RP Yokell, DL (reprint author), Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Dept Radiol, 55 Fruit St,Edwards 019B, Boston, MA 02114 USA. EM dyokell@mgh.harvard.edu NR 34 TC 0 Z9 0 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0362-4803 EI 1099-1344 J9 J LABELLED COMPD RAD JI J. Label. Compd. Radiopharm. PD FEB PY 2017 VL 60 IS 2 BP 140 EP 146 DI 10.1002/jlcr.3482 PG 7 WC Biochemical Research Methods; Chemistry, Medicinal; Chemistry, Analytical SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry GA EO9RC UT WOS:000397024800007 PM 27859483 ER PT J AU Kesler, SR Noll, K Cahill, DP Rao, G Wefel, JS AF Kesler, Shelli R. Noll, Kyle Cahill, Daniel P. Rao, Ganesh Wefel, Jeffrey S. TI The effect of IDH1 mutation on the structural connectome in malignant astrocytoma SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE IDH1; Astrocytoma; Connectome; Cognition; MRI ID DEFAULT MODE NETWORK; COGNITIVE RESERVE; BREAST-CANCER; GRAY-MATTER; BRAIN NETWORKS; RANDOM FORESTS; NORMATIVE DATA; GLIOMAS; AGE; CLASSIFICATION AB Mutation of the IDH1 gene is associated with differences in malignant astrocytoma growth characteristics that impact phenotypic severity, including cognitive impairment. We previously demonstrated greater cognitive impairment in patients with IDH1 wild type tumor compared to those with IDH1 mutant, and therefore we hypothesized that brain network organization would be lower in patients with wild type tumors. Volumetric, T1-weighted MRI scans were obtained retrospectively from 35 patients with IDH1 mutant and 32 patients with wild type malignant astrocytoma (mean age = 45 +/- 14 years) and used to extract individual level, gray matter connectomes. Graph theoretical analysis was then applied to measure efficiency and other connectome properties for each patient. Cognitive performance was categorized as impaired or not and random forest classification was used to explore factors associated with cognitive impairment. Patients with wild type tumor demonstrated significantly lower network efficiency in several medial frontal, posterior parietal and subcortical regions (p < 0.05, corrected for multiple comparisons). Patients with wild type tumor also demonstrated significantly higher incidence of cognitive impairment (p = 0.03). Random forest analysis indicated that network efficiency was inversely, though nonlinearly associated with cognitive impairment in both groups (p < 0.0001). Cognitive reserve appeared to mediate this relationship in patients with mutant tumor suggesting greater neuroplasticity and/or benefit from neuroprotective factors. Tumor volume was the greatest contributor to cognitive impairment in patients with wild type tumor, supporting our hypothesis that greater lesion momentum between grades may cause more disconnection of core neurocircuitry and consequently lower efficiency of information processing. C1 [Kesler, Shelli R.; Noll, Kyle; Wefel, Jeffrey S.] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, 1515 Holcombe Blvd,Unit 431, Houston, TX 77030 USA. [Cahill, Daniel P.] Massachusetts Gen Hosp, Dept Neurosurg, Harvard Neurosurg Serv, Boston, MA 02114 USA. [Rao, Ganesh] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA. RP Kesler, SR (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, 1515 Holcombe Blvd,Unit 431, Houston, TX 77030 USA. EM skesler@mdanderson.org FU National Institutes of Health [1R01CA172145, 1R03CA191559, 1R01NR014195, K08NS070928] FX This work was supported by grants from the National Institutes of Health (1R01CA172145 to S.R.K, 1R03CA191559 to S.R.K, 1R01NR014195 to J.S.W./S.R.K. and K08NS070928 to G.R.). NR 72 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD FEB PY 2017 VL 131 IS 3 BP 565 EP 574 DI 10.1007/s11060-016-2328-1 PG 10 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA EP4CV UT WOS:000397329100015 PM 27848136 ER PT J AU Kalpathy-Cramer, J Chandra, V Da, X Ou, YM Emblem, KE Muzikansky, A Cai, XZ Douw, L Evans, JG Dietrich, J Chi, AS Wen, PY Stufflebeam, S Rosen, B Duda, DG Jain, RK Batchelor, TT Gerstner, ER AF Kalpathy-Cramer, Jayashree Chandra, Vyshak Da, Xiao Ou, Yangming Emblem, Kyrre E. Muzikansky, Alona Cai, Xuezhu Douw, Linda Evans, John G. Dietrich, Jorg Chi, Andrew S. Wen, Patrick Y. Stufflebeam, Stephen Rosen, Bruce Duda, Dan G. Jain, Rakesh K. Batchelor, Tracy T. Gerstner, Elizabeth R. TI Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Glioblastoma; Anti-angiogenesis; MRI; Progression-free survival; Overall survival; Tivozanib ID ENDOTHELIAL GROWTH-FACTOR; KINASE INHIBITOR; SOLID TUMORS; ANGIOGENESIS; SURVIVAL; BRAIN; CEDIRANIB; BIOMARKER; NETWORK; GLIOMAS AB Targeting tumor angiogenesis is a potential therapeutic strategy for glioblastoma because of its high vascularization. Tivozanib is an oral pan-VEGF receptor tyrosine kinase inhibitor that hits a central pathway in glioblastoma angiogenesis. We conducted a phase II study to test the effectiveness of tivozanib in patients with recurrent glioblastoma. Ten adult patients were enrolled and treated with tivozanib 1.5 mg daily, 3 weeks on/1 week off in 28-day cycles. Brain MRI and blood biomarkers of angiogenesis were performed at baseline, within 24-72 h of treatment initiation, and monthly thereafter. Dynamic contrast enhanced MRI, dynamic susceptibility contrast MRI, and vessel architecture imaging were used to assess vascular effects. Resting state MRI was used to assess brain connectivity. Best RANO criteria responses were: 1 complete response, 1 partial response, 4 stable diseases, and 4 progressive disease (PD). Two patients were taken off study for toxicity and 8 patients were taken off study for PD. Median progression-free survival was 2.3 months and median overall survival was 8.1 months. Baseline abnormal tumor vascular permeability, blood flow, tissue oxygenation and plasma sVEGFR2 significantly decreased and plasma PlGF and VEGF increased after treatment, suggesting an anti-angiogenic effect of tivozanib. However, there were no clear structural changes in vasculature as vessel caliber and enhancing tumor volume did not significantly change. Despite functional changes in tumor vasculature, tivozanib had limited anti-tumor activity, highlighting the limitations of anti-VEGF monotherapy. Future studies in glioblastoma should leverage the anti-vascular activity of agents targeting VEGF to enhance the activity of other therapies. C1 [Kalpathy-Cramer, Jayashree; Chandra, Vyshak; Da, Xiao; Ou, Yangming; Emblem, Kyrre E.; Cai, Xuezhu; Douw, Linda; Evans, John G.; Stufflebeam, Stephen; Rosen, Bruce] Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Muzikansky, Alona; Dietrich, Jorg; Duda, Dan G.; Jain, Rakesh K.; Batchelor, Tracy T.; Gerstner, Elizabeth R.] Massachusetts Gen Hosp, Ctr Canc, Stephen E & Catherine Pappas Ctr Neurooncol, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA. [Emblem, Kyrre E.] Oslo Univ Hosp, Intervent Ctr, Oslo, Norway. [Douw, Linda] Vrije Univ Amsterdam Med Ctr, VUmc CCA Brain Tumor Ctr Amsterdam, Dept Anat & Neurosci, Amsterdam, Netherlands. [Wen, Patrick Y.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chi, Andrew S.] NYU, Laura & Isaac Perlmutter Canc Ctr, Langone Med Ctr, New York, NY USA. RP Gerstner, ER (reprint author), Massachusetts Gen Hosp, Ctr Canc, Stephen E & Catherine Pappas Ctr Neurooncol, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA. EM egerstner@partners.org FU National Comprehensive Cancer Network (NCCN) Oncology Research Program from AVEO Pharmaceuticals, Inc.; National Cancer Institute [P01CA80124]; National Foundation for Cancer Research; [U24CA180918]; [U01CA154601]; [S10RR023043]; [P41RR14075] FX This study was approved and funded by the National Comprehensive Cancer Network (NCCN) Oncology Research Program from general research support provided by AVEO Pharmaceuticals, Inc. (to E.G.). The research of R.K.J. and D.G.D. is funded by National Cancer Institute Grant P01CA80124 and the National Foundation for Cancer Research. Funding was also provided by U24CA180918 and U01CA154601 (to J.K.C.) and S10RR023043 and P41RR14075. NR 33 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD FEB PY 2017 VL 131 IS 3 BP 603 EP 610 DI 10.1007/s11060-016-2332-5 PG 8 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA EP4CV UT WOS:000397329100019 PM 27853960 ER PT J AU Pardeshi, NN Qi, W Dahl, K Caplan, L Carpenter, JF AF Pardeshi, Neha N. Qi, Wei Dahl, Kevin Caplan, Liron Carpenter, John F. TI Microparticles and Nanoparticles Delivered in Intravenous Saline and in an Intravenous Solution of a Therapeutic Antibody Product SO JOURNAL OF PHARMACEUTICAL SCIENCES LA English DT Article DE protein aggregation; microparticles; nanoparticles; IgG antibody; protein delivery; adsorption; particle size ID POLYVINYL-CHLORIDE BAGS; MONOCLONAL-ANTIBODY; PROTEIN AGGREGATION; GROWTH-HORMONE; FACTOR-VIII; PARTICLES; STABILITY; INFUSION; MICE; IMMUNOGENICITY AB Intravenous ( IV) infusion is used for administration of a large proportion of biologic therapeutics, including most monoclonal antibody products. In this study, we determined the subvisible particle levels in IV solutions and after the solutions were processed with an IV administration setup that mimicked the typical clinical method of administration. IV saline in bags manufactured by both Hospira and Baxter contained 1600-8000 microparticles/mL and 4-73 x 10(6) nanoparticles/mL in solution. When IV immunoglobulin was diluted into the IV saline, 3700-23,000 microparticles/mL and 18-240 x 10(6) nanoparticles/mL were detected. During processing of the solution through the IV system, in-line filters removed most microparticles. However, there were still 1-21 x 10(6) nanoparticles/mL in IV saline and 7-83 x 10(6) nanoparticles/mL in IV immunoglobulin diluted in saline. Finally, in samples processed through in-line filters, we found relatively large microparticles ( 20-60 mm) that were composed of protein or polycarbonate. These particles resulted from shedding of polycarbonate and sloughing off of protein films downstream from the filter membrane. Overall, the results document that even with in-line filters in place, high levels of subvisible particles are delivered to patients and there is a need for improved, more effective filters and IV solutions with lower particle levels. (C) 2017 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved. C1 [Pardeshi, Neha N.; Carpenter, John F.] Univ Colorado, Sch Pharm, Dept Pharmaceut Sci, Anschutz Med Campus, Aurora, CO 80045 USA. [Qi, Wei; Dahl, Kevin] Malvern Instruments, Columbia, MD 21046 USA. [Caplan, Liron] Univ Colorado, Denver Vet Affairs Hosp, Rheumatol Sect, Aurora, CO 80045 USA. [Caplan, Liron] Univ Colorado, Sch Med, Aurora, CO 80045 USA. RP Carpenter, JF (reprint author), Univ Colorado, Sch Pharm, Dept Pharmaceut Sci, Anschutz Med Campus, Aurora, CO 80045 USA. EM john.carpenter@ucdenver.edu FU NIH [5RO1 EB006006] FX The authors would like to thank Beth Moran, RN, and Mary Cousins, RN, for expert advice about the clinical practices for preparation and IV infusion of therapeutic proteins and for their help in replicating the IV infusion system in the laboratory. We gratefully acknowledge support from NIH Grant 5RO1 EB006006. NR 30 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3549 EI 1520-6017 J9 J PHARM SCI-US JI J. Pharm. Sci. PD FEB PY 2017 VL 106 IS 2 BP 511 EP 520 DI 10.1016/j.xphs.2016.09.028 PG 10 WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy SC Pharmacology & Pharmacy; Chemistry GA EP3KE UT WOS:000397280400008 PM 27832839 ER PT J AU Murillo, R Lambiase, MJ Rockette-Wagner, BJ Kriska, AM Halbach, JP Thurston, RC AF Murillo, Rosenda Lambiase, Maya J. Rockette-Wagner, Bonny J. Kriska, Andrea M. Halbach, Jeffrey P. Thurston, Rebecca C. TI Racial/Ethnic Differences in the Associations Between Physical Activity and Sleep Duration: A Population-Based Study SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE health disparities; exercise; epidemiology ID HEALTH DISPARITIES; MIDLIFE WOMEN; LEISURE-TIME; WORK; METAANALYSIS; EXERCISE AB Background: This study examined associations between physical activity (recreational, nonrecreational) and sleep duration among a nationally representative diverse sample of U.S. adults. Methods: We used cross-sectional data from 9,205 National Health and Nutrition Examination Survey 2007 to 2012 participants aged 20 to 65 years who identified as White, Black, or Hispanic. Activity (ie, recreation, occupation, and transportation activity) was categorized into quartiles. Sleep duration was categorized as short (56 hours/night) or normal (>6 to 59 hours/night). Logistic regression was used to estimate associations of activity with sleep duration. Results: Recommended levels of recreation activity and moderate levels of transportation activity were associated with normal sleep duration [Odds Ratio (OR): = 1.33, 95% Confidence Interval (CI) = 1.08, 1.65; OR = 1.28, 95% CI = 1.02, 1.62, respectively]. High occupation physical activity was associated with shorter sleep duration (OR = 0.59, 95% CI = 0:49, 0.71). Differences were observed by race/ethnicity in associations of recreation and occupation activity with sleep duration. Conclusions: White individuals who engaged in some recreation activity, relative to being inactive, had more favorable sleep duration; whereas, high levels of occupation activity were associated with worse sleep duration among White and Black individuals. Physical activity was not associated with sleep duration among Hispanics. C1 [Murillo, Rosenda] Univ Houston, Dept Psychol Hlth & Learning Sci, Houston, TX 77004 USA. [Lambiase, Maya J.] VA Pittsburgh Healthcare Syst, Dept Vet Affairs, Pittsburgh, PA USA. [Rockette-Wagner, Bonny J.; Kriska, Andrea M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Halbach, Jeffrey P.] US Dept Vet Affairs, Hlth Serv Res & Dev, Washington, DC USA. [Thurston, Rebecca C.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. RP Murillo, R (reprint author), Univ Houston, Dept Psychol Hlth & Learning Sci, Houston, TX 77004 USA. EM rmurillo3@uh.edu FU Department of Veterans Affairs Advanced Fellowship in Women's Health, VA Pittsburgh Healthcare System FX This work was supported by resources and funding from the Department of Veterans Affairs Advanced Fellowship in Women's Health, VA Pittsburgh Healthcare System. The contents do not represent the views of the Department of Veterans Affairs, Department of Defense, or the United States Government. NR 36 TC 0 Z9 0 U1 0 U2 0 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 EI 1543-5474 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD FEB PY 2017 VL 14 IS 2 BP 138 EP 144 DI 10.1123/jpah.2015-0638 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EO8UB UT WOS:000396964900009 PM 27918684 ER PT J AU Jassar, AS Kim, JB Sundt, TM AF Jassar, Arminder S. Kim, Joon Bum Sundt, Thoralf M. TI THE MORE I LEARN THE LESS I KNOW SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Letter ID AORTIC-VALVE; ENDOCARDITIS; REPLACEMENT C1 [Jassar, Arminder S.; Kim, Joon Bum; Sundt, Thoralf M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Jassar, AS (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD FEB PY 2017 VL 153 IS 2 BP 282 EP 283 DI 10.1016/j.jtcvs.2016.09.056 PG 3 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EO7TY UT WOS:000396894200035 PM 28104193 ER PT J AU Roshanravan, B Patel, KV Fried, LF Robinson-Cohen, C de Boer, IH Harris, T Murphy, RA Satterfield, S Goodpaster, BH Shlipak, M Newman, AB Kestenbaum, B AF Roshanravan, Baback Patel, Kushang V. Fried, Linda F. Robinson-Cohen, Cassianne de Boer, Ian H. Harris, Tamara Murphy, Rachel A. Satterfield, Suzanne Goodpaster, Bret H. Shlipak, Michael Newman, Anne B. Kestenbaum, Bryan CA Hlth ABC Study TI Association of Muscle Endurance, Fatigability, and Strength With Functional Limitation and Mortality in the Health Aging and Body Composition Study SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Mobility; Muscle; Fatigue; Strength; Sarcopenia ID CHRONIC KIDNEY-DISEASE; OLDER-ADULTS; WALKING SPEED; MOBILITY DISABILITY; CYSTATIN C; GAIT SPEED; FRAILTY; PREVALENCE; CREATININE; INCHIANTI AB Background: Mobility limitation is highly prevalent among older adults and is central to the loss of functional independence. Dynamic isokinetic muscle fatigue testing may reveal increased vulnerability to disability and mortality beyond strength testing. Methods: We studied community-dwelling older adults enrolled in the Health Aging and Body Composition study (age range: 71-82) free of mobility disability and who underwent isokinetic muscle fatigue testing in 1999-2000 (n = 1,963). Isokinetic quadriceps work and fatigue index was determined over 30 repetitions and compared with isometric quadriceps maximum torque. Work was normalized to leg lean mass accounting for gender-specific differences (specific work). The primary outcome was incident persistent severe lower extremity limitation (PSLL), defined as two consecutive reports of either having a lot of difficulty or being unable to walk 1/4 mile or climb 10 steps without resting. The secondary outcome was all-cause mortality. Results: There were 608 (31%) occurrences of incident PSLL and 488 (25%) deaths during median follow-up of 9.3 years. After adjustment, lower isokinetic work was associated with significantly greater risks of PSLL and mortality across the full measured range. Hazard ratios per standard deviation lower specific isokinetic work were 1.22 (95% CI 1.12, 1.33) for PSLL and 1.21 (95% CI 1.13, 1.30) for mortality, respectively. Lower isometric strength was associated with PSLL, but not mortality. Fatigue index was not associated with PSLL or mortality. Conclusions: Muscle endurance, estimated by isokinetic work, is an indicator of muscle health associated with mobility limitation and mortality providing important insight beyond strength testing. C1 [Roshanravan, Baback; Robinson-Cohen, Cassianne; de Boer, Ian H.; Kestenbaum, Bryan] Univ Washington, Dept Med, Div Nephrol, Kidney Res Inst, 325 9th Ave,Room 3NJ350,Box 359606, Seattle, WA 98104 USA. [Patel, Kushang V.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. [Fried, Linda F.] Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. [Harris, Tamara] NIA, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA. [Murphy, Rachel A.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada. [Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Goodpaster, Bret H.] Florida Hosp, Orlando, FL USA. [Goodpaster, Bret H.] Sanford Burnham Presbys Translat Res Inst Metab &, Orlando, FL USA. [Shlipak, Michael] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Newman, Anne B.] Univ Pittsburgh, Sch Med, Dept Epidemiol, Pittsburgh, PA 15260 USA. RP Roshanravan, B (reprint author), Univ Washington, Dept Med, Div Nephrol, Kidney Res Inst, 325 9th Ave,Room 3NJ350,Box 359606, Seattle, WA 98104 USA. EM broshanr@uw.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [K23-DK099442]; National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIA [R01-AG028050]; NINR [R01-NR012459]; NIH, National Institute on Aging; Northwest Kidney Centers FX This research was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (K23-DK099442 to B.R.); National Institute on Aging (NIA) Contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106; NIA grant R01-AG028050; and NINR grant R01-NR012459. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging. This work was also supported by an unrestricted fund from the Northwest Kidney Centers (B.R.). NR 30 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD FEB PY 2017 VL 72 IS 2 BP 284 EP 291 DI 10.1093/gerona/glw210 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EP2EC UT WOS:000397194800019 PM 27907890 ER PT J AU Sigel, K Wisnivesky, J Crothers, K Gordon, K Brown, ST Rimland, D Rodriguez-Barradas, MC Gibert, C Goetz, MB Bedimo, R Park, LS Dubrow, R AF Sigel, Keith Wisnivesky, Juan Crothers, Kristina Gordon, Kirsha Brown, Sheldon T. Rimland, David Rodriguez-Barradas, Maria C. Gibert, Cynthia Goetz, Matthew Bidwell Bedimo, Roger Park, Lesley S. Dubrow, Robert TI Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study SO LANCET HIV LA English DT Article ID CIGARETTE-SMOKING; UNITED-STATES; ANTIRETROVIRAL THERAPY; CD4/CD8 RATIO; AIDS; INDIVIDUALS; IMMUNODEFICIENCY; DISEASE; PEOPLE; PROGRESSION AB Background HIV infection is independently associated with risk of lung cancer, but few data exist for the relation between longitudinal measurements of immune function and lung-cancer risk in people living with HIV. Methods We followed up participants with HIV from the Veterans Aging Cohort Study for a minimum of 3 years between Jan 1, 1998, and Dec 31, 2012, and used cancer registry data to identify incident cases of lung cancer. The index date for each patient was the later of the date HIV care began or Jan 1, 1998. We excluded patients with less than 3 years' follow-up, prevalent diagnoses of lung cancer, or incomplete laboratory data. We used Cox regression models to investigate the relation between different time-updated lagged and cumulative exposures (CD4 cell count, CD8 cell count, CD4/CD8 ratio, HIV RNA, and bacterial pneumonia) and risk of lung cancer. Models were adjusted for age, race or ethnicity, smoking, hepatitis C virus infection, alcohol use disorders, drug use disorders, and history of chronic obstructive pulmonary disease and occupational lung disease. Findings We identified 277 cases of incident lung cancer in 21 666 participants with HIV. In separate models for each time-updated 12 month lagged, 24 month simple moving average cumulative exposure, increased risk of lung cancer was associated with low CD4 cell count (p trend= 0.001), low CD4/CD8 ratio (p trend= 0.0001), high HIV RNA concentration (p=0.004), and more cumulative bacterial pneumonia episodes (12 month lag only; p trend= 0.0004). In a mutually adjusted model including these factors, CD4/CD8 ratio and cumulative bacterial pneumonia episodes remained significant (p trends 0.003 and 0.004, respectively). Interpretation In our large HIV cohort in the antiretroviral therapy era, we found evidence that dysfunctional immune activation and chronic inflammation contribute to the development of lung cancer in the setting of HIV infection. These findings could be used to target lung-cancer prevention measures to high-risk groups. C1 [Sigel, Keith; Wisnivesky, Juan; Brown, Sheldon T.] Icahn Sch Med Mt Sinai, Dept Med, 17 East 102nd St, New York, NY 10029 USA. [Crothers, Kristina] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Gordon, Kirsha] VA Connecticut Healthcare Syst, Dept Med, New Haven, CT USA. [Gordon, Kirsha] Yale Sch Med & Publ Hlth, New Haven, CT USA. [Brown, Sheldon T.] James J Peters VA Med Ctr, Infect Dis Sect, Bronx, NY USA. [Rimland, David] Atlanta VA Med Ctr, Infect Dis Sect, Decatur, GA USA. [Rimland, David] Emory Univ, Sch Med, Decatur, GA 30033 USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA. [Gibert, Cynthia] George Washington Univ, Sch Med, Dept Med, Washington, DC USA. [Gibert, Cynthia] Washington DC Vet Affairs Med Ctr, Washington, DC USA. [Goetz, Matthew Bidwell] VA Los Greater Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Bedimo, Roger] VA North Texas Hlth Care Syst, Div Infect Dis, Dallas, TX USA. [Park, Lesley S.] Stanford Univ, Sch Med, Ctr Populat Hlth Sci, Palo Alto, CA 94304 USA. [Dubrow, Robert] Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT USA. RP Sigel, K (reprint author), Icahn Sch Med Mt Sinai, Dept Med, 17 East 102nd St, New York, NY 10029 USA. EM keith.sigel@mssm.edu OI Sigel, Keith/0000-0002-4051-4861 FU US National Institutes of Health FX US National Institutes of Health. NR 30 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 2352-3018 J9 LANCET HIV JI Lancet HIV PD FEB PY 2017 VL 4 IS 2 BP E67 EP E73 DI 10.1016/S2352-3018(16)30215-6 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EP3EV UT WOS:000397266500008 PM 27916584 ER PT J AU Spatz, JM Ellman, R Cloutier, AM Louis, L van Vliet, M Dwyer, D Stolina, M Ke, HZ Bouxsein, ML AF Spatz, J. M. Ellman, R. Cloutier, A. M. Louis, L. van Vliet, M. Dwyer, D. Stolina, M. Ke, H. Z. Bouxsein, M. L. TI Sclerostin antibody inhibits skeletal deterioration in mice exposed to partial weight-bearing SO LIFE SCIENCES IN SPACE RESEARCH LA English DT Article DE Bone loss; Partial weight-bearing; Sclerostin antibody; Bone; Moon; Mars ID INCREASES BONE-FORMATION; VAN-BUCHEM-DISEASE; SOST GENE; MINERAL DENSITY; RAT MODEL; MASS; DELETION; OSTEOPOROSIS; POPULATION; DEFICIENCY AB Whereas much is known regarding the musculoskeletal responses to full unloading, little is known about the physiological effects and response to pharmacological agents in partial unloading (e. g. Moon and Mars) environments. To address this, we used a previously developed ground-based model of partial weight-bearing (PWB) that allows chronic exposure to reduced weight-bearing in mice to determine the effects of murine sclerostin antibody (SclAbII) on bone microstructure and strength across different levels of mechanical unloading. We hypothesize that treatment with SclAbII would improve bone mass, microarchitecture and strength in all loading conditions, but that there would be a greater skeletal response in the normally loaded mice than in partially unloaded mice suggesting the importance of combined countermeasures for exploration-class long duration spaceflight missions. Eleven-week-old female mice were assigned to one of four loading groups: normal weight-bearing controls (CON) or weight-bearing at 20% (PWB20), 40% (PWB40) or 70% (PWB70) of normal. Mice in each group received either SclAbII (25 mg/kg) or vehicle (VEH) via twice weekly subcutaneous injection for 3 weeks. In partially-unloaded VEH-treated groups, leg BMD decreased -5 to -10% in a load-dependent manner. SclAbII treatment completely inhibited bone deterioration due to PWB, with bone properties in SclAbII-treated groups being equal to or greater than those of CON, VEH-treated mice. SclAbII treatment increased leg BMD from + 14 to + 18% in the PWB groups and 30 +/- 3% in CON (p < 0.0 0 01 for all). Trabecular bone volume, assessed by mu CT at the distal femur, was lower in all partially unloaded VEH-treated groups vs. CON-VEH (p < 0.05), and was 2-3 fold higher in SclAbII-treated groups (p < 0.001). Midshaft femoral strength was also significantly higher in SclAbII vs. VEH-groups in all-loading conditions. These results suggest that greater weight bearing leads to greater benefits of SclAbII on bone mass, particularly in the trabecular compartment. Altogether, these results demonstrate the efficacy of sclerostin antibody therapy in preventing astronaut bone loss during terrestrial solar system exploration. c 2017 The Committee on Space Research (COSPAR). Published by Elsevier Ltd. All rights reserved. C1 [Spatz, J. M.; Ellman, R.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Spatz, J. M.; Ellman, R.; Cloutier, A. M.; Louis, L.; van Vliet, M.; Bouxsein, M. L.] Beth Israel Deaconess Med Ctr, Ctr Adv Orthoped Studies, Boston, MA 02215 USA. [Spatz, J. M.; Bouxsein, M. L.] Massachusetts Gen Hosp, Div Endocrine, Boston, MA 02114 USA. [Bouxsein, M. L.] Harvard Med Sch, Dept Orthopaed Surg, Boston, MA USA. [Dwyer, D.; Stolina, M.] Amgen Inc, Thousand Oaks, CA USA. [Ke, H. Z.] UCB Pharma, Bone Res, Slough, Berks, England. RP Spatz, JM (reprint author), MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Spatz, JM (reprint author), Beth Israel Deaconess Med Ctr, Ctr Adv Orthoped Studies, Boston, MA 02215 USA.; Spatz, JM (reprint author), Massachusetts Gen Hosp, Div Endocrine, Boston, MA 02114 USA. EM mbouxsei@bidmc.harvard.edu FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [R21 AR057522, S10RR017868]; NASA [NNX10AE39G]; National Space Biomedical Research Institute through NASA [NCC 9-58]; Amgen; NASA-Jenkins pre-doctoral fellowship; Northrop Grumman Aerospace Systems FX Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number R21 AR057522 and S10RR017868. The work was also supported by NASA NNX10AE39G, the National Space Biomedical Research Institute through NASA NCC 9-58, and a research grant from Amgen. RE was supported by a NASA-Jenkins pre-doctoral fellowship. JMS was supported by a Northrop Grumman Aerospace Systems Ph.D. Training Fellowship and Hugh Hampton Young Fellowship. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 37 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2214-5524 EI 2214-5532 J9 LIFE SCI SPACE RES JI Life Sci. Space Res. PD FEB PY 2017 VL 12 BP 32 EP 38 DI 10.1016/j.lssr.2017.01.001 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EO9ZH UT WOS:000397046100004 PM 28212706 ER PT J AU Ikeda, H Souda, H Puspitasari, A Held, KD Hidema, J Nikawa, T Yoshida, Y Kanai, T Takahashi, A AF Ikeda, Hiroko Souda, Hikaru Puspitasari, Anggraeini Held, Kathryn D. Hidema, Jun Nikawa, Takeshi Yoshida, Yukari Kanai, Tatsuaki Takahashi, Akihisa TI Development and performance evaluation of a three-dimensional clinostat synchronized heavy-ion irradiation system SO LIFE SCIENCES IN SPACE RESEARCH LA English DT Article DE Microgravity; Three-dimensional clinostat; Space radiation; Heavy-ion; Combined effects ID DNA-DAMAGE; MICROGRAVITY; RADIATION; SPACEFLIGHT; REPAIR; SPACE; CELLS; FIBROBLASTS AB Outer space is an environment characterized by microgravity and space radiation, including high-energy charged particles. Astronauts are constantly exposed to both microgravity and radiation during long-term stays in space. However, many aspects of the biological effects of combined microgravity and space radiation remain unclear. We developed a new three-dimensional (3D) clinostat synchronized heavy-ion irradiation system for use in ground-based studies of the combined exposures. Our new system uses a particle accelerator and a respiratory gating system from heavy-ion radiotherapy to irradiate samples being rotated in the 3D clinostat with carbon-ion beams only when the samples are in the horizontal position. A Peltier module and special sample holder were loaded on a static stage (standing condition) and the 3D clinostat (rotation condition) to maintain a suitable temperature under atmospheric conditions. The performance of the new device was investigated with normal human fibroblasts 1BR-hTERT in a disposable closed cell culture chamber. Live imaging revealed that cellular adhesion and growth were almost the same for the standing control sample and rotation sample over 48 h. Dose flatness and symmetry were judged according to the relative density of Gafchromic films along the X-axis and Y-axis of the positions of the irradiated sample to confirm irradiation accuracy. Doses calculated using the carbon-ion calibration curve were almost the same for standing and rotation conditions, with the difference being less than 5% at 1 Gy carbon-ion irradiation. Our new device can accurately synchronize carbon-ion irradiation and simulated microgravity while maintaining the temperature under atmospheric conditions at ground level. (C) 2017 Published by Elsevier Ltd on behalf of The Committee on Space Research (COSPAR). C1 [Ikeda, Hiroko; Souda, Hikaru; Yoshida, Yukari; Kanai, Tatsuaki; Takahashi, Akihisa] Gunma Univ, Heavy Ion Med Ctr, Maebashi, Gunma 3718511, Japan. [Puspitasari, Anggraeini; Held, Kathryn D.] Gunma Univ, Initiat Adv Res, Maebashi, Gunma 3718511, Japan. [Held, Kathryn D.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Hidema, Jun] Tohoku Univ, Grad Sch Life Sci, Dept Environm Life Sci, Sendai, Miyagi 9808577, Japan. [Nikawa, Takeshi] Univ Tokushima, Grad Sch, Inst Med Nutr, Dept Nutr Physiol, Tokushima, Tokushima 7708503, Japan. RP Takahashi, A (reprint author), Gunma Univ, Heavy Ion Med Ctr, Maebashi, Gunma 3718511, Japan. EM a-takahashi@gunma-u.ac.jp FU MEXT [JP15H05935]; unma University Initiative for Advanced Research FX This work was supported by a MEXT Grant-in-Aid for Scientific Research on Innovative Areas, Grant Number JP15H05935 "Living in Space", Research Projects with Heavy Ions at the GHMC and the Gunma University Initiative for Advanced Research. We thank Mr. Y. Kakehashi, Mr. N. Nakamura and Mr. T. Harada (AES) for providing and improving the 3D clinostat, Mr. M. Inaba (Konno Co.) for producing the special sample stage, Mr. Y. Kano (Accelerator Engineering Co., Chiba, Japan) for supporting our experiments, and Dr. P. A. Jeggo (Sussex University, UK) and Dr. A. Shibata (Gunma University) for supplying 1BR-hTERT cells. NR 38 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2214-5524 EI 2214-5532 J9 LIFE SCI SPACE RES JI Life Sci. Space Res. PD FEB PY 2017 VL 12 BP 51 EP 60 DI 10.1016/j.lssr.2017.01.003 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EO9ZH UT WOS:000397046100006 PM 28212708 ER PT J AU Cockrell, AS Yount, BL Scobey, T Jensen, K Douglas, M Beall, A Tang, XC Marasco, WA Heise, MT Baric, RS AF Cockrell, Adam S. Yount, Boyd L. Scobey, Trevor Jensen, Kara Douglas, Madeline Beall, Anne Tang, Xian-Chun Marasco, Wayne A. Heise, Mark T. Baric, Ralph S. TI A mouse model for MERS coronavirus-induced acute respiratory distress syndrome SO NATURE MICROBIOLOGY LA English DT Article ID DIPEPTIDYL PEPTIDASE 4; MONOCLONAL-ANTIBODY; TRANSGENIC MICE; COV INFECTION; PATHOLOGY; DISEASE; PATHOGENESIS; GENERATION; HUMANS; CELLS AB Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel virus that emerged in 2012, causing acute respiratory distress syndrome (ARDS), severe pneumonia-like symptoms and multi-organ failure, with a case fatality rate of similar to 36%. Limited clinical studies indicate that humans infected with MERS-CoV exhibit pathology consistent with the late stages of ARDS, which is reminiscent of the disease observed in patients infected with severe acute respiratory syndrome coronavirus. Models of MERS-CoV-induced severe respiratory disease have been difficult to achieve, and small-animal models traditionally used to investigate viral pathogenesis (mouse, hamster, guinea-pig and ferret) are naturally resistant to MERS-CoV. Therefore, we used CRISPR-Cas9 gene editing to modify the mouse genome to encode two amino acids (positions 288 and 330) that match the human sequence in the dipeptidyl peptidase 4 receptor, making mice susceptible to MERS-CoV infection and replication. Serial MERS-CoV passage in these engineered mice was then used to generate a mouse-adapted virus that replicated efficiently within the lungs and evoked symptoms indicative of severe ARDS, including decreased survival, extreme weight loss, decreased pulmonary function, pulmonary haemorrhage and pathological signs indicative of end-stage lung disease. Importantly, therapeutic countermeasures comprising MERS-CoV neutralizing antibody treatment or a MERS-CoV spike protein vaccine protected the engineered mice against MERS-CoVinduced ARDS. C1 [Cockrell, Adam S.; Yount, Boyd L.; Scobey, Trevor; Jensen, Kara; Douglas, Madeline; Beall, Anne; Baric, Ralph S.] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USA. [Tang, Xian-Chun; Marasco, Wayne A.] Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA. [Tang, Xian-Chun; Marasco, Wayne A.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA. [Heise, Mark T.; Baric, Ralph S.] Univ North Carolina Chapel Hill, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA. [Heise, Mark T.] Univ North Carolina Chapel Hill, Dept Genet, Chapel Hill, NC 27599 USA. RP Cockrell, AS; Baric, RS (reprint author), Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USA.; Heise, MT; Baric, RS (reprint author), Univ North Carolina Chapel Hill, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.; Heise, MT (reprint author), Univ North Carolina Chapel Hill, Dept Genet, Chapel Hill, NC 27599 USA. EM adam_cockrell@unc.edu; mark_heisem@med.unc.edu; rbaric@email.unc.edu FU National Institute of Allergy and Infectious Disease of the US NIH [HHSN272201000019I-HHSN27200003, AI106772, AI108197, AI110700, AI109761, U19 AI100625] FX These studies were supported by grants from the National Institute of Allergy and Infectious Disease of the US NIH by awards HHSN272201000019I-HHSN27200003 (R.S.B. and M.T.H.), AI106772, AI108197, AI110700 and AI109761 (R.S.B.), and U19 AI100625 (R.S.B. and M.T.H.). GOF research considerations involving MERS-0 in vivo passage in mice and the current manuscript were both reviewed and approved by the funding agency, the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Generation of CRISPR-Cas9-modified mice was performed at the UNC Animal Models Core Facility under the direction of Dale Cowley. NR 37 TC 1 Z9 1 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2058-5276 J9 NAT MICROBIOL JI NAT. MICROBIOL PD FEB PY 2017 VL 2 IS 2 AR 16226 DI 10.1038/nmicrobiol.2016.226 PG 11 WC Microbiology SC Microbiology GA EP0VN UT WOS:000397104900018 PM 27892925 ER PT J AU van Gils, MJ van den Kerkhof, TLGM Ozorowski, G Cottrell, CA Sok, D Pauthner, M Pallesen, J de Val, N Yasmeen, A de Taeye, SW Schorcht, A Gumbs, S Johanna, I Saye-Francisco, K Liang, CH Landais, E Nie, XY Pritchard, LK Crispin, M Kelsoe, G Wilson, IA Schuitemaker, H Klasse, PJ Moore, JP Burton, DR Ward, AB Sanders, RW AF van Gils, Marit J. van den Kerkhof, Tom L. G. M. Ozorowski, Gabriel Cottrell, Christopher A. Sok, Devin Pauthner, Matthias Pallesen, Jesper de Val, Natalia Yasmeen, Anila de Taeye, Steven W. Schorcht, Anna Gumbs, Stephanie Johanna, Inez Saye-Francisco, Karen Liang, Chi-Hui Landais, Elise Nie, Xiaoyan Pritchard, Laura K. Crispin, Max Kelsoe, Garnett Wilson, Ian A. Schuitemaker, Hanneke Klasse, Per Johan Moore, John P. Burton, Dennis R. Ward, Andrew B. Sanders, Rogier W. TI An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability SO NATURE MICROBIOLOGY LA English DT Article ID CRYO-EM STRUCTURE; MONOCLONAL-ANTIBODIES; ENVELOPE TRIMERS; ENV TRIMERS; CRYOELECTRON MICROSCOPY; GP41-GP120 INTERFACE; DEPENDENT EPITOPE; VACCINE DESIGN; BINDING; BROAD AB The induction by vaccination of broadly neutralizing antibodies (bNAbs) capable of neutralizing various HIV-1 viral strains is challenging, but understanding how a subset of HIV-infected individuals develops bNAbs may guide immunization strategies. Here, we describe the isolation and characterization of the bNAb ACS202 from an elite neutralizer that recognizes a new, trimer-specific and cleavage-dependent epitope at the gp120-gp41 interface of the envelope glycoprotein (Env), involving the glycan N88 and the gp41 fusion peptide. In addition, an Env trimer, AMC011 SOSIP.v4.2, based on early virus isolates from the same elite neutralizer, was constructed, and its structure by cryo-electron microscopy at 6.2 angstrom resolution reveals a closed, pre-fusion conformation similar to that of the BG505 SOSIP. 664 trimer. The availability of a native-like Env trimer and a bNAb from the same elite neutralizer provides the opportunity to design vaccination strategies aimed at generating similar bNAbs against a key functional site on HIV-1. C1 [van Gils, Marit J.; van den Kerkhof, Tom L. G. M.; de Taeye, Steven W.; Schorcht, Anna; Gumbs, Stephanie; Johanna, Inez; Sanders, Rogier W.] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands. [van Gils, Marit J.; Sok, Devin; Pauthner, Matthias; Saye-Francisco, Karen; Liang, Chi-Hui; Landais, Elise; Burton, Dennis R.] Scripps Res Inst, Scripps CHAVI ID IAVI Neutralizing Antibody Ctr, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA. [van Gils, Marit J.; Ozorowski, Gabriel; Cottrell, Christopher A.; Sok, Devin; Pauthner, Matthias; Pallesen, Jesper; Saye-Francisco, Karen; Liang, Chi-Hui; Landais, Elise; Wilson, Ian A.; Burton, Dennis R.; Ward, Andrew B.] Scripps Res Inst, CAVD, La Jolla, CA 92037 USA. [van den Kerkhof, Tom L. G. M.; Schuitemaker, Hanneke] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands. [Ozorowski, Gabriel; Cottrell, Christopher A.; Pallesen, Jesper; de Val, Natalia; Wilson, Ian A.; Ward, Andrew B.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, Scripps CHAVI ID IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA. [Yasmeen, Anila; Klasse, Per Johan; Moore, John P.; Sanders, Rogier W.] Cornell Univ, Dept Microbiol & Immunol, Weill Med Coll, New York, NY 10021 USA. [Nie, Xiaoyan; Kelsoe, Garnett] Duke Univ, Dept Immunol, Durham, NC 27710 USA. [Nie, Xiaoyan; Kelsoe, Garnett] Duke Univ, Vaccine Inst, Durham, NC 27710 USA. [Pritchard, Laura K.; Crispin, Max] Univ Oxford, Oxford Glycobiol Inst, Dept Biochem, Oxford OX1 3QU, England. [Schuitemaker, Hanneke] Johnson & Johnson, Janssen Pharmaceut Co, Archimedesweg 4-6, NL-2301 CA Leiden, Netherlands. [Burton, Dennis R.] MIT, Massachusetts Gen Hosp, Ragon Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Burton, Dennis R.] Harvard Univ, Cambridge, MA 02139 USA. RP van Gils, MJ; Sanders, RW (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands.; van Gils, MJ (reprint author), Scripps Res Inst, Scripps CHAVI ID IAVI Neutralizing Antibody Ctr, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.; van Gils, MJ (reprint author), Scripps Res Inst, CAVD, La Jolla, CA 92037 USA.; Sanders, RW (reprint author), Cornell Univ, Dept Microbiol & Immunol, Weill Med Coll, New York, NY 10021 USA. EM m.j.vangils@amc.uva.nl; r.w.sanders@amc.uva.nl FU Center for Infectious Disease Control of The Netherlands National Institute for Public Health and the Environment; Dutch Aids Fonds [2012041]; EMBO [ASTF 260-2013]; Netherlands Organization for Scientific Research [917.11.314, 918.66.628]; European Research Council [ERC-StG-2011-280829-SHEV]; International AIDS Vaccine Initiative through the Neutralizing Antibody Consortium [SFP1849]; NIH [R01 AI033292, P01 AI110657, R37 AI36082]; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery [UM1AI100663]; Collaboration for AIDS Vaccine Development (CAVD) [OPP1111923, OPP1132237]; Bill and Melinda Gates Foundation [OPP1115782]; European Union [681137]; NIH Interdisciplinary Training Program in Immunology [5T32AI007606-10] FX The Amsterdam Cohort Studies (ACS) on HIV infection and AIDS, a collaboration between the Amsterdam Health Service, the Academic Medical Center of the University of Amsterdam, Sanquin Blood Supply Foundation and the Jan van Goyen Clinic, are part of The Netherlands HIV Monitoring Foundation and are financially supported by the Center for Infectious Disease Control of The Netherlands National Institute for Public Health and the Environment. M.J.v.G. is a recipient of a Dutch Aids Fonds (grant no. 2012041) and EMBO short-term fellowship (ASTF 260-2013). R.W.S. is a recipient of a Vidi grant from the Netherlands Organization for Scientific Research (grant no. 917.11.314) and a Starting Investigator Grant from the European Research Council (ERC-StG-2011-280829-SHEV). This work was also supported by a Vici grant to H.S. from The Netherlands Organization for Scientific Research (grant no. 918.66.628), the International AIDS Vaccine Initiative through the Neutralizing Antibody Consortium SFP1849 (to D.R.B. and A.B.W.), NIH R01 AI033292 (to D.R.B.), NIH P01 AI110657 (to J.P.M., A.B.W., I.A.W. and R.W.S.), NIH R37 AI36082 (to J.P.M.), Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery Grant UM1AI100663 (to D.R.B., A.B.W. and I.A.W.), Collaboration for AIDS Vaccine Development (CAVD) grants OPP1111923 and OPP1132237 (to J.P.M. and R.W.S.) and OPP1115782 (A.B.W.) from the Bill and Melinda Gates Foundation, and European Union's Horizon 2020 research and innovation programme under grant agreement no. 681137 (to R.W.S). Funding was also provided by the NIH Interdisciplinary Training Program in Immunology 5T32AI007606-10 (to D.S.). The authors thank D. Burton, M. Nussenzweig and J. Mascola for providing bNAbs. NR 56 TC 3 Z9 3 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2058-5276 J9 NAT MICROBIOL JI NAT. MICROBIOL PD FEB PY 2017 VL 2 IS 2 AR 16199 DI 10.1038/nmicrobiol.2016.199 PG 10 WC Microbiology SC Microbiology GA EP0VN UT WOS:000397104900005 PM 27841852 ER PT J AU Ray, SK Samantaray, S Banik, NL AF Ray, Swapan K. Samantaray, Supriti Banik, Naren L. TI Future directions for using estrogen receptor agonists in the treatment of acute and chronic spinal cord injury (vol 11, pg 1418, 2016) SO NEURAL REGENERATION RESEARCH LA English DT Correction C1 [Ray, Swapan K.] Univ South Carolina, Dept Pathol Microbiol & Immunol, Sch Med, Columbia, SC 29208 USA. [Samantaray, Supriti] Med Univ South Carolina, Dept Neurosci, Columbia, SC USA. [Banik, Naren L.] Med Univ South Carolina, Dept Neurol & Neurosurg, Charleston, SC USA. [Banik, Naren L.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Ray, SK (reprint author), Univ South Carolina, Dept Pathol Microbiol & Immunol, Sch Med, Columbia, SC 29208 USA. EM swapan.ray@uscmed.sc.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 1673-5374 EI 1876-7958 J9 NEURAL REGEN RES JI Neural Regen. Res. PD FEB PY 2017 VL 12 IS 2 BP 266 EP 266 DI 10.4103/1673-5374.200818 PG 1 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA EO9QN UT WOS:000397023300021 ER PT J AU Fan, JJ Li, Y Fu, XY Li, LJ Hao, XT Li, SS AF Fan, Jingjing Li, Yi Fu, Xinyu Li, Lijuan Hao, Xiaoting Li, Shasha TI Nonhuman primate models of focal cerebral ischemia SO NEURAL REGENERATION RESEARCH LA English DT Review DE nerve regeneration; stroke; cerebral ischemia; middle cerebral artery occlusion; nonhuman primates; model selection; neural regeneration ID DIFFUSION TENSOR MRI; ARTERY OCCLUSION; ISCHEMIA/REPERFUSION INJURY; ANESTHETIZED BABOON; RHESUS MACAQUE; STROKE MODEL; REPERFUSION; ENDOTHELIN; INFARCTION; MARMOSET AB Rodents have been widely used in the production of cerebral ischemia models. However, successful therapies have been proven on experimental rodent stroke model, and they have often failed to be effective when tested clinically. Therefore, nonhuman primates were recommended as the ideal alternatives, owing to their similarities with the human cerebrovascular system, brain metabolism, grey to white matter ratio and even their rich behavioral repertoire. The present review is a thorough summary of ten methods that establish nonhuman primate models of focal cerebral ischemia; electrocoagulation, endothelin-1-induced occlusion, microvascular clip occlusion, autologous blood clot embolization, balloon inflation, microcatheter embolization, coil embolization, surgical suture embolization, suture, and photochemical induction methods. This review addresses the advantages and disadvantages of each method, as well as precautions for each model, compared nonhuman primates with rodents, different species of nonhuman primates and different modeling methods. Finally it discusses various factors that need to be considered when modelling and the method of evaluation after modelling. These are critical for understanding their respective strengths and weaknesses and underlie the selection of the optimum model. C1 [Fan, Jingjing; Li, Yi; Fu, Xinyu; Li, Lijuan; Li, Shasha] Sichuan Univ, West China Hosp, Dept Rehabil Med, Chengdu, Sichuan, Peoples R China. [Fan, Jingjing; Li, Yi; Fu, Xinyu; Li, Lijuan; Li, Shasha] Sichuan Univ, West China Hosp, Prov Key Lab Rehabil Med, Chengdu, Sichuan, Peoples R China. [Hao, Xiaoting] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Sichuan, Peoples R China. [Li, Shasha] Harvard Med Sch, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA USA. [Li, Shasha] Harvard Med Sch, Massachusetts Gen Hosp, Athinoula A Martions Ctr Biomed Imaging, Boston, MA USA. RP Li, SS (reprint author), Sichuan Univ, West China Hosp, Dept Rehabil Med, Chengdu, Sichuan, Peoples R China.; Li, SS (reprint author), Sichuan Univ, West China Hosp, Prov Key Lab Rehabil Med, Chengdu, Sichuan, Peoples R China.; Li, SS (reprint author), Harvard Med Sch, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA USA.; Li, SS (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Athinoula A Martions Ctr Biomed Imaging, Boston, MA USA. EM pmr.shashali@gmail.com FU National Natural Science Foundation of China [81000852, 81301677]; AHA [17POST32530004]; Science & Technology of Sichuan Province of China [2012SZ0140]; Research Foundation of Zhejiang Province of China [201022896] FX This work was supported by the National Natural Science Foundation of China, No. 81000852 and 81301677; the AHA Award, No. 17POST32530004; the Supporting Project of Science & Technology of Sichuan Province of China, No. 2012SZ0140; the Research Foundation of Zhejiang Province of China, No. 201022896. NR 50 TC 0 Z9 0 U1 0 U2 0 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 1673-5374 EI 1876-7958 J9 NEURAL REGEN RES JI Neural Regen. Res. PD FEB PY 2017 VL 12 IS 2 BP 321 EP 328 DI 10.4103/1673-5374.200815 PG 8 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA EO9QN UT WOS:000397023300029 ER PT J AU Simonett, JM Chan, EW Chou, J Skondra, D Colon, D Chee, CK Lingam, G Fawzi, AA AF Simonett, Joseph M. Chan, Errol W. Chou, Jonathan Skondra, Dimitra Colon, Daniel Chee, Caroline K. Lingam, Gopal Fawzi, Amani A. TI Quantitative Analysis of En Face Spectral-Domain Optical Coherence Tomography Imaging in Polypoidal Choroidal Vasculopathy SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA LA English DT Article ID MACULAR DEGENERATION; RANIBIZUMAB; VERTEPORFIN AB BACKGROUND AND OBJECTIVE: Spectral-domain optical coherence tomography (SD-OCT) imaging can be used to visualize polypoidal choroidal vasculopathy (PCV) lesions in the en face plane. Here, the authors describe a novel lesion quantification technique and compare PCV lesion area measurements and morphology before and after anti-vascular endothelial growth factor (VEGF) treatment. PATIENTS AND METHODS: Volumetric SD-OCT scans in eyes with PCV before and after induction anti-VEGF therapy were retrospectively analyzed. En face SD-OCT images were generated and a pixel intensity thresholding process was used to quantify total lesion area. RESULTS: Thirteen eyes with PCV were analyzed. En face SD-OCT PCV lesion area quantification showed good intergrader reliability (intraclass correlation coefficient = 0.944). Total PCV lesion area was significantly reduced after anti-VEGF therapy (2.22 mm(2) vs. 2.73 mm(2); P =.02). The overall geographic pattern of the branching vascular network was typically preserved. CONCLUSION: PCV lesion area analysis using en face SD-OCT is a reproducible tool that can quantify treatment related changes. C1 [Simonett, Joseph M.; Chou, Jonathan; Skondra, Dimitra; Colon, Daniel; Fawzi, Amani A.] Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, 645 N Michigan Ave, Chicago, IL 60611 USA. [Chan, Errol W.] McGill Univ, McGill Univ Hlth Ctr, Dept Ophthalmol, Montreal, PQ, Canada. [Chan, Errol W.; Chee, Caroline K.] Natl Univ Singapore, Hlth Syst, Dept Ophthalmol, Singapore, Singapore. [Chan, Errol W.; Chee, Caroline K.] Yong Loo Lin Sch Med, Singapore, Singapore. [Chou, Jonathan] Massachusetts Eye & Ear Infirm, Harvard Med Sch, Dept Ophthalmol, Boston, MA 02114 USA. RP Fawzi, AA (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, 645 N Michigan Ave, Chicago, IL 60611 USA. EM afawzimd@gmail.com FU National University Health System Clinician-Scientist Program Grant (Singapore) FX This study is supported by the National University Health System Clinician-Scientist Program Grant (Singapore). NR 19 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 2325-8160 EI 2325-8179 J9 OSLI RETINA JI Ophthalmic Surg. Lasers Imag. Retin. PD FEB PY 2017 VL 48 IS 2 BP 126 EP + DI 10.3928/23258160-20170130-06 PG 11 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA EP2TG UT WOS:000397235600006 PM 28195615 ER PT J AU Linnstaedt, SD Walker, MG Riker, KD Nyland, JE Hu, JM Rossi, C Swor, RA Jones, JS Diatchenko, L Bortsov, AV Peak, DA McLean, SA AF Linnstaedt, Sarah D. Walker, Margaret G. Riker, Kyle D. Nyland, Jennifer E. Hu, JunMei Rossi, Catherine Swor, Robert A. Jones, Jeffrey S. Diatchenko, Luda Bortsov, Andrey V. Peak, David A. McLean, Samuel A. TI Genetic variant rs3750625 in the 3 ' UTR of ADRA2A affects stress-dependent acute pain severity after trauma and alters a microRNA-34a regulatory site SO PAIN LA English DT Article; Proceedings Paper CT Meeting of the American-Pain-Society CY 2014 CL Tampa, FL SP Amer Pain Soc DE Motor vehicle collision; Sexual assault; Stress; Trauma; Musculoskeletal pain; Polymorphism; Single nucleotide; microRNA; miR-34a; Adrenergic receptor ID ADRENERGIC-RECEPTOR IMMUNOREACTIVITY; PERITRAUMATIC DISTRESS INVENTORY; MOTOR-VEHICLE COLLISION; EPSTEIN-BARR-VIRUS; RAT SPINAL-CORD; TARGET RECOGNITION; MAMMALIAN-CELLS; SEXUAL ASSAULT; EXPRESSION; DISORDER AB alpha 2A adrenergic receptor (alpha 2A-AR) activation has been shown in animal models to play an important role in regulating the balance of acute pain inhibition vs facilitation after both physical and psychological stress. To our knowledge, the influence of genetic variants in the gene encoding alpha 2A-AR, ADRA2A, on acute pain outcomes in humans experiencing traumatic stress has not been assessed. In this study, we tested whether a genetic variant in the 3 ' UTR of ADRA2A, rs3750625, is associated with acute musculoskeletal pain (MSP) severity following motor vehicle collision (MVC, n = 948) and sexual assault (n 5 84), and whether this influence was affected by stress severity. We evaluated rs3750625 because it is located in the seed binding region of miR-34a, a microRNA (miRNA) known to regulate pain and stress responses. In both cohorts, the minor allele at rs3750625 was associated with increased musculoskeletal pain in distressed individuals (stress rs3750625 P = 0.043 for MVC cohort and P = 0.007 for sexual assault cohort). We further found that (1) miR-34a binds the 3 ' UTR of ADRA2A, (2) the amount of repression is greater when the minor (risk) allele is present, (3) miR-34a in the IMR-32 adrenergic neuroblastoma cell line affects ADRA2A expression, (4) miR-34a and ADRA2A are expressed in tissues known to play a role in pain and stress, (5) following forced swim stress exposure, rat peripheral nerve tissue expression changes are consistent with miR-34a regulation of ADRA2A. Together, these results suggest that ADRA2A rs3750625 contributes to poststress musculoskeletal pain severity by modulating miR-34a regulation. C1 [Linnstaedt, Sarah D.; Walker, Margaret G.; Riker, Kyle D.; Hu, JunMei; Bortsov, Andrey V.; McLean, Samuel A.] Univ N Carolina, TRYUMPH Res Program, Chapel Hill, NC USA. [Linnstaedt, Sarah D.; Walker, Margaret G.; Riker, Kyle D.; Hu, JunMei; Bortsov, Andrey V.; McLean, Samuel A.] Univ N Carolina, Dept Anesthesiol, Chapel Hill, NC USA. [Nyland, Jennifer E.] Dept Battlefield Pain Res, Fort Sam, TX USA. [Rossi, Catherine] Cone Hlth Syst, Family Med, Forens Nursing Program, Greensboro, NC USA. [Swor, Robert A.] William Beaumont Hosp, Dept Emergency Med, Royal Oak, MI USA. [Jones, Jeffrey S.] Dept EmergencyMed, SpectrumHlth Butterworth Campus, Grand Rapids, MI USA. [Diatchenko, Luda] McGill Univ, Allan Edwards Ctr Emergency Med, Montreal, PQ, Canada. [Peak, David A.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA. [McLean, Samuel A.] Univ N Carolina, Dept Emergency Med, Chapel Hill, NC USA. RP Linnstaedt, SD (reprint author), Univ N Carolina, Med Sch Wing C, CB 7010, Chapel Hill, NC 27599 USA. EM slinnstaedt@aims.unc.edu FU NIAMS NIH HHS [R01 AR056328, R01 AR064700] NR 62 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0304-3959 EI 1872-6623 J9 PAIN JI Pain PD FEB PY 2017 VL 158 IS 2 BP 230 EP 239 DI 10.1097/j.pain.0000000000000742 PG 10 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA EO9NN UT WOS:000397015500007 PM 27805929 ER PT J AU Beaudoin, FL Gutman, R Merchant, RC Clark, MA Swor, RA Jones, JS Lee, DC Peak, DA Domeier, RM Rathlev, NK McLean, SA AF Beaudoin, Francesca L. Gutman, Roee Merchant, Roland C. Clark, Melissa A. Swor, Robert A. Jones, Jeffrey S. Lee, David C. Peak, David A. Domeier, Robert M. Rathlev, Niels K. McLean, Samuel A. TI Persistent pain after motor vehicle collision: comparative effectiveness of opioids vs nonsteroidal antiinflammatory drugs prescribed from the emergency department-a propensity matched analysis SO PAIN LA English DT Article DE Opioid analgesics; Nonsteroidal antiinflammatory drugs; Acute pain; Persistent pain; Chronic pain; Motor-vehicle collision; Causal inference; Propensity matching ID LOW-BACK-PAIN; CHRONIC WIDESPREAD PAIN; MULTIPLE IMPUTATION; UNITED-STATES; TASK-FORCE; SENSITIZATION; PREDICTORS; SYMPTOMS; OUTCOMES; DESIGN AB Each year millions of Americans present to the emergency department (ED) for care after a motor vehicle collision (MVC); the majority (> 90%) are discharged to home after evaluation. Acute musculoskeletal pain is the norm in this population, and such patients are typically discharged to home with prescriptions for oral opioid analgesics or nonsteroidal antiinflammatory drugs (NSAIDs). The influence of acute painmanagement on subsequent pain outcomes in this commonEDpopulation is unknown. Weevaluated the effect of opioid analgesics vs NSAIDs initiated from the ED on the presence of moderate to severe musculoskeletal pain and ongoing opioid use at 6 weeks in a large cohort of adult ED patients presenting to the ED after MVC (n = 948). The effect of opioids vs NSAIDs was evaluated using an innovative quasi-experimental designmethod using propensity scores to account for covariate imbalances between the 2 treatment groups. No difference in risk for moderate to severe musculoskeletal pain at 6 weeks was observed between those discharged with opioid analgesics vs NSAIDs (risk difference = 7.2% [95% confidence interval: 25.2% to 19.5%]). However, at followup participants prescribed opioids were more likely than those prescribed NSAIDs to report use of prescription opioids medications at week 6 (risk difference = 17.5%[95% confidence interval: 5.8%-29.3%]). These results suggest that analgesic choice at ED discharge does not influence the development of persistent moderate to severe musculoskeletal pain 6 weeks after an MVC, but may result in continued use of prescription opioids. Supported by NIAMS R01AR056328 and AHRQ 5K12HS022998. C1 [Beaudoin, Francesca L.; Merchant, Roland C.] Brown Univ, Alpert Med Sch, Dept Emergency Med, Providence, RI 02912 USA. [Beaudoin, Francesca L.; Merchant, Roland C.; Clark, Melissa A.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA. [Gutman, Roee] Brown Univ, Dept Biostat, Providence, RI 02912 USA. [Clark, Melissa A.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA. [Swor, Robert A.] William Beaumont Hosp, Dept Emergency Med, Royal Oak, MI 48072 USA. [Jones, Jeffrey S.] Spectrum Hlth Butterworth Campus, Dept Emergency Med, Grand Rapids, MI USA. [Lee, David C.] North Shore Univ Hosp, Dept Emergency Med, Manhasset, NY USA. [Peak, David A.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Domeier, Robert M.] St Joseph Mercy Hosp, Dept Emergency Med, Yipsilanti, MI USA. [Rathlev, Niels K.] Baystate Med Ctr, Dept Emergency Med, Springfield, MA USA. [McLean, Samuel A.] Univ N Carolina, Dept Emergency Med, Chapel Hill, NC USA. [McLean, Samuel A.] Univ N Carolina, Dept Anesthesiol, Chapel Hill, NC USA. [McLean, Samuel A.] Univ N Carolina, TRYUMPH Res Program, Chapel Hill, NC USA. RP Beaudoin, FL (reprint author), Rhode Isl Hosp, Dept Emergency Med, 55 Claverick St,2nd Floor, Providence, RI 02903 USA. EM Francesca_Beaudoin@brown.edu FU AHRQ HHS [K12 HS022998]; NCATS NIH HHS [UL1 TR001111]; NIAMS NIH HHS [R01 AR056328] NR 45 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0304-3959 EI 1872-6623 J9 PAIN JI Pain PD FEB PY 2017 VL 158 IS 2 BP 289 EP 295 DI 10.1097/j.pain.0000000000000756 PG 7 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA EO9NN UT WOS:000397015500013 PM 28092325 ER PT J AU Engel, AJ Kreiner, DS Stojanovic, MP AF Engel, Andrew J. Kreiner, D. Scott Stojanovic, Milan P. TI Finding an Answer: Comments on a Randomized Trial of Epidural Glucocorticoid Injections for Lumbar Spinal Stenosis SO PAIN MEDICINE LA English DT Editorial Material ID LOW-BACK-PAIN; CAUDA-EQUINA; INTERMITTENT CLAUDICATION; RADIOFREQUENCY NEUROTOMY; TRANSFORAMINAL INJECTION; STEROID INJECTIONS; RADICULAR PAIN; INFLAMMATION; COMPRESSION; HYPERTROPHY C1 [Engel, Andrew J.] Affordable Pain Management, Chicago, IL USA. [Kreiner, D. Scott] Ahwatukee Sport & Spine, Phoenix, AZ USA. [Stojanovic, Milan P.] VA Boston Healthcare Syst, Crit Care & Pain Med Serv, Anesthesiol, Boston, MA USA. RP Engel, AJ (reprint author), Affordable Pain Management, Chicago, IL USA. NR 52 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD FEB PY 2017 VL 18 IS 2 BP 204 EP 210 DI 10.1093/pm/pnw127 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA EP0VB UT WOS:000397103700002 PM 28204744 ER PT J AU Zhang, PP Bookstaver, ML Jewell, CM AF Zhang, Peipei Bookstaver, Michelle L. Jewell, Christopher M. TI Engineering Cell Surfaces with Polyelectrolyte Materials for Translational Applications SO POLYMERS LA English DT Review DE polyelectrolyte; multilayer; cell modification; sensing and signaling; drug delivery; vaccine and immunotherapy; surface protein; tissue engineering; regenerative medicine ID LYMPH-NODE MICROENVIRONMENT; STEM-CELLS; GENE-THERAPY; DRUG-DELIVERY; LIVING CELLS; BIOMEDICAL APPLICATIONS; ISLET TRANSPLANTATION; MEDIATED DELIVERY; INDIVIDUAL CELLS; CLINICAL-TRIALS AB Engineering cell surfaces with natural or synthetic materials is a unique and powerful strategy for biomedical applications. Cells exhibit more sophisticated migration, control, and functional capabilities compared to nanoparticles, scaffolds, viruses, and other engineered materials or agents commonly used in the biomedical field. Over the past decade, modification of cell surfaces with natural or synthetic materials has been studied to exploit this complexity for both fundamental and translational goals. In this review we present the existing biomedical technologies for engineering cell surfaces with one important class of materials, polyelectrolytes. We begin by introducing the challenges facing the cell surface engineering field. We then discuss the features of polyelectrolytes and how these properties can be harnessed to solve challenges in cell therapy, tissue engineering, cell-based drug delivery, sensing and tracking, and immune modulation. Throughout the review, we highlight opportunities to drive the field forward by bridging new knowledge of polyelectrolytes with existing translational challenges. C1 [Zhang, Peipei; Bookstaver, Michelle L.; Jewell, Christopher M.] Univ Maryland, Fischell Dept Bioengn, College Pk, MD 20742 USA. [Jewell, Christopher M.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA. [Jewell, Christopher M.] Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA. [Jewell, Christopher M.] US Dept Vet Affairs, Baltimore, MA 21201 USA. RP Jewell, CM (reprint author), Univ Maryland, Fischell Dept Bioengn, College Pk, MD 20742 USA.; Jewell, CM (reprint author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.; Jewell, CM (reprint author), Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA.; Jewell, CM (reprint author), US Dept Vet Affairs, Baltimore, MA 21201 USA. EM pzhang14@umd.edu; mlbooks@umd.edu; cmjewell@umd.edu OI Jewell, Christopher/0000-0002-6668-6928 FU NSF CAREER Award [1351688]; Damon Runyon Foundation [DRR3415]; Young Investigator of the Alliance for Cancer Gene Therapy [15051543]; Melanoma Research Alliance [348963] FX This work was supported in part by NSF CAREER Award # 1351688. Christopher M. Jewell is a Damon Runyon-Rachleff Innovator supported by the Damon Runyon Foundation (# DRR3415), and a Young Investigator of the Alliance for Cancer Gene Therapy (# 15051543) and the Melanoma Research Alliance (# 348963). NR 115 TC 0 Z9 0 U1 0 U2 0 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 2073-4360 J9 POLYMERS-BASEL JI Polymers PD FEB PY 2017 VL 9 IS 2 AR 40 DI 10.3390/polym9020040 PG 21 WC Polymer Science SC Polymer Science GA EP2RL UT WOS:000397230800010 ER PT J AU Nelson, K Taylor, L Silverman, J Kiefer, M Hebert, P Lessler, D Krieger, J AF Nelson, Karin Taylor, Leslie Silverman, Julie Kiefer, Meghan Hebert, Paul Lessler, Dan Krieger, James TI Randomized Controlled Trial of a Community Health Worker Self-Management Support Intervention Among Low-Income Adults With Diabetes, Seattle, Washington, 2010-2014 SO PREVENTING CHRONIC DISEASE LA English DT Article ID BASE-LINE CHARACTERISTICS; GLYCEMIC CONTROL; CARE; ADHERENCE; VALIDITY; PEOPLE; COMPLICATIONS; AMERICAN; DESIGN; IMPACT AB Introduction Community health workers (CHWs) can improve diabetes outcomes; however, questions remain about translating research findings into practical low-intensity models for safety-net providers. We tested the effectiveness of a home-based low-intensity CHW intervention for improving health outcomes among low-income adults with diabetes. Methods Low-income patients with glycated hemoglobin A 1c (HbA 1c) of 8.0% or higher in the 12 months before enrollment from 3 safetynet providers were randomized to a 12-month CHW-delivered diabetes self-management intervention or usual care. CHWs were based at a local health department. The primary outcome was change in HbA 1c from baseline enrollment to 12 months; secondary outcomes included blood pressure and lipid levels, quality of life, and health care use. Results The change in HbA 1c in the intervention group (n = 145) (unadjusted mean of 9.09% to 8.58%, change of -0.51) compared with the control group (n = 142) (9.04% to 8.71%, change of -0.33) was not significant (P =.54). In an analysis of participants with poor glycemic control (HbA 1c > 10%), the intervention group had a 1.23-point greater decrease in HbA 1c compared with controls (P =.046). For the entire study population, we found a decrease in reported physician visits (P <.001) and no improvement in healthrelated quality of life (P =.07) in the intervention group compared with the control group. Conclusion A low-intensity CHW-delivered intervention to support diabetes self-management did not significantly improve HbA 1c relative to usual care. Among the subgroup of participants with poor glycemic control (HbA 1c > 10% at baseline), the intervention was effective. C1 [Nelson, Karin; Taylor, Leslie; Silverman, Julie; Kiefer, Meghan; Hebert, Paul] VA Hlth Serv Res & Dev, Seattle Denver Ctr Innovat Veteran Ctr & Value Dr, Seattle, WA USA. [Nelson, Karin; Silverman, Julie; Kiefer, Meghan] VA Puget Sound Hlth Care Syst, Gen Internal Med Serv, Seattle, WA USA. [Nelson, Karin; Silverman, Julie; Kiefer, Meghan; Hebert, Paul; Lessler, Dan; Krieger, James] Univ Washington, Sch Med, Seattle, WA USA. [Nelson, Karin; Krieger, James] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Krieger, James] Publ Hlth Seattle & King Cty, Seattle, WA USA. RP Nelson, K (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way, Seattle, WA 98108 USA. EM Karin.Nelson@va.gov FU National Institutes of Health, National Institute for Diabetes and Digestive and Kidney Diseases [5R18DK088072]; Veterans Health Administration (VHA) Diabetes Quality Enhancement Research Initiative FX This study was supported by the National Institutes of Health, National Institute for Diabetes and Digestive and Kidney Diseases grant 5R18DK088072 (K. Nelson and J. Krieger, co-principal investigators). Supplemental funding was provided by the Veterans Health Administration (VHA) Diabetes Quality Enhancement Research Initiative. The views expressed in this article are those of the authors and do not necessarily reflect the views of the US Department of Veterans Affairs. The authors have no financial conflicts of interest to report. NR 29 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD FEB PY 2017 VL 14 AR 160344 DI 10.5888/pcd14.160344 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP1KW UT WOS:000397144800006 ER PT J AU Johnson, RS Stolar, AG McGuire, JF Mittakanti, K Clark, S Coonan, LA Graham, DP AF Johnson, R. Scott Stolar, Andrea G. McGuire, James F. Mittakanti, Krithika Clark, Sean Coonan, Loretta A. Graham, David P. TI Predictors of Incarceration of Veterans Participating in US Veterans' Courts SO PSYCHIATRIC SERVICES LA English DT Article AB Objective: Significant variability exists regarding the criteria and procedures used by different veterans' courts (VCs) across the country. Limited guidance is available regarding which VC model has the most successful outcomes. The purpose of this study was to examine factors associated with incarceration during VC participation. Methods: This study used data for 1,224 veterans collected from the HOMES (Homeless Operations Management and Evaluation System) database of the Department of Veterans Affairs, as well as data from a national phone survey inventory of all U.S. VCs. To identify variables associated with incarceration during VC participation, four backward conditional logistic regressions were performed. Results: The following variables were associated with higher rates of incarceration because of a veteran's noncompletion of the VC program: charges of probation or parole violations, longer stays in the VC program, end of VC participation because of incarceration for a new arrest or case transfer by the legal system, and requiring mental health follow-up but not undergoing treatment. The following variables were associated with lower rates of incarceration: stable housing and participating in a VC program that referred veterans for substance abuse treatment. Conclusions: This study offers VCs a thorough review of an extensive set of recidivism data. Further investigation is necessary to understand the impact of VCs. C1 [Johnson, R. Scott] Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA. [Johnson, R. Scott] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Stolar, Andrea G.; Mittakanti, Krithika] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [McGuire, James F.] Vet Hlth Adm, Vet Justice Program, Washington, DC USA. [Clark, Sean] Vet Justice Outreach, Lexington, KY USA. [Coonan, Loretta A.; Graham, David P.] Michael E DeBakey VA Med Ctr, Mental Hlth Care Line, Houston, TX USA. RP Johnson, RS (reprint author), Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA.; Johnson, RS (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM rscottjohnson3@gmail.com NR 16 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD FEB 1 PY 2017 VL 68 IS 2 BP 144 EP 150 DI 10.1176/appi.ps.201500266 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA EP0PZ UT WOS:000397090500009 PM 27745530 ER PT J AU Rosen, CS Azevedo, KJ Tiet, QQ Greene, CJ Wood, AE Calhoun, P Bowe, T Capehart, BP Crawford, EF Greenbaum, MA Harris, AHS Hertzberg, M Lindley, SE Smith, BN Schnurr, PP AF Rosen, Craig S. Azevedo, Kathryn J. Tiet, Quyen Q. Greene, Carolyn J. Wood, Amanda E. Calhoun, Patrick Bowe, Thomas Capehart, Bruce P. Crawford, Eric F. Greenbaum, Mark A. Harris, Alex H. S. Hertzberg, Michael Lindley, Steven E. Smith, Brandy N. Schnurr, Paula P. TI An RCT of Effects of Telephone Care Management on Treatment Adherence and Clinical Outcomes Among Veterans With PTSD SO PSYCHIATRIC SERVICES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH TREATMENT; COGNITIVE PROCESSING THERAPY; RANDOMIZED CONTROLLED-TRIAL; ADDICTION SEVERITY INDEX; AFGHANISTAN VETERANS; MEDICATION ADHERENCE; TREATMENT ENGAGEMENT; PROLONGED EXPOSURE; TREATMENT-SEEKING AB Objective: This study assessed whether adding telephone care management to usual outpatient mental health care improved treatment attendance, medication compliance, and clinical outcomes of veterans with posttraumatic stress disorder (PTSD). Methods: In a multisite randomized controlled trial, 358 veterans were assigned to either usual outpatient mental health treatment (N=165) or usual care plus twice-a-month telephone care management (TCM) and support in the first three months of treatment (N=193). Treatment utilization and medication refills were determined from U.S. Department of Veterans Affairs administrative data. PTSD, depression, quality of life, aggressive behavior, and substance use were assessed with self-report questionnaires at intake, four months, and 12 months. Results: Telephone care managers reached 95% of TCM participants (N=182), completing an average 5.1 of 6.0 planned telephone calls. During the three-month intervention period, TCM participants completed 43% more mental health visits (M +/- SD=5.9 +/- 6.8) than did those in usual care (4.1 +/- 4.2) ( incident rate ratio=1.36, x(2)=6.56, df=1, p<.01).Treatment visits in the nine-month follow-up period and medication refills did not differ by condition. Only 9% of participants were scheduled to receive evidence-based psychotherapy. Slopes of improvement in PTSD, depression, alcohol misuse, drug problems, aggressive behavior, and quality of life did not differ by condition or treatment attendance. Conclusions: TCM improved PTSD patients' treatment attendance but not their outcomes. TCM can enhance treatment engagement, but outcomes depend on the effectiveness of the treatments that patients receive. C1 [Rosen, Craig S.] Vet Affairs VA Palo Alto Hlth Care Syst, Natl Ctr PTSD Disseminat & Training Div, Menlo Pk, CA 94025 USA. [Rosen, Craig S.; Tiet, Quyen Q.; Lindley, Steven E.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Lindley, Steven E.] VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA. [Azevedo, Kathryn J.; Bowe, Thomas; Harris, Alex H. S.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Hlth Serv Res & Dev Serv, Menlo Pk, CA USA. [Harris, Alex H. S.] Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA. [Greene, Carolyn J.] VA Off Mental Hlth Serv, Menlo Pk, CA USA. [Wood, Amanda E.] VA Puget Sound Hlth Care Syst, Mental Hlth Serv Amer Lake Div, Tacoma, WA USA. [Calhoun, Patrick] VA Midatlantic Mental Illness Res Educ & Clin Ctr, Durham, NC USA. [Capehart, Bruce P.; Hertzberg, Michael] Durham VA Med Ctr, Dept Psychiat, Durham, NC USA. [Calhoun, Patrick; Capehart, Bruce P.; Hertzberg, Michael] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC 27706 USA. [Crawford, Eric F.] Midatlantic Reg MIRECC, Clin Core, Durham, NC USA. [Crawford, Eric F.] Sheridan VA Med Ctr, Sheridan, WY USA. [Greenbaum, Mark A.] VA Sierra Pacific MIRECC, Menlo Pk, CA USA. [Schnurr, Paula P.] White River Junct VA Med Ctr, Natl Ctr PTSD Execut Div, White River Jct, VT USA. [Schnurr, Paula P.] Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA. RP Rosen, CS (reprint author), Vet Affairs VA Palo Alto Hlth Care Syst, Natl Ctr PTSD Disseminat & Training Div, Menlo Pk, CA 94025 USA. EM craig.rosen@va.gov FU Congressionally Directed Medical Research Program [W81XWH-08-2-0096] FX Dr. Rosen, Dr. Azevedo, Dr. Tiet, and Ms. Smith are with the National Center for PTSD Dissemination and Training Division, Veterans Affairs (VA) Palo Alto Health Care System, Menlo Park, California (e-mail: craig.rosen@va.gov). Dr. Rosen and Dr. Tiet are also with the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, where Dr. Lindley is affiliated. Dr. Lindley is also with the VA Palo Alto Health Care System, Menlo Park. Dr. Azevedo is also with the Center for Innovation to Implementation, Health Services Research and Development Service, VA Palo Alto Health Care System, Menlo Park, where Dr. Bowe and Dr. Harris are affiliated. Dr. Harris is also with the Department of Surgery, Stanford University School of Medicine, Stanford. Dr. Greene is with the VA Office of Mental Health Services, Menlo Park. Dr. Wood is with Mental Health Services American Lake Division, VA Puget Sound Health Care System, Tacoma, Washington. Dr. Calhoun is with the VA Mid-Atlantic Mental Illness Research, Education and Clinical Center (MIRECC). Dr. Capehart and Dr. Hertzberg are with the Department of Psychiatry, Durham VA Medical Center, Durham, North Carolina. Dr. Calhoun, Dr. Capehart, and Dr. Hertzberg are also with the Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham. Dr. Crawford, formerly with the Clinical Core, Mid-Atlantic Region MIRECC, Durham, is now with the Sheridan VA Medical Center, Sheridan, Wyoming. Mr. Greenbaum is with the VA Sierra-Pacific MIRECC, Menlo Park. Dr. Schnurr is with the National Center for PTSD Executive Division, White River Junction VA Medical Center, White River Junction, Vermont, and the Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire. This study is registered on Clinicaltrials.gov as NCT02655991. This research was supported by the Congressionally Directed Medical Research Program, grant W81XWH-08-2-0096 awarded to Dr. Rosen. The authors thank the veterans who participated in this research; the VA staff members who supported this study; study coordinator Emerald Adler; and Kathy Blau, Julia Hernandez, Nate Hawkins, Niall Kavanagh, Caitlin McLean, and Olga Rosito, who provided compassionate telephone support to the veterans in this trial. The opinions expressed are those of the authors and do not represent the position of the U.S. Department of Veterans Affairs. NR 58 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD FEB 1 PY 2017 VL 68 IS 2 BP 151 EP 158 DI 10.1176/appi.ps.201600069 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA EP0PZ UT WOS:000397090500010 PM 27745535 ER PT J AU Beck, AK Forbes, E Baker, AL Kelly, PJ Deane, FP Shakeshaft, A Hunt, D Kelly, JF AF Beck, Alison K. Forbes, Erin Baker, Amanda L. Kelly, Peter J. Deane, Frank P. Shakeshaft, Anthony Hunt, David Kelly, John F. TI Systematic Review of SMART Recovery: Outcomes, Process Variables, and Implications for Research SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Review DE systematic review; SMART Recovery; mutual aid; self-help groups; addiction ID SUBSTANCE USE DISORDERS; ALCOHOL DEPENDENCE; INTERVENTIONS; PROGRAMS; 12-STEP; PARTICIPATION; QUALITY; PEOPLE AB Clinical guidelines recommend Self-Management and Recovery Training (SMART Recovery) and 12-step models of mutual aid as important sources of long-term support for addiction recovery. Methodologically rigorous reviews of the efficacy and potential mechanisms of change are available for the predominant 12-step approach. A similarly rigorous exploration of SMART Recovery has yet to be undertaken. We aim to address this gap by providing a systematic overview of the evidence for SMART Recovery in adults with problematic alcohol, substance, and/or behavioral addiction, including (i) a commentary on outcomes assessed, process variables, feasibility, current understanding of mental health outcomes, and (ii) a critical evaluation of the methodology. We searched six electronic peer-reviewed and four gray literature databases for Englishlanguage SMART Recovery literature. Articles were classified, assessed against standardized criteria, and checked by an independent assessor. Twelve studies (including three evaluations of effectiveness) were identified. Alcohol-related outcomes were the primary focus. Standardized assessment of nonalcohol substance use was infrequent. Information about behavioral addiction was restricted to limited prevalence data. Functional outcomes were rarely reported. Feasibility was largely indexed by attendance. Economic analysis has not been undertaken. Little is known about the variables that may influence treatment outcome, but attendance represents a potential candidate. Assessment and reporting of mental health status was poor. Although positive effects were found, the modest sample and diversity of methods prevent us from making conclusive remarks about efficacy. Further research is needed to understand the clinical and public health utility of SMART as a viable recovery support option. C1 [Beck, Alison K.; Forbes, Erin; Baker, Amanda L.] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW, Australia. [Kelly, Peter J.; Deane, Frank P.] Univ Wollongong, Sch Psychol, Wollongong, NSW, Australia. [Shakeshaft, Anthony] Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia. [Hunt, David] SMART Recovery Australia, Haymarket, NSW, Australia. [Kelly, John F.] Massachusetts Gen Hosp, Recovery Res Inst, Boston, MA 02114 USA. [Kelly, John F.] Harvard Med Sch, Dept Psychiat, Boston, MA USA. RP Beck, AK (reprint author), Calvary Mater Newcastle, McCauley Ctr, Level 5,Edith St, Waratah, NSW 2298, Australia. EM alison.beck@newcastle.edu.au FU National Health and Medical Research Council FX Alison K. Beck is supported by the National Health and Medical Research Council's Centre of Research Excellence for Mental Health and Substance Use. The funder had no involvement in the development, conduct, or interpretation of this systematic review. We thank Mary Kumvaj for her assistance with designing the search strategy. Protocol Registration: PROSPERO CRD42015025574. NR 38 TC 0 Z9 0 U1 1 U2 1 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X EI 1939-1501 J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD FEB PY 2017 VL 31 IS 1 BP 1 EP 20 DI 10.1037/adb0000237 PG 20 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA EN1SZ UT WOS:000395791600001 PM 28165272 ER PT J AU Wilson, SM Krenek, M Dennis, PA Yard, SS Browne, KC Simpson, TL AF Wilson, Sarah M. Krenek, Marketa Dennis, Paul A. Yard, Samantha S. Browne, Kendall C. Simpson, Tracy L. TI Daily Associations Between PTSD, Drinking, and Self-Appraised Alcohol-Related Problems SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article DE alcohol use disorder (AUD); posttraumatic stress disorder (PTSD); psychiatric comorbidities; longitudinal; interactive voice recognition (IVR) ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY; CONFIRMATORY FACTOR-ANALYSIS; TIMELINE FOLLOW BACK; ALL-CAUSE MORTALITY; SUBSTANCE USE; BETWEEN-PERSON; CONDITIONS-III; LIFETIME PTSD; WITHIN-PERSON AB Alcohol dependence (AD) and posttraumatic stress disorder (PTSD) are highly comorbid, yet limited research has focused on PTSD and daily drinking as they relate to self-appraised alcohol-related problems. In treatment contexts, patients' appraisals of alcohol-related problems have implications for assessment, intervention strategies, and prognosis. This study investigated the moderating effect of within-person (daily symptoms) and between-person (overall severity) differences in PTSD on the association between daily drinking and same-day alcohol-related problems. Participants with comorbid AD and PTSD (N = 86) completed 1 week of Interactive Voice Recognition data collection, and logistic and gamma-adjusted multilevel models were used to estimate odds and magnitude of self-appraised alcohol-related problems. Results revealed that both within-person and between-person PTSD moderated the association between number of drinks and severity of self-appraised problems. As within-person and between-person PTSD symptoms increased, there was a weaker association between number of drinks consumed and perceived alcohol-related problems. Contrasts further revealed that on nondrinking and light-drinking days, PTSD (both daily symptoms and overall severity) was positively associated with ratings of alcohol-related problems. However, PTSD was not associated with alcohol-related problems on heavier drinking days. In conclusion, more severe PTSD is associated with a less directly contingent relationship between drinking quantity and perceived alcohol-related problems. These findings suggest the importance of further investigations of this moderating effect as well as clinical treatment of comorbid AD and severe PTSD with functional analysis of drinking. C1 [Wilson, Sarah M.] Midatlantic Mental Illness Res Educ & Clin Ctr MI, 508 Fulton St, Durham, NC 27705 USA. [Wilson, Sarah M.; Dennis, Paul A.] Durham VA Hlth Care Syst, Durham, NC USA. [Krenek, Marketa; Browne, Kendall C.] VA Puget Sound Hlth Care Syst, VISN MIRECC 20, Seattle, WA USA. [Dennis, Paul A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [Yard, Samantha S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Browne, Kendall C.; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, CESATE, Seattle, WA USA. RP Wilson, SM (reprint author), Midatlantic Mental Illness Res Educ & Clin Ctr MI, 508 Fulton St, Durham, NC 27705 USA. EM sarah.wilson@duke.edu FU NIH/NIAAA [R21AA17130-01]; U.S. Department of Veterans Affairs Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment FX This study was supported in part by a grant from NIH/NIAAA award (R21AA17130-01; PI: TLS) and by resources from the Center of Excellence in Substance Abuse Treatment and Education (CESATE; TLS), the VISN 20 and VISN 6 Mental Illness Research, Education, and Clinical Centers (MIRECC), the U.S. Department of Veterans Affairs Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment (SMW, MK, SSY, and KCB), and the VA Puget Sound Health Care System, Seattle, WA. NR 50 TC 0 Z9 0 U1 0 U2 0 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X EI 1939-1501 J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD FEB PY 2017 VL 31 IS 1 BP 27 EP 35 DI 10.1037/adb0000238 PG 9 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA EN1SZ UT WOS:000395791600003 PM 28068120 ER PT J AU Fernandez, AC Yurasek, AM Merrill, JE Miller, MB Zamboanga, BL Carey, KB Borsari, B AF Fernandez, Anne C. Yurasek, Ali M. Merrill, Jennifer E. Miller, Mary Beth Zamboanga, Byron L. Carey, Kate B. Borsari, Brian TI Do Brief Motivational Interventions Reduce Drinking Game Frequency in Mandated Students? An Analysis of Data From Two Randomized Controlled Trials SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article DE drinking games; brief intervention; motivational interviewing; college; alcohol ID COLLEGE-STUDENTS; ALCOHOL INTERVENTIONS; AUSTRALIAN UNIVERSITY; STEPPED CARE; PARTICIPATION; CONSUMPTION; DRINKERS; DETERMINANTS; METAANALYSIS; EFFICACY AB College students frequently engage in drinking games (DGs) and experience a variety of consequences as a result. It is currently unknown whether brief motivational interventions (BMIs) that provide feedback on DG participation can reduce this high risk behavior. This study examined outcome data from 2 randomized clinical trials to examine whether BMIs facilitate change in DG frequency and how these changes may occur. Mandated college students (Trial 1, N = 198, 46% female; Trial 2, N = 412; 32% female) were randomized to BMI or comparison control conditions. Hierarchical linear modeling (HLM) was used to compare the BMI and comparison groups to determine whether the BMI reduced DG participation over time. Percent change talk (PCT) during the discussion of DG during the session was examined as a predictor of change in DG frequency, and gender was examined as a moderator of treatment effects. Controlling for regular drinking frequency, participants who received a BMI did not significantly reduce their DG frequency relative to the comparison group in either sample, and the BMI was equally ineffective at reducing DG behavior for men and women. DG-related PCT during the BMI was associated with lower DG frequency at the second follow-up in both trials. In Trial 1, PCT during the BMI was associated with less steep increases in DG frequency across the course of all follow-ups. Effects of PCT on DG behavior were not moderated by gender. Findings did not support hypothesized reductions in DG participation following a BMI. Future research should explore whether targeted DG-specific interventions could reduce DG participation and the role of in-session client language in facilitating such change. C1 [Fernandez, Anne C.] Univ Michigan, Dept Psychiat, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA. [Yurasek, Ali M.] Univ Florida, Coll Hlth & Human Performance, Dept Hlth Educ & Behav, Gainesville, FL 32611 USA. [Merrill, Jennifer E.; Miller, Mary Beth; Carey, Kate B.] Brown Univ, Ctr Alcohol & Addict Studies, Sch Publ Hlth, Providence, RI 02912 USA. [Zamboanga, Byron L.] Smith Coll, Dept Psychol, Northampton, MA 01063 USA. [Borsari, Brian] San Francisco VA Med Ctr, San Francisco, CA USA. [Borsari, Brian] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Fernandez, AC (reprint author), Univ Michigan, Dept Psychiat, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA. EM acfernan@med.umich.edu FU National Institute on Alcohol Abuse and Alcoholism [R01-AA015518, R01 AA017427, T32 AA007459]; VISN1 Career Development Award [V1CDA2012-18]; [R01 AA012518] FX This work was supported by National Institute on Alcohol Abuse and Alcoholism Grants R01-AA015518, R01 AA017427, and VISN1 Career Development Award V1CDA2012-18 to Brian Borsari and Grant R01 AA012518 to Kate B. Carey. The contributions of Anne C. Fernandez, Ali M. Yurasek and Mary Beth Miller were supported by Grant T32 AA007459 from the National Institute on Alcohol Abuse and Alcoholism. NR 50 TC 0 Z9 0 U1 0 U2 0 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X EI 1939-1501 J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD FEB PY 2017 VL 31 IS 1 BP 36 EP 45 DI 10.1037/adb0000239 PG 10 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA EN1SZ UT WOS:000395791600004 PM 27936818 ER PT J AU Magidson, JF Robustelli, BL Seitz-Brown, CJ Whisman, MA AF Magidson, Jessica F. Robustelli, Briana L. Seitz-Brown, C. J. Whisman, Mark A. TI Activity Enjoyment, Not Frequency, Is Associated With Alcohol-Related Problems and Heavy Episodic Drinking SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article DE alcohol-related problems; heavy drinking; depression; behavioral theory ID BEHAVIORAL ACTIVATION TREATMENT; SUBSTANCE USE; USE DISORDERS; DEPRESSION; PLEASANT; CHOICE; ADULTS; REINFORCEMENT; OUTCOMES; EVENTS AB Depression and alcohol use disorder (AUD) commonly co-occur, and this comorbidity is associated with greater impairment and higher likelihood of relapse compared to either disorder alone. Identifying shared vulnerability across depression and AUD may aid in developing more parsimonious treatment approaches. Low levels of positive reinforcement for healthy behaviors have been implicated as a shared vulnerability across both depression and AUD. However, prior research in this area has largely been conducted among college students and has rarely examined depression and AUD symptoms together. This study aims to extend prior literature by examining the association between both the frequency and enjoyment of activities and AUD symptoms in a national sample of adults (n = 609) while also accounting for depressive symptoms. Study results indicated that low levels of enjoyment were associated with greater alcohol-related problems and frequency of heavy episodic drinking, above and beyond depressive symptoms. The frequency of potentially pleasurable activities was unrelated to alcohol-related problems or heavy episodic drinking. Findings extend prior literature by providing evidence for the association between enjoyment of activities and alcohol use, above and beyond depressive symptoms, among a national sample of adults. These results suggest that prioritizing enjoyment of activities, rather than frequency, may be important for behavioral intervention efforts to address heavy drinking and associated problems. Future longitudinal research using observational methods of behavior is needed to identify causal relationships between activity enjoyment and AUD symptoms. C1 [Magidson, Jessica F.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Magidson, Jessica F.] Harvard Med Sch, Dept Psychiat, 1 Bowdoin Sq,7th Floor, Boston, MA 02108 USA. [Robustelli, Briana L.; Whisman, Mark A.] Univ Colorado Boulder, Dept Psychol & Neurosci, Boulder, CO USA. [Seitz-Brown, C. J.] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. RP Magidson, JF (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.; Magidson, JF (reprint author), Harvard Med Sch, Dept Psychiat, 1 Bowdoin Sq,7th Floor, Boston, MA 02108 USA. EM Jmagidson@mgh.harvard.edu FU National Institute on Aging [P01-AG020166]; General Clinical Research Centers Program [M01-RR023942, M01-RR00865]; Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, National Institutes of Health [1UL1RR025011]; John D. and Catherine T. MacArthur Foundation Research Network on Successful Midlife Development; National Institutes of Health [K23DA041901]; National Insitutes of Health [F31DA039612] FX This research was supported by a grant from the National Institute on Aging (P01-AG020166) to conduct a longitudinal follow-up of the MIDUS (Midlife in the U.S.) investigation and by grants M01-RR023942 (Georgetown), M01-RR00865 (UCLA) from the General Clinical Research Centers Program, and 1UL1RR025011 (UW) from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, National Institutes of Health. The original study was supported by the John D. and Catherine T. MacArthur Foundation Research Network on Successful Midlife Development. Jessica F. Magidson's time on this manuscript was supported by National Institutes of Health Grant K23DA041901. C.J. Seitz-Brown's time on this manuscript was supported by National Insitutes of Health Grant F31DA039612. NR 26 TC 0 Z9 0 U1 0 U2 0 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X EI 1939-1501 J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD FEB PY 2017 VL 31 IS 1 BP 73 EP 78 DI 10.1037/adb0000220 PG 6 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA EN1SZ UT WOS:000395791600008 PM 27631613 ER PT J AU Brumpton, BM Langhammer, A Henriksen, AH Camargo, CA Chen, Y Romundstad, PR Mai, XM AF Brumpton, Ben M. Langhammer, Arnulf Henriksen, Anne H. Camargo, Carlos A., Jr. Chen, Yue Romundstad, Pl R. Mai, Xiao-Mei TI Physical activity and lung function decline in adults with asthma: The HUNT Study SO RESPIROLOGY LA English DT Article DE forced expiratory volume in 1 s; forced vital capacity; leisure time; peak expiratory flow; prospective ID BRONCHIAL HYPERRESPONSIVENESS; RESPIRATORY-FUNCTION; NORD-TRONDELAG; EXERCISE; POPULATION; SMOKING; PROGRAM; HEALTH; COHORT; MEN AB Background and objective: People with asthma may seek advice about physical activity. However, the benefits of leisure time physical activity on lung function are unclear. We investigated the association between leisure time physical activity and lung function decline in adults with asthma. Methods: In a population-based cohort study in Norway, we used multiple linear regressions to estimate the annual mean decline in lung function (and 95% CI) in 1329 people with asthma over a mean follow-up of 11.6 years. The durations of light and hard physical activity per week in the last year were collected by questionnaire. Inactive participants did not report any light or hard activity, while active participants reported light or hard activity. Results: The mean decline in forced expiratory volume in 1 s (FEV1) was 37 mL/year among inactive participants and 32 mL/year in active participants (difference: -5 mL/year (95% CI: -13 to 3)). The mean decline in forced vital capacity (FVC) was 33 mL/year among inactive participants and 31 mL/year in active participants (difference: -2 mL/year (95% CI: -11 to 7)). The mean decline in FEV1/FVC ratio was 0.36%/year among inactive participants and 0.22%/year in active participants (difference: -0.14%/year (95% CI: -0.27 to -0.01)). The mean decline in peak expiratory flow (PEF) was 14 mL/ year among the inactive participants and 10 mL/year in active participants (difference: -4 mL/year (95% CI: -9 to 1)). Conclusion: We observed slightly less decline in lung function in physically active than inactive participants with asthma, particularly for FEV1, FEV1/FVC ratio and PEF. C1 [Brumpton, Ben M.; Langhammer, Arnulf; Romundstad, Pl R.; Mai, Xiao-Mei] Norwegian Univ Sci & Technol, NTNU, Dept Publ Hlth & Gen Practice, Fac Med, Trondheim, Norway. [Henriksen, Anne H.] Norwegian Univ Sci & Technol, NTNU, Dept Circulat & Med Imaging, Trondheim, Norway. [Henriksen, Anne H.] Univ Trondheim Hosp, Dept Thorac & Occupat Med, Trondheim, Norway. [Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA. [Camargo, Carlos A., Jr.] Harvard Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Chen, Yue] Univ Ottawa, Fac Med, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada. RP Brumpton, BM (reprint author), Norwegian Univ Sci & Technol NTNU, Dept Publ Hlth & Gen Practice, Fac Med, MTFS, Postbox 8905, NO-7491 Trondheim, Norway. EM ben.brumpton@ntnu.no FU Liaison Committee FX The HUNT Study) is a collaboration between HUNT Research Centre (Faculty of Medicine, Norwegian University of Science and Technology, NTNU), Nord-Trondelag County Council, Central Norway Health Authority and the Norwegian Institute of Public Health. B.M.B. received a post-doctoral fellowship grant from the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology. NR 28 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD FEB PY 2017 VL 22 IS 2 BP 278 EP 283 DI 10.1111/resp.12884 PG 6 WC Respiratory System SC Respiratory System GA EO6FS UT WOS:000396788000009 PM 27696634 ER PT J AU Uraki, R Hwang, J Jurado, KA Householder, S Yockey, LJ Hastings, AK Homer, RJ Iwasaki, A Fikrig, E AF Uraki, Ryuta Hwang, Jesse Jurado, Kellie Ann Householder, Sarah Yockey, Laura J. Hastings, Andrew K. Homer, Robert J. Iwasaki, Akiko Fikrig, Erol TI Zika virus causes testicular atrophy SO SCIENCE ADVANCES LA English DT Article ID HUMAN LEYDIG-CELLS; SEXUAL TRANSMISSION; NEURAL PROGENITORS; MICE; INFECTION; BRAIN; ORGANOIDS; EXPOSURE; LEADS; PERSISTENCE AB Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that has recently been found to cause fetal infection and neonatal abnormalities, including microcephaly and neurological dysfunction. ZIKV persists in the semen months after the acute viremic phase in humans. To further understand the consequences of ZIKV persistence in males, we infected Ifnar1(-/-) mice via subcutaneous injection of a pathogenic but nonlethal ZIKV strain. ZIKV replication persists within the testes even after clearance from the blood, with interstitial, testosterone-producing Leydig cells supporting virus replication. We found high levels of viral RNA and antigen within the epididymal lumen, where sperm is stored, and within surrounding epithelial cells. Unexpectedly, at 21 days post-infection, the testes of the ZIKV-infected mice were significantly smaller compared to those of mock-infected mice, indicating progressive testicular atrophy. ZIKV infection caused a reduction in serum testosterone, suggesting that male fertility can be affected. Our findings have important implications for nonvector-borne vertical transmission, as well as long-term potential reproductive deficiencies, in ZIKV-infected males. C1 [Uraki, Ryuta; Hwang, Jesse; Householder, Sarah; Hastings, Andrew K.; Fikrig, Erol] Yale Univ, Sch Med, Dept Internal Med, Sect Infect Dis, 333 Cedar St, New Haven, CT 06520 USA. [Jurado, Kellie Ann; Yockey, Laura J.; Iwasaki, Akiko] Yale Univ, Sch Med, Dept Immunobiol, 333 Cedar St, New Haven, CT 06520 USA. [Homer, Robert J.] Yale Univ, Sch Med, Dept Pathol, 333 Cedar St, New Haven, CT 06520 USA. [Homer, Robert J.] US Dept Vet Affairs, Affairs Connecticut Healthcare Syst Pathol & Lab, West Haven, CT 06516 USA. [Iwasaki, Akiko; Fikrig, Erol] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. RP Fikrig, E (reprint author), Yale Univ, Sch Med, Dept Internal Med, Sect Infect Dis, 333 Cedar St, New Haven, CT 06520 USA.; Fikrig, E (reprint author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. EM erol.fikrig@yale.edu FU NIH [5T32 AI007019-40, 4T32HL007974-15, T32 GM007205] FX This work was supported by NIH grants 5T32 AI007019-40 (to K.A.J.), 4T32HL007974-15 (to J.H.), and T32 GM007205 (to L.J.Y.). NR 43 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 2375-2548 J9 SCI ADV JI Sci. Adv. PD FEB PY 2017 VL 3 IS 2 AR e1602899 DI 10.1126/sciadv.1602899 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EO9WT UT WOS:000397039500038 ER PT J AU Rai, SK Avina-Zubieta, JA McCormick, N De Vera, MA Shojania, K Sayre, EC Choi, HK AF Rai, Sharan K. Avina-Zubieta, J. Antonio McCormick, Natalie De Vera, Mary A. Shojania, Kam Sayre, Eric C. Choi, Hyon K. TI The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012 SO SEMINARS IN ARTHRITIS AND RHEUMATISM LA English DT Review DE Gout; Epidemiology; Prevalence; Incidence; Urate-lowering therapy; Prescription patterns; Canada ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; US GENERAL-POPULATION; PURINE-RICH FOODS; URIC-ACID LEVEL; PROSPECTIVE COHORT; SOFT DRINKS; NEW-ZEALAND; FOLLOW-UP; RISK AB Objectives: Gout is increasingly recognized as the most common form of inflammatory arthritis worldwide; however, no Canadian data on the disease burden of gout are available. We estimated the prevalence, incidence, prescription patterns, and comorbidity burden of gout in an entire Canadian province [British Columbia (BC)] over the last decade. Methods: We utilized PopulationData BC, a province-wide database, to estimate temporal trends in the prevalence and incidence of gout from 2000 to 2012, as well as according to age category. Annual estimates were age-sex-standardized using 2012 as the reference. We also examined annual trends in prescription patterns of common gout medications and assessed the comorbidity burden among gout patients in 2012. Results: The 2012 prevalence of gout was 3.8% among the overall population, and the incidence rate was 2.9 per 1000 person-years. Both gout prevalence and incidence increased substantially over the study period. This burden additionally increased according to age category, affecting over 8% of those ages 60-69 years in 2012. Approximately 22% of gout patients received a prescription for urate-lowering therapy (ULT), which remained stable over the study period, while colchicine and oral glucocorticoid use both increased modestly. By 2012, 72%, 52%, and 18% of prevalent gout patients had been diagnosed with hypertension, hyperlipidemia, and diabetes, respectively. Conclusions: The burden of gout in BC, Canada, is substantial, and both the prevalence and incidence have increased over the past decade, while prescription of ULT remains low. These data support the need to improve gout prevention and care. (C) 2017 Elsevier Inc. All rights reserved. C1 [Rai, Sharan K.; Avina-Zubieta, J. Antonio; McCormick, Natalie; De Vera, Mary A.; Shojania, Kam; Sayre, Eric C.; Choi, Hyon K.] Arthrit Res Canada, Vancouver, BC, Canada. [Rai, Sharan K.] Univ British Columbia, Dept Expt Med, Vancouver, BC, Canada. [Avina-Zubieta, J. Antonio; Shojania, Kam] Univ British Columbia, Dept Med, Div Rheumatol, Vancouver, BC, Canada. [McCormick, Natalie; De Vera, Mary A.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada. [Choi, Hyon K.] Harvard Med Sch, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Dept Med, 55 Fruit St,Bulfinch 165, Boston, MA 02114 USA. RP Choi, HK (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Dept Med, 55 Fruit St,Bulfinch 165, Boston, MA 02114 USA. EM hchoi@partners.org FU Team Grant from the Canadian Institutes of Health Research, Canada [135235]; National Institute of Arthritis and Musculoskeletal and Skin Diseases, United States [R01AR065944] FX This study was funded by a Team Grant from the Canadian Institutes of Health Research, Canada (Grant ID 135235). This study was also supported in part from a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, United States (R01AR065944). NR 44 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0049-0172 EI 1532-866X J9 SEMIN ARTHRITIS RHEU JI Semin. Arthritis Rheum. PD FEB PY 2017 VL 46 IS 4 BP 451 EP 456 DI 10.1016/j.semarthrit.2016.08.006 PG 6 WC Rheumatology SC Rheumatology GA EO0JK UT WOS:000396383900010 PM 28040245 ER PT J AU Rosenblau, G Kliemann, D Dziobek, I Heekeren, HR AF Rosenblau, Gabriela Kliemann, Dorit Dziobek, Isabel Heekeren, Hauke R. TI Emotional prosody processing in autism spectrum disorder SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE LA English DT Article DE emotion; prosody; behavioral assessment; fMRI; autism ID SUPERIOR TEMPORAL SULCUS; HIGH-FUNCTIONING AUTISM; ASPERGER-SYNDROME; DIAGNOSTIC INTERVIEW; MEANINGLESS SPEECH; SOCIAL COGNITION; BRAIN MECHANISMS; RIGHT-HEMISPHERE; REVISED VERSION; NORMAL ADULTS AB Individuals with Autism Spectrum Disorder (ASD) are characterized by severe deficits in social communication, whereby the nature of their impairments in emotional prosody processing have yet to be specified. Here, we investigated emotional prosody processing in individuals with ASD and controls with novel, lifelike behavioral and neuroimaging paradigms. Compared to controls, individuals with ASD showed reduced emotional prosody recognition accuracy on a behavioral task. On the neural level, individuals with ASD displayed reduced activity of the STS, insula and amygdala for complex vs basic emotions compared to controls. Moreover, the coupling between the STS and amygdala for complex vs basic emotions was reduced in the ASD group. Finally, groups differed with respect to the relationship between brain activity and behavioral performance. Brain activity during emotional prosody processing was more strongly related to prosody recognition accuracy in ASD participants. In contrast, the coupling between STS and anterior cingulate cortex (ACC) activity predicted behavioral task performance more strongly in the control group. These results provide evidence for aberrant emotional prosody processing of individuals with ASD. They suggest that the differences in the relationship between the neural and behavioral level of individuals with ASD may account for their observed deficits in social communication. C1 [Rosenblau, Gabriela; Kliemann, Dorit; Dziobek, Isabel; Heekeren, Hauke R.] Free Univ Berlin, Cluster Excellence Languages Emot, D-14195 Berlin, Germany. [Rosenblau, Gabriela; Kliemann, Dorit; Heekeren, Hauke R.] Free Univ Berlin, Dept Educ & Psychol, D-14195 Berlin, Germany. [Rosenblau, Gabriela] Yale Univ, Yale Child Study Ctr, 230 S Frontage Rd, New Haven, CT 06519 USA. [Kliemann, Dorit] MIT, McGovern Inst Brain Res, 43 Vassar St, Cambridge, MA 02139 USA. [Kliemann, Dorit] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, 149 Thirteenth St, Charlestown, MA 02129 USA. [Dziobek, Isabel] Humboldt Univ, Berlin Sch Mind & Brain, Unter Linden 6, D-10099 Berlin, Germany. [Heekeren, Hauke R.] Freie Univ, Dahlem Inst Neuroimaging Emot, Berlin, Germany. RP Rosenblau, G (reprint author), Yale Univ, Yale Child Study Ctr, Ctr Translat Dev Neurosci, 230 S Frontage Rd, New Haven, CT 06519 USA. EM gabriela.rosenblau@yale.edu FU German Research Foundation (DFG) [EXC 302] FX The study was funded by a grant from the German Research Foundation (DFG; EXC 302). NR 76 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1749-5016 EI 1749-5024 J9 SOC COGN AFFECT NEUR JI Soc. Cogn. Affect. Neurosci. PD FEB PY 2017 VL 12 IS 2 BP 224 EP 239 DI 10.1093/scan/nsw118 PG 16 WC Neurosciences; Psychology; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA EP3WK UT WOS:000397312200005 ER PT J AU Connell, NT Abel, GA Connors, JM AF Connell, Nathan T. Abel, Gregory A. Connors, Jean M. TI Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis SO THROMBOSIS RESEARCH LA English DT Article ID RECURRENT VENOUS THROMBOEMBOLISM; CLINICAL-PRACTICE GUIDELINES; ANTICOAGULANT-THERAPY; SECONDARY PROPHYLAXIS; ORAL ANTICOAGULANTS; AMERICAN-COLLEGE; ACTIVE CANCER; WARFARIN; PREVENTION; EVENTS AB Introduction: Cancer-associated venous thromboembolism(VTE) is primarily treated with low-molecular weight heparin (LMWH), a strategy based on studies showing it to be superior to the vitamin K antagonist (VKA) warfarin for preventing VTE recurrence. Subsequent analyses suggest that the magnitude of this benefit might be less than previously determined. Neither patient-focused measures of utility nor the costs of each strategy have been evaluated in the current treatment era. Methods: This is a cost-effectiveness analysis of VKA and LMWH for the treatment of cancer-associated thrombosis through use of a microsimulation model of outcomes for competing anticoagulation management strategies from a 2014 United States societal perspective. Results: LMWH therapy added 0.27 QALYs relative to VKA treatment with an ICER of $217,007. One-way sensitivity analysis evaluating the utility of LMWH revealed that VKA was always the preferred strategy at a willingness to pay(WTP) threshold of $ 100,000 per QALY. Limitations include that the model incorporates a low VKA time in therapeutic range (TTR) and that the TTR in some centers may be higher thereby increasing the cost-effectiveness of the VKA strategy. Utilities for anticoagulation strategies were not derived from cancer patients, and preference is known to vary depending on how anticoagulation method is integrated with cancer treatment. Conclusions: Our findings suggest that compared to LMWH, warfarin is a more cost-effective strategy to treat cancer-associated VTE. Although LMW His associated with a modest increase in life expectancy, this increase comes at significant cost. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Connell, Nathan T.; Connors, Jean M.] Brigham & Womens Hosp, Div Hematol, 75 Francis St,SR322, Boston, MA 02115 USA. [Abel, Gregory A.] Dana Farber Canc Inst, Div Populat Sci, 450 Brookline Ave, Boston, MA 02115 USA. [Connell, Nathan T.; Abel, Gregory A.; Connors, Jean M.] Harvard Med Sch, Boston, MA USA. RP Connell, NT (reprint author), Brigham & Womens Hosp, Div Hematol, 75 Francis St,SR322, Boston, MA 02115 USA. EM NTConnell@partners.org NR 29 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0049-3848 J9 THROMB RES JI Thromb. Res. PD FEB PY 2017 VL 150 BP 53 EP 58 DI 10.1016/j.thromres.2016.12.017 PG 6 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA EO9YY UT WOS:000397045200010 PM 28039844 ER PT J AU Pine, AB Lee, EJ Sekeres, M Steensma, DP Zelterman, D Prebet, T DeZern, A Komrokji, R Litzow, M Luger, S Stone, R Erba, HP Garcia-Manero, G Lee, AI Podoltsev, NA Barbarotta, L Kasberg, S Hendrickson, JE Gore, SD Zeidan, AM AF Pine, Alexander B. Lee, Eun-Ju Sekeres, Mikkael Steensma, David P. Zelterman, Daniel Prebet, Thomas DeZern, Amy Komrokji, Rami Litzow, Mark Luger, Selina Stone, Richard Erba, Harry P. Garcia-Manero, Guillermo Lee, Alfred I. Podoltsev, Nikolai A. Barbarotta, Lisa Kasberg, Stephanie Hendrickson, Jeanne E. Gore, Steven D. Zeidan, Amer M. TI Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States SO TRANSFUSION LA English DT Article ID CLINICAL-PRACTICE GUIDELINE; ACUTE MYELOID-LEUKEMIA; PLATELET-TRANSFUSION; CELL TRANSFUSION; RESTRICTIVE TRANSFUSION; RISK-FACTORS; MANAGEMENT; SURGERY; AABB AB BACKGROUND: Transfusion of blood products is a key component of the supportive management in patients with acute leukemia (AL). However high-quality trial evidence and clinical outcome data to support specific transfusion goals for blood products for patients with AL remain limited leading to diverse transfusion practices. The primary objective of this study was to determine the spectrum of transfusion patterns in a variety of care settings among providers who treat AL patients. STUDY DESIGN AND METHODS: A 31-question survey queried providers caring for AL patients about the existence of institutional guidelines for transfusion of blood products, transfusion triggers for hemoglobin (Hb), platelets (PLTs), and fibrinogen in various settings including inpatient and outpatient and before procedures. RESULTS: We analyzed 130 responses and identified divergent transfusion Hb goals in hospitalized and ambulatory patients, fibrinogen goals for cryoprecipitate transfusions, and variation in practice for use of certain PLTs and red blood cell products. The least variable transfusion patterns were reported for PLT goals in thrombocytopenia and in the setting of invasive procedures such as bone marrow biopsy and lumbar punctures. CONCLUSIONS: This survey confirmed wide variations in blood product transfusion practices across several clinical scenarios in patients with AL. The findings emphasized the need for large prospective randomized trials to develop standardized evidence-based guidelines for blood product transfusions in patients with AL with the goal of limiting unnecessary transfusions without compromising outcomes. C1 [Pine, Alexander B.; Barbarotta, Lisa; Kasberg, Stephanie] Yale New Haven Med Ctr, 20 York St, New Haven, CT 06504 USA. [Lee, Eun-Ju; Prebet, Thomas; Lee, Alfred I.; Podoltsev, Nikolai A.; Gore, Steven D.; Zeidan, Amer M.] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA. [Hendrickson, Jeanne E.] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA. [Zelterman, Daniel] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Sekeres, Mikkael] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA. [Steensma, David P.; Stone, Richard] Dana Farber Canc Inst, Boston, MA 02115 USA. [DeZern, Amy] Johns Hopkins Sch Med, Baltimore, MD USA. [Komrokji, Rami] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA. [Litzow, Mark] Mayo Clin, Rochester, MN USA. [Luger, Selina] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Erba, Harry P.] Univ Alabama Birmingham, Birmingham, AL USA. [Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. RP Zeidan, AM (reprint author), Yale Univ, Dept Internal Med, Sect Hematol, 333 Cedar St,POB 208028, New Haven, CT 06520 USA. EM amer.zeidan@yale.edu FU NCI NIH HHS [K24 CA111717, U10 CA013650, U10 CA015488, U10 CA016116, U10 CA021115, U10 CA073590, U10 CA180790, U10 CA180802, U10 CA180820, U10 CA180826, U10 CA180853, U10 CA180855, U10 CA180858, U10 CA180867] NR 19 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD FEB PY 2017 VL 57 IS 2 BP 289 EP 295 DI 10.1111/trf.13934 PG 7 WC Hematology SC Hematology GA EO9ZW UT WOS:000397047600011 PM 27878822 ER PT J AU Hamada, T Nishihara, R Ogino, S AF Hamada, Tsuyoshi Nishihara, Reiko Ogino, Shuji TI Post-colonoscopy colorectal cancer: the key role of molecular pathological epidemiology SO TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Editorial Material ID FUSOBACTERIUM-NUCLEATUM; TASK-FORCE; RISK; PREVENTION; CARCINOMA; FEATURES; DISEASE; LESIONS C1 [Hamada, Tsuyoshi; Nishihara, Reiko; Ogino, Shuji] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [Nishihara, Reiko; Ogino, Shuji] Harvard Med Sch, Brigham & Womens Hosp, Div MPE Mol Pathol Epidemiol, Dept Pathol, Boston, MA USA. [Nishihara, Reiko] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Nishihara, Reiko; Ogino, Shuji] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Nishihara, Reiko] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Ogino, Shuji] Harvard Med Sch, Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA USA. RP Nishihara, R (reprint author), Brigham & Womens Hosp, Div MPE Mol Pathol Epidemiol, 75 Francis St,Room TH530a, Boston, MA 02115 USA.; Ogino, S (reprint author), Brigham & Womens Hosp, Div MPE Mol Pathol Epidemiol, 450 Brookline Ave,Room SM1036, Boston, MA 02215 USA. EM rnishiha@hsph.harvard.edu; shuji_ogino@dfci.harvard.edu FU U.S. National Institutes of Health (NIH) [R35 CA197735, K07 CA190673]; Dana-Farber Harvard Cancer Center; Friends of the Dana-Farber Cancer Institute; Mitsukoshi Health and Welfare Foundation FX This work was supported by U.S. National Institutes of Health (NIH) grants (R35 CA197735 to Shuji Ogino and K07 CA190673 to Reiko Nishihara); by Nodal Award from the Dana-Farber Harvard Cancer Center (to Shuji Ogino); and by The Friends of the Dana-Farber Cancer Institute. Tsuyoshi Hamada was supported by a fellowship grant from the Mitsukoshi Health and Welfare Foundation. NR 25 TC 0 Z9 0 U1 0 U2 0 PU AME PUBL CO PI SHEUNG WAN PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG 00000, PEOPLES R CHINA SN 2224-476X EI 2415-1289 J9 TRANSL GASTROENT HEP JI Transl. Gastroenterol. Hepatol. PD FEB PY 2017 VL 2 AR 9 DI 10.21037/tgh.2017.01.05 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EO0SH UT WOS:000396407700002 PM 28275741 ER PT J AU Hu, KJ Moses, ZB Hutter, MM Williams, Z AF Hu, Kejia Moses, Ziev B. Hutter, Matthew M. Williams, Ziv TI Short-Term Adverse Outcomes After Deep Brain Stimulation Treatment in Patients with Parkinson Disease SO WORLD NEUROSURGERY LA English DT Article DE Complication; Deep brain stimulation; Discharge destination; NSQIP; Parkinson disease; Unplanned readmission ID PREDICT DISCHARGE DESTINATION; QUALITY IMPROVEMENT PROGRAM; OF-THE-LITERATURE; BODY-MASS INDEX; NATIONWIDE INPATIENT SAMPLE; SUBTHALAMIC NUCLEUS; MOVEMENT-DISORDERS; UNITED-STATES; SUBARACHNOID HEMORRHAGE; HARDWARE COMPLICATIONS AB BACKGROUND: Despite ongoing progress in our understanding of long-term outcomes after neuromodulation procedures, acute adverse outcomes shortly after deep brain stimulation (DBS) treatment have remained remarkably limited. OBJECTIVE: To identify risk factors associated with acute 30-day outcomes after DBS treatment in patients with Parkinson disease (PD). METHODS: We evaluated patients who underwent DBS treatment for PD from 2005 to 2014 through the American College of Surgeons National Surgical Quality Improvement Program database. We used bivariate analysis and multivariate logistic regression to identify short-term postoperative outcomes, including 30-day complication, discharge destination, and unplanned readmission. RESULTS: Overall, 650 patients with PD underwent DBS procedures and complications were identified in 32 patients (4.9%). Of 481 patients who had complete discharge data, 18 patients (3.7%) were discharged to a facility and 16 patients (3.3%) experienced an unplanned readmission. Patients with PD who were obese (P = 0.045), who had preoperative anemia (P = 0.008), and who experienced longer operative durations (P = 0.01) had increased odds of postoperative complications. Inpatient status (P = 0.001), dependent functional status (P < 0.001), and anemia (P =0.043) were all associated with discharge to a facility other than home. Longer operative duration (P = 0.013), anemia (P = 0.036), and dependent functional status (P = 0.03) were significantly associated with unplanned readmission. As expected, complications increased the likelihood of unplanned readmission (P < 0.001). CONCLUSIONS: This study provides individualized estimates of the risks associated with short-term adverse outcomes based on patient demographics and comorbidities. These data can be used as an adjunct for short-term risk stratification of patients with PD being considered for DBS treatment. C1 [Hu, Kejia; Moses, Ziev B.; Williams, Ziv] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA. [Hutter, Matthew M.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA USA. [Moses, Ziev B.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA USA. [Hu, Kejia] Fudan Univ, Huashan Hosp, Dept Microsurg, Shanghai, Peoples R China. RP Williams, Z (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA. EM zwilliams@mgh.harvard.edu FU China Scholarship Council FX We greatly thank Donna M. Antonelli and Sarah H. Bird, who assisted with obtaining and using NSQIP datasets. We also thank Mohsen Jamali, Raymundo Baez-Mendoza, Firas Bounni, Gabriel Friedman, William Li, Jonas St Fleur, and Emma Mastrobattista in MGH-HMS Center for Nervous System Repair for their insightful discussion. Kejia Hu also specially thanks Professor Wendong Xu (Huashan Hospital, Fudan University), Professor Bomin Sun (Ruijin Hospital, Shanghai Jiao Tong University School of Medicine), Dr. Yu Zhu (Xuanwu Hospital, Capital Medical University) and The China Scholarship Council for support and encouragement. NR 48 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1878-8750 EI 1878-8769 J9 WORLD NEUROSURG JI World Neurosurg. PD FEB PY 2017 VL 98 BP 365 EP 374 DI 10.1016/j.wneu.2016.10.138 PG 10 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA EO9SL UT WOS:000397028300042 PM 27826085 ER PT J AU Muskens, IS Senders, JT Dasenbrock, HH Smith, TRS Broekman, MLD AF Muskens, Ivo S. Senders, Joeky T. Dasenbrock, Hormuzdiyar H. Smith, Timothy R. S. Broekman, Marike L. D. TI The Woven Endobridge Device for Treatment of Intracranial Aneurysms: A Systematic Review SO WORLD NEUROSURGERY LA English DT Review DE Endovascular treatment; Intracranial aneurysm; WEB device ID SINGLE-CENTER EXPERIENCE; ENDOVASCULAR TREATMENT; WEB DEVICE; UNRUPTURED ANEURYSMS; EMBOLIZATION DEVICE; FLOW DISRUPTION; MULTICENTER; COILING; TRIAL; COMPLICATIONS AB INTRODUCTION: The Woven Endobridge (WEB) device is an innovative endovascular device for treatment of intracranial aneurysms, especially bifurcation and wide-neck aneurysms. Although not approved by the U.S. Food and Drug Administration, it has been available in Europe since 2011. The aim of this review is to evaluate the outcomes of WEB device use for intracranial aneurysm treatment. METHODS: A systematic review was conducted with MEDLINE search engines PubMed and Embase from 2011. The search strategy provided 6229 articles, and 19 articles were included. RESULTS: A total of 19 papers were identified describing the use of WEB devices in 687 patients with 718 aneurysms. The 2 largest prospective multi-center studies (WEBCAST and the French Observatory Trial) reported successful treatment, defined as complete closure or a neck remnant, in 85% and 79% of aneurysms, respectively. The use of a WEB device in combination with coiling or stenting was described with varying results in multiple small series. Outcomes of WEB device use in ruptured aneurysms in 2 studies showed 94% and 80% adequate treatment. Thromboembolic events were described in 71 patients (10.3% of all patients) and infarctions in 8 patients (1.2% of all patients). CONCLUSIONS: Despite initial promising results, the WEB device should be used with caution given its potentially large learning curve and because it has primarily been investigated only in wide-neck and bifurcation aneurysms. In addition, currently available prospective studies have short follow-up, and the device has not been directly compared with other treatment modalities. C1 [Muskens, Ivo S.; Senders, Joeky T.; Broekman, Marike L. D.] Univ Med Ctr Utrecht, Dept Neurosurg, Utrecht, Netherlands. [Muskens, Ivo S.; Senders, Joeky T.; Dasenbrock, Hormuzdiyar H.; Smith, Timothy R. S.] Brigham & Womens Hosp, Harvard Med Sch, Cushing Neurosurg Outcomes Ctr, Dept Neurosurg, Boston, MA USA. [Broekman, Marike L. D.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA USA. RP Broekman, MLD (reprint author), Univ Med Ctr Utrecht, Dept Neurosurg, Utrecht, Netherlands.; Broekman, MLD (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA USA. EM M.L.D.Broekman-4@umcutrecht.nl NR 39 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1878-8750 EI 1878-8769 J9 WORLD NEUROSURG JI World Neurosurg. PD FEB PY 2017 VL 98 BP 809 EP 817 DI 10.1016/j.wneu.2016.11.020 PG 9 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA EO9SL UT WOS:000397028300100 PM 27856383 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI A Bias Toward Action in Gastrointestinal Bleeding SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter C1 [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Div Gastroenterol Hepatol, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.; Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Div Gastroenterol Hepatol, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD FEB PY 2017 VL 112 IS 2 BP 395 EP 396 DI 10.1038/ajg.2016.558 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EK7VP UT WOS:000394133600042 PM 28154390 ER PT J AU O'Reilly, EJ Liu, DW Johns, DR Cudkowicz, ME Paganoni, S Schwarzschild, MA Leitner, M Ascherio, A AF O'Reilly, Eilis J. Liu, Dawei Johns, Donald R. Cudkowicz, Merit E. Paganoni, Sabrina Schwarzschild, Michael A. Leitner, Melanie Ascherio, Alberto TI Serum urate at trial entry and ALS progression in EMPOWER SO AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION LA English DT Article DE Survival; progression; urate; body mass index; biomarkers ID AMYOTROPHIC-LATERAL-SCLEROSIS; URIC-ACID LEVELS; PARKINSON-DISEASE; OXIDATIVE STRESS; CLINICAL-TRIALS; POPULATION; SURVIVAL; PREVALENCE; CREATININE; PREDICTOR AB Our objective was to determine whether serum urate predicts ALS progression. A study population comprised adult participants of EMPOWER (n = 942), a phase III clinical trial to evaluate the efficacy of dexpramipexole to treat ALS. Urate was measured in blood samples collected during enrollment as part of the routine block chemistry. We measured outcomes by combined assessment of function and survival rank (CAFs), and time to death, by 12 months. Results showed that in females there was not a significant relation between urate and outcomes. In males, outcomes improved with increasing urate (comparing highest to lowest urate quartile: CAFS was 53 points better with p for trend = 0.04; and hazard ratio for death was 0.60 with p for trend = 0.07), but with adjustment for body mass index (BMI) at baseline, a predictor of both urate levels and prognosis, associations were attenuated and no longer statistically significant. Overall, participants with urate levels equal to or above the median (5.1 mg/dl) appeared to have a survival advantage compared to those below (hazard ratio adjusted for BMI: 0.67; 95% confidence interval 0.47-0.95). In conclusion, these findings suggest that while the association between urate at baseline and ALS progression is partially explained by BMI, there may be an independent beneficial effect of urate. C1 [O'Reilly, Eilis J.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [O'Reilly, Eilis J.; Ascherio, Alberto] Harvard Med Sch, Channing Div Network Med, Boston, MA USA. [O'Reilly, Eilis J.; Ascherio, Alberto] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Liu, Dawei; Johns, Donald R.; Leitner, Melanie] Biogen, ALS Neurosci Discovery & Dev, Cambridge, MA USA. [Cudkowicz, Merit E.; Paganoni, Sabrina; Schwarzschild, Michael A.] Massachusetts Gen Hosp, Dept Neurol, MassGen Inst Neurodegenerat Dis, Boston, MA 02114 USA. [Paganoni, Sabrina] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA. [Paganoni, Sabrina] VA Healthcare Syst, Boston, MA USA. [Ascherio, Alberto] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol & Nutr, Boston, MA USA. RP O'Reilly, EJ (reprint author), Harvard TH Chan Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA. EM poeor@channing.harvard.edu FU NIH [NS045893]; Target ALS; NIH Career Development Award [2K12HD001097-16]; Biogen Idec FX Funding for this study includes NIH grant awarded to AA [NS045893]. MAS is funded by Target ALS. SP is funded by an NIH Career Development Award [2K12HD001097-16]. The EMPOWER trial was designed by Biogen Idec and Knopp Biosciences and sponsored by Biogen Idec. NR 29 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 2167-8421 EI 2167-9223 J9 AMYOTROPH LAT SCL FR JI Amyotroph. Lateral Scher. Frontotemp. Degenerat. PD FEB PY 2017 VL 18 IS 1-2 BP 120 EP 125 DI 10.1080/21678421.2016.1214733 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA EL1TQ UT WOS:000394404400017 PM 27677562 ER PT J AU Alday, PH Bruzual, I Nilsen, A Pou, S Winter, R Ben Mamoun, C Riscoe, MK Doggett, JS AF Alday, P. Holland Bruzual, Igor Nilsen, Aaron Pou, Sovitj Winter, Rolf Ben Mamoun, Choukri Riscoe, Michael K. Doggett, J. Stone TI Genetic Evidence for Cytochrome b Q(i) Site Inhibition by 4(1H)-Quinolone-3-Diarylethers and Antimycin in Toxoplasma gondii SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article DE Toxoplasma gondii; apicomplexan parasites; cytochrome b; cytochrome bc(1); drug targets; experimental therapeutics; mechanisms of action; mitochondria; parasitology; preclinical drug studies ID ENDOCHIN-LIKE QUINOLONE; BC(1) COMPLEX; PLASMODIUM-FALCIPARUM; QUINONE REDUCTION; CRYSTAL-STRUCTURE; BOUND SUBSTRATE; ATOVAQUONE; ENCEPHALITIS; BABESIOSIS AB Toxoplasma gondii is an apicomplexan parasite that causes fatal and debilitating brain and eye disease. Endochinlike quinolones (ELQs) are preclinical compounds that are efficacious against apicomplexan-caused diseases, including toxoplasmosis, malaria, and babesiosis. Of the ELQs, ELQ-316 has demonstrated the greatest efficacy against acute and chronic experimental toxoplasmosis. Although genetic analyses in other organisms have highlighted the importance of the cytochrome bc(1) complex Q(i) site for ELQ sensitivity, the mechanism of action of ELQs against T. gondii and the specific mechanism of ELQ-316 remain unknown. Here, we describe the selection and genetic characterization of T. gondii clones resistant to ELQ-316. A T. gondii strain selected under ELQ-316 drug pressure was found to possess a Thr222-Pro amino acid substitution that confers 49-fold resistance to ELQ-316 and 19-fold resistance to antimycin, a well-characterized Q(i) site inhibitor. These findings provide further evidence for ELQ Q(i) site inhibition in T. gondii and greater insight into the interactions of Q(i) site inhibitors with the apicomplexan cytochrome bc(1) complex. C1 [Alday, P. Holland; Doggett, J. Stone] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. [Bruzual, Igor; Nilsen, Aaron; Pou, Sovitj; Winter, Rolf; Riscoe, Michael K.; Doggett, J. Stone] Portland VA Med Ctr, Dept Res & Dev, Portland, OR USA. [Ben Mamoun, Choukri] Yale Sch Med, Infect Dis Sect, Dept Internal Med, New Haven, CT USA. RP Doggett, JS (reprint author), Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA.; Doggett, JS (reprint author), Portland VA Med Ctr, Dept Res & Dev, Portland, OR USA. EM doggettj@ohsu.edu FU U.S. Department of Veterans Affairs Biomedical Laboratory Research and Development [BX002440]; NIH [R01 AI100569]; Peer Reviewed Medical Research Program Project [PR130649]; U.S. Department of Veterans Affairs [BX003312] FX This work was supported by Career Development Award BX002440 to J. Stone Doggett from the U.S. Department of Veterans Affairs Biomedical Laboratory Research and Development. We also acknowledge support for Michael K. Riscoe from NIH R01 AI100569, Peer Reviewed Medical Research Program Project PR130649, and VA Merit Review Funds from the U.S. Department of Veterans Affairs BX003312. NR 29 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD FEB PY 2017 VL 61 IS 2 AR e01866-16 DI 10.1128/AAC.01866-16 PG 8 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA EK7JQ UT WOS:000394102500042 ER PT J AU Lin, JJ Riely, GJ Shaw, AT AF Lin, Jessica J. Riely, Gregory J. Shaw, Alice T. TI Targeting ALK: Precision Medicine Takes on Drug Resistance SO CANCER DISCOVERY LA English DT Review ID CELL LUNG-CANCER; ANAPLASTIC LYMPHOMA KINASE; INFLAMMATORY MYOFIBROBLASTIC TUMOR; RECEPTOR TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; OF-THE-LITERATURE; ACQUIRED-RESISTANCE; OPEN-LABEL; CRIZOTINIB RESISTANCE AB Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK rearranged malignancies, including non-small cell lung cancer. However, the clinical benefi t of targeting ALK using tyrosine kinase inhibitors (TKI) is almost universally limited by the emergence of drug resistance. Diverse mechanisms of resistance to ALK TKIs have now been discovered, and these basic mechanisms are informing the development of novel therapeutic strategies to overcome resistance in the clinic. In this review, we summarize the current successes and challenges of targeting ALK. Significance: Effective long-term treatment of ALK-rearranged cancers requires a mechanistic understanding of resistance to ALK TKIs so that rational therapies can be selected to combat resistance. This review underscores the importance of serial biopsies in capturing the dynamic therapeutic vulnerabilities within a patient's tumor and offers a perspective into the complexity of on-target and off-target ALK TKI resistance mechanisms. Therapeutic strategies that can successfully overcome, and potentially prevent, these resistance mechanisms will have the greatest impact on patient outcome. (C) 2017 AACR. C1 [Lin, Jessica J.; Shaw, Alice T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Riely, Gregory J.] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY USA. RP Shaw, AT (reprint author), Massachusetts Gen Hosp, Ctr Canc, Dept Thorac Oncol, 32 Fruit St, Boston, MA 02114 USA. EM ashaw1@mgh.harvard.edu FU NCI [5R01CA164273]; National Foundation for Cancer Research; Be a Piece of the Solution; LungStrong; Evan Spirito Foundation FX This work was supported by grants from the NCI (5R01CA164273, to A.T. Shaw) and the National Foundation for Cancer Research (to A.T. Shaw), and by Be a Piece of the Solution, LungStrong, and The Evan Spirito Foundation. NR 184 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2159-8274 EI 2159-8290 J9 CANCER DISCOV JI Cancer Discov. PD FEB PY 2017 VL 7 IS 2 BP 137 EP 155 DI 10.1158/2159-8290.CD-16-1123 PG 19 WC Oncology SC Oncology GA EN5AM UT WOS:000396018000021 PM 28122866 ER PT J AU Montero, J Stephansky, J Cai, TY Griffin, GK Cabal-Hierro, L Togami, K Hogdal, LJ Galinsky, I Morgan, EA Aster, JC Davids, MS LeBoeuf, NR Stone, RM Konopleva, M Pemmaraju, N Letai, A Lane, AA AF Montero, Joan Stephansky, Jason Cai, Tianyu Griffin, Gabriel K. Cabal-Hierro, Lucia Togami, Katsuhiro Hogdal, Leah J. Galinsky, Ilene Morgan, Elizabeth A. Aster, Jon C. Davids, Matthew S. LeBoeuf, Nicole R. Stone, Richard M. Konopleva, Marina Pemmaraju, Naveen Letai, Anthony Lane, Andrew A. TI Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax SO CANCER DISCOVERY LA English DT Article ID CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; SEQUENCING REVEALS; RECURRENT; INHIBITION; RESISTANCE; MUTATIONS; ABT-199; ABT-737; DEATH AB Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with dismal outcomes for which no standard therapy exists. We found that primary BPDCN cells were dependent on the antiapoptotic protein BCL2 and were uniformly sensitive to the BCL2 inhibitor venetoclax, as measured by direct cytotoxicity, apoptosis assays, and dynamic BH3 profi ling. Animals bearing BPDCN patient-derived xenografts had disease responses and improved survival after venetoclax treatment in vivo. Finally, we report on 2 patients with relapsed/ refractory BPDCN who received venetoclax off-label and experienced signifi cant disease responses. We propose that venetoclax or other BCL2 inhibitors undergo expedited clinical evaluation in BPDCN, alone or in combination with other therapies. In addition, these data illustrate an example of precision medicine to predict treatment response using ex vivo functional assessment of primary tumor tissue, without requiring a genetic biomarker. SIGNIFICANCE: Therapy for BPDCN is inadequate, and survival in patients with the disease is poor. We used primary tumor cell functional profi ling to predict BCL2 antagonist sensitivity as a common feature of BPDCN, and demonstrated in vivo clinical activity of venetoclax in patient-derived xenografts and in 2 patients with relapsed chemotherapy-refractory disease. (C) 2017 AACR. C1 [Montero, Joan; Stephansky, Jason; Cabal-Hierro, Lucia; Togami, Katsuhiro; Hogdal, Leah J.; Galinsky, Ilene; Davids, Matthew S.; Stone, Richard M.; Letai, Anthony; Lane, Andrew A.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [Cai, Tianyu; Konopleva, Marina; Pemmaraju, Naveen] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Griffin, Gabriel K.; Morgan, Elizabeth A.; Aster, Jon C.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA. [LeBoeuf, Nicole R.] Harvard Med Sch, Dana Farber Brigham & Womens Canc Ctr, Ctr Cutaneous Oncol, Dept Dermatol, Boston, MA USA. [Lane, Andrew A.] Broad Inst Harvard & MIT, Cambridge, MA USA. RP Lane, AA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,Mayer 413, Boston, MA 02215 USA.; Pemmaraju, N (reprint author), Univ Texas MD Anderson Canc Ctr, Unit 428, POB 301402, Houston, TX 77230 USA.; Letai, A (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,Mayer 430, Boston, MA 02215 USA. EM npemmaraju@mdanderson.org; anthony_letai@dfci.harvard.edu; andrew_lane@dfci.harvard.edu FU DFCI Medical Oncology Research Grant; Ludwig Cancer Research Foundation; American Society of Hematology Scholar Award FX This work was supported by a DFCI Medical Oncology Research Grant (A. Letai and A.A. Lane), the Ludwig Cancer Research Foundation (J. Stephansky and J.C. Aster), and an American Society of Hematology Scholar Award (A.A. Lane). NR 25 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2159-8274 EI 2159-8290 J9 CANCER DISCOV JI Cancer Discov. PD FEB PY 2017 VL 7 IS 2 BP 156 EP 164 DI 10.1158/2159-8290.CD-16-0999 PG 9 WC Oncology SC Oncology GA EN5AM UT WOS:000396018000022 PM 27986708 ER PT J AU Goddard, ET Hill, RC Nemkov, T D'Alessandro, A Hansen, KC Maller, O Mongoue-Tchokote, S Mori, M Partridge, AH Borges, VF Schedin, P AF Goddard, Erica T. Hill, Ryan C. Nemkov, Travis D'Alessandro, Angelo Hansen, Kirk C. Maller, Ori Mongoue-Tchokote, Solange Mori, Motomi Partridge, Ann H. Borges, Virginia F. Schedin, Pepper TI The Rodent Liver Undergoes Weaning-Induced Involution and Supports Breast Cancer Metastasis SO CANCER DISCOVERY LA English DT Article ID MAMMARY-GLAND INVOLUTION; PROGNOSTIC-FACTORS; PREGNANCY; POSTPARTUM; GROWTH; PROTEOMICS; COLLAGEN; NICHE; CELLS; RECRUITMENT AB Patients with postpartum breast cancer are at increased risk for metastasis compared with age-matched nulliparous or pregnant patients. Here, we address whether circulating tumor cells have a metastatic advantage in the postpartum host and fi nd the postlactation rodent liver preferentially supports metastasis. Upon weaning, we observed liver weight loss, hepatocyte apoptosis, extracellular matrix remodeling including deposition of collagen and tenascin-C, and myeloid cell infl ux, data consistent with weaning-induced liver involution and establishment of a prometastatic microenvironment. Using intracardiac and intraportal metastasis models, we observed increased liver metastasis in post-weaning BALB/c mice compared with nulliparous controls. Human relevance is suggested by a similar to 3-fold increase in liver metastasis in patients with postpartum breast cancer (n = 564) and by liver-specifi c tropism (n = 117). In sum, our data reveal a previously unknown biology of the rodent liver, weaning-induced liver involution, which may provide insight into the increased liver metastasis and poor prognosis of women diagnosed with postpartum breast cancer. SIGNIFICANCE: We fi nd that patients with postpartum breast cancer are at elevated risk for liver metastasis. We identify a previously unrecognized biology, namely weaning-induced liver involution, that establishes a prometastatic microenvironment, and which may account in part for the poor prognosis of patients with postpartum breast cancer. (C) 2017 AACR. C1 [Goddard, Erica T.; Schedin, Pepper] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA. [Hill, Ryan C.; Nemkov, Travis; D'Alessandro, Angelo; Hansen, Kirk C.] Univ Colorado Denver, Dept Biochem & Mol Genet, Aurora, CO USA. [Maller, Ori] Univ Calif San Francisco, Dept Surg, Ctr Bioengn & Tissue Regenerat, San Francisco, CA 94143 USA. [Mongoue-Tchokote, Solange; Mori, Motomi; Schedin, Pepper] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Mori, Motomi] Oregon Hlth & Sci Univ, Sch Publ Hlth, Portland, OR 97201 USA. [Partridge, Ann H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Borges, Virginia F.] Univ Colorado, Dept Med, Div Med Oncol, Anschutz Med Campus, Aurora, CO USA. [Borges, Virginia F.] Univ Colorado, Ctr Canc, Aurora, CO USA. [Borges, Virginia F.; Schedin, Pepper] Univ Colorado, Young Womens Breast Canc Translat Program, Anschutz Med Campus, Aurora, CO USA. RP Schedin, P (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.; Borges, VF (reprint author), Univ Colorado, Anschutz Med Campus,12801 East 17th Ave,Room 8121, Aurora, CO 80045 USA. EM virginia.borges@ucdenver.edu; schedin@ohsu.edu FU NIH/NCI NRSA [F31CA186524]; NIH/NCATS Colorado CTSI [UL1 TR001082]; NIH/NCI [R33 CA183685, 5R01CA169175]; DOD [BC123567, BC123567P1]; Grohne Family Foundation FX Funding for this project includes NIH/NCI NRSA F31CA186524 (to E.T. Goddard); NIH/NCATS Colorado CTSI UL1 TR001082 for proteomic support and REDCap database support; NIH/NCI R33 CA183685 (to K.C. Hansen); DOD BC123567 (to P. Schedin); BC123567P1 (to K. C. Hansen); NIH/NCI 5R01CA169175 (to V.F. Borges and P. Schedin); and the Grohne Family Foundation. NR 34 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2159-8274 EI 2159-8290 J9 CANCER DISCOV JI Cancer Discov. PD FEB PY 2017 VL 7 IS 2 BP 177 EP 187 DI 10.1158/2159-8290.CD-16-0822 PG 11 WC Oncology SC Oncology GA EN5AM UT WOS:000396018000024 PM 27974414 ER PT J AU Olsen, SN Wronski, A Castano, Z Dake, B Malone, C De Raedt, T Enos, M DeRose, YS Zhou, WH Guerra, S Loda, M Welm, A Partridge, AH McAllister, SS Kuperwasser, C Cichowski, K AF Olsen, Sarah Naomi Wronski, Ania Castano, Zafira Dake, Benjamin Malone, Clare De Raedt, Thomas Enos, Miriam DeRose, Yoko S. Zhou, Wenhui Guerra, Stephanie Loda, Massimo Welm, Alana Partridge, Ann H. McAllister, Sandra S. Kuperwasser, Charlotte Cichowski, Karen TI Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers SO CANCER DISCOVERY LA English DT Article ID GTPASE-ACTIVATING PROTEINS; GENE-EXPRESSION PATTERNS; CELL-LINES; MOLECULAR PORTRAITS; METASTASIS; DISEASE; KINASE; MUTATIONS; CARCINOMA; SUBTYPES AB Luminal breast cancers are typically estrogen receptor-positive and generally have the best prognosis. However, a subset of luminal tumors, namely luminal B cancers, frequently metastasize and recur. Unfortunately, the causal events that drive their progression are unknown, and therefore it is diffi cult to identify individuals who are likely to relapse and should receive escalated treatment. Here, we identify a bifunctional RasGAP tumor suppressor whose expression is lost in almost 50% of luminal B tumors. Moreover, we show that two RasGAP genes are concomitantly suppressed in the most aggressive luminal malignancies. Importantly, these genes cooperatively regulate two major oncogenic pathways, RAS and NF-kappa B, through distinct domains, and when inactivated drive the metastasis of luminal tumors in vivo. Finally, although the cooperative effects on RAS drive invasion, NF-kappa B activation triggers epithelial-to-mesenchymal transition and is required for metastasis. Collectively, these studies reveal important mechanistic insight into the pathogenesis of luminal B tumors and provide functionally relevant prognostic biomarkers that may guide treatment decisions. SIGNIFICANCE: The lack of insight into mechanisms that underlie the aggressive behavior of luminal B breast cancers impairs treatment decisions and therapeutic advances. Here, we show that two RasGAP tumor suppressors are concomitantly suppressed in aggressive luminal B tumors and demonstrate that they drive metastasis by activating RAS and NF-kappa B. (C) 2017 AACR. C1 [Olsen, Sarah Naomi; Malone, Clare; De Raedt, Thomas; Enos, Miriam; Guerra, Stephanie; Cichowski, Karen] Brigham & Womens Hosp, Dept Med, Div Genet, 75 Francis St, Boston, MA 02115 USA. [Olsen, Sarah Naomi; Castano, Zafira; Malone, Clare; De Raedt, Thomas; Enos, Miriam; Guerra, Stephanie; Partridge, Ann H.; McAllister, Sandra S.; Cichowski, Karen] Harvard Med Sch, 77 Ave Louis Pasteur, Boston, MA 02115 USA. [Wronski, Ania; Dake, Benjamin; Zhou, Wenhui; Kuperwasser, Charlotte] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA USA. [Wronski, Ania; Dake, Benjamin; Zhou, Wenhui; Kuperwasser, Charlotte] Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA. [Castano, Zafira; McAllister, Sandra S.] Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA. [Castano, Zafira; McAllister, Sandra S.] Broad Inst Harvard & MIT, Cambridge, MA USA. [Castano, Zafira; McAllister, Sandra S.] Harvard Stem Cell Inst, Cambridge, MA USA. [Loda, Massimo] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [DeRose, Yoko S.; Welm, Alana] Huntsman Canc Inst, Salt Lake City, UT USA. [Partridge, Ann H.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Cichowski, Karen] Dana Farber Harvard Canc Ctr, Ludwig Ctr, Boston, MA USA. RP Cichowski, K (reprint author), Harvard Med Sch, 77 Ave Louis Pasteur, Boston, MA 02115 USA. EM kcichowski@rics.bwh.harvard.edu FU Ludwig Center at DF/HCC; NCI [R01 1R01CA188659] FX This work was supported by grants from the Ludwig Center at DF/HCC (K. Cichowski) and the NCI (R01 1R01CA188659; K. Cichowski). NR 42 TC 1 Z9 1 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2159-8274 EI 2159-8290 J9 CANCER DISCOV JI Cancer Discov. PD FEB PY 2017 VL 7 IS 2 BP 202 EP 217 DI 10.1158/2159-8290.CD-16-0520 PG 16 WC Oncology SC Oncology GA EN5AM UT WOS:000396018000026 PM 27974415 ER PT J AU Perez-Gracia, JL Sanmamed, MF Bosch, A Patino-Garcia, A Schalper, KA Segura, V Bellmunt, J Tabernero, J Sweeney, CJ Choueiri, TK Martin, M Fusco, JP Rodriguez-Ruiz, ME Calvo, A Prior, C Paz-Ares, L Pio, R Gonzalez-Billalabeitia, E Hernandez, AG Paez, D Piulats, JM Gurpide, A Andueza, M de Velasco, G Pazo, R Grande, E Nicolas, P Abad-Santos, F Garcia-Donas, J Castellano, D Pajares, MJ Suarez, C Colomer, R Montuenga, LM Melero, I AF Perez-Gracia, Jose Luis Sanmamed, Miguel F. Bosch, Ana Patino-Garcia, Ana Schalper, Kurt A. Segura, Victor Bellmunt, Joaquim Tabernero, Josep Sweeney, Christopher J. Choueiri, Toni K. Martin, Miguel Pablo Fusco, Juan Esperanza Rodriguez-Ruiz, Maria Calvo, Alfonso Prior, Celia Paz-Ares, Luis Pio, Ruben Gonzalez-Billalabeitia, Enrique Gonzalez Hernandez, Alvaro Paez, David Maria Piulats, Jose Gurpide, Alfonso Andueza, Mapi de Velasco, Guillermo Pazo, Roberto Grande, Enrique Nicolas, Pilar Abad-Santos, Francisco Garcia-Donas, Jesus Castellano, Daniel Pajares, Maria J. Suarez, Cristina Colomer, Ramon Montuenga, Luis M. Melero, Ignacio TI Strategies to design clinical studies to identify predictive biomarkers in cancer research SO CANCER TREATMENT REVIEWS LA English DT Review DE Biomarkers; Clinical trial design; Extreme phenotypes; Rearrangement; Mutation ID CELL LUNG-CANCER; GROWTH-FACTOR-RECEPTOR; GASTROINTESTINAL STROMAL TUMORS; METASTATIC COLORECTAL-CANCER; TYROSINE KINASE INHIBITOR; PHASE-III TRIAL; ANAPLASTIC LYMPHOMA KINASE; GENE-EXPRESSION PROFILES; ADVANCED BREAST-CANCER; BRAF V600 MUTATIONS AB The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been established. This has led to the proliferation of a myriad of exploratory studies using dissimilar strategies, most of which fail to identify any promising targets and are seldom validated. The lack of a proper methodology also determines that many anti-cancer drugs are developed below their potential, due to failure to identify predictive biomarkers. While some drugs will be systematically administered to many patients who will not benefit from them, leading to unnecessary toxicities and costs, others will never reach registration due to our inability to identify the specific patient population in which they are active. Despite these drawbacks, a limited number of outstanding predictive biomarkers have been successfully identified and validated, and have changed the standard practice of oncology. In this manuscript, a multidisciplinary panel reviews how those key biomarkers were identified and, based on those experiences, proposes a methodological framework the DESIGN guidelines-to-standardize the clinical design of biomarker identification studies and to develop future research in this pivotal field. (C) 2017 The Authors. Published by Elsevier Ltd. C1 [Perez-Gracia, Jose Luis; Pablo Fusco, Juan; Esperanza Rodriguez-Ruiz, Maria; Gurpide, Alfonso; Andueza, Mapi; Melero, Ignacio] Univ Navarra Clin, Dept Oncol, Avda Pio 12,36, Pamplona 31008, Spain. [Perez-Gracia, Jose Luis; Patino-Garcia, Ana; Esperanza Rodriguez-Ruiz, Maria; Calvo, Alfonso; Pio, Ruben; Gurpide, Alfonso; Pajares, Maria J.; Montuenga, Luis M.; Melero, Ignacio] Hlth Res Inst Navarra IDISNA, Pamplona, Spain. [Sanmamed, Miguel F.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA. [Bosch, Ana] Lund Univ, Dept Clin Sci, Div Oncol & Pathol, S-22100 Lund, Sweden. [Patino-Garcia, Ana] Univ Navarra Clin, Dept Pediat, Pamplona, Spain. [Patino-Garcia, Ana] Univ Navarra Clin, CIMA LAB Diagnost, Pamplona, Spain. [Schalper, Kurt A.] Yale Sch Med, Dept Pathol, New Haven, CT USA. [Segura, Victor] Univ Navarra, IDISNA, Navarra, Spain. [Segura, Victor] Univ Navarra, Bioinformat Unit, Ctr Appl Med Res CIMA, Navarra, Spain. [Bellmunt, Joaquim; Sweeney, Christopher J.; Choueiri, Toni K.; de Velasco, Guillermo] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Bellmunt, Joaquim; Sweeney, Christopher J.; Choueiri, Toni K.; de Velasco, Guillermo] Harvard Med Sch, Boston, MA USA. [Tabernero, Josep; Suarez, Cristina] Univ Autonoma Barcelona, Dept Med Oncol, Vall dHebron Univ Hosp, Barcelona, Spain. [Tabernero, Josep; Suarez, Cristina] Univ Autonoma Barcelona, Inst Oncol VHIO, Barcelona, Spain. [Martin, Miguel] Univ Complutense, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain. [Esperanza Rodriguez-Ruiz, Maria; Melero, Ignacio] Univ Navarra, Ctr Appl Med Res CIMA, Pamplona, Spain. [Calvo, Alfonso; Pajares, Maria J.; Montuenga, Luis M.] Univ Navarra, Sch Med, Dept Histol & Pathol, Pamplona, Spain. [Prior, Celia] Univ Navarra, Dept Gene Therapy & Regulat Gene Express, Ctr Appl Med Res CIMA, Pamplona, Spain. [Paz-Ares, Luis; Castellano, Daniel] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain. [Pio, Ruben; Pajares, Maria J.; Montuenga, Luis M.] Univ Navarra, CIMA, Program Solid Tumors & Biomarkers, E-31080 Pamplona, Spain. [Gonzalez-Billalabeitia, Enrique] Univ Catolica San Antonio de Murcia, Hosp Univ Morales Meseguer, Dept Hematol & Med Oncol, Murcia, Spain. [Gonzalez Hernandez, Alvaro] Univ Navarra Clin, Dept Biochem, Pamplona, Spain. [Paez, David] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain. [Maria Piulats, Jose] Inst Catala Oncol, Dept Med Oncol, Barcelona, Spain. [Pazo, Roberto] Hosp Univ Miguel Server, Dept Med Oncol, Zaragoza, Spain. [Grande, Enrique] Hosp Univ Ramon y Cajal, Dept Med Oncol, Madrid, Spain. [Nicolas, Pilar] Univ Basque Country, Chair Law & Human Genome, Bizkaia, Spain. [Abad-Santos, Francisco] Univ Autonoma Madrid, Inst Invest Sanitaria Princesa IP, Clin Pharmacol Serv, Hosp Univ Princesa,Inst Teofilo Hernando, Madrid, Spain. [Garcia-Donas, Jesus] HM Hosp Ctr Integral Oncol HM Clara Campal, Dept Med Oncol, Madrid, Spain. [Colomer, Ramon] Hosp Univ Princesa, Dept Oncol, Madrid, Spain. RP Perez-Gracia, JL (reprint author), Univ Navarra Clin, Dept Oncol, Avda Pio 12,36, Pamplona 31008, Spain. EM jlgracia@unav.es RI Pio, Ruben/F-5353-2017 OI Pio, Ruben/0000-0002-6831-6111 FU Spanish Society of Medical Oncology (SEOM); Fundacion SEOM and Fundacion Salud; Health Department of Gobierno de Navarra, Spain FX We are indebted to Paul Miller for revising the manuscript. Granted by the Spanish Society of Medical Oncology (SEOM, 2010), by Fundacion SEOM and Fundacion Salud 2000 (2014) and by the Health Department of Gobierno de Navarra, Spain (2014). NR 213 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0305-7372 EI 1532-1967 J9 CANCER TREAT REV JI Cancer Treat. Rev. PD FEB PY 2017 VL 53 BP 79 EP 97 DI 10.1016/j.ctrv.2016.12.005 PG 19 WC Oncology SC Oncology GA EK6ZS UT WOS:000394075400009 PM 28088073 ER PT J AU Bayona, AMD Mroz, P Thunshelle, C Hamblin, MR AF Bayona, Alejandra Martinez De Pinillos Mroz, Pawel Thunshelle, Connor Hamblin, Michael R. TI Design features for optimization of tetrapyrrole macrocycles as antimicrobial and anticancer photosensitizers SO CHEMICAL BIOLOGY & DRUG DESIGN LA English DT Article DE bacteriochlorin; biodistribution; chlorin; pharmacodynamics; photodynamic therapy; photosensitizer; phthalocyanine; porphyrin ID STABLE SYNTHETIC BACTERIOCHLORINS; IN-VIVO PHARMACOKINETICS; CHINESE-HAMSTER-CELLS; PHOTODYNAMIC THERAPY; SINGLET OXYGEN; CREMOPHOR EL; ALUMINUM PHTHALOCYANINE; BIOLOGICAL-ACTIVITIES; TISSUE DISTRIBUTION; ANTITUMOR-ACTIVITY AB Photodynamic therapy (PDT) uses non-toxic dyes called photosensitizers (PS) and harmless visible light that combine to form highly toxic reactive oxygen species that kill cells. Originally, a cancer therapy, PDT, now includes applications for infections. The most widely studied PS are tetrapyrrole macrocycles including porphyrins, chlorins, bacteriochlorins, and phthalocyanines. The present review covers the design features in PS that can work together to maximize the PDT activity for various disease targets. Photophysical and photochemical properties include the wavelength and size of the long-wavelength absorption peak (for good light penetration into tissue), the triplet quantum yield and lifetime, and the propensity to undergo type I (electron transfer) or type II (energy transfer) photochemical mechanisms. The central metal in the tetrapyrrole macrocycle has a strong influence on the PDT activity. Hydrophobicity and charge are important factors that govern interactions with various types of cells (cancer and microbial) in vitro and the pharmacokinetics and biodistribution in vivo. Hydrophobic structures tend to be water insoluble and require a drug delivery vehicle for maximal activity. Molecular asymmetry and amphiphilicity are also important for high activity. In vivo some structures possess the ability to selectively accumulate in tumors and to localize in the tumor microvasculature producing vascular shutdown after illumination. C1 [Bayona, Alejandra Martinez De Pinillos; Thunshelle, Connor; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Bayona, Alejandra Martinez De Pinillos] UCL, Royal Free Hosp, Div Surg & Intervent Sci, London, England. [Mroz, Pawel] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA. [Thunshelle, Connor] Harvard Univ, Cambridge, MA USA. [Hamblin, Michael R.] Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA. [Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.; Hamblin, MR (reprint author), Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA.; Hamblin, MR (reprint author), Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. EM hamblin@helix.mgh.harvard.edu FU US NIH grant [R01AI050875]; Bogue Research Fellowship, from UCL FX Michael R. Hamblin was supported by US NIH grant R01AI050875. Alejandra Martinez De Pinillos Bayona was supported by the Bogue Research Fellowship, from UCL. NR 74 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1747-0277 EI 1747-0285 J9 CHEM BIOL DRUG DES JI Chem. Biol. Drug Des. PD FEB PY 2017 VL 89 IS 2 BP 192 EP 206 DI 10.1111/cbdd.12792 PG 15 WC Biochemistry & Molecular Biology; Chemistry, Medicinal SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy GA EK5IA UT WOS:000393958900003 ER PT J AU Rask-Madsen, C Park, K Li, Q King, GL AF Rask-Madsen, Christian Park, Kyoungmin Li, Qian King, George L. TI Letter by Rask-Madsen et al Regarding Article, "Selective Enhancement of Insulin Sensitivity in the Endothelium In Vivo Reveals a Novel Proatherosclerotic Signaling Loop" SO CIRCULATION RESEARCH LA English DT Letter ID ZUCKER FA/FA RATS; RESISTANCE; ATHEROSCLEROSIS; CELLS; MICE; DYSFUNCTION; MUSCLE; LEADS; AKT C1 [Rask-Madsen, Christian] Joslin Diabet Ctr, Boston, MA 02215 USA. Harvard Med Sch, Boston, MA USA. RP Rask-Madsen, C (reprint author), Joslin Diabet Ctr, Boston, MA 02215 USA. FU NCI NIH HHS [R21 CA185196] NR 18 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7330 EI 1524-4571 J9 CIRC RES JI Circ.Res. PD FEB PY 2017 VL 120 IS 4 BP E2 EP E3 DI 10.1161/CIRCRESAHA.116.310491 PG 2 WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Hematology GA EL2JP UT WOS:000394446200001 PM 28209799 ER PT J AU Han, JH Gordon, K Womack, JA Gibert, CL Leaf, DA Rimland, D Rodriguez-Barradas, MC Bisson, GP AF Han, Jennifer H. Gordon, Kirsha Womack, Julie A. Gibert, Cynthia L. Leaf, David A. Rimland, David Rodriguez-Barradas, Maria C. Bisson, Gregory P. TI Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans SO DIABETES CARE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; CORONARY-HEART-DISEASE; NUCLEOSIDE ANALOG; CLINICAL-TRIALS; DATA-COLLECTION; TOTAL BILIRUBIN; ADVERSE EVENTS; ASSOCIATION; MELLITUS; THERAPY AB OBJECTIVE Type 2 diabetes is increasingly common in HIV-infected individuals. The objective of this study was to compare the glycemic effectiveness of oral diabetic medications among patients with and without HIV infection. RESEARCH DESIGN AND METHODS A longitudinal cohort study was conducted among HIV-infected and uninfected veterans with type 2 diabetes initiating diabetic medications between 1999 and 2010. Generalized estimating equations were used to compare changes in hemoglobin A(1c) (HbA(1c)) through the year after medication initiation, adjusting for baseline HbA1c level and clinical covariates. A subanalysis using propensity scores was conducted to account for confounding by indication. RESULTS A total of 2,454 HIV-infected patients and 8,892 HIV-uninfected patients initiated diabetic medications during the study period. The most commonly prescribed medication was metformin (n = 5,647, 50%), followed by a sulfonylurea (n = 5,554, 49%) and a thiazolidinedione (n = 145, 1%). After adjustment for potential confounders, there was no significant difference in the change in HbA(1c) level among the three groups of new users. HIV infection was not significantly associated with glycemic response (P = 0.24). Black and Hispanic patients had a poorer response to therapy compared with white patients, with a relative increase in HbA1c level of 0.16% (95% CI 0.08, 0.24) [1.7 mmol/mol (0.9, 2.6)] (P < 0.001) and 0.25% (0.11, 0.39) [2.7 mmol/mol (1.2, 4.3)] (P = 0.001), respectively. CONCLUSIONS We found that glycemic response was independent of the initial class of diabetic medication prescribed among HIV-uninfected and HIV-infected adults with type 2 diabetes. The mechanisms leading to poorer response among black and Hispanic patients, who make up a substantial proportion of those with HIV infection and type 2 diabetes, require further investigation. C1 [Han, Jennifer H.; Bisson, Gregory P.] Univ Penn, Dept Med, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Han, Jennifer H.; Bisson, Gregory P.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Han, Jennifer H.; Bisson, Gregory P.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Gordon, Kirsha; Womack, Julie A.] West Haven VA Med Ctr, Dept Internal Med, West Haven, CT USA. [Womack, Julie A.] Yale Univ, Yale Sch Nursing, New Haven, CT USA. [Gibert, Cynthia L.] George Washington Univ, Sch Med & Hlth Sci, Sect Infect Dis, Washington, DC 20052 USA. [Gibert, Cynthia L.] Washington DC VA Med Ctr, Dept Med, Washington, DC USA. [Leaf, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA. [Leaf, David A.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Rimland, David] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA. [Rimland, David] Atlanta VA Med Ctr, Div Infect Dis, Atlanta, GA USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Han, JH (reprint author), Univ Penn, Dept Med, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA.; Han, JH (reprint author), Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA.; Han, JH (reprint author), Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. EM jennifer.han@uphs.upenn.edu FU Veterans Aging Cohort Study; National Institute on Alcohol Abuse and Alcoholism [U10-AA-13566] FX This study was supported by the Veterans Aging Cohort Study and by National Institute on Alcohol Abuse and Alcoholism grant U10-AA-13566. NR 37 TC 0 Z9 0 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2017 VL 40 IS 2 BP 218 EP 225 DI 10.2337/dc16-0718 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EL2ZL UT WOS:000394489300020 PM 27634393 ER PT J AU Cefalu, WT Buse, JB Tuomilehto, J Fleming, GA Ferrannini, E Gerstein, HC Bennett, PH Ramachandran, A Raz, I Rosenstock, J Kahn, SE AF Cefalu, William T. Buse, John B. Tuomilehto, Jaakko Fleming, G. Alexander Ferrannini, Ele Gerstein, Hertzel C. Bennett, Peter H. Ramachandran, Ambady Raz, Itamar Rosenstock, Julio Kahn, Steven E. TI Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2016; 39: 1186-1201 SO DIABETES CARE LA English DT Editorial Material C1 [Cefalu, William T.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. [Buse, John B.] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Tuomilehto, Jaakko] Natl Inst Hlth & Welf, Chron Dis Prevent Unit, Helsinki, Finland. [Tuomilehto, Jaakko] Dasman Diabet Inst, Dasman, Kuwait. [Tuomilehto, Jaakko] King Abdulaziz Univ, Saudi Diabet Res Grp, Jeddah, Saudi Arabia. [Tuomilehto, Jaakko] Danube Univ Krems, Ctr Vasc Prevent, Krems, Austria. [Fleming, G. Alexander] Kinexum, Harpers Ferry, WV USA. [Ferrannini, Ele] CNR, Inst Clin Physiol, Pisa, Italy. [Gerstein, Hertzel C.] McMaster Univ, Hamilton, ON, Canada. [Gerstein, Hertzel C.] Hamilton Hlth Sci, Hamilton, ON, Canada. [Bennett, Peter H.] NIH, Phoenix, AZ USA. [Ramachandran, Ambady] India Diabet Res Fdn, Madras, Tamil Nadu, India. [Ramachandran, Ambady] Dr A Ramachandrans Diabet Hosp, Madras, Tamil Nadu, India. [Raz, Itamar] Hadassah Hebrew Univ Hosp, Dept Internal Med, Diabet Unit, Jerusalem, Israel. [Rosenstock, Julio] Med City, Dallas Diabet Res Ctr, Dallas, TX 75390 USA. [Rosenstock, Julio] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. RP Cefalu, WT (reprint author), Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. EM william.cefalu@pbrc.edu FU National Institutes of Health (NIH) [1U54-GM-104940, P50-AT-002776] FX W.T.C. is supported in part by National Institutes of Health (NIH) grant 1U54-GM-104940, which funds the Louisiana Clinical and Translational Science Center, and NIH grant P50-AT-002776. NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2017 VL 40 IS 2 BP E23 EP E24 DI 10.2337/dci16-0036 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EL2ZL UT WOS:000394489300009 PM 28108540 ER PT J AU Garvey, WT AF Garvey, W. Timothy TI Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2016; 39: 1186-1201 SO DIABETES CARE LA English DT Editorial Material ID METABOLIC SYNDROME; OBESITY C1 [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. RP Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.; Garvey, WT (reprint author), Birmingham VA Med Ctr, Birmingham, AL 35233 USA. EM garveyt@uab.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [DK-038765]; National Institute of Diabetes and Digestive and Kidney Diseases (UAB Diabetes Research Center) [P30 DK079626]; U.S. Department of Veterans Affairs (Merit Review program) FX W.T.G. acknowledges support from grants awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (DK-038765 and UAB Diabetes Research Center [P30 DK079626]) and the U.S. Department of Veterans Affairs (Merit Review program). NR 6 TC 1 Z9 1 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2017 VL 40 IS 2 BP E21 EP E22 DI 10.2337/dci16-0022 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EL2ZL UT WOS:000394489300008 PM 28108539 ER PT J AU Hammad, H Kaltenbach, T Soetikno, R AF Hammad, Hazem Kaltenbach, Tonya Soetikno, Roy TI Surveillance for dysplasia in inflammatory bowel disease: it is time to move forward SO ENDOSCOPY LA English DT Editorial Material ID DEPRESSED COLORECTAL NEOPLASMS; STANDING ULCERATIVE-COLITIS; NONPOLYPOID FLAT; COLONOSCOPY; MANAGEMENT; ENDOSCOPY; CONSENSUS; BIOPSIES C1 [Hammad, Hazem] Univ Colorado, Div Gastroenterol & Hepatol, Anschutz Med Campus, Aurora, CO USA. [Kaltenbach, Tonya] Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. [Soetikno, Roy] Grad Sch Business, Stanford, CA 94305 USA. RP Soetikno, R (reprint author), Grad Sch Business, Stanford, CA 94305 USA. EM soetikno@earthlink.net NR 16 TC 0 Z9 0 U1 0 U2 0 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X EI 1438-8812 J9 ENDOSCOPY JI Endoscopy PD FEB PY 2017 VL 49 IS 2 BP 110 EP 112 DI 10.1055/s-0043-100097 PG 3 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA EK9PX UT WOS:000394257500003 PM 28147393 ER PT J AU Francioli, LC Cretu-Stancu, M Garimella, KV Fromer, M Kloosterman, WP Samocha, KE Neale, BM Daly, MJ Banks, E DePristo, MA de Bakker, PIW AF Francioli, Laurent C. Cretu-Stancu, Mircea Garimella, Kiran V. Fromer, Menachem Kloosterman, Wigard P. Samocha, Kaitlin E. Neale, Benjamin M. Daly, Mark J. Banks, Eric DePristo, Mark A. de Bakker, Paul I. W. CA Genome Netherlands Consortium TI A framework for the detection of de novo mutations in family-based sequencing data SO EUROPEAN JOURNAL OF HUMAN GENETICS LA English DT Article ID DISCOVERY; PATTERNS; DISEASE; HUMANS; RATES AB Germline mutation detection from human DNA sequence data is challenging due to the rarity of such events relative to the intrinsic error rates of sequencing technologies and the uneven coverage across the genome. We developed PhaseByTransmission (PBT) to identify de novo single nucleotide variants and short insertions and deletions (indels) from sequence data collected in parent-offspring trios. We compute the joint probability of the data given the genotype likelihoods in the individual family members, the known familial relationships and a prior probability for the mutation rate. Candidate de novo mutations (DNMs) are reported along with their posterior probability, providing a systematic way to prioritize them for validation. Our tool is integrated in the Genome Analysis Toolkit and can be used together with the ReadBackedPhasing module to infer the parental origin of DNMs based on phase-informative reads. Using simulated data, we show that PBT outperforms existing tools, especially in low coverage data and on the X chromosome. We further show that PBT displays high validation rates on empirical parent-offspring sequencing data for whole-exome data from 104 trios and X-chromosome data from 249 parent-offspring families. Finally, we demonstrate an association between father's age at conception and the number of DNMs in female offspring's X chromosome, consistent with previous literature reports. C1 [Francioli, Laurent C.; Cretu-Stancu, Mircea; Kloosterman, Wigard P.; de Bakker, Paul I. W.] Univ Med Ctr Utrecht, Dept Med Genet, Ctr Mol Med, Utrecht, Netherlands. [Francioli, Laurent C.; Fromer, Menachem; Samocha, Kaitlin E.; Neale, Benjamin M.; Daly, Mark J.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA. [Francioli, Laurent C.; Fromer, Menachem; Samocha, Kaitlin E.; Neale, Benjamin M.; Daly, Mark J.; Banks, Eric; DePristo, Mark A.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA. [Garimella, Kiran V.] Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford, England. [Fromer, Menachem] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Fromer, Menachem] Icahn Sch Med Mt Sinai, Dept Genom Sci, New York, NY 10029 USA. [de Bakker, Paul I. W.] Univ Med Ctr Utrecht, Dept Epidemiol, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands. RP Francioli, LC (reprint author), Univ Utrecht, Dept Med Genet, Heidelberglaan 100, Utrecht, Netherlands. EM lfran@broadinstitute.org RI Suchiman, H. Eka D./F-5024-2017; OI Suchiman, H. Eka D./0000-0002-7168-5516; Karssen, Lennart C./0000-0002-1959-342X FU Genome of the Netherlands (GoNL) project by the Biobanking and Biomolecular Research Infrastructure (BBMRI-NL) - Netherlands Organization for Scientific Research (NWO project) [184.021.007] FX This work was funded as part of the Genome of the Netherlands (GoNL) project by the Biobanking and Biomolecular Research Infrastructure (BBMRI-NL), which is financed by the Netherlands Organization for Scientific Research (NWO project 184.021.007). NR 19 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1018-4813 EI 1476-5438 J9 EUR J HUM GENET JI Eur. J. Hum. Genet. PD FEB PY 2017 VL 25 IS 2 BP 227 EP 233 DI 10.1038/ejhg.2016.147 PG 7 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA EK7RM UT WOS:000394122900016 PM 27876817 ER PT J AU Chisholm, KM Ohgami, RS Tan, B Hasserjian, RP Weinberg, OK AF Chisholm, Karen M. Ohgami, Robert S. Tan, Brent Hasserjian, Robert P. Weinberg, Olga K. TI 6 Primary lymphoma of bone in the pediatric and young adult population SO HUMAN PATHOLOGY LA English DT Article DE Bone; Lymphoma; Pediatric; Primary lymphoma of bone ID NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; MALIGNANT-LYMPHOMA; CHILDREN; EXPERIENCE; THERAPY; TRIAL AB Primary lymphoma of bone (PLB) accounts for 3% to 7% of primary neoplasms of bone and must be distinguished from more common bone tumors in the pediatric population such as osteosarcoma, Ewing sarcoma, and other small round blue cell tumors. In this study, pathology databases from 4 institutions were queried for PLB in individuals 1 to 21 years old. A total of 54 cases of PLB were identified, including 41 diffuse large B-cell lymphomas (DLBCL, 76%), 8 B-lymphoblastic lymphomas (BLL, 15%), 3 anaplastic large cell lymphomas (ALCL, 6%), and 2 low-grade follicular lymphomas (4%). The male/female ratio was 1.8:1 and median age was 16 years (range, 2-21). Patients with DLBCL were significantly older (P < .001), and patients with ALCL and BLL were significantly younger (P = .050 and P = .008, respectively) when compared with the other patients. Due to necrosis, crush artifact, and/or insufficient material, 30% of cases required multiple biopsies for diagnosis. The femur, tibia, pelvic bones, humerus, and vertebrae were most commonly involved. DLBCL patients had significantly more solitary bone involvement (P = .001), whereas BLL had significantly more polyostotic involvement (P < .001). Of the 37 patients with outcome data, all had no evidence of disease on last follow-up. This largest pediatric series of PLB identifies DLBCL as the most frequent subtype and documents rarer occurrences of BLL, ALCL, and follicular lymphomas. The differential diagnosis of bone neoplasms in pediatric patients, including those with necrosis, should include PLB. (C) 2016 Elsevier Inc. All rights reserved. C1 [Chisholm, Karen M.; Weinberg, Olga K.] Boston Childrens Hosp, Dept Pathol, 300 Longwood Ave,Bader 126-2, Boston, MA 02115 USA. [Ohgami, Robert S.; Tan, Brent] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA. [Hasserjian, Robert P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Weinberg, Olga K.] Brigham Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Chisholm, Karen M.] Seattle Childrens Hosp, Dept Labs, Seattle, WA USA. RP Weinberg, OK (reprint author), Boston Childrens Hosp, Dept Pathol, 300 Longwood Ave,Bader 126-2, Boston, MA 02115 USA. EM olga.weinberg@childrens.harvard.edu NR 34 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0046-8177 EI 1532-8392 J9 HUM PATHOL JI Hum. Pathol. PD FEB PY 2017 VL 60 BP 1 EP 10 DI 10.1016/j.humpath.2016.07.028 PG 10 WC Pathology SC Pathology GA EK6XO UT WOS:000394069800001 PM 27554207 ER PT J AU Nin, N Muriel, A Penuelas, O Brochard, L Lorente, JA Ferguson, ND Raymondos, K R-Os, F Violi, DA Thille, AW Gonzalez, M Villagomez, AJ Hurtado, J Davies, AR Du, B Maggiore, SM Soto, L D'Empaire, G Matamis, D Abroug, F Moreno, RP Soares, MA Arabi, Y Sandi, F Jibaja, M Amin, P Koh, Y Kuiper, MA Bulow, HH Zeggwagh, AA Anzueto, A Sznajder, JI Esteban, A AF Nin, Nicolas Muriel, Alfonso Penuelas, Oscar Brochard, Laurent Angel Lorente, Jose Ferguson, Niall D. Raymondos, Konstantinos R-Os, Fernando Violi, Damian A. Thille, Arnaud W. Gonzalez, Marco Villagomez, Asisclo J. Hurtado, Javier Davies, Andrew R. Du, Bin Maggiore, Salvatore M. Soto, Luis D'Empaire, Gabriel Matamis, Dimitrios Abroug, Fekri Moreno, Rui P. Soares, Marco Antonio Arabi, Yaseen Sandi, Freddy Jibaja, Manuel Amin, Pravin Koh, Younsuck Kuiper, Michael A. Bulow, Hans-Henrik Zeggwagh, Amine Ali Anzueto, Antonio Sznajder, Jacob I. Esteban, Andres CA VENTILA Grp TI Severe hypercapnia and outcome of mechanically ventilated patients with moderate or severe acute respiratory distress syndrome SO INTENSIVE CARE MEDICINE LA English DT Article DE Mechanical ventilation; Acute respiratory distress syndrome; Hypercapnia; ICU mortality ID ACUTE LUNG INJURY; END-EXPIRATORY PRESSURE; PERMISSIVE HYPERCAPNIA; PROTECTIVE-VENTILATION; CARBON-DIOXIDE; PULMONARY-EDEMA; TIDAL VOLUME; MORTALITY; ACIDOSIS; DYSFUNCTION AB Purpose: To analyze the relationship between hypercapnia developing within the first 48 h after the start of mechanical ventilation and outcome in patients with acute respiratory distress syndrome (ARDS). Patients and methods: We performed a secondary analysis of three prospective non-interventional cohort studies focusing on ARDS patients from 927 intensive care units (ICUs) in 40 countries. These patients received mechanical ventilation for more than 12 h during 1-month periods in 1998, 2004, and 2010. We used multivariable logistic regression and a propensity score analysis to examine the association between hypercapnia and ICU mortality. Main outcomes: We included 1899 patients with ARDS in this study. The relationship between maximum PaCO2 in the first 48 h and mortality suggests higher mortality at or above PaCO2 of >= 50 mmHg. Patients with severe hypercapnia (PaCO2 >= 50 mmHg) had higher complication rates, more organ failures, and worse outcomes. After adjusting for age, SAPS II score, respiratory rate, positive end-expiratory pressure, PaO2/FiO(2) ratio, driving pressure, pressure/volume limitation strategy (PLS), corrected minute ventilation, and presence of acidosis, severe hypercapnia was associated with increased risk of ICU mortality [odds ratio (OR) 1.93, 95% confidence interval (CI) 1.32 to 2.81; p = 0.001]. In patients with severe hypercapnia matched for all other variables, ventilation with PLS was associated with higher ICU mortality (OR 1.58, CI 95% 1.04-2.41; p = 0.032). Conclusions: Severe hypercapnia appears to be independently associated with higher ICU mortality in patients with ARDS. Trial registration: Clinicaltrials.gov identifier, NCT01093482. C1 [Nin, Nicolas] Hosp Torrejon, Madrid, Spain. [Muriel, Alfonso] Hosp Ramon & Cajal, Dept Clin Biostat, IRICYS, Madrid, Spain. [Muriel, Alfonso] CIBERESP, Madrid, Spain. [Penuelas, Oscar; Angel Lorente, Jose; Esteban, Andres] CIBER Enfermedades Resp, Madrid, Spain. [Brochard, Laurent] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada. [Brochard, Laurent; Ferguson, Niall D.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada. [Ferguson, Niall D.] Univ Toronto, Dept Med, Toronto, ON, Canada. [Ferguson, Niall D.] Univ Toronto, Dept Physiol, Toronto, ON, Canada. [Raymondos, Konstantinos] Hannover Med Sch, Hannover, Germany. [R-Os, Fernando] Hosp Nacl Alejandro Posadas, Buenos Aires, DF, Argentina. [Violi, Damian A.] Hosp HIGA Guemes, Haedo, Argentina. [Thille, Arnaud W.] Univ Hosp Poitiers, Poitiers, France. [Gonzalez, Marco] Clin Medellin, Medellin, Colombia. [Gonzalez, Marco] Univ Pontificia Bolivariana, Medellin, Colombia. [Villagomez, Asisclo J.] Hosp Reg 1 Octubre, Mexico City, DF, Mexico. [Hurtado, Javier] Hosp Espanol, Montevideo, Uruguay. [Davies, Andrew R.] Alfred Hosp, Melbourne, Vic, Australia. [Davies, Andrew R.] Monash Univ, Melbourne, Vic, Australia. [Du, Bin] Beijing Union Med Coll Hosp, Beijing, Peoples R China. [Maggiore, Salvatore M.] Univ Cattolica Sacro Cuore, Policlin Agostino Gemelli, Rome, Italy. [Soto, Luis] Inst Nacl Torax Santiago, Santiago, Chile. [D'Empaire, Gabriel] Hosp Clin Caracas, Caracas, Venezuela. [Matamis, Dimitrios] Papageorgiou Hosp, Thessaloniki, Greece. [Abroug, Fekri] Hosp Fattouma Bourguina, Monastir, Tunisia. [Moreno, Rui P.] Ctr Hosp Lisboa Cent, EPE, UCINC, Hosp Sao Jose, Lisbon, Portugal. [Soares, Marco Antonio] Hosp Univ Sao Jose, Belo Horizonte, MG, Brazil. [Arabi, Yaseen] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia. [Sandi, Freddy] Hosp Obrero 1, La Paz, Bolivia. [Jibaja, Manuel] Hosp Eugenio Espejo, Quito, Ecuador. [Amin, Pravin] Bombay Hosp Inst Med Sci, Bombay, Maharashtra, India. [Koh, Younsuck] Univ Ulsan, Asan Med Ctr, Seoul, South Korea. [Kuiper, Michael A.] Med Ctr Leeuwarden MCL, Leeuwarden, Netherlands. [Bulow, Hans-Henrik] Univ Copenhagen, Holbaek Hosp, Copenhagen, Region Zealand, Denmark. [Zeggwagh, Amine Ali] Hosp Ibn Sina, Rabat, Morocco. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sznajder, Jacob I.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Esteban, Andres] Hosp Univ Getafe, Carretera Toledo,Km 12,500, Madrid 28905, Spain. RP Esteban, A (reprint author), Hosp Univ Getafe, Carretera Toledo,Km 12,500, Madrid 28905, Spain. EM aesteban@ucigetafe.com OI Muriel, Alfonso /0000-0002-4805-4011 FU CIBER Enfermedades Respiratorias (CIBERES); CIBER en Epidemiologia y Salud Publica (CIBERESP); Instituto de Salud Carlos III, Madrid, Spain; Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), Madrid, Spain; Canadian Institutes of Health Research New Investigator Award (Ottawa, Canada); [HL-048129]; [HL-071643]; [HL-085534] FX Funding for this study was provided by CIBER Enfermedades Respiratorias (CIBERES), CIBER en Epidemiologia y Salud Publica (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain and the Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), Madrid, Spain. Dr. Ferguson was supported by a Canadian Institutes of Health Research New Investigator Award (Ottawa, Canada). Dr. Sznajder is funded by HL-048129, HL-071643 and HL-085534. NR 40 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0342-4642 EI 1432-1238 J9 INTENS CARE MED JI Intensive Care Med. PD FEB PY 2017 VL 43 IS 2 BP 200 EP 208 DI 10.1007/s00134-016-4611-1 PG 9 WC Critical Care Medicine SC General & Internal Medicine GA EL0OE UT WOS:000394320900005 PM 28108768 ER PT J AU Kleinman, RE Nicklas, T AF Kleinman, Ronald E. Nicklas, Theresa TI TheWomen, Infants, and Children Food Package and 100% Fruit Juice SO JAMA PEDIATRICS LA English DT Letter C1 [Kleinman, Ronald E.] Harvard Med Sch, MassGen Hosp Children, Dept Pediat, 175 Cambridge St,Ste 578, Boston, MA 02114 USA. [Nicklas, Theresa] Baylor Coll Med, Childrens Nutr Res Ctr, Dept Pediat, Houston, TX 77030 USA. RP Kleinman, RE (reprint author), Harvard Med Sch, MassGen Hosp Children, 175 Cambridge St,Ste 578, Boston, MA 02114 USA. EM rkleinman@partners.org FU Nutrition Impact FX Dr Nicklas has received funding from Nutrition Impact and Dr Pepper Snapple in the past 3 years. No other disclosures were reported. NR 3 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD FEB PY 2017 VL 171 IS 2 BP 197 EP 197 DI 10.1001/jamapediatrics.2016.4116 PG 1 WC Pediatrics SC Pediatrics GA EM9QN UT WOS:000395646300027 PM 27992618 ER PT J AU Alberdi, T Castro-Wagner, JB Patel, B Joychan, S Lindsey, D Laham, FR Csomos, K Ujhazi, B Duff, CM Trotter, J Bleesing, JJ Kumanovics, A Chang, YH Hale, JH Sriaroon, P Hale, G Oshrine, BR Notarangelo, L Abraham, RS Comeau, AM Petrovic, A Leiding, JW Walter, JE AF Alberdi, Taylor Castro-Wagner, Johana B. Patel, Bhumika Joychan, Sonia Lindsey, David Laham, Frederico R. Csomos, Krisztian Ujhazi, Boglarka Duff, Carla M. Trotter, Jessica Bleesing, Jack J. Kumanovics, Attila Chang, Yenhui Hale, Jamie H. Sriaroon, Panida Hale, Greg Oshrine, Benjamin R. Notarangelo, Luigi Abraham, Roshini S. Comeau, Anne Marie Petrovic, Aleksandra Leiding, Jennifer W. Walter, Jolan E. TI An Atypical Severe Combined Immunodeficiency (SCID) Case Diagnosis Complicated by Alternative Care in the Era of Newborn Screening (NBS) for SCID SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 03-16, 2017 CL Atlanta, GA SP Amer Acad Allergy, Asthma & Immunol C1 [Alberdi, Taylor; Lindsey, David; Ujhazi, Boglarka; Trotter, Jessica] Univ S Florida, Morsani Coll Med, Tampa, FL USA. [Castro-Wagner, Johana B.; Patel, Bhumika; Joychan, Sonia; Sriaroon, Panida] Univ S Florida, Morsani Coll Med, St Petersburg, FL USA. [Laham, Frederico R.] Arnold Palmer Hosp, Orlando, FL USA. [Csomos, Krisztian] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Duff, Carla M.; Leiding, Jennifer W.] Univ S Florida, St Petersburg, FL USA. [Bleesing, Jack J.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Kumanovics, Attila] Univ Utah, Dept Pathol, Salt Lake City, UT USA. [Chang, Yenhui; Hale, Greg; Oshrine, Benjamin R.; Petrovic, Aleksandra] John Hopkins All Childrens Hosp, St Petersburg, FL USA. [Hale, Jamie H.] UMass Med Sch, New England Newborn Screening Program, Boston, MA USA. [Notarangelo, Luigi] Childrens Hosp, Boston, MA 02115 USA. [Abraham, Roshini S.] Mayo Clin, Rochester, MN USA. [Comeau, Anne Marie] UMass Med Sch, New England Newborn Screening Program, Jamaica Plain, MA USA. [Walter, Jolan E.] Univ S Florida, Tampa, FL USA. [Walter, Jolan E.] Johns Hopkins All Childrens Hosp, St Petersburg, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2017 VL 139 IS 2 SU S MA 60 BP AB18 EP AB18 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA EO8NM UT WOS:000396946000061 ER PT J AU Haibach, JP Haibach, MA Hall, KS Masheb, RM Little, MA Shepardson, RL Dobmeyer, AC Funderburk, JS Hunter, CL Dundon, M Hausmann, LRM Trynosky, SK Goodrich, DE Kilbourne, AM Knight, SJ Talcott, GW Goldstein, MG AF Haibach, Jeffrey P. Haibach, Michael Ann Hall, Katherine S. Masheb, Robin M. Little, Melissa A. Shepardson, Robyn L. Dobmeyer, Anne C. Funderburk, Jennifer S. Hunter, Christopher L. Dundon, Margaret Hausmann, Leslie R. M. Trynosky, Stephen K. Goodrich, David E. Kilbourne, Amy M. Knight, Sara J. Talcott, Gerald W. Goldstein, Michael G. TI Military and veteran health behavior research and practice: challenges and opportunities SO JOURNAL OF BEHAVIORAL MEDICINE LA English DT Article DE Military; Veteran; Servicemember; Health behavior; Health promotion; Healthcare; Behavioral health ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; SUBSTANCE-USE DISORDERS; DEPARTMENT-OF-DEFENSE; ACTIVE-DUTY MILITARY; US AIR-FORCE; WEIGHT MANAGEMENT PROGRAM; ALCOHOL-RELATED OUTCOMES; BODY-MASS INDEX; PRIMARY-CARE AB There are 2.1 million current military servicemembers and 21 million living veterans in the United States. Although they were healthier upon entering military service compared to the general U.S. population, in the longer term veterans tend to be of equivalent or worse health than civilians. One primary explanation for the veterans' health disparity is poorer health behaviors during or after military service, especially areas of physical activity, nutrition, tobacco, and alcohol. In response, the Department of Defense and Department of Veterans Affairs continue to develop, evaluate, and improve health promotion programs and healthcare services for military and veteran health behavior in an integrated approach. Future research and practice is needed to better understand and promote positive health behavior during key transition periods in the military and veteran life course. Also paramount is implementation and evaluation of existing interventions, programs, and policies across the population using an integrated and person centered approach. C1 [Haibach, Jeffrey P.; Kilbourne, Amy M.] US Dept Vet Affairs, Hlth Serv Res & Dev Serv, 810 Vermont Ave NW 10P9H, Washington, DC 20420 USA. [Haibach, Michael Ann] US Air Force, Wright Patterson AFB, OH USA. [Hall, Katherine S.] Durham VA Med Ctr, Durham, NC USA. [Hall, Katherine S.] Duke Univ, Dept Med, Durham, NC USA. [Masheb, Robin M.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Masheb, Robin M.] Yale Sch Med, New Haven, CT USA. [Little, Melissa A.; Talcott, Gerald W.] Univ Tennessee, Ctr Hlth Sci, Ctr Populat Sci, Memphis, TN 38163 USA. [Shepardson, Robyn L.; Funderburk, Jennifer S.] Syracuse VA Med Ctr, VA Ctr Integrated Healthcare, Syracuse, NY USA. [Shepardson, Robyn L.; Funderburk, Jennifer S.] Syracuse Univ, Dept Psychol, Syracuse, NY USA. [Dobmeyer, Anne C.] Deployment Hlth Clin Ctr, Def Ctr Excellence Psychol Hlth, Bethesda, MD USA. [Dobmeyer, Anne C.] Deployment Hlth Clin Ctr, Def Ctr Traumat Brain Injury, Bethesda, MD USA. [Funderburk, Jennifer S.] Univ Rochester, Dept Psychiat, Rochester, NY USA. [Hunter, Christopher L.] Def Hlth Agcy, Patient Ctr Med Home Branch, Clin Support Div, Washington, DC USA. [Dundon, Margaret; Goldstein, Michael G.] US Dept Vet Affairs, Natl Ctr Hlth Promot & Dis Prevent, Durham, NC USA. [Hausmann, Leslie R. M.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Hausmann, Leslie R. M.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Trynosky, Stephen K.] US Dept Vet Affairs, Off Acad Affiliat, Washington, DC USA. [Trynosky, Stephen K.] US Army Reserve, Med Serv Corps, Washington, DC USA. [Goodrich, David E.] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA. [Kilbourne, Amy M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA. [Knight, Sara J.] Birmingham VA Med Ctr, Birmingham, AL USA. [Knight, Sara J.] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA. RP Haibach, JP (reprint author), US Dept Vet Affairs, Hlth Serv Res & Dev Serv, 810 Vermont Ave NW 10P9H, Washington, DC 20420 USA. EM Jeffrey.Haibach@va.gov; Michael.Glotfelter.1@us.af.mil; Katherine.Hall@duke.edu; Robin.Masheb@yale.edu; Mlittl18@uthsc.edu; Robyn.Shepardson@va.gov; Anne.C.Dobmeyer.mil@mail.mil; Jennifer.Funderburk@va.gov; Christopher.L.Hunter16.mil@mail.mil; Margaret.Dundon@va.gov; Leslie.Hausmann@va.gov; Steve.Trynosky@va.gov; David.Goodrich2@va.gov; Amy.Kilbourne@va.gov; Sara.Knight@va.gov; Wtalcott@uthsc.edu; Michael.Goldstein2@va.gov NR 168 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0160-7715 EI 1573-3521 J9 J BEHAV MED JI J. Behav. Med. PD FEB PY 2017 VL 40 IS 1 BP 175 EP 193 DI 10.1007/s10865-016-9794-y PG 19 WC Psychology, Clinical SC Psychology GA EL0WK UT WOS:000394342300013 PM 27678001 ER PT J AU Haibach, JP Haibach, MA Hall, KS Masheb, RM Little, MA Shepardson, RL Dobmeyer, AC Funderburk, JS Hunter, CL Dundon, M Hausmann, LRM Trynosky, SK Goodrich, DE Kilbourne, AM Knight, SJ Talcott, GW Goldstein, M AF Haibach, Jeffrey P. Haibach, Michael Ann Hall, Katherine S. Masheb, Robin M. Little, Melissa A. Shepardson, Robyn L. Dobmeyer, Anne C. Funderburk, Jennifer S. Hunter, Christopher L. Dundon, Margaret Hausmann, Leslie R. M. Trynosky, Stephen K. Goodrich, David E. Kilbourne, Amy M. Knight, Sara J. Talcott, Gerald W. Goldstein, Michael TI Military and veteran health behavior research and practice: challenges and opportunities (vol 40, pg 175, 2017) SO JOURNAL OF BEHAVIORAL MEDICINE LA English DT Correction C1 [Haibach, Jeffrey P.; Kilbourne, Amy M.] US Dept Vet Affairs, Hlth Serv Res & Dev Serv, 810 Vermont Ave NW 10P9H, Washington, DC 20420 USA. [Haibach, Michael Ann] US Air Force, Wright Patterson AFB, OH USA. [Hall, Katherine S.] Durham VA Med Ctr, Durham, NC USA. [Hall, Katherine S.] Duke Univ, Dept Med, Durham, NC USA. [Masheb, Robin M.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Masheb, Robin M.] Yale Sch Med, New Haven, CT USA. [Little, Melissa A.; Talcott, Gerald W.] Univ Tennessee, Ctr Hlth Sci, Ctr Populat Sci, Memphis, TN 38163 USA. [Shepardson, Robyn L.; Funderburk, Jennifer S.] Syracuse VA Med Ctr, VA Ctr Integrated Healthcare, Syracuse, NY USA. [Shepardson, Robyn L.; Funderburk, Jennifer S.] Syracuse Univ, Dept Psychol, Syracuse, NY USA. [Dobmeyer, Anne C.] Deployment Hlth Clin Ctr, Def Ctr Excellence Psychol Hlth, Bethesda, MD USA. [Dobmeyer, Anne C.] Deployment Hlth Clin Ctr, Def Ctr Traumat Brain Injury, Bethesda, MD USA. [Funderburk, Jennifer S.] Univ Rochester, Dept Psychiat, Rochester, NY USA. [Hunter, Christopher L.] Def Hlth Agcy, Patient Ctr Med Home Branch, Clin Support Div, Washington, DC USA. [Dundon, Margaret; Goldstein, Michael] US Dept Vet Affairs, Natl Ctr Hlth Promot & Dis Prevent, Durham, NC USA. [Hausmann, Leslie R. M.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Hausmann, Leslie R. M.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Trynosky, Stephen K.] US Dept Vet Affairs, Off Acad Affiliat, Washington, DC USA. [Trynosky, Stephen K.] US Army Reserve, Med Serv Corps, Washington, DC USA. [Goodrich, David E.] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA. [Kilbourne, Amy M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA. [Knight, Sara J.] Birmingham VA Med Ctr, Birmingham, AL USA. [Knight, Sara J.] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA. RP Haibach, JP (reprint author), US Dept Vet Affairs, Hlth Serv Res & Dev Serv, 810 Vermont Ave NW 10P9H, Washington, DC 20420 USA. EM Jeffrey.Haibach@va.gov; Michael.Glotfelter.1@us.af.mil; Katherine.Hall@duke.edu; Robin.Masheb@yale.edu; Mlittl18@uthsc.edu; Robyn.Shepardson@va.gov; Anne.C.Dobmeyer.mil@mail.mil; Jennifer.Funderburk@va.gov; Christopher.L.Hunter16.mil@mail.mil; Margaret.Dundon@va.gov; Leslie.Hausmann@va.gov; Steve.Trynosky@va.gov; David.Goodrich2@va.gov; Amy.Kilbourne@va.gov; Sara.Knight@va.gov; Wtalcott@uthsc.edu; Michael.Goldstein2@va.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0160-7715 EI 1573-3521 J9 J BEHAV MED JI J. Behav. Med. PD FEB PY 2017 VL 40 IS 1 BP 227 EP 228 DI 10.1007/s10865-016-9801-3 PG 2 WC Psychology, Clinical SC Psychology GA EL0WK UT WOS:000394342300017 PM 27757768 ER PT J AU Jung, M Kwon, D Oh, JY AF Jung, Minsoo Kwon, Dongseok Oh, Ji-young TI Associated with Differences in Sexual Risk-Taking Behaviors Among Migrants in South Korea SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Migrant; Homosexual; Sexually transmitted disease; HIV/AIDS; Sexual risk-taking; South Korea ID IMMIGRANT MEN; HIV RISK; ACCULTURATION; DETERMINANTS; SHANGHAI; WORKERS; AIDS AB We investigated influential factors on differences in sexual risk-taking among homosexual migrants. The data used in this paper are based on the survey and medical examination for migrants' sexual behaviors that was carried out by the Korea Federation for HIV/AIDS Prevention in 2011-2013 on participants living in South Korea. Among 1141 migrants, homosexuals were 0.54 times less likely to use condom than heterosexuals. Homosexuals were 2.93 times more likely to be infected with sexually transmitted diseases (STDs) than heterosexuals. Among 250 homosexual migrants, those who preferred risky sexual intercourse were 0.19 times less likely to use a condom than heterosexual migrants. Those who have a fixed sexual partner were 0.35 times less likely to be infected with HIV than their counterparts. Administrative programs for STDs prevention of migrants should be focused on their sexual risk-taking, which were limited to casual partnership, unprotected sex, and previous contraction of sexual diseases. C1 [Jung, Minsoo] Dongduk Womens Univ, Dept Hlth Sci, Coll Nat Sci, 23-1 Wolgok Dong, Seoul 136714, South Korea. [Jung, Minsoo] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. [Kwon, Dongseok; Oh, Ji-young] Korea Federat HIV AIDS Prevent, Seoul, South Korea. RP Jung, M (reprint author), Dongduk Womens Univ, Dept Hlth Sci, Coll Nat Sci, 23-1 Wolgok Dong, Seoul 136714, South Korea.; Jung, M (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. EM mj748@dongduk.ac.kr NR 45 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 EI 1557-1920 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD FEB PY 2017 VL 19 IS 1 BP 24 EP 32 DI 10.1007/s10903-015-0300-3 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EK8ZK UT WOS:000394213200004 PM 26455719 ER PT J AU Caspi, CE Tucker-Seeley, RD Adamkiewicz, G Roberto, CA Stoddard, AM Sorensen, GC AF Caspi, Caitlin E. Tucker-Seeley, Reginald D. Adamkiewicz, Gary Roberto, Christina A. Stoddard, Anne M. Sorensen, Glorian C. TI Food Hardship and Obesity in a Sample of Low-Income Immigrants SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Immigrant; Obesity; Hardship; Food insecurity ID HOUSING RESIDENTS; AFRICAN REFUGEES; SECURITY STATUS; LATIN-AMERICAN; INSECURITY; HEALTH; WOMEN; ACCULTURATION; OVERWEIGHT; WEIGHT AB Very little work has examined the relationship between food hardship (having inconsistent financial resources to buy food) and obesity among immigrant groups. A cross-sectional study was conducted in a low-income, multi-racial/ethnic adult sample in greater Boston, MA (n = 828). Modified Poisson regression models estimated the association between food hardship obesity (BMI 30) among adults reporting food hardship; interactions were tested by place of birth. Body mass index (BMI) was based on anthropometric height and weight. In adjusted models, those experiencing food hardship were more likely to be obese (RR 1.17, CI 1.07, 1.29) than those not experiencing food hardship. Participants from Haiti reporting food hardship were more likely to be obese than those not reporting hardship (RR 1.58, CI 1.23, 2.04); this was not the case among other groups (US born, Puerto Rican, Latin American, Other). The relationship between food hardship and weight may vary among immigrant subgroups. C1 [Caspi, Caitlin E.] Univ Minnesota, Dept Family Med & Community Hlth, Program Hlth Dispar Res, 717 Delaware St SE, Minneapolis, MN 55414 USA. [Tucker-Seeley, Reginald D.; Sorensen, Glorian C.] Dana Farber Canc Inst, Ctr Community Based Res, 450 Brookline Ave, Boston, MA 02215 USA. [Tucker-Seeley, Reginald D.; Roberto, Christina A.; Sorensen, Glorian C.] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington St, Boston, MA 02215 USA. [Adamkiewicz, Gary] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, 677 Huntington St, Boston, MA 02215 USA. [Roberto, Christina A.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, 423 Guardian Dr, Philadelphia, PA 19104 USA. [Stoddard, Anne M.] New England Res Inst, 9 Galen St, Watertown, MA 02472 USA. RP Caspi, CE (reprint author), Univ Minnesota, Dept Family Med & Community Hlth, Program Hlth Dispar Res, 717 Delaware St SE, Minneapolis, MN 55414 USA. EM cecaspi@umn.edu FU National Cancer Institutes [R01 CA111310-01A, R25 CA057713, R25 CA163184, K01 CA169041, K05 CA108663]; Robert Wood Johnson Foundation Health & Society Scholars program FX The authors would like to thank the research participants and the Cambridge, Somerville and Chelsea Public Housing Authorities. The authors also thank Marty Alvarez-Reeves, Ruth Lederman, Samuel Lipson, Carol Lowenstein, Brianna Wadler, May Yang and Lorraine Wallace for their contributions to the study design and implementation. This research was supported by the National Cancer Institutes, grant numbers R01 CA111310-01A (GS), R25 CA057713 (CEC), R25 CA163184 (CEC), K01 CA169041 (RTS), K05 CA108663 (GS), and by the Robert Wood Johnson Foundation Health & Society Scholars program (CAR). The National Cancer Institute and the Robert Wood Johnson Foundation had no role in the design, analysis or writing of this article. NR 52 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 EI 1557-1920 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD FEB PY 2017 VL 19 IS 1 BP 130 EP 137 DI 10.1007/s10903-016-0344-z PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EK8ZK UT WOS:000394213200016 PM 26872640 ER PT J AU Swain, JD Sharma, G Rumma, RT Fisichella, PM Whang, E AF Swain, JaBaris D. Sharma, Gaurav Rumma, Rowza T. Fisichella, P. Marco Whang, Edward TI A Century of Surgical Innovation at a Boston Hospital SO JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES LA English DT Article DE innovation; surgery; Brigham and Women's Hospital ID IDENTICAL-TWINS; ELECTROSURGERY; HOMOTRANSPLANTATION; CUSHING,HARVEY; PRINCIPLES; LEGACY; LIFE; SKIN AB Background: Innovation has been a central focus of the Department of Surgery at the Brigham and Women's Hospital since its very inception. Here we review examples of innovations originating in this Department and analyze factors that have been critical to successful innovation. Finally, we discuss challenges to sustainability of innovation in this Department. Methods: Narrative review of the literature, interviews, and personal observations. Results: Examples of innovations reviewed here were each dependent on three critical elements: 1) multi-disciplinary collaboration among surgical innovators and individuals outside of surgery who offered complementary skills and expertise, 2) a rich institutional environment that sustained a diverse complement of innovators working in close proximity, and 3) Department Chairmen who facilitated the work of innovators and promoted their contributions, rather than seeking personal prestige or financial gain. Contemporary challenges to sustainability of innovation include the prevailing emphasis on clinical efficiency and on cost containment. Conclusion: We have identified factors critical to successful innovation in a Department of Surgery. The relevance of these factors is unlikely to be diminished, even in the changing landscape of modern medicine. C1 [Swain, JaBaris D.; Sharma, Gaurav; Rumma, Rowza T.; Whang, Edward] Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA. [Fisichella, P. Marco; Whang, Edward] VA Boston Healthcare, Dept Surg, West Roxbury Campus, Boston, MA USA. RP Fisichella, PM (reprint author), Boston VA Brigham & Womens, Dept Surg, West Roxbury, MA 02132 USA. EM JLAST@liebertpub.com NR 29 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1092-6429 EI 1557-9034 J9 J LAPAROENDOSC ADV S JI J. Laparoendosc. Adv. Surg. Tech. PD FEB PY 2017 VL 27 IS 2 BP 156 EP 161 DI 10.1089/lap.2016.0531 PG 6 WC Surgery SC Surgery GA EL0ZV UT WOS:000394351200011 PM 28068187 ER PT J AU Wiesel, O Whang, B Cohen, D Fisichella, PM AF Wiesel, Ory Whang, Brian Cohen, Daniel Fisichella, P. Marco TI Minimally Invasive Esophagectomy for Adenocarcinomas of the Gastroesophageal Junction and Distal Esophagus: Notes on Technique SO JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES LA English DT Article DE esophagectomy; ivor-lewis esophagectomy; minimally invasive esophagectomy ID IVOR LEWIS ESOPHAGECTOMY; RANDOMIZED CONTROLLED-TRIAL; CANCER; SURGERY; THERAPY; LYMPHADENECTOMY; INTERVENTION; IMPACT AB In the last three decades, with the advancement of laparoscopic and thoracoscopic surgery, minimally invasive approaches for benign and malignant diseases of the esophagus have been developed and more experience is starting to accumulate across the world. Minimally invasive esophagectomy (MIE) has demonstrated acceptable lymph node retrieval, good postoperative outcomes, and low mortality. In this article, we review our preferred technique of MIE for adenocarcinomas of the gastroesophageal junction and distal esophagus. C1 [Wiesel, Ory; Whang, Brian; Cohen, Daniel] Boston Healthcare Syst, Vet Hlth Adm, Brigham & Womens Hosp, Div Thorac Surg, Boston, MA USA. [Fisichella, P. Marco] Boston Healthcare Syst, Vet Hlth Adm, Brigham & Womens Hosp, Dept Surg, Boston, MA USA. RP Fisichella, PM (reprint author), Harvard Med Sch, Dept Surg, Brigham & Womens Hosp, Boston VA Healthcare Syst, 1400 VFW Pkwy, West Roxbury, MA 02132 USA. EM piero.fisichella@va.gov NR 32 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1092-6429 EI 1557-9034 J9 J LAPAROENDOSC ADV S JI J. Laparoendosc. Adv. Surg. Tech. PD FEB PY 2017 VL 27 IS 2 BP 162 EP 169 DI 10.1089/lap.2016.0430 PG 8 WC Surgery SC Surgery GA EL0ZV UT WOS:000394351200012 PM 27858584 ER PT J AU Sinha, S Dedmon, MM Naunheim, MR Fuller, JC Gray, ST Lin, DT AF Sinha, Sumi Dedmon, Matthew M. Naunheim, Matthew R. Fuller, Jennifer C. Gray, Stacey T. Lin, Derrick T. TI Update on Surgical Outcomes of Lateral Temporal Bone Resection for Ear and Temporal Bone Malignancies SO JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE LA English DT Article DE lateral temporal bone resection; cancer; malignancy; outcomes ID SQUAMOUS-CELL CARCINOMA AB Objectives Review outcomes of lateral temporal bone resections for ear and temporal bone malignancy. Design, Setting, and Participants Retrospective review of all lateral temporal bone resections performed from 2008 to 2015 at a single tertiary care center. Main Outcome Measures Patient demographics, perioperative variables, overall survival, disease-free survival (DFS), and comparison of Kaplan-Meier curves. Results Overall, 56 patients were identified with amean follow-up period of 2.3 +/- 1.8 years. The predominant histopathologic diagnosis was squamous cell carcinoma (SCC, 54%), followed by salivary gland tumors (18%), and basal cell carcinoma (9%). Tumor stages were T1-T2 in 23%, T3-T4 in 73%, and two unknown primary lesions. Mean overall survival was 4.6 +/- 0.4 years. Comparison of tumors with and without lymph node involvement or perineural invasion approached statistical significance for overall survival (p = 0.07 and 0.06, respectively). DFS was 2.5 +/- 0.3 years. Stratification by lymph node status had a statistically significant difference in DFS (p = 0.03). Subgroup analysis of SCC patients did not reveal significant differences. Conclusions Based on our cohort, most patients with temporal bone malignancies present with advanced disease, making it difficult to achieve negative margins. Overall, lymph node status was the strongest predictor of survival in this group. C1 [Sinha, Sumi; Dedmon, Matthew M.; Naunheim, Matthew R.; Fuller, Jennifer C.; Gray, Stacey T.; Lin, Derrick T.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. RP Dedmon, MM (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM matthew_dedmon@meei.harvard.edu NR 14 TC 0 Z9 0 U1 0 U2 0 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 2193-6331 EI 2193-634X J9 J NEUROL SURG PART B JI Journal of Neurol. Surg. Part B PD FEB PY 2017 VL 78 IS 1 BP 37 EP 42 DI 10.1055/s-0036-1584310 PG 6 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA EL0WF UT WOS:000394341800007 PM 28180041 ER PT J AU Oduro, K Masia, R Sillero, MC Ebb, D Mark, E Hedley-Whyte, ET AF Oduro, Kwadwo Masia, Ricard Sillero, Maria Cobos Ebb, David Mark, Eugene Hedley-Whyte, E. Tessa TI Metastatic Atypical Teratoid Rhabdoid Tumor (ATRT) in an Adolescent SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 22 BP 9A EP 9A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400023 ER PT J AU Chebib, I Kurzawa, P Mullen, JT Johnstone, SE Deshpande, V Nielsen, GP AF Chebib, Ivan Kurzawa, Pawel Mullen, John T. Johnstone, Sarah E. Deshpande, Vikram Nielsen, G. Petur TI Prognostic Value of Myogenic Differentiation in Dedifferentiated Liposarcoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Med Sch, Boston, MA USA. Poznan Univ Med Sci, Poznan, Poland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 42 BP 14A EP 14A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400043 ER PT J AU Larque, AB Deshpande, V Nielsen, GP Chebib, I AF Larque, Ana B. Deshpande, Vikram Nielsen, G. Petur Chebib, Ivan TI Prognostic Features in Uniformly Treated Synovial Sarcoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Larque, Ana B.; Deshpande, Vikram; Nielsen, G. Petur; Chebib, Ivan] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 62 BP 18A EP 19A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400063 ER PT J AU Biernacka, A Deshpande, V Brachtel, E AF Biernacka, Anna Deshpande, Vikram Brachtel, Elena TI Loss of XIST - The Potential Breast Cancer X Factor SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 118 BP 32A EP 32A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400119 ER PT J AU Gonzales-Ericcson, P Mayer, IA Jovanovic, B Lehmann, B Estrada, MV Kuba, G Abramson, V Mayer, E Dillon, P Aditya, B Chang, J Forero, A Meszoely, I Grau, A Pietenpol, J Sanders, M AF Gonzales-Ericcson, Paula Mayer, Ingrid A. Jovanovic, Bojana Lehmann, Brian Estrada, Monica V. Kuba, Gabriela Abramson, Vandana Mayer, Erica Dillon, Patrick Aditya, Bardia Chang, Jenny Forero, Andres Meszoely, Ingrid Grau, Ana Pietenpol, Jennifer Sanders, Melinda TI Histopathologic Subgroups of AR plus TNBC Predict Pathologic Complete Response to Neoadjuvant Chemotherapy in Localized Breast Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA. Dana Farber Canc Ctr, Boston, MA USA. Univ Virginia, Hlth Sci Ctr, Charlottesville, VA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Methodist Hosptal, Res Inst, Houston, TX USA. Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 164 BP 43A EP 43A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400164 ER PT J AU Kuba, MG Lester, SC Bowman, T Garber, J Dillon, DA AF Kuba, Marta G. Lester, Susan C. Bowman, Teresa Garber, Judy Dillon, Deborah A. TI Breast Cancer in Li-Fraumeni Syndrome: Morphologic Evaluation of Invasive and In Situ Carcinomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 202 BP 53A EP 53A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400202 ER PT J AU Papadodima, S Masia, R Stone, JR AF Papadodima, Stavroula Masia, Ricard Stone, James R. TI Cardiac Iron Overload Following Liver Transplantation in Patients without Hemochromatosis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Univ Athens, Athens, Greece. Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 320 BP 84A EP 84A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400320 ER PT J AU Darras, N Agarwal, S Faquin, WC Wang, HH Sacks, BA Nishino, M AF Darras, Natasha Agarwal, Shweta Faquin, William C. Wang, Helen H. Sacks, Barry A. Nishino, Michiya TI ThyroSeq Testing for Indeterminate Thyroid Nodules: An Institutional Experience SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 358 BP 92A EP 93A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400358 ER PT J AU Eng, G Rao, RA Chebib, I AF Eng, George Rao, Rema A. Chebib, Ivan TI Use of Novel Image Analysis to Characterize and Quantify Nuclear Features of Papillary Thyroid Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. 2New York Presbyterian Hosp, New York, NY USA. Weill Cornell Med Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 364 BP 94A EP 94A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400364 ER PT J AU Hang, JF Charu, V Zhang, MJL Vandenbussche, C AF Hang, Jen-Fan Charu, Vivek Zhang, Mingjuan L. Vandenbussche, Christopher TI Maximum WC Ratio in the "Atypical Urothelial Cells" Category Correlates with Follow-Up Malignant Results in Liquid-Based Voided Urine Specimens SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 375 BP 97A EP 97A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400375 ER PT J AU Hoda, RS Arpin, R Rosenbaum, MW Pitman, MB AF Hoda, Raza S. Arpin, Ronald Rosenbaum, Matthew W. Pitman, Martha B. TI Risk of Malignancy in Pancreatic Cysts with High-Grade Atypical Cytology SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Hoda, Raza S.; Arpin, Ronald; Rosenbaum, Matthew W.; Pitman, Martha B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 378 BP 98A EP 98A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400378 ER PT J AU Rosenbaum, MW England, JS Hoda, RS Arpin, R Le, L Forcione, DG Iafrate, A Pitman, MB AF Rosenbaum, Matthew W. England, Jonathan S. Hoda, Raza S. Arpin, Ronald Le, Long Forcione, David G. Iafrate, Anthony Pitman, Martha B. TI Next Generation Sequencing Adds Value to Cytology and Fluorescence In Situ Hybridization in the Diagnosis of Bile Duct Brushing Specimens SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Rosenbaum, Matthew W.; England, Jonathan S.; Hoda, Raza S.; Arpin, Ronald; Le, Long; Forcione, David G.; Iafrate, Anthony; Pitman, Martha B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 438 BP 113A EP 114A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400438 ER PT J AU Dewar, R Tambouret, RH AF Dewar, Rajan Tambouret, Rosemary H. TI Can Pathology Skills Be Learnt Exclusively Through Online Resources?: MOOC for PAPs - A Massive Open Online Course to Raise Pap Smear Cytoscreener Workforce in Low and Middle Income Countries SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Univ Michigan, Ann Arbor, MI 48109 USA. Udhavum Ullangal NGO, Madras, Tamil Nadu, India. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 549 BP 139A EP 139A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400547 ER PT J AU Farhat, N Xu, B Onernek, AM Tuttle, RM Roman, B Katabi, N Nose, V Sadow, PM Tallini, G Faquin, W Ghossein, R AF Farhat, Nada Xu, Bin Onernek, Ayse Mine Tuttle, R. Michael Roman, Benjamin Katabi, Nora Nose, Vania Sadow, Peter M. Tallini, Giovanni Faquin, William Ghossein, Ronald TI Should Subcentimeter Non-Invasive Encapsulated, Follicular Variant of Papillary Thyroid Carcinoma (NI-EFV PTC) Be Diagnosed as Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP)? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Bologna, Sch Med, Bologna, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 581 BP 147A EP 147A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400579 ER PT J AU Hernandez-Prera, J Machado, R Asa, SL Baloch, Z Faquin, W Ghossein, R LiVolsi, VA Lloyd, RV Mete, O Nikiforov, Y Thompson, LDR Turk, AT Seethala, RR Suster, S Urken, ML Wenig, BM AF Hernandez-Prera, Juan Machado, Rosalie Asa, Sylvia L. Baloch, Zubair Faquin, William Ghossein, Ronald LiVolsi, Virginia A. Lloyd, Ricardo V. Mete, Ozgur Nikiforov, Yuri Thompson, Lester D. R. Turk, Andrew T. Seethala, Raja R. Suster, Saul Urken, Mark L. Wenig, Bruce M. TI Pathologic Reporting of Tall Call Variant of Papillary Thyroid Cancer: Have We Reached Consensus? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Mt Sinai Beth Israel, New York, NY USA. Univ Toronto, Toronto, ON, Canada. Univ Penn, Philadelphia, PA 19104 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. Univ Wisconsin, Madison, WI USA. Univ Pittsburgh, Pittsburgh, PA USA. Southern Calif Permanente Med Grp, Woodland Hills, CA USA. Columbia Univ, New York, NY USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 582 BP 147A EP 148A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400580 ER PT J AU Arora, KS Michelakos, T Cai, L Ting, DT Ferrone, C Ferrone, S Deshpande, V AF Arora, Kshitij S. Michelakos, Theodoros Cai, Lei Ting, David T. Ferrone, Cristina Ferrone, Soldano Deshpande, Vikram TI Colonic Carcinomas with Sporadic Loss of Mismatch Repair Proteins Are Associated with Loss of HLA Class I SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Arora, Kshitij S.; Michelakos, Theodoros; Cai, Lei; Ting, David T.; Ferrone, Cristina; Ferrone, Soldano; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 631 BP 159A EP 159A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400629 ER PT J AU Choi, WT Brown, I Ushiku, T Yozu, M Setia, N Srivastava, A Johncilla, M Pai, RK Fukayama, M Misdraji, J Lauwers, GY AF Choi, Won-Tak Brown, Ian Ushiku, Tetsuo Yozu, Masato Setia, Namrata Srivastava, Amitabh Johncilla, Melanie Pai, Rish K. Fukayama, Masashi Misdraji, Joseph Lauwers, Gregory Y. TI Gastric Pyloric Gland Adenoma: A Multicenter Clinicopathologic Study of 65 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 UCSF, Med Ctr, San Francisco, CA USA. Envoi Pathol, Kelvin Grove, Qld, Australia. Univ Tokyo, Tokyo, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Chicago, Chicago, IL 60637 USA. Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Mayo Clin, Phoenix, AZ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 662 BP 166A EP 166A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400660 ER PT J AU Horvath, B Brown, I Setia, N Mattia, A Lamps, L Lauwers, GE Misdraji, J AF Horvath, Bela Brown, Ian Setia, Namrata Mattia, Anthony Lamps, Laura Lauwers, Gregory E. Misdraji, Joseph TI A Crohn's-Like Appearance Characterizes Actinomycotic Appendicitis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Envoi Specialist Pathologists, Kelvin Grove, Qld, Australia. Univ Chicago, Chicago, IL 60637 USA. Univ Arkansas Med Sci, Little Rock, AR 72205 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 698 BP 175A EP 175A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400696 ER PT J AU Jayakumar, R Qin, J Siddiqi, MA Gupta, R AF Jayakumar, Rajeswari Qin, Jia Siddiqi, M. A. Gupta, Raavi TI EZH2 as a Useful Diagnostic Tool for Grading Gastrointestinal (GI) Neuroendocrine Tumors SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 707 BP 177A EP 178A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400705 ER PT J AU Jeck, WR Arora, KS Brachtel, E Deshpande, V AF Jeck, William Richard Arora, Kshitij S. Brachtel, Elena Deshpande, Vikram TI Harnessing TCGA RNAseq Data as a Springboard to Novel Tumor Markers SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Jeck, William Richard; Arora, Kshitij S.; Brachtel, Elena; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 708 BP 178A EP 178A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724400706 ER PT J AU Oduro, K Arora, KS Deshpande, V AF Oduro, Kwadwo Arora, Kshitij S. Deshpande, Vikram TI Chromogenic In Situ Hybridization (CISH) Based Tracking of Donor Derived Lymphocytes Augments the Histologic Evaluation of Human Acute Graft versus Host Disease (GVHD) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Oduro, Kwadwo; Arora, Kshitij S.; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 765 BP 191A EP 191A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401038 ER PT J AU Rosenbaum, MW Bledsoe, JR Kem, M Huynh, T Mino-Kenudson, M AF Rosenbaum, Matthew W. Bledsoe, Jacob R. Kem, Marina Huynh, Tiffany Mino-Kenudson, Mari TI Immune Checkpoint Expression and the Tumor Immune Environment in Colorectal Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Massachusetts, Sch Med, Worcester, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 789 BP 197A EP 197A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401062 ER PT J AU Calagua, C Shaw, K Russo, J Schaefer, R Lis, R Zhang, ZW Loda, M Taplin, ME Balk, SP Sun, Y Ye, HH AF Calagua, Carla Shaw, Kristin Russo, Joshua Schaefer, Rachel Lis, Rosina Zhang, Zhenwei Loda, Massimo Taplin, Mary-Ellen Balk, Steven P. Sun, Yue Ye, Huihui TI Effect of Neoadjuvant Intense Androgen Deprivation Therapy in PD-L1 Expression in Prostate Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 873 BP 217A EP 217A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401146 ER PT J AU Elfandy, H Pederzoli, F Pullman, E Tyekucheva, S Schultz, N Loda, M AF Elfandy, Habiba Pederzoli, Filippo Pullman, Eli Tyekucheva, Svitlana Schultz, Nicholas Loda, Massimo TI Molecular Characterization of Prostatic Adenocarcinoma Gleason 4, Cribriform Pattern SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA. Cairo Univ, Natl Canc Inst, Cairo, Egypt. Univ Vita Salute San Raffaele, Milan, Italy. George Washington Univ, Washington, DC USA. Harvard Sch Publ Hlth, Boston, MA USA. Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. Harvard Med Sch, Boston, MA USA. DFCI, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 897 BP 222A EP 223A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401171 ER PT J AU Kandukuri, S Choueiri, TK Hirsch, MS AF Kandukuri, Shivani Choueiri, Toni K. Hirsch, Michelle S. TI PD-L1 Expression in High Grade Locally-Advanced Renal Cell Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 949 BP 234A EP 234A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401223 ER PT J AU Montaser, L Calagua, C Schaefer, R Lis, R Zhang, ZW Loda, M Taplin, ME Balk, SP Ye, HH AF Montaser, Laleh Calagua, Carla Schaefer, Rachel Lis, Rosina Zhang, Zhenwei Loda, Massimo Taplin, Mary-Ellen Balk, Steven P. Ye, Huihui TI Effect of Neoadjuvant Intense Androgen Deprivation Therapy in Neuroendocrine Differentiation of Prostate Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 East Tennessee State Univ, Johnson City, TN USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 987 BP 244A EP 244A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401261 ER PT J AU Bennett, J Nardi, V Rouzbahman, M Morales-Oyarvide, V Kim, KR Nielsen, GP Oliva, E AF Bennett, Jennifer Nardi, Valentina Rouzbahman, Marjan Morales-Oyarvide, Vicente Kim, Kyu-Rae Nielsen, G. P. Oliva, Esther TI Inflammatory Myofibroblastic Tumor of the Uterus: A Clinicopathological, Immunohistochemical, and Molecular Analysis of 13 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Lahey Hosp, Burlington, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Toronto Gen Hosp, Toronto, ON, Canada. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Ulsan, Seoul, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1109 BP 275A EP 276A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401385 ER PT J AU Bennett, J Pesci, A Badrinarain, J Da Silva, A Oliva, E AF Bennett, Jennifer Pesci, Anna Badrinarain, Jason Da Silva, Annacarolina Oliva, Esther TI Mismatch Repair Protein Expression in Endometrioid Carcinoma of the Ovary: Incidence and Clinicopathologic Associations in 77 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Lahey Hosp, Burlington, MA USA. Osped Sacro Cuore Don Calabria, Verona, Italy. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1110 BP 276A EP 276A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401386 ER PT J AU Bosse, T Nout, RA McAlpine, JN McConechy, M Britton, H Ganesan, R Steele, JC Harrison, BT Oliva, E Matias-Guiu, X Gilks, B Soslow, R AF Bosse, Tjalling Nout, Remi A. McAlpine, Jessica N. McConechy, Melissa Britton, Heidi Ganesan, Raji Steele, Jane C. Harrison, Beth T. Oliva, Esther Matias-Guiu, Xavier Gilks, Blake Soslow, Robert TI Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Leiden Univ, Med Ctr, Leiden, Netherlands. Univ British Columbia, Vancouver, BC, Canada. BC Canc Agcy, Vancouver, BC, Canada. Birmingham Womens HS Fdn Trust, Birmingham, W Midlands, England. Massachussets Gen Hosp, Boston, MA USA. Hosp Arnau Vilanova, Lleida, Spain. Hosp Univ Bellvitge, Lleida, Spain. Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. McGill Univ, Montreal, PQ, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1113 BP 277A EP 277A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401389 ER PT J AU Chiang, S Hensley, M Antonescu, CR Oliva, E Soslow, R AF Chiang, Sarah Hensley, Martee Antonescu, Cristina R. Oliva, Esther Soslow, Robert TI BCOR Is a Robust Diagnostic Immunohistochemical Marker of YWHAE-Rearranged High-Grade Endometrial Stromal Sarcoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1125 BP 280A EP 280A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401401 ER PT J AU Howitt, BE Garcia, E Sholl, LM Lindeman, NI MacConaill, LE Dong, F Hirsch, MS Nucci, MR Crum, CP McCluggage, WG Mirkovic, J AF Howitt, Brooke E. Garcia, Elizabeth Sholl, Lynette M. Lindeman, Neal I. MacConaill, Laura E. Dong, Fei Hirsch, Michelle S. Nucci, Marisa R. Crum, Christopher P. McCluggage, W. Glenn Mirkovic, Jelena TI Targeted Genomic Profiling of Female Adnexal Tumors of Probable Wolffian Origin SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1162 BP 289A EP 289A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401438 ER PT J AU Klystel-Whittemore, M Oliva, E AF Klystel-Whittemore, Melissa Oliva, Esther TI Patterns of Recurrences in Grade 1 Endometrioid Endometrial Adenocarcinoma (EEC) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Klystel-Whittemore, Melissa; Oliva, Esther] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1186 BP 294A EP 295A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401462 ER PT J AU Stolnicu, S Berman, I Hoang, L Terinte, C Pesci, A Aviel-Ronen, S Kiyokawa, T Alvarado-Cabrero, I Park, K Oliva, E Soslow, R AF Stolnicu, Simona Berman, Iulia Hoang, Lien Terinte, Cristina Pesci, Anna Aviel-Ronen, Sarit Kiyokawa, Takako Alvarado-Cabrero, Isabel Park, Kay Oliva, Esther Soslow, Robert TI International Endocervical Criteria and Classification: Mucinous Endocervical Adenocarcinomas (MEA) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Univ Med & Pharm, Targu Mures, Romania. Vancouver Gen Hosp, Vancouver, BC, Canada. Inst Oncol, Iasi, Romania. Osped Sacro Coure Don Calabria, Negrar, Italy. Sheba Med Ctr, Tel Hashomer, Israel. Jikei Univ, Sch Med, Tokyo, Japan. Hosp Oncol, Mexico City, DF, Mexico. MSKCC, New York, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1245 BP 310A EP 310A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401521 ER PT J AU Stolnicu, S Barsan, J Hoang, L Terinte, C Pesci, A Aviel-Ronen, S Kiyokawa, T Alvarado-Cabrero, I Park, K Oliva, E Soslow, R AF Stolnicu, Simona Barsan, Julia Hoang, Lien Terinte, Cristina Pesci, Anna Aviel-Ronen, Sarit Kiyokawa, Takako Alvarado-Cabrero, Isabel Park, Kay Oliva, Esther Soslow, Robert TI International Endocervical Adenocarcinoma Criteria and Classification (IECC) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Univ Med & Pharm, Targu Mures, Mures, Romania. Vancouver Gen Hosp, Vancouver, BC, Canada. Inst Oncol, Iasi, Romania. Osped Sacro Coure Don Calabria, Negrar, Italy. Sheba Med Ctr, Tel Hashomer, Israel. Jikei Univ, Sch Med, Tokyo, Japan. Hosp Oncol, Mexico City, DF, Mexico. MSKCC, New York, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1244 BP 310A EP 310A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401520 ER PT J AU Wong, A Borger, D Oliva, E AF Wong, Adele Borger, Darrell Oliva, Esther TI Clinicopathological Features of Uterine Neuroendocrine Tumors (NET)s SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. KK Womens & Childrens Hosp, Singapore, Singapore. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1265 BP 315A EP 315A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401541 ER PT J AU Wong, A Arora, KS Ordulu, Z Deshpande, V Oliva, E AF Wong, Adele Arora, Kshitij S. Ordulu, Zehra Deshpande, Vikram Oliva, Esther TI TERRA Amplified (+) Primary Leiomyosarcomas (LMS) of the Gynecologic (GYN)-Tract SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. KK Womens & Childrens Hosp, Singapore, Singapore. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1266 BP 315A EP 315A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401542 ER PT J AU Bundele, MM Weinreb, I Xu, B Chiosea, S Faquin, W Dias-Santagata, D Seethala, RR AF Bundele, Manish M. Weinreb, Ilan Xu, Bin Chiosea, Simon Faquin, William Dias-Santagata, Dora Seethala, Raja R. TI Mucoacinar Carcinoma: A Rare Intercalated Duct/Acinar Variant of Mucoepidermoid Carcinoma, Hybrid Tumor, or Distinct Entity? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Tan Tock Seng Hosp, Sg, Singapore. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Hlth Network, Toronto, ON, Canada. Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1294 BP 322A EP 322A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401570 ER PT J AU Jo, VY Chau, NG Hornick, JL Krane, JF Sholl, LM AF Jo, Vickie Y. Chau, Nicole G. Hornick, Jason L. Krane, Jeffrey F. Sholl, Lynette M. TI Recurrent IDH2 R172X Mutations Define Sinonasal Undifferentiated Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1310 BP 326A EP 326A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401586 ER PT J AU Boiocchi, L Ferry, JA Deshpande, V AF Boiocchi, Leonardo Ferry, Judith A. Deshpande, Vikram TI Lymph Node Fibrosis in IgG4-Related Disease SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Boiocchi, Leonardo; Ferry, Judith A.; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1362 BP 339A EP 339A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401638 ER PT J AU Boyer, D McKelvie, P de Leval, L Edlefsen, KL Ko, YH Aberman, Z Kovach, A Masih, A Nishino, H Weiss, L Meeker, A Nardi, V Palisoc, M Shao, LN Pittaluga, S Ferry, JA Harris, N Sohani, A AF Boyer, Daniel McKelvie, Penelope de Leval, Laurence Edlefsen, Kerstin L. Ko, Young-Hyeh Aberman, Zachary Kovach, Alexandra Masih, Aneal Nishino, Ha Weiss, Lawrence Meeker, Alan Nardi, Valentina Palisoc, Maryknoll Shao, Lina Pittaluga, Stefania Ferry, Judith A. Harris, Nancy Sohani, Aliyah TI Fibrin-Associated EBV plus Large B-Cell Lymphoma: An Indolent Neoplasm Distinct from DLBCL-CI SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Univ Michigan, Ann Arbor, MI 48109 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. St Vincents Hosp, Melbourne, Vic, Australia. CHU Vaudois, Lausanne, Switzerland. Univ Washington, Seattle, WA 98195 USA. Sungkyunkwan Univ, Seoul, South Korea. Florida Int Univ, Miami, FL 33199 USA. Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA. Holmes Reg Med Ctr, Melbourne, FL USA. North Shore Med Ctr, Salem, MA USA. NeoGen Labs, Aliso Viejo, CA USA. Johns Hopkins Univ, Baltimore, MD USA. NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1363 BP 339A EP 340A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401639 ER PT J AU Crotty, R Pozdnyakova, O Chen, YB Ballen, K Hassesjian, RP AF Crotty, Rosy Pozdnyakova, Olga Chen, Yi-Bin Ballen, Karen Hassesjian, Robert P. TI Lymphoid Proliferations Following Umbilical Cord Stem Cell Transplant SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1381 BP 344A EP 344A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401657 ER PT J AU Margolskee, E Mikita, G Oak, J Allen, MB Zuo, Z Wang, S Arber, DA George, T Hasserjian, RP Orazi, A AF Margolskee, Elizabeth Mikita, Geoffrey Oak, Jean Allen, M. B. Zuo, Zhuang Wang, Sa Arber, Daniel A. George, Tracy Hasserjian, Robert P. Orazi, Attilio TI Acute Myeloid Leukemia with Erythroid Predominance: Are All Cases MDS-Related? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA. Stanford Univ, Stanford, CA 94305 USA. Univ New Mexico, Albuquerque, NM 87131 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1452 BP 362A EP 362A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401728 ER PT J AU Matyamchik, E Van Cott, EM AF Matyamchik, Elena Van Cott, Elizabeth M. TI The Effects of Rivaroxaban on Activated Protein C Resistance and Protein S Testing SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Matyamchik, Elena; Van Cott, Elizabeth M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1454 BP 363A EP 363A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401730 ER PT J AU Shih, A Bledsoe, JR McKelvie, P Harris, N Zukerberg, L AF Shih, Angela Bledsoe, Jacob R. McKelvie, Penny Harris, Nancy Zukerberg, Lawrence TI CD5-Negative Mantle Cell Lymphoma Shows a More Indolent Outcome and Variable SOX11 Staining SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 [Shih, Angela; Bledsoe, Jacob R.; McKelvie, Penny; Harris, Nancy; Zukerberg, Lawrence] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1513 BP 378A EP 378A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724401789 ER PT J AU Tashakori, M Sanchez, J Michalowski, SM Louissaint, A Inamdar, KV Gomez-Gelvez, J Carey, JL Menon, MP AF Tashakori, Mehrnoosh Sanchez, Jessica Michalowski, Susan M. Louissaint, Abner Inamdar, Kedar V. Gomez-Gelvez, Juan Carey, John L. Menon, Madhu P. TI Follicular Lymphoma Transforming to Double and Triple Hit Lymphoma; a Clinicopathologic, Morphologic and Cytogenetic Analysis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Henry Ford Hlth Syst, Detroit, MI USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2017 VL 97 SU 1 MA 1525 BP 380A EP 381A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA EK1YT UT WOS:000393724402009 ER EF